Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof

ABSTRACT

This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119(e) to U.S.Provisional Patent Application No. 63/016,569, filed Apr. 28, 2020, toU.S. Provisional Patent Application No. 63/021,387, filed May 7, 2020,to U.S. Provisional Patent Application No. 63/032,112, filed May 29,2020, to U.S. Provisional Patent Application No. 63/038,384, filed Jun.12, 2020, and to U.S. Provisional Patent Application No. 63/119,088,filed Nov. 30, 2020. The foregoing applications are incorporated byreference herein in their entireties.

STATEMENT REGARDING FEDERALLY FUNDED RESEARCH

This invention was made with government support under grant nos.P01-AI138398-S1 and 2U19AI111825 awarded by the National Institutes ofHealth. The government has certain rights in the invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Jun. 8, 2021, isnamed 070413_20615_SL.txt and is 3,009,383 bytes in size.

FIELD OF THE INVENTION

The present invention relates to antibodies directed to epitopes ofSARS-CoV-2 Coronavirus 2 (“SARS-CoV-2”). The present invention furtherrelates to the preparation and use of broadly neutralizing antibodiesdirected to the SARS-CoV-2 spike (S) glycoproteins for the preventionand treatment of SARS-CoV-2 infection.

BACKGROUND OF THE INVENTION

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19).It contains four structural proteins, including spike (S), envelope (E),membrane (M), and nucleocapsid (N) proteins. Among them, S protein playsthe most important roles in viral attachment, fusion, and entry, and itserves as a target for development of antibodies, entry inhibitors, andvaccines. The S protein mediates viral entry into host cells by firstbinding to a host receptor through the receptor-binding domain (RBD) inthe S1 subunit and then fusing the viral and host membranes through theS2 subunit. SARS-CoV and MERS-CoV RBDs recognize different receptors.SARS-CoV recognizes angiotensin-converting enzyme 2 (ACE2) as itsreceptor, whereas MERS-CoV recognizes dipeptidyl peptidase 4 (DPP4) asits receptor. Similar to SARS-CoV, SARS-CoV-2 also recognizes ACE2 asits host receptor binding to viral S protein.

As of Apr. 25, 2020, a total of 2.84 million confirmed cases of COVID-19were reported, including 199,000 deaths, in the United States and atleast 85 other countries and/or territories. Currently, the intermediatehost of SARS-CoV-2 is still unknown, and no effective prophylactics ortherapeutics are available. This calls for the immediate development ofvaccines and antiviral drugs for prevention and treatment of COVID-19.

In addition, due to the ability of SARS-CoV-2 to be spread through anairborne route, SARS-CoV-2 presents a particular threat to the health oflarge populations of people throughout the world. Accordingly, methodsto immunize people before infection, diagnose infection, immunize peopleduring infection, and treat infected persons infected with SARS-CoV-2are urgently needed.

SUMMARY OF THE INVENTION

This disclosure addresses the need mentioned above in a number ofaspects by providing broadly neutralizing anti-SARS-CoV-2 antibodies orantigen-binding fragments thereof.

In one aspect, this disclosure provides an isolated anti-SARS-CoV-2antibody or antigen-binding fragment thereof that binds specifically toa SARS-CoV-2 antigen. In some embodiments, the SARS-CoV-2 antigencomprises a Spike (S) polypeptide, such as a S polypeptide of a human oran animal SARS-CoV-2. In some embodiments, the SARS-CoV-2 antigencomprises the receptor-binding domain (RBD) of the S polypeptide. Insome embodiments, the RBD comprises amino acids 319-541 of the Spolypeptide.

In some embodiments, the antibody or antigen-binding fragment thereof iscapable of neutralizing a plurality of SARS-CoV-2 strains.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises three heavy chain complementarity determining regions (HCDRs)(HCDR1, HCDR2, and HCDR3) of a heavy chain variable region having anamino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19,21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55,57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91,93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121,123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149,151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177,179, 181, 183, 185, 187, 2876, or 2900; and three light chain CDRs(LCDR1, LCDR2, and LCDR3) of a light chain variable region having theamino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20,22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56,58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92,94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122,124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150,152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178,180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise respective amino acid sequences of (i) SEQ ID NOs: 2878, 2880,2882, 2890, 2892, and 2894; or (ii) SEQ ID NOs: 2902, 2904, 2906, 2914,2916, and 2918.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises: (i) a heavy chain variable region having an amino acidsequence with at least 75% identity to SEQ ID NOs: 1, 3, 5, 7, 9, 11,13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47,49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83,85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115,117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143,145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171,173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; or (ii) a lightchain variable region having an amino acid sequence with at least 75%identity to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26,28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62,64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98,100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126,128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154,156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182,184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises: (i) a heavy chain variable region having an amino acidsequence with at least 75% identity to SEQ ID NOs: 1, 3, 5, 7, 9, 11,13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47,49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83,85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115,117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143,145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171,173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; and (ii) a lightchain variable region having an amino acid sequence with at least 75%identity to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26,28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62,64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98,100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126,128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154,156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182,184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises: (i) a heavy chain variable region having the amino acidsequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25,27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61,63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97,99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125,127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153,155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181,183, 185, 187, 2876, or 2900; or (ii) a light chain variable regionhaving the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14,16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86,88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116,118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144,146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172,174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises: (i) a heavy chain variable region having the amino acidsequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25,27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61,63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97,99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125,127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153,155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181,183, 185, 187, 2876, or 2900; and (ii) a light chain variable regionhaving the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14,16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86,88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116,118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144,146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172,174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises a heavy chain variable region and a light chain variableregion that comprise the respective amino acid sequences of SEQ ID NOs:1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22,23-24, 25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42,43-44, 45-46, 47-48, 49-50, 51-52, 53-54, 55-56, 57-58, 59-60, 61-62,63-64, 65-66, 67-68, 69-70, 71-72, 73-74, 75-76, 77-78, 79-80, 81-82,83-84, 85-86, 87-88, 89-90, 91-92, 93-94, 95-96, 97-98, 99-100, 101-102,103-104, 105-106, 107-108, 109-110, 111-112, 113-114, 115-116, 117-118,119-120, 121-122, 123-124, 125-126, 127-128, 129-130, 131-132, 133-134,135-136, 137-138, 139-140, 141-142, 143-144, 145-146, 147-148, 149-150,151-152, 153-154, 155-156, 157-158, 159-160, 161-162, 163-164, 165-166,167-168, 169-170, 171-172, 173-174, 175-176, 177-178, 179-180, 181-182,183-184, 185-186, 187-188, 2876 and 2888, or 2900 and 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises a heavy chain variable region and a light chain variableregion that comprise the respective amino acid sequences of SEQ ID NOs:1-2; 13-14; 25-26; 49-50, 55-56, 57-58, 65-66, 81-82, 85-86, 113-114,125-126, 2876 and 2888, or 2900 and 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises a heavy chain/light chain sequence pair of SEQ ID NOs:2886/2898, 2887/2899, 2910/2921, or 2911/2922.

In some embodiments, the antibody or antigen-binding fragment thereof isa multivalent antibody that comprises (a) a first target binding sitethat specifically binds to an epitope within the S polypeptide, and (b)a second target binding site that binds to a different epitope on the Spolypeptide or a different molecule. In some embodiments, themultivalent antibody is a bivalent or bispecific antibody.

In some embodiments, the antibody or the antigen-binding fragmentthereof further comprises a variant Fc constant region. In someembodiments, the antibody is a monoclonal antibody. In some embodiments,the antibody is a chimeric antibody, a humanized antibody, or ahumanized monoclonal antibody. In some embodiments, the antibody is asingle-chain antibody, Fab or Fab2 fragment.

In some embodiments, the antibody or antigen-binding fragment thereof isdetectably labeled or conjugated to a toxin, a therapeutic agent, apolymer, a receptor, an enzyme or a receptor ligand. In someembodiments, the polymer is polyethylene glycol (PEG).

For example, an antibody of the invention may be coupled to a toxin.Such antibodies may be used to treat animals, including humans, that areinfected with the virus that is etiologically linked to SARS-CoV-2. Forexample, an antibody that binds to the spike protein of the coronavirusthat is etiologically linked to SARS-CoV-2 may be coupled to a tetanustoxin and administered to an animal suffering from infection by theaforementioned virus. The toxin-coupled antibody is thought to bind to aportion of a spike protein presented on an infected cell, and then killthe infected cell.

An antibody of the invention may be coupled to a detectable tag. Suchantibodies may be used within diagnostic assays to determine if ananimal, such as a human, is infected with SARS-CoV-2. Examples ofdetectable tags include fluorescent proteins (i.e., green fluorescentprotein, red fluorescent protein, yellow fluorescent protein),fluorescent markers (i.e., fluorescein isothiocyanate, rhodamine, texasred), radiolabels (i.e., 3H, 32P, 125I), enzymes (i.e., β-galactosidase,horseradish peroxidase, β-glucuronidase, alkaline phosphatase), or anaffinity tag (i.e., avidin, biotin, streptavidin).

In another aspect, this disclosure provides a pharmaceutical compositioncomprising: the antibody or antigen-binding fragment thereof of any oneof the preceding claims and optionally a pharmaceutically acceptablecarrier or excipient.

In some embodiments, the pharmaceutical comprises two or more of theantibody or antigen-binding fragment thereof of described above, such asany combinations of the antibody or antigen-binding fragment thereofcomprising a heavy chain and a light chain that comprise the respectiveamino acid sequences of SEQ ID NOs: 1-2; 13-14; 25-26; 49-50, 55-56,57-58, 65-66, 81-82, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and2912.

In some embodiments, the two or more of the antibody or antigen-bindingfragment thereof comprise: (1) a first antibody set comprising: (i) afirst antibody or antigen-binding fragment thereof comprising a heavychain variable region and a light chain variable region comprising therespective amino acid sequences of SEQ ID NOs: 57-58; and (ii) a secondantibody or antigen-binding fragment thereof comprising a heavy chainvariable region and a light chain variable region comprising therespective amino acid sequences of SEQ ID NOs: 1-2, 55-56, 57-58, 65-66,81-82, or 85-86; or (2) a second antibody set comprising: (a) a thirdantibody or antigen-binding fragment thereof comprising a heavy chainvariable region and a light chain variable region comprising therespective amino acid sequences of of SEQ ID NOs: 13-14, 49-50, 85-86,113-114, 125-126, 2876 and 2888, or 2900 and 2912; and (b) a fourthantibody or antigen-binding fragment thereof comprising a heavy chainvariable region and a light chain variable region comprising therespective amino acid sequences of of SEQ ID NOs: 13-14, 49-50, 85-86,113-114, 125-126, 2876 and 2888, or 2900 and 2912, wherein the thirdantibody is different from the fourth antibody.

In some embodiments, the pharmaceutical composition further comprises asecond therapeutic agent. In some embodiments, the second therapeuticagent comprises an anti-inflammatory drug or an antiviral compound. Insome embodiments, the antiviral compound comprises: a nucleoside analog,a peptoid, an oligopeptide, a polypeptide, a protease inhibitor, a3C-like protease inhibitor, a papain-like protease inhibitor, or aninhibitor of an RNA dependent RNA polymerase. In some embodiments, theantiviral compound may include: acyclovir, gancyclovir, vidarabine,foscarnet, cidofovir, amantadine, ribavirin, trifluorothymidine,zidovudine, didanosine, zalcitabine or an interferon. In someembodiments, the interferon is an interferon-α or an interferon-β.

Also within the scope of this disclosure is use of the pharmaceuticalcomposition, as described above, in the preparation of a medicament forthe diagnosis, prophylaxis, treatment, or combination thereof of acondition resulting from a SARS-CoV-2.

In another aspect, this disclosure also provides (i) a nucleic acidmolecule encoding a polypeptide chain of the antibody or antigen-bindingfragment thereof described above; (ii) a vector comprising the nucleicacid molecule as described; and (iii) a cultured host cell comprisingthe vector as described. Also provided is a method for producing apolypeptide, comprising: (a) obtaining the cultured host cell asdescribed; (b) culturing the cultured host cell in a medium underconditions permitting expression of a polypeptide encoded by the vectorand assembling of an antibody or fragment thereof; and (c) purifying theantibody or fragment from the cultured cell or the medium of the cell.

In another aspect, this disclosure provides a kit comprising apharmaceutically acceptable dose unit of the antibody or antigen-bindingfragment thereof of or the pharmaceutical composition as describedabove. Also within the scope of this disclosure is a kit for thediagnosis, prognosis or monitoring the treatment of SARS-CoV-2 in asubject, comprising: the antibody or antigen-binding fragment thereof asdescribed; and a least one detection reagent that binds specifically tothe antibody or antigen-binding fragment thereof.

In yet another aspect, this disclosure further provides a method ofneutralizing SARS-CoV-2 in a subject, comprising administering to asubject in need thereof a therapeutically effective amount of theantibody or antigen-binding fragment thereof or a therapeuticallyeffective amount of the pharmaceutical composition, as described above.

In yet another aspect, this disclosure additionally provides a method ofpreventing or treating a SARS-CoV-2 infection, comprising administeringto a subject in need thereof a therapeutically effective amount of theantibody or antigen-binding fragment thereof or a therapeuticallyeffective amount of the pharmaceutical composition, as described above.

In some embodiments, the method of neutralizing SARS-CoV-2 in a subjectcomprises administering to a subject in need thereof a therapeuticallyeffective amount of a first antibody or antigen-binding fragment thereofand a second antibody or antigen-binding fragment thereof of theantibody or antigen-binding fragment or a therapeutically effectiveamount of the pharmaceutical composition described above, as describedabove, wherein the first antibody or antigen-binding fragment thereofand the second antibody or antigen binding fragment thereof exhibitsynergistic activity.

In some embodiments, the method of preventing or treating a SARS-CoV-2infection, comprising administering to a subject in need thereof atherapeutically effective amount of a first antibody or antigen-bindingfragment thereof and a second antibody or antigen-binding fragmentthereof of the antibody or antigen-binding fragment or a therapeuticallyeffective amount of the pharmaceutical composition described above, asdescribed above, wherein the first antibody or antigen-binding fragmentthereof and the second antibody or antigen binding fragment thereofexhibit synergistic activity. In some embodiments, the first antibody orantigen-binding fragment thereof is administered before, after, orconcurrently with the second antibody or antigen-binding fragmentthereof.

In some embodiments, the first antibody or antigen-binding fragmentthereof and the second antibody or antigen-binding fragment thereof canbe any combinations of the antibody or antigen-binding fragment thereofcomprising a heavy chain and a light chain that comprise the respectiveamino acid sequences of SEQ ID NOs: 1-2; 13-14; 25-26; 49-50, 55-56,57-58, 65-66, 81-82, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and2912.

In some embodiments, the first antibody or antigen-binding fragmentthereof comprises a heavy chain variable region and a light chainvariable region comprising the respective amino acid sequences of SEQ IDNOs: 57-58 and the second antibody or antigen-binding fragment thereofcomprises a heavy chain variable region and a light chain variableregion comprising the respective amino acid sequences of SEQ ID NOs:1-2, 55-56, 57-58, 65-66, 81-82, or 85-86.

In some embodiments, the first antibody or antigen-binding fragmentthereof comprises a heavy chain variable region and a light chainvariable region comprising the respective amino acid sequences of SEQ IDNOs: 13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and2912, and the second antibody or antigen-binding fragment thereofcomprises a heavy chain variable region and a light chain variableregion comprising the respective amino acid sequences of SEQ ID NOs:13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912,wherein the first antibody and the second antibody are different.

In some embodiments, the method comprises administering to the subject atherapeutically effective amount of a second therapeutic agent ortherapy. In some embodiments, the antibody or antigen-binding fragmentthereof comprises a heavy chain variable region and a light chainvariable region comprising the respective amino acid sequences of SEQ IDNOs: 57-58; and the second therapeutic agent or therapy comprises anantibody or antigen-binding fragment thereof comprising a heavy chainvariable region and a light chain variable region that comprise therespective amino acid sequences of SEQ ID NOs: 1-2, 55-56, 57-58, 65-66,81-82, or 85-86.

In some embodiments, the second therapeutic agent comprises ananti-inflammatory drug or an antiviral compound. In some embodiments,the antiviral compound comprises a nucleoside analog, a peptoid, anoligopeptide, a polypeptide, a protease inhibitor, a 3C-like proteaseinhibitor, a papain-like protease inhibitor, or an inhibitor of an RNAdependent RNA polymerase. In some embodiments, the antiviral compoundmay include: acyclovir, gancyclovir, vidarabine, foscarnet, cidofovir,amantadine, ribavirin, trifluorothymidine, zidovudine, didanosine,zalcitabine or an interferon. In some embodiments, the interferon is aninterferon-α or an interferon-β.

In some embodiments, the antibody or antigen-binding fragment thereof isadministered before, after, or concurrently with the second therapeuticagent or therapy. In some embodiments, the antibody or antigen-bindingfragment thereof is administered to the subject intravenously,subcutaneously, or intraperitoneally. In some embodiments, the antibodyor antigen-binding fragment thereof is administered prophylactically ortherapeutically.

In another aspect, this disclosure further provides a method fordetecting the presence of SARS CoV-2 in a sample comprising the stepsof: (i) contacting a sample with the antibody or antigen-bindingfragment thereof described above; and (ii) determining binding of theantibody or antigen-binding fragment to one or more SARS CoV-2 antigens,wherein binding of the antibody to the one or more SARS CoV-2 antigensis indicative of the presence of SARS CoV-2 in the sample. In someembodiments, the sample is a blood sample.

In some embodiments, the SARS-CoV-2 antigen comprises a S polypeptide,such as a S polypeptide of a human or an animal SARS-CoV-2. In someembodiments, the SARS-CoV-2 antigen comprises the receptor-bindingdomain (RBD) of the S polypeptide. In some embodiments, the RBDcomprises amino acids 319-541 of the S polypeptide.

In some embodiments, the antibody or antigen-binding fragment thereof isconjugated to a label. In some embodiments, the step of detectingcomprises contacting a secondary antibody with the antibody orantigen-binding fragment thereof and wherein the secondary antibodycomprises a label. In some embodiments, the label includes a fluorescentlabel, a chemiluminescent label, a radiolabel, and an enzyme.

In some embodiments, the step of detecting comprises detectingfluorescence or chemiluminescence. In some embodiments, the step ofdetecting comprises a competitive binding assay or ELISA.

In some embodiments, the method further comprises binding the sample toa solid support. In some embodiments, the solid support includesmicroparticles, microbeads, magnetic beads, and an affinity purificationcolumn.

The foregoing summary is not intended to define every aspect of thedisclosure, and additional aspects are described in other sections, suchas the following detailed description. The entire document is intendedto be related as a unified disclosure, and it should be understood thatall combinations of features described herein are contemplated, even ifthe combination of features are not found together in the same sentence,or paragraph, or section of this document. Other features and advantagesof the invention will become apparent from the following detaileddescription. It should be understood, however, that the detaileddescription and the specific examples, while indicating specificembodiments of the disclosure, are given by way of illustration only,because various changes and modifications within the spirit and scope ofthe disclosure will become apparent to those skilled in the art fromthis detailed description.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B are a set of graphs showing the results of monoclonalantibodies for neutralization of SARS-CoV-2 pseudovirus expressingnanoluciferase.

FIGS. 2A and 2B (collectively “FIG. 2 ”) are a set of graphs showing theresults of monoclonal antibodies in ELISA for binding to the ReceptorBinding Domain (RBD) of the virus Spike protein.

FIGS. 3A, 3B, 3C, 3D, 3E, 3F, 3G, and 3H (collectively “FIG. 3 ”) are aset of graphs showing results of ELISAs measuring plasma reactivity toRBD (FIGS. 3A and 3B) and S protein (FIGS. 3C and 3D). Left showsoptical density units at 450 nm (OD, Y axis) and reciprocal plasmadilutions (X axis). Negative controls in black; individuals 21, and 47in blue and red lines and arrowheads, respectively. Right showsnormalized area under the curve (AUC) for 8 controls and each of 149individuals in the cohort. FIG. 3E shows symptom (Sx) onset to time ofsample collection in days (X axis) plotted against normalized AUC forIgM binding to RBD (Y axis); r=0.5517 and p=<0.0001. FIG. 3F showsparticipant age in years (X axis) plotted against normalized AUC for IgGbinding to RBD (Y axis); r=0.1827 and p=0.0258. The r and p values forthe correlations in FIGS. 3E and 3F were determined by two-tailedSpearman's. FIG. 3G shows normalized AUC of anti-RBD IgG ELISA foroutpatients (n=138) and hospitalized (n=11) individuals; p=0.0178. FIG.3H shows normalized AUC of anti-RBD IgG ELISA for males (n=83) andfemales (n=66); p=0.0063. For FIGS. 3G and 3H, horizontal bars indicatemedian values. Statistical significance was determined using two-tailedMann-Whitney U test.

FIGS. 4A, 4B, 4C, 4D, 4E, and 4F (collectively “FIG. 4 ”) are a set ofgraphs showing neutralization of SARS-CoV-2 pseudovirus by plasma. FIG.4A shows normalized relative luminescence values (RLU, Y axis) in celllysates of 293 T_(ACE2) cells 48 hours after infection withnanoluc-expressing SARS-CoV-2 pseudovirus in the presence of increasingconcentrations of plasma (X axis) derived from 149 participants (grey,except individuals 21 and 47 in blue and red lines, bars and arrowheads,respectively) and 3 negative controls (black lines). Mean of duplicates;representative of two independent experiments. FIG. 4B shows rankedaverage half-maximal inhibitory plasma neutralizing titer (NT₅₀) for the59 of 149 individuals with NT₅₀s>500 and individual 107. Asterisksindicate donors from which antibody sequences were derived. FIG. 4Cshows normalized AUC for anti-RBD IgG ELISA (X axis) plotted againstNT₅₀ (Y axis); r=0.6432, p=<0.0001. FIG. 4D shows normalized AUC foranti-S IgG ELISA (X axis) plotted against NT₅₀ (Y axis); r=0.6721,p=<0.0001. The r and p values for the correlations in FIGS. 4C and 4Dwere determined by two-tailed Spearman's. FIG. 4E shows NT₅₀ foroutpatients (n=138) and hospitalized (n=11) individuals; p=0.0495. FIG.4F shows NT₅₀ for males (n=83) and females (n=66) in the cohort;p=0.0031. Statistical significance in e and f was determined usingtwo-tailed Mann-Whitney U test and horizontal bars indicate medianvalues. Dotted lines in FIGS. 4E and 4F (NT₅₀=5) represents lower limitof detection (LLOD). Samples with neutralizing titers below 1:50 wereplotted at LLOD.

FIGS. 5A, 5B, 5C, and 5D (collectively “FIG. 5 ”) are a set of graphsshowing activities of anti-SARS-CoV-2 RED antibodies. FIG. 5A showsrepresentative flow cytometry plots displaying dual AF647- and PE-RBDbinding B cells in control and 6 study individuals (for gating strategysee FIG. 12 ). Percentages of antigen specific B cells are indicated.Control is a healthy control sample obtained pre-COVID-19. FIG. 5B is aset of pie charts depicting the distribution of antibody sequences from6 individuals. The number in the inner circle indicates the number ofsequences analyzed for the individual denoted above the circle. Whiteindicates sequences isolated only once, and grey or colored pie slicesare proportional to the number of clonally related sequences. Red, blue,orange, and yellow pie slices indicate clones that share the same IGHVand IGLV genes. FIG. 5C is circos plot showing sequences from all 6individuals with clonal relationships depicted as in FIG. 5B.Interconnecting lines indicate the relationship between antibodies thatshare V and J gene segment sequences at both IGH and IGL. Purple, green,and gray lines connect related clones, clones and singles, and singlesto each other, respectively. FIG. 5D shows sample sequence alignment forantibodies originating from different individuals that display highlysimilar IGH V(D)J and IGL VJ sequences including CDR3s. Amino aciddifferences in CDR3s to the bolded reference sequence above areindicated in red and dots represent identities. FIG. 5D discloses SEQ IDNOS 598, 602, 1434, 1438, 2445, 2449, 578, 582, 586, 1754, 1758, 600,600, 1436, 600, 2487, 600, 580, 584, 580, 580, and 580, respectively, inorder of column.

FIGS. 6A, 6B, 6C, 6D, 6E, 6F, 6G, 6H, 6I, 6J, 6K, 6L, 6M, 6N, 6O, 6P,6Q, and 6R (collectively “FIG. 6 ”) are a set of graphs showinganti-SARS-CoV-2 RBD antibody reactivity. FIG. 6A is a graph showing theresults of ELISA assays measuring monoclonal antibody binding to RBD.Optical density units at 450 nm (OD, Y axis) vs. antibody concentrations(X axis); 94 samples and 1 isotype control. C121, C135 C144 and isotypecontrol in red, green, purple, and black respectively, in all panels.FIG. 6B is a graph showing normalized relative luminescence values (RLU,Y axis) in cell lysates of 293T_(ACE2) cells 48 hours after infectionwith SARS-CoV-2 pseudovirus in the presence of increasing concentrationsof monoclonal antibodies (X axis). 89 samples and 1 isotype control.FIG. 6C shows normalized RLU for SARS-CoV-2 pseudovirus neutralization(Y axis) vs. titration of monoclonal antibodies C121, C135 and C144.FIG. 6D shows SARS-CoV-2 real virus neutralization assay. Normalizedinfected cells (Y axis, determined by dividing the amount of infectionper well by the average of control wells infected in the absence ofantibodies) vs. titration of monoclonal antibodies C121, C135, and C144.FIGS. 6A, 6B, 6C, and 6D show a representative of two independentexperiments. In FIG. 6B and FIG. 6C is mean of duplicates and in FIG. 6Dis mean with a standard deviation of triplicates. FIG. 6E shows IC₅₀sfor antibodies assayed in FIGS. 6B and 6D, the average value of at leasttwo experiments is shown. Samples with IC₅₀s above 1 mg/ml were plottedat 1 μg/ml; n=89 (pseudovirus) and n=3 (virus), respectively. FIG. 6F isa diagrammatic representation of biolayer interferometry experiment.FIG. 6G is a graph showing binding of C144, C101, C121, C009, C135, andCR3022 to RBD. FIGS. 6H, 6I, 6J, 6K, 6L, 6M, and 6N shows secondaryantibody binding to preformed IgG-RBD complexes (Ab1). The tabledisplays the shift in nanometers after second antibody (Ab2) binding tothe antigen in the presence of the first antibody (Ab1). Values arenormalized by the subtraction of the autologous antibody control.Representative of two experiments. FIGS. 6O, 6P, and 6Q showrepresentative 2D-class averages and 3D reconstructed volumes forSARS-CoV-S 2P trimers complexed with C002, C119, and C121 Fabs. 2D classaverages with observable Fab density are boxed. FIG. 6R shows overlay ofS-Fab complexes with fully-occupied C002 (blue), C121 (magenta) and C119(orange) Fabs. The SARS-CoV-2 S model from PDB 6VYB was fit into thedensity and the SARS-CoV mAb S230 (PDB 6NB6) is shown as a reference(green ribbon).

FIGS. 7A, 7B, 7C, 7D, 7E, 7F, 7G, 7H, 7I, 7J, 7K, and 7L (collectively“FIG. 7 ”) are a set of graphs showing clinical correlates. FIG. 7Ashows summary of the cohort's characteristics. FIG. 7B shows agedistribution (Y axis) for all males (n=83) and females (n=66) in thecohort; p=0.2074. FIG. 7C shows duration of symptoms in days (Y axis)for all males (n=83) and females (n=66) in the cohort; p=0.8704. FIG. 7Dshows time between symptom onset and plasma collection (Y axis) for allmales (n=83) and females (n=66) in the cohort; p=0.5514. FIG. 7E showssubjective symptom severity on a scale of 0-10 (Y axis) for all males(n=83) and females (n=66) in the cohort; p=0.1888. FIG. 7F shows agedistribution (Y axis) for all cases (n=111) and contacts (n=38) in thecohort; p=0.0305. FIG. 7G shows duration of symptoms in days (Y axis)for all cases (n=111) and contacts (n=38) in the cohort; p=0.1241. FIG.7H shows time between symptom onset and plasma collection in days (Yaxis) for all cases (n=111) and contacts (n=38) in the cohort; p=0.1589.FIG. 7I shows symptom severity (Y axis) for all cases (n=111) andcontacts (n=38) in the cohort; p=0.0550. FIG. 7J shows age distribution(Y axis) for all outpatient (n=138) and hospitalized (n=11)participants; p=0.0024. FIG. 7K shows duration of symptoms in days (Yaxis) for all outpatient (n=138) and hospitalized (n=11) participants inthe cohort; p=<0.0001. FIG. 7L shows time between symptom onset andplasma collection in days (Y axis) for all outpatient (n=138) andhospitalized (n=11) participants in the cohort; p=0.0001. Horizontalbars indicate median values. Statistical significance was determinedusing two-tailed Mann-Whitney U test.

FIGS. 8A, 8B, 8C, 8D, 8E, 8F, 8G, 8H, 8I, and 8J (collectively “FIG. 8”) are a set of graphs showing clinical correlates of plasma antibodytiters. FIG. 8A shows normalized AUC for IgG anti-RBD (Y axis) for allcases (n=111) and contacts (n=38) in the cohort; p=0.0107. FIG. 8B showsnormalized AUC for IgM anti-RBD (Y axis) for all cases (n=111) andcontacts (n=38) in the cohort; p=0.5371. FIG. 8C shows normalized AUCfor IgG anti-S (Y axis) for all cases (n=111) and contacts (n=38) in thecohort; p=0.0135. FIG. 8D shows normalized AUC for IgM anti-S(Y axis)for all cases (n=111) and contacts (n=38) in the cohort; p=0.7838. FIG.8E shows normalized AUC for IgM anti-RBD (Y axis) for all males (n=83)and females (n=66) in the cohort; p=0.9597. FIG. 8F shows normalized AUCfor IgG anti-S (Y axis) for all males (n=83) and females (n=66) in thecohort; p=0.0275. FIG. 8E shows normalized AUC for IgM anti-S (Y axis)for all males (n=83) and females (n=66) in the cohort; p=0.5363. FIG. 8Hshows normalized AUC for IgM anti-RBD (Y axis) for all outpatient (=138)and hospitalized (n=11) participants in the cohort; p=0.0059. FIG. 8Ishows normalized AUC for IgG anti-S (Y axis) for all outpatient (=138)and hospitalized (=11) participants in the cohort; p=0.0623. FIG. 8Jshows normalized AUC for IgM anti-S (Y axis) for all outpatient (=138)and hospitalized (=11) participants in the cohort; p=0.2976. Horizontalbars indicate median values. Statistical significance was determinedusing two-tailed Mann-Whitney U test.

FIGS. 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 9I, 9J, 9K, 9L, 9M, and 9N(collectively “FIG. 9 ”) are a set of graphs showing additional clinicalcorrelates of plasma antibody titers. FIG. 9A shows time between symptomonset and plasma collection in days (X axis) plotted against normalizedAUC for IgG anti-RBD (Y axis); r=−0.0261 p=0.7533. FIG. 9B shows timebetween symptom onset and plasma collection in days (X axis) plottedagainst normalized AUC for IgG anti-S(Y axis); r=−0.1495 p=0.0697. FIG.9C shows time between symptom onset and plasma collection in days (Xaxis) plotted against normalized AUC for IgM anti-S (Y axis); r=0.1496p=0.0695. FIG. 9D shows age (X axis) plotted against AUC for IgManti-RBD (Y axis); r=0.0172 p=0.8355. FIG. 9E shows age (X axis) plottedagainst normalized AUC for IgG anti-S (Y axis); r=0.1523 p=0.0638. FIG.9F shows age (X axis) plotted against normalized AUC for IgM anti-S (Yaxis); r=0.0565 p=0.4934. FIG. 9G shows duration of symptoms in days (Xaxis) plotted against normalized AUC for IgG anti-RBD (Y axis);r=0.1525, p=0.0633. FIG. 9H shows duration of symptoms in days (X axis)plotted against normalized AUC for IgM anti-RBD (Y axis); r=−0.3187,p=<0.0001. FIG. 9I shows duration of symptoms in days (X axis) plottedagainst normalized AUC for IgG anti-S (Y axis); r=0.0329, p=0.6904. FIG.9J shows duration of symptoms in days (X axis) plotted againstnormalized AUC for IgM anti-S (Y axis); r=0.0824, p=0.3177. FIG. 9Kshows severity of symptoms (X axis) plotted against normalized AUC forIgG anti-RBD (Y axis); r=0.2679 p=0.0010. FIG. 9L shows severity ofsymptoms (X axis) plotted against normalized AUC for IgM anti-RBD (Yaxis); r=−0.1943 p=0.0176. FIG. 9M shows severity of symptoms (X axis)plotted against normalized AUC for IgG anti-S (Y axis); r=0.1187p=0.1492. FIG. 9N shows severity of symptoms (X axis) plotted againstnormalized AUC for IgM anti-S (Y axis); r=0.1597 p=0.0517. Allcorrelations were analyzed by two-tailed Spearman's.

FIGS. 10A, 10B, and 10C (collectively “FIG. 10 ”) show a diagrammaticrepresentation of the SARS-CoV2-Strunc luciferase assay. FIG. 10A showsthat co-transfection of pNL4-3ΔEnv-nanoluc and pSARS-CoV-2 spike vectorsinto 293T cells (ATCC) leads to production of SARS-CoV-2Spike-pseudotyped HIV-1 particles (SARS-CoV-2 pseudovirus) carrying theNanoluc gene. FIG. 10B shows that SARS-CoV-2 pseudovirus was incubatedfor 1 h at 37° C. with plasma or monoclonal antibody dilutions. Thevirus-antibody mixture is used to infect ACE2-expressing 293T cells,which will express nanoluc Luciferase upon infection. FIG. 10C showsrelative luminescence units (RLU) reads from lysates of ACE2-expressing293T cells infected with increasing amounts of SARS-CoV-2 pseudovirus.Error bars represent standard deviation of triplicates, two experiments.

FIGS. 11A, 11B, 11C, 11D, 11E, and 11F (collectively “FIG. 11 ”) are aset of graphs showing clinical correlates of neutralization. FIG. 11Ashows normalized AUC for anti-RBD IgM (X axis) plotted against NT₅₀ (Yaxis); r=0.3119, p=0.0001. FIG. 11B shows normalized AUC for anti-S IgM(X axis) plotted against NT₅₀ (Y axis); r=0.3211, p=<0.0001. FIG. 11Cshows duration of symptoms in days (X axis) plotted against NT₅₀ (Yaxis); r=0.1997, p=0.0146. FIG. 11D shows time between symptom onset andplasma collection in days (X axis) plotted against NT₅₀ (Y axis);r=−0.1344, p=0.1033. FIG. 11E shows symptom severity (X axis) plottedagainst NT₅₀ (Y axis); r=0.2234, p=0.0062. FIG. 11F shows age (X axis)plotted against NT₅₀ (Y axis); r=0.3005, p=0.0002. All correlations wereanalyzed by two-tailed Spearman's. Dotted line (NT₅₀=5) represents lowerlimit of detection (LLOD) of pseudovirus neutralization assay. Sampleswith neutralizing titers below 1:50 were plotted at LLOD.

FIG. 12 shows the results of flow cytometry and gating strategy used forcell sorting. Gating was on singlets that were CD20⁺ andCD3⁻CD8⁻CD16⁻Ova⁻. Sorted cells were RBD-PE⁺ and RBD-AF647⁺.

FIG. 13 shows frequency distributions of human V genes. The two-tailed ttest with unequal variance was used to compare the frequencydistributions of human V genes of anti-SARS-CoV-2 antibodies from thisstudy to Sequence Read Archive SRP010970 (Rubelt, F. et al. PLoS One).

FIGS. 14A, 14B, and 14C (collectively “FIG. 14 ”) show the analysis ofantibody somatic hypermutation and CDR3 length. FIG. 14A shows that foreach individual, the number of somatic nucleotide mutations (Y axis) atthe IGVH and IGVL are shown on the left panel, and the amino acid lengthof the CDR3s (Y axis) are shown on the right panel. The horizontal barsindicate the mean. The number of antibody sequences (IGVH and IGVL)evaluated in each participant are n=118 (COV107), n=127 (COV21), n=79(COV47), n=54 (COV57), n=78 (COV72), n=78 (COV96). FIG. 14B is the sameas in FIG. 14A but for all antibodies combined (n=534 for both IGVH andIGVL). FIG. 14C shows distribution of the hydrophobicity GRAVY scores atthe IGH CDR3 in antibody sequences from this study compared to a publicdatabase (see Methods for statistical analysis in EXAMPLE 1). The boxlimits are at the lower and upper quartiles, the center line indicatesthe median, the whiskers are 1.5× interquartile range, and the dotsrepresent outliers.

FIGS. 15A, 15B, 15C, 15D, and 15E (collectively “FIG. 15 ”) show Bindingof the monoclonal antibodies to the RBD of SARS-CoV-2 andcross-reactivity to SARS-CoV. FIG. 15A shows EC₃₀ values for binding tothe RBD of SARS-CoV-2. Average of two or more experiments; n=89. FIGS.15B and 15C show binding curves and EC₃₀ values (average of twoexperiments) for binding to the RBD of SARS-CoV; n=20 and n=17(excluding isotype and CR3022), respectively. FIGS. 15D and 15E showSARS-CoV pseudovirus neutralization curves and IC₅₀ values. Shown inFIG. 15D are the standard deviations of duplicates for onerepresentative experiment and in FIG. 15E is the average of twoexperiments (n=10, excluding CR3022). Samples with IC₅₀s above 1 μg/mlwere plotted at 1 μg/ml.

FIG. 16 shows the results of the biolayer interferometry experiment thatdepicts binding of antibodies C144, C101, C002, C121, C009, C119. Graphsshow secondary antibody binding to preformed C121 IgG-RBD complexes. Thetable displays the shift in nanometers after second antibody (Ab2)binding to the antigen in the presence of the first antibody (Ab1).Values are normalized by the subtraction of the autologous antibodycontrol.

FIGS. 17A, 17B, and 17C (collectively “FIG. 17 ”) are a set of diagramsdepicting that coronavirus S proteins show localized regions ofconservation and variability. FIG. 17A is a schematic of SARS-CoV-2 Sprotein domain architecture. The 51 and S2 subunits are indicated, withscissors representing the locations of proteolytic cleavage sitesrequired for S priming prior to fusion. UH=upstream helix, FP=fusionpeptide, HR1=heptad repeat 1, CH=central helix, BH=β-hairpin, HR2=heptadrepeat 2, TM=transmembrane region, CT=cytoplasmic tail. FIG. 17B showsphylogenetic trees of selected coronaviruses based on protein sequencesof S proteins and RBD/S1B domains. FIG. 17C shows sequence conservationof 7 human coronaviruses plotted as a surface. The sequence alignmentwas generated using SARS-CoV-2 (GenBank MN985325.1), SARS-CoV(AAP13441.1), MERS-CoV (JX869059.2), HCoV-OC43 (AAT84362.1), HCoV-229E(AAK32191.1), HCoV-NL63 (AAS58177.1), and HCoV-HKU1 (QOZME7.1).Conservation was calculated by ConSurf Database (Landau et al., 2005)and displayed using a surface representation of the structure of theSARS-CoV-2 S protein (PDB code 6VXX).

FIGS. 18A, 18B, and 18C (collectively “FIG. 18 ”) are a set of diagramsshowing that plasma Fabs bind to SARS-CoV-2 S protein. FIG. 18A shows aschematic of polyclonal IgG and Fab purification from human plasma fornsEMPEM protocol. FIG. 18B shows an SEC profile of Fabs (left) andSDS-PAGE of purified IgGs and Fabs (right) from COV21, COV57, and COV107plasma samples. FIG. 18C shows SEC demonstration that plasma-derivedFabs from COV21 and COV57 shift the SARS-CoV-2 S protein trimer to ahigher apparent molecular weight. No shift was observed when Fabs fromCOV107 were analyzed by SEC with S protein. Fractions pooled andconcentrated for nsEMPEM are boxed. See also FIG. 24 .

FIGS. 19A, 19B, 19C, 19D, 19E, 19F, 19G, and 19H (collectively “FIG. 19”) show convalescent plasma IgG and Fab binding properties demonstratingrecognition of diverse coronaviruses and effects of avidity. Resultsfrom ELISAs assessing binding of IgGs and Fabs purified from plasmasfrom 10 COVID-19 individuals (X-axis) presented as area under the curve(AUC; shown as mean±S.D. of values derived from experiments conducted intriplicate). FIGS. 19A, 19B, 19C, 19D, 19E, and 19F show that bindingwas assessed against S and RBD proteins for SARS-CoV-2 (FIG. 19A),SARS-CoV (FIG. 19B), MERS-CoV (FIG. 19C), HCoV-NL63 (FIG. 19D),HCoV-OC43 (FIG. 19E), and HCoV-229E (FIG. 19F). Polyclonal IgGs or Fabswere evaluated at a top concentration of 50 μg/mL and 7 additional4-fold serial dilutions. Binding of the IgG and Fab from IOMA, anantibody against HIV-1 (Gristick et al., 2016), was used as a control ineach assay. FIG. 19G shows in vitro neutralization assays comparing thepotencies of purified plasma IgGs and purified plasma Fabs. COV21,COV57, and COV107 plasma Fabs and IgGs are highlighted in the indicatedcolors; curves for 10 other plasmas (listed in FIG. 19H) are gray. FIG.19H shows molar IC₅₀ values for purified plasma IgGs and Fabs for theindicated plasmas are listed with the molar ratio for IC₅₀ (Fab) to IC₅₀(IgG) shown in the right column. See also FIGS. 25 and 26 .

FIGS. 20A, 20B, and 20C (collectively “FIG. 20 ”) show the results ofthe EM study that reveals distinct predominant epitopes targeted byconvalescent plasma antibodies. FIG. 20A shows side and top views forrepresentative 3D reconstructions of four nsEMPEM datasets (S proteinalone, S+COV21 Fabs, S+COV57 Fabs, S+COV107 Fabs). Bound Fabs observedin reconstructions from COV21 and COV57 plasmas are highlighted withfalse coloring as orange and green, respectively. No Fabs were observedin the reconstruction of COV107 Fabs plus S protein. Refined 3D modelsfor SARS-CoV-2 S trimer-polyclonal Fab complexes from COV21 (panel B),and COV57 (panel C) were rigid-body fit with reference structures inChimera (Goddard et al., 2007; Pettersen et al., 2004), displayed ascartoons (S1^(A): blue, S1^(B): red, S2: gray). FIG. 20B shows that forCOV21, the volume was best-fitted with PDB 6VYB (SARS-CoV-2, one “up”S1^(B) conformation, inset). Overlay of PDB 6NB6 showed similarities inS1^(B) epitope targeting of COV21 Fab (orange) and the human SARS-CoVneutralizing antibody, S230 (magenta, cartoon). FIG. 20C shows thatCOV57 was fitted with PDB 6VXX (closed, prefusion conformation, inset).Fab density (green) was focused on the S1^(A) domain. See also FIG. 27 .

FIGS. 21A, 21B, 21C, 21D, 21E, and 21F (collectively “FIG. 21 ”) show acryo-EM structure of a monoclonal Fab-S protein complex that resemblesthe COV21 Fab(s)-S reconstruction. FIG. 21A shows reconstructed volumesfor mAb C105 bound to SARS-CoV-2 S trimers in state 1 (two “up” RBDs,two bound Fabs) and state 2 (three “up” RBDs, three bound Fabs). FIG.21B shows cartoon representation of VH-VL domains of C105 bound to anRBD (left panel) and CDR loops of C105 overlaid on surfacerepresentation of the RBD (shown as a gray surface) (right panel). FIG.21C shows RBD surface showing contacts by C105 VH-VL (contacts definedas an RBD residue within 7 Å of a VH or VL residue Ca atom). FIG. 21Dshows RBD surface fitted with volume representing the variable domainsof the COV21 Fab(s) nsEMPEM reconstruction. FIG. 21E shows CDR loops ofB38 mAb overlaid on surface representation of the RBD (from PDB code7BZ5). FIG. 21F shows RBD surface showing contacts by ACE2 (contactsdefined as an RBD residue within 7 Å of an ACE2 residue Ca atom) (fromPDB code 6VW1). See also FIGS. 29 and 30 .

FIGS. 22A, 22B, and 22C (collectively “FIG. 22 ”) show identified Smutations that are unlikely to affect epitopes revealed by nsEMPEM andsingle-particle cryo-EM. FIGS. 22A and 22B show the refined 3D model ofSARS-CoV-2 S trimer alone that was fitted with a reference structure(PDB 6VYB; gray cartoon) with locations of mutations observed incirculating SARS-CoV-2 isolates (Table 17) highlighted (red spheres).Residues affected by mutations that are disordered in the SARS-CoV-2 Sstructure (V483A) or in regions that are not included in the Sectodomain (signal sequence or cytoplasmic tail) are not shown.Densities corresponding to Fabs were separated, colored, and displayedon the same 3D volume. FIG. 22C shows C105-RBD interaction from thecryo-EM structure of the C105-S complex (FIG. 21 ), showing locations ofRBD mutations. V483 is ordered in this structure. See also Table 17.

FIGS. 23A, 23B, and 23C (collectively “FIG. 23 ”) show S proteinepitopes that offer different possibilities for avidity effects duringIgG and receptor binding. FIG. 23A, left panel, shows a model of twoadjacent S trimers separated by ˜15 nm, as seen on coronaviruses bycryo-electron tomography (Neuman et al., 2011), demonstrating that theorientation of COV21 Fab(s) on S could accommodate inter-spikecrosslinking by a single IgG. The Fc portion of the IgG (PDB code 1IGT)was modeled assuming flexibility between the Fabs and the Fc (Sandin etal., 2004) and with the hinge region indicated by a dotted line since itis disordered in crystal structures of intact IgGs (Harris et al., 1992;Harris et al., 1998; Saphire et al., 2001). FIG. 23A, right panel, showsan example of a model of two adjacent S trimers with bound Fab(s) in theorientation observed in the COV57 Fab(s)-S reconstruction demonstratingthat inter-spike crosslinking is unlikely due to the “downward”orientation of the Fab(s), which does not permit linking by an Fcregion, and predicted steric clashes between adjacent Fabs. Inter-spikecrosslinking is also not possible for other orientations of two adjacentCOV57 Fab(s)-S complexes (not shown). FIG. 23B show a model of S trimerswith two RBDs in an “up” position based on a cryo-EM structure ofSARS-CoV S trimer (Kirchdoerfer et al., 2018) (PDB code 6CRX)interacting with full-length ACE2 receptors from the cryo-EM structureof soluble SARS-CoV-2 RBDs bound to the dimeric membrane form of ACE2(Yan et al., 2020) (PDB code 6M17). Inter-spike crosslinking is possibleif ACE2 dimers cluster in the membrane. FIG. 23C shows a model ofintra-spike crosslinking between dimeric ACE2 and an S protein trimerwith two RBDs in an “up” position. The RBDs were rotated by ˜180 abouttheir long axes to allow binding of the ACE2 ectodomains. Rotation ofthe RBD is a possibility since its position is flexible with respect tothe remaining part of the S trimer (Walls et al., 2019). In this model,RBDs from a single S trimer could bind the ACE2 dimer in the sameconfiguration as seen in the B^(o)AT1-ACE2-SARS-CoV-2 RBD structure (PDBcode 6M17).

FIGS. 24A, 24B, 24C, 24D, 24E, 24F, 24G, 24H, 24I, 24J, 24K, and 24L(collectively “FIG. 24 ”) show SEC-MALS characterization of purifiedproteins (related to FIGS. 18 and 19 ). FIGS. 24A, 24B, 24C, 24G, 24H,24I show the SEC-MALS results of CoV S trimers, and FIGS. 24D, 24E, 24F,24J, 24K, and 24L show corresponding representative nsEM. Scale bar onmicrographs represents 50 nm.

FIGS. 25A, 25B, 25C, 25D, 25E, and 25F (collectively “FIG. 25 ”) showSARS-CoV-2, SARS-CoV, MERS-CoV and common cold coronavirus ELISA curves(related to FIG. 19 ). Anti-S IgG (left panel), Anti-S Fab (middle leftpanel), Anti-RBD/S1^(B) IgG (middle right panel), and Anti-RBD/S1^(B)Fab (right panel) ELISA binding data for (FIG. 25A) SARS-CoV-2, (FIG.25B) SARS-CoV, (FIG. 25C) MERS-CoV, (FIG. 25D) HCoV-NL63, (FIG. 25E)HCoV-OC43, and (FIG. 25F) HCoV-229E. COV21: red curves; COV57: greencurves; COV107: magenta curves. Curves for other plasmas are in gray.Each curve represents the average of three independent experiments.Binding of the IgG and Fab from IOMA, an antibody against HIV-1(Gristick et al., 2016), was used as a control in each assay.

FIGS. 26A, 26B, 26C, 26D, 26E, and 26F (collectively “FIG. 26 ”) showRBD adsorption experiments to assess degrees of cross-reactive RBDrecognition by plasma IgGs (related to FIG. 19 ). Purified IgGs fromCOVID-19 plasmas (indicated by numbers) and control plasmas (indicatedas “con”) were adsorbed with one of two resins: a SARS-CoV-2 RBD resin(IgGs remaining after RBD adsorption; light gray bars) and a 2G12 mAbcontrol resin (IgGs remaining after control adsorption; dark gray bars).IgGs remaining after adsorption were evaluated in ELISAs against theindicated RBD (or S1^(B)) domains. Binding of IgGs after adsorption toIOMA, an antibody against HIV-1 (Gristick et al., 2016), was used as acontrol in each assay. Results are presented as area under the curve(AUC; shown as mean of experiments conducted in duplicate).

FIGS. 27A, 27B, 27C, 27D, 27E, and 27F (collectively “FIG. 27 ”) showrepresentative 2D class-averages and 3D models from nsEMPEM of humanconvalescent plasma (related to FIG. 20 ). FIGS. 27A, 27C, and 27E showrepresentative reference-free 2D class-averages obtained from EM datacollections of (FIG. 27A) SARS-CoV-2 S trimers alone, (FIG. 27C)SARS-CoV-2 S complexed with COV21 polyclonal Fabs, and (FIG. 27E)SARS-CoV-2 S complexed with COV57 polyclonal Fabs. For COV21 and COV57,class-averages demonstrating extra density beyond the S trimer core arehighlighted (red boxes). For COV107, no extra density was observed inclass averages or a 3D construction. FIGS. 27B, 27D, and 27F showrefined 3D models after iterative rounds of 2D and 3D classification.Features corresponding to Fabs are denoted.

FIGS. 28A, 28B, and 28C (collectively “FIG. 28 ”) show data collectionand processing pipeline for the cryo-EM structure of the C105-SARS-CoV-2S complex (related to FIG. 21 ). FIG. 28A shows a representativemicrograph of C105-S complex in vitreous ice. Power spectrum ofmicrograph determined during CTF estimation showing Thon rings to 3.2 Åis shown in the inset. FIG. 28B shows reference-free 2D classificationof extracted particles. FIG. 28C shows workflow for classification andrefinement of selected particles. Briefly, after selection of good 2Dclass averages, an ab initio model was generated, which was thenhomogeneously refined before further 3D classification. To improvefeatures at the SARS-CoV-2 RBD-C105 Fab interface, particles from states1 and 2 were combined and used for nonuniform, focused refinement toyield a state 1-like reconstruction to an FSC=0.143 resolution of 3.4 Å.

FIGS. 29A, 29B, 29C, 29D, and 29E (collectively “FIG. 29 ”) show cryo-EMstructure validation (related to FIG. 21 ). FIG. 29A shows fourier shellcorrelation (FSC) plots calculated from half-maps of state 1 (black),state 1 after focused refinement (blue) and state 2 (red). Dotted linesfor FSC values of 0.5 and 0.143 are shown. FIGS. 29B and 29C show 2Dangular distribution plot for state 1 (FIG. 29B) and state 2 (FIG. 29C)reconstructions. FIG. 29D shows local resolution estimations for states1 and 2 and at the RBD-C105 Fab interface. FIG. 29E shows representativedensity from S trimer and Fab regions of the state 1 reconstructedvolume. Maps are contoured at 6σ.

FIGS. 30A and 30B (collectively “FIG. 30 ”) show CDRH3 lengthdistributions (related to FIG. 21 ). FIG. 30A shows the CDRH3 lengths(IMGT definition) (Lefranc et al., 2015) of anti-SARS-CoV-2 RBD-bindingmAbs (Robbiani et al., 2020) are shown in three groups: all 534 mAbs(dark gray), those derived from VH3-53 (red), and those derived fromVH3-66 (green). For comparison, the CDRH3 length distribution from thehuman antibody repertoire (Briney et al., 2019) is also shown(normalized to the same total count as the set of 534). The CDRH3 lengthof mAb B38 is indicated with an arrow. FIG. 30B shows the length ofCDRH3s in human antibodies versus predicted clashes with SARS-CoV-2 RBDif binding in the orientation observed for the mAbs B38 and C105. The VHdomains of 1364 human antibody structures with resolutions of ≤3.5 Ådownloaded from SAbDab (Dunbar et al., 2014) were aligned to the B38 VHdomain in complex with SARS-CoV-2 RBD (PDB code 7BZ5) (Wu et al.,2020c). In cases in which there was more than one Fab in thecrystallographic asymmetric unit, each VH was evaluated and enumeratedseparately. CDRH3 clashes were defined if any CDRH3 atom was within 2.0Å of an atom in the RBD, a stringent criterion devised to account fornot allowing CDR flexibility or different side chain rotamerconformations.

FIGS. 31A, 31B, 31C, and 31D are a set of diagrams showing SARS-CoV-2pseudovirus neutralization of C135 and C144′. FIGS. 31A and 31B show thetitration curves (FIG. 31A) and IC50 and IC90 values (FIG. 31B) of C135and C144′ from different lots (also see Table 14 for the sequences).FIG. 31C shows the titration curves of C135, C144′, and C135 combinedwith C144′ from the GMP lots, with the IC50 and IC90 values summarizedin FIG. 31D.

DETAILED DESCRIPTION OF THE INVENTION

SARS-CoV-2 represents a serious public health concern. Methods todiagnose and treat persons who are infected with SARS-CoV-2 provide theopportunity to either prevent or control further spread of infection bySARS-CoV-2. These methods are especially important due to the ability ofSARS-CoV-2 to infect persons through an airborne route.

This invention is based, at least in part, on unexpected broadlyneutralizing activities of the disclosed anti-SARS-CoV-2 antibodies orantigen-binding fragments thereof. These antibodies and antigen-bindingfragments constitute a novel therapeutic strategy in protection fromSARS-CoV-2 infections.

A. BROADLY NEUTRALIZING ANTI-SARS-COV-2 ANTIBODIES

a. Antibodies

The invention disclosed herein involves broadly neutralizinganti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. Theseantibodies refer to a class of neutralizing antibodies that neutralizemultiple SARS-CoV-2 virus strains. The antibodies are able to protect asubject prophylactically and therapeutically against a lethal challengewith a SARS-CoV-2 virus.

In one aspect, this disclosure provides an isolated anti-SARS-CoV-2antibody or antigen-binding fragment thereof that binds specifically toa SARS-CoV-2 antigen. In some embodiments, the SARS-CoV-2 antigencomprises a portion of a Spike (S) polypeptide, such as a S polypeptideof a human or an animal SARS-CoV-2. In some embodiments, the SARS-CoV-2antigen comprises the receptor-binding domain (RBD) of the Spolypeptide. In some embodiments, the RBD comprises amino acids 319-541of the S polypeptide. In some embodiments, the antibody orantigen-binding fragment thereof is capable of neutralizing a pluralityof SARS-CoV-2 strains.

In some embodiments, the antibody or antigen-binding fragment thereof iscapable of neutralizing a SARS-CoV-2 virus at an IC50 concentration ofless than 50 μg/ml.

The spike protein is important because it is present on the outside ofintact SARS-CoV-2. Thus, it presents a target that can be used toinhibit or eliminate an intact virus before the virus has an opportunityto infect a cell. A representative amino acid sequence is providedbelow:

(Accession ID: NC_045512.2; SEQ ID NO: 2927)MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

Listed below in TABLES 4-5 and 7-14 are amino acid sequences of theheavy chain (HC) variable regions and light chain (LC) variable regionsof exemplary antibodies.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises three heavy chain complementarity determining regions (HCDRs)(HCDR1, HCDR2, and HCDR3) of a heavy chain variable region having anamino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19,21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55,57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91,93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121,123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149,151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177,179, 181, 183, 185, 187, 2876, or 2900; and three light chain CDRs(LCDR1, LCDR2, and LCDR3) of a light chain variable region having theamino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20,22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56,58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92,94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122,124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150,152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178,180, 182, 184, 186, 188, 2888, or 2912.

HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising respective aminoacid sequences of (i) SEQ ID NOs: 2878, 2880, 2882, 2890, 2892, and2894; or (ii) SEQ ID NOs: 2902, 2904, 2906, 2914, 2916, and 2918.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises: (i) a heavy chain variable region having an amino acidsequence with at least 75% identity to SEQ ID NOs: 1, 3, 5, 7, 9, 11,13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47,49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83,85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115,117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143,145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171,173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; or (ii) a lightchain variable region having an amino acid sequence with at least 75%identity to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26,28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62,64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98,100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126,128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154,156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182,184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises: (i) a heavy chain variable region having an amino acidsequence with at least 75% identity to SEQ ID NOs: 1, 3, 5, 7, 9, 11,13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47,49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83,85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115,117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143,145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171,173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; and (ii) a lightchain variable region having an amino acid sequence with at least 75%identity to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26,28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62,64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98,100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126,128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154,156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182,184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises: (i) a heavy chain variable region having the amino acidsequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25,27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61,63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97,99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125,127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153,155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181,183, 185, 187, 2876, or 2900; or (ii) a light chain variable regionhaving the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14,16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86,88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116,118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144,146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172,174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises: (i) a heavy chain variable region having the amino acidsequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25,27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61,63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97,99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125,127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153,155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181,183, 185, 187, 2876, or 2900; and (ii) a light chain variable regionhaving the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14,16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86,88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116,118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144,146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172,174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises a heavy chain variable region and a light chain variableregion comprise the respective amino acid sequences of SEQ ID NOs: 1-2,3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22, 23-24,25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42, 43-44,45-46, 47-48, 49-50, 51-52, 53-54, 55-56, 57-58, 59-60, 61-62, 63-64,65-66, 67-68, 69-70, 71-72, 73-74, 75-76, 77-78, 79-80, 81-82, 83-84,85-86, 87-88, 89-90, 91-92, 93-94, 95-96, 97-98, 99-100, 101-102,103-104, 105-106, 107-108, 109-110, 111-112, 113-114, 115-116, 117-118,119-120, 121-122, 123-124, 125-126, 127-128, 129-130, 131-132, 133-134,135-136, 137-138, 139-140, 141-142, 143-144, 145-146, 147-148, 149-150,151-152, 153-154, 155-156, 157-158, 159-160, 161-162, 163-164, 165-166,167-168, 169-170, 171-172, 173-174, 175-176, 177-178, 179-180, 181-182,183-184, 185-186, 187-188, 2876 and 2888, or 2900 and 2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises a heavy chain and a light chain that comprise the respectiveamino acid sequences of SEQ ID NOs: 1-2; 13-14; 25-26; 49-50, 55-56,57-58, 65-66, 81-82, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and2912.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises a heavy chain/light chain sequence pair of SEQ ID NOs:2886/2898, 2887/2899, 2910/2921, or 2911/2922.

In some embodiments, the antibody or antigen-binding fragment thereofcomprises (a) a first target binding site that specifically binds to anepitope within the S polypeptide, and (b) a second target binding sitethat binds to a different epitope on the S polypeptide or on a differentmolecule. In some embodiments, the multivalent antibody is a bivalent orbispecific antibody.

In some embodiments, the antibody or the antigen-binding fragmentthereof further comprises a variant Fc constant region. In someembodiments, the antibody is a monoclonal antibody. In some embodiments,the antibody is a chimeric antibody, a humanized antibody, or ahumanized monoclonal antibody. In some embodiments, the antibody is asingle-chain antibody, Fab or Fab2 fragment.

In some embodiments, the antibody or the antigen-binding fragmentthereof further comprises a variant Fc constant region. The antibody canbe a monoclonal antibody. In some embodiments, the antibody can be achimeric antibody, a humanized antibody, or humanized monoclonalantibody. In some embodiments, the antibody can be a single-chainantibody, Fab or Fab2 fragment.

In some embodiments, the antibody or antigen-binding fragment thereofcan be detectably labeled or conjugated to a toxin, a therapeutic agent,a polymer (e.g., polyethylene glycol (PEG)), a receptor, an enzyme or areceptor ligand. For example, an antibody of the present invention maybe coupled to a toxin (e.g., a tetanus toxin). Such antibodies may beused to treat animals, including humans, that are infected with thevirus that is etiologically linked to SARS-CoV-2. The toxin-coupledantibody is thought to bind to a portion of a spike protein presented onan infected cell, and then kill the infected cell.

In another example, an antibody of the present invention may be coupledto a detectable tag. Such antibodies may be used within diagnosticassays to determine if an animal, such as a human, is infected withSARS-CoV-2. Examples of detectable tags include: fluorescent proteins(i.e., green fluorescent protein, red fluorescent protein, yellowfluorescent protein), fluorescent markers (i.e., fluoresceinisothiocyanate, rhodamine, texas red), radiolabels (i.e., 3H, 32P,125I), enzymes (i.e., β-galactosidase, horseradish peroxidase,β-glucuronidase, alkaline phosphatase), or an affinity tag (i.e.,avidin, biotin, streptavidin). Methods to couple antibodies to adetectable tag are known in the art. Harlow et al., Antibodies: ALaboratory Manual, page 319 (Cold Spring Harbor Pub. 1988).

b. Fragment

In some embodiments, an antibody provided herein is an antibodyfragment. Antibody fragments include, but are not limited to, Fab, Fab′,Fab′-SH, F(ab′)2, Fv, and single-chain Fv (scFv) fragments, and otherfragments described below, e.g., diabodies, triabodies tetrabodies, andsingle-domain antibodies. For a review of certain antibody fragments,see Hudson et al., Nat. Med. 9:129-134 (2003). For a review of scFvfragments, see, e.g., Pluckthun, in The Pharmacology of MonoclonalAntibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, NewYork), pp. 269-315 (1994); see also WO 93/16185; and U.S. Pat. Nos.5,571,894 and 5,587,458. For discussion of Fab and F(ab′)2 fragmentscomprising salvage receptor binding epitope residues and havingincreased in vivo half-life, see U.S. Pat. No. 5,869,046.

Diabodies are antibody fragments with two antigen-binding sites that maybe bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161;Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc.Natl. Acad. Sci. USA 90: 6444-6448 (1993). Triabodies and tetrabodiesare also described in Hudson et al., Nat. Med. 9:129-134 (2003).

Single-domain antibodies are antibody fragments comprising all or aportion of the heavy chain variable domain or all or a portion of thelight chain variable domain of an antibody. In some embodiments, asingle-domain antibody is a human single-domain antibody (DOMANTIS,Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516).

Antibody fragments can be made by various techniques, including but notlimited to proteolytic digestion of an intact antibody as well asproduction by recombinant host cells (e.g., E. coli or phage), asdescribed herein.

c. Chimeric and Humanized Antibodies

In some embodiments, an antibody provided herein is a chimeric antibody.Certain chimeric antibodies are described, e.g., in U.S. Pat. No.4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855(1984)). In one example, a chimeric antibody comprises a non-humanvariable region (e.g., a variable region derived from a mouse, rat,hamster, rabbit, or non-human primate, such as a monkey) and a humanconstant region. In a further example, a chimeric antibody is a “classswitched” antibody in which the class or subclass has been changed fromthat of the parent antibody. Chimeric antibodies include antigen-bindingfragments thereof.

In some embodiments, a chimeric antibody is a humanized antibody.Typically, a non-human antibody is humanized to reduce immunogenicity tohumans, while retaining the specificity and affinity of the parentalnon-human antibody. Generally, a humanized antibody comprises one ormore variable domains in which HVRs, e.g., CDRs, (or portions thereof)are derived from a non-human antibody, and FRs (or portions thereof) arederived from human antibody sequences. A humanized antibody optionallywill also comprise at least a portion of a human constant region. Insome embodiments, some FR residues in a humanized antibody aresubstituted with corresponding residues from a non-human antibody (e.g.,the antibody from which the HVR residues are derived), e.g., to restoreor improve antibody specificity or affinity.

Humanized antibodies and methods of making them are reviewed, e.g., inAlmagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and arefurther described, e.g., in Riechmann et al., Nature 332:323-329 (1988);Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S.Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri etal., Methods 36:25-34 (2005) (describing specificity determining region(SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing“resurfacing”); Dall'Acqua et al., Methods 36:43-60 (2005) (describing“FR shuffling”); and Osbourn et al., Methods 36:61-68 (2005) and Klimkaet al., Br. J. Cancer, 83:252-260 (2000) (describing the “guidedselection” approach to FR shuffling).

Human framework regions that may be used for humanization include butare not limited to: framework regions selected using the “best-fit”method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); frameworkregions derived from the consensus sequence of human antibodies of aparticular subgroup of light or heavy chain variable regions (see, e.g.,Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta etal. J. Immunol., 151:2623 (1993)); human mature (somatically mutated)framework regions or human germline framework regions (see, e.g.,Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and frameworkregions derived from screening FR libraries (see, e.g., Baca et al., J.Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem.271:22611-22618 (1996)).

d. Human Antibodies

In some embodiments, an antibody provided herein is a human antibody.Human antibodies can be produced using various techniques known in theart or using techniques described herein. Human antibodies are describedgenerally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).

Human antibodies may be prepared by administering an immunogen to atransgenic animal that has been modified to produce intact humanantibodies or intact antibodies with human variable regions in responseto antigenic challenge. Such animals typically contain all or a portionof the human immunoglobulin loci, which replace the endogenousimmunoglobulin loci, or which are present extrachromosomally orintegrated randomly into the animal's chromosomes. In such transgenicmice, the endogenous immunoglobulin loci have generally beeninactivated. For review of methods for obtaining human antibodies fromtransgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). Seealso, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 describing XENOMOUSEtechnology; U.S. Pat. No. 5,770,429 describing HUMAB technology; U.S.Pat. No. 7,041,870 describing K-M MOUSE technology, and U.S. PatentApplication Publication No. US 2007/0061900, describing VELOCIMOUSEtechnology). Human variable regions from intact antibodies generated bysuch animals may be further modified, e.g., by combining with adifferent human constant region.

Human antibodies can also be made by hybridoma-based methods. Humanmyeloma and mouse-human heteromyeloma cell lines for the production ofhuman monoclonal antibodies have been described. (See, e.g., Kozbor J.Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal AntibodyProduction Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc.,New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991).) Humanantibodies generated via human B-cell hybridoma technology are alsodescribed in Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562(2006). Additional methods include those described, for example, in U.S.Pat. No. 7,189,826 (describing production of monoclonal human IgMantibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue,26(4):265-268 (2006) (describing human-human hybridomas). Humanhybridoma technology (Trioma technology) is also described in Vollmersand Brandlein, Histology and Histopathology, 20(3):927-937 (2005) andVollmers and Brandlein, Methods and Findings in Experimental andClinical Pharmacology, 27(3):185-91 (2005).

Human antibodies may also be generated by isolating Fv clone variabledomain sequences selected from human-derived phage display libraries.Such variable domain sequences may then be combined with a desired humanconstant domain. Techniques for selecting human antibodies from antibodylibraries are described below.

Antibodies of the invention may be isolated by screening combinatoriallibraries for antibodies with the desired activity or activities. Forexample, a variety of methods are known in the art for generating phagedisplay libraries and screening such libraries for antibodies possessingthe desired binding characteristics. Such methods are reviewed, e.g., inHoogenboom et al., in Methods in Molecular Biology 178:1-37 (O'Brien etal., ed., Human Press, Totowa, N.J., 2001) and further described, e.g.,in the McCafferty et al., Nature 348:552-554; Clackson et al., Nature352: 624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992);Marks and Bradbury, in Methods in Molecular Biology 248:161-175 (Lo,ed., Human Press, Totowa, N.J., 2003); Sidhu et al., J. Mol. Biol.338(2): 299-310 (2004); Lee et al., J. Mol. Biol. 340(5): 1073-1093(2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472(2004); and Lee et al., J. Immunol. Methods 284(1-2): 119-132 (2004).

In certain phage display methods, repertoires of VH and VL genes areseparately cloned by polymerase chain reaction (PCR) and recombinedrandomly in phage libraries, which can then be screened forantigen-binding phage as described in Winter et al., Ann. Rev. Immunol.,12: 433-455 (1994). Phage typically display antibody fragments, eitheras scFv fragments or as Fab fragments. Libraries from immunized sourcesprovide high-affinity antibodies to the immunogen without therequirement of constructing hybridomas. Alternatively, the naiverepertoire can be cloned (e.g., from human) to provide a single sourceof antibodies to a wide range of non-self and also self-antigens withoutany immunization as described by Griffiths et al., EMBO J, 12: 725-734(1993). Finally, naive libraries can also be made synthetically bycloning unrearranged V-gene segments from stem cells and using PCRprimers containing random sequence to encode the highly variable CDR3regions and to accomplish rearrangement in vitro, as described byHoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992). Patentpublications describing human antibody phage libraries include, forexample, U.S. Pat. No. 5,750,373, and US Patent Publication Nos.2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598,2007/0237764, 2007/0292936, and 2009/0002360. Antibodies or antibodyfragments isolated from human antibody libraries are considered humanantibodies or human antibody fragments herein.

e. Variants

In some embodiments, amino acid sequence variants of the antibodiesprovided herein are contemplated. For example, it may be desirable toimprove the binding affinity and/or other biological properties of theantibody. Amino acid sequence variants of an antibody may be prepared byintroducing appropriate modifications into the nucleotide sequenceencoding the antibody, or by peptide synthesis. Such modificationsinclude, for example, deletions from, and/or insertions into and/orsubstitutions of residues within the amino acid sequences of theantibody. Any combination of deletion, insertion, and substitution canbe made to arrive at the final construct, provided that the finalconstruct possesses the desired characteristics, e.g., antigen binding.

Substitution, Insertion, and Deletion Variants

In some embodiments, antibody variants having one or more amino acidsubstitutions are provided. Sites of interest for substitutionalmutagenesis include the HVRs and FRs. Conservative substitutions aredefined herein. Amino acid substitutions may be introduced into anantibody of interest and the products screened for a desired activity,e.g., retained/improved antigen binding, decreased immunogenicity, orimproved antibody-dependent cell-mediated cytotoxicity (ADCC) andcomplement-dependent cytotoxicity (CDC).

Accordingly, an antibody of the invention can comprise one or moreconservative modifications of the CDRs, heavy chain variable region, orlight variable regions described herein. A conservative modification orfunctional equivalent of a peptide, polypeptide, or protein disclosed inthis invention refers to a polypeptide derivative of the peptide,polypeptide, or protein, e.g., a protein having one or more pointmutations, insertions, deletions, truncations, a fusion protein, or acombination thereof. It substantially retains the activity to of theparent peptide, polypeptide, or protein (such as those disclosed in thisinvention). In general, a conservative modification or functionalequivalent is at least 60% (e.g., any number between 60% and 100%,inclusive, e.g., 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, and99%) identical to a parent. Accordingly, within the scope of thisinvention are heavy chain variable region or light variable regionshaving one or more point mutations, insertions, deletions, truncations,a fusion protein, or a combination thereof, as well as antibodies havingthe variant regions.

As used herein, the percent homology between two amino acid sequences isequivalent to the percent identity between the two sequences. Thepercent identity between the two sequences is a function of the numberof identical positions shared by the sequences (i.e., % homology=# ofidentical positions/total # of positions×100), taking into account thenumber of gaps, and the length of each gap, which need to be introducedfor optimal alignment of the two sequences. The comparison of sequencesand determination of percent identity between two sequences can beaccomplished using a mathematical algorithm, as described in thenon-limiting examples below.

The percent identity between two amino acid sequences can be determinedusing the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci.,4:11-17 (1988)) which has been incorporated into the ALIGN program(version 2.0), using a PAM120 weight residue table, a gap length penaltyof 12 and a gap penalty of 4. In addition, the percent identity betweentwo amino acid sequences can be determined using the Needleman andWunsch (J. Mol. Biol. 48:444-453 (1970)) algorithm which has beenincorporated into the GAP program in the GCG software package (availableat www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix,and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1,2, 3, 4, 5, or 6.

Additionally or alternatively, the protein sequences of the presentinvention can further be used as a “query sequence” to perform a searchagainst public databases to, for example, identify related sequences.Such searches can be performed using the XBLAST program (version 2.0) ofAltschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST protein searchescan be performed with the XBLAST program, score=50, wordlength=3 toobtain amino acid sequences homologous to the antibody molecules of theinvention. To obtain gapped alignments for comparison purposes, GappedBLAST can be utilized as described in Altschul et al., (1997) NucleicAcids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLASTprograms, the default parameters of the respective programs (e.g.,XBLAST and NBLAST) can be used. (See www.ncbi.nlm.nih.gov).

As used herein, the term “conservative modifications” refers to aminoacid modifications that do not significantly affect or alter the bindingcharacteristics of the antibody containing the amino acid sequence. Suchconservative modifications include amino acid substitutions, additionsand deletions. Modifications can be introduced into an antibody of theinvention by standard techniques known in the art, such as site-directedmutagenesis and PCR-mediated mutagenesis. Conservative amino acidsubstitutions are ones in which the amino acid residue is replaced withan amino acid residue having a similar side chain. Families of aminoacid residues having similar side chains have been defined in the art.These families include: (i) amino acids with basic side chains (e.g.,lysine, arginine, histidine), (ii) acidic side chains (e.g., asparticacid, glutamic acid), (iii) uncharged polar side chains (e.g., glycine,asparagine, glutamine, serine, threonine, tyrosine, cysteine,tryptophan), (iv) nonpolar side chains (e.g., alanine, valine, leucine,isoleucine, proline, phenylalanine, methionine), (v) beta-branched sidechains (e.g., threonine, valine, isoleucine), and (vi) aromatic sidechains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

Non-conservative substitutions will entail exchanging a member of one ofthese classes for another class.

An exemplary substitutional variant is an affinity matured antibody,which may be conveniently generated, e.g., using phage display-basedaffinity maturation techniques such as those described in, e.g.,Hoogenboom et al., in Methods in Molecular Biology 178:1-37 (O'Brien etal., ed., Human Press, Totowa, N.J., (2001). Amino acid sequenceinsertions include amino- and/or carboxyl-terminal fusions ranging inlength from one residue to polypeptides containing a hundred or moreresidues, as well as intrasequence insertions of single or multipleamino acid residues. Examples of terminal insertions include an antibodywith an N-terminal methionyl residue. Other insertional variants of theantibody molecule include the fusion to the N- or C-terminus of theantibody to an enzyme (e.g., for ADEPT) or a polypeptide which increasesthe serum half-life of the antibody.

Glycosylation Variants

In some embodiments, an antibody provided herein is altered to increaseor decrease the extent to which the antibody is glycosylated. Additionor deletion of glycosylation sites to an antibody may be convenientlyaccomplished by altering the amino acid sequence such that one or moreglycosylation sites are created or removed.

For example, an aglycoslated antibody can be made (i.e., the antibodylacks glycosylation). Glycosylation can be altered to, for example,increase the affinity of the antibody for antigen. Such carbohydratemodifications can be accomplished by, for example, altering one or moresites of glycosylation within the antibody sequence. For example, one ormore amino acid substitutions can be made that result in elimination ofone or more variable region framework glycosylation sites to therebyeliminate glycosylation at that site. Such aglycosylation may increasethe affinity of the antibody for antigen. Such an approach is describedin further detail in U.S. Pat. Nos. 5,714,350 and 6,350,861 by Co et al.

Glycosylation of the constant region on N297 may be prevented bymutating the N297 residue to another residue, e.g., N297A, and/or bymutating an adjacent amino acid, e.g., 298 to thereby reduceglycosylation on N297.

Additionally or alternatively, an antibody can be made that has analtered type of glycosylation, such as a hypofucosylated antibody havingreduced amounts of fucosyl residues or an antibody having increasedbisecting GlcNac structures. Such altered glycosylation patterns havebeen demonstrated to increase the ADCC ability of antibodies. Suchcarbohydrate modifications can be accomplished by, for example,expressing the antibody in a host cell with altered glycosylationmachinery. Cells with altered glycosylation machinery have beendescribed in the art and can be used as host cells in which to expressrecombinant antibodies described herein to thereby produce an antibodywith altered glycosylation. For example, EP 1,176,195 by Hanai et al.describes a cell line with a functionally disrupted FUT8 gene, whichencodes a fucosyltransferase, such that antibodies expressed in such acell line exhibit hypofucosylation. PCT Publication WO 03/035835 byPresta describes a variant Chinese Hamster Ovary cell line, Led 3 cells,with reduced ability to attach fucose to Asn(297)-linked carbohydrates,also resulting in hypofucosylation of antibodies expressed in that hostcell (see also Shields, R. L. et al. (2002) J. Biol. Chem.277:26733-26740). PCT Publication WO 99/54342 by Umana et al. describescell lines engineered to express glycoprotein-modifyingglycosyltransferases (e.g., beta(1,4)-N-acetylglucosaminyltransferaseIII (GnTIII)) such that antibodies expressed in the engineered celllines exhibit increased bisecting GlcNac structures which result inincreased ADCC activity of the antibodies (see also Umana et al. (1999)Nat. Biotech. 17: 176-180).

Fc Region Variants

The variable regions of the antibody described herein can be linked(e.g., covalently linked or fused) to an Fc, e.g., an IgG1, IgG2, IgG3or IgG4 Fc, which may be of any allotype or isoallotype, e.g., for IgG1:Glm, Glm1(a), Glm2(x), Glm3(f), Glm17(z); for IgG2: G2m, G2m23(n); forIgG3: G3m, G3m21(g1), G3m28(g5), G3m11(b0), G3m5(b1), G3m13(b3),G3m14(b4), G3m10(b5), G3m15(s), G3m16(t), G3m6(c3), G3m24(c5), G3m26(u),G3m27(v); and for K: Km, Km1, Km2, Km3 (see, e.g., Jefferies et al.(2009) mAbs 1: 1). In some embodiments, the antibodies variable regionsdescribed herein are linked to an Fc that binds to one or moreactivating Fc receptors (FcγI, FcγIIa or FcγIIIa), and thereby stimulateADCC and may cause T cell depletion. In some embodiments, the antibodyvariable regions described herein are linked to an Fc that causesdepletion.

In some embodiments, the antibody variable regions described herein maybe linked to an Fc comprising one or more modifications, typically toalter one or more functional properties of the antibody, such as serumhalf-life, complement fixation, Fc receptor binding, and/orantigen-dependent cellular cytotoxicity. Furthermore, an antibodydescribed herein may be chemically modified (e.g., one or more chemicalmoieties can be attached to the antibody) or be modified to alter itsglycosylation, to alter one or more functional properties of theantibody. The numbering of residues in the Fc region is that of the EUindex of Kabat.

The Fc region encompasses domains derived from the constant region of animmunoglobulin, preferably a human immunoglobulin, including a fragment,analog, variant, mutant or derivative of the constant region. Suitableimmunoglobulins include IgG1, IgG2, IgG3, IgG4, and other classes suchas IgA, IgD, IgE and IgM, The constant region of an immunoglobulin isdefined as a naturally-occurring or synthetically-produced polypeptidehomologous to the immunoglobulin C-terminal region, and can include aCH1 domain, a hinge, a CH2 domain, a CH3 domain, or a CH4 domain,separately or in combination. In some embodiments, an antibody of thisinvention has an Fc region other than that of a wild type IgA1. Theantibody can have an Fc region from that of IgG (e.g., IgG1, IgG2, IgG3,and IgG4) or other classes such as IgA2, IgD, IgE, and IgM. The Fc canbe a mutant form of IgA1.

The constant region of an immunoglobulin is responsible for manyimportant antibody functions, including Fc receptor (FcR) binding andcomplement fixation. There are five major classes of heavy chainconstant region, classified as IgA, IgG, IgD, IgE, IgM, each withcharacteristic effector functions designated by isotype. For example,IgG is separated into four subclasses known as IgG1, IgG2, IgG3, andIgG4.

Ig molecules interact with multiple classes of cellular receptors. Forexample, IgG molecules interact with three classes of Fcγ receptors(FcγR) specific for the IgG class of antibody, namely FcγRI, FcγRII, andFcγRIIL. The important sequences for the binding of IgG to the FcγRreceptors have been reported to be located in the CH2 and CH3 domains.The serum half-life of an antibody is influenced by the ability of thatantibody to bind to an FcR.

In some embodiments, the Fc region is a variant Fc region, e.g., an Fcsequence that has been modified (e.g., by amino acid substitution,deletion and/or insertion) relative to a parent Fc sequence (e.g., anunmodified Fc polypeptide that is subsequently modified to generate avariant), to provide desirable structural features and/or biologicalactivity. For example, one may make modifications in the Fc region inorder to generate an Fc variant that (a) has increased or decreasedADCC, (b) increased or decreased CDC, (c) has increased or decreasedaffinity for Clq and/or (d) has increased or decreased affinity for anFc receptor relative to the parent Fc. Such Fc region variants willgenerally comprise at least one amino acid modification in the Fcregion. Combining amino acid modifications is thought to be particularlydesirable. For example, the variant Fc region may include two, three,four, five, etc. substitutions therein, e.g., of the specific Fc regionpositions identified herein.

A variant Fc region may also comprise a sequence alteration whereinamino acids involved in disulfide bond formation are removed or replacedwith other amino acids. Such removal may avoid reaction with othercysteine-containing proteins present in the host cell used to producethe antibodies described herein. Even when cysteine residues areremoved, single chain Fc domains can still form a dimeric Fc domain thatis held together non-covalently. In other embodiments, the Fc region maybe modified to make it more compatible with a selected host cell. Forexample, one may remove the PA sequence near the N-terminus of a typicalnative Fc region, which may be recognized by a digestive enzyme in E.coli such as proline iminopeptidase. In other embodiments, one or moreglycosylation sites within the Fc domain may be removed. Residues thatare typically glycosylated (e.g., asparagine) may confer cytolyticresponse. Such residues may be deleted or substituted withunglycosylated residues (e.g., alanine). In other embodiments, sitesinvolved in interaction with complement, such as the Clq binding site,may be removed from the Fc region. For example, one may delete orsubstitute the EKK sequence of human IgG1. In some embodiments, sitesthat affect binding to Fc receptors may be removed, preferably sitesother than salvage receptor binding sites. In other embodiments, an Fcregion may be modified to remove an ADCC site. ADCC sites are known inthe art; see, for example, Molec. Immunol. 29 (5): 633-9 (1992) withregard to ADCC sites in IgG1. Specific examples of variant Fc domainsare disclosed, for example, in WO 97/34631 and WO 96/32478.

In one embodiment, the hinge region of Fc is modified such that thenumber of cysteine residues in the hinge region is altered, e.g.,increased or decreased. This approach is described further in U.S. Pat.No. 5,677,425 by Bodmer et al. The number of cysteine residues in thehinge region of Fc is altered to, for example, facilitate assembly ofthe light and heavy chains or to increase or decrease the stability ofthe antibody. In one embodiment, the Fc hinge region of an antibody ismutated to decrease the biological half-life of the antibody. Morespecifically, one or more amino acid mutations are introduced into theCH2-CH3 domain interface region of the Fc-hinge fragment such that theantibody has impaired Staphylococcal protein A (SpA) binding relative tonative Fc-hinge domain SpA binding. This approach is described infurther detail in U.S. Pat. No. 6,165,745 by Ward et al.

In yet other embodiments, the Fc region is altered by replacing at leastone amino acid residue with a different amino acid residue to alter theeffector function(s) of the antibody. For example, one or more aminoacids selected from amino acid residues 234, 235, 236, 237, 297, 318,320 and 322 can be replaced with a different amino acid residue suchthat the antibody has an altered affinity for an effector ligand butretains the antigen-binding ability of the parent antibody. The effectorligand to which affinity is altered can be, for example, an Fc receptoror the CI component of complement. This approach is described in furtherdetail in U.S. Pat. Nos. 5,624,821 and 5,648,260, both by Winter et al.

In another example, one or more amino acids selected from amino acidresidues 329, 331 and 322 can be replaced with a different amino acidresidue such that the antibody has altered Clq binding and/or reduced orabolished CDC. This approach is described in further detail in U.S. Pat.No. 6,194,551 by Idusogie et al.

In another example, one or more amino acid residues within amino acidpositions 231 and 239 are altered to thereby alter the ability of theantibody to fix complement. This approach is described further in PCTPublication WO 94/29351 by Bodmer et al.

In yet another example, the Fc region may be modified to increase ADCCand/or to increase the affinity for an Fcγ receptor by modifying one ormore amino acids at the following positions: 234, 235, 236, 238, 239,240, 241, 243, 244, 245, 247, 248, 249, 252, 254, 255, 256, 258, 262,263, 264, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286,289, 290, 292, 293, 294, 295, 296, 298, 299, 301, 303, 305, 307, 309,312, 313, 315, 320, 322, 324, 325, 326, 327, 329, 330, 331, 332, 333,334, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414,416, 419, 430, 433, 434, 435, 436, 437, 438 or 439. Exemplarysubstitutions include 236A, 239D, 239E, 268D, 267E, 268E, 268F, 324T,332D, and 332E. Exemplary variants include 239D/332E, 236A/332E,236A/239D/332E, 268F/324T, 267E/268F, 267E/324T, and 267E/268F7324T.Other modifications for enhancing FcγR and complement interactionsinclude but are not limited to substitutions 298A, 333A, 334A, 326A,2471, 339D, 339Q, 280H, 290S, 298D, 298V, 243L, 292P, 300L, 396L, 3051,and 396L. These and other modifications are reviewed in Strohl, 2009,Current Opinion in Biotechnology 20:685-691.

Fc modifications that increase binding to an Fcγ receptor include aminoacid modifications at any one or more of amino acid positions 238, 239,248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 279,280, 283, 285, 298, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303,305, 307, 312, 315, 324, 327, 329, 330, 335, 337, 3338, 340, 360, 373,376, 379, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438 or439 of the Fc region, wherein the numbering of the residues in the Fcregion is that of the EU index as in abat (WO00/42072).

Other Fc modifications that can be made to Fcs are those for reducing orablating binding to FcγR and/or complement proteins, thereby reducing orablating Fc-mediated effector functions such as ADCC, antibody-dependentcellular phagocytosis (ADCP), and CDC. Exemplary modifications includebut are not limited substitutions, insertions, and deletions atpositions 234, 235, 236, 237, 267, 269, 325, and 328, wherein numberingis according to the EU index. Exemplary substitutions include but arenot limited to 234G, 235G, 236R, 237K, 267R, 269R, 325L, and 328R,wherein numbering is according to the EU index. An Fc variant maycomprise 236R/328R. Other modifications for reducing FcγR and complementinteractions include substitutions 297A, 234A, 235A, 237A, 318A, 228P,236E, 268Q, 309L, 330S, 331S, 220S, 226S, 229S, 238S, 233P, and 234V, aswell as removal of the glycosylation at position 297 by mutational orenzymatic means or by production in organisms such as bacteria that donot glycosylate proteins. These and other modifications are reviewed inStrohl, 2009, Current Opinion in Biotechnology 20:685-691.

Optionally, the Fc region may comprise a non-naturally occurring aminoacid residue at additional and/or alternative positions known to oneskilled in the art (see, e.g., U.S. Pat. Nos. 5,624,821; 6,277,375;6,737,056; 6,194,551; 7,317,091; 8,101,720; WO00/42072; WO01/58957;WO02/06919; WO04/016750; WO04/029207; WO04/035752; WO04/074455;WO04/099249; WO04/063351; WO05/070963; WO05/040217, WO05/092925 andWO06/020114). Fc variants that enhance affinity for an inhibitoryreceptor FcγRIIb may also be used. Such variants may provide an Fcfusion protein with immune-modulatory activities related to FcγRIIbcells, including, for example, B cells and monocytes. In one embodiment,the Fc variants provide selectively enhanced affinity to FcγRIIbrelative to one or more activating receptors. Modifications for alteringbinding to FcγRIIb include one or more modifications at a positionselected from the group consisting of 234, 235, 236, 237, 239, 266, 267,268, 325, 326, 327, 328, and 332, according to the EU index. Exemplarysubstitutions for enhancing FcγRIIb affinity include but are not limitedto 234D, 234E, 234F, 234W, 235D, 235F, 235R, 235Y, 236D, 236N, 237D,237N, 239D, 239E, 266M, 267D, 267E, 268D, 268E, 327D, 327E, 328F, 328W,328Y, and 332E. Exemplary substitutions include 235Y, 236D, 239D, 266M,267E, 268D, 268E, 328F, 328W, and 328Y. Other Fc variants for enhancingbinding to FcγRllb include 235Y/267E, 236D/267E, 239D/268D, 239D/267E,267E/268D, 267E/268E, and 267E/328F.

The affinities and binding properties of an Fc region for its ligand maybe determined by a variety of in vitro assay methods (biochemical orimmunological based assays) known in the art including but not limitedto, equilibrium methods (e.g., ELISA, or radioimmunoassay), or kinetics(e.g., BIACORE analysis), and other methods such as indirect bindingassays, competitive inhibition assays, fluorescence resonance energytransfer (FRET), gel electrophoresis and chromatography (e.g., gelfiltration). These and other methods may utilize a label on one or moreof the components being examined and/or employ a variety of detectionmethods including but not limited to chromogenic, fluorescent,luminescent, or isotopic labels. A detailed description of bindingaffinities and kinetics can be found in Paul, W. E., ed., FundamentalImmunology, 4th Ed., Lippincott-Raven, Philadelphia (1999), whichfocuses on antibody-immunogen interactions.

In some embodiments, the antibody is modified to increase its biologicalhalf-life. Various approaches are possible. For example, this may bedone by increasing the binding affinity of the Fc region for FcRn. Forexample, one or more of the following residues can be mutated: 252, 254,256, 433, 435, 436, as described in U.S. Pat. No. 6,277,375. Specificexemplary substitutions include one or more of the following: T252L,T254S, and/or T256F. Alternatively, to increase the biologicalhalf-life, the antibody can be altered within the CH1 or CL region tocontain a salvage receptor binding epitope taken from two loops of a CH2domain of an Fc region of an IgG, as described in U.S. Pat. Nos.5,869,046 and 6,121,022 by Presta et al. Other exemplary variants thatincrease binding to FcRn and/or improve pharmacokinetic propertiesinclude substitutions at positions 259, 308, 428, and 434, including forexample 2591, 308F, 428L, 428M, 434S, 434H, 434F, 434Y, and 434M. Othervariants that increase Fc binding to FcRn include: 250E, 250Q, 428L,428F, 250Q/428L (Hinton et al, 2004, J. Biol. Chem. 279(8): 6213-6216,Hinton et al. 2006 Journal of Immunology 176:346-356), 256A, 272A, 286A,305A, 307A, 307Q, 311A, 312A, 376A, 378Q, 380A, 382A, 434A (Shields etal, Journal of Biological Chemistry, 2001, 276(9):6591-6604), 252F,252T, 252Y, 252W, 254T, 256S, 256R, 256Q, 256E, 256D, 256T, 309P, 311S,433R, 433S, 4331, 433P, 433Q, 434H, 434F, 434Y, 252Y/254T/256E,433K/434F/436H, 308T/309P/311S (Dall Acqua et al. Journal of Immunology,2002, 169:5171-5180, Dall'Acqua et al., 2006, Journal of BiologicalChemistry 281:23514-23524). Other modifications for modulating FcRnbinding are described in Yeung et al., 2010, J Immunol, 182:7663-7671.In some embodiments, hybrid IgG isotypes with particular biologicalcharacteristics may be used. For example, an IgG1/IgG3 hybrid variantmay be constructed by substituting IgG 1 positions in the CH2 and/or CH3region with the amino acids from IgG3 at positions where the twoisotypes differ. Thus a hybrid variant IgG antibody may be constructedthat comprises one or more substitutions, e.g., 274Q, 276K, 300F, 339T,356E, 358M, 384S, 392N, 397M, 4221, 435R, and 436F. In other embodimentsdescribed herein, an IgG1/IgG2 hybrid variant may be constructed bysubstituting IgG2 positions in the CH2 and/or CH3 region with aminoacids from IgG1 at positions where the two isotypes differ. Thus ahybrid variant IgG antibody may be constructed chat comprises one ormore substitutions, e.g., one or more of the following amino acidsubstitutions: 233E, 234L, 235L, 236G (referring to an insertion of aglycine at position 236), and 321 h.

Moreover, the binding sites on human IgG1 for FcγRI, FcγRII, FcγRIII,and FcRn have been mapped and variants with improved binding have beendescribed (see Shields, R. L. et al. (2001) J. Biol. Chem.276:6591-6604). Specific mutations at positions 256, 290, 298, 333, 334,and 339 were shown to improve binding to FcγRIII Additionally, thefollowing combination mutants were shown to improve FcγRIII binding:T256A/S298A, S298A/E333A, S298A/K224A, and S298A/E333A/K334A, which hasbeen shown to exhibit enhanced FcγRIIIa binding and ADCC activity(Shields et al., 2001). Other IgG1 variants with strongly enhancedbinding to FcγRIIIa have been identified, including variants withS239D/I332E and S239D/I332E/A330L mutations which showed the greatestincrease in affinity for FcγRIIIa, a decrease in FcγRIIb binding, andstrong cytotoxic activity in cynomolgus monkeys (Lazar et al., 2006).Introduction of the triple mutations into antibodies such as alemtuzumab(CD52-specific), trastuzumab (HER2/neu-specific), rituximab(CD20-specific), and cetuximab (EGFR-specific) translated into greatlyenhanced ADCC activity in vitro, and the S239D/I332E variant showed anenhanced capacity to deplete B cells in monkeys (Lazar et al., 2006). Inaddition, IgG1 mutants containing L235V, F243L, R292P, Y300L and P396Lmutations which exhibited enhanced binding to FcγRIIIa and concomitantlyenhanced ADCC activity in transgenic mice expressing human FcγRIIIa inmodels of B cell malignancies and breast cancer have been identified(Stavenhagen et al., 2007; Nordstrom et al., 2011). Other Fc mutantsthat may be used include: S298A/E333A/L334A, S239D/I332E,S239D/I332E/A330L, L235V/F243L/R292P/Y300L/P396L, and M428L/N434S.

In some embodiments, an Fc is chosen that has reduced binding to FcγRs.An exemplary Fc, e.g., IgGl Fc, with reduced FcγR binding, comprises thefollowing three amino acid substitutions: L234A, L235E, and G237A.

In some embodiments, an Fc is chosen that has reduced complementfixation. An exemplary Fc, e.g., IgG1 Fc, with reduced complementfixation, has the following two amino acid substitutions: A330S andP331S.

In some embodiments, an Fc is chosen that has essentially no effectorfunction, i.e., it has reduced binding to FcγRs and reduced complementfixation. An exemplary Fc, e.g., IgGl Fc, that is effectorless,comprises the following five mutations: L234A, L235E, G237A, A330S, andP331S.

When using an IgG4 constant domain, it is usually preferable to includethe substitution S228P, which mimics the hinge sequence in IgG1 andthereby stabilizes IgG4 molecules.

f. Multivalent Antibodies

In one embodiment, the antibodies of the invention may be monovalent ormultivalent (e.g., bivalent, trivalent, etc.). As used herein, the term“valency” refers to the number of potential target binding sitesassociated with an antibody. Each target binding site specifically bindsone target molecule or specific position or locus on a target molecule.When an antibody is monovalent, each binding site of the molecule willspecifically bind to a single antigen position or epitope. When anantibody comprises more than one target binding site (multivalent), eachtarget binding site may specifically bind the same or differentmolecules (e.g., may bind to different ligands or different antigens, ordifferent epitopes or positions on the same antigen). See, for example,U.S.P.N. 2009/0129125. In each case, at least one of the binding siteswill comprise an epitope, motif or domain associated with a DLL3isoform.

In one embodiment, the antibodies are bispecific antibodies in which thetwo chains have different specificities, as described in Millstein etal., 1983, Nature, 305:537-539. Other embodiments include antibodieswith additional specificities such as trispecific antibodies. Other moresophisticated compatible multispecific constructs and methods of theirfabrication are set forth in U.S.P.N. 2009/0155255, as well as WO94/04690; Suresh et al., 1986, Methods in Enzymology, 121:210; andWO96/27011.

As stated above, multivalent antibodies may immunospecifically bind todifferent epitopes of the desired target molecule or mayimmunospecifically bind to both the target molecule as well as aheterologous epitope, such as a heterologous polypeptide or solidsupport material. In some embodiments, the multivalent antibodies mayinclude bispecific antibodies or trispecific antibodies. Bi specificantibodies also include cross-linked or “heteroconjugate” antibodies.For example, one of the antibodies in the heteroconjugate can be coupledto avidin, the other to biotin. Such antibodies have, for example, beenproposed to target immune system cells to unwanted cells (U.S. Pat. No.4,676,980), and for treatment of HIV infection (WO 91/00360, WO92/200373, and EP 03089). Heteroconjugate antibodies may be made usingany convenient cross-linking methods. Suitable cross-linking agents arewell known in the art and are disclosed in U.S. Pat. No. 4,676,980,along with a number of cross-linking techniques.

In some embodiments, antibody variable domains with the desired bindingspecificities (antibody-antigen combining sites) are fused toimmunoglobulin constant domain sequences, such as an immunoglobulinheavy chain constant domain comprising at least part of the hinge, CH2,and/or CH3 regions, using methods well known to those of ordinary skillin the art.

g. Antibody Derivatives

An antibody provided herein may be further modified to containadditional nonproteinaceous moieties that are known in the art andreadily available. The moieties suitable for derivatization of theantibody include but are not limited to water-soluble polymers.

Non-limiting examples of water-soluble polymers include, but are notlimited to, PEG, copolymers of ethylene glycol/propylene glycol,carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleicanhydride copolymer, polyaminoacids (either homopolymers or randomcopolymers), and dextran or poly(n-vinyl pyrrolidone)polyethyleneglycol, propropylene glycol homopolymers, polypropylene oxide/ethyleneoxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinylalcohol, and mixtures thereof. Polyethylene glycol propionaldehyde mayhave advantages in manufacturing due to its stability in water. Thepolymer may be of any molecular weight and may be branched orunbranched. The number of polymers attached to the antibody may vary,and if more than one polymer is attached, they can be the same ordifferent molecules. In general, the number and/or type of polymers usedfor derivatization can be determined based on considerations including,but not limited to, the particular properties or functions of theantibody to be improved, whether the antibody derivative will be used ina therapy under defined conditions, etc.

In another embodiment, conjugates of an antibody and nonproteinaceousmoiety that may be selectively heated by exposure to radiation areprovided. In one embodiment, the nonproteinaceous moiety is a carbonnanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605(2005)). The radiation may be of any wavelength, and includes, but isnot limited to, wavelengths that do not harm ordinary cells, but whichheat the nonproteinaceous moiety to a temperature at which cellsproximal to the antibody-nonproteinaceous moiety are killed.

Another modification of the antibodies described herein is pegylation.An antibody can be pegylated to, for example, increase the biological(e.g., serum) half-life of the antibody. To pegylate an antibody, theantibody, or fragment thereof, typically is reacted with PEG, such as areactive ester or aldehyde derivative of PEG, under conditions in whichone or more PEG groups become attached to the antibody or antibodyfragment. Preferably, the pegylation is carried out via an acylationreaction or an alkylation reaction with a reactive PEG molecule (or ananalogous reactive water-soluble polymer). As used herein, the term“polyethylene glycol” is intended to encompass any of the forms of PEGthat have been used to derivatize other proteins, such as mono (CI-CIO)alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide.In some embodiments, the antibody to be pegylated is an aglycosylatedantibody. Methods for pegylating proteins are known in the art and canbe applied to the antibodies described herein. See, for example, EP 0154 316 by Nishimura et al. and EP0401384 by Ishikawa et al.

The present invention also encompasses a human monoclonal antibodydescribed herein conjugated to a therapeutic agent, a polymer, adetectable label or enzyme. In one embodiment, the therapeutic agent isa cytotoxic agent. In one embodiment, the polymer is PEG.

h. Nucleic Acids, Expression Cassettes, and Vectors

The present invention provides isolated nucleic acid segments thatencode the polypeptides, peptide fragments, and coupled proteins of theinvention. The nucleic acid segments of the invention also includesegments that encode for the same amino acids due to the degeneracy ofthe genetic code. For example, the amino acid threonine is encoded byACU, ACC, ACA, and ACG and is therefore degenerate. It is intended thatthe invention includes all variations of the polynucleotide segmentsthat encode for the same amino acids. Such mutations are known in theart (Watson et al., Molecular Biology of the Gene, Benjamin Cummings1987). Mutations also include alteration of a nucleic acid segment toencode for conservative amino acid changes, for example, thesubstitution of leucine for isoleucine and so forth. Such mutations arealso known in the art. Thus, the genes and nucleotide sequences of theinvention include both the naturally occurring sequences as well asmutant forms.

The nucleic acid segments of the invention may be contained within avector. A vector may include, but is not limited to, any plasmid,phagemid, F-factor, virus, cosmid, or phage in a double- orsingle-stranded linear or circular form which may or may not be selftransmissible or mobilizable. The vector can also transform aprokaryotic or eukaryotic host either by integration into the cellulargenome or exist extra-chromosomally (e.g., autonomous replicatingplasmid with an origin of replication).

Preferably the nucleic acid segment in the vector is under the controlof, and operably linked to, an appropriate promoter or other regulatoryelements for transcription in vitro or in a host cell, such as aeukaryotic cell, or a microbe, e.g., bacteria. The vector may be ashuttle vector that functions in multiple hosts. The vector may also bea cloning vector that typically contains one or a small number ofrestriction endonuclease recognition sites at which foreign DNAsequences can be inserted in a determinable fashion. Such insertion canoccur without loss of essential biological function of the cloningvector. A cloning vector may also contain a marker gene that is suitablefor use in the identification and selection of cells transformed withthe cloning vector. Examples of marker genes are tetracycline resistanceor ampicillin resistance. Many cloning vectors are commerciallyavailable (Stratagene, New England Biolabs, Clonetech).

The nucleic acid segments of the invention may also be inserted into anexpression vector. Typically an expression vector contains prokaryoticDNA elements coding for a bacterial replication origin and an antibioticresistance gene to provide for the amplification and selection of theexpression vector in a bacterial host; regulatory elements that controlinitiation of transcription such as a promoter; and DNA elements thatcontrol the processing of transcripts such as introns, or atranscription termination/polyadenylation sequence.

Methods to introduce nucleic acid segment into a vector are available inthe art (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rdedition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001)).Briefly, a vector into which a nucleic acid segment is to be inserted istreated with one or more restriction enzymes (restriction endonuclease)to produce a linearized vector having a blunt end, a “sticky” end with a5′ or a 3′ overhang, or any combination of the above. The vector mayalso be treated with a restriction enzyme and subsequently treated withanother modifying enzyme, such as a polymerase, an exonuclease, aphosphatase or a kinase, to create a linearized vector that hascharacteristics useful for ligation of a nucleic acid segment into thevector. The nucleic acid segment that is to be inserted into the vectoris treated with one or more restriction enzymes to create a linearizedsegment having a blunt end, a “sticky” end with a 5′ or a 3′ overhang,or any combination of the above. The nucleic acid segment may also betreated with a restriction enzyme and subsequently treated with anotherDNA modifying enzyme. Such DNA modifying enzymes include, but are notlimited to, polymerase, exonuclease, phosphatase or a kinase, to createa nucleic acid segment that has characteristics useful for ligation of anucleic acid segment into the vector.

The treated vector and nucleic acid segment are then ligated together toform a construct containing a nucleic acid segment according to methodsavailable in the art (Sambrook et al., Molecular Cloning: A LaboratoryManual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.(2001)). Briefly, the treated nucleic acid fragment, and the treatedvector are combined in the presence of a suitable buffer and ligase. Themixture is then incubated under appropriate conditions to allow theligase to ligate the nucleic acid fragment into the vector.

The invention also provides an expression cassette which contains anucleic acid sequence capable of directing expression of a particularnucleic acid segment of the invention, either in vitro or in a hostcell. Also, a nucleic acid segment of the invention may be inserted intothe expression cassette such that an anti-sense message is produced. Theexpression cassette is an isolatable unit such that the expressioncassette may be in linear form and functional for in vitro transcriptionand translation assays. The materials and procedures to conduct theseassays are commercially available from Promega Corp. (Madison, Wis.).For example, an in vitro transcript may be produced by placing a nucleicacid sequence under the control of a T7 promoter and then using T7 RNApolymerase to produce an in vitro transcript. This transcript may thenbe translated in vitro through use of a rabbit reticulocyte lysate.Alternatively, the expression cassette can be incorporated into a vectorallowing for replication and amplification of the expression cassettewithin a host cell or also in vitro transcription and translation of anucleic acid segment.

Such an expression cassette may contain one or a plurality ofrestriction sites allowing for placement of the nucleic acid segmentunder the regulation of a regulatory sequence. The expression cassettecan also contain a termination signal operably linked to the nucleicacid segment as well as regulatory sequences required for propertranslation of the nucleic acid segment. The expression cassettecontaining the nucleic acid segment may be chimeric, meaning that atleast one of its components is heterologous with respect to at least oneof its other components. The expression cassette may also be one that isnaturally occurring but has been obtained in a recombinant form usefulfor heterologous expression. Expression of the nucleic acid segment inthe expression cassette may be under the control of a constitutivepromoter or an inducible promoter, which initiates transcription onlywhen the host cell is exposed to some particular external stimulus.

The expression cassette may include in the 5′-3′ direction oftranscription, a transcriptional and translational initiation region, anucleic acid segment and a transcriptional and translational terminationregion functional in vivo and/or in vitro. The termination region may benative with the transcriptional initiation region, may be native withthe nucleic acid segment, or may be derived from another source.

The regulatory sequence can be a polynucleotide sequence locatedupstream (5′ non-coding sequences), within, or downstream (3′ non-codingsequences) of a coding sequence, and which influences the transcription,RNA processing or stability, or translation of the associated codingsequence. Regulatory sequences can include, but are not limited to,enhancers, promoters, repressor binding sites, translation leadersequences, introns, and polyadenylation signal sequences. They mayinclude natural and synthetic sequences as well as sequences, which maybe a combination of synthetic and natural sequences. While regulatorysequences are not limited to promoters, some useful regulatory sequencesinclude constitutive promoters, inducible promoters, regulatedpromoters, tissue-specific promoters, viral promoters, and syntheticpromoters.

A promoter is a nucleotide sequence that controls the expression of thecoding sequence by providing the recognition for RNA polymerase andother factors required for proper transcription. A promoter includes aminimal promoter, consisting only of all basal elements needed fortranscription initiation, such as a TATA-box and/or initiator that is ashort DNA sequence comprised of a TATA-box and other sequences thatserve to specify the site of transcription initiation, to whichregulatory elements are added for control of expression. A promoter maybe derived entirely from a native gene, or be composed of differentelements derived from different promoters found in nature, or even becomprised of synthetic DNA segments. A promoter may contain DNAsequences that are involved in the binding of protein factors thatcontrol the effectiveness of transcription initiation in response tophysiological or developmental conditions.

The invention also provides a construct containing a vector and anexpression cassette. The vector may be selected from, but not limitedto, any vector previously described. Into this vector may be inserted anexpression cassette through methods known in the art and previouslydescribed (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rdedition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001)). Inone embodiment, the regulatory sequences of the expression cassette maybe derived from a source other than the vector into which the expressioncassette is inserted. In another embodiment, a construct containing avector and an expression cassette is formed upon insertion of a nucleicacid segment of the invention into a vector that itself containsregulatory sequences. Thus, an expression cassette is formed uponinsertion of the nucleic acid segment into the vector. Vectorscontaining regulatory sequences are available commercially, and methodsfor their use are known in the art (Clonetech, Promega, Stratagene).

In another aspect, this disclosure also provides (i) a nucleic acidmolecule encoding a polypeptide chain of the antibody or antigen-bindingfragment thereof described above; (ii) a vector comprising the nucleicacid molecule as described; and (iii) a cultured host cell comprisingthe vector as described. Also provided is a method for producing apolypeptide, comprising: (a) obtaining the cultured host cell asdescribed; (b) culturing the cultured host cell in a medium underconditions permitting expression of a polypeptide encoded by the vectorand assembling of an antibody or fragment thereof; and (c) purifying theantibody or fragment from the cultured cell or the medium of the cell.

i. Methods of Production

Antibodies may be produced using recombinant methods and compositions,e.g., as described in U.S. Pat. No. 4,816,567. In one embodiment, anisolated nucleic acid encoding an antibody described herein is provided.Such nucleic acid may encode an amino acid sequence comprising the VLand/or an amino acid sequence comprising the VH of the antibody (e.g.,the light and/or heavy chains of the antibody). In a further embodiment,one or more vectors (e.g., expression vectors) comprising such nucleicacid are provided. In a further embodiment, a host cell comprising suchnucleic acid is provided. In one such embodiment, a host cell comprises(e.g., has been transformed with): (1) a vector comprising a nucleicacid that encodes an amino acid sequence comprising the VL of theantibody and an amino acid sequence comprising the VH of the antibody,or (2) a first vector comprising a nucleic acid that encodes an aminoacid sequence comprising the VL of the antibody and a second vectorcomprising a nucleic acid that encodes an amino acid sequence comprisingthe VH of the antibody. In one embodiment, the host cell is eukaryotic,e.g., a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0,NS0, Sp20 cell). In one embodiment, a method of making an antibody isprovided, wherein the method comprises culturing a host cell comprisinga nucleic acid encoding the antibody, as provided above, underconditions suitable for expression of the antibody, and optionallyrecovering the antibody from the host cell (or host cell culturemedium).

For recombinant production of an antibody, a nucleic acid encoding anantibody, e.g., as described above, is isolated and inserted into one ormore vectors for further cloning and/or expression in a host cell. Suchnucleic acid may be readily isolated and sequenced using conventionalprocedures (e.g., by using oligonucleotide probes that are capable ofbinding specifically to genes encoding the heavy and light chains of theantibody).

Suitable host cells for cloning or expression of antibody-encodingvectors include prokaryotic or eukaryotic cells described herein. Forexample, antibodies may be produced in bacteria, in particular whenglycosylation and Fc effector function are not needed. For expression ofantibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat.Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods inMolecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa,N.J., 2003), pp. 245-254, describing expression of antibody fragments inE. coli.) After expression, the antibody may be isolated from thebacterial cell paste in a soluble fraction and can be further purified.

In addition to prokaryotes, eukaryotic microbes such as filamentousfungi or yeast are suitable cloning or expression hosts forantibody-encoding vectors, including fungi and yeast strains whoseglycosylation pathways have been “humanized,” resulting in theproduction of an antibody with a partially or fully human glycosylationpattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li etal., Nat. Biotech. 24:210-215 (2006).

Suitable host cells for the expression of glycosylated antibody are alsoderived from multicellular organisms (invertebrates and vertebrates).Examples of invertebrate cells include plant and insect cells. Numerousbaculoviral strains have been identified, which may be used inconjunction with insect cells, particularly for transfection ofSpodoptera frugiperda cells.

Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat.Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429(describing PLANTIBODIES technology for producing antibodies intransgenic plants).

Vertebrate cells may also be used as hosts. For example, mammalian celllines that are adapted to grow in suspension may be useful. Otherexamples of useful mammalian host cell lines are monkey kidney CV1 linetransformed by SV40 (COS-7); human embryonic kidney line (293 or 293cells as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977));baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells asdescribed, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkeykidney cells (CV1); African green monkey kidney cells (VERO-76); humancervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo ratliver cells (BRL 3A); human lung cells (W138); human liver cells (HepG2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., inMather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; andFS4 cells. Other useful mammalian host cell lines include CHO cells,including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA77:4216 (1980)); and myeloma cell lines such as Y0, NS0, and Sp2/0. Fora review of certain mammalian host cell lines suitable for antibodyproduction, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol.248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).

B. COMPOSITIONS AND FORMULATIONS

The antibodies of this invention represent an excellent way for thedevelopment of antiviral therapies either alone or in antibody cocktailswith additional anti-SARS-CoV-2 virus antibodies for the treatment ofhuman SARS-CoV-2 infections in humans.

In another aspect, the present invention provides a pharmaceuticalcomposition comprising the antibodies of the present invention describedherein formulated together with a pharmaceutically acceptable carrier.The composition may optionally contain one or more additionalpharmaceutically active ingredients, such as another antibody or atherapeutic agent.

In some embodiments, the pharmaceutical comprises two or more of theantibody or antigen-binding fragment thereof of described above, such asany combinations of the antibody or antigen-binding fragment thereofcomprising a heavy chain and a light chain that comprise the respectiveamino acid sequences of SEQ ID NOs: 1-2; 13-14; 25-26; 49-50, 55-56,57-58, 65-66, 81-82, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and2912.

In some embodiments, the two or more of the antibody or antigen-bindingfragment thereof comprise: (1) a first antibody set comprising: (i) afirst antibody or antigen-binding fragment thereof comprising a heavychain variable region and a light chain variable region comprising therespective amino acid sequences of SEQ ID NOs: 57-58; and (ii) a secondantibody or antigen-binding fragment thereof comprising a heavy chainvariable region and a light chain variable region comprising therespective amino acid sequences of SEQ ID NOs: 1-2, 55-56, 57-58, 65-66,81-82, or 85-86; or (2) a second antibody set comprising: (a) a thirdantibody or antigen-binding fragment thereof comprising a heavy chainvariable region and a light chain variable region comprising therespective amino acid sequences of of SEQ ID NOs: 13-14, 49-50,85-86113-114, 125-126, 2876 and 2888, or 2900 and 2912; and (b) a fourthantibody or antigen-binding fragment thereof comprising a heavy chainvariable region and a light chain variable region comprising therespective amino acid sequences of of SEQ ID NOs: 13-14, 49-50, 85-86,113-114, 125-126, 2876 and 2888, or 2900 and 2912, wherein the thirdantibody is different from the fourth antibody.

The pharmaceutical compositions of the invention also can beadministered in a combination therapy with, for example, anotherimmune-stimulatory agent, an antiviral agent, or a vaccine, etc. In someembodiments, a composition comprises an antibody of this invention at aconcentration of at least 1 mg/ml, 5 mg/ml, 10 mg/ml, 50 mg/ml, 100mg/ml, 150 mg/ml, 200 mg/ml, 1-300 mg/ml, or 100-300 mg/ml.

In some embodiments, the second therapeutic agent comprises ananti-inflammatory drug or an antiviral compound. In some embodiments,the antiviral compound comprises: a nucleoside analog, a peptoid, anoligopeptide, a polypeptide, a protease inhibitor, a 3C-like proteaseinhibitor, a papain-like protease inhibitor, or an inhibitor of an RNAdependent RNA polymerase. In some embodiments, the antiviral compoundmay include: acyclovir, gancyclovir, vidarabine, foscarnet, cidofovir,amantadine, ribavirin, trifluorothymidine, zidovudine, didanosine,zalcitabine or an interferon. In some embodiments, the interferon is aninterferon-α or an interferon-β.

Also within the scope of this disclosure is use of the pharmaceuticalcomposition in the preparation of a medicament for the diagnosis,prophylaxis, treatment, or combination thereof of a condition resultingfrom a SARS-CoV-2.

The pharmaceutical composition can comprise any number of excipients.Excipients that can be used include carriers, surface-active agents,thickening or emulsifying agents, solid binders, dispersion orsuspension aids, solubilizers, colorants, flavoring agents, coatings,disintegrating agents, lubricants, sweeteners, preservatives, isotonicagents, and combinations thereof. The selection and use of suitableexcipients is taught in Gennaro, ed., Remington: The Science andPractice of Pharmacy, 20th Ed. (Lippincott Williams & Wilkins 2003), thedisclosure of which is incorporated herein by reference.

Preferably, a pharmaceutical composition is suitable for intravenous,intramuscular, subcutaneous, parenteral, spinal or epidermaladministration (e.g., by injection or infusion). Depending on the routeof administration, the active compound can be coated in a material toprotect it from the action of acids and other natural conditions thatmay inactivate it. The phrase “parenteral administration” as used hereinmeans modes of administration other than enteral and topicaladministration, usually by injection, and includes, without limitation,intravenous, intramuscular, intraarterial, intrathecal, intracapsular,intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal,subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid,intraspinal, epidural and intrasternal injection and infusion.Alternatively, an antibody of the present invention described herein canbe administered via a non-parenteral route, such as a topical, epidermalor mucosal route of administration, e.g., intranasally, orally,vaginally, rectally, sublingually or topically.

The pharmaceutical compositions of the invention may be prepared in manyforms that include tablets, hard or soft gelatin capsules, aqueoussolutions, suspensions, and liposomes and other slow-releaseformulations, such as shaped polymeric gels. An oral dosage form may beformulated such that the antibody is released into the intestine afterpassing through the stomach. Such formulations are described in U.S.Pat. No. 6,306,434 and in the references contained therein.

Oral liquid pharmaceutical compositions may be in the form of, forexample, aqueous or oily suspensions, solutions, emulsions, syrups orelixirs, or may be presented as a dry product for constitution withwater or other suitable vehicle before use. Such liquid pharmaceuticalcompositions may contain conventional additives such as suspendingagents, emulsifying agents, non-aqueous vehicles (which may includeedible oils), or preservatives.

An antibody can be formulated for parenteral administration (e.g., byinjection, for example, bolus injection or continuous infusion) and maybe presented in unit dosage form in ampules, prefilled syringes, smallvolume infusion containers or multi-dose containers with an addedpreservative. The pharmaceutical compositions may take such forms assuspensions, solutions, or emulsions in oily or aqueous vehicles, andmay contain formulatory agents such as suspending, stabilizing and/ordispersing agents. Pharmaceutical compositions suitable for rectaladministration can be prepared as unit dose suppositories. Suitablecarriers include saline solution and other materials commonly used inthe art.

For administration by inhalation, an antibody can be convenientlydelivered from an insufflator, nebulizer or a pressurized pack or otherconvenient means of delivering an aerosol spray. Pressurized packs maycomprise a suitable propellant such as dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide orother suitable gas. In the case of a pressurized aerosol, the dosageunit may be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, anantibody may take the form of a dry powder composition, for example, apowder mix of a modulator and a suitable powder base such as lactose orstarch. The powder composition may be presented in unit dosage form in,for example, capsules or cartridges or, e.g., gelatin or blister packsfrom which the powder may be administered with the aid of an inhalatoror insufflator. For intra-nasal administration, an antibody may beadministered via a liquid spray, such as via a plastic bottle atomizer.

Pharmaceutical compositions of the invention may also contain otheringredients such as flavorings, colorings, anti-microbial agents, orpreservatives. It will be appreciated that the amount of an antibodyrequired for use in treatment will vary not only with the particularcarrier selected but also with the route of administration, the natureof the condition being treated and the age and condition of the patient.Ultimately the attendant health care provider may determine properdosage. In addition, a pharmaceutical composition may be formulated as asingle unit dosage form.

The pharmaceutical composition of the present invention can be in theform of sterile aqueous solutions or dispersions. It can also beformulated in a microemulsion, liposome, or other ordered structuresuitable to high drug concentration.

An antibody of the present invention described herein can beadministered as a sustained release formulation, in which case lessfrequent administration is required. Dosage and frequency vary dependingon the half-life of the antibody in the patient. In general, humanantibodies show the longest half-life, followed by humanized antibodies,chimeric antibodies, and nonhuman antibodies. The dosage and frequencyof administration can vary depending on whether the treatment isprophylactic or therapeutic. In prophylactic applications, a relativelylow dosage is administered at relatively infrequent intervals over along period of time. Some patients continue to receive treatment for therest of their lives. In therapeutic applications, a relatively highdosage at relatively short intervals is sometimes required untilprogression of the disease is reduced or terminated, and preferably,until the patient shows partial or complete amelioration of symptoms ofdisease. Thereafter, the patient can be administered a prophylacticregime.

The amount of active ingredient that can be combined with a carriermaterial to produce a single dosage form will vary depending upon thesubject being treated and the particular mode of administration and willgenerally be that amount of the composition, which produces atherapeutic effect. Generally, out of one hundred percent, this amountwill range from about 0.01% to about 99% of active ingredient,preferably from about 0.1% to about 70%, most preferably from about 1%to about 30% of active ingredient in combination with a pharmaceuticallyacceptable carrier.

Dosage regimens can be adjusted to provide the optimum desired response(e.g., a therapeutic response). For example, a single bolus can beadministered, several divided doses can be administered over time or thedose can be proportionally reduced or increased as indicated by theexigencies of the therapeutic situation. It is especially advantageousto formulate parenteral compositions in dosage unit form for ease ofadministration and uniformity of dosage. Dosage unit form as used hereinrefers to physically discrete units suited as unitary dosages for thesubjects to be treated; each unit contains a predetermined quantity ofactive compound calculated to produce the desired therapeutic effect inassociation with the required pharmaceutical carrier. Alternatively, theantibody can be administered as a sustained release formulation, inwhich case less frequent administration is required. For administrationof the antibody, the dosage ranges from about 0.0001 to 800 mg/kg, andmore usually 0.01 to 5 mg/kg, of the host body weight. For exampledosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg bodyweight, 5 mg/kg body weight or 10 mg/kg body weight or within the rangeof 1-10 mg/kg. An exemplary treatment regime entails administration onceper week, once every two weeks, once every three weeks, once every fourweeks, once a month, once every 3 months or once every three to 6months. Preferred dosage regimens for an antibody of the inventioninclude 1 mg/kg body weight or 3 mg/kg body weight via intravenousadministration, with the antibody being given using one of the followingdosing schedules: (i) every four weeks for six dosages, then every threemonths; (ii) every three weeks; (iii) 3 mg/kg body weight once followedby 1 mg/kg body weight every three weeks. In some methods, dosage isadjusted to achieve a plasma antibody concentration of about 1-1000μg/ml and in some methods about 25-300 μg/ml. A “therapeuticallyeffective dosage” of an antibody of the invention preferably results ina decrease in severity of disease symptoms, an increase in frequency andduration of disease symptom-free periods, or a prevention of impairmentor disability due to the disease affliction. For example, for thetreatment of SARS-CoV-2 infection in a subject, a “therapeuticallyeffective dosage” preferably inhibits SARS-CoV-2 virus replication oruptake by host cells by at least about 20%, more preferably by at leastabout 40%, even more preferably by at least about 60%, and still morepreferably by at least about 80% relative to untreated subjects. Atherapeutically effective amount of a therapeutic compound canneutralize SARS-CoV-2 virus, or otherwise ameliorate symptoms in asubject, which is typically a human or can be another mammal.

The pharmaceutical composition can be a controlled release formulation,including implants, transdermal patches, and microencapsulated deliverysystems. Biodegradable, biocompatible polymers can be used, such asethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen,polyorthoesters, and polylactic acid. See, e.g., Sustained andControlled Release Drug Delivery Systems, J. R. Robinson, ed., MarcelDekker, Inc., New York, 1978.

Therapeutic compositions can be administered via medical devices such as(1) needleless hypodermic injection devices (e.g., U.S. Pat. Nos.5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; and4,596,556); (2) micro-infusion pumps (U.S. Pat. No. 4,487,603); (3)transdermal devices (U.S. Pat. No. 4,486,194); (4) infusion apparati(U.S. Pat. Nos. 4,447,233 and 4,447,224); and (5) osmotic devices (U.S.Pat. Nos. 4,439,196 and 4,475,196); the disclosures of which areincorporated herein by reference.

In some embodiments, the human monoclonal antibodies of the inventiondescribed herein can be formulated to ensure proper distribution invivo. For example, to ensure that the therapeutic compounds of theinvention cross the blood-brain barrier, they can be formulated inliposomes, which may additionally comprise targeting moieties to enhanceselective transport to specific cells or organs. See, e.g., U.S. Pat.Nos. 4,522,811; 5,374,548; 5,416,016; and 5,399,331; V. V. Ranade (1989)Clin. Pharmacol. 29:685; Umezawa et al., (1988) Biochem. Biophys. Res.Commun. 153:1038; Bloeman et al. (1995) FEBS Lett. 357:140; M. Owais etal. (1995) Antimicrob. Agents Chemother. 39:180; Briscoe et al. (1995)Am. Physiol. 1233:134; Schreier et al. (1994). Biol. Chem. 269:9090;Keinanen and Laukkanen (1994) FEBS Lett. 346:123; and Killion and Fidler(1994) Immunomethods 4:273.

In some embodiments, the initial dose may be followed by administrationof a second or a plurality of subsequent doses of the antibody orantigen-binding fragment thereof in an amount that can be approximatelythe same or less than that of the initial dose, wherein the subsequentdoses are separated by at least 1 day to 3 days; at least one week, atleast 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; atleast 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; atleast 10 weeks; at least 12 weeks; or at least 14 weeks.

Various delivery systems are known and can be used to administer thepharmaceutical composition of the invention, e.g., encapsulation inliposomes, microparticles, microcapsules, recombinant cells capable ofexpressing the mutant viruses, receptor-mediated endocytosis (see, e.g.,Wu et al. (1987) J. Biol. Chem. 262:4429-4432). Methods of introductioninclude, but are not limited to, intradermal, transdermal,intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal,epidural, and oral routes. The composition may be administered by anyconvenient route, for example by infusion or bolus injection, byabsorption through epithelial or mucocutaneous linings (e.g., oralmucosa, rectal and intestinal mucosa, etc.) and may be administeredtogether with other biologically active agents. Administration can besystemic or local. The pharmaceutical composition can also be deliveredin a vesicle, in particular, a liposome (see, for example, Langer (1990)Science 249: 1527-1533).

The use of nanoparticles to deliver the antibodies of the presentinvention is also contemplated herein. Antibody-conjugated nanoparticlesmay be used both for therapeutic and diagnostic applications.Antibody-conjugated nanoparticles and methods of preparation and use aredescribed in detail by Arruebo, M., et al. 2009 (“Antibody-conjugatednanoparticles for biomedical applications” in J. Nanomat. Volume 2009,Article ID 439389), incorporated herein by reference. Nanoparticles maybe developed and conjugated to antibodies contained in pharmaceuticalcompositions to target cells. Nanoparticles for drug delivery have alsobeen described in, for example, U.S. Pat. No. 8,257,740, or U.S. Pat.No. 8,246,995, each incorporated herein in its entirety.

In certain situations, the pharmaceutical composition can be deliveredin a controlled release system. In one embodiment, a pump may be used.In another embodiment, polymeric materials can be used. In yet anotherembodiment, a controlled release system can be placed in proximity ofthe composition's target, thus requiring only a fraction of the systemicdose.

The injectable preparations may include dosage forms for intravenous,subcutaneous, intracutaneous, intracranial, intraperitoneal andintramuscular injections, drip infusions, etc. These injectablepreparations may be prepared by methods publicly known. For example, theinjectable preparations may be prepared, e.g., by dissolving, suspendingor emulsifying the antibody or its salt described above in a sterileaqueous medium or an oily medium conventionally used for injections. Asthe aqueous medium for injections, there are, for example, physiologicalsaline, an isotonic solution containing glucose and other auxiliaryagents, etc., which may be used in combination with an appropriatesolubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol(e.g., propylene glycol, polyethylene glycol), a nonionic surfactant[e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct ofhydrogenated castor oil)], etc. As the oily medium, there are employed,e.g., sesame oil, soybean oil, etc., which may be used in combinationwith a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc.The injection thus prepared is preferably filled in an appropriateampoule.

A pharmaceutical composition of the present invention can be deliveredsubcutaneously or intravenously with a standard needle and syringe. Inaddition, with respect to subcutaneous delivery, a pen delivery devicereadily has applications in delivering a pharmaceutical composition ofthe present invention. Such a pen delivery device can be reusable ordisposable. A reusable pen delivery device generally utilizes areplaceable cartridge that contains a pharmaceutical composition. Onceall of the pharmaceutical composition within the cartridge has beenadministered and the cartridge is empty, the empty cartridge can readilybe discarded and replaced with a new cartridge that contains thepharmaceutical composition. The pen delivery device can then be reused.In a disposable pen delivery device, there is no replaceable cartridge.Rather, the disposable pen delivery device comes prefilled with thepharmaceutical composition held in a reservoir within the device. Oncethe reservoir is emptied of the pharmaceutical composition, the entiredevice is discarded.

Numerous reusable pen and autoinjector delivery devices haveapplications in the subcutaneous delivery of a pharmaceuticalcomposition of the present invention. Examples include, but certainlyare not limited to AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK),DISETRONIC™ pen (Disetronic Medical Systems, Burghdorf, Switzerland),HUMALOG MIX 75/25™ pen, HUMALOG™ pen, HUMALIN 70/30™ pen (Eli Lilly andCo., Indianapolis, Ind.), NOVOPEN™ I, II and III (Novo Nordisk,Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen,Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, N.J.), OPTIPEN™,OPTIPEN PRO™, OPTIPEN STARLET™, and OPTICLIK™ (Sanofi-Aventis,Frankfurt, Germany), to name only a few. Examples of disposable pendelivery devices having applications in subcutaneous delivery of apharmaceutical composition of the present invention include, butcertainly are not limited to the SOLOSTAR™ pen (Sanofi-Aventis), theFLEXPEN™ (Novo Nordisk), and the KWIKPEN™ (Eli Lilly), the SURECLICK™Autoinjector (Amgen, Thousand Oaks, Calif.), the PENLET™ (Haselmeier,Stuttgart, Germany), the EPIPEN (Dey, L. P.) and the HUMIRA™ Pen (AbbottLabs, Abbott Park, Ill.), to name only a few.

Advantageously, the pharmaceutical compositions for oral or parenteraluse described above are prepared into dosage forms in a unit dose suitedto fit a dose of the active ingredients. Such dosage forms in a unitdose include, for example, tablets, pills, capsules, injections(ampoules), suppositories, etc. The amount of the antibody contained isgenerally about 5 to about 500 mg per dosage form in a unit dose;especially in the form of injection, it is preferred that the antibodyis contained in about 5 to about 300 mg and in about 10 to about 300 mgfor the other dosage forms.

C. METHODS AND USES

a. Methods of Treatment

The antibodies, compositions, and formulations described herein can beused to neutralize SARS-CoV-2 virus and thereby treating or preventingSARS-CoV-2 infections.

Accordingly, in one aspect, this disclosure further provides a method ofneutralizing SARS-CoV-2 in a subject, comprising administering to asubject in need thereof a therapeutically effective amount of theantibody or antigen-binding fragment thereof or a therapeuticallyeffective amount of the pharmaceutical composition, as described above.

In another aspect, this disclosure additionally provides a method ofpreventing or treating a SARS-CoV-2 infection, comprising administeringto a subject in need thereof a therapeutically effective amount of theantibody or antigen-binding fragment thereof or a therapeuticallyeffective amount of the pharmaceutical composition, as described above.

The neutralizing of the SARS-CoV-2 virus can be done via (i) inhibitingSARS-CoV-2 virus binding to a target cell; (ii) inhibiting SARS-CoV-2virus uptake by a target cell; (iii) inhibiting SARS-CoV-2 virusreplication; and (iv) inhibiting SARS-CoV-2 virus particles release frominfected cells. One skilled in the art possesses the ability to performany assay to assess neutralization of SARS-CoV-2 virus.

Notably, the neutralizing properties of antibodies may be assessed by avariety of tests, which all may assess the consequences of (i)inhibition of SARS-CoV-2 virus binding to a target cell; (ii) inhibitionof SARS-CoV-2 virus uptake by a target cell; (iii) inhibition ofSARS-CoV-2 virus replication; and (iv) inhibition of SARS-CoV-2 virusparticles release from infected cells. In other words, implementingdifferent tests may lead to the observation of the same consequence,i.e., the loss of infectivity of the SARS-CoV-2 virus. Thus, in oneembodiment, the present invention provides a method of neutralizingSARS-CoV-2 virus in a subject comprising administering to the subject atherapeutically effective amount of the antibody of the presentinvention described herein.

Another aspect of the present invention provides a method of treating aSARS-CoV-2-related disease. Such a method includes therapeutic(following SARS-CoV-2 infection) and prophylactic (prior to SARS-CoV-2exposure, infection or pathology). For example, therapeutic andprophylactic methods of treating an individual for a SARS-CoV-2infection include treatment of an individual having or at risk of havinga SARS-CoV-2 infection or pathology, treating an individual with aSARS-CoV-2 infection, and methods of protecting an individual from aSARS-CoV-2 infection, to decrease or reduce the probability of aSARS-CoV-2 infection in an individual, to decrease or reducesusceptibility of an individual to a SARS-CoV-2 infection, or to inhibitor prevent a SARS-CoV-2 infection in an individual, and to decrease,reduce, inhibit or suppress transmission of a SARS-CoV-2 from aninfected individual to an uninfected individual. Such methods includeadministering an antibody of the present invention or a compositioncomprising the antibody disclosed herein to therapeutically orprophylactically treat (vaccinate or immunize) an individual having orat risk of having a SARS-CoV-2 infection or pathology. Accordingly,methods can treat the SARS-CoV-2 infection or pathology, or provide theindividual with protection from infection (e.g., prophylacticprotection).

In one embodiment, a method of treating a SARS-CoV-2-related diseasecomprises administering to an individual in need thereof an antibody ortherapeutic composition disclosed herein in an amount sufficient toreduce one or more physiological conditions or symptoms associated witha SARS-CoV-2 infection or pathology, thereby treating theSARS-CoV-2-related disease.

In one embodiment, an antibody or therapeutic composition disclosedherein is used to treat a SARS-CoV-2-related disease. Use of an antibodyor therapeutic composition disclosed herein treats a SARS-CoV-2-relateddisease by reducing one or more physiological conditions or symptomsassociated with a SARS-CoV-2 infection or pathology. In aspects of thisembodiment, administration of an antibody or therapeutic compositiondisclosed herein is in an amount sufficient to reduce one or morephysiological conditions or symptoms associated with a SARS-CoV-2infection or pathology, thereby treating the SARS-CoV-2-based disease.In other aspects of this embodiment, administration of an antibody ortherapeutic composition disclosed herein is in an amount sufficient toincrease, induce, enhance, augment, promote or stimulate SARS-CoV-2clearance or removal; or decrease, reduce, inhibit, suppress, prevent,control, or limit transmission of SARS-CoV-2 to another individual.

One or more physiological conditions or symptoms associated with aSARS-CoV-2 infection or pathology will respond to a method of treatmentdisclosed herein. The symptoms of SARS-CoV-2 infection or pathologyvary, depending on the phase of infection.

In some embodiments, the method of neutralizing SARS-CoV-2 in a subjectcomprises administering to a subject in need thereof a therapeuticallyeffective amount of a first antibody or antigen-binding fragment thereofand a second antibody or antigen-binding fragment thereof of theantibody or antigen-binding fragment or a therapeutically effectiveamount of the pharmaceutical composition, as described above, whereinthe first antibody or antigen-binding fragment thereof and the secondantibody or antigen binding fragment thereof exhibit synergisticactivity.

In some embodiments, the method of preventing or treating a SARS-CoV-2infection, comprising administering to a subject in need thereof atherapeutically effective amount of a first antibody or antigen-bindingfragment thereof and a second antibody or antigen-binding fragmentthereof of the antibody or antigen-binding fragment or a therapeuticallyeffective amount of the pharmaceutical composition, as described above,wherein the first antibody or antigen-binding fragment thereof and thesecond antibody or antigen binding fragment thereof exhibit synergisticactivity. In some embodiments, the first antibody or antigen-bindingfragment thereof is administered before, after, or concurrently with thesecond antibody or antigen-binding fragment thereof.

In some embodiments, the first antibody or antigen-binding fragmentthereof and the second antibody or antigen-binding fragment thereof canbe any combinations of the antibody or antigen-binding fragment thereofcomprising a heavy chain and a light chain that comprise the respectiveamino acid sequences of SEQ ID NOs: 1-2; 13-14; 25-26; 49-50, 55-56,57-58, 65-66, 81-82, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and2912.

In some embodiments, the first antibody or antigen-binding fragmentthereof comprises a heavy chain variable region and a light chainvariable region comprising the respective amino acid sequences of SEQ IDNOs: 57-58 and the second antibody or antigen-binding fragment thereofcomprises a heavy chain variable region and a light chain variableregion comprising the respective amino acid sequences of SEQ ID NOs:1-2, 55-56, 57-58, 65-66, 81-82, or 85-86.

In some embodiments, the first antibody or antigen-binding fragmentthereof comprises a heavy chain variable region and a light chainvariable region comprising the respective amino acid sequences of SEQ IDNOs: 13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and2912, and the second antibody or antigen-binding fragment thereofcomprises a heavy chain variable region and a light chain variableregion comprising the respective amino acid sequences of SEQ ID NOs:13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912,wherein the first antibody and the second antibody are different.

In some embodiments, the method comprises administering to the subject atherapeutically effective amount of a second therapeutic agent ortherapy. In some embodiments, the antibody or antigen-binding fragmentthereof comprises a heavy chain variable region and a light chainvariable region comprising the respective amino acid sequences of SEQ IDNOs: 57-58; and the second therapeutic agent or therapy comprises anantibody or antigen-binding fragment thereof comprising a heavy chainvariable region and a light chain variable region that comprise therespective amino acid sequences of SEQ ID NOs: 1-2, 55-56, 57-58, 65-66,81-82, or 85-86.

In some embodiments, the second therapeutic agent comprises ananti-inflammatory drug or an antiviral compound. In some embodiments,the antiviral compound comprises: a nucleoside analog, a peptoid, anoligopeptide, a polypeptide, a protease inhibitor, a 3C-like proteaseinhibitor, a papain-like protease inhibitor, or an inhibitor of an RNAdependent RNA polymerase. In some embodiments, the antiviral compoundmay include: acyclovir, gancyclovir, vidarabine, foscarnet, cidofovir,amantadine, ribavirin, trifluorothymidine, zidovudine, didanosine,zalcitabine or an interferon. In some embodiments, the interferon is aninterferon-α or an interferon-β.

In some embodiments, the antibody or antigen-binding fragment thereof isadministered before, after, or concurrently with the second therapeuticagent or therapy. In some embodiments, the antibody or antigen-bindingfragment thereof is administered to the subject intravenously,subcutaneously, or intraperitoneally. In some embodiments, the antibodyor antigen-binding fragment thereof is administered prophylactically ortherapeutically.

The antibodies described herein can be used together with one or more ofother anti-SARS-CoV-2 virus antibodies to neutralize SARS-CoV-2 virusand thereby treating SARS-CoV-2 infections.

b. Combination Therapies

Combination therapies may include an anti-SARS-CoV-2 antibody of theinvention and any additional therapeutic agent that may beadvantageously combined with an antibody of the invention or with abiologically active fragment of an antibody of the invention. Theantibodies of the present invention may be combined synergistically withone or more drugs or therapy used to treat a disease or disorderassociated with a viral infection, such as a SARS-CoV-2 infection. Insome embodiments, the antibodies of the invention may be combined with asecond therapeutic agent to ameliorate one or more symptoms of saiddisease. In some embodiments, the antibodies of the invention may becombined with a second antibody to provide synergistic activity inameliorating one or more symptoms of said disease. In some embodiments,the first antibody or antigen-binding fragment thereof is administeredbefore, after, or concurrently with the second antibody orantigen-binding fragment thereof.

For example, the antibody described herein can be used in variousdetection methods for use in, e.g., monitoring the progression of aSARS-CoV-2 infection; monitoring patient response to treatment for suchan infection, etc. The present disclosure provides methods of detectinga neuraminidase polypeptide in a biological sample obtained from anindividual. The methods generally involve: a) contacting the biologicalsample with a subject anti-neuraminidase antibody; and b) detectingbinding, if any, of the antibody to an epitope present in the sample. Insome instances, the antibody comprises a detectable label. The level ofneuraminidase polypeptide detected in the biological sample can providean indication of the stage, degree, or severity of a SARS-CoV-2infection. The level of the neuraminidase polypeptide detected in thebiological sample can provide an indication of the individual's responseto treatment for a SARS-CoV-2 infection.

In some embodiments, the second therapeutic agent is another antibody toa SARS-COV-2 protein or a fragment thereof. It is contemplated herein touse a combination (“cocktail”) of antibodies with broad neutralizationor inhibitory activity against SARS-COV-2. In some embodiments,non-competing antibodies may be combined and administered to a subjectin need thereof. In some embodiments, the antibodies comprising thecombination bind to distinct non-overlapping epitopes on the protein. Insome embodiments, the second antibody may possess longer half-life inhuman serum.

As used herein, the term “in combination with” means that additionaltherapeutically active component(s) may be administered prior to,concurrent with, or after the administration of the anti-SARS-COV-2antibody of the present invention. The term “in combination with” alsoincludes sequential or concomitant administration of an anti-SARS-COV-2antibody and a second therapeutic agent.

The additional therapeutically active component(s) may be administeredto a subject prior to administration of an anti-SARS-COV-2 antibody ofthe present invention. For example, a first component may be deemed tobe administered “prior to” a second component if the first component isadministered 1 week before, 72 hours before, 60 hours before, 48 hoursbefore, 36 hours before, 24 hours before, 12 hours before, 6 hoursbefore, 5 hours before, 4 hours before, 3 hours before, 2 hours before,1 hour before, 30 minutes before, 15 minutes before, 10 minutes before,5 minutes before, or less than 1 minute before administration of thesecond component. In other embodiments, the additional therapeuticallyactive component(s) may be administered to a subject afteradministration of an anti-SARS-COV-2 antibody of the present invention.For example, a first component may be deemed to be administered “after”a second component if the first component is administered 1 minuteafter, 5 minutes after, 10 minutes after, 15 minutes after, 30 minutesafter, 1 hour after, 2 hours after, 3 hours after, 4 hours after, 5hours after, 6 hours after, 12 hours after, 24 hours after, 36 hoursafter, 48 hours after, 60 hours after, 72 hours after administration ofthe second component. In yet other embodiments, the additionaltherapeutically active component(s) may be administered to a subjectconcurrent with administration of an anti-SARS-COV-2 antibody of thepresent invention. “Concurrent” administration, for purposes of thepresent invention, includes, e.g., administration of an anti-SARS-COV-2antibody and an additional therapeutically active component to a subjectin a single dosage form, or in separate dosage forms administered to thesubject within about 30 minutes or less of each other. If administeredin separate dosage forms, each dosage form may be administered via thesame route (e.g., both the anti-SARS-COV-2 antibody and the additionaltherapeutically active component may be administered intravenously,etc.); alternatively, each dosage form may be administered via adifferent route (e.g., the anti-SARS-COV-2 antibody may be administeredintravenously, and the additional therapeutically active component maybe administered orally). In any event, administering the components in asingle dosage from, in separate dosage forms by the same route, or inseparate dosage forms by different routes are all considered “concurrentadministration,” for purposes of the present disclosure. For purposes ofthe present disclosure, administration of an anti-SARS-COV-2 antibody“prior to,” “concurrent with,” or “after” (as those terms are definedhereinabove) administration of an additional therapeutically activecomponent is considered administration of an anti-SARS-COV-2 antibody“in combination with” an additional therapeutically active component.

The present invention includes pharmaceutical compositions in which ananti-SARS-COV-2 antibody of the present invention is co-formulated withone or more of the additional therapeutically active component(s) asdescribed elsewhere herein.

c. Administration Regimens

According to certain embodiments, a single dose of an anti-SARS-COV-2antibody of the invention (or a pharmaceutical composition comprising acombination of an anti-SARS-COV-2 antibody and any of the additionaltherapeutically active agents mentioned herein) may be administered to asubject in need thereof. According to certain embodiments of the presentinvention, multiple doses of an anti-SARS-COV-2 antibody (or apharmaceutical composition comprising a combination of ananti-SARS-COV-2 antibody and any of the additional therapeuticallyactive agents mentioned herein) may be administered to a subject over adefined time course. The methods according to this aspect of theinvention comprise sequentially administering to a subject multipledoses of an anti-SARS-COV-2 antibody of the invention. As used herein,“sequentially administering” means that each dose of anti-SARS-COV-2antibody is administered to the subject at a different point in time,e.g., on different days separated by a predetermined interval (e.g.,hours, days, weeks or months). The present invention includes methodswhich comprise sequentially administering to the patient a singleinitial dose of an anti-SARS-COV-2 antibody, followed by one or moresecondary doses of the anti-SARS-COV-2 antibody, and optionally followedby one or more tertiary doses of the anti-SARS-COV-2 antibody.

The terms “initial dose,” “secondary doses,” and “tertiary doses,” referto the temporal sequence of administration of the anti-SARS-COV-2antibody of the invention. Thus, the “initial dose” is the dose which isadministered at the beginning of the treatment regimen (also referred toas the “baseline dose”); the “secondary doses” are the doses which areadministered after the initial dose; and the “tertiary doses” are thedoses which are administered after the secondary doses. The initial,secondary, and tertiary doses may all contain the same amount ofanti-SARS-COV-2 antibody, but generally may differ from one another interms of frequency of administration. In some embodiments, however, theamount of anti-SARS-COV-2 antibody contained in the initial, secondaryand/or tertiary doses varies from one another (e.g., adjusted up or downas appropriate) during the course of treatment. In some embodiments, twoor more (e.g., 2, 3, 4, or 5) doses are administered at the beginning ofthe treatment regimen as “loading doses” followed by subsequent dosesthat are administered on a less frequent basis (e.g., “maintenancedoses”).

In certain exemplary embodiments of the present invention, eachsecondary and/or tertiary dose is administered 1 to 48 hours (e.g., 1,1½, 2, 2½, 3, 3½, 4, 4½, 5, 5½, 6, 6½, 7, 7½, 8, 8½, 9, 9½, 10, 10½, 11,11½, 12, 12½, 13, 13½, 14, 14½, 15, 15½, 16, 16½, 17, 17½, 18, 18½, 19,19½, 20, 20½, 21, 21½, 22, 22½, 23, 23½, 24, 24½, 25, 25½, 26, 26½, ormore) after the immediately preceding dose. The phrase “the immediatelypreceding dose,” as used herein, means, in a sequence of multipleadministrations, the dose of anti-SARS-COV-2 antibody, which isadministered to a patient prior to the administration of the very nextdose in the sequence with no intervening doses.

The methods, according to this aspect of the invention, may compriseadministering to a patient any number of secondary and/or tertiary dosesof an anti-SARS-COV-2 antibody. For example, In some embodiments, only asingle secondary dose is administered to the patient. In otherembodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondarydoses are administered to the patient. Likewise, In some embodiments,only a single tertiary dose is administered to the patient. In otherembodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiarydoses are administered to the patient.

In some embodiments of the invention, the frequency at which thesecondary and/or tertiary doses are administered to a patient can varyover the course of the treatment regimen. The frequency ofadministration may also be adjusted during the course of treatment by aphysician depending on the needs of the individual patient followingclinical examination.

d. Diagnostic Uses of the Antibodies

The anti-SARS-COV-2 antibodies of the present invention may be used todetect and/or measure SARS-COV-2 in a sample, e.g., for diagnosticpurposes. Some embodiments contemplate the use of one or more antibodiesof the present invention in assays to detect aSARS-COV-2-associated-disease or disorder. Exemplary diagnostic assaysfor SARS-COV-2 may comprise, e.g., contacting a sample, obtained from apatient, with an anti-SARS-COV-2 antibody of the invention, wherein theanti-SARS-COV-2 antibody is labeled with a detectable label or reportermolecule or used as a capture ligand to selectively isolate SARS-COV-2from patient samples. Alternatively, an unlabeled anti-SARS-COV-2antibody can be used in diagnostic applications in combination with asecondary antibody, which is itself detectably labeled. The detectablelabel or reporter molecule can be a radioisotope, such as H, C, P, S, orI; a fluorescent or chemiluminescent moiety such as fluoresceinisothiocyanate, or rhodamine; or an enzyme such as alkaline phosphatase,β-galactosidase, horseradish peroxidase, or luciferase. Specificexemplary assays that can be used to detect or measure SARS-COV-2 in asample include enzyme-linked immunosorbent assay (ELISA),radioimmunoassay (MA), and fluorescence-activated cell sorting (FACS).

In another aspect, this disclosure further provides a method fordetecting the presence of SARS CoV-2 in a sample comprising the stepsof: (i) contacting a sample with the antibody or antigen-bindingfragment thereof described above; and (ii) determining binding of theantibody or antigen-binding fragment to one or more SARS CoV-2 antigens,wherein binding of the antibody to the one or more SARS CoV-2 antigensis indicative of the presence of SARS CoV-2 in the sample.

In some embodiments, the SARS-CoV-2 antigen comprises a S polypeptide,such as a S polypeptide of a human or an animal SARS-CoV-2. In someembodiments, the SARS-CoV-2 antigen comprises the receptor-bindingdomain (RBD) of the S polypeptide. In some embodiments, the RBDcomprises amino acids 319-541 of the S polypeptide.

In some embodiments, the antibody or antigen-binding fragment thereof isconjugated to a label. In some embodiments, the step of detectingcomprises contacting a secondary antibody with the antibody orantigen-binding fragment thereof and wherein the secondary antibodycomprises a label. In some embodiments, the label includes a fluorescentlabel, a chemiluminescent label, a radiolabel, and an enzyme.

In some embodiments, the step of detecting comprises detectingfluorescence or chemiluminescence. In some embodiments, the step ofdetecting comprises a competitive binding assay or ELISA.

In some embodiments, the method further comprises binding the sample toa solid support. In some embodiments, the solid support includesmicroparticles, microbeads, magnetic beads, and an affinity purificationcolumn.

Samples that can be used in SARS-COV-2 diagnostic assays according tothe present invention include any tissue or fluid sample obtainable froma patient, which contains detectable quantities of either SARS-COV-2protein, or fragments thereof, under normal or pathological conditions.Generally, levels of SARS-COV-2 protein in a particular sample obtainedfrom a healthy patient (e.g., a patient not afflicted with a diseaseassociated with SARS-COV-2) will be measured to initially establish abaseline, or standard, level of SARS-COV-2. This baseline level ofSARS-COV-2 can then be compared against the levels of SARS-COV-2measured in samples obtained from individuals suspected of having aSARS-COV-2-associated condition, or symptoms associated with suchcondition.

The antibodies specific for SARS-COV-2 protein may contain no additionallabels or moieties, or they may contain an N-terminal or C-terminallabel or moiety. In one embodiment, the label or moiety is biotin. In abinding assay, the location of a label (if any) may determine theorientation of the peptide relative to the surface upon which thepeptide is bound. For example, if a surface is coated with avidin, apeptide containing an N-terminal biotin will be oriented such that theC-terminal portion of the peptide will be distal to the surface.

D. KITS

In another aspect, this disclosure provides a kit comprising apharmaceutically acceptable dose unit of the antibody or antigen-bindingfragment thereof of or the pharmaceutical composition as describedabove. Also within the scope of this disclosure is a kit for thediagnosis, prognosis or monitoring the treatment of SARS-CoV-2 in asubject, comprising: the antibody or antigen-binding fragment thereof asdescribed; and a least one detection reagent that binds specifically tothe antibody or antigen-binding fragment thereof.

In some embodiments, the kit also includes a container that contains thecomposition and optionally informational material. The informationalmaterial can be descriptive, instructional, marketing or other materialthat relates to the methods described herein and/or the use of theagents for therapeutic benefit. In an embodiment, the kit also includesan additional therapeutic agent, as described above. For example, thekit includes a first container that contains the composition and asecond container for the additional therapeutic agent.

The informational material of the kits is not limited in its form. Insome embodiments, the informational material can include informationabout production of the composition, concentration, date of expiration,batch or production site information, and so forth. In one embodiment,the informational material relates to methods of administering thecomposition, e.g., in a suitable dose, dosage form, or mode ofadministration (e.g., a dose, dosage form, or mode of administrationdescribed herein), to treat a subject in need thereof. In oneembodiment, the instructions provide a dosing regimen, dosing schedule,and/or route of administration of the composition or the additionaltherapeutic agent. The information can be provided in a variety offormats, including printed text, computer-readable material, videorecording, or audio recording, or information that contains a link oraddress to substantive material.

The kit can include one or more containers for the composition. In someembodiments, the kit contains separate containers, dividers orcompartments for the composition and informational material. Forexample, the composition can be contained in a bottle or vial, and theinformational material can be contained in a plastic sleeve or packet.In other embodiments, the separate elements of the kit are containedwithin a single, undivided container. For example, the composition iscontained in a bottle or vial that has attached thereto theinformational material in the form of a label. In some embodiments, thekit includes a plurality (e.g., a pack) of individual containers, eachcontaining one or more unit dosage forms (e.g., a dosage form describedherein) of the agents.

The kit optionally includes a device suitable for administration of thecomposition or other suitable delivery device. The device can beprovided pre-loaded with one or both of the agents or can be empty, butsuitable for loading. Such a kit may optionally contain a syringe toallow for injection of the antibody contained within the kit into ananimal, such as a human.

E. DEFINITIONS

To aid in understanding the detailed description of the compositions andmethods according to the disclosure, a few express definitions areprovided to facilitate an unambiguous disclosure of the various aspectsof the disclosure. Unless otherwise defined, all technical andscientific terms used herein have the same meaning as commonlyunderstood by one of ordinary skill in the art to which this disclosurebelongs.

The term “antibody” as referred to herein includes whole antibodies andany antigen-binding fragment or single chains thereof. Whole antibodiesare glycoproteins comprising at least two heavy (H) chains and two light(L) chains inter-connected by disulfide bonds. Each heavy chain iscomprised of a heavy chain variable region (abbreviated herein as VH)and a heavy chain constant region. The heavy chain constant region iscomprised of three domains, CH1, CH2 and CH3. Each light chain iscomprised of a light chain variable region (abbreviated herein as VL)and a light chain constant region. The light chain constant region iscomprised of one domain, CL. The VH and VL regions can be furthersubdivided into regions of hypervariability, termed complementaritydetermining regions (CDR), interspersed with regions that are moreconserved, termed framework regions (FR). Each VH and VL is composed ofthree CDRs and four FRs, arranged from amino-terminus tocarboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3,CDR3, FR4. The heavy chain variable region CDRs and FRs are HFR1, HCDR1,HFR2, HCDR2, HFR3, HCDR3, HFR4. The light chain variable region CDRs andFRs are LFR1, LCDR1, LFR2, LCDR2, LFR3, LCDR3, LFR4. The variableregions of the heavy and light chains contain a binding domain thatinteracts with an antigen. The constant regions of the antibodies canmediate the binding of the immunoglobulin to host tissues or factors,including various cells of the immune system (e.g., effector cells) andthe first component (CIq) of the classical complement system.

The term “antigen-binding fragment or portion” of an antibody (or simply“antibody fragment or portion”), as used herein, refers to one or morefragments of an antibody that retain the ability to specifically bind toan antigen (e.g., a Spike or S protein of SARS-CoV-2 virus). It has beenshown that the antigen-binding function of an antibody can be performedby fragments of a full-length antibody. Examples of binding fragmentsencompassed within the term “antigen-binding fragment or portion” of anantibody include (i) a Fab fragment, a monovalent fragment consisting ofthe VL, VH, CL and CHI domains; (ii) a F(ab′)2 fragment, a bivalentfragment comprising two Fab fragments linked by a disulfide bridge atthe hinge region; (iii) a Fab′ fragment, which is essentially a Fab withpart of the hinge region (see, FUNDAMENTAL IMMUNOLOGY (Paul ed., 3rd ed.1993)); (iv) a Fd fragment consisting of the VH and CHI domains; (v) aFv fragment consisting of the VL and VH domains of a single arm of anantibody, (vi) a dAb fragment (Ward et al., (1989) Nature 341:544-546),which consists of a VH domain; (vii) an isolated CDR; and (viii) ananobody, a heavy chain variable region containing a single variabledomain and two constant domains. Furthermore, although the two domainsof the Fv fragment, VL and VH, are coded for by separate genes, they canbe joined, using recombinant methods, by a synthetic linker that enablesthem to be made as a single protein chain in which the VL and VH regionspair to form monovalent molecules (known as single chain Fv or scFv);see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al.(1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chainantibodies are also intended to be encompassed within the term“antigen-binding fragment or portion” of an antibody. These antibodyfragments are obtained using conventional techniques known to those withskill in the art, and the fragments are screened for utility in the samemanner as are intact antibodies.

An “isolated antibody,” as used herein, is intended to refer to anantibody that is substantially free of other antibodies having differentantigenic specificities (e.g., an isolated antibody that specificallybinds to a Spike or S protein of SARS-CoV-2 virus is substantially freeof antibodies that specifically bind antigens other than theneuraminidase). An isolated antibody can be substantially free of othercellular material and/or chemicals.

The terms “monoclonal antibody” or “monoclonal antibody composition” asused herein refer to a preparation of antibody molecules of singlemolecular composition. A monoclonal antibody composition displays asingle binding specificity and affinity for a particular epitope.

The term “human antibody” is intended to include antibodies havingvariable regions in which both the framework and CDR regions are derivedfrom human germline immunoglobulin sequences. Furthermore, if theantibody contains a constant region, the constant region also is derivedfrom human germline immunoglobulin sequences. The human antibodies ofthe invention can include amino acid residues not encoded by humangermline immunoglobulin sequences (e.g., mutations introduced by randomor site-specific mutagenesis in vitro or by somatic mutation in vivo).However, the term “human antibody,” as used herein, is not intended toinclude antibodies in which CDR sequences derived from the germline ofanother mammalian species, such as a mouse, have been grafted onto humanframework sequences.

The term “human monoclonal antibody” refers to antibodies displaying asingle binding specificity, which have variable regions in which boththe framework and CDR regions are derived from human germlineimmunoglobulin sequences. In one embodiment, the human monoclonalantibodies can be produced by a hybridoma that includes a B cellobtained from a transgenic nonhuman animal, e.g., a transgenic mouse,having a genome comprising a human heavy chain transgene and a lightchain transgene fused to an immortalized cell.

The term “recombinant human antibody,” as used herein, includes allhuman antibodies that are prepared, expressed, created or isolated byrecombinant means, such as (a) antibodies isolated from an animal (e.g.,a mouse) that is transgenic or transchromosomal for human immunoglobulingenes or a hybridoma prepared therefrom (described further below), (b)antibodies isolated from a host cell transformed to express the humanantibody, e.g., from a transfectoma, (c) antibodies isolated from arecombinant, combinatorial human antibody library, and (d) antibodiesprepared, expressed, created or isolated by any other means that involvesplicing of human immunoglobulin gene sequences to other DNA sequences.Such recombinant human antibodies have variable regions in which theframework and CDR regions are derived from human germline immunoglobulinsequences. In some embodiments, however, such recombinant humanantibodies can be subjected to in vitro mutagenesis (or, when an animaltransgenic for human Ig sequences is used, in vivo somatic mutagenesis)and thus the amino acid sequences of the VH and VL regions of therecombinant antibodies are sequences that, while derived from andrelated to human germline VH and VL sequences, may not naturally existwithin the human antibody germline repertoire in vivo.

The term “isotype” refers to the antibody class (e.g., IgM or IgG1) thatis encoded by the heavy chain constant region genes. The phrases “anantibody recognizing an antigen” and “an antibody specific for anantigen” are used interchangeably herein with the term “an antibodywhich binds specifically to an antigen.”

The term “human antibody derivatives” refers to any modified form of thehuman antibody, e.g., a conjugate of the antibody and another agent orantibody. The term “humanized antibody” is intended to refer toantibodies in which CDR sequences derived from the germline of anothermammalian species, such as a mouse, have been grafted onto humanframework sequences. Additional framework region modifications can bemade within the human framework sequences.

The term “chimeric antibody” is intended to refer to antibodies in whichthe variable region sequences are derived from one species, and theconstant region sequences are derived from another species, such as anantibody in which the variable region sequences are derived from a mouseantibody, and the constant region sequences are derived from a humanantibody. The term can also refer to an antibody in which its variableregion sequence or CDR(s) is derived from one source (e.g., an IgA1antibody) and the constant region sequence or Fc is derived from adifferent source (e.g., a different antibody, such as an IgG, IgA2, IgD,IgE or IgM antibody).

The invention encompasses isolated or substantially purified nucleicacids, peptides, polypeptides or proteins. In the context of the presentinvention, an “isolated” nucleic acid, DNA or RNA molecule or an“isolated” polypeptide is a nucleic acid, DNA molecule, RNA molecule, orpolypeptide that exists apart from its native environment and istherefore not a product of nature. An isolated nucleic acid, DNAmolecule, RNA molecule or polypeptide may exist in a purified form ormay exist in a non-native environment such as, for example, a transgenichost cell. A “purified” nucleic acid molecule, peptide, polypeptide orprotein, or a fragment thereof, is substantially free of other cellularmaterial, or culture medium when produced by recombinant techniques, orsubstantially free of chemical precursors or other chemicals whenchemically synthesized. In one embodiment, an “isolated” nucleic acid isfree of sequences that naturally flank the nucleic acid (i.e., sequenceslocated at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA ofthe organism from which the nucleic acid is derived. For example, invarious embodiments, the isolated nucleic acid molecule can contain lessthan about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotidesequences that naturally flank the nucleic acid molecule in genomic DNAof the cell from which the nucleic acid is derived. A protein, peptideor polypeptide that is substantially free of cellular material includespreparations of protein, peptide or polypeptide having less than about30%, 20%, 10%, or 5% (by dry weight) of contaminating protein. When theprotein of the invention, or biologically active portion thereof, isrecombinantly produced, preferably culture medium represents less thanabout 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors ornon-protein-of-interest chemicals.

The terms polypeptide, peptide, and protein are used interchangeablyherein.

The terms “polypeptide,” “peptide,” and “protein” are usedinterchangeably herein to refer to polymers of amino acids of anylength. The polymer may be linear or branched, it may comprise modifiedamino acids, and it may be interrupted by non-amino acids. The termsalso encompass an amino acid polymer that has been modified; forexample, disulfide bond formation, glycosylation, lipidation,acetylation, phosphorylation, pegylation, or any other manipulation,such as conjugation with a labeling component. As used herein, the term“amino acid” includes natural and/or unnatural or synthetic amino acids,including glycine and both the D or L optical isomers, and amino acidanalogs and peptidomimetics.

A peptide or polypeptide “fragment” as used herein refers to a less thanfull-length peptide, polypeptide or protein. For example, a peptide orpolypeptide fragment can have is at least about 3, at least about 4, atleast about 5, at least about 10, at least about 20, at least about 30,at least about 40 amino acids in length, or single unit lengths thereof.For example, fragment may be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,or more amino acids in length. There is no upper limit to the size of apeptide fragment. However, in some embodiments, peptide fragments can beless than about 500 amino acids, less than about 400 amino acids, lessthan about 300 amino acids or less than about 250 amino acids in length.Preferably the peptide fragment can elicit an immune response when usedto inoculate an animal. A peptide fragment may be used to elicit animmune response by inoculating an animal with a peptide fragment incombination with an adjuvant, a peptide fragment that is coupled to anadjuvant, or a peptide fragment that is coupled to arsanilic acid,sulfanilic acid, an acetyl group, or a picryl group. A peptide fragmentcan include a non-amide bond and can be a peptidomimetic.

As used herein, the term “conjugate” or “conjugation” or “linked” asused herein refers to the attachment of two or more entities to form oneentity. A conjugate encompasses both peptide-small molecule conjugatesas well as peptide-protein/peptide conjugates.

The term “recombinant,” as used herein, refers to antibodies orantigen-binding fragments thereof of the invention created, expressed,isolated or obtained by technologies or methods known in the art asrecombinant DNA technology which include, e.g., DNA splicing andtransgenic expression. The term refers to antibodies expressed in anon-human mammal (including transgenic non-human mammals, e.g.,transgenic mice), or a cell (e.g., CHO cells) expression system orisolated from a recombinant combinatorial human antibody library.

A “nucleic acid” or “polynucleotide” refers to a DNA molecule (forexample, but not limited to, a cDNA or genomic DNA) or an RNA molecule(for example, but not limited to, an mRNA), and includes DNA or RNAanalogs. A DNA or RNA analog can be synthesized from nucleotide analogs.The DNA or RNA molecules may include portions that are not naturallyoccurring, such as modified bases, modified backbone,deoxyribonucleotides in an RNA, etc. The nucleic acid molecule can besingle-stranded or double-stranded.

The term “substantial identity” or “substantially identical,” whenreferring to a nucleic acid or fragment thereof, indicates that, whenoptimally aligned with appropriate nucleotide insertions or deletionswith another nucleic acid (or its complementary strand), there isnucleotide sequence identity in at least about 90%, and more preferablyat least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases, asmeasured by any well-known algorithm of sequence identity, such asFASTA, BLAST or GAP, as discussed below. A nucleic acid molecule havingsubstantial identity to a reference nucleic acid molecule may, incertain instances, encode a polypeptide having the same or substantiallysimilar amino acid sequence as the polypeptide encoded by the referencenucleic acid molecule.

As applied to polypeptides, the term “substantial similarity” or“substantially similar” means that two peptide sequences, when optimallyaligned, such as by the programs GAP or BESTFIT using default gapweights, share at least 90% sequence identity, even more preferably atleast 95%, 98% or 99% sequence identity. Preferably, residue positions,which are not identical, differ by conservative amino acidsubstitutions. A “conservative amino acid substitution” is one in whichan amino acid residue is substituted by another amino acid residuehaving a side chain (R group) with similar chemical properties (e.g.,charge or hydrophobicity). In general, a conservative amino acidsubstitution will not substantially change the functional properties ofa protein. In cases where two or more amino acid sequences differ fromeach other by conservative substitutions, the percent or degree ofsimilarity may be adjusted upwards to correct for the conservativenature of the substitution. Means for making this adjustment are wellknown to those of skill in the art. See, e.g., Pearson (1994) MethodsMol. Biol. 24: 307-331, which is herein incorporated by reference.Examples of groups of amino acids that have side chains with similarchemical properties include 1) aliphatic side chains: glycine, alanine,valine, leucine, and isoleucine; 2) aliphatic-hydroxyl side chains:serine and threonine; 3) amide-containing side chains: asparagine andglutamine; 4) aromatic side chains: phenylalanine, tyrosine, andtryptophan; 5) basic side chains: lysine, arginine, and histidine; 6)acidic side chains: aspartate and glutamate, and 7) sulfur-containingside chains: cysteine and methionine. Preferred conservative amino acidssubstitution groups are: valine-leucine-isoleucine,phenylalanine-tyrosine, lysine-arginine, alanine-valine,glutamate-aspartate, and asparagine-glutamine. Alternatively, aconservative replacement is any change having a positive value in thePAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science256: 1443 45, herein incorporated by reference. A “moderatelyconservative” replacement is any change having a nonnegative value inthe PAM250 log-likelihood matrix.

Sequence similarity for polypeptides is typically measured usingsequence analysis software. Protein analysis software matches similarsequences using measures of similarity assigned to varioussubstitutions, deletions, and other modifications, includingconservative amino acid substitutions. For instance, GCG softwarecontains programs such as GAP and BESTFIT, which can be used withdefault parameters to determine sequence homology or sequence identitybetween closely related polypeptides, such as homologous polypeptidesfrom different species of organisms or between a wild type protein and amutein thereof. See, e.g., GCG Version 6.1. Polypeptide sequences alsocan be compared using FASTA with default or recommended parameters; aprogram in GCG Version 6.1. FASTA (e.g., FASTA2 and FASTA3) providesalignments and percent sequence identity of the regions of the bestoverlap between the query and search sequences (Pearson (2000) supra).Another preferred algorithm when comparing a sequence of the inventionto a database containing a large number of sequences from differentorganisms is the computer program BLAST, especially BLASTP or TBLASTN,using default parameters. See, e.g., Altschul et al. (1990) J. Mol.Biol. 215: 403-410 and (1997) Nucleic Acids Res. 25:3389-3402, each ofwhich is herein incorporated by reference.

As used herein, the term “affinity” refers to the strength of the sumtotal of noncovalent interactions between a single binding site of amolecule (e.g., an antibody) and its binding partner (e.g., an antigen).Unless indicated otherwise, as used herein, “binding affinity” refers tointrinsic binding affinity, which reflects a 1:1 interaction betweenmembers of a binding pair (e.g., antibody and antigen). The affinity ofa molecule X for its partner Y can generally be represented by thedissociation constant (KD). Affinity can be measured by common methodsknown in the art, including those described herein.

The term “specifically binds,” or “binds specifically to,” or the like,refers to an antibody that binds to a single epitope, e.g., underphysiologic conditions, but which does not bind to more than oneepitope. Accordingly, an antibody that specifically binds to apolypeptide will bind to an epitope that present on the polypeptide, butwhich is not present on other polypeptides. Specific binding can becharacterized by an equilibrium dissociation constant of at least about1×10-8 M or less (e.g., a smaller KD denotes a tighter binding). Methodsfor determining whether two molecules specifically bind are well knownin the art and include, for example, equilibrium dialysis, surfaceplasmon resonance, and the like. As described herein, antibodies havebeen identified by surface plasmon resonance, e.g., BIACORE™, which bindspecifically to a Spike or S protein of SARS-CoV-2 virus.

Preferably, the antibody binds to a Spike or S protein with “highaffinity,” namely with a KD of 1×10−7 M or less, more preferably 5×10−8M or less, more preferably 3×10−8 M or less, more preferably 1×10−8 M orless, more preferably 5×10−9 M or less or even more preferably 1×10−9 Mor less, as determined by surface plasmon resonance, e.g., BIACORE. Theterm “does not substantially bind” to a protein or cells, as usedherein, means does not bind or does not bind with a high affinity to theprotein or cells, i.e., binds to the protein or cells with a KD of1×10−6 M or more, more preferably 1×10−5 M or more, more preferably1×10−4 M or more, more preferably 1×10−3 M or more, even more preferably1×10−2 M or more.

The term “Kassoc” or “Ka,” as used herein, is intended to refer to theassociation rate of a particular antibody-antigen interaction, whereasthe term “Kdis” or “Kd,” as used herein, is intended to refer to thedissociation rate of a particular antibody-antigenn interaction. Theterm “KD,” as used herein, is intended to refer to the dissociationconstant, which is obtained from the ratio of Kd to Ka (i.e., Kd/Ka) andis expressed as a molar concentration (M). KD values for antibodies canbe determined using methods well established in the art. A preferredmethod for determining the KD of an antibody is by using surface plasmonresonance, preferably using a biosensor system such as a BIACORE system.

Antibodies that “compete with another antibody for binding to a target”refer to antibodies that inhibit (partially or completely) the bindingof the other antibody to the target. Whether two antibodies compete witheach other for binding to a target, i.e., whether and to what extent oneantibody inhibits the binding of the other antibody to a target, may bedetermined using known competition experiments. In some embodiments, anantibody competes with, and inhibits binding of another antibody to atarget by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%.The level of inhibition or competition may be different depending onwhich antibody is the “blocking antibody” (i.e., the cold antibody thatis incubated first with the target). Competition assays can be conductedas described, for example, in Ed Harlow and David Lane, Cold Spring HarbProtoc; 2006 or in Chapter 11 of “Using Antibodies” by Ed Harlow andDavid Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,N.Y., USA 1999. Competing antibodies bind to the same epitope, anoverlapping epitope or to adjacent epitopes (e.g., as evidenced bysteric hindrance). Other competitive binding assays include: solid phasedirect or indirect radioimmunoassay (MA), solid phase direct or indirectenzyme immunoassay (EIA), sandwich competition assay (see Stahli et al.,Methods in Enzymology 9:242 (1983)); solid phase direct biotin-avidinEIA (see Kirkland et al., J. Immunol. 137:3614 (1986)); solid phasedirect labeled assay, solid phase direct labeled sandwich assay (seeHarlow and Lane, Antibodies: A Laboratory Manual, Cold Spring HarborPress (1988)); solid phase direct label RIA using 1-125 label (see Morelet al., Mol. Immunol. 25(1):7 (1988)); solid phase direct biotin-avidinEIA (Cheung et al., Virology 176:546 (1990)); and direct labeled RIA.(Moldenhauer et al., Scand. J. Immunol. 32:77 (1990)).

The term “epitope” as used herein refers to an antigenic determinantthat interacts with a specific antigen-binding site in the variableregion of an antibody molecule known as a paratope. A single antigen mayhave more than one epitope. Thus, different antibodies may bind todifferent areas on an antigen and may have different biological effects.The term “epitope” also refers to a site on an antigen to which B and/orT cells respond. It also refers to a region of an antigen that is boundby an antibody. Epitopes may be defined as structural or functional.Functional epitopes are generally a subset of the structural epitopesand have those residues that directly contribute to the affinity of theinteraction. Epitopes may also be conformational, that is, composed ofnon-linear amino acids. In some embodiments, epitopes may includedeterminants that are chemically active surface groupings of moleculessuch as amino acids, sugar side chains, phosphoryl groups, or sulfonylgroups, and, In some embodiments, may have specific three-dimensionalstructural characteristics, and/or specific charge characteristics. Anepitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14 or 15 amino acids in a unique spatial conformation. Methods fordetermining what epitopes are bound by a given antibody (i.e., epitopemapping) are well known in the art and include, for example,immunoblotting and immune-precipitation assays, wherein overlapping orcontiguous peptides from a Spike or S protein are tested for reactivitywith a given antibody. Methods of determining spatial conformation ofepitopes include techniques in the art and those described herein, forexample, x-ray crystallography and 2-dimensional nuclear magneticresonance (see, e.g., Epitope Mapping Protocols in Methods in MolecularBiology, Vol. 66, G. E. Morris, Ed. (1996)).

The term “epitope mapping” refers to the process of identification ofthe molecular determinants for antibody-antigen recognition.

The term “binds to an epitope” or “recognizes an epitope” with referenceto an antibody or antibody fragment refers to continuous ordiscontinuous segments of amino acids within an antigen. Those of skillin the art understand that the terms do not necessarily mean that theantibody or antibody fragment is in direct contact with every amino acidwithin an epitope sequence.

The term “binds to the same epitope” with reference to two or moreantibodies means that the antibodies bind to the same, overlapping orencompassing continuous or discontinuous segments of amino acids. Thoseof skill in the art understand that the phrase “binds to the sameepitope” does not necessarily mean that the antibodies bind to orcontact exactly the same amino acids. The precise amino acids that theantibodies contact can differ. For example, a first antibody can bind toa segment of amino acids that is completely encompassed by the segmentof amino acids bound by a second antibody. In another example, a firstantibody binds one or more segments of amino acids that significantlyoverlap the one or more segments bound by the second antibody. For thepurposes herein, such antibodies are considered to “bind to the sameepitope.”

As used herein, the term “immune response” refers to a biologicalresponse within a vertebrate against foreign agents, which responseprotects the organism against these agents and diseases caused by them.An immune response is mediated by the action of a cell of the immunesystem (for example, a T lymphocyte, B lymphocyte, natural killer (NK)cell, macrophage, eosinophil, mast cell, dendritic cell or neutrophil)and soluble macromolecules produced by any of these cells or the liver(including antibodies, cytokines, and complement) that results inselective targeting, binding to, damage to, destruction of, and/orelimination from the vertebrate's body of invading pathogens, cells ortissues infected with pathogens, cancerous or other abnormal cells, or,in cases of autoimmunity or pathological inflammation, normal humancells or tissues. An immune reaction includes, e.g., activation orinhibition of a T cell, e.g., an effector T cell or a Th cell, such as aCD4+ or CD8+ T cell, or the inhibition of a Treg cell.

The term “detectable label” as used herein refers to a molecule capableof detection, including, but not limited to, radioactive isotopes,fluorescers, chemiluminescers, chromophores, enzymes, enzyme substrates,enzyme cofactors, enzyme inhibitors, chromophores, dyes, metal ions,metal sols, ligands (e.g., biotin, avidin, streptavidin or haptens),intercalating dyes and the like. The term “fluorescer” refers to asubstance or a portion thereof that is capable of exhibitingfluorescence in the detectable range.

In many embodiments, the terms “subject” and “patient” are usedinterchangeably irrespective of whether the subject has or is currentlyundergoing any form of treatment. As used herein, the terms “subject”and “subjects” may refer to any vertebrate, including, but not limitedto, a mammal (e.g., cow, pig, camel, llama, horse, goat, rabbit, sheep,hamsters, guinea pig, cat, dog, rat, and mouse, a non-human primate (forexample, a monkey, such as a cynomolgus monkey, chimpanzee, etc.) and ahuman). The subject may be a human or a non-human. In more exemplaryaspects, the mammal is a human. As used herein, the expression “asubject in need thereof” or “a patient in need thereof” means a human ornon-human mammal that exhibits one or more symptoms or indications ofdisorders (e.g., neuronal disorders, autoimmune diseases, andcardiovascular diseases), and/or who has been diagnosed withinflammatory disorders. In some embodiments, the subject is a mammal. Insome embodiments, the subject is human.

As used herein, the term “disease” is intended to be generallysynonymous and is used interchangeably with, the terms “disorder” and“condition” (as in medical condition), in that all reflect an abnormalcondition (e.g., inflammatory disorder) of the human or animal body orof one of its parts that impairs normal functioning, is typicallymanifested by distinguishing signs and symptoms, and causes the human oranimal to have a reduced duration or quality of life.

As used herein, the term “treating” or “treatment” of any disease ordisorder refers in one embodiment, to ameliorating the disease ordisorder (i.e., arresting or reducing the development of the disease orat least one of the clinical symptoms thereof). In another embodiment,“treating” or “treatment” refers to ameliorating at least one physicalparameter, which may not be discernible by the patient. In yet anotherembodiment, “treating” or “treatment” refers to modulating the diseaseor disorder, either physically, (e.g., stabilization of a discerniblesymptom), physiologically, (e.g., stabilization of a physicalparameter), or both. In yet another embodiment, “treating” or“treatment” refers to preventing or delaying the onset or development orprogression of the disease or disorder.

The terms “prevent,” “preventing,” “prevention,” “prophylactictreatment” and the like refer to reducing the probability of developinga disorder or condition in a subject, who does not have, but is at riskof or susceptible to developing a disorder or condition.

The terms “decrease,” “reduced,” “reduction,” “decrease,” or “inhibit”are all used herein generally to mean a decrease by a statisticallysignificant amount. However, for avoidance of doubt, “reduced,”“reduction” or “decrease” or “inhibit” means a decrease by at least 10%as compared to a reference level, for example, a decrease by at leastabout 20%, or at least about 30%, or at least about 40%, or at leastabout 50%, or at least about 60%, or at least about 70%, or at leastabout 80%, or at least about 90% or up to and including a 100% decrease(e.g., absent level as compared to a reference sample), or any decreasebetween 10-100% as compared to a reference level.

As used herein, the term “agent” denotes a chemical compound, a mixtureof chemical compounds, a biological macromolecule (such as a nucleicacid, an antibody, a protein or portion thereof, e.g., a peptide), or anextract made from biological materials such as bacteria, plants, fungi,or animal (particularly mammalian) cells or tissues. The activity ofsuch agents may render it suitable as a “therapeutic agent,” which is abiologically, physiologically, or pharmacologically active substance (orsubstances) that acts locally or systemically in a subject.

As used herein, the terms “therapeutic agent,” “therapeutic capableagent,” or “treatment agent” are used interchangeably and refer to amolecule or compound that confers some beneficial effect uponadministration to a subject. The beneficial effect includes enablementof diagnostic determinations; amelioration of a disease, symptom,disorder, or pathological condition; reducing or preventing the onset ofa disease, symptom, disorder, or condition; and generally counteractinga disease, symptom, disorder or pathological condition.

The term “therapeutic effect” is art-recognized and refers to a local orsystemic effect in animals, particularly mammals, and more particularlyhumans caused by a pharmacologically active substance.

The term “effective amount,” “effective dose,” or “effective dosage” isdefined as an amount sufficient to achieve or at least partially achievea desired effect. A “therapeutically effective amount” or“therapeutically effective dosage” of a drug or therapeutic agent is anyamount of the drug that, when used alone or in combination with anothertherapeutic agent, promotes disease regression evidenced by a decreasein severity of disease symptoms, an increase in frequency and durationof disease symptom-free periods, or a prevention of impairment ordisability due to the disease affliction. A “prophylactically effectiveamount” or a “prophylactically effective dosage” of a drug is an amountof the drug that, when administered alone or in combination with anothertherapeutic agent to a subject at risk of developing a disease or ofsuffering a recurrence of disease, inhibits the development orrecurrence of the disease. The ability of a therapeutic or prophylacticagent to promote disease regression or inhibit the development orrecurrence of the disease can be evaluated using a variety of methodsknown to the skilled practitioner, such as in human subjects duringclinical trials, in animal model systems predictive of efficacy inhumans, or by assaying the activity of the agent in in vitro assays.

Doses are often expressed in relation to bodyweight. Thus, a dose whichis expressed as [g, mg, or other unit]/kg (or g, mg etc.) usually refersto [g, mg, or other unit] “per kg (or g, mg etc.) bodyweight,” even ifthe term “bodyweight” is not explicitly mentioned.

As used herein, the term “composition” or “pharmaceutical composition”refers to a mixture of at least one component useful within theinvention with other components, such as carriers, stabilizers,diluents, dispersing agents, suspending agents, thickening agents,and/or excipients. The pharmaceutical composition facilitatesadministration of one or more components of the invention to anorganism.

As used herein, the term “pharmaceutically acceptable” refers to amaterial, such as a carrier or diluent, which does not abrogate thebiological activity or properties of the composition, and is relativelynon-toxic, i.e., the material may be administered to an individualwithout causing undesirable biological effects or interacting in adeleterious manner with any of the components of the composition inwhich it is contained.

As used herein, the term “pharmaceutically acceptable carrier” includesa pharmaceutically acceptable salt, pharmaceutically acceptablematerial, composition or carrier, such as a liquid or solid filler,diluent, excipient, solvent or encapsulating material, involved incarrying or transporting a compound(s) of the present invention withinor to the subject such that it may perform its intended function.Typically, such compounds are carried or transported from one organ, orportion of the body, to another organ, or portion of the body. Each saltor carrier must be “acceptable” in the sense of being compatible withthe other ingredients of the formulation and not injurious to thesubject. Some examples of materials that may serve as pharmaceuticallyacceptable carriers include: sugars, such as lactose, glucose, andsucrose; starches, such as corn starch and potato starch; cellulose, andits derivatives, such as sodium carboxymethyl cellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin;talc; excipients, such as cocoa butter and suppository waxes; oils, suchas peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil,corn oil, and soybean oil; glycols, such as propylene glycol; polyols,such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters,such as ethyl oleate and ethyl laurate; agar; buffering agents, such asmagnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-freewater; isotonic saline; Ringer's solution; ethyl alcohol; phosphatebuffer solutions; diluent; granulating agent; lubricant; binder;disintegrating agent; wetting agent; emulsifier; coloring agent; releaseagent; coating agent; sweetening agent; flavoring agent; perfumingagent; preservative; antioxidant; plasticizer; gelling agent; thickener;hardener; setting agent; suspending agent; surfactant; humectant;carrier; stabilizer; and other non-toxic compatible substances employedin pharmaceutical formulations, or any combination thereof. As usedherein, “pharmaceutically acceptable carrier” also includes any and allcoatings, antibacterial and antifungal agents, and absorption delayingagents, and the like that are compatible with the activity of one ormore components of the invention, and are physiologically acceptable tothe subject. Supplementary active compounds may also be incorporatedinto the compositions.

“Combination” therapy, as used herein, unless otherwise clear from thecontext, is meant to encompass administration of two or more therapeuticagents in a coordinated fashion and includes, but is not limited to,concurrent dosing. Specifically, combination therapy encompasses bothco-administration (e.g., administration of a co-formulation orsimultaneous administration of separate therapeutic compositions) andserial or sequential administration, provided that administration of onetherapeutic agent is conditioned in some way on the administration ofanother therapeutic agent. For example, one therapeutic agent may beadministered only after a different therapeutic agent has beenadministered and allowed to act for a prescribed period of time. See,e.g., Kohrt et al. (2011) Blood 117:2423.

As used herein, the term “co-administration” or “co-administered” refersto the administration of at least two agent(s) or therapies to asubject. In some embodiments, the co-administration of two or moreagents/therapies is concurrent. In other embodiments, a firstagent/therapy is administered prior to a second agent/therapy. Those ofskill in the art understand that the formulations and/or routes ofadministration of the various agents/therapies used may vary.

As used herein, the term “contacting,” when used in reference to any setof components, includes any process whereby the components to becontacted are mixed into the same mixture (for example, are added intothe same compartment or solution), and does not necessarily requireactual physical contact between the recited components. The recitedcomponents can be contacted in any order or any combination (orsub-combination) and can include situations where one or some of therecited components are subsequently removed from the mixture, optionallyprior to addition of other recited components. For example, “contactingA with B and C” includes any and all of the following situations: (i) Ais mixed with C, then B is added to the mixture; (ii) A and B are mixedinto a mixture; B is removed from the mixture, and then C is added tothe mixture; and (iii) A is added to a mixture of B and C.

“Sample,” “test sample,” and “patient sample” may be usedinterchangeably herein. The sample can be a sample of serum, urineplasma, amniotic fluid, cerebrospinal fluid, cells, or tissue. Such asample can be used directly as obtained from a patient or can bepre-treated, such as by filtration, distillation, extraction,concentration, centrifugation, inactivation of interfering components,addition of reagents, and the like, to modify the character of thesample in some manner as discussed herein or otherwise as is known inthe art. The terms “sample” and “biological sample” as used hereingenerally refer to a biological material being tested for and/orsuspected of containing an analyte of interest such as antibodies. Thesample may be any tissue sample from the subject. The sample maycomprise protein from the subject.

As used herein, the term “in vitro” refers to events that occur in anartificial environment, e.g., in a test tube or reaction vessel, in cellculture, etc., rather than within a multi-cellular organism.

As used herein, the term “in vivo” refers to events that occur within amulti-cellular organism, such as a non-human animal.

As used herein, the singular forms “a,” “an,” and “the” include pluralreferences unless the context clearly dictates otherwise.

As used herein, the terms “including,” “comprising,” “containing,” or“having” and variations thereof are meant to encompass the items listedthereafter and equivalents thereof as well as additional subject matterunless otherwise noted.

As used herein, the phrases “in one embodiment,” “in variousembodiments,” “in some embodiments,” and the like are used repeatedly.Such phrases do not necessarily refer to the same embodiment, but theymay unless the context dictates otherwise.

As used herein, the terms “and/or” or “/” means any one of the items,any combination of the items, or all of the items with which this termis associated.

As used herein, the word “substantially” does not exclude “completely,”e.g., a composition which is “substantially free” from Y may becompletely free from Y. Where necessary, the word “substantially” may beomitted from the definition of the invention.

As used herein, the term “each,” when used in reference to a collectionof items, is intended to identify an individual item in the collectionbut does not necessarily refer to every item in the collection.Exceptions can occur if explicit disclosure or context clearly dictatesotherwise.

As used herein, the term “approximately” or “about,” as applied to oneor more values of interest, refers to a value that is similar to astated reference value. In some embodiments, the term “approximately” or“about” refers to a range of values that fall within 25%, 20%, 19%, 18%,17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%,1%, or less in either direction (greater than or less than) of thestated reference value unless otherwise stated or otherwise evident fromthe context (except where such number would exceed 100% of a possiblevalue). Unless indicated otherwise herein, the term “about” is intendedto include values, e.g., weight percents, proximate to the recited rangethat are equivalent in terms of the functionality of the individualingredient, the composition, or the embodiment.

As disclosed herein, a number of ranges of values are provided. It isunderstood that each intervening value, to the tenth of the unit of thelower limit, unless the context clearly dictates otherwise, between theupper and lower limits of that range is also specifically disclosed.Each smaller range between any stated value or intervening value in astated range and any other stated or intervening value in that statedrange is encompassed within the invention. The upper and lower limits ofthese smaller ranges may independently be included or excluded in therange, and each range where either, neither, or both limits are includedin the smaller ranges is also encompassed within the invention, subjectto any specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either orboth of those included limits are also included in the invention.

The use of any and all examples, or exemplary language (e.g., “such as”)provided herein, is intended merely to better illuminate the inventionand does not pose a limitation on the scope of the invention unlessotherwise claimed. No language in the specification should be construedas indicating any non-claimed element as essential to the practice ofthe invention.

All methods described herein are performed in any suitable order unlessotherwise indicated herein or otherwise clearly contradicted by context.In regard to any of the methods provided, the steps of the method mayoccur simultaneously or sequentially. When the steps of the method occursequentially, the steps may occur in any order, unless noted otherwise.In cases in which a method comprises a combination of steps, each andevery combination or sub-combination of the steps is encompassed withinthe scope of the disclosure, unless otherwise noted herein.

Each publication, patent application, patent, and other reference citedherein is incorporated by reference in its entirety to the extent thatit is not inconsistent with the present disclosure. Publicationsdisclosed herein are provided solely for their disclosure prior to thefiling date of the present invention. Nothing herein is to be construedas an admission that the present invention is not entitled to antedatesuch publication by virtue of prior invention. Further, the dates ofpublication provided may be different from the actual publication dates,which may need to be independently confirmed.

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to persons skilled in the art and areto be included within the spirit and purview of this application andscope of the appended claims.

F. EXAMPLES Example 1

This example describes the materials, methods, and instrumentation usedin EXAMPLE 2.

Study participants. Study participants were recruited at the RockefellerUniversity Hospital in New York from April 1 through May 8, 2020.Eligible participants were adults aged 18-76 years who were eitherdiagnosed with SARS-CoV-2 infection by RT-PCR and were free of symptomsof COVID-19 for at least 14 days (cases), or who were close contacts(e.g., household, co-workers, members of the same religious community)with someone who had been diagnosed with SARS-CoV-2 infection by RT-PCRand were free of symptoms suggestive of COVID-19 for at least 14 days(contacts). Exclusion criteria included the presence of symptomssuggestive of active SARS-CoV-2 infection, or hemoglobin <12 g/dL formales and <11 g/dL for females.

Most study participants were residents of the Greater New York Citytri-state region and were enrolled sequentially according to eligibilitycriteria. Participants were first interviewed by phone to collectinformation on their clinical presentation and subsequently presented tothe Rockefeller University Hospital for a single blood samplecollection. Participants were asked to rate the highest severity oftheir symptoms on a numeric rating scale ranging from 0 to 10. The scorewas adapted from the pain scale chart, where 0 was the lack of symptoms,4 were distressing symptoms (e.g., fatigue, myalgia, fever, cough,shortness of breath) that interfered with daily living activities, 7were disabling symptoms that prevented the performance of daily livingactivities, and 10 were unimaginable/unspeakable discomfort (in thiscase, distress due to shortness of breath). All participants providedwritten informed consent before participation in the study, and thestudy was conducted in accordance with Good Clinical Practice, andclinical data collection and management was with software iRIS byiMedRIS. The study was performed in compliance with all relevant ethicalregulations, and the protocol for human subject studies was approved bythe Institutional Review Board (IRB) of the Rockefeller University.

Blood samples processing and storage. Peripheral Blood Mononuclear Cells(PBMCs) were obtained by gradient centrifugation and stored in liquidnitrogen in the presence of FCS and DMSO. Heparinized plasma and serumsamples were aliquoted and stored at −20° C. or less. Prior toexperiments, aliquots of plasma samples were heat-inactivated (56C for 1hour) and then stored at 4C.

Cloning, expression, and purification of recombinant coronavirusproteins. Codon-optimized nucleotide sequences encoding the SARS-CoV-2 Sectodomain (residues 16-1206) and receptor-binding domain (RBD; residues331-524) were synthesized and subcloned into the mammalian expressionpTwist-CMV BetaGlobin vector by Twist Bioscience Technologies based onan early SARS-CoV-2 sequence isolate (GenBank MN985325.1). TheSARS-CoV-2 RBD construct included an N-terminal human IL-2 signalpeptide and dual C-terminal tags ((GGGGS)₂-HHHHHHHH (SEQ ID NO: 3233)(octa-histidine), and GLNDIFEAQKIEWHE (SEQ ID NO: 3234) (AviTag)). Inaddition, the corresponding S1^(B) or receptor binding domains forSARS-CoV (residues 318-510; GenBank AAP13441.1), MERS-CoV (residues367-588; GenBank JX869059.2), HCoV-NL63 (residues 481-614; GenBankAAS58177.1), HCoV-OC43 (residues 324-632; GenBank AAT84362.1), andHCoV-229E (residues 286-434; GenBank AAK32191.1) were synthesized withthe same N- and C-terminal extensions as the SARS-CoV-2 RBD constructand subcloned into the mammalian expression pTwist-CMV BetaGlobin vector(Twist Bioscience Technologies). The SARS-CoV-2 S ectodomain wasmodified as previously described (Walls, A. C. et al. Cell 181, 281-292e286 (2020).). Briefly, the S ectodomain construct included anN-terminal mu-phosphatase signal peptide, 2P stabilizing mutations(K986P and V987P), mutations to remove the S1/S2 furin cleavage site(₆₈₂RRAR₆₈₅ (SEQ ID NO: 3235) to GSAS (SEQ ID NO: 3236)), a C-terminalextension (IKGSG-RENLYFQG (SEQ ID NO: 3237) (TEV protease site),GGGSG-YIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO: 3238) (foldon trimerizationmotif), G-HHHHHHHH (SEQ ID NO: 3239) (octa-histidine tag), andGLNDIFEAQKIEWHE (SEQ ID NO: 3234) (AviTag)). The SARS-CoV-2 S 2Pectodomain and RBD constructs were produced by transient transfection of500 mL of Expi293F cells (Thermo Fisher) and purified from clarifiedtransfected cell supernatants four days post-transfection using Ni²⁺-NTAaffinity chromatography (GE Life Sciences). Affinity-purified proteinswere concentrated and further purified by size-exclusion chromatography(SEC) using a Superdex200 16/60 column (GE Life Sciences) running in1×TBS (20 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.02% NaN3). Peakfractions were analyzed by SDS-PAGE, and fractions corresponding tosoluble S 2P trimers or monomeric RBD proteins were pooled and stored at4° C.

ELISAs. Validated ELISAs to evaluate antibodies binding to SARS-CoV-2RBD and trimeric spike proteins, and to SARS-CoV RBD, were performed bycoating of high binding 96 half well plates (Corning #3690) with 50 μLper well of a 1 μg/mL protein solution in PBS overnight at 4° C.(Amanat, F. et al. Nat Med, doi:10.1038/s41591-020-0913-5 (2020);Grifoni, A. et al. Cell, doi:10.1016/j.cell.2020.05.015 (2020)). Plateswere washed 6 times with washing buffer (1×PBS with 0.05% Tween 20(Sigma-Aldrich)) and incubated with 170 μL per well blocking buffer(1×PBS with 2% BSA and 0.05% Tween20 (Sigma)) for 1 hour at roomtemperature (RT). Immediately after blocking, monoclonal antibodies orplasma samples were added in PBS and incubated for 1 hr at RT. Plasmasamples were assayed at a 1:200 starting dilution and seven additional3-fold serial dilutions. Monoclonal antibodies were tested at 10 μg/mlstarting concentration and 10 additional 4-fold serial dilutions. Plateswere washed 6 times with washing buffer and then incubated withanti-human IgG or IgM secondary antibody conjugated to horseradishperoxidase (HRP) (Jackson Immuno Research 109-036-088 and 109-035-129)in blocking buffer at a 1:5000 dilution. Plates were developed byaddition of the HRP substrate, TMB (ThermoFisher) for 10 minutes, thenthe developing reaction was stopped by adding 50 μl 1M H₂SO₄ andabsorbance was measured at 450 nm with an ELISA microplate reader(FluoStar Omega, BMG Labtech) with Omega and Omega MARS software foranalysis. For plasma samples, a positive control (plasma from patientCOV21, diluted 200-fold in PBS) and negative control historical plasmasamples were added in duplicate to every assay plate for validation. Theaverage of its signal was used for normalization of all the other valueson the same plate with Excel software prior to calculating the areaunder the curve using Prism 8 (GraphPad). For monoclonal antibodies, thehalf-maximal effective concentration (EC₅₀) was determined using4-parameter nonlinear regression (GraphPad Prism).

293T_(ACE2) cells. For constitutive expression of ACE2 in 293T cells, acDNA encoding ACE2, carrying two inactivating mutations in the catalyticsite (H374N & H378N), was inserted into CSIB 3′ to the SFFV promoter(Kane, M. et al. Cell Host Microbe 20, 392-405 (2016).). 293T_(ACE2)cells were generated by transduction with CSIB based virus followed byselection with 5 μg/ml Blasticidin.

SARS-CoV-2 and SARS-CoV pseudotyped reporter viruses. A plasmidexpressing a C-terminally truncated SARS-CoV-2 S protein(pSARS-CoV2-S_(trunc)) was generated by insertion of a human-codonoptimized cDNA encoding SARS-CoV-2 S lacking the C-terminal 19 codons(GENEART) into pCR3.1. The S ORF was taken from “Wuhan seafood marketpneumonia virus isolate Wuhan-Hu-1” (NC_045512). For expression offull-length SARS-CoV S protein, “Human SARS coronavirus Spikeglycoprotein Gene ORF cDNA clone expression plasmid (Codon Optimized)”(here referred to as pSARS—CoV-S) was obtained from SinoBiological (Cat:VG40150-G-N). An env-inactivated HIV-1 reporter construct(pNL4-3ΔFnv-nanoluc) was generated from pNL4-3 by introducing a 940 bpdeletion 3′ to the vpu stop-codon, resulting in a frameshift in env(Adachi, A. et al. J Virol 59, 284-291 (1986).). The humancodon-optimized nanoluc Luciferase reporter gene (Nluc, Promega) wasinserted in place of nucleotides 1-100 of the nef-gene. To generatepseudotyped viral stocks, 293T cells were transfected withpNL4-3ΔEnv-nanoluc and pSARS-CoV2-S_(trunc) or pSARS—CoV-S usingpolyethyleneimine. Co-transfection of pNL4-3ΔFnv-nanoluc andS-expression plasmids leads to production of HIV-1-based virionscarrying either the SARS-CoV-2 or SARS-CoV spike protein on the surface.Eight hours after transfection, cells were washed twice with PBS, andfresh media was added. Supernatants containing virions were harvested 48hours post transfection, filtered, and stored at −80° C. Infectivity ofvirions was determined by titration on 293T_(ACE2) cells. See alsohttps://www.biorxiv.org/content/10.1101/2020.06.08.140871v1.

Pseudotyped virus neutralization assay. Five-fold serially dilutedplasma from COVID-19 convalescent individuals and healthy donors orfour-fold serially diluted monoclonal antibodies were incubated with theSARS-CoV-2 or SARS-CoV pseudotyped virus for 1 hour at 37° C. degrees.The mixture was subsequently incubated with 293T_(ACE2) cells for 48hours, after which cells were washed twice with PBS and lysed withLuciferase Cell Culture Lysis 5× reagent (Promega). Nanoluc Luciferaseactivity in lysates was measured using the Nano-Glo Luciferase AssaySystem (Promega) with Modulus II Microplate Reader User interface(TURNER BioSystems). Relative luminescence units obtained werenormalized to those derived from cells infected with SARS-CoV-2 orSARS-CoV pseudotyped virus in the absence of plasma or monoclonalantibodies. The half-maximal inhibitory concentration for plasma (NT₅₀)or monoclonal antibodies (IC₅₀) was determined using 4-parameternonlinear regression (GraphPad Prism).

Cell lines, virus, and virus titration. VeroE6 kidney epithelial cells(Chlorocebus sabaeus; ATCC) and Huh-7.5 hepatoma cells (H. sapiens; Dr.Charles Rice, Laboratory of Virology and Infectious Disease, TheRockefeller University) were cultured in Dulbecco's Modified EagleMedium (DMEM) supplemented with 1% nonessential amino acids (NEAA) and10% fetal bovine serum (FBS) at 37° C. and 5% CO₂. All cell lines havebeen tested negative for contamination with mycoplasma and were obtainedfrom the ATCC (with the exception for Huh-7.5). SARS-CoV-2, strainUSA-WA1/2020, was obtained from BEI Resources and amplified in VeroE6cells at 33° C. Viral titers were measured on Huh-7.5 cells by standardplaque assay (PA). Briefly, 500 μL of serial 10-fold virus dilutions inOpti-MEM were used to infect 400,000 cells seeded the day prior in a6-well plate format. After 90 min adsorption, the virus inoculum wasremoved, and cells were overlayed with DMEM containing 10% FBS with 1.2%microcrystalline cellulose (Avicel). Cells were incubated for five daysat 33° C., followed by fixation with 3.5% formaldehyde and crystalviolet staining for plaque enumeration. All experiments were performedin a biosafety level 3 laboratory.

Microscopy-based neutralization assay of authentic SARS-CoV-2. The dayprior to infection, VeroE6 cells were seeded at 12,500 cells/well into96-well plates. Antibodies were serially diluted in BA-1, mixed with aconstant amount of SARS-CoV-2 (grown in VeroE6), and incubated for 60min at 37° C. The antibody-virus-mix was then directly applied to VeroE6cells (MOI of ˜0.1 PFU/cell). Cells were fixed 18 hours post infectionby adding an equal volume of 7% formaldehyde to the wells, followed bypermeabilization with 0.1% Triton X-100 for 10 min. After extensivewashing, cells were incubated for 1 hour at room temperature withblocking solution of 5% goat serum in PBS (catalog no. 005-000-121;Jackson ImmunoResearch). A rabbit polyclonal anti-SARS-CoV-2nucleocapsid antibody (catalog no. GTX135357; GeneTex) was added to thecells at 1:500 dilution in blocking solution and incubated at 4° C.overnight. A goat anti-rabbit AlexaFluor 594 (catalog no. A-11012; LifeTechnologies) at a dilution of 1:2,000 was used as a secondary antibody.Nuclei were stained with Hoechst 33342 (catalog no. 62249; ThermoScientific) at a 1:1,000 dilution. Images were acquired with afluorescence microscope and analyzed using ImageXpress Micro XLS andMetaXpress software (Molecular Devices, Sunnyvale, Calif.). Allstatistical analyses were done using Prism 8 software (GraphPad).

Biotinylation of viral protein for use in flow cytometry. Purified andAvi-tagged SARS-CoV-2 RBD was biotinylated using the Biotin-ProteinLigase-BIRA kit according to manufacturer's instructions (Avidity).Ovalbumin (Sigma, A5503-1G) was biotinylated using the EZ-LinkSulfo-NHS-LC-Biotinylation kit according to the manufacturer'sinstructions (Thermo Scientific). Biotinylated Ovalbumin was conjugatedto streptavidin-BV711 (BD biosciences, 563262) and RBD tostreptavidin-PE (BD biosciences, 554061) and streptavidin-Alexa Fluor647 (AF647, Biolegend, 405237) respectively (Wang, Z. et al. J ImmunolMethods 478, 112734, (2020)).

Single cell sorting by flow cytometry. PBMCs were enriched for B cellsby negative selection using a pan B cell isolation kit according to themanufacturer's instructions (Miltenyi Biotec, 130-101-638). The enrichedB cells were incubated in FACS buffer (1×Phosphate-buffered Saline(PBS), 2% calf serum, 1 mM EDTA) with the following anti-humanantibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences,335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41),anti-CD8-APC-eFluro 780 (Invitrogen, 47-0086-42), anti-CD16-APC-eFluro780 (Invitrogen, 47-0168-41), anti-CD14-APC-eFluro 780 (Invitrogen,47-0149-42), as well as Zombie NIR (BioLegend, 423105), andfluorophore-labeled RBD and Ovalbumin for 30 minutes on ice (Wang, Z. etal. J Immunol Methods 478, 112734 (2020).). SingleCD3⁻CD8⁻CD16⁻CD20⁺Ova⁻RBD-PE⁺RBD-AF647⁺ B cells were sorted intoindividual wells of 96-well plates containing 4 μl of lysis buffer(0.5×PBS, 10 mM DTT, 3000 units/mL RNasin Ribonuclease Inhibitors(Promega, N2615) per well using a FACS Aria III and FACSDiva software(Becton Dickinson) for acquisition and FlowJo for analysis. The sortedcells were frozen on dry ice, and then stored at −80° C. or immediatelyused for subsequent RNA reverse transcription. Although cells were notstained for IgG expression, they are memory B cells based on the factthat they are CD20⁺ (a marker absent in plasmablasts) and they expressIgG (since antibodies were amplified from these cells using IgG-specificprimers).

Antibody sequencing, cloning, and expression. Antibodies were identifiedand sequenced as described previously (Robbiani, D. F. et al. Cell 169,597-609 e511 (2017); Tiller, T. et al. J Immunol Methods 329, 112-124(2008); von Boehmer, L. et al. Nat Protoc 11, 1908-1923 (2016)).Briefly, RNA from single cells was reverse-transcribed (SuperScript IIIReverse Transcriptase, Invitrogen, 18080-044) and the cDNA stored at−20° C. or used for subsequent amplification of the variable IGH, IGLand IGK genes by nested PCR and Sanger sequencing (Tiller, T. et al. JImmunol Methods 329, 112-124 (2008)). Anti-Zika virus monoclonalantibody Z021 (Robbiani, D. F. et al. Cell 169, 597-609 e511 (2017)) wasused as isotype control. Sequence analysis was with MacVector. Ampliconsfrom the first PCR reaction were used as templates for Sequence- andLigation-Independent Cloning (SLIC) into antibody expression vectors.Recombinant monoclonal antibodies and Fabs were produced and purified aspreviously described (Klein, F. et al. J Exp Med 211, 2361-2372 (2014);Schoofs, T. et al. Immunity 50, 1513-1529 (2019)).

Biolayer interferometry. BLI assays were performed on the Octet Redinstrument (ForteBio) at 30° C. with shaking at 1,000 r.p.m. Epitopebinding assays were performed with protein A biosensor (ForteBio18-5010), following the manufacturer's protocol “classical sandwichassay.” (1) Sensor check: sensors immersed 30 sec in buffer alone(buffer ForteBio 18-1105). (2) Capture 1^(st) Ab: sensors immersed 10min with Ab1 at 40 μg/mL. (3) Baseline: sensors immersed 30 sec inbuffer alone. (4) Blocking: sensors immersed 5 min with IgG isotypecontrol at 50 μg/mL. (6) Antigen association: sensors immersed 5 minwith RBD at 100 μg/mL. (7) Baseline: sensors immersed 30 sec in bufferalone. (8) Association Ab2: sensors immersed 5 min with Ab2 at 40 μg/mL.Curve fitting was performed using the Fortebio Octet Data analysissoftware (ForteBio).

Computational analyses of antibody sequences. Antibody sequences weretrimmed based on quality and annotated using Igblastn v1.14.0 (Ye, J.,et al. IgBLAST: an immunoglobulin variable domain sequence analysistool. Nucleic Acids Res 41, W34-40 (2013)) with IMGT domain delineationsystem. Annotation was performed systematically using Change-0 toolkitv.0.4.5 (Gupta, N. T. et al. Bioinformatics 31, 3356-3358 (2015).).Heavy and light chains derived from the same cell were paired, andclonotypes were assigned based on their V and J genes using in-house Rand Perl scripts (FIGS. 5B and 5C). All scripts and the data used toprocess antibody sequences are publicly available on GitHub(https://github.com/stratust/igpipeline).

The frequency distributions of human V genes in anti-SARS-CoV-2antibodies from this study were compared to Sequence Read ArchiveSRP010970 (Rubelt, F. et al. PLoS One 7, e49774 (2012).). The V(D)Jassignments were done using IMGT/High V-Quest, and the frequencies ofheavy and light chain V genes were calculated for 14 and 13 individuals,respectively, using sequences with unique CDR3 s. The two-tailed t testwith unequal variances was used to determine statistical significance(FIG. 13 ).

Nucleotide somatic hypermutation and CDR3 length were determined usingin-house R and Perl scripts. For somatic hypermutations, IGHV and IGLVnucleotide sequences were aligned against their closest germlines usingIgblastn, and the number of differences was considered nucleotidemutations. The average mutations for V genes were calculated by dividingthe sum of all nucleotide mutations across all patients by the number ofsequences used for the analysis. To calculate the GRAVY scores ofhydrophobicity (Kyte, J. & Doolittle, R. F. J Mol Biol 157, 105-132(1982).) we used Guy H. R. Hydrophobicity scale based on free energy oftransfer (kcal/mole) (Guy, H. R. Biophys J 47, 61-70 (1985).)implemented by the R package Peptides available in the Comprehensive RArchive Network repository(https://journal.r-project.org/archive/2015/RJ-2015-001/RJ-2015-001.pdf).We used 533 heavy chain CDR3 amino acid sequences from this study(sequence COV047_P4_IgG_51-P1369 lacks CDR3 amino acid sequence) and22,654,256 IGH CDR3 sequences from the public database of memory B-cellreceptor sequences (DeWitt, W. S. et al. PLoS One 11, e0160853 (2016).).The Shapiro-Wilk test was used to determine whether the GRAVY scores arenormally distributed. The GRAVY scores from all 533 IGH CDR3 amino acidsequences from this study were used to perform the test, and 5000 GRAVYscores of the sequences from the public database were randomly selected.The Shapiro-Wilk p-values were 6.896×10⁻³ and 2.217×10′ for sequencesfrom this study and the public database, respectively, indicating thedata are not normally distributed. Therefore, we used the Wilcoxonnon-parametric test to compare the samples, which indicated a differencein hydrophobicity distribution (p=5×10′; FIG. 14 ).

Negative-stain EM Data Collection and Processing. Purified Fabs (C002,C119, and C121) were complexed with SARS-CoV-2 S trimer at a 2-foldmolar excess for 1 min and diluted to 40 μg/mL in TBS immediately beforeadding 3 μL to a freshly-glow discharged ultrathin, 400 meshcarbon-coated copper grid (Ted Pella, Inc.). Samples were blotted aftera 1 min incubation period and stained with 1% uranyl formate for anadditional minute before imaging. Micrographs were recorded on a ThermoFisher Talos Arctica transmission electron microscope operating at 200keV using a K3 direct electron detector (Gatan, Inc) and SerialEMautomated image acquisition software (Mastronarde, D. N. J Struct Biol152, 36-51 (2005).). Images were acquired at a nominal magnification of28,000× (1.44 Å/pixel size) and a −1.5 to −2.0 μm defocus range. Imageswere processed in cryoSPARC, and reference-free particle picking wascompleted using a gaussian blob picker (Punjani, A., et al. Nat Methods14, 290-296 (2017).). Reference-free 2D class averages and ab initiovolumes were generated in cryoSPARC, and subsequently 3D-classified toidentify classes of S-Fab complexes, that were then homogenouslyrefined. Figures were prepared using UCSF Chimera (Goddard, T. D., etal. J Struct Biol 157, 281-287 (2007).). The resolutions of the finalsingle particle reconstructions were ˜17-20 Å calculated using agold-standard FSC (0.143 cutoff) and ˜24-28 Å using a 0.5 cutoff.

Example 2

During the COVID-19 pandemic, SARS-CoV-2 infected millions of people andclaimed hundreds of thousands of lives. Virus entry into cells dependson the receptor binding domain (RBD) of the SARS-CoV-2 spike protein(S). Although there is no vaccine, it is likely that antibodies will beessential for protection. However, little is known about the humanantibody response to SARS-CoV-2 (Graham, R. L., et al. Nat Rev Microbiol11, 836-848 (2013); Gralinski, L. E. & Baric, R. S. J Pathol 235,185-195 (2015); Hoffmann, M. et al. Cell 181, 271-280 e278 (2020);Walls, A. C. et al. Cell 181, 281-292 (2020); Jiang, S., et al. TrendsImmunol (2020).). This disclosure reports on 149 COVID-19 convalescentindividuals. Plasmas collected an average of 39 days after the onset ofsymptoms had variable half-maximal pseudovirus neutralizing titers: lessthan 1:50 in 33% and below 1:1000 in 79%, while only 1% showedtiters >1:5000. Antibody sequencing revealed expanded clones ofRBD-specific memory B cells expressing closely related antibodies indifferent individuals. Despite low plasma titers, antibodies to threedistinct epitopes on RBD neutralized at half-maximal inhibitoryconcentrations (IC₅₀s) as low as single-digit ng/mL. Thus, mostconvalescent plasmas obtained from individuals who recover from COVID-19do not contain high levels of neutralizing activity. Nevertheless, rarebut recurring RBD-specific antibodies with potent antiviral activitywere found in all individuals tested, suggesting that a vaccine designedto elicit such antibodies could be broadly effective.

Between Apr. 1 and May 8, 2020, 157 eligible participants enrolled inthe study. Of these, 111 (70.7%) were individuals diagnosed withSARS-CoV-2 infection by RT-PCR (cases), and 46 (29.3%) were closecontacts of individuals diagnosed with SARS-CoV-2 infection (contacts).While inclusion criteria allowed for enrollment of asymptomaticparticipants, 8 contacts that did not develop symptoms were excludedfrom further analyses. The 149 cases and contacts were free of symptomssuggestive of COVID-19 for at least 14 days at the time of samplecollection. Participant demographics and clinical characteristics areshown in Tables 2 and 3 and FIG. 7A. Only one individual who testedpositive for SARS-CoV-2 infection by RT-PCR remained asymptomatic. Theother 148 participants reported symptoms suggestive of COVID-19 with anaverage onset of approximately 39 days (range 17 to 67 days) beforesample collection. In this cohort, symptoms lasted for an average of 12days (0-35 days), and 11 (7%) of the participants were hospitalized. Themost common symptoms were fever (83.9%), fatigue (71.1%), cough (62.4%),and myalgia (61.7%), while baseline comorbidities were infrequent(10.7%) (Tables 2 and 3). There were no significant differences induration or severity (see Methods) of symptoms, or in time from onset ofsymptoms to sample collection between genders or between cases andcontacts. There was no age difference between females and males in ourcohort (FIG. 7 ).

Plasma samples were tested for binding to the SARS-CoV-2 RBD andtrimeric spike (S) proteins by a validated ELISA using anti-IgG or -IgMsecondary antibodies for detection (FIG. 7 , Table 2, FIGS. 8 and 9 )(Amanat, F. et al. Nat Med (2020); Grifoni, A. et al. Cell (2020).).Eight independent negative controls and the positive control plasmasample from participant 21 (COV21) were included for normalization ofthe area under the curve in all experiments (AUC). Overall, 78% and 70%of the plasma samples tested showed anti-RBD and anti-S IgG AUCs thatwere at least 2 standard deviations above the control (FIGS. 7A and 7B).In contrast, only 15% and 34% of the plasma samples showed IgM responsesto anti-RBD and anti-S that were at least 2 standard deviations abovecontrol, respectively (FIGS. 7C and 7D). There was no positivecorrelation between anti-RBD or -S IgG or IgM levels and duration ofsymptoms or the timing of sample collection relative to the onset ofsymptoms (FIG. 3E and FIGS. 9A-9C and 9G-9J). On the contrary, as mightbe expected, anti-RBD IgM titers were negatively correlated withduration of symptoms and the timing of sample collection (FIG. 3E andFIG. 9H). Anti-RBD IgG levels were modestly correlated to age and theseverity of symptoms including hospitalization (FIGS. 3F-3G and FIG.9K). Interestingly, females had lower anti-RBD and -S IgG titers thanmales (FIG. 3H and FIG. 8F).

To measure the neutralizing activity in convalescent plasmas, we usedHIV-1-based virions carrying a nanoluc luciferase reporter that waspseudotyped with the SARS-CoV-2 spike (SARS-CoV-2 pseudovirus, seeMethods, FIG. 4 and FIG. 10 ). Negative (historical) and positive(COV21) controls were included in all experiments. The overall level ofneutralizing activity in the cohort, as measured by the half-maximalneutralizing titer (NT₅₀) was generally low, with 33% less than 50 and79% below 1,000 (FIGS. 4A and 4B). The geometric mean NT₅₀ was 121(arithmetic mean=714), and only 2 individuals reached NT₅₀s above 5,000(FIGS. 4A and 4B and Table 2).

Notably, levels of anti-RBD- and -S IgG antibodies correlated stronglywith NT₅₀ (FIGS. 4C and 4D). The neutralizing activity also correlatedwith age, duration of symptoms, and symptom severity (FIG. 11 ).Consistent with this observation, hospitalized individuals with longersymptom duration showed slightly higher average levels of neutralizingactivity than non-hospitalized individuals (p=0.0495, FIG. 4E). Finally,a significant difference in neutralizing activity between males andfemales (p=0.0031, FIG. 4F) was observed. The difference between malesand females was consistent with higher anti-RBD and -S IgG titers inmales, and could not be attributed to age, severity, timing of samplecollection relative to the onset of symptoms or duration of symptoms(FIG. 3H and FIGS. 8A-8D and 8F).

To determine the nature of the antibodies elicited by SARS-CoV-2infection, flow cytometry was used to isolate individual B lymphocyteswith receptors that bound to RBD from the blood of 6 selectedindividuals, including the 2 top and 4 high to intermediate neutralizers(FIG. 5 ). The frequency of antigen-specific B cells, identified bytheir ability to bind to both Phycoerythrin (PE)- and AF647-labeled RBD,ranged from 0.07 to 0.005% of all circulating B cells in COVID-19convalescents but they were undetectable in pre-COVID-19 controls (FIG.5A and FIG. 12 ). 534 paired IgG heavy and light chain (IGH and IGL)sequences were obtained by reverse transcription and subsequent PCR fromindividual RBD-binding B cells from the 6 convalescent individuals (seeMethods and Tables 4-5 and 7-14). When compared to the human antibodyrepertoire, several IGHV and IGLV genes were significantlyover-represented (FIG. 13 ). The average number of V genes nucleotidemutations for IGH and IGL was 4.2 and 2.8, respectively (FIG. 14 ),which is lower than in antibodies cloned from individuals suffering fromchronic infections such as Hepatitis B or HIV-1, and similar toantibodies derived from primary malaria infection ornon-antigen-enriched circulating IgG memory cells (Scheid, J. F. et al.Nature 458, 636-640 (2009); Tiller, T. et al. Immunity 26, 205-213(2007); Murugan, R. et al. Sci Immunol 3 (2018); Wang, Q. et al. CellHost Microbe, doi:10.1016/j.chom.2020.05.010 (2020).). Among otherantibody features, IGH CDR3 length was indistinguishable from thereported norm, and hydrophobicity was below average (FIG. 14 ) (Briney,B., et al. Nature 566, 393-397 (2019).).

As is the case with other human pathogens, there were expanded clones ofviral antigen binding B cells in all COVID-19 individuals tested (seeMethods and FIGS. 5B and 5C). Overall, 32.2% of the recovered IGH andIGL sequences were from clonally expanded B cells (range 21.8-57.4%across individuals, FIG. 5B). Antibodies that shared specificcombinations of IGHV and IGLV genes in different individuals comprised14% of all the clonal sequences (colored pie slices in FIGS. 5B and 5C).Remarkably, the amino acid sequences of some antibodies found indifferent individuals were nearly identical (FIGS. 5D and 5E). Forexample, antibodies expressed by clonally expanded B cells withIGHV1-58/IGKV3-20 and IGHV3-30-3/IGKV1-39 found repeatedly in differentindividuals had amino acid sequence identities of up to 99% and 92%,respectively (FIG. 5D and Table 4). It was concluded that the IgG memoryresponse to the SARS-CoV-2 RBD is rich in recurrent and clonallyexpanded antibody sequences.

To examine the binding properties of anti-SARS-CoV-2 antibodies, 94representative antibodies, 67 from clones and 27 from singlets (Tables 4and 5), were expressed. ELISA assays showed that 95% (89 out of 94) ofthe antibodies tested including clonal and unique sequences bound to theSARS-CoV-2 RBD with an average half-maximal effective concentration(EC₅₀) of 6.9 ng/mL (FIG. 6A and FIG. 15A). A fraction of these (7 outof 77 that were tested, or 9%) cross-reacted with the RBD of SARS-CoVwith EC₅₀s below 1 mg/mL (FIGS. 15B and 15C). No significantcross-reactivity was noted to the RBDs of MERS, HCoV-OC43, HCoV-229E orHCoV-NL63.

To determine whether the monoclonal antibodies have neutralizingactivity, we tested them against the SARS-CoV-2 pseudovirus (FIG. 6 andTable 6). Among 89 RBD binding antibodies tested, it was found 52 thatneutralized SARS-CoV-2 pseudovirus with nanogram per milliliterhalf-maximal inhibitory concentrations (IC₅₀s) ranging from 3 to 709(FIGS. 6B, 6C, and 6E; Table 6). A subset of the most potent of theseantibodies was also tested against authentic SARS-CoV-2 and neutralizedwith IC₅₀s of less than 5 ng/ml (FIGS. 6D and 6E). Only two of theantibodies which cross-reacted with the RBD of SARS-CoV showedsignificant neutralizing activity against SARS-CoV pseudovirus (FIGS.15D and 15E).

Potent neutralizing antibodies were found in individuals irrespective oftheir plasma NT₅₀s. For example, C121, C144, and C135 with IC₅₀s of1.64, 2.55 and 2.98 ng/mL against authentic SARS-CoV-2, respectively,were obtained from individuals COV107, COV47, and COV72 whose plasmaNT₅₀ values were of 297, 10,433 and 3,138, respectively (FIG. 4B andFIG. 6 ). Finally, clones of antibodies with shared IGHV and IGLV geneswere among the best neutralizers, e.g., antibody C002 composed ofIGHV3-30/IGKV1-39 is shared by the 2 donors with the best plasmaneutralizing activity (red pie slice in FIGS. 5B and 6 ). It wasconcluded that even individuals with modest plasma neutralizing activityharbor rare IgG memory B cells that produce potent SARS-CoV-2neutralizing antibodies.

To determine whether human anti-SARS-CoV-2 monoclonal antibodies withneutralizing activity can bind to distinct domains on the RBD, weperformed bilayer interferometry experiments in which a preformedantibody-RBD immune complex was exposed to a second monoclonal. Theantibodies tested comprised 3 groups, all of which differ in theirbinding properties from CR3022, an antibody that neutralizes SARS-CoVand binds to, but does not neutralize SARS-CoV-2 (ter Meulen, J. et al.PLoS Med 3, e237(2006); Yuan, M. et al. Science 368, 630-633 (2020).).Representatives of each of the 3 groups include: C144 and C101 in Group1; C121 and C009 in Group 2; C135 in Group 3. All of these antibodiescan bind after CR3022. Groups 1 and 2 also bind after Group 3, andGroups 1 and 2 differ in that Group 1 can bind after Group 2 but notvice versa (FIGS. 6F-6N). It was concluded that similar to SARS-CoV,there are multiple distinct neutralizing epitopes on the RBD ofSARS-CoV-2.

To further define the binding characteristics of Groups 1 and 2antibodies, SARS-CoV-2 S-Fab complexes were imaged by negative stainelectron microscopy (nsEM) using C002 (Group 1, an IGHV3-30/IGKV1-39antibody, which is clonally expanded in 2 donors), C119 and C121 (bothin Group 2) Fabs (FIGS. 6F-6R and FIG. 16 ). Consistent with theconformational flexibility of the RBD, 2D class averages showedheterogeneity in both occupancy and orientations of bound Fabs for bothgroups (FIGS. 40-6Q). The low resolution of NS EM reconstructionsprecludes detailed binding interpretations, but the results areconsistent with Fabs from both groups being able to recognize “up” and“down” states of the RBD, as previously described for some antibodiestargeting this epitope (Walls, A. C. et al. Cell 176, 1026-1039 (2019);Pinto, D. et al. Nature, doi:10.1038/s41586-020-2349-y (2020).). The 3Dreconstructions are also consistent with competition measurementsindicating that Groups 1 and 2 antibodies bind a RBD epitope distinctfrom antibody CR3022 (FIGS. 6F-6N) and with a single-particle cryo-EMstructure of a C105-S complex(https://www.biorxiv.org/content/10.1101/2020.05.28.121533v1.full.pdf).In addition, the structures suggest that the antibodies bind the RBDwith different angles of approach, with Group 1 antibodies more similarto the approach angle of the SARS-CoV antibody S230 (Zhu, Z. et al. ProcNatl Acad Sci USA 104, 12123-12128 (2007).) (FIG. 6R).

Human monoclonal antibodies with neutralizing activity against pathogensranging from viruses to parasites have been obtained from naturallyinfected individuals by single cell antibody cloning. Several have beenshown to be effective in protection and therapy in model organisms andin early phase clinical studies, but only one antiviral monoclonal iscurrently in clinical use (Salazar, G., et al. NPJ Vaccines 2, 19(2017).). Antibodies are relatively expensive and more difficult toproduce than small molecule drugs. However, they differ from drugs inthat they can engage the host immune system through their constantdomains that bind to Fc gamma receptors on host immune cells (Bournazos,S. & Ravetch, J. V. Immunol Rev 275, 285-295 (2017).). Theseinteractions can enhance immunity and help clear the pathogen orinfected cells, but they can also lead to disease enhancement duringDengue (Feinberg, M. B. & Ahmed, R. Science 358, 865-866 (2017)) andpossibly coronavirus infections (Iwasaki, A. & Yang, Y. Nat Rev Immunol,doi:10.1038/s41577-020-0321-6 (2020).). This problem has impeded Denguevaccine development but would not interfere with the clinical use ofpotent neutralizing antibodies that can be modified to prevent Fc gammareceptor interactions and remain protective against viral pathogens (VanRompay, K. K. A. et al. Proc Natl Acad Sci USA 117, 7981-7989 (2020).).

Antibodies are essential elements of most vaccines and will likely be acrucial component of an effective vaccine against SARS-CoV-2 (Plotkin,S. A. Clin Vaccine Immunol 17, 1055-1065 (2010); Yu, J. et al. Science,doi:10.1126/science.abc6284 (2020); Chandrashekar, A. et al. Science,doi:10.1126/science.abc4776 (2020).). Recurrent antibodies have beenobserved in other infectious diseases and vaccinal responses (Wang, Q.et al. Cell Host Microbe, doi:10.1016/j.chom.2020.05.010 (2020); Scheid,J. F. et al. Science 333, 1633-1637 (2011); Robbiani, D. F. et al. Cell169, 597-609 e511(2017); Ehrhardt, S. A. et al. Nat Med 25, 1589-1600(2019); Pappas, L. et al. Nature 516, 418-422 (2014).). The observationthat plasma neutralizing activity is low in most convalescentindividuals, but that recurrent anti-SARS-CoV-2 RBD antibodies withpotent neutralizing activity can be found in individuals withunexceptional plasma neutralizing activity suggests that humans areintrinsically capable of generating anti-RBD antibodies that potentlyneutralize SARS-CoV-2. Thus, vaccines that selectively and efficientlyinduce antibodies targeting the SARS-CoV-2 RBD may be especiallyeffective.

Example 3

This example describes the materials, methods, and instrumentation usedin EXAMPLE 4.

Human subjects. Samples of peripheral blood were obtained upon writtenconsent from community participants under protocols approved by theInstitutional Review Board of the Rockefeller University (DRO-1006).Details on the demographics of the cohort are provided in (Robbiani etal., 2020).

Cell lines. HEK293T cells for pseudovirus production and HEK293TACE2cells for pseudovirus neutralization experiments were cultured at 37° C.and 5% CO2 in Dulbecco's modified Eagle's medium (DMEM, Gibco)supplemented with 10% heat-inactivated fetal bovine serum (FBS,Sigma-Aldrich) and 5 μg/ml Gentamicin (Sigma-Aldrich). The medium forthe 293TAce2 cells additionally contained 5 μg/ml Blasticidin (Gibco).For constitutive expression of ACE2 in 293T cells, a Cdna encoding ACE2,carrying two inactivating mutations in the catalytic site (H374N &H378N), was inserted into CSIB 3′ to the SFFV promoter (Kane et al.,2016). 293TACE2 cells were generated by transduction with CSIB basedvirus followed by selection with 5 μg/ml Blasticidin (Gibco). Expi293Fcells (Gibco) for protein expression were maintained at 37° C. and 8%CO2 in Expi293 Expression medium (Gibco), transfected using Expi293Expression System Kit (Gibco) and maintained under shaking at 130 rpm.The gender of the HEK293T, HEK293TACE2 and Expi293F cell lines isfemale. Cell lines were not specifically authenticated.

Bacteria. E. coli DH5α (Zymo Research) for propagation of expressionplasmids were cultured at 37° C. in LB broth (Sigma-Aldrich) withshaking at 250 rpm.

Viruses. To generate pseudotyped viral stocks, HEK293T cells weretransfected with pNL4-3ΔEnv-nanoluc and pSARS-CoV2-Strunc (Robbiani etal., 2020) using polyethyleneimine, leading to production of HIV-1-basedvirions carrying the SARS-CoV-2 S protein at the surface. Eight hoursafter transfection, cells were washed twice with PBS and fresh media wasadded. Supernatants containing virions were harvested 48 hours posttransfection, filtered and stored at −80° C. Infectivity of virions wasdetermined by titration on 293TACE2 cells.

Collection of human samples. Convalescent and healthy donor plasmasamples were collected and processed as described (Robbiani et al.,2020). The convalescent plasma samples used for nsEMPEM were fromresidents in the State of New York: COV21 (a 54-year-old male Hispanic,collection 27 days after symptom onset), COV57 (a 66-year-old maleCaucasian, collection 21 days after symptom onset), and COV107 (a53-year-old female Caucasian, collection 29 days after symptom onset).An analysis of SARS-CoV-2 genomes in the GISAID database with samplecollection dates in March 2020 (contemporaneous with the infections ofindividuals COV21, COV57, and COV107) was performed to identify anyviral spike mutations likely to have been present. For SARS-CoV-2genomes of New York State residents from March 2020, 468 of 475contained the D614G mutation. Thus, based on state-level mutantfrequencies, these individuals were likely to have been infected withD614G-containing viruses. All other spike mutations in these genomes hada frequency below 2%. All participants provided written informed consentbefore sample collection at the Rockefeller University Hospital and thestudy was conducted in accordance with Good Clinical Practice.Anti-coagulated plasma was heat-inactivated (56° C. for 1 hour) prior toshipment to Caltech and stored at 4° C. thereafter (Robbiani et al.,2020).

Phylogenetic trees. Sequence alignments of S proteins and RBD/S1^(B)domains were made with Clustal Omega (Sievers et al., 2011).Phylogenetic trees were calculated from these amino acid alignmentsusing PhyML 3.0 (Guindon et al., 2010) and visualized with PRESTO(http://www.atgc-montpellier.fr/presto).

Cloning and expression of recombinant CoV proteins. Codon-optimizednucleotide sequences encoding the SARS-CoV-2 S ectodomain (residues161206 of an early SARS-CoV-2 sequence isolate; GenBank MN985325.1,which has an Asp at position 614, so does not include the D614G mutationdescribed as possibly more transmissible in (Korber et al., 2020)),SARS-CoV S (residues 12-1193; GenBank AAP13441.1), MERS-CoV S (residues19-1294; GenBank JX869059.2), HCoV-OC43 (residues 15-1263; GenBankAAT84362.1), HCoV-NL63 (residues 16-1291; GenBank AAS58177.1), andHCoV-229E (residues 17-1113; GenBank AAK32191.1) were synthesized andsubcloned into the mammalian expression pTwist-CMV BetaGlobin vector byTwist Bioscience Technologies. The S proteins were modified aspreviously described (Li et al., 2019; Tortorici et al., 2019; Walls etal., 2020). Briefly, the S ectodomain constructs included an N-terminalmu-phosphatase signal peptide, 2P stabilizing mutations (Pallesen etal., 2017) and a C-terminal extension (GSG-RENLYFQG (SEQ ID NO: 3240)(TEV protease site), GGGSG-YIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO: 3238)(foldon trimerization motif), G-HHHHHHH (SEQ ID NO: 3239)(octa-histidine tag), and GLNDIFEAQKIEWHE (SEQ ID NO: 3234) (AviTag)).For SARS-CoV-2, MERS-CoV, HCoV-NL63 and HCoV-OC43 mutations to removethe S1/S2 furin cleavage site were introduced.

Codon-optimized nucleotide sequences encoding the receptor bindingdomain (RBD) for SARS-CoV-2 (residues 331-524) SARS-CoV S (residues318-510), MERS-CoV S (residues 367-588), HCoV-NL63 (residues 481-614),and corresponding S1^(B) domains for HCoV-OC43 (residues 324-632), andHCoV-229E (residues 286-434) were synthesized and subcloned into themammalian expression pTwist-CMV BetaGlobin vector by Twist BioscienceTechnologies. The RBD/S1^(B) constructs included an N-terminal humanIL-2 signal peptide and dual C-terminal tags (G-HHHHHHH (SEQ ID NO:3239) (octa-histidine), and GLNDIFEAQKIEWHE (SEQ ID NO: 3234) (AviTag)).

The S protein and RBD/S1^(B) constructs were expressed by transienttransfection of Expi293F cells (Gibco) and purified from clarifiedtransfected cell supernatants four days post-transfection using HisTrapFF and HisTrap HP columns (GE Healthcare Life Sciences). Afterconcentration, affinity-purified proteins were further purified bysize-exclusion chromatography (SEC) using a HiLoad 16/600 Superdex 200pg column (GE Healthcare Life Sciences) in 1×TBS (20 mM Tris-HCl pH 8.0,150 mM NaCl, 0.02% NaN3). Peak fractions were analyzed by SDS-PAGE, andfractions corresponding to S trimers or monomeric RBD/S1^(B) proteinswere pooled and stored at 4° C.

SEC-MALS. Purified CoV-S trimers were concentrated to 1 mg/mL and loadedonto a Superose 6 Increase 10/300 GL column (GE Healthcare LifeSciences) and passed through a Wyatt DAWN coupled to a Wyatt UT-rEXdifferential refractive index detector (Wyatt Technology). Data wereanalyzed using Astra 6 software (Wyatt Technology) to determineglycoprotein molecular weights.

Purification of plasma IgGs and Fabs. IgGs were purified from plasmasamples using 5-mL HiTrap MabSelect SuRe columns (GE Healthcare LifeSciences). Heat-inactivated plasma was diluted 10-fold with cold PBS,and samples were applied to prepacked columns at 1 mL/min. Bound IgGswere washed with 10 column volumes (CV) PBS and eluted with 5 CV 0.1Mglycine, 100 mM NaCl, pH 3.0 directly into 10% v/v 1M Tris-HCl, pH 8. Toproduce polyclonal Fab fragments, IgGs were buffer exchanged into PBS bycentrifugation with 30 kDa MWCO membrane centrifugal filter units(Millipore). Fabs were generated by papain digestion using crystallizedpapain (Sigma-Aldrich) in 50 mM sodium phosphate, 2 mM EDTA, 10 mML-cysteine, pH 7.4 for 30-60 min at 37° C. at a 1:100 enzyme:IgG ratio.To remove undigested IgGs and Fc fragments, digested products wereapplied to a 1-mL HiTrap MabSelect SuRe column (GE Healthcare LifeSciences) and the flow-through containing cleaved Fabs was collected.Fabs were further purified by SEC using a Superdex 200 Increase 10/300column (GE Healthcare Life Sciences) in TBS, before concentrating andstorage at 4° C.

To evaluate binding of purified polyclonal IgGs or Fabs to CoV proteins,purified S1^(B)/RBD or S proteins were biotinylated using theBiotin-Protein Ligase-BIRA kit according to manufacturer's instructions(Avidity). Biotinylated-CoV proteins were captured on streptavidincoated 96-well plates (Thermo Scientific) by incubating with 100 pL of 2pg/mL protein solution in TBS overnight at 4° C. Plates were washed 3×in washing buffer (1×TBST: 20 mM Tris, 150 mM NaCl, 0.05% Tween20, pH8.0) and blocked with 200 pL blocking buffer (TBST-MS: 1×TBST+1% w/vmilk, 1% v/v goat serum (Gibco) for 1 h at RT. Immediately afterblocking, polyclonal IgGs or Fabs were assayed for binding at a 50 pg/mLstarting concentration and seven 4-fold serial dilutions in blockingbuffer. After 2 h incubation at RT, plates were washed 5 times withwashing buffer and incubated with goat-anti-human IgG or goat-anti-humanIgG(H+L) secondary antibody conjugated to horseradish peroxidase (HRP)(SouthernBiotech) in blocking buffer at a 1:4000 or 1:2000 dilution,respectively. Plates were washed 5 times with washing buffer anddeveloped by addition of 100 pL 1-Step™ Ultra TMB-ELISA SubstrateSolution (Thermo Scientific) for 3 min. The developing reaction wasquenched by addition of 100 pl 1N HCl and absorbance was measured at 450nm using Gen5 software on a Synergy Neo2 Reader (BioTek).

RBD Adsorption ELISAs. Plasmids for SARS-CoV-2 RBD 6×HisTag constructs(residues 319-541, GenBank: MN908947.3) were a gift from the lab ofFlorian Krammer (Mount Sinai) (“6×HisTag” disclosed as SEQ ID NO: 3241).SARS-CoV-2 RBD 6×HisTag constructs (“6×HisTag” disclosed as SEQ ID NO:3241) were expressed by transient transfection of Expi293F cells (Gibco)and purified using HisTrap FF and HisTrap HP columns (GE Healthcare LifeSciences), followed by SEC using a HiLoad 16/600 Superdex 200 pg column(GE Healthcare Life Sciences) against 1×TBS (20 mM Tris-HCl pH 8.0, 150mM NaCl, 0.02% NaN3). Purified protein was concentrated and bufferexchanged into 100 mM Sodium Bicarbonate pH 8.3, 500 mM NaCl using agravity-flow chromatography with a PD-10 desalting column (GE HealthcareLife Sciences). Buffer-exchanged RBD was concentrated to 5 mL andcovalently coupled to a 5 mL HiTrap NETS-activated Sepharose column (GEHealthcare Life Sciences) according to the manufacturer's protocol.Control resin was made using the same procedure to covalently couple2G12, an HIV-1 mAb, as described (Scharf et al., 2015).

For RBD-absorption ELISA experiments to evaluate binding of purifiedpolyclonal IgGs to CoV S1^(B)/RBD proteins after absorption ofSARS-CoV-2 RBD-specific antibodies, biotinylated-S1^(B)/RBD proteinswere captured on high-capacity streptavidin coated 96-well plates(Thermo Scientific) by incubating with 100 μL of 2 μg/mL proteinsolution in TBS overnight at 4° C. Plates were washed 3× in washingbuffer and blocked as described above. For absorption of RBD-specificantibodies, 100 μL of SARS-CoV-2 RBD-coupled resin or 2G12 control resinwas incubated with 100 μL of purified IgGs diluted to −1 mg/mL for 1 hat RT with agitation. After incubation, SARS-CoV-2 RBD-coupled resin wasgently centrifuged at 250×g for 2 min, and non-absorbed IgGs wereremoved by careful pipetting of the aqueous layer above the pelletedRBD-coupled resin. Unadsorbed and absorbed IgG samples were assayed at a50 μg/mL starting concentration and seven 4-fold serial dilutions asdescribed above.

Pseudotyped virus neutralization assays. Pseudoviruses based on HIVlentiviral particles were prepared as described (Robbiani et al., 2020).Four-fold serially diluted purified polyclonal IgGs and Fabs fromCOVID-19 plasmas were incubated with SARS-CoV-2 pseudotyped virus for 1hour at 37° C. After incubation with 293TACE2 cells for 48 hours at 37°C., cells were washed twice with PBS, lysed with Luciferase Cell CultureLysis 5× reagent (Promega), and NanoLuc Luciferase activity in lysateswas measured using the Nano-Glo Luciferase Assay System (Promega).Relative luminescence units (RLUs) were normalized to values derivedfrom cells infected with pseudotyped virus in the absence of purifiedplasma IgGs or Fabs. Half-maximal inhibitory concentrations _((IC50)values) for purified plasma IgGs and Fabs were determined as molarconcentrations (to account for the IgG versus Fab difference inmolecular weight) using 4-parameter nonlinear regression (Prism,GraphPad).

Negative-stain electron microscopy (nsEM). Purified CoV-S trimers wereadsorbed to freshly-glow discharged PureC 300 mesh carbon-coated coppergrids (EMD Sciences) for 1 min followed by 2% uranyl formate staining.Micrographs were recorded using Digital Micrograph software on a 120 kVFEI Tecnai T12 equipped with a Gatan Ultrascan 2 k×2 k CCD at a 52,000×nominal magnification.

nsEMPEM. Methods were adapted from (Bianchi et al., 2018). To formpolyclonal Fab-S complexes, 30 μg of SARS-CoV-2 S trimers were incubatedovernight at RT with 30-50 mg/mL Fabs in 100 μL total volume(corresponding to ˜1000× the _(EC50) values for ELISAs using purifiedpolyclonal Fabs), and the complexes were purified by SEC on a Superose 6increase 10/300 GL column (GE Healthcare Life Sciences). Fractionscontaining complexes were pooled and concentrated to 50 μg/mL and passedthrough a 0.1 μm filter before deposition on 300 mesh carbon-coatedcopper grids (source?) and stained with 1% (w/v) uranyl formate(source?). Grids were imaged at 300 keV using a Titan Krios transmissionelectron microscope (Thermo Fisher) operating at RT, equipped with a K3direct electron detector (Gatan) using SerialEM 3.7? (Mastronarde,2005). Images were processed in cryoSPARC v 2.14, and a reference-freeparticle stack was generated using a Gaussian blob picker (Punjani etal., 2017). Particles corresponding to S-Fab complexes were identifiedby extensive 2D classification to identify class averages that displayedstructural elements interpreted as Fab density and also representeddifferent views. Extracted particles were used to generate ab initiomodels in cryoSPARC that were further processed by 3D classification toseparate out complexes and S trimer structures alone. Figures wereprepared using UCSF Chimera (Goddard et al., 2007; Pettersen et al.,2004).

X-ray crystallography. The Fab from the C105 monoclonal IgG wasexpressed, purified, and stored as described (Scharf et al., 2015;Schoofs et al., 2019). Crystallization trials were performed at roomtemperature using the sitting drop vapor diffusion method by mixingequal volumes of C105 Fab and reservoir using a TTP LabTech Mosquitorobot and commercially-available screens (Hampton Research). Afteroptimization of initial hits, crystals were obtained in 0.15 M lithiumsulfate, 0.1 M citric acid pH 3.5, 18% v/v PEG 6000 at 20° C. Crystalswere transferred stepwise to 20% glycerol cryoprotectant before beingcryopreserved in liquid nitrogen.

X-ray diffraction data were collected for C105 Fab at the StanfordSynchroton Radiation Lightsource (SSRL) beamline 12-1 on a Pilatus 6Mpixel detector (Dectris). Data from a single crystal were indexed andintegrated in XDS (Kabsch, 2010) and merged using AIMLESS in CCP4 (Winnet al., 2011) (Table 16). The structure of C105 Fab was determined bymolecular replacement in PHASER (McCoy et al., 2007) using the B38 Fabcoordinates from PDB code 7BZ5 after removal of CDR loops as a searchmodel. The C105 Fab coordinates were refined using Phenix (Adams et al.,2010) and cycles of manual building in Coot (Emsley et al., 2010) (Table16).

Cryo-EM Sample Preparation. Purified C105 Fab was incubated withSARS-CoV-2 S trimer at a 2:1 molar ratio per protomer on ice for 30minutes prior to purification by SEC on a Superose 6 Increase 10/300 GLcolumn (GE Healthcare Life Sciences). Fab-S complexes were concentratedto 1.6 mg/ml in Tris-buffered saline (TB S). Immediately beforedeposition onto a 300 mesh, 1.2/1.3 AuUltraFoil grid (ElectronMicroscopy Sciences) that had been freshly glow-discharged for 1 min at20 mA using a PELCO easiGLOW (Ted Pella), 3 μL of complex was mixed with0.5 μL of a 0.5% w/v octyl-maltoside solution (Anatrace). Samples werevitrified in 100% liquid ethane using a Mark IV Vitrobot (Thermo Fisher)after blotting for 3 s with Whatman No. 1 filter paper at 22° C. and100% humidity.

Cryo-EM Data Collection and Processing. For the C105-S trimer complex,micrographs were collected on a Titan Krios transmission electronmicroscope (Thermo Fisher) operating at 300 kV using SerialEM automateddata collection software (Mastronarde, 2005). Movies were obtained on aGatan K3 Summit direct electron detector operating in counting mode at anominal magnification of 105,000× (super-resolution 0.418 Å/pixel) usinga defocus range of −1 to −2.5 μm. Movies were collected with an 1.9 sexposure time with a rate of 22 eipix/s, which resulted in a total doseof ˜60 e−/Å² over 40 frames. The 5,940 cryo-EM movies were patch motioncorrected for beam-induced motion including dose-weighting withincryoSPARC v2.15 (Punjani et al., 2017) after binning super resolutionmovies by 2 (0.836 Å/pixel). The non-dose-weighted images were used toestimate CTF parameters using CTFFIND4 (Rohou and Grigorieff, 2015), andmicrographs with power spectra that showed poor CTF fits or signs ofcrystalline ice were discarded, leaving 5,316 micrographs. Particleswere picked in a reference-free manner using Gaussian blob picker incryoSPARC (Punjani et al., 2017). An initial 565,939 particle stack wasextracted, binned ×2 (1.68 Å/pixel), and subjected to iterative roundsof reference-free 2D classification to identify class averagescorresponding to intact S-trimer complexes with well-defined structuralfeatures. This routine resulted in a new particle stack of 71,289particles, which were unbinned (0.836 Å/pixel) and re-extracted using a352 box size. Two ab initio volumes were generated, with one class of61,737 particles revealing an S-trimer complexed with two C105 Fabs.

Particles were further 3D classified (k=3) and heterogeneously refinedto reveal two distinct states of the C105-S trimer complex. State 1(37,615 particles) displaying 2 “up” RBD conformations bound by 2 C105Fabs, and state 2 (14,119 particles) that displayed 3 “up” RBDconformations bound by 3 C105 Fabs. Particles from states 1 and 2 wereseparately refined using non-uniform 3D refinement imposing either C1 orC3 symmetry, respectively, to final resolutions of 3.6 Å (state 1;37,615 particles) and 3.7 Å (state 2; 14,119 particles) according to thegold-standard FSC (Bell et al., 2016). Given that the RBD “up”conformations with C105 Fabs bound were similar in both states 1 and 2,improvements to the resolution at the RBD-C105 Fab interface wereachieved by combining the entire particle stack (˜52 k particles) for afocused, non-uniform 3D refinement. A soft mask was generated from thestate 1 volume (5-pixel extension, 10-pixel soft cosine edge) for the S1subunits and C105 Fab variable domains. These efforts resulted in amodest improvement in the RBD-C105 Fab interface (FIG. 29D), and anoverall resolution of 3.4 Å according to the gold-standard FSC.

Cryo-EM Structure Modeling and Refinement. Initial coordinates weregenerated by docking individual chains from reference structures intocryo-EM density using UCSF Chimera (Goddard et al., 2007). The followingcoordinates were used: SARS-CoV-2 S trimer: PDB code 6VYB, “up” RBDconformations: PDB code 7BZ5, C105 Fab: this study. These initial modelswere then refined into cryo-EM maps using one round of rigid bodyrefinement followed by real space refinement. Sequence-updated modelswere built manually in Coot (Emsley et al., 2010) and then refined usingiterative rounds of refinement in Coot and Phenix (Adams et al., 2010).Glycans were modeled at possible N-linked glycosylation sites (PNGSs) inCoot using ‘blurred’ maps processed with a variety of B-factors(Terwilliger et al., 2018). Validation of model coordinates wasperformed using MolProbity (Chen et al., 2010) and is reported in Table17.

Structural Analyses. Structural figures were made using PyMOL (Version1.8.2.1 Schrodinger, LLC) or UCSF Chimera (Goddard et al., 2007). Localresolution maps were calculated using cryoSPARC v 2.15 (Punjani et al.,2017).

Example 4

A newly-emergent betacoronavirus, SARS-CoV-2, resulted in a pandemic in2020, causing the respiratory disease COVID-19 (Wu et al., 2020b; Zhouet al., 2020). SARS-CoV-2 is the third zoonotic betacoronavirus toinfect humans this century, following SARS-CoV and MERS-CoV (Middle EastRespiratory Syndrome) infections in 2003 and 2012, respectively (de Witet al., 2016). In addition, four globally-distributed humancoronaviruses, HCoV-OC43, HCoV-HKU1 (beta coronaviruses), and HCoV-NL63,HCoV-229E (alpha coronaviruses), contribute to 15-30% of common colds(Fung and Liu, 2019). The neutralizing antibody response tocoronaviruses is primarily directed against the trimeric spikeglycoprotein (S) on the viral membrane envelope, which serves as themachinery to fuse the viral and host cell membranes (Fung and Liu,2019). Coronavirus S proteins contain three copies of an S1 subunitcomprising the S1^(A) through S1^(D) domains, which mediates attachmentto target cells, and three copies of an S2 subunit, which contains thefusion peptide and functions in membrane fusion (FIG. 17A). Neutralizingantibody responses against SARS-CoV-2, SARS-CoV, and MERS-CoV S proteinsoften target the receptor-binding domain (RBD; also called the S1^(B)domain) (Hwang et al., 2006; Pinto et al., 2020; Prabakaran et al.,2006; Reguera et al., 2012; Rockx et al., 2008; Walls et al., 2020;Walls et al., 2019; Widjaja et al., 2019; Wrapp and McLellan, 2019;Wrapp et al., 2020).

The S proteins of SARS-CoV-2 (1273 residues, strain Wuhan-Hu-1) andSARS-CoV (1255 residues, strain Urbani) share 77.5% amino acid sequenceidentity, while the S proteins of SARS-CoV-2 and MERS-CoV (1353residues, strain EMC2012) are more distantly related, sharing only 31%identity (FIGS. 17B and 17C). Sequence identities between SARS-CoV-2 andcommon cold coronavirus S proteins are even lower, varying between 25%and 30%. Phylogenetic analyses confirm that SARS-CoV-2 and SARS-CoV aremore closely related to each other than to other human coronaviruses(FIG. 1B). The RBD/S1^(B) domains show varying degrees of sequenceidentity, ranging from 13% (SARS-CoV-2 and HCoV-NL63) to 74% (SARS-CoV-2and SARS-CoV). Nevertheless, the 3D structures of S protein trimerectodomains are similar to each other and to other coronavirus Sstructures, including the finding of flexible RBDs (S1^(B) domains) thatcan be in various “up” conformations or in the “down” conformation ofthe closed pre-fusion trimer (Kirchdoerfer et al., 2016; Li et al.,2019; Walls et al., 2020; Walls et al., 2016; Wrapp et al., 2020; Yuanet al., 2017). Primary amino acid sequence differences in the RBDs ofSARS-CoV-2 and SARS-CoV compared with MERS-CoV (FIG. 1B,C) result inbinding to different host receptors: angiotensin-converting enzyme 2(ACE2) for SARS-CoV-2 and SARS-CoV (Hoffmann et al., 2020; Li et al.,2003; Zhou et al., 2020) and dipeptidyl peptidase 4 for MERS-CoV (Raj etal., 2013). One of the common cold coronaviruses, HCoV-NL63, also usesits RBD (S1^(B)) to bind ACE2, although its interactions differstructurally from RBD-ACE2 interactions of SARS-CoV-2 and SARS-CoV(Tortorici and Veesler, 2019), whereas HCoV-OC43 and HCoV-HKU1 usestheir S1^(A) domains to bind host receptors including 9-O-acetylatedsialic acids (Tortorici et al., 2019).

Understanding the antibody response to SARS-CoV-2 S protein is ofcritical importance because correlates of protection for vaccinesusually involve antibodies (Plotkin, 2001, 2008, 2010). Moreover,antibodies are being considered as therapeutics for COVID-19 patients(Zhou and Zhao, 2020). Relatively little is known about antibodyrecognition of SARS-CoV-2 S compared with other coronavirus S proteins(Graham et al., 2013; Gralinski and Baric, 2015; Wan et al., 2020).However, structures of S trimer, RBD-Fab, RBD-ACE2, and S trimer-Fabcomplexes for SARS-CoV-2 and other coronaviruses are informative forinterpreting and understanding the antibody response to SARS-CoV-2 (Guiet al., 2017; Kirchdoerfer et al., 2020; Kirchdoerfer et al., 2016;Kirchdoerfer et al., 2018; Pallesen et al., 2017; Pinto et al., 2020;Shang et al., 2020; Shang et al., 2018; Walls et al., 2016; Walls etal., 2017; Walls et al., 2019; Wang et al., 2020; Xiong et al., 2018;Yuan et al., 2020).

Here, we analyzed purified IgG and Fabs from the plasmas of 10 COVID-19convalescent individuals (Robbiani et al., 2020) for binding to trimericS and monomeric RBD/S1^(B) domains of six human coronaviruses and forneutralization of SARS-CoV-2 pseudoviruses. To better understand thebinding mechanism of polyclonal antibodies, we further characterizedplasma Fabs from two individuals using negative-stain electronmicroscopy polyclonal epitope mapping (nsEMPEM), showing that thepolyclonal landscape includes antibodies that target epitopes in bothSARS-CoV-2 S1^(A) and RBD domains. In addition, we solved a 3.4 Åsingle-particle cryo-EM structure of an S trimer bound to a neutralizingmonoclonal antibody (mAb), which targeted an epitope on an “up” RBD thatoverlapped with the RBD epitope identified by nsEMPEM and wouldsterically block ACE2 receptor binding. The epitopes we found representbinding classes defined by distinct VH gene segments, suggesting thatthese recurring classes are commonly represented in neutralizingantibodies against SARS-CoV-2 and provide criteria for evaluatingneutralizing antibodies raised by infection or vaccination. Finally, weused modeling to suggest that distinct binding orientations allow fordifferential avidity effects, demonstrating the potential forinter-spike crosslinking that would increase effective affinities forsome anti-S IgGs on SARS-CoV-2 virions.

Convalescent plasma IgG and Fab binding properties demonstraterecognition of diverse coronaviruses and effects of avidity.Convalescent plasma samples were collected from individuals who hadrecovered from COVID-19 at Rockefeller University Hospital (Robbiani etal., 2020). We isolated polyclonal IgGs from 10 convalescent plasmas(FIG. 18 ), most of which had high neutralizing titers (Robbiani et al.,2020), and compared binding of their IgGs to purified S proteins fromSARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, and HCoV-229E(FIG. 24 ) by ELISA (FIGS. 18 and 26 ). Purified plasma IgGs recognizedS proteins from all coronaviruses evaluated, with weaker bindingobserved for most samples to MERS-CoV (FIG. 19C) and common coldcoronavirus S proteins (FIGS. 19D-F).

Amongst the plasmas (COV21, COV57, and COV107) chosen for furtheranalysis based on ELISA EC50 values and strong neutralization potencies(Robbiani et al., 2020), IgGs from COV21 and COV57 showed the strongestbinding to the S proteins from SARS-CoV-2 and SARS-CoV, with only theCOV57 IgGs showing measurable binding to MERS-CoV S protein. The COV107IgGs showed intermediate binding to SARS-CoV-2 and SARS-CoV and nobinding to MERS-CoV S proteins (FIGS. 19A-C).

ELISAs against RBD (or S1^(B) domain for two of the common coldcoronavirus S proteins) showed the strongest binding to SARS-CoV-2 RBDfor COV21, followed by COV57 and then COV107 IgGs, with the proportionof RBD versus S binding from COV21, COV72, and COV47 suggesting that themajority of the IgG responses from these plasmas were focused on theRBD, often a target of neutralizing antibodies in coronavirus infections(Hwang et al., 2006; Pinto et al., 2020; Prabakaran et al., 2006;Reguera et al., 2012; Rockx et al., 2008; Walls et al., 2020; Walls etal., 2019; Widjaja et al., 2019; Wrapp et al., 2020). The onlyappreciable reactivity with SARS-CoV and MERS-CoV RBDs was exhibited byCOV21 IgG, which bound to SARS-CoV RBD (FIG. 19B). Although we cannotdetermine whether the same IgGs are binding all three S proteins, thepotential for cross-reactive binding of SARS-CoV antibodies wasdemonstrated for a mAb that was isolated from a SARS-infectedindividual, which was shown to recognize SARS-CoV and SARS-CoV-2 RBDs(Pinto et al., 2020). No reactivity with MERS-CoV RBD was observed forany of the polyclonal IgGs (FIG. 19C). For most of the plasma IgGs,binding to the RBD was substantially weaker than binding to thecounterpart S protein, with the exception of the strong COV21 and COV72responses to the SARS-CoV-2 RBD. Most of the plasma IgGs exhibitedstronger binding to the common cold S1^(B)/RBDs than to the counterpartS protein trimers (FIGS. 19D-F).

To assess the degree to which cross-reactive recognition contributed tobinding of plasma IgGs to RBD/S1^(B) domains, we repeated the ELISAsbefore and after adsorption with SARS-CoV-2 RBD-coupled resin or acontrol resin for five plasma IgG samples (FIG. 26 ). As a positivecontrol, purified IgGs incubated with the RBD resin showed little or noSARS-CoV-2 RBD binding (FIG. 26A). Binding to SARS-CoV RBD was alsoreduced for the IgGs remaining after SARS-CoV-2 RBD adsorption (FIG.26B), suggesting cross-reactive recognition consistent with the 78%sequence conservation and structural homology of SARS-CoV-2 RBD andSARS-CoV RBD (Walls et al., 2020). By contrast, adsorption of plasmaIgGs with SARS-CoV-2 RBD resins had only a modest effect on binding tocommon cold coronavirus RBDs (FIGS. 26D-F), consistent with little to nocross-reactive antibody recognition, likely due to the low conservationbetween the SARS-CoV-2 RBD and mild coronavirus RBDs (Premkumar et al.,2020). We also note that IgGs from control plasmas collected fromindividuals not exposed to SARS-CoV-2 exhibited binding to common coldcoronavirus RBDs that was not affected by SARS-CoV-2 RBD adsorption(FIG. 26 ), again consistent with pre-exposure to mild coronavirusesrather than cross-reactivity with SARS-CoV-2 RBD.

Taken together, these results indicate: (i) The binding strengths andpatterns of different coronavirus S protein recognition were diverseacross COVID-19 individual plasma samples, (ii) Convalescent COVID-19individuals harbor antibodies to the SARS-CoV-2 S protein, and to alesser extent, the RBD/S1B, as well as reactivity to othercoronaviruses, which likely represents previous exposure to common coldviruses, (iii) Polyclonal IgGs from individual plasma samples that bindto S proteins from MERS-CoV and/or SARS-CoV may display cross-reactiverecognition, since the plasma donors were unlikely to have been infectedwith either of these coronaviruses, and (iv) Compared to the COV57 andCOV107 plasmas, the COV21 IgG response had a higher proportion of IgGsthat recognized the SARS-CoV-2 RBD.

We also evaluated the degree to which avidity effects contributed to thestrength of binding of plasma IgGs to S proteins and RBDs by comparingthe binding of bivalent polyclonal IgGs to monovalent Fabs, prepared byproteolytic cleavage of purified polyclonal IgGs (FIGS. 18B and 18C).Differential effects were evident in IgG to Fab comparisons: most of theSARS-CoV-2 anti-S response was reduced by at least 50% in the case ofmonovalent Fabs for all plasmas except for COV57 (FIG. 19A). Recognitionof the other coronavirus S proteins was also diminished for Fabscompared to intact IgGs (FIGS. 19B-F). For the three plasma IgGs thatwere further evaluated, the largest relative differences in IgG versusFab binding to SARS-CoV-2 S protein was observed for COV21 and COV107;the IgG versus Fab binding difference for COV57 was less pronounced(FIG. 19A). Notably, the SARS-CoV-2 S protein and RBD ELISAs showed thata higher fraction of the COV21 plasma IgGs were RBD-specific comparedwith the COV57 IgGs (FIGS. 19A and 19B) (Robbiani et al., 2020).

In summary, the ELISA data indicate that IgGs in plasma samples differin their degree of focus upon epitopes within the S protein RBD/S1^(B)domain, their relative amounts of reactivity with SARS-CoV, MERS-CoV,and common cold coronaviruses, and the extent to which avidity effectscontribute to the tighter binding of polyclonal bivalent IgGs ascompared with monovalent Fab s.

Plasma IgGs are more potent neutralizers than plasma Fabs. Toinvestigate whether the bivalent architecture or larger size of IgGscompared with Fabs resulted in increased neutralization potencies, wemeasured the potencies of purified plasma IgGs and Fabs using in vitroneutralization assays (FIG. 19G). SARS-CoV-2 pseudoviruses wereconstructed as described (Robbiani et al., 2020), and the concentrationsof IgGs and Fabs at which 50% neutralization was achieved _((IC50)values) were calculated. All tested plasma IgGs neutralizedpseudoviruses at lower molar concentrations than their Fab counterparts,with increased potencies ranging from 6- to 100-fold (FIG. 19H). Theincreased potency of the IgGs compared to Fabs was statisticallysignificant (p=0.0003), even when accounting for two Fabs per IgG. Weconclude that bivalent IgGs more effectively neutralize SARS-CoV-2pseudoviruses than monovalent Fabs.

EM reveals distinct predominant epitopes targeted by convalescent plasmaantibodies. We next used negative stain polyclonal electron microscopy(nsEMPEM) (Bianchi et al., 2018; Nogal et al., 2020) to map epitopesfrom Fabs isolated from convalescent COVID-19 plasma IgGs onto theSARS-CoV-2 S protein. In this method, Fabs that bind to an antigenictarget are separated from non-binding Fabs in a polyclonal mixture bysize-exclusion chromatography (SEC), Fab-antigen complexes are imaged byEM, and 2D/3D classification were used to identify predominant epitopes(Bianchi et al., 2018; Nogal et al., 2020) (FIGS. 18A-C). Typically,Fabs are incubated at 1000-2000× above EC50 values calculated frombinding assays (Bianchi et al., 2018; Nogal et al., 2020). For mostCOVID-19 plasmas, Anti-S Fab EC50 values were estimated to be >50 μg/mL(FIG. 25 ). However, purified polyclonal Fabs from COV21 and COV57plasmas, which had approximate EC50s ranging from 20-50 μg/mL, showedstable binding by SEC after incubation with SARS-CoV-2 S trimers (FIG.18D), and 2D class averages showed evidence of bound Fabs (FIG. 28 ). Bycontrast, purified Fabs from COV107 _((EC50)>50 μg/mL) showed noevidence of binding to S by SEC (data not shown) or in a 3Dreconstruction (FIG. 20A).

In order to verify that extra densities in nsEMPEM 3D reconstructionscorresponded to bound Fab(s), we first solved a 3D reconstruction ofSARS-CoV-2 S alone, revealing the expected low-resolution structure ofthe closed, prefusion S trimer (FIG. 20A). A 3D reconstruction of COV21Fabs complexed with S showed recognizable density for the S trimer witha single extending density at the apex of the trimer corresponding to aFab or mixture of Fabs bound to a similar epitope (FIG. 20A). Thedensity could be fit to an S trimer with a Fab bound to a single RBD inan “up” position using coordinates from SARS-CoV-2 S trimer structures(Walls et al., 2020; Wrapp et al., 2020), consistent with ELISA resultsmapping the COV21 response to the SARS-CoV-2 RBD (FIG. 19A). The complexstructure and the position of the COV21 Fab(s) closely resembled astructure of SARS-CoV S bound to a Fab from the S230 mAb isolated from aSARS-CoV-infected individual, whose epitope overlaps with the bindingsite for the ACE2 receptor (Walls et al., 2019) (FIG. 20B).Interestingly, S230 binding was shown to functionally mimic ACE2binding, allowing cleavage of the SARS-CoV S protein to promotefusogenic conformational rearrangements (Walls et al., 2019). While theCOV21 Fab complex reconstruction showed occupancy for one S-protomerwith an RBD in an “up” position (FIG. 20A), COV21 Fab(s) could also bindanalogous to the S230 Fab-SARS-Cov S complex, where classes of S trimerstructures were found with two “up”/one “down” and three “up” RBDconformations (Walls et al., 2019).

Moreover, antibody S230, whose binding orientation resembles theposition observed in the COV21 Fab(s) reconstruction (FIG. 20B), appearsto be a member of a class of recurrent anti-SARS mAbs. It belongs to aset of 10 non-clonally-related VH3-30-derived mAbs isolated from anindividual infected with SARS-CoV, which represented 40% of the clonesisolated from this individual (Pinto et al., 2020). Notably, theseclones contained similar 9 amino acid CDRL3 sequences (consensussequence MQGTHWPPT (SEQ ID NO: 3656)), suggesting that this group ofmAbs has a common mode of binding, partially dependent on VH3-30-derivedfeatures. RBD residues 473 and 475 contacted by the antibody heavy chainin the S230 Fab-SARS-CoV structure (Walls et al., 2019) are conservedbetween SARS-CoV and SARS-CoV-2, and these residues are in the vicinityof antibody heavy chain residues N57 and K58. The only VH gene segmentsencoding the N57/K58 pair are VH3-30, VH3-30-3, and VH3-33 (Lefranc etal., 2015). When mAbs were isolated after single B cell sorting usingSARS-CoV-2 RBD as a bait, COV21 antibodies included heavy chains derivedfrom IGHV3-30, which were also found in sequenced antibodies from fiveother donor plasmas (Robbiani et al., 2020). The similarity in bindingorientation of COV21 Fab(s) with S230 (FIG. 20B) suggests that COV21Fab(s) may be members of the S230 recurrent class. Consistent with thishypothesis, 38 of 127 sequenced antibodies from the COV21 donor werederived from VH3-30 or from the closely-related VH3-30-3 or VH3-33 VHgene segments (Robbiani et al., 2020).

The COV57 Fab(s)-S structure also showed recognizable density for boththe S trimer and a single bound Fab(s) (FIG. 20C). However, in thiscomplex, the S trimer appeared closed with no RBDs in an “up” position,and the Fab density was not associated with an RBD, but rather with oneof the S1^(A) subunits. In the complex, the Fab(s) pointed downwards(i.e., towards the viral membrane) rather that upwards (away from theviral membrane), as seen for the COV21 Fab(s). The COV57 Fab(s) densitywas in the vicinity of loops on the S1^(A) domain that were disorderedin SARS-CoV-2 S trimer structures (Walls et al., 2020; Wrapp et al.,2020). Such flexibility could explain the diffuse nature of the COV57Fab(s) density in this reconstruction. Interestingly, characterizationof COV57 neutralization showed less correlation with RBD-specificantibodies relative to COV21 (Robbiani et al., 2020), consistent withthe ELISAs (FIG. 19A) and nsEMPEM characterizations (FIG. 20C) reportedhere. This suggests that targeting S1 regions outside of the RBD mayrepresent alternative modes for potent neutralization of SARS-CoV-2, asfound for neutralizing antibodies isolated after vaccination againstMERS-CoV in nonhuman primates (Wang et al., 2015).

A cryo-EM structure of a monoclonal Fab-S protein complex resembles theCOV21 Fab(s)-S reconstruction. Although we could not resolve densitiesfor bound Fabs in the COV107-S nsEMPEM reconstruction (FIG. 20A),RBD-binding mAbs isolated from the COV107 individual were potentlyneutralizing (Robbiani et al., 2020). We determined a 3.4 Åsingle-particle cryo-EM structure of the complex of one such antibody(C105; IC₅₀ for neutralization of SARS-CoV-2 pseudovirus=26.1 ng/mL)(Robbiani et al., 2020) bound to the SARS-CoV-2 S protein using a 1.8 Åcrystal structure of the unbound C105 Fab for fitting to the cryo-EMdensity (FIGS. 21, 28 , and 29; Tables 15 and 16).

We found two populations of C105 Fab-S complexes: an asymmetric S trimerwith two “up” RBDs (state 1; 3.4 Å resolution), each of which wascomplexed with a Fab, and a symmetric trimer with three RBDs in the same“up” conformation (state 2; 3.7 Å resolution), again with each RBDcomplexed with a Fab (FIG. 21A). A subset of complexes in the cryo-EMstructure of the S230 mAb bound to SARS-CoV S trimer were also foundwith three “up” RBDs bound to three Fabs (Walls et al., 2019), althoughin that structure, as in the C105-S structure, the majority of complexeshad their RBDs in a two “up,” one “down” configuration.

The C105-RBD interfaces were similar across the five examples in thestate 1 and state 2 complex structures (FIG. 28 ), thus we describe theinterface for one of the Fab-RBD complexes in the state 1 complex inwhich the resolution at the interface was improved by performing afocused refinement (Punjani et al., 2017) on the C105 Fab-RBD portion ofthe complex (FIG. 28 ). The C105 Fab uses its three heavy chaincomplementarity determining regions (CDRH1, CDRH2, and CDRH3) and two ofits light chain CDRs (CDRL1 and CDRL3) to rest against thereceptor-binding ridge of the RBD (FIGS. 21B and 21C). The majority ofthe antibody contacts are made by CDRH1, CDRH2, and CDRL1, with CDRH3and CDRL3 playing minor roles. The C105 epitope overlaps with the COV21epitope defined by nsEMPEM, which also rests against thereceptor-binding ridge in the RBD, although the Fab(s) in the COV21reconstruction are predicted to adopt a different angle of approach(FIG. 21D). Interestingly, the C105-RBD interaction closely resemblesthe RBD interaction of another COVID-19 donor-derived neutralizing mAb,B38 (FIG. 21E), as reported in a recent Fab-RBD crystal structure (Wu etal., 2020c). The heavy chains of both B38 and C105 are derived from theVH3-53 gene segment, whereas the light chain gene segments differ: KVJ-9for B38 (Wu et al., 2020c) and LV2-8 for C105 (Robbiani et al., 2020).Accordingly, the CDRH1 and CDRH2 loops of both neutralizing antibodiesshare similar conformations and contribute more to the antibody-RBDinterface than their CDRH3 loops (FIGS. 21B and 21E).

The common epitope of C105 and B38 overlaps with the binding site forACE2 (FIG. 21F), rationalizing their potent neutralizing activities(Robbiani et al., 2020; Wu et al., 2020c). Given that COV21 was one ofthe more potent neutralizing plasmas of the 149 that were collected(Robbiani et al., 2020), the overlap in the C105/B38 neutralizingepitope with the nsEMPEM-defined predominant COV21 epitope suggests thatrecognition of the COV21 epitope by S230-like antibodies would also beneutralizing.

CDRH3 length is a characteristic of the recurring VH3-53/VH3-66 class ofanti-SARS-CoV-2 RBD neutralizing antibodies. The shared binding mode ofB38 and C105, both VH3-53-derived mAbs, defines a recurrent class ofanti-SARS-CoV-2 mAbs. Among a large set (n=534) of clonedanti-SARS-CoV-2 mAbs against the RBD, those derived from VH3-53 andVH3-66 were over-represented (Robbiani et al., 2020). Other studies havealso reported anti-SARS-CoV-2 mAbs derived from these genes (Brouwer etal., 2020; Cao et al., 2020; Chi et al., 2020; Ju et al., 2020; Rogerset al., 2020; Seydoux et al., 2020; Wu et al., 2020c; Zost et al.,2020). These VH gene segments encode V regions that differ in only oneamino acid position, which is not in a CDR. Thus, in terms ofV-gene-determined mAb classes, they are functionally equivalent. Whengrouping VH3-53 and VH3-66, over-representation of VH3-53/VH3-66-derivedmAbs is significant (p=0.035). A notable characteristic of theVH3-53/VH3-66-derived subset (75 mAbs) within the 534 anti-RBD mAbs(Robbiani et al., 2020) was a bias towards shorter CDRH3s (as defined byIMGT) (Lefranc et al., 2015): 75% had lengths between 9 and 12 residues,which is significantly different from the human repertoire and from theentire set of 534 anti-SARS-CoV-2 RBD mAbs (two sampleKolmogorov-Smirnov test, p<0.001) (FIG. 30A).

Superposition of VH domains from unrelated antibodies with longer CDRH3ssuggests that RBD residues 456-457 and/or 484-493 present a stericbarrier limiting the CDRH3 loop lengths that are compatible with thisbinding orientation (FIG. 30B). A recent report identified aclonally-unrelated group of VH3-53/VH3-66 anti-SARS-CoV-2 mAbs based onCDRH3 sequence similarity to the anti-SARS-CoV mAb m396 (derived fromVH1-69) (Cao et al., 2020). The structure of a SARS-CoV RDB complex withm396 (PDB code 2DD8) (Prabakaran et al., 2006) shows that mAb m396 doesnot share the B38/C105 binding mode. We suggest that the key feature ofthe VH3-53/VH3-66 mAbs identified based on CDRH3 sequence similarity tom396 (Cao et al., 2020) is their CDRH3 length (11 residues), and thatthese mAbs will share the B38/C105 binding mode, not the m396 bindingmode.

Identified S mutations are unlikely to affect epitopes revealed bynsEMPEM and single-particle cryo-EM. A recent report suggested that amutation in the S protein (D614G) increases transmissibility ofSARS-CoV-2 (Korber et al., 2020), and it has been speculated that thissubstitution, or others found in different S protein sequences, couldaffect antibody recognition. In cryo-EM structures of the prefusion Strimer (Walls et al., 2020; Wrapp et al., 2020) and in our C105-Scomplex (FIG. 21 ), S protein residue D614 is located in S1^(D), whereit makes contact with an adjacent protomer. To address whether the D614Gmutation could affect binding of antibodies in COV21 and COV57 plasmasamples, we marked the location of the D614 residues and other residuesthat were reported to mutate (Korber et al., 2020) on the COV21 andCOV57 nsEMPEM reconstructions (FIGS. 22A and 22B) and on the C105-Scryo-EM structure (FIG. 22C). The RBD-binding COV21 Fab(s) and the C105Fab are distant from residue D614 (FIGS. 22A and 22C). Therefore, if theCOV21 reconstruction reflects the predominant epitope in the COV21plasma, it is unlikely that antibodies elicited in the COV21 individualwould be sensitive to the D614G substitution. Indeed, in the absence oflarge conformational changes, all anti-RBD antibodies, including C105(Robbiani et al., 2020) and B38 (Wu et al., 2020c), would be unaffectedby this substitution. Mutations in the SARS-CoV-2 RBD identified bygenome sequencing also include N439K, V483A, and V367F (Tables S3,S4),but the affected residues are not within the epitopes of the COV21Fab(s) (FIGS. 22A and 22B) or the C105 Fab (FIG. 22C), and residue 483is disordered in unliganded S protein structures (Walls et al., 2020;Wrapp et al., 2020). The predominant epitope in the COV57 plasma iscloser to S protein D614, but this residue appears to be outside of thebinding interface. In addition, mutations in the S1^(A) domainidentified by genome sequencing (Tables S3,S4) reside outside of theCOV57 Fab(s) epitope (FIGS. 22A and 22B). Thus in the absence of a majorconformational change induced by mutation, the observed substitutions,particularly the D614G mutation, are unlikely to affect antibodieselicited in the COV21 or COV57 individuals or in RBD-binding antibodiessuch as C105.

S protein epitopes offer different possibilities for avidity effectsduring IgG and receptor binding. IgGs contain two identicalantigen-binding Fabs, thus offering the opportunity to bind pathogenswith regularly-spaced antigen sites using avidity effects, eitherthrough inter-spike crosslinking (binding the same epitope on adjacentspikes) and/or intra-spike crosslinking (binding the same epitope onidentical subunits of a single multimeric spike) (Klein and Bjorkman,2010).

To address whether inter-spike crosslinking by anti-SARS-CoV-2 IgGscould occur, we modeled adjacent S proteins on a virion membraneassuming a minimum inter-spike separation distance of ˜15 nm, asobserved from cryo-electron tomography analyses of SARS-CoV and othercoronaviruses (Neuman et al., 2011). By including a bound Fab on each Strimer in the position of the COV21 Fab(s) from the nsEMPEMreconstruction, we addressed whether the Fabs from a single IgG couldbind to two adjacent S trimers. The modeling predicts that inter-spikecrosslinking could occur for the COV21 epitope (FIG. 23A). By contrast,the downward-pointing Fab(s) in the COV57-S nsEMPEM reconstructionappear unlikely to participate in inter-spike crosslinking by an IgG dueto the Fab orientations being unable to accommodate an Fc in a positionthat could join two Fabs (FIG. 23A). These predictions are consistentwith ELISA results demonstrating diminished binding for COV21 Fabscompared with their IgG counterparts, but less pronounced differencesfor the Fab versus IgG comparison for COV57 (FIG. 18 ).

We also used modeling to predict whether avidity effects could influencethe interaction between ACE2, an integral membrane protein thatdimerizes on the target cell surface (Yan et al., 2020), with viral Strimers. Starting with a cryo-EM structure of dimeric full-length ACE2associated with the integral membrane protein B^(O)AT1 bound tomonomeric SARS-CoV-2 RBDs, we modeled bound S trimers from a cryo-EMstructure of SARS-CoV S trimers with two RBDs in an “up” position(Kirchdoerfer et al., 2018). Assuming that there are adjacentACE2-B^(O)AT1 complexes in the host cell membrane, the modeling predictsthat inter-spike crosslinking is possible (FIG. 23B). Assuming rotationof the RBDs in a two “up”/one “down” S trimer, intra-spike cross-linkingcould also occur (FIG. 23C). If S trimers can indeed crosslink adjacentACE2 receptors or bind as a single trimer to both ACE2 subunits in anACE2 dimer, they could take advantage of avidity effects to bind moretightly than predicted from affinity measurements involving theinteractions of monomeric ACE2 ectodomains to monomeric coronavirus RBDs(Shang et al., 2020; Walls et al., 2020; Wrapp et al., 2020).

The possibility of avidity effects during the interactions of SARS-CoV-2S with ACE2 dimers has implications for interpretation of pseudovirusassays to measure coronavirus infectivity in the presence and absence ofpotential inhibitors such as antibodies. In vitro neutralization assaysfor SARS-CoV-2 include pseudoviruses based on HIV lentiviral particles(Chen et al., 2020; Crawford et al., 2020; Ou et al., 2020; Robbiani etal., 2020; Wu et al., 2020a), murine leukemia virus retroviral particles(Pinto et al., 2020; Quinlan et al., 2020), and vesicular stomatitisvirus (Hoffmann et al., 2020; Nie et al., 2020; Xiong et al., 2020).Each of these pseudovirus types could potentially incorporate differentnumbers of spikes, in which case the overall spike density would altersensitivity to antibody avidity. In any case, the effects of avidity onIgG binding to a tethered antigen are a complicated mixture of intrinsicFab-antigen affinity, kinetics, input concentration, and incubation time(Klein and Bjorkman, 2010; Wu et al., 2005), thus neutralizationpotencies of some, but not all, IgGs could be affected in in vitroneutralization assays. In addition, when considering therapeuticapplications of convalescent plasma or purified antibodies, avidityeffects would be difficult to predict given uncertainties about antibodyconcentrations, viral titers, and potentially different S trimerspacings and densities on infectious virions.

The results, as presented above, provide a glimpse into diverse antibodyresponses in neutralizing plasmas from donors who recovered fromCOVID-19. We characterized polyclonal plasma IgGs that exhibiteddifferent degrees of cross-reactive binding between S proteins fromSARS-CoV-2, SARS-CoV, and MERS-CoV and showed that the plasma IgGs alsoincluded non-cross-reactive antibodies against common cold virus RBDs.By mapping SARS-CoV-2 S epitopes targeted by convalescent plasma IgGs,we not only observed the expected targeting of the S protein RBD, butalso discovered an epitope outside of the RBD, which may represent analternative binding site for neutralizing antibodies. The RBD-bindingFab(s) from COV21 plasma resembled binding of S230, a VH3-30 mAbisolated from a SARS-CoV patient that blocks ACE2 receptor binding(Rockx et al., 2008). We found another type of ACE2 receptor-blockinganti-SARS-CoV-2 antibody in our analysis of a neutralizing mAb derivedfrom the COV107 individual. In a 3.4 cryo-EM structure SARS-CoV-2 Sprotein bound to this mAb, C105, we observed an epitope on the RBD thatoverlapped with the binding site for COV21 Fab(s) and closely resembledthe binding of another mAb, B38 (Wu et al., 2020c). Like C105, B38 isalso derived from the VH3-53 VH gene segment. Our structural studiessupport the hypothesis that recurrent classes of anti-SARS-CoV-2neutralizing antibodies derived from the VH3-53/VH3-66 and VH3-30 genesegments use the distinct RBD-binding modes of the B38/C105 and S230mAbs, respectively, providing valuable information for evaluatingantibodies raised by infection or vaccination by sequences alone.Finally, the RBD and S1^(A) epitopes we mapped by nsEMPEM andsingle-particle cryo-EM are unlikely to be affected by common mutationsin different SARS-CoV-2 isolates, offering hope that antibodytherapeutics and/or a vaccine might be effective in combatting thecurrent pandemic.

TABLE 1 Cohort characteristics Average duration Average ELISA binding(AUC) Average Case/ Sx Sx onset Sx Severity RBD S Neutralization Gendern age Contact total to visit (0-10) IgG IgM IgG IgM (NT50) Male 83 4565/18 12 39 5.8 2.44 1.61 4.65 1.62 867 (19-76) (0-31) (21-63) (0-10)Female 66 42 46/20 12 38 5.4 1.99 1.58 4.36 1.86 522 (19-75) (1-35)(17-67) (1-9) Sx = symptoms

TABLE 2 Individual participant demographics and clinical characteristicsDuration ELISA g p (days) Sx binding (AUC) p p Case/ Sx Sx onsetSeverity RBD S Neutralization ID Age Gender Race Ethnicity Contact totalto visit (0-10) IgG IgM IgG IgM (NT50) 5 43 M White Non-Hispanic Case 941 9 2.52 2.35 5.51 2.43 5.0 7 40 M White Non-Hispanic Case 11 30 6 2.922.54 7.39 2.37 2730.4 8 37 M White Non-Hispanic Case 3 57 5 2.11 0.814.46 0.88 5.0 9 35 F White Non-Hispanic Case 12 54 5 2.90 1.07 4.44 2.805.0 12 27 F White Non-Hispanic Contact 7 24 3 1.47 1.71 4.31 1.23 5.0 1328 M White Non-Hispanic Case 5 25 3 1.97 4.10 3.95 1.38 173.2 18 55 MWhite Non-Hispanic Case 16 28 6 2.57 1.75 3.92 1.31 410.3 20 26 F WhiteNon-Hispanic Case 2 17 5 1.80 2.00 4.49 1.68 5.0 21 54 M White HispanicContact 11 27 7 5.60 2.88 7.60 2.47 5052.7 24 34 M White Non-HispanicCase 15 30 4 2.29 1.97 4.36 1.45 280.7 26 66 M White Non-Hispanic Case 235 3 1.67 1.86 4.00 1.58 276.1 27 26 M White Non-Hispanic Case 9 32 41.79 1.64 4.41 1.30 739.3 28 26 M White Non-Hispanic Case 7 21 4 2.392.25 4.93 1.66 888.9 29 26 F White Non-Hispanic Contact 5 35 4 1.69 1.543.93 1.97 5.0 30 30 M White Non-Hispanic Contact 3 35 4 3.07 2.55 4.861.34 5.0 31 51 M White Non-Hispanic Case 9 33 3 1.29 1.60 4.69 1.20192.3 32 46 F White Non-Hispanic Case 8 32 3 1.30 2.18 3.79 0.83 47.4 3727 M White Non-Hispanic Case 6 26 6 2.13 1.52 4.11 1.04 286.3 38 57 FWhite Non-Hispanic Case 10 38 4 1.87 2.02 4.30 1.12 518.9 40 44 M WhiteNon-Hispanic Case 7 23 5 1.72 1.50 3.81 1.47 42.1 41 35 M WhiteNon-Hispanic Contact 10 29 8 2.13 1.67 4.15 0.98 302.5 42 40 M WhiteNon-Hispanic Contact 20 36 8 2.37 1.50 5.82 1.43 627.1 45 55 F WhiteNon-Hispanic Case 7 46 6 1.95 0.97 3.53 0.75 5.0 46 39 M WhiteNon-Hispanic Case 6 30 2 2.68 1.45 4.14 1.29 59.2 47 43 F WhiteNon-Hispanic Case 11 33 5 3.02 2.30 6.23 2.66 10433.3 46 37 F WhiteNon-Hispanic Case 7 21 5 1.51 1.85 3.47 1.51 173.4 50 27 F WhiteNon-Hispanic Contact 7 28 4 1.64 2.32 5.42 1.45 924.7 51 21 M WhiteNon-Hispanic Contact 8 31 5 1.76 1.69 3.94 1.03 1499.2 54 40 F WhiteNon-Hispanic Contact 3 24 3 1.80 2.10 4.99 1.42 5.0 55 36 M WhiteNon-Hispanic Case 3 49 2 1.43 1.23 3.90 2.09 5.0 56 75 F WhiteNon-Hispanic Case 22 40 3 1.79 1.81 5.89 1.47 1388.4 57 66 M WhiteNon-Hispanic Case 6 21 5 1.54 2.10 4.33 1.00 2048.9 58 64 F WhiteNon-Hispanic Contact 1 32 2 1.20 1.71 3.95 1.21 5.0 64 28 F WhiteNon-Hispanic Contact 11 32 6 2.36 2.06 4.48 1.66 776.7 67 19 F N/AHispanic Case 5 29 6 2.56 1.98 5.48 1.32 2052.9 71 45 F WhiteNon-Hispanic Case 12 48 7 1.55 2.04 3.86 1.53 33.3 72 42 M WhiteNon-Hispanic Case 16 35 8 4.05 3.58 6.05 2.59 3136.2 75 46 F WhiteNon-Hispanic Case 10 36 4 1.64 2.37 3.98 1.20 271.5 76 49 F WhiteNon-Hispanic Case 28 34 4 1.88 1.65 5.17 0.97 219.8 77 37 M WhiteNon-Hispanic Contact 6 33 4 1.33 1.83 3.56 1.16 5.0 81 44 F WhiteNon-Hispanic Contact 3 35 2 1.58 1.73 3.82 1.10 5.0 82 46 M N/ANon-Hispanic Case 0 0 2.19 1.92 5.41 1.81 130.7 88 41 M WhiteNon-Hispanic Case 7 23 4 1.82 3.32 4.97 1.37 424.7 95 44 M WhiteNon-Hispanic Case 9 36 6 2.61 1.62 6.03 1.62 961.9 96 48 F WhiteNon-Hispanic Case 9 30 3 3.93 1.93 6.25 2.26 927.7 97 39 M WhiteNon-Hispanic Case 9 31 3 1.58 1.61 4.03 2.33 202.7 98 35 F WhiteNon-Hispanic Case 2 24 4 1.78 1.47 5.38 1.22 249.0 99 36 F WhiteNon-Hispanic Case 13 29 5 2.50 3.27 4.38 2.49 1127.6 107 53 F WhiteNon-Hispanic Contact 10 29 4 1.74 1.41 4.66 0.90 297.5 108 75 M WhiteNon-Hispanic Case 16 41 7 1.37 0.88 3.47 1.36 557.5 110 27 M WhiteNon-Hispanic Case 1 25 1 1.30 1.60 4.00 0.93 5.0 114 30 F WhiteNon-Hispanic Case 15 36 7 1.65 1.92 3.53 1.55 110.9 115 65 F WhiteNon-Hispanic Contact 20 41 6 2.10 3.28 4.32 3.27 1127.7 119 56 M WhiteNon-Hispanic Case 13 48 3 1.36 1.26 4.41 1.59 650.3 120 56 F WhiteNon-Hispanic Case 26 48 6 0.99 0.97 3.65 1.21 100.6 121 19 M WhiteNon-Hispanic Contact 3 42 2 0.85 0.87 3.56 1.26 5.0 122 21 F WhiteNon-Hispanic Contact 3 36 1 1.44 0.94 3.39 1.22 5.0 123 26 M WhiteNon-Hispanic Contact 12 34 6 0.94 0.95 3.39 1.40 5.0 124 63 F AsianNon-Hispanic Contact 4 37 3 1.58 2.06 3.49 1.32 5.0 125 51 F WhiteNon-Hispanic Case 10 26 3 1.92 3.49 3.86 1.24 126.5 127 24 F WhiteNon-Hispanic Case 10 43 6 1.80 2.50 4.37 2.41 883.5 130 39 M WhiteNon-Hispanic Contact 7 26 5 1.24 1.72 3.91 1.34 5.0 131 39 M WhiteNon-Hispanic Case 5 25 4 1.46 1.38 4.44 1.03 7.8 132 36 M WhiteNon-Hispanic Contact 10 50 6 2.15 1.76 4.84 1.97 5.0 134 27 F WhiteNon-Hispanic Contact 16 22 5 2.51 2.18 6.84 1.94 2700.6 135 62 F WhiteNon-Hispanic Case 8 31 6 2.20 2.02 3.80 1.13 350.0 140 63 F WhiteNon-Hispanic Case 28 47 1 1.05 1.24 3.58 1.28 52.4 149 41 M WhiteNon-Hispanic Contact 17 28 6 1.68 2.02 3.67 1.09 494.9 150 50 F WhiteNon-Hispanic Contact 12 45 7 1.15 0.43 3.18 1.82 5.0 154 66 M AsianNon-Hispanic Case 16 30 9 3.19 2.19 4.85 1.29 928.2 157 50 M WhiteNon-Hispanic Case 10 32 8 2.40 2.86 3.90 2.06 741.7 166 28 F WhiteNon-Hispanic Case 13 45 2 1.27 0.66 3.45 0.94 5.0 167 50 F WhiteNon-Hispanic Contact 11 41 6 1.43 3.71 3.93 8.74 5.0 172 36 F WhiteNon-Hispanic Case 6 22 9 1.71 2.58 4.29 1.20 301.1 173 47 M WhiteNon-Hispanic Case 5 47 7 2.57 4.14 4.78 4.48 646.9 178 26 F WhiteNon-Hispanic Case 6 24 4 1.54 1.59 3.66 1.02 5.0 179 39 M WhiteNon-Hispanic Contact 10 37 3 1.89 2.25 3.83 1.73 370.1 182 44 F WhiteNon-Hispanic Contact 10 38 6 3.80 1.77 5.36 8.05 1503.7 183 43 F WhiteNon-Hispanic Case 13 44 8 1.56 1.02 3.88 1.55 240.1 185 54 M WhiteNon-Hispanic Case 11 44 8 3.51 1.39 5.55 2.11 1806.8 186 38 F N/A N/ACase 8 26 2 1.73 2.47 4.37 1.23 296.9 190 54 F White Non-Hispanic Case18* 63 9 3.24 1.24 7.38 1.42 598.1 195 24 M White Non-Hispanic Case 1842 5 2.74 2.55 5.01 2.33 1315.1 200 60 F White Non-Hispanic Case 17 39 72.40 1.00 4.38 1.51 1014.4 201 50 M White Non-Hispanic Contact 15 33 64.37 2.57 6.15 1.57 3897.4 202 57 M White Non-Hispanic Case 21 34 7 2.102.08 5.07 1.17 257.9 205 64 M White Non-Hispanic Case 7 36 4 4.51 0.706.12 1.69 924.4 222 28 M Asian Non-Hispanic Case 11 29 7 1.28 0.69 3.943.46 5.0 229 45 M White Non-Hispanic Case 10 63 4 2.92 1.42 4.90 1.581272.9 230 50 M White Non-Hispanic Case 18 33 7 3.80 0.47 3.48 0.88 5.0232 38 F White Non-Hispanic Case 13 43 7 1.57 0.70 4.24 5.70 94.3 233 55M White Non-Hispanic Case 20 41 3 2.07 2.11 4.51 1.07 173.2 241 36 MWhite Non-Hispanic Case 12 30 7 2.27 2.66 4.54 1.46 923.1 242 59 M WhiteNon-Hispanic Case 10 42 6 4.91 1.94 4.81 2.16 1353.0 243 30 F AsianNon-Hispanic Case 6 26 5 2.92 2.57 5.06 1.14 1300.2 246 44 F WhiteNon-Hispanic Case 10 38 7 2.05 2.79 6.09 1.32 566.0 255 33 M WhiteNon-Hispanic Case 14 44 6 2.14 0.70 4.20 1.24 172.5 256 63 F WhiteNon-Hispanic Case 27 42 6 1.72 1.96 4.26 7.79 141.6 258 52 M WhiteNon-Hispanic Contact 14 48 6 2.64 1.20 4.52 1.85 4145.9 279 41 M WhiteNon-Hispanic Case 7 38 8 1.68 2.13 3.77 1.90 308.9 280 59 M WhiteNon-Hispanic Case 6 32 7 2.53 3.07 4.61 1.19 1072.1 302 47 F WhiteNon-Hispanic Case 35* 49 7 1.48 0.97 4.06 1.26 5.0 310 34 F WhiteNon-Hispanic Case 17 35 5 3.95 1.24 9.44 3.07 485.5 314 46 M WhiteNon-Hispanic Case 11 38 7 2.12 0.88 4.56 1.51 667.1 315 29 F WhiteNon-Hispanic Case 15 42 8 3.02 0.69 3.98 1.03 376.5 319 50 M WhiteNon-Hispanic Case 5 38 6 3.71 2.28 3.79 1.05 5.0 323 39 F WhiteNon-Hispanic Case 7 45 7 1.05 1.03 3.53 1.42 5.0 325 52 M WhiteNon-Hispanic Case 16 38 8 2.25 1.47 4.83 2.28 1603.3 343 21 F WhiteNon-Hispanic Case 16 49 5 1.63 0.94 3.37 1.70 5.0 352 44 M WhiteNon-Hispanic Case 16 43 4 3.54 0.92 4.50 1.07 519.2 353 60 M WhiteNon-Hispanic Case 14 49 6 5.38 1.12 5.69 1.05 855.5 356 22 F WhiteNon-Hispanic Contact 16 38 3 1.37 0.61 2.98 1.09 5.0 357 27 F WhiteNon-Hispanic Contact 34 56 5 7.49 1.10 2.77 1.13 5.0 364 29 M WhiteNon-Hispanic Contact 14 49 6 0.97 0.58 2.90 0.89 5.0 366 41 F WhiteNon-Hispanic Contact 9 34 7 0.98 0.52 3.51 1.19 5.0 373 35 F WhiteNon-Hispanic Case 12 51 7 1.69 1.26 5.14 1.69 5.0 388 47 F WhiteNon-Hispanic Contact 14 41 9 1.57 1.06 3.61 1.69 5.0 393 69 M WhiteNon-Hispanic Case 23* 54 9 1.28 1.74 3.81 2.65 715.4 394 48 F MultipleHispanic Case 7 67 4 2.05 0.87 4.34 2.02 1281.5 397 52 M WhiteNon-Hispanic Case 22 45 8 3.32 0.59 5.01 0.87 1516.9 403 52 M AsianNon-Hispanic Case 18* 39 10 5.36 1.09 10.01 1.36 3887.8 406 65 M WhiteNon-Hispanic Case 20 56 8 4.69 0.90 7.51 1.15 1288.7 410 34 M WhiteNon-Hispanic Case 12 46 8 1.06 0.56 3.95 0.76 5.0 421 62 F WhiteNon-Hispanic Contact 12 43 9 0.95 1.07 3.34 1.35 5.0 426 65 M WhiteNon-Hispanic Case 18 51 6 2.07 0.55 3.95 1.49 804.8 437 43 F AsianNon-Hispanic Case 14 34 7 2.54 0.47 4.30 1.44 698.8 460 36 M WhiteNon-Hispanic Case 11 39 6 2.94 3.18 5.51 2.80 1906.7 461 49 M WhiteNon-Hispanic Case 7 39 5 3.38 0.94 4.67 2.02 1076.6 462 28 F WhiteNon-Hispanic Case 16 45 5 1.36 0.38 3.07 1.11 5.0 470 28 F WhiteNon-Hispanic Case 17 51 4 1.26 0.86 3.97 1.50 5.0 478 31 M WhiteNon-Hispanic Case 16 52 4 1.43 0.93 3.70 1.97 263.2 481 28 F AsianNon-Hispanic Case 15 43 8 1.70 0.39 3.46 1.24 5.0 486 64 F WhiteNon-Hispanic Case 11 41 10 1.70 1.00 3.68 1.29 5.0 500 46 M WhiteNon-Hispanic Case 12 53 5 1.10 0.82 3.49 1.34 5.0 501 32 M AsianNon-Hispanic Case 18* 53 10 2.62 0.65 4.51 1.21 718.8 502 52 M WhiteNon-Hispanic Case 16* 53 9 5.10 0.61 5.10 1.62 2171.8 506 46 M WhiteNon-Hispanic Case 12 59 9 0.84 0.81 3.13 1.21 5.0 507 39 M WhiteNon-Hispanic Case 15 60 8 1.92 0.96 4.56 1.52 5.0 509 36 M WhiteNon-Hispanic Case 11 50 5 1.99 1.01 3.99 1.45 5.0 526 49 M AsianNon-Hispanic Case 11 34 7 3.36 1.45 5.88 1.57 4193.3 537 52 M WhiteNon-Hispanic Case 15 45 6 1.47 0.95 3.65 1.58 923.3 539 73 F WhiteNon-Hispanic Case 19* 54 10 2.82 0.63 4.46 1.45 487.9 547 59 M WhiteNon-Hispanic Case 15* 36 9 2.97 1.53 5.08 2.59 2900.6 587 54 M PI N/ACase 17* 51 8 3.22 0.60 4.01 1.49 473.1 632 38 M White Non-HispanicContact 10 43 6 2.49 0.86 4.50 1.63 572.3 633 39 M White Non-HispanicContact 8 57 4 1.25 1.04 3.38 1.73 5.0 652 76 M White Non-Hispanic Case18* 56 10 4.75 1.46 8.96 3.80 2324.0 664 45 F White Non-Hispanic Case17* 42 10 1.68 0.43 3.93 1.32 5.0 675 47 M White Non-Hispanic Contact 3147 5 0.79 0.93 2.94 1.38 5.0 *hospitalized, Sx = symptoms

q y y p Participants Symptom (n = 149) % Fever 125 83.9 Fatigue 106 71.1Cough  93 62.4 Myalgia  92 61.7 Shortness of breath  66 44.3 Headache 63 42.3 Loss of smell/taste  50 33.3 Sore throat  38 25.3 Diarrhea  3221.3 Presence of  16 10.7 comorbidities (HTN, CAD, DM, COPD, asthma,cancer) HTN (hypertension), CAD (coronary artery disease), DM (diabetesmellitus), COPD (chronic obstructive pulmonary disease)

TABLE 4Representative amino acid sequences of cloned recombinant antibodies OldSEQ SEQ Antibody antibody ID ID ID ID NO IGH VDJ (aa) NO IGL VJ (aa)C002 A-C002   1 EVQLVESGGGVVQPGRSLRLSCA   2 DIQLTQSPSSLSASVGDRVTITCRAASGFTFSIYGMHWVRQAPGKGLE SQSISSYLNWYQQKPGKAPKLLIY WAVISYDGSNKYYADSVKGRFTIAASSLQSGVPSRFSGSGSGTDFTL SRDNSKNTLYLQMNSLRAEDTAVTISSLQPEDFATYYCQQSYSTPRT YYCAKEGRPSDIVVVVAFDYWGQ FGQGTKVEIK GTLVTVSSC003 A-C003   3 EVQLVESGGGLIQPGGSLRLSCA   4 EIVLTQSPGTLSLSPGERATLSCRAASGFTVSSNYMSWVRQAPGKGL SQSVSSTYLAWYQQKPGQAPRLLI EWVSVIYSGGSTYYADSVKGRFTIYGASSRATGIPDRFSGSGSGTDFT SRDNSKNTLYLQMNSLRAGDTAVLTISRLEPEDFAVYYCQQYGSSPR YYCARDYGDFYFDYWGQGTLVT TFGQGTKLEIK VSS C004A-C004   5 QVQLVQSGAEVKKPGASVKVSCK   6 AIRMTQSPSSLSASVGDRVTITCQASGYTFTGYYMHWVRQAPGQGL ASQDISNYLNWYQQKPGKAPKLLI EWMGWINPISGGTNYAQKFQGRYDASNLETGVPSRFSGSGSGTDFT VTMTRDTSISTAYMELSRLRSDDTFTISSLQPEDIATYYCQQYDNLPITF AVYYCASPASRGYSGYDHGYYYY GQGTRLEIKMDVWGKGTTVTVSS C005 A-C005   7 QVQLVQSGPEVKKPGTSVKVSCK   8EIVLTQSPGTLSLSPGERATLSCRA ASGFTFTSSAVQWVRQARGQRLSQSVRSSYLAWYQQKPGQAPRLLI EWIGWIVVGSGNTNYAQKFQERVYGASSRATGIPDRFSGSGSGTDFT TITRDMSTSTAYMELSSLRSEDTALTISRLEPEDFAVYYCQQYGSSPW VYYCAAPHCSGGSCLDAFDIWGQ TFGQGTKVEIK GTMVTVSSC006 A-C006   9 QVQLVESGGGLVKPGGSLRLSCA  10 QSVLTQPPSASGTPGQRVTVSCSASGFIFSDYCMSWIRRAPGKGLE GSSSNIGSNTVNWYQQLPGTAPKLWLSYISNSGTTRYYADSVKGRFTI LIYSNNQRPSGVPDRFSGSKSGTSSRDNGRNSLYLQMDSLSAEDTAV ASLAISGLQSEDEADYFCAAWDDS YYCARRGDGSSSIYYYNYMDVWLNGPVFGGGTKLTVL GKGTTVTVSS C008 A-C008  11 EVQLVESGGGVVQPGRSLRLSCA  12DIQMTQSPSTLSASVGDRVTITCR ASGFTFSSYGMHWVRQAPGKGL ANQSISSWLAWYQQKPGKAPKLLIEWVTVISYDGRNKYYADSVKGRF YKASSLESGVPSRFSGSGSGTEFTTISRDNSKNTLYLQMNSLRAEDTA LTISSLQPDDFATYYCQQYNSYWT VYYCAREFGDPEWYFDYWGQGTFGQGTKVEIK LVTVSS C009 A-C009  13 QVQLVQSGAEVKKPGASVKVSC  14QSALTQPPSASGSPGQSVTISCTG MASGYTFTGYYMHWVRQAPGQG TSSDVGGYNYVSWYQQHPGKAPKLEWMGWINPNSGGTNYAQKFQG LMIYEVSKRPSGVPDRFSGSKSGN RVTMTRDTSISTAYMELSRLRSDDTASLTVSGLQAEDEAEYYCSSDAG TAVYYCARDSPFSALGASNDYWG SNNVVFGGGTKLTVLQGTLVTVSS C010 A-C010  15 EVQLVESGGGVVQPGRSLRLSCA  16DIQLTQSPSSLSASVGDRVTITCRA ASGFTFSSYAMHWVRQAPAKGLESQSISTYLNWYQQKPGKAPKLLIYA WVAVILYDGSGKYYADSVKGRFTIASSLQSGVPSRFSGSGSGTDFTLT SRDNSKNTLYLQMNSLRAEDTAVISSLQPEDFATYYCQQSYSTPPWT YYCARDGIVDTALVTWFDYWGQG FGQGTKVEIK TLVTVSS C013A-C013  17 QVQLVQSGAEVKKPGSSVKVSCK  18 EIVLTQSPATLSLSPGERATLSCRAASGGTFSSYAISWVRQAPGQGLE SQSVSSYLAWYQQKPGQAPRLLIYWMGGIIPIFGTANYAQKFQGRVTI DASNRATGIPARFSGSGSGTDFTLTADESTSTAYMELSSLRSEDTAVY TISSLEPEDFAVYYCQQRSNWPLTYCARGNRLLYCSSTSCYLDAVRQ FGGGTKVEIK GYYYYYYMDVWGKGTTVTVSS C016 A-C016  19EVQLVESGGGVVQPGRSLRLSCA  20 AIRMTQSPSSLSASVGDRVTITCQASGFTFSRYGMHWVRQAPGKGL ASQDISNYLNWYQQKPGKAPKLLI EWVAVISYDGSNKYYADSVKGRFYDASNLETGVPSRFSGSGSGTDFT TISRDNSKNTLYLQMNSLRAEDTAFTINSLQPEDIATYYCQQYDNLPPT VYYCAKVTAPYCSGGSCYGGNFD FGGGTKVEIKYWGQGTLVTVSS C017 A-C017  21 EVQLVESGGGLVQPGRSLRLSCA  22EIVLTQSPATLSLSPGERATLSCRA ASGFTFDDYAMHWVRQAPGKGLSQSVSSYLAWYQQKPGQAPRLLIY EWVSGISWNSGTIGYADSVKGRFDASNRATGIPARFSGSGSGTDFTL TISRDNAKNSLYLQMNSLRAEDTATISSLEPEDFAVYYCQQRITFGQGT FYYCAKAGVRGIAAAGPDLNFDH RLEIK WGQGTLVTVSS C018A-C018  23 EVQLVESGGGVVQPGRSLRLSCA  24 DIQLTQSPSSLSASVGDRVTITCRAASGFTFSNYAIHWVRQAPGKGLE SQSIRSYLNWYQQKPGKAPKLLIYWVAVISYDGSNKYYADSVKGRFTI AASSLQSGVPSRFSGSGSGTDFTLSRDNSKNTLYLQMNSLRAEDTAV TISSLQPDDFATYYCQQSYSTPPA YYCARDFDDSSFWAFDYWGQGTTFGQGTKLEIK LVTVSS C019 A-C019  25 QVQLVQSGAEVKKPGASVKVSCK  26SYELTQPPSVSVAPGKTARITCGE ASGYTFTSYYMHWVRQAPGQGL NNIGSKSVHWYQQKPGQAPVLVIYEWMGIINPSGGSTSYAQKFQGRV YDSDRPSGIPERFSGSNSGNTATL TMTRDTSTSTVYMELSSLRSEDTTINRVEAGDEADYYCQVWDSSSD AVYYCARVPREGTPGFDPWGQG HVVFGGGTKLTVL TLVTVSSC021 A-C021  27 QVQLQESGPGLVKPSQTLSLTCT  28 DIVMTQSPLSLPVTPGEPASISCRSVSGGSISSGGYYWSWIRQHPGK SQSLLHSNGYNYLDWYLQKPGQS GLEWIGYIYYSGSTYYNPSLKSRVPQLLIYLGSNRASGVPDRFSGSGS TISVDTSKNQFSLKLSSVTAADTAGTDFTLKISRVEAEDVGVYYCMQA VYYCARVWQYYDSSGSFDYWGQ LQTPFTFGPGTKVDIKGTLVTVSS C022 A-C022  29 QVQLQESGPGLVKPSETLSVTCT  30DIQMTQSPSTLSASVGDSVTITCRA VSGGSISSSRYYWGWIRQPPGKGSQSISSWLAWYQQKPGKAPKLLIY LEWIGSIYYSGSTYYNPSLKSRVTIKASSLESGVPSRFSGSGSGTEFTL SVDTSKNQFSLKLSSVTAADTAVYTISSLQPDDFATYYCQQYNNYRYT YCARHAAAYYDRSGYYFIEYFQH FGQGTKLEIK WGQGTLVTVSSC027 A-C027  31 EVQLVESGGGVVQPGRSLRLSCA  32 DIQMTQSPSTLSASVGDRVTITCRASGFTFSSYGMHWVRQAPGKGL ASQSISSWLAWYQQKPGKAPKLLI EWVAVISYDGSNKYYADSVKGRFYKASSLESGVPSRFSGSGSGTEFT TISRDNSKNTLYLQMNSLRAEDTALTISSLQPDDFATYYCQQYNSYST VYYCAKASGIYCSGGDCYSYYFD FGQGTKVEIK YWGQGTLVTVSSC029 A-C029  33 QVQLQESGPGLVKPSQTLSLTCT  34 DIVMTQSPLSLPVTPGEPASISCRSVSGGSISSGGYYWSWIRQHPGK SQSLLHSNGYNYLDWYLQKPGQS GLEWIGYIYYSGSTYYNPSLKSRVPQLLIYLGSNRASGVPDRFSGSGS TISVDTSKNQFSLKLSSVTAADTAGTDFTLKISRVEAEDVGVYYCMQA VYYCARTMYYYDSSGSFDYWGQ LQTPHTFGGGTKVEIKGTLVTVSS C030 A-C030  35 EVQLVESGGGVVQPGRSLRLSCA  36DIQMTQSPSTLSASVGDRVTITCR ASGFTFSSYGMHVWRQAPGKGL ASQSISSWLAWYQQKPGKAPKLLIEWVAVISYDGSNKYYADSVKGRF YKASSLESGVPSRFSGSGSGTEFTTISRDNSKNTLYLQMNSLRAEDTA LTISSLQPDDFATYYCQQYNSYSTVYYCAKASGIYCSGGNCYSYYFD FGQGTKVEIK YWGQGTLVTVSS C031 A-C031  37EVQLVESGGGLVQPGGSLRLSCA  38 DIQMTQSPSSLSASVGDRVTITCRASGFTFSSYDMHWVRQATGKGL ASQSISSYLNWYQQKPGKAPKVLI EWVSAIGTAGDTYYPGSVKGRFTIYAASSLQSGVPSRFSGSGSGTDF SRENAKNSLYLQMNSLRAGDTAVTLTISSLQPEDFATYYCQQSYSTPP YYCARVGYDSSGYSGWYFDLWG LTFGGGTKVEIK RGTLVTVSSC032 A-C032  39 EVQLVQSGAEVKKPGESLKISCK  40 QSVLTQPPSVSGAPGQRVTISCTGGSGYSFTSYWIGWVRQMPGKGL SSSNIGAGYDVHWYQQLPGTAPK EWMGIIYPGDSDTRYSPSFQGQVLLIYGNSNRPSGVPDRFSGSKSGT TISADKSISTAYLQWSSLKASDTASASLAITGLQAEDEADYYCQSYDS MYYCARGVAVDWYFDLWGRGTL SLSALYVFGTGTKVTVL VTVSSC036 A-C036  41 QVQLQQWGAGLLKPSETLSRTCA  42 DIVMTQSPLSLPVTPGEPASISCRSVFGGSFTNYYWSWIRQSPGKGLE SQSLLHRNGYNYLDWYLQKPGQSWIGEINDSGITNYNPSLKSRVTISV PQLLIYLGSNRASGVPDRFRGSGSDTSKNQFSLSLRSVTAADTAVYYC GTDFTLKISRVEAEDVGVYYCMQAARRRSFSRPSSIDYWGQGTLVTV LQTLTFGQGTRLEIK SS C037 A-C037  43QLVQSGPEVKKPGTSVKVSCKAS  44 EIVLTQSPGTLSLSPGERATLSCRAGFTFTSSAMQWVRQARGQRLEW SQSVSSSYLAWYQQKPGQAPRLLI IGWIVVGSGNTNYAQKFQERVTITYGASSRATGIPDRFSGSGSGTDFT RDMSTSTAYMELSSLRSEDTAVYLTISRLEPEDFAVYYCQQYGSSPW YCAAPYCSGGSCNDAFDIWGQG TFGQGTKVEIK TMVTVSS C038A-C038  45 VQLVESGGGVVQPGRSLRLSCAA  46 NFMLTQPHSVSESPGKTVTISCTGSGFTFNRIAMYWVRQAPGKGLE SSGSIASNYVQWYQQRPGSAPTT WVAVISFDGSYEYYAESVKGRFAIVIYEDTQRPSGVPDRFSGSIDSSS SRDNSKNTLYLQMNSLRAEDTAVNSASLTISGLKTEDEADYYCQSYDI YYCAKSPMGYCTNGVCYPDSWG NSRWVFGGGTKLTVLQGTLVTVSS C040 A-C040  47 EVQLVESGGGLVKPGGSLRLSCA  48SYELTQPPSVSVAPGQTARITCGG ASGFTFSNAWMSWVRQAPGKGL NNIGSKSVHWYQQKPGQAPVLVVEWVGRIKSKTDGGTTDYAAPVKG YDDSDRPSGIPERFSGSNSGNTATRFTISRDDSKNTLYLQMNSLKTED LTISRVEAGDEADYYCQVWDSSSDTAVYYCTTDPHCSSTSCPIFYYYY QGVFGGGTKLTVL MDVWGKGTTVTVSS C101 V-C001  49QVQLVESGGGLIQPGGSLRLSCA  50 EIVLTQSPGTLSLSPGERATLSCRAASGFIVSSNYMSWVRQAPGKGLE SQSVSSSYLAWYQQKPGQAPRLLIWVSVIYSGGSTFYTDSVKGRFTIS YGASSRATGIPDRFSGGGSETDFTRDNSKNTLYLQMNSLRAEDTAVY LTISRLEPEDCAVYYCQQYGSSPR YCVRDYGDFYFDYWGQGTLVTVTFGQGTKVEIK SS C102 V-C002  51 QVQLVESGGGLIQPGGSLRLSCA  52EIVLTQSPGTLSLSPGERATLSCRA ASGFIVSSNYMSWVRQAPGKGLESQSVSSSYLAWYQQKPGQAPRLLI WVSVIYSGGSTFYADSVKGRFTISYGASSRATGIPDRFSGSGSGTDFT RDNSKNTLYLQMNSLRAEDTAVYLTISRLEPEDFAVYYCQQYGSSPR YCARDYGDYYFDYWGQGTLVTV TFGQGTKVEIK SS C103V-C003  53 QVQLQQWGAGLLKPSETLSLTCA  54 EIVLTQSPGTLSLSPGERATLSCRAVSGGSLSGFYWTWIRQPPGKGLE SQTVTANYLAWYQQKPGQAPRLLIWIGETNHFGSTGYKPSLKSRVTIS YGASKRATGIPDRFSGSGSGTDFTVDMSRNQFSLKVTSVTAADTAVY LSISRLEPEDFAVYYCQQYTTTPRTYCARKPLLYSDFSPGAFDIWGQG FGGGTKVEIK TMVTVSS C104 V-C004  55QVQLQQWGAGLLKPSETLSLSCA  56 EIVLTQSPGTVSLSPGERATLSCWVYGGSLSGYYWSWIRQPPGKGL ASQSVSASYLAWYQQKPGQAPRL EWIGEINHFGSTGYNPSLKSRVTILIYGASSRATGIPDRFSGSGSGTD SVDTSKSQFSVKLSSVTAADTAVYFTLTISRLEPEDFAVYYCQQYGTTP YCARKPLLYSNLSPGAFDIWGQG RTFGGGTKVEIK TMVTVSSC105 V-C005  57 QVQLVESGGGLIQPGGSLRLSCA  58 QSALTQPPSASGSPGQSVTISCTGASGFTVSSNYMSWVRQAPGKGL TSSDVGGYKYVSWYQQHPGKAPK EWVSVIYSGGSTYYADSVKGRFTILMIYEVSKRPSGVPDRFSGSKSGN SRDNSKNTLYLQMNSLRAEDTAVTASLTVSGLQAEDEADYYCSSYEG YYCARGEGWELPYDYWGQGTLV SNNFVVFGGGTKLTVL TVSSC106 V-C006  59 QLQLQESGPGLVKPSETLSLTCTV  60 SYELTQPPSVSVAPGKTARITCGGSGASVSSGSYYWSWIRQPPGKG NNIGSKSVHWYQQKPGQAPVLVIYLEWIGYIYYSGSTNYNPSLKSRVTI FDSDRPSGIPERFSGSNSGNTATLSVDTSKNQFSLKLSSVTAADTAVY TISRVEAGDEADYYCQVWDSSRD YCARERPGGTYSNTWYTPTDTNHVVFGGGTKLTVL WFDTWGQGTLVTVSS C107 V-C007  61 QVQLVQSGAEVKKPGASVRVSCK 62 QSVLTQPPSASGTPGQRVTISCSG ASGYTFTSYGFSWVRQAPGQGLSSSNIGSNYVYWYQQLPGTAPKLL EWMGWISAYNGNTNFAQKLQGR IYRNNQRPSGVPDRFSGSKSGTSAVTMTTDTSTSTAYMELRSLRSDD SLAISGLRSEDEADYYCAAWDDSL TAVYYCARGEAVAGTTGFFDYWGSGFVVFGGGTKLTVL QGTLVTVSS C108 V-C008  63 QVQLQESGPGLVKPSGTLSLTCA  64QSALTQPASVSGSPGQSITISCTGT VSGGSISSTNWWSWVRQPPGKG SSDVGGYNYVSWYQQHPGKAPKLLEWIGEIYHTGSTNYNPSLKSRVTI MIYDVSNRPSGVSNRFSGSKSGNSVDKSKNQFSLKLSSVTAADTAVY TASLTISGLQAEDEADYYCNSYTS YCVRDGGRPGDAFDIWGQGTMVSSTRVFGTGTKVTVL TVSS C110 V-C010  65 QVQLQQSGAEVKKPGESLKISCK  66DIQMTQSPSTLSASVGDRVTITCR GSGYSFTSYWIGWVRQMPGKGL ASQSISYWLAWYQQKPGKAPKLLIEWMGIIYPGDSDTRYSPSFQGQV YQASSLESGVPSRFSGSESGTEFTTISADKSISTAYMQWSSLKASDTA LTISSLQPDDFATYYCQQYNSYPYMYYCARSFRDDPRIAVAGPADAF TFGQGTKLEIK DIWGQGTMVTVSS C112 V-C012  67QVQLVESGGGVVQPGRSLRLSCA  68 QSALTQPASVSGSPGQSITISCTGTASGFTFSSHAMHWVRQAPGKGL SSDVGGYNYVSWYQQHPGKAPKL EWVAVISYDGSNKYYADSVKGRFMIYDVSNRPSGVSNRFSGSKSGN TISRDNSKNTLYLQMNSLRAEDTATASLTISGLQAEDEADYYCSSYTSS VYYCAREDYYDSSGSFDYWGQG STWVFGGGTKLTVL TLVTVSSC113 V-C013  69 QVQLVESGGGVVQPGRSLRLSCA  70 DIQMTQSPSTLSASVGDRVTITCRASGFTFSNFGMHWVRQAPGKGL ASQSMSSWLAWYQQKPGNAPKLL EWVAVIWYDGSNKYYADSVKGRFIYKASSLESGVPSRFSGSGSGTEF TISRDNSKNTLYLQMNSLRAEDTATLTISSLQPDDFATYYCQQHNSSP VYYCARGVNPDDILTGVDAFDIW LTFGGGTKVEIK GQGTMVTVSSC114 V-C014  71 QVQLVESGGGLIQPGGSLKLSCV  72 QSVLTQPPSVSGAPGQRVTISCTGVSGFTVSKNYISWVRQAPGKGLE TSSNIGAGYDVHWYQQLPGRAPK WVSVIFAGGSTFYADSVKGRFAISVLISGNNIRPSEVPDRFSGSRSGT RDNSNNTLFLQMNSLRVEDTAIYYSASLAITSLQPEDEAQYYCQSYDS CARGDGELFFDQWGQGTLVTVSS SLYAVFGGGTKLTVL C115V-C015  73 QVQLVESGGGLIKPGRSLRLSCTA  74 DIVMTQSPLSLSVTPGEPASISCRSSGFTFGDYAMTWFRQAPGKGLE SQSLLHSNGNNYFDWYLQKPGQS WVGFIRSKAYGGTTGYAASVKYRPQLLIYLGSNRASGVPDRFSGSGS FTISRDDSKSIAYLQMDSLKTEDTGTDFTLKISRVEAEDVGVYYCMQV AVYYCTRWDGWSQHDYWGQGT LQIPYTFGQGTKLEIK LVTVSSC116 V-C016  75 QVQLVESGGGVVQPGRSLRLSCA  76 NFMLTQPHSVSESPGKTVTISCTGASGFTYSTYAMHWVRQAPGKGL SSGSIASNYVQWYQQRPGSAPTT EWVAFISYDGSNKYYADSVKGRFVIYEDNQRPSGVPDRFSGSIDRSS TISRDNSKNTLYLQMNSLRAEDTANSASLTISGLKTEDEADYYCQSYD VYYCARDFYHNWFDPWGQGTLV SGNHWVVFGGGTRLTVL TVSSC117 V-C017  77 QVQLVESGGGVVQPGRSLRLSCA  78 QSVLTQPPSVSAAPGQKVTISCSGASGFTFSTYAMHWVRQAPGEGL SSSNIGNNLVSWYQQLPGTAPKLLI EWVAVISYDGSNTYYADSVKGRFYENNKRPSGIPDRFSGSKSGTSAT TISRDNSKNTLYLQMNSLRAEDTALGITGLQTGDEADYYCGAWDSSLS VYYCARDPIWFGELLSPPFVHFDY AGGVYVFGTGTKVTVLWGQGTLVTVSS C118 V-C018  79 QVQLVESGGGVVQPGRSLRLSCA  80QPVLTQSPSASASLGASVKLTCTL ASGFTFSNYAMHWVRQAPGKGL SSGHSSYAIAWHQQQPEKGPRYLEWVAVISYDGSNKYYADSVKGRF MKLNTDGSHSKGDGIPDRFSGSS TISRDNSKNTLYLQMNSLRAEDTASGAERYLTISSLQSEDEADYYCQT IYYCASGYTGYDYFVRGDYYGLD WGTGILVFGGGTKLTVLVWGQGTTVTVSS C119 V-C019  81 QVQLVQSGAEVKKPGASVKVSCK  82QSALTQPASVSGSPGQSITISCTGT ASGYTFTSYYMHWVRQAPGQGL SSDVGGYKYVSWYQRHPGKAPKLEWMGIINPSGGSTSYAQKLQGRV MIYDVSNRPSGVSNRFSGSKSGN TMTRDTSTSTVYMELSSLRSEDTTASLTISGLQAEDEADYYCSSYTSS AVYYCARANHETTMDTYYYYYYM STSVVFGGGTQLTVLDVWGKGTTVTVSS C120 V-C020  83 EVQLVESGGGLIQPGGSLRLSCA  84AIRMTQSPSSLSASVGDTVTITCQA ASGFTVSSNYMTWVRQAPGKGLSQDISKYLNWYQQKPGKAPKLLIY EWVSLIYPGGSTYYADSVKGRFTIDASNLETGVPSRFSGSGSGTDFTF SRDNSKNTLYLQMNSLRAEDTAVTISSLQPEDIATYYCQQYDNLPQTF YYCAREGMGMAAAGTWGQGTLV GGGTKVEIK TVSS C121V-C021  85 QVQLVQSGAEVKKPGASVKVSCK  86 QSALTQPASVSGSPGQSITISCTGTASGYTFTGYYMHWVRQAPGQGL SSDVGSYNLVSWYQQHPGKAPKL EWMGWISPVSGGTNYAQKFQGRMIYEGSKRPSGVSNRFSGSKSGN VTMTRDTSISTAYMELSRLRSDDTTASLTISGLQAEDEADYYCCSYAG AVYYCARAPLFPTGVLAGDYYYY SSTLVFGGGTKLTVLGMDVWGQGTTVTVSS C122 V-C022  87 EVQLVESGGGLIQPGGSLRLSCA  88DIQLTQSPSFLSASVGDRVTITCRA ASGLTVSSNYMSWVRQAPGKGLSQGISSYLAWYQQKPGKAPKLLIY EWVSVLYSGGSSFYADSVKGRFTAASTLQSGVPSRFSGSGSGTEFTL ISRDNSKNTLYLQMNSLRAEDTAVTISSLQPEDFATYYCQQLNSDSYT YYCARESGDTTMAFDYWGQGTL FGQGTKLEIK VTVSS C123V-C023  89 EVQLVESGGGLIQPGGSLRLSCA  90 DIQLTQSPSFLSASVGDRVTITCRAASGVTVSRNYMSWVRQAPGKGL SQGISSYLAWYQQKPGKAPKLLIY EWVSVIYSGGSTYYADSVKGRFTIAASTLQSGVPSRFSGSGSGTEFTL SRDNSKNTLYLQMNSLRAEDTAVTISSLQPEDFATYYCQQLNSYPPA YYCARDLSAAFDIWGQGTMVTVSS FGQGTRLEIK C124 V-C024 91 EVQLVESGGGLVQPGGSLRLSCA  92 EIVLTQSPATLSLSPGERATLSCRAASGFTFSGYSMNWVRQAPGKGP SQSFSSYLAWYQQKPGQAPRLLIYEWVSYISRSSSTIYYADSVKGRFTI DASNRATGIPARFSGSGSGTDFTLSRDNAKNSLYLQMNSLRDEDTAV TISSLEPEDFAVYYCQQRNNWPPE YYCAREGARVGATYDTYYFDYWWTFGQGTKVEIK GQGTLVTVSS C125 V-C025  93 QVQLVQSGPEVKKPGTSVKVSCK  94EIVLTQSPGTLSLSPGERATLSCRA ASGFTFTSSAVQWVRQARGQRLSQSVSSSYLAWYQQKPGQAPRLLI EWIGWIVVGSGNTNYAQKFQERVYGASSRATGIPDRFSGSGSGTDFT TITRDMSTSTAYMELSSLRSEDTALTISRLEPEDFAVYYCQQYGSSPW VYYCAAPYCSGGSCSDAFDIWGQ TFGQGTKVEIK GTMVTVSSC126 V-C026  95 QVQLQESGPGLVKPSETLSLSCA  96 NFMLTQPHSVSESPGKTVTISCTGVSGGSIGSYFWSWIRQPPGKGLE SSGSIASNYVQWYQQRPGSAPTT WIGYLHYSGSTNYNPSLKSRVTISVINEDNQRPSGVPDRFSGSIDSSS VDTSKNQFSLKLSSVTAADTAVYYNSASLTISGLKTEDEADYYCQSYD CARLQWLRGAFDIWGQGTMVTV SSNLVFGGGTKLTVL SS C127V-C027  97 QVQLVQSGAEVKKPGASVKVSCK  98 QSVLTQPPSASGTPGQRVTISCSGASGYTFTGYYMHWVRQAPGQGL SSSNIGSNTVNWYQQLPGTAPKLL EWMGWINPNSGGTNYAQKFQGRIYSNNQRPSGVPDRFSGSKSGTSA VTMTRDTSISTAYMELSRLRSDDTSLAISGLQSEDEADYYCAAWDDSL AVYYCATAHPRRIQGVFFLGPGV NGVVFGGGTKLTVLWGQGTTVTVSS C128 V-C028  99 EVQLLESGGGLVQPGGSLRLSCA 100EIVLTQSPGTLSLSPGERATLSCRA ASGFTFSTYAMSWVRQAPGKGLESQSVNSRQLAWYQQKPGQAPRLL WVSTITGSGRDTYYADSVKGRFTIIYGASSRATGIPERFSGSGSGTDF SRDNSKNTLFLQLNSLRAEDAAVYTLTISRLESEDFAVYHCQQYGSSR SCANHPLASGDDYYHYYMDVWG ALTFGGGTKVEIK KGTTVTVSSC129 V-C029 101 QVQLVESGGGVVQPGRSLRLSCA 102 DIQMTQSPSSLSASVGDRVTITCQASGFTFSSYGMNWVRQAPGKGL ASQDISNYLNWYQQKPGKAPKLLI EWVAVISYDGSNTYYTDSVKGRFYDASNLETGVPSRFSGSESGTDFT TISRDNSKNTLYLQMNSLRVDDTAFTISSLQPEDIATYYCQQYDNLPITF TYYCAKGPRFGWSYRGGSGFDI GQGTRLEIK WGQGTMVTVSSC130 V-C030 103 QVQLVQSGAEVKKPGASVKVSCK 104 SYELTQPPSVSVAPGKTARITCGGASGYTFTNYYMHWVRQAPGQGL NNIGSKSVHWYQQKPGQAPVLVIY EWMGIINPSGGSTGYAQKFQGRVYDSDRPSGIPERFSGSNSGNTATL TMTRDTSTSTVYMELSSLRSEDT TISRVEAGDEADYYCQVWDSSSDAVYYCARSRPTPDWYFDLWGRG HPGVVFGGGTKLTVL TLVTVSS C131 V-C031 105QVQLVQSGSEVKKPGSSVKVSCK 106 EIVMTQSPATLSVSPGERATLSCRASGGTFSSYAFSWVRQAPGQGL ASQSVSSNLAWYQQKPGQAPRLLIEWMGRIIPILALANYAQKFQGRVTI YGASTRATGIPARFSGSGSGTEFTTADKSTSTAYMELSSLRSEDTAVY LTISSLQSEDFAVYYCQQYNNWPI YCARVNQAVTTPFSMDVWGQGTTFGQGTRLEIK TVTVSS C132 V-C032 107 QVQLQESGPGLVKPSGTLSLTCA 108QSALTQPASVSGSPGQSITISCTGT VSGGSISSNNWWSCVRQPPGKG SSDVGGYNYVSWYQQHPGKAPKLLEWIGEIYHSGSTNYNPSLKSRVTI MIYDVSNRPSGVSNRFSGSKSGNSVDKSKNQFSLKLSSVTAADTAVY TASLTISGLQAEDEADYYCSSYTSSYCARGGDTAMGPEYFDYWGQGT STLLFGGGTKLTVL LVTVSS C133 V-C033 109QVQLVESGGGVVQPGRSLRLSCA 110 DIQMTQSPSSLSASVGDRVTITCRASGFTFSSYAMHWVRQAPGKGL ASQSISSYLNWYQQKPGKAPKLLI EWVAVILYDGSNKYYADSVKGRFYAASSLQSGVPSRFSGSGSGTDF TISRDNSKNTLYLQMNSLRAEDTATLTISSLQPEDFATYYCQQSYSTPP VYYCARDSDVDTSMVTWFDYWG WTFGQGTKVEIK QGTLVTVSSC134 V-C034 111 EVQLLESGGGLVQPGGSLRLSCA 112 SYELTQPPSVSVAPGKTARITCGGASGFTFSNYAMSWVRQAPGKGL NNIGSKSVHWYQQKPGQAPVLVIY EWVSAISGSDGSTYYAGSVKGRFYDSDRPSGIPERFSGSNSGNTATL TISRDNSKNTLYLQMNSLRAEDTATISRVEAGDEAEYHCQVWDSSSD VYYCAKDPLITGPTYQYFHYWGQ RPGVVFGGGTKLTVL GTLVTVSSC135 V-C035 113 QVQLVESGGGVVQPGRSLRLSCA 114 DIQMTQSPSTLSASVGDRVTITCRASGFTFSSYAMHWVRQAPGKGL ASQSISNWLAWFQQKPGKAPKLLI EWVAVIPFDGRNKYYADSVTGRFYEASSLESGVPSRFSGSGSGTEFT TISRDNSKNTLYLQMNSLRAEDTALTISSLQPDDFATYYCQQYNSYPW VYYCASSSGYLFHSDYWGQGTLV TFGQGTKVEIK TVSS C138V-C038 115 EVQLVESGGGLVQPGGSLRLSCA 116 NFMLTQPHSVSESPGKTVTISCTGASGFTFSTYWMSWVRQPPGKGL SSGSIASNYVQWYQQRPGSAPTT EWVANIKQDGSEKYYVDSVKGRFVIYEDNQRPSGVPDRFSGSIDSSS TISRDNAKNSLYLQMNSLRADDTANSASLTISGLKTEDEADYYCQSYD VYYCAGGTWLRSSFDYWGQGTL SSNWVFGGGTKLTVL VTVSSC139 V-C039 117 EVQLVESGGGVVQPGRSLRLSCA 118 DIQMTQSPSSLSASVGDRVTITCQASGFTFSSYAMHWVRQAPGKGL ASQDISNYLNWYQQKPGKAPKLLI EWVAVISYDGSNKYSADSVKGRFYDASNLETGVPSRFSGSGSGTDFT TISRDNSKNTLYLQMNSLRAEDTAFTISSLQPEDIATYYCQQYDNLPLT VYYCAKGGAYSYYYYMDVWGKG FGGGTKVEIK TTVTVSS C140V-C040 119 EVQLVESGGGLVQPGGSLRLSCA 120 DIQLTQSPSFLSASVGDRVTITCRAASGVTVSSNYMSWVRQAPGKGL SQGISSYLAWYQQKPGKAPKLLIY EWVSLIYSGGSTFYADSVKGRFTIAASTLQSGVPSRFSGSGSGTEFTL SRDNSENTLYLQMNTLRAEDTAVTISSLQPEDFATYYCQQLNSYSYTF YYCARDLYYYGMDVWGQGTTVT GQGTKLEIK VSS C141V-C041 121 EVQLVESGGGWQPGRSLRLSCA 122 NFMLTQPHSVSESPGKTVTISCTGASGFTFSSYAMFWVRQAPGKGLE SSGSIASNYVQWYQQRPGSAPTT WVAVISYDGSNKYYADSVKGRFTIVIYEDNQRPSGVPDRFSGSIDSSS SRDNSKNTLYLQMNSLRAEDTAVNSASLTISGLKTEDEADYYCQSYD YYCARADLGYCTNGVCYVDYWG SSNWVFGGGTKLTVLQGTLVTVSS C143 V-C043 123 EVQLVESGGGLVQPGGSLRLSCA 124QSALTQPASVSGSPGQSITISCTGT ASGFSVSTKYMTWVRQAPGKGL SNDVGSYTLVSWYQQYPGKAPKLEWVSVLYSGGSDYYADSVKGRFT LIFEGTKRSSGISNRFSGSKSGNTAISRDNSKNALYLQMNSLRVEDTG SLTISGLQGEDEADYYCCSYAGAS VYYCARDSSEVRDHPGHPGRSVTFVFGGGTKLTVL GAFDIWGQGTMVTVSS C144 V-C044 125 EVQLVESGGGLIQPGGSLRLSCA126 QSALTQPASVSGSPGQSITISCTGT ASGFTVSNNYMSWVRQAPGKGLSSDVGGYNYVSWYQQHPGKAPKL EWVSVIYSGGSTYYADSVKGRFTI MIYDVSNRPSGVSNRFSGSKSGNSRDKSKNTLYLQMNRLRAEDTAV TASLTISGLQAEDEADYYCSSYTSS YYCAREGEVEGYNDFWSGYSRDSTRVFGTGTKVTVL RYYFDYWGQGTLVTVSS C145 V-C045 127 EVQLVESGGGLIQPGGSLRLSCA128 QSALTQPASVSGSPGQSITISCTGT ASGFSVSSNYMSWVRQAPGKGLSSDVGGYNYVSWYQQHPGKAPKL EWVSVIYSGGSTYYADSVKGRFTI MIYDVSNRPSGVSNRFSGSKSGNSRDNSKNTLYLQMNSLRAEDTAV TASLTISGLQAEDEADYYCSSYTSS YYCAREGEVEGYYDFWSGYSRDTTRVFGTGTRVTVL RYYFDYWGQGTLVTVSS C146 V-C046 129 EVQLVESGGGLVKPGGSLRLSCA130 QSALTQPASVSGSPGQSITISCTGT ASGLTFTAYRMNWVRQAPGKGLSSDIGVYNYISWSQQHPGKAPKVM EWLSSISNTNGDIYYADSVKGRFTIYDVTNRPSGVSNRFSGSKSGNTA ISRDNAKNSLYLQMNSLRADDTAVSLTISGLQAEDEADYYCSSYRGSS YYCARDVASNYAYFDLWGQGTLV TPYVFGTGTKVTVL TVSSC147 V-C047 131 EVQLVQSGAEVKKPGESLKISCK 132 QAVVTQEPSLTVSPGGTVTLTCGSGSGYRFTNYWIGWVRQMPGKGL STGAVTSGHYPYWFQQKSGQAPR EWMGIIYPGDSDTRYSPSFQGQVTLIYETSIKHSWTPARFSGSLLGGK TISADKSITTAYLQWSSLKASDTAAALTLSGAQPEDEADYYCLLSYSG MYYCARLSDRWYSPFDPWGQGT ARPVFGGGTKLTVL LVTVSSC148 V-C048 133 EVQLVESGGGLVQPGGSQRLSC 134 EIVMTQSPATLSVSPGERATLSCRAASGFTVSSNYMSWIRQAPGKGL ASQSVSSHLAWYQQKPGQAPRLLIEWVSVIYSGGSAYYVDSVKGRFTI YGASTRATGIPTRFSGSGSGTEFTSRDNSKNTLYLQMNSLRPEDTAV LTISSLQSEDFAVYYCQQYNNWPP YYCARIANYMDVWGKGTTVTVSSLTFGGGTKVEIK C149 V-C049 135 QVQLVESGGGVVQPGRSLRLSCA 136DIQMTQSPSSLSASVGDRVTITCR ASGFTFSTYGMHWVRQAPGKGL ASQSISSYLNWYQQKPGKVPKLLIEWVAVISYDGSNKYFADSVKGRF YAASSLQSGVPSRFSGSGSGTDF TISRDNSKNTLYLQMNSLRPEDTATLTISSLQPEDFATYYCQQSYRTPL VYYCAKVGMEYSSGWYGEEIDF TFGGGTKVEIK WGQGTLVTVSSC150 V-C050 137 EVQLVESGGGLVQPGGSLRLSCV 138 QSALTQPASVSGSPGQSITISCTGTASGFTFSSYWMHWVRQVPGKGP SSDVGYYNFVSWYQQHPGKAPKL VWVSHINSEGSSTNYADSVRGRFMIYEVSNRPSGVSNRFSGSKSGNT TISRDNAKDTLYLQMNNLRAEDTAASLIISGLQAEDEADYYCSSYRSSS VYYCARPTAVAAAGNYFYYYGMD TLVFGGGTKLTVLVWGQGTTVTVSS C151 V-C051 139 EVQLVESGGGLVKPGGSLRLSCA 140NFMLTQPHSVSESPGKTVTISCTG ASGFTFSSYNMNWVRQAPGKGL SSGSIASNYVQWYQQRPGSAPTTEWVSCISSSSSYIYYADSVKGRFTI VIYEDNQRPSGVPDRFSGSIDSSSSRDNAKNSLYLQMNSLRAEDTAV NSASLTISGLKTEDEADYYCQSYD YYCARERGYDGGKTPPFLGGQGSSNYWVFGGGTKLTVL TLVTVSS C152 V-C052 141 QVQLVQSGAEVKKPGASVKVSCK 142DIQMTQSPSSLSASVGDRVTITCR ASGYTFTSYGISWVRQAPGQGLEASQGISNYLAWYQQRPGKVPKLLI WMGWISAYNGNTNYAQKLQGRV FAASTLQSGVPSRFSGSGSGTDFTTMTTDTSTSTAYMELRSLRSDDT LTISSLQPEDVATYYCQKYNSAPR AVFYCARDRGGHDFWSGYGFYYTFGQGTKVEIK YYGMDVWGQGTTVTVSS C153 V-C053 143 EVQLVESGGGLIQPGGSLRLSCA144 QSALTQPASVSGSPGQSITISCTGT ASGFTVSSNYMSVWRQAPGKGLSSDVGSYNLVSWYQQHPGKAPKL EWVSVIYSGYSTYYVDSVKGRFTI MIYEGSKRPSGVSNRFSGSKSGNSRDNSKNTLYLQMNSLRAEDTAV TASLTISGLQAEDEADYYCCSYAG YYCARVGGAHSGYDGSFDYWGQSSTWVFGGGTKLTVL GTLVTVSS C154 V-C054 145 QVQLVESGGGVVQPGRSLRLSCA 146DIQMTQSPSSLSASVGDRVTITCQ ASGFTFSRYGMHWVRQAPGKGL ASQGISNYLNWYQQKPGKAPKLLIEWVAVMSYDGSSKYYADSVKGR YDASNLETGVPSRFSGSGSGTDFT FTISRDNSKNTLCLQMNSLRAEDTFTISSLQPEDIATYYCQQYDNLPITF AVYYCAKQAGPYCSGGSCYSAPF GQGTRLEIKDYWGQGTLVTVSS C155 V-C055 147 EVQLVESGGGLIQPGGSLRLSCA 148EIVMTQSPATLSVSPGERATLSCR ASGFIVSSNYMSWVRQAPGKGLEASQSVSSNLAWYQQKPGQAPRLLI WVSVIYSGGSTFYADSVKGRFTISYGASTRATAIPARFSGSGSGTEFT RDNSKNTLYLQMNSLRAEDTAVYLTISSLQSEDFAVYYCQQYNNWPR YCARDFGEFYFDYWGQGTLVTVSS TFGQGTKVEIK C156V-C056 149 QVQLVESGGGVVQPGRSLRLSCA 150 SYELTQPPSVSVAPGQTARISCGGASGFTFSNYGMHWVRQAPGKGL NNIGSKNVHWYQQKPGQAPVLVV EWVAVISYDGNNKYYADSVKGRFYDDSDRPSGIPERFSGSNSGNTAT TISRDNSKNTLYLQMNSLRAEDTALTISRVEAGDEADYYCQVWDSSSD VYYCAKDPFPLAVAGTGYFDYWG PWVFGGGTKLTVL QGTLVTVSSC160 V-C060 151 QVQLVQSGAEVKKPGASVKVSCK 152 SYELTQPPSVSVSPGQTARITCSGASGYTFTSYGISWVRQAPGQGLE DALPKQYAYWYQQKPGQAPVLVIY WMGWISAYNGNTNYAQKLQGRVKDSERPSGIPERFSGSSSGTTVTL TMTTDTSTSTAYMELRSLRSDDTTISGVQAEDEADYYCQSADSSGTL AVYYCARVPASYGDDDYYYYYG VWFGGGTKLTVLMDVWGQGTTVTVSS C161 V-C061 153 QVQLQQWGAGLLKPSETLSLTCA 154EIVLTQSPGTLSLSPGERATLSCRA VSGGSLSGFYWTWIRQPPGKGLESQTLTANYLAWYQQKPGQAPRLLI WIGETNHFGSTDYKPSLKSRVTISYGASKRATGIPDRFSGSGSGTDFT VDMSRNQFSLIMTSVTAADTAVYYLSISRLEPEDFAVYYCQQYGTTPR CARKTLLFSDFSPGAFDIWGQGT TFGGGTKVEI MVTVSS C162V-C062 155 QVQLQQWGAGLLKPSETLSLTCA 156 EIVLTQSPGTLSLSPGERATLSCRAVSGGSLSGFYWTWIRQPPGKGLE SQTLTANYLAWYQQKPGQAPRLLIWIGETNHFGSTDYKASLKSRVTIS YGASKRAAGIPDRFSGSGSGTDFTVGMSRNQFSLKVTSLTAADTAVY LSITRLEPEDFAVYYCQQYHTTPRTYCARKPLLYSDFSPGAFDVWGQG FGGGTKVEI TMVTVSS C163 V-C063 157QVQLQQWGAGLLKPSETLSLTCA 158 EIVLTQSPGTLSLSPGERATLSCRAVSGGSLSGFYWTWIRQPPGKGLE SQTVSANYLAWYQQKAGQAPRLLIWIGETNHFGSTDYKPSLKSRVTIS YGASKRATGIPDRFSGSGSGTDFTVDMSRNQFSLKVTSVTAADTAVY LSISRLEPEDFAVYYCQQYVTTPRTYCARKPLLHSDLSPGAFDIWGQG FGGGTKVEI TMVTVSS C164 V-C064 159EVQLVESGGGLVQPGGSLRLSCA 160 QSALTQPASVSGSPGQSITISCTGTASGFSVSTKYMTWVRQAPGKGL SNDVGSYTLVSWYQQYPGKAPKL EWVSVLYSGGSDYYADSVKGRFTLIFEVTKRSSGISNRFSGSKSGNTA ISRDNSKNALYLQMNSLRVEDTGSLTISGLQGEDEADYYCCSYAGAS VYYCARDSSEVRDHPGHPGRSV TFVFGGGTKLTVLGAFDIWGQGTMVTVSS C165 V-C065 161 QVQLVQSGAEVKKPGSSVKVSCK 162EIVLTQSPGTLSLSPGERATLSCRA ASGGTFSSYAINWVRQAPGQGLESQSVSSTYLAWYQQKPGQAPRLLI WMGRHPIVGIANYAQKFQGRVTITYGASSRATGIPDRFSGSGSGTDFT ADKSSSTAYMELSSLRSEDTAVYLTISRLEPEDFAVYYCQQYGSSPW YCARDLLDPQLDDAFDIWGQGTM TFGQGTKVEIK VTVSS C201M-C001 163 EVQLVESGGGLVQPGRSLRLSCA 164 IRMTQSPSSVSASVGDRVTITCRAASGFTFDDYAMHWVRQAPGKGL SQGISSWLAWYQQKPGKAPKLLIY EWVSGISWNSGSIGYADSVKGRFVESSLQSGVPSRFSGSGSGTDFTL TISRDNAKNSLYLQMNSLRAEDTATISSLQPEDFATYYCQQANSFPLTF LYYCVKGVEYSSSSNFDYWGQG GGGTKVEIK TLVTVSS C202M-C002 165 EVQLVESGGGLVQPGGSLRLSCA 166 DIQLTQSPSSLSASVGDRVTITCQAASGFTVSSNYMSWVRQAPGKGL SQDISNYLNWYQQKPGKAPKLLIY EWVSLIYSGGSTYYADSVKGRFTIDASNLETGVPSRFSGSGSGTDFTF SRDNSKNTLYLQMNSLRAEDTAVTISSLQPEDIATYYCQQYDNLPRSF YYCARDTLGRGGDYWGQGTLVT GQGTKLEIK VSS C204M-C004 167 EVQLLESGGGLEQPGGSLRLSCA 168 DIQLTQSPSSLSASVGDRVTITCRAASGFTFSTYAMSWVRQAPGKGLE SQSISSYLNWYQQKPGKAPKLLIYWVSAISGSGAGTFYADSVKGRFTI AASSLQSGVPSRFSGSGSGTDFTLSRDNSKNTLYLQMNSLRAEDTAV TISSLQPEDFATYYCQQSYSTPPW YYCARESDCGSTSCYQVGWFDPTFGQGTKVEIK WGQGTLVTVSS C205 M-C005 169 QVQLVQSGAEVKKPGASVKVSCK 170EIVLTQSPGTLSLSPGERATLSCRA ASGHTFTSYYMHWVRQAPGQGLSQSVSSSYLAWYQQKPGQAPRLLI EWMGIINPSGGSTSYAQKFQGRVYGASSRATGIPDRFSGSGSGTDFT TMTRDTSTSTVYMELSSLRSEDTLTISRLEPEDFAVYYCQQYVSSPW AVYYCARGPERGIVGATDYFDYW TFGQGTKVEIK GQGTLVTVSSC207 M-C007 171 EVQLLESGGGLVQPGGSLRLSCA 172 EIVLTQSPATLSLSPGERATLSCRAASGFTFSSYAMSWVRQAPGKGL SQSVSSYLAWYQQKPGQAPRLLIY EWVSAISGSGGSTYYADSVKGRFDASNRATGIPARFSGSGSGTDFTL TISRDNSKNTLYLQMNSLRAEDTATISSLEPEDFAVYYCQQRSNWPRG VYYCAKEPIGQPLLWWDYWGQG FGQGTKVEIK TLVTVSS C208M-C008 173 EVQLVQSGAEVKKPGESLKISCK 174 EIVLTQSPGTLSLSPGERATLSCRAGSGYSFTSYWIGWVRQMPGKGL SQSVSGSYLAWYQQRPGQAPRLL EWMGIIYPGDSDTRYSPSFQGQVIYGASSRATGIPDRFSGSGSGTDF TISADKSISTAYLKWSSLKASDSATLTISRLEPEDFAVYYCQQYGSSLT MYYCARGPNLQNWFDPWGQGTL FGGGTKVEIK VTVSS C209M-C009 175 QVQLVQSGAEVKKSGASVKVSCK 176 SYELTQPPSVSVAPGKTARITCGGASGYTFTSYDINWVRQATGQGLE NNIGSKSVHWYQQKPGHAPVLVV WMGWMNPNSGNTGYAQKFQGRYDDSDRPSGIPERFSGSNSGNTAT VTMTRNTSISTAYMXLSSLXSXXTLTISRVEAGDEADYYCQVWDSTG AVYYCAXGFSLTWYFDLWGRGXL GHPDVVFGGGTKLTVL VTXSSC210 M-C010 177 EVQLVESGGGLIQPGGSLRLSCA 178 DIQLTQSPSFLSASVGDRVTITCRAASGFTVSSNYMSWVRQAPGKGL SQGISSYLAWYQQKPGKAPKLLIY EWVSVIYSGGSTFYADSVKGRFTAASTLQSGVPSRFSGSGSGTEFTL FSRDNSKNTLYLQMNSLRAEDTATISSLQPEDFATYYCQQLNSYPQG VYYCARDLMAYGMDVWGQGTTV TFGGGTKVEIK TVSS C211M-C011 179 EVQLVESGGGLVQPGGSLRLSCA 180 EIVMTQSPATLSVSPGERATLSCRASEFTVSSNYMSWVRQAPGKGL ASQSVSSNLAWYQQKPGQGPRLL EWVSVIYSGGSTFYADSVKGRFTIIYGASTRATGIPARFSGSGSGTEFT SRDNSKNTLYLQMNSLRPEDTAVLTISSLQSEDFAVYYCQQYNNWPR YYCARDYGDFYFDFWGQGTLVTV TFGQGTKVEIK SS C212M-C012 181 QVQLVQSGAEVKKPGASVKVSCK 182 LTQPASVSGSPGQSITISCTGTSSDASGYTVTGYYIHWVRQAPGQGLE VGSYNLVSWYQQHPGKAPKLMIY WMGWISPNSGGTNYAQKFQGWVEDSKRPSGVSNRFSGSKSGNTAS TMTRDMSITTAYMELSRLRSDDTALTISGLQAEDEADYYCCSYAGSST VYYCARERYFDLGGMDVWGQGT RLFGGGTKLTVL TVTVSS C214M-C014 183 QVQLVESGGGVVQPGRSLRLSCA 184 DIQLTQSPSSLSASVGDRVTITCRAASGFTFSSYGMHWVRQAPGKGL SQSISSYLTWYQQKPGKAPKLLIYA EWVAAIWYDGSNKHYADSVKGRFASSLQSGVPSRFSGSGSGTDFTLT TISRDNSKNTLYLQMNSLRAEDTAISSLQPEDFATYYCQQSYSTPPWT VYYCARDVGRVTTWFDPWGQGT FGQGTKVEIK LVTVSS C215M-C015 185 EVQLLESGGGLVQPGGSLRLSCA 186 DIQLTQSPSSLSASVGDRVTITCRAASGFTFSSYAMSWVRQAPGKGL SQSISSYLNWYQQKPGKAPKLLIY EWVSAITDSGDGTFYADSVKGRFAASSLQSGVPSRFSGSGSGTDFTL TISRDNSKNTLYLQMNSLRAEDTATISSLQPEDFATYYCQQSYSTPPW VYYCASEEDYSNYVGWFDPWGQ TFGQGTKVEIK GTLVTVSSC216 M-C016 187 EVQLVESGGGLVQPGGSLRLSCA 188 DIQLTQSPSSLSASVGDRVTITCRAASGFTFSSYDMHWVRQATGKGL SQSISSYLNWYQQKPGKAPKLLIY EWVSAIGTAGDTYYPDSVKGRFTIVASSLQSGVPSRFSGSGSGTDFTL SRENAKNSLYLQMNSLRAGDTAVTISSLQPEDFATYYCQQSYSTPPIT YYCARDRGSSGWYGWYFDLWG FGQGTRLEIK RGTLVTVSS

TABLE 5Representative nucleotide sequences of cloned recombinant antibodies OldSEQ SEQ Antibody antibody ID ID ID ID IGH VDJ (nt) NO IGL VJ (nt) NOC002 A-C002 GAGGTGCAGCTGGTGGAGTCTGGGGG 189 GACATCCAGTTGACCCAGTCTCCATCCTC190 AGGCGTGGTCCAGCCTGGGAGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCGGGCAAGTCAGAGCATTTCACCTTCAGTATCTATGGCATGCACT AGCAGCTATTTAAATTGGTATCAGCAGAAAGGGTCCGCCAGGCTCCAGGCAAGGGG CCAGGGAAAGCCCCTAAGCTCCTGATCTACTGGAGTGGGTGGCAGTTATATCATAT TGCTGCATCCAGTTTGCAAAGTGGGGTCCGATGGAAGTAATAAATACTATGCAGAC CATCAAGGTTCAGTGGCAGTGGATCTGGGTCCGTGAAGGGCCGATTCACCATCTCC ACAGATTTCACTCTCACCATCAGCAGTCTGAGAGACAATTCCAAGAACACGCTGTAT CAACCTGAAGATTTTGCAACTTACTACTGTCTGCAAATGAACAGCCTGAGAGCTGAG CAACAGAGTTACAGTACCCCTCGGACGTTGACACGGCTGTGTATTACTGTGCGAAA CGGCCAAGGGACCAAGGTGGAAATCAAACGAGGGGAGACCATCTGATATTGTAGTG GTGGTGGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C003 A-C003 GAGGTGCAGCTGGTGGAGTCTGGAGG 191GAAATTGTGTTGACGCAGTCTCCAGGCAC 192 AGGCTTGATCCAGCCTGGGGGGTCCCCCTGTCTTTGTCTCCAGGGGAAAGAGCCA TGAGACTCTCCTGTGCAGCCTCTGGGTCCCTCTCCTGCAGGGCCAGTCAGAGTGTT TCACCGTCAGTAGCAACTACATGAGCTAGCAGCACCTACTTAGCCTGGTACCAGCA GGGTCCGCCAGGCTCCAGGCAAGGGGGAAACCTGGCCAGGCTCCCAGGCTCCTCA CTGGAGTGGGTCTCAGTTATTTATAGCTCTATGGTGCATCCAGCAGGGCCACTGGC GGTGGTAGCACATACTACGCAGACTCCATCCCAGACAGGTTCAGTGGCAGTGGGTC GTGAAGGGCCGATTCACCATCTCCAGATGGGACAGACTTCACTCTCACCATCAGCA GACAATTCCAAGAACACGCTGTATCTTGACTGGAGCCTGAAGATTTTGCAGTGTATT CAAATGAACAGCCTGAGAGCCGGGGAACTGTCAGCAGTATGGTAGCTCACCTAGG CACGGCCGTGTATTACTGTGCGAGGGACTTTTGGCCAGGGGACCAAGCTGGAGAT ATTACGGTGACTTCTACTTTGACTACTG CAAACGGGCCAGGGAACCCTGGTCACCGTCT CCTCAG C004 A-C004 CAGGTGCAGCTGGTGCAGTCTGGGGC193 GCCATCCGGATGACCCAGTCTCCATCCTC 194 TGAGGTGAAGAAGCCTGGGGCCTCAGCCTGTCTGCATCTGTAGGAGACAGAGTCA TGAAGGTCTCCTGCAAGGCTTCTGGATCCATCACTTGCCAGGCGAGTCAGGACATT ACACCTTCACCGGCTACTATATGCACTAGCAACTATTTAAATTGGTATCAGCAGAAA GGGTGCGACAGGCCCCTGGACAAGGGCCAGGGAAAGCCCCTAAGCTCCTGATCTA CTTGAGTGGATGGGATGGATCAACCCTCGATGCATCCAATTTGGAAACAGGGGTCC ATCAGTGGTGGCACAAACTATGCACAGCATCAAGGTTCAGTGGAAGTGGATCTGGG AAGTTTCAGGGCAGGGTCACCATGACCACAGATTTTACTTTCACCATCAGCAGCCTG AGGGACACGTCCATCAGCACAGCCTACCAGCCTGAAGATATTGCAACATATTACTGT ATGGAGCTGAGCAGGCTGAGATCTGACAACAGTATGATAATCTCCCTATCACCTTC CGACACGGCCGTGTATTACTGTGCGAGGGCCAAGGGACACGACTGGAGATTAAAC CCCAGCATCACGTGGATATAGTGGCTACGATCATGGGTACTACTACTACATGGA CGTCTGGGGCAAAGGGACCACGGTCA CCGTCTCCTCA C005A-C005 CAGGTGCAGCTGGTGCAGTCTGGGCC 195 GAAATTGTGTTGACGCAGTCTCCAGGCAC 196TGAGGTGAAGAAGCCTGGGACCTCAG CCTGTCTTTGTCTCCAGGGGAAAGAGCCATGAAGGTCTCCTGCAAGGCTTCTGGAT CCCTCTCCTGCAGGGCCAGTCAGAGTGTTTCACCTTTACTAGCTCTGCTGTGCAGT AGAAGCAGCTACTTAGCCTGGTACCAGCAGGGTGCGACAGGCTCGTGGACAACGC GAAACCTGGCCAGGCTCCCAGGCTCCTCACTTGAGTGGATAGGATGGATCGTCGTT TCTATGGTGCATCCAGCAGGGCCACTGGCGGCAGTGGTAACACAAACTACGCACAG ATCCCAGACAGGTTCAGTGGCAGTGGGTCAAGTTCCAGGAAAGAGTCACCATTACC TGGGACAGACTTCACTCTCACCATCAGCAAGGGACATGTCCACAAGCACAGCCTAC GACTGGAGCCTGAAGATTTTGCAGTGTATTATGGAGCTGAGCAGCCTGAGATCCGA ACTGTCAGCAGTATGGTAGCTCACCGTGGGGACACGGCCGTGTATTACTGTGCGG ACGTTCGGCCAAGGGACCAAGGTGGAAATCTCCCCATTGTAGCGGTGGTAGCTGCC CAAAC TTGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG C006 A-C006 CAGGTGCAGCTGGTGGAGTCTGGGGG 197CAGTCTGTGCTGACTCAGCCACCCTCAGC 198 AGGCTTGGTCAAGCCTGGAGGGTCCCGTCTGGGACCCCCGGACAGAGGGTCACC TGAGACTCTCCTGTGCAGCCTCTGGATGTCTCTTGTTCTGGAAGCAGCTCCAACATC TCATCTTCAGTGACTACTGCATGAGCTGGAAGCAATACTGTAAACTGGTACCAGCA GGATCCGCCGGGCTCCAGGGAAGGGGGCTCCCAGGAACGGCCCCCAAACTCCTCA CTGGAATGGCTTTCATATATTAGTAATATCTATAGTAATAATCAGCGGCCCTCAGGG GTGGTACCACCAGATACTACGCAGACTGTCCCTGACCGATTCTCTGGCTCCAAGTC CTGTGAAGGGCCGATTCACCATCTCCATGGCACCTCAGCCTCCCTGGCCATCAGTG GGGACAACGGCAGGAACTCACTGTATCGGCTCCAGTCTGAGGATGAGGCTGATTAT TGCAAATGGACAGCCTGAGCGCCGAATTCTGTGCAGCATGGGATGACAGCCTGAA GACACGGCCGTTTATTACTGTGCGAGATGGTCCGGTATTCGGCGGAGGGACCAAG AGGGGGGACGGTAGCAGCTCGATCTA CTGACCGTCCTAGCTACTACAACTACATGGACGTCTGGGG CAAAGGGACCACGGTCACCGTCTCCTCA C008 A-C008GAGGTGCAGCTGGTGGAGTCTGGGGG 199 GACATCCAGATGACCCAGTCTCCTTCCAC 200AGGCGTGGTCCAGCCTGGGAGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCGGGCCAATCAGAGTATTTCACCTTCAGTAGCTATGGCATGCACT AGTAGCTGGTTGGCCTGGTATCAGCAGAAGGGTCCGCCAGGCTCCAGGCAAGGGG ACCAGGGAAAGCCCCTAAGCTCCTGATCTCTGGAGTGGGTGACAGTTATTTCATAT ATAAGGCGTCTAGTTTAGAAAGTGGGGTCGATGGAAGGAATAAATACTATGCAGAC CCATCAAGGTTCAGCGGCAGTGGATCTGGTCCGTGAAGGGCCGATTCACCATCTCC GACAGAATTCACTCTCACCATCAGCAGCCAGAGACAACTCCAAGAACACGCTGTAT TGCAGCCTGATGATTTTGCAACTTATTACTCTGCAAATGAACAGCCTGAGAGCTGAG GCCAACAGTATAATAGTTATTGGACGTTCGGACACGGCTGTGTATTACTGTGCGAGA GCCAAGGGACCAAGGTGGAAATCAAACGAATTCGGTGACCCCGAGTGGTACTTT GACTACTGGGGCCAGGGAACCCTGGT CACCGTCTCCTCAGC009 A-C009 CAGGTGCAGCTGGTGCAGTCTGGGGC 201 CAGTCTGCCCTGACTCAGCCTCCCTCCGC202 TGAGGTGAAGAAGCCTGGGGCCTCAG GTCCGGGTCTCCTGGACAGTCAGTCACCATGAAGGTCTCCTGCATGGCTTCTGGAT TCTCCTGCACTGGAACCAGCAGTGACGTTACACCTTCACCGGCTACTATATGCACT GGTGGTTATAACTATGTCTCCTGGTACCAAGGGTGCGACAGGCCCCTGGACAAGGG CAGCACCCAGGCAAAGCCCCCAAACTCATCTTGAGTGGATGGGATGGATCAACCCT GATTTATGAGGTCAGTAAGCGGCCCTCAGAACAGTGGTGGCACAAACTATGCACAG GGGTCCCTGATCGCTTCTCTGGCTCCAAGAAGTTTCAGGGCAGGGTCACCATGACC TCTGGCAACACGGCCTCCCTGACCGTCTCAGGGACACGTCCATCAGCACAGCCTAC TGGGCTCCAGGCTGAGGATGAGGCTGAGATGGAGCTGAGCAGGCTGAGATCTGA TATTACTGCAGCTCAGATGCAGGCAGCAACGACACGGCCGTGTATTACTGTGCGAG CAATGTGGTATTCGGCGGAGGGACCAAGCAGACTCCCCATTTAGTGCTTTAGGGGC TGACCGTCCTAG CTCCAATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C010 A-C010 GAGGTGCAGCTGGTGGAGTCTGGGGG 203GACATCCAGTTGACCCAGTCTCCATCCTC 204 AGGCGTGGTCCAGCCTGGGAGGTCCCCCTGTCTGCATCTGTAGGAGACAGAGTCA TGAGACTCTCCTGTGCAGCCTCTGGATCCATCACTTGCCGGGCAAGTCAGAGCATT TCACCTTCAGTAGCTATGCTATGCACTAGCACCTATTTAAATTGGTATCAGCAGAAA GGGTCCGCCAGGCTCCAGCCAAGGGGCCAGGGAAAGCCCCTAAGCTCCTGATCTA CTGGAGTGGGTGGCAGTTATATTATATTGCTGCATCCAGTTTGCAAAGTGGGGTCC GATGGAAGCGGTAAATACTACGCAGACCATCAAGGTTCAGTGGCAGTGGATCTGGG TCCGTGAAGGGCCGATTCACCATCTCCACAGATTTCACTCTCACCATCAGCAGTCTG AGAGACAATTCCAAGAACACGTTGTATCAACCTGAAGATTTTGCAACTTACTACTGT CTGCAAATGAACAGCCTGAGAGCTGAGCAACAGAGTTACAGTACCCCTCCGTGGAC GACACGGCTGTGTATTACTGTGCGAGAGTTCGGCCAAGGGACCAAGGTGGAGATCA GACGGGATCGTGGATACAGCTCTGGTT AACACGTGGTTTGACTACTGGGGCCAGGG AACCCTGGTCACCGTCTCCTCAG C013 A-C013CAGGTGCAGCTGGTGCAGTCTGGGGC 205 GAAATTGTGTTGACACAGTCTCCAGCCAC 206TGAGGTGAAGAAGCCTGGGTCCTCGG CCTGTCTTTGTCTCCAGGGGAAAGAGCCATGAAGGTCTCCTGCAAGGCTTCTGGAG CCCTCTCCTGCAGGGCCAGTCAGAGTGTTGCACCTTCAGCAGCTATGCTATCAGCT AGCAGCTACTTAGCCTGGTACCAACAGAAGGGTGCGACAGGCCCCTGGACAAGGG ACCTGGCCAGGCTCCCAGGCTCCTCATCTCTTGAGTGGATGGGAGGGATCATCCCT ATGATGCATCCAACAGGGCCACTGGCATCATCTTTGGTACAGCAAACTACGCACAG CCAGCCAGGTTCAGTGGCAGTGGGTCTGAAGTTCCAGGGCAGAGTCACGATTACC GGACAGACTTCACTCTCACCATCAGCAGCGCGGACGAATCCACGAGCACAGCCTA CTAGAGCCTGAAGATTTTGCAGTTTATTACCATGGAGCTGAGCAGCCTGAGATCTGA TGTCAGCAGCGTAGCAACTGGCCCCTCACGGACACGGCCGTGTATTACTGTGCGA TTTCGGCGGAGGGACCAAGGTGGAGATCAGAGGGAATCGACTACTTTATTGTAGTA AAC GTACCAGCTGCTATCTAGATGCGGTTAGGCAGGGGTACTACTACTACTACTACA TGGACGTCTGGGGCAAAGGGACCACG GTCACCGTCTCCTCAC016 A-C016 GAGGTGCAGCTGGTGGAGTCTGGGGG 207 GCCATCCGGATGACCCAGTCTCCATCCTC208 AGGCGTGGTCCAGCCTGGGAGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCAGGCGAGTCAGGACATTTCACCTTCAGTAGATATGGCATGCACT AGCAACTATTTAAATTGGTATCAGCAGAAAGGGTCCGCCAGGCTCCAGGCAAGGGG CCAGGGAAAGCCCCTAAGCTCCTGATCTACTGGAGTGGGTGGCAGTTATATCATAT CGATGCATCCAATTTGGAAACAGGGGTCCGATGGAAGTAATAAATACTATGCAGAC CATCAAGGTTCAGCGGAAGTGGATCTGGGTCCGTGAAGGGCCGATTCACCATCTCC ACAGATTTTACTTTCACCATCAACAGCCTGAGAGACAATTCCAAGAACACGCTGTAT CAGCCTGAAGATATTGCAACATATTACTGTCTGCAAATGAACAGCCTGAGAGCTGAG CAACAGTATGATAATCTCCCTCCTACTTTCGACACGGCTGTGTATTACTGTGCGAAA GGCGGAGGGACCAAGGTGGAGATCAAACGTGACCGCCCCTTATTGTAGTGGTGGT AGCTGCTACGGAGGTAACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGT CTCCTCAG C017 A-C017GAAGTGCAGCTGGTGGAGTCTGGGGG 209 GAAATTGTGTTGACACAGTCTCCAGCCAC 210AGGCTTGGTACAGCCTGGCAGGTCCC CCTGTCTTTGTCTCCAGGGGAAAGAGCCATGAGACTCTCCTGTGCAGCCTCTGGAT CCCTCTCCTGCAGGGCCAGTCAGAGTGTTTCACCTTTGATGATTATGCCATGCACTG AGCAGCTACTTAGCCTGGTACCAACAGAAGGTCCGGCAAGCTCCAGGGAAGGGCC ACCTGGCCAGGCTCCCAGGCTCCTCATCTTGGAGTGGGTCTCAGGTATTAGTTGGA ATGATGCATCCAACAGGGCCACTGGCATCATAGTGGTACCATAGGCTATGCGGACT CCAGCCAGGTTCAGTGGCAGTGGGTCTGCTGTGAAGGGCCGATTCACCATCTCCA GGACAGACTTCACTCTCACCATCAGCAGCGAGACAACGCCAAGAACTCCCTGTATC CTAGAGCCTGAAGATTTTGCAGTTTATTACTGCAAATGAACAGTCTGAGAGCTGAGG TGTCAGCAGCGTATCACCTTCGGCCAAGGACACGGCCTTTTATTACTGTGCAAAAG GACACGACTGGAGATTAAACCGGGCGTAAGGGGTATAGCAGCAGCT GGTCCCGACCTCAACTTCGACCACTGGGGCCAGGGAACCCTGGTCACCGTCTC CTCAG C018 A-C018 GAGGTGCAGCTGGTGGAGTCTGGGGG211 GACATCCAGTTGACCCAGTCTCCATCCTC 212 AGGCGTGGTCCAGCCTGGGAGGTCCCCCTGTCTGCGTCTGTAGGAGACAGAGTCA TGAGACTCTCCTGTGCAGCCTCTGGATCCATCACTTGCCGGGCAAGTCAGAGCATT TCACCTTCAGTAACTATGCTATACACTGCGCAGCTATTTAAATTGGTATCAACAGAAA GGTCCGCCAGGCTCCAGGCAAGGGGCCCAGGGAAAGCCCCTAAGCTCCTGATCTA TGGAGTGGGTGGCAGTTATATCATATGTGCTGCATCCAGTTTGCAAAGTGGGGTCC ATGGAAGCAATAAATACTACGCAGACTCTTCAAGGTTCAGTGGCAGTGGATCTGGG CCGTGAAGGGCCGATTCACCATCTCCAACAGATTTCACTCTCACCATCAGCAGTCTG GAGACAATTCCAAGAACACGCTGTATCCAACCTGATGATTTTGCAACTTACTACTGT TGCAAATGAACAGCCTGAGAGCTGAGGCAACAGAGTTACAGTACCCCTCCGGCCAC ACACGGCTGTGTATTACTGTGCGAGAGTTTTGGCCAGGGGACCAAGCTGGAGATCA ATTTTGACGATAGTTCGTTCTGGGCGT AACTTGACTACTGGGGCCAGGGAACCCTG GTCACCGTCTCCTCAG C019 A-C019CAGGTGCAGCTGGTGCAGTCTGGGGC 213 TCCTATGAGCTGACACAGCCACCCTCAGT 214TGAGGTGAAGAAGCCTGGGGCCTCAG GTCAGTGGCCCCAGGAAAGACGGCCAGGTGAAGGTTTCCTGCAAGGCATCTGGAT ATTACCTGTGGGGAAAACAACATTGGAAGACACCTTCACCAGTTACTATATGCACTG TAAAAGTGTGCACTGGTACCAGCAGAAGCGGTGCGACAGGCCCCTGGACAAGGGC CAGGCCAGGCCCCTGTGCTGGTCATCTATTTGAGTGGATGGGAATAATCAACCCTA TATGATAGCGACCGGCCCTCAGGGATCCCGTGGTGGTAGCACAAGCTACGCACAG TGAGCGATTCTCTGGCTCCAACTCTGGGAAAGTTCCAGGGCAGAGTCACCATGACC ACACGGCCACCCTGACCATCAACAGGGTCAGGGACACGTCCACGAGCACAGTCTA GAAGCCGGGGATGAGGCCGACTATTACTGCATGGAGCTGAGCAGCCTGAGATCTGA TCAGGTGTGGGATAGTAGTAGTGATCATGGGACACGGCCGTGTATTACTGTGCTAG TGGTATTCGGCGGAGGGACCAAGCTGACCAGTGCCCCGTGAGGGGACCCCAGGGT GTCCTAG TCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C021 A-C021 CAGGTGCAGCTGCAGGAGTCGGGCCC 215GATATTGTGATGACTCAGTCTCCACTCTCC 216 AGGACTGGTGAAGCCTTCACAGACCCTCTGCCCGTCACCCCTGGAGAGCCGGCCT GTCCCTCACCTGCACTGTCTCTGGTGGCCATCTCCTGCAGGTCTAGTCAGAGCCTC CTCCATCAGCAGTGGTGGTTACTACTGCTGCATAGTAATGGATACAACTATTTGGAT GAGCTGGATCCGCCAGCACCCAGGGATGGTACCTGCAGAAGCCAGGGCAGTCTCC AGGGCCTGGAGTGGATTGGGTACATCTACAGCTCCTGATCTATTTGGGTTCTAATCG ATTACAGTGGGAGCACCTACTACAACCGGCCTCCGGGGTCCCTGACAGGTTCAGT CGTCCCTCAAGAGTCGAGTTACCATATGGCAGTGGATCAGGCACAGATTTTACACT CAGTAGACACGTCTAAGAACCAGTTCTGAAAATCAGCAGAGTGGAGGCTGAGGATG CCCTGAAGCTGAGCTCTGTGACTGCCGTTGGGGTTTATTACTGCATGCAAGCTCTAC CGGACACGGCCGTGTATTACTGTGCGAAAACTCCATTCACTTTCGGCCCTGGGACC GAGTTTGGCAATACTATGATAGTAGTGAAAGTGGATATCAAAC GTTCCTTTGACTACTGGGGCCAGGGAA CCCTGGTCACCGTCTCCTCAG C022A-C022 CAGGTGCAGTTGCAGGAGTCGGGCCC 217 GACATCCAGATGACCCAGTCTCCTTCCAC 218AGGACTGGTGAAGCCTTCGGAGACCC CCTGTCTGCATCTGTAGGAGACAGCGTCATGTCCGTCACTTGCACTGTCTCTGGTG CCATCACTTGCCGGGCCAGTCAGAGTATTGCTCCATCAGCAGTAGTAGGTACTACT AGTAGCTGGTTGGCCTGGTATCAGCAGAAGGGGCTGGATCCGCCAGCCCCCAGGG ACCAGGGAAAGCCCCTAAGCTCCTGATCTAAGGGGCTGGAGTGGATTGGGAGTAT ATAAGGCGTCTAGTTTAGAAAGTGGGGTCCTATTATAGTGGGAGCACCTACTACAA CCATCAAGGTTCAGCGGCAGTGGATCTGGCCCGTCCCTCAAGAGTCGAGTCACCAT GACAGAATTCACTCTCACCATCAGCAGCCATCCGTGGACACGTCCAAGAACCAGTT TGCAGCCTGATGATTTTGCAACTTATTACTCTCCCTGAAGCTGAGCTCTGTGACCGC GCCAACAGTATAATAATTACCGGTACACTTCGCAGACACGGCTGTGTATTACTGTGC TTGGCCAGGGGACCAAGCTGGAGATCAAACGAGACATGCGGCAGCATACTATGATAG AAGTGGTTATTATTTCATCGAATACTTCCAGCACTGGGGCCAGGGCACCCTGGT CACCGTCTCCTCAG C027 A-C027GAGGTGCAGCTGGTGGAGTCTGGGGG 219 GACATCCAGATGACCCAGTCTCCTTCCAC 220AGGCGTGGTCCAGCCTGGGAGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCGGGCCAGTCAGAGTATTTCACCTTCAGTAGCTATGGCATGCACT AGTAGCTGGTTGGCCTGGTATCAGCAGAAGGGTCCGCCAGGCTCCAGGCAAGGGG ACCAGGGAAAGCCCCTAAGCTCCTGATCTCTGGAGTGGGTGGCAGTTATATCATAT ATAAGGCGTCTAGTTTAGAAAGTGGGGTCGATGGAAGTAATAAATACTATGCAGAC CCATCAAGGTTCAGCGGCAGTGGATCTGGTCCGTGAAGGGCCGATTCACCATCTCC GACAGAATTCACTCTCACCATCAGCAGCCAGAGACAATTCCAAGAACACGCTGTAT TGCAGCCTGATGATTTTGCAACTTATTACTCTGCAAATGAACAGCCTGAGAGCTGAG GCCAACAGTATAATAGTTATTCGACGTTCGGACACGGCTGTGTATTACTGTGCGAAA GCCAAGGGACCAAGGTGGAAATCAAACGCAAGTGGAATTTATTGTAGTGGTGGA GACTGCTACTCATACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTC TCCTCAG C029 A-C029CAGGTGCAGCTGCAGGAGTCGGGCCC 221 GATATTGTGATGACTCAGTCTCCACTCTCC 222AGGACTGGTGAAGCCTTCACAGACCCT CTGCCCGTCACCCCTGGAGAGCCGGCCTGTCCCTCACCTGCACTGTCTCTGGTGG CCATCTCCTGCAGGTCTAGTCAGAGCCTCCTCCATCAGCAGTGGTGGTTACTACTG CTGCATAGTAATGGATACAACTATTTGGATGAGCTGGATCCGCCAGCACCCAGGGA TGGTACCTGCAGAAGCCAGGGCAGTCTCCAGGGCCTGGAGTGGATTGGGTACATCT ACAGCTCCTGATCTATTTGGGTTCTAATCGATTACAGTGGGAGCACCTACTACAACC GGCCTCCGGGGTCCCTGACAGGTTCAGTCGTCCCTCAAGAGTCGAGTTACCATAT GGCAGTGGATCAGGCACAGATTTTACACTCAGTAGACACGTCTAAGAACCAGTTCT GAAAATCAGCAGAGTGGAGGCTGAGGATGCCCTGAAGCTGAGCTCTGTGACTGCCG TTGGGGTTTATTACTGCATGCAAGCTCTACCGGACACGGCCGTGTATTACTGTGCGA AAACTCCTCACACTTTCGGCGGAGGGACCGAACAATGTATTACTATGATAGTAGTGG AAGGTGGAGATCAAACTTCCTTTGACTACTGGGGCCAGGGAAC CCTGGTCACCGTCTCCTCAG C030 A-C030GAGGTGCAGCTGGTGGAGTCTGGGGG 223 GACATCCAGATGACCCAGTCTCCTTCCAC 224AGGCGTGGTCCAGCCTGGGAGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCGGGCCAGTCAGAGTATTTCACCTTCAGTAGCTATGGCATGCACT AGTAGCTGGTTGGCCTGGTATCAGCAGAAGGGTCCGCCAGGCTCCAGGCAAGGGG ACCAGGGAAAGCCCCTAAGCTCCTCATCTCTGGAGTGGGTGGCAGTTATATCATAT ATAAGGCGTCTAGTTTAGAAAGTGGGGTCGATGGAAGTAATAAATACTATGCAGAC CCATCAAGGTTCAGCGGCAGTGGATCTGGTCCGTGAAGGGCCGATTCACCATCTCC GACAGAATTCACTCTCACCATCAGCAGCCAGAGACAATTCCAAGAACACGCTGTAT TGCAGCCTGATGATTTTGCAACTTATTACTCTGCAAATGAACAGCCTGAGAGCTGAG GCCAACAGTATAATAGTTATTCGACGTTCGGACACGGCTGTGTATTACTGTGCGAAA GCCAAGGGACCAAGGTGGAAATCAAACGCAAGTGGAATATATTGTAGTGGTGGT AACTGCTACTCATACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTC TCCTCAG C031 A-C031GAGGTGCAGCTGGTGGAGTCTGGGGG 225 GACATCCAGATGACCCAGTCTCCATCCTC 226AGGCTTGGTACAGCCTGGGGGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCGGGCAAGTCAGAGCATTTCACCTTCAGTAGCTACGACATGCACT AGCAGCTATTTAAATTGGTATCAGCAGAAAGGGTCCGCCAAGCTACAGGAAAAGGT CCAGGGAAAGCCCCTAAGGTCCTGATCTACTGGAGTGGGTCTCAGCTATTGGTACT TGCTGCATCCAGTTTGCAAAGTGGGGTCCGCTGGTGACACATACTATCCAGGCTCC CATCAAGGTTCAGTGGCAGTGGATCTGGGGTGAAGGGCCGATTCACCATCTCCAGA ACAGATTTCACTCTCACCATCAGCAGTCTGGAAAATGCCAAGAACTCCTTGTATCTTC CAACCTGAAGATTTTGCAACTTACTACTGTAAATGAACAGCCTGAGAGCCGGGGAC CAACAGAGTTACAGTACCCCTCCGCTCACACGGCTGTGTATTACTGTGCAAGAGTA TTTCGGCGGAGGGACCAAGGTGGAGATCAGGGTATGATAGTAGTGGTTATTCGGGC AAC TGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCCTCAG C032 A-C032 GAGGTGCAGCTGGTGCAGTCTGGAGC 227CAGTCTGTGCTGACTCAGCCGCCCTCAGT 228 AGAGGTGAAAAAGCCCGGGGAGTCTCGTCTGGGGCCCCAGGGCAGAGGGTCACC TGAAGATCTCCTGTAAGGGTTCTGGATATCTCCTGCACTGGGAGCAGCTCCAACAT ACAGCTTTACCAGCTACTGGATCGGCTCGGGGCAGGTTATGATGTACACTGGTACC GGGTGCGCCAGATGCCCGGGAAAGGCAGCAGCTTCCAGGAACAGCCCCCAAACTC CTGGAGTGGATGGGGATCATCTATCCTCTCATCTATGGTAACAGCAATCGGCCCTC GGTGACTCTGATACCAGATACAGCCCGAGGGGTCCCTGACCGATTCTCTGGCTCCA TCCTTCCAAGGCCAGGTCACCATCTCAAGTCTGGCACCTCAGCCTCCCTGGCCATC GCCGACAAGTCCATCAGCACCGCCTACACTGGGCTCCAGGCTGAGGATGAGGCTG CTGCAGTGGAGCAGCCTGAAGGCCTCATTATTACTGCCAGTCCTATGACAGCAGCC GGACACCGCCATGTATTACTGTGCGAGTGAGTGCCCTTTATGTCTTCGGAACTGGG AGGGGTAGCAGTGGACTGGTACTTCGACCAAGGTCACCGTCCTAG ATCTCTGGGGCCGTGGCACCCTGGTC ACCGTCTCCTCAG C036 A-C036CAGGTGCAGCTACAGCAGTGGGGCGC 229 GATATTGTGATGACTCAGTCTCCACTCTCC 230AGGACTGTTGAAGCCTTCGGAGACCCT CTGCCCGTCACCCCTGGAGAGCCGGCCTGTCCCGCACCTGCGCTGTCTTTGGTGG CCATCTCCTGCAGGTCTAGTCAGAGCCTCGTCCTTCACTAATTACTACTGGAGTTG CTGCATAGAAATGGATACAACTATTTGGATGATCCGCCAGTCCCCAGGGAAGGGGC TGGTACCTGCAGAAGCCAGGGCAGTCTCCTGGAGTGGATTGGGGAAATCAATGATA ACAGCTCCTGATCTATTTGGGTTCCAATCGGTGGAATCACCAACTACAACCCGTCCC GGCCTCCGGGGTCCCTGACAGGTTCAGGTCAAGAGTCGAGTCACCATCTCAGTAG GGCAGTGGATCAGGCACAGATTTCACACTACACGTCCAAGAACCAGTTCTCCCTGA GAAAATCAGCAGAGTGGAGGCTGAGGATGGCCTGAGGTCTGTGACCGCCGCGGAC TTGGGGTTTATTACTGCATGCAAGCTCTACACGGCTGTGTATTACTGTGCCAGAAGG AAACTCTCACCTTCGGCCAAGGGACACGAAGGTCCTTCTCTCGTCCTTCGTCTATC CTGGAGATTAAAC GACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C037 A-C037 TGCAGCTGGTGCAGTCTGGGCCTGAG 231GAAATTGTGTTGACGCAGTCTCCAGGCAC 232 GTGAAGAAGCCTGGGACCTCAGTGAACCTGTCTTTGTCTCCAGGGGAAAGAGCCA GGTCTCCTGCAAGGCTTCTGGATTCACCCCTCTCCTGCAGGGCCAGTCAGAGTGTT CTTTACTAGCTCTGCTATGCAGTGGGTAGCAGCAGCTACTTAGCCTGGTACCAGCA GCGACAGGCTCGTGGACAACGCCTTGGAAACCTGGCCAGGCTCCCAGGCTCCTCA AGTGGATAGGATGGATCGTCGTTGGCATCTATGGTGCATCCAGCAGGGCCACTGGC GTGGTAACACAAACTACGCACAGAAGTATCCCAGACAGGTTCAGTGGCAGTGGGTC TCCAGGAAAGAGTCACCATTACCAGGGTGGGACAGACTTCACTCTCACCATCAGCA ACATGTCCACAAGCACAGCCTACATGGGACTGGAGCCTGAAGATTTTGCAGTGTATT AGCTGAGCAGCCTGAGATCCGAGGACACTGTCAGCAGTATGGTAGCTCACCGTGG ACGGCCGTGTATTACTGTGCGGCCCCAACGTTCGGCCAAGGGACCAAGGTGGAAAT TATTGTAGTGGTGGTAGCTGCAATGAT CAAACGCTTTTGATATCTGGGGCCAAGGGACA ATGGTCACCGTCTCTTCAG C038 A-C038AGGTGCAGCTGGTGGAGTCTGGGGGA 233 AATTTTATGCTGACTCAGCCCCACTCTGTG 234GGCGTGGTCCAGCCTGGGAGGTCCCT TCGGAGTCTCCGGGGAAGACGGTTACCATGAGACTCTCCTGTGCAGCCTCTGGATT CTCCTGCACCGGCAGCAGTGGCAGCATTGCACCTTCAATAGAATTGCCATGTACTG CCAGCAACTATGTGCAGTGGTACCAGCAGGGTCCGCCAGGCTCCAGGCAAGGGGC CGCCCGGGCAGTGCCCCCACCACTGTGATGGAATGGGTGGCAGTTATATCATTTG TCTATGAAGATACCCAAAGACCCTCTGGGATGGAAGTTATGAATACTATGCAGAGT GTCCCTGATCGGTTCTCTGGCTCCATCGACCGTGAAGGGCCGGTTCGCCATCTCC CAGCTCCTCCAATTCTGCCTCCCTCACCATAGAGACAATTCCAAGAACACGCTGTAT CTCTGGACTGAAGACTGAGGACGAGGCTGCTACAGATGAACAGCCTGAGAGCTGAG ACTACTACTGTCAGTCTTATGATATCAACAGACACGGCTGTCTATTACTGTGCGAAA GTCGTTGGGTGTTCGGCGGAGGGACCAAAGTCCGATGGGTTATTGCACTAATGGT GCTGACCGTCCTA GTATGCTATCCTGACTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C040 A-C040 GAGGTGCAGCTGGTGGAGTCTGGGGG 235TCCTATGAGCTGACTCAGCCACCCTCGGT 236 AGGCTTGGTAAAGCCTGGGGGGTCCCGTCAGTGGCCCCAGGACAGACGGCCAGG TTAGACTCTCCTGTGCAGCCTCTGGATATTACCTGTGGGGGAAACAACATTGGAAG TCACTTTCAGTAACGCCTGGATGAGCTTAAAAGTGTGCACTGGTACCAGCAGAAGC GGGTCCGCCAGGCTCCAGGGAAGGGGCAGGCCAGGCCCCTGTGCTGGTCGTCTAT CTGGAGTGGGTTGGCCGTATTAAAAGCGATGATAGCGACCGGCCCTCAGGGATCCC AAAACTGATGGTGGGACAACAGACTACTGAGCGATTCTCTGGCTCCAACTCTGGGA GCTGCACCCGTGAAAGGCAGATTCACCACACGGCCACCCTGACCATCAGCAGGGTC ATCTCAAGAGATGATTCAAAAAACACGGAAGCCGGGGATGAGGCCGACTATTACTG CTGTATCTGCAAATGAACAGCCTGAAATCAGGTGTGGGATAGTAGTAGTGATCAGG ACCGAGGACACAGCCGTGTATTACTGTGGGTATTCGGCGGAGGGACCAAGCTGAC ACCACAGATCCCCATTGTAGTAGTACC CGTCCTAGAGCTGCCCCATTTTTTACTACTACTACA TGGACGTCTGGGGCAAAGGGACCACG GTCACCGTCTCCTCAGC101 V-C001 CAGGTGCAGCTGGTGGAGTCTGGAGG 237 GAAATTGTGTTGACGCAGTCTCCAGGCAC238 AGGCTTGATCCAGCCTGGGGGGTCCC CCTGTCTTTGTCTCCAGGGGAAAGAGCCATGAGACTCTCCTGTGCAGCCTCTGGGT CCCTCTCCTGCAGGGCCAGTCAGAGTGTTTCATCGTCAGTAGCAACTACATGAGCT AGCAGCAGCTACTTAGCCTGGTACCAGCAGGGTCCGCCAGGCTCCAGGGAAGGGG GAAACCTGGCCAGGCTCCCAGGCTCCTCACTGGAGTGGGTCTCAGTTATTTATAGC TCTATGGTGCATCCAGCAGGGCCACTGGCGGTGGTAGCACATTCTACACAGACTCC ATCCCAGACAGGTTCAGTGGCGGTGGGTCGTGAAGGGCCGATTCACCATCTCCAGA TGAGACAGACTTCACTCTCACCATCAGCAGACAATTCCAAGAACACTCTGTATCTTC GACTGGAGCCTGAAGATTGTGCAGTGTATAAATGAACAGCCTGAGAGCCGAGGAC TACTGTCAGCAGTATGGTAGCTCACCCCGACGGCCGTGTATTACTGTGTGCGGGAC GACGTTCGGCCAAGGGACCAAGGTGGAATACGGTGACTTCTACTTTGACTACTGG ATCAAAC GGCCAGGGAACCCTGGTCACCGTCTC CTCAGC102 V-C002 CAGGTGCAGCTGGTGGAGTCTGGAGG 239 GAAATTGTGTTGACGCAGTCTCCAGGCAC240 AGGCTTGATCCAGCCTGGGGGGTCCC CCTGTCTTTGTCTCCAGGGGAAAGAGCCATGAGACTCTCCTGTGCAGCCTCTGGGT CCCTCTCCTGCAGGGCCAGTCAGAGTGTTTCATCGTCAGTAGCAACTACATGAGCT AGCAGCAGCTACTTAGCCTGGTACCAGCAGGGTCCGCCAGGCTCCAGGGAAGGGG GAAACCTGGCCAGGCTCCCAGGCTCCTCACTGGAGTGGGTCTCAGTTATTTATAGC TCTATGGTGCATCCAGCAGGGCCACTGGCGGTGGTAGCACATTCTACGCAGACTCC ATCCCAGACAGGTTCAGTGGCAGTGGGTCGTGAAGGGCCGATTCACCATCTCCAGA TGGGACAGACTTCACTCTCACCATCAGCAGACAATTCCAAGAACACGCTGTATCTT GACTGGAGCCTGAAGATTTTGCAGTCTATTCAAATGAACAGCCTGAGAGCCGAGGA ACTGTCAGCAGTATGGTAGCTCACCTCGGCACGGCCGTGTATTACTGTGCGAGGG ACGTTCGGCCAAGGGACCAAGGTGGAAATACTACGGTGACTACTACTTTGACTACT CAAAC GGGGCCAGGGAACCCTGGTCACCGTC TCCTCAGC103 V-C003 CAGGTGCAGCTACAGCAGTGGGGCGC 241 GAAATTGTGTTGACGCAGTCTCCAGGCAC242 AGGACTGTTGAAGCCTTCGGAGACCCT CCTGTCTTTGTCTCCAGGGGAAAGAGCCAGTCCCTCACCTGCGCTGTCTCTGGTGG CCCTCTCCTGCAGGGCCAGTCAGAGTGTTGTCACTCAGTGGTTTCTACTGGACCTG ACCGCCAACTACTTAGCCTGGTACCAGCAGATCCGCCAGCCCCCAGGAAAGGGGC GAAACCTGGCCAGGCTCCCAGACTCCTCATGGAGTGGATTGGGGAAACCAATCATT TCTATGGTGCATCCAAGAGGGCCACTGGCTTGGAAGCACCGGCTACAAGCCGTCC ATCCCAGACAGGTTCAGTGGCAGTGGGTCCTCAAGAGTCGAGTCACCATATCAGTA TGGGACAGACTTCACTCTCAGCATCAGCAGACATGTCCAGGAACCAGTTCTCCCTG GACTGGAGCCTGAAGATTTTGCAGTGTATTAAGGTGACCTCTGTGACCGCCGCGGA ACTGTCAGCAGTATACTACTACACCTCGGACACGGCTGTGTATTACTGTGCGAGAAA CTTTCGGCGGAGGGACCAAGGTGGAGATGCCCCTCCTCTACAGTGACTTCTCTCC CAAAC TGGTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG C104 V-C004 CAGGTGCAGCTACAGCAGTGGGGCGC 243GAAATTGTGTTGACGCAGTCTCCAGGCAC 244 AGGACTGTTGAAGCCTTCGGAGACCCTCGTGTCTTTGTCTCCAGGGGAAAGAGCCA GTCCCTCTCCTGCGCTGTCTATGGTGGCCCTCTCCTGCTGGGCCAGTCAGAGTGTT GTCCCTCAGTGGTTACTACTGGAGCTGAGCGCCAGCTACTTAGCCTGGTACCAGCA GATCCGCCAGCCCCCAGGGAAGGGGCGAAACCTGGCCAGGCTCCCAGGCTCCTCA TGGAGTGGATTGGGGAGATCAATCATTTCTATGGTGCATCCAGCAGGGCCACTGGC TTGGAAGCACCGGCTACAACCCGTCCCATCCCAGACAGGTTCAGTGGCAGTGGGTC TCAAGAGTCGAGTCACCATCTCCGTGGTGGGACAGACTTCACTCTCACCATCAGTA ACACGTCCAAGAGCCAGTTCTCCGTGAGACTGGAGCCTGAAGATTTTGCAGTATATT AGCTGAGCTCTGTGACCGCCGCGGACACTGTCAGCAGTACGGTACTACACCTCGG ACGGCTGTCTATTACTGCGCGAGAAAGACTTTCGGCGGAGGGACCAAGGTGGAGAT CCCCTCCTCTACAGTAACTTATCCCCT CAAACGGTGCTTTTGATATCTGGGGCCAAGGG ACAATGGTCACCGTCTCTTCAG C105 V-C005CAGGTGCAGCTGGTGGAGTCTGGAGG 245 CAGTCTGCCCTGACTCAGCCTCCCTCCGC 246AGGCTTGATCCAGCCTGGGGGGTCCC GTCCGGGTCTCCTGGACAGTCAGTCACCATGAGACTCTCCTGTGCAGCCTCTGGGT TCTCCTGCACTGGAACCAGCAGTGACGTTTCACCGTCAGTAGCAACTACATGAGCT GGTGGTTATAAGTATGTCTCCTGGTACCAAGGGTCCGCCAGGCTCCAGGGAAGGGG CAGCACCCAGGCAAAGCCCCCAAACTCATCTGGAGTGGGTCTCAGTTATTTATAGC GATTTATGAGGTCAGTAAGCGGCCCTCAGGGTGGTAGTACATACTACGCAGACTCC GGGTCCCTGATCGCTTCTCTGGCTCCAAGGTGAAGGGCCGATTCACCATCTCCAGA TCTGGCAACACGGCCTCCCTGACCGTTTCGACAATTCCAAGAACACGCTGTATCTT TGGGCTCCAGGCTGAGGATGAGGCTGATTCAAATGAACAGCCTGAGAGCCGAGGA ATTACTGCAGCTCATATGAAGGCAGCAACCACGGCCGTGTATTACTGTGCGAGAG AATTTTGTGGTATTCGGCGGAGGGACCAAGCGAGGGGTGGGAGCTACCATACGAC GCTGACCGTCCTAG TACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C106 V-C006 CAGCTGCAGCTGCAGGAGTCGGGCCC 247TCCTATGAGCTGACACAGCCACCCTCAGT 248 AGGACTGGTGAAGCCTTCGGAGACCCGTCAGTGGCCCCAGGAAAGACGGCCAGG TGTCCCTCACCTGCACTGTCTCTGGTGATTACCTGTGGGGGAAACAACATTGGAAG CCTCCGTCAGCAGTGGTAGTTACTACTTAAAAGTGTGCACTGGTACCAGCAGAAGC GGAGCTGGATCCGGCAGCCCCCAGGGCAGGCCAGGCCCCTGTGCTGGTCATCTAT AAGGGACTGGAATGGATTGGGTATATCTTTGATAGCGACCGGCCCTCAGGGATCCC TATTACAGTGGGAGCACCAACTACAACTGAGCGATTCTCTGGCTCCAACTCTGGGA CCCTCCCTCAAGAGTCGAGTCACCATAACACGGCCACCCTGACCATCAGCAGGGTC TCAGTGGACACGTCCAAGAACCAGTTCGAAGCCGGGGATGAGGCCGACTATTACTG TCCCTGAAGCTGAGCTCTGTGACCGCTTCAGGTGTGGGATAGTAGTCGTGATCATG GCGGACACGGCCGTGTATTACTGTGCTGGTATTCGGCGGAGGGACCAAGCTGACC GAGAGAGCGGCCCGGTGGAACGTATA GTCCTAGGCAACACCTGGTACACCCCAACCGATA CCAACTGGTTCGACACCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C107 V-C007 CAGGTTCAGCTGGTGCAGTCTGGAGCT 249CAGTCTGTGCTGACTCAGCCACCCTCAGC 250 GAGGTGAAGAAGCCTGGGGCCTCAGTGTCTGGGACCCCCGGGCAGAGGGTCACC GAGGGTCTCCTGCAAGGCTTCTGGTTAATCTCTTGTTCTGGAAGCAGCTCCAACATC CACCTTTACCAGCTATGGTTTCAGCTGGGAAGTAATTATGTATACTGGTACCAGCAG GGTGCGACAGGCCCCTGGACAAGGGCCTCCCAGGAACGGCCCCCAAACTCCTCAT TTGAGTGGATGGGATGGATCAGCGCTTCTATAGGAATAATCAGCGGCCCTCAGGGG ACAATGGTAACACAAACTTTGCACAGATCCCTGACCGATTCTCTGGCTCCAAGTCT AGCTCCAGGGCAGAGTCACCATGACCGGCACCTCAGCCTCCCTGGCCATCAGTGG ACAGACACATCCACGAGCACAGCCTACGCTCCGGTCCGAGGATGAGGCTGATTATT ATGGAGCTGAGGAGCCTGAGATCTGAACTGTGCAGCATGGGATGACAGCCTGAGT CGACACGGCCGTGTATTACTGTGCGAGGGTTTTGTGGTATTCGGCGGAGGGACCAA AGGGGAAGCAGTGGCTGGTACAACCG GCTGACCGTCCTAGGTTTTTTTGACTACTGGGGCCAGGGAA CCCTGGTCACCGTCTCCTCAG C108 V-C008CAGGTGCAGCTGCAGGAGTCGGGCCC 251 CAGTCTGCCCTGACTCAGCCTGCCTCCGT 252AGGACTGGTGAAGCCTTCGGGGACCC GTCTGGGTCTCCTGGACAGTCGATCACCATGTCCCTCACCTGCGCTGTCTCTGGTG TCTCCTGCACTGGAACCAGCAGTGACGTTGCTCCATCAGCAGTACTAACTGGTGGA GGTGGTTATAACTATGTCTCCTGGTACCAAGTTGGGTCCGCCAGCCCCCAGGGAAG CAACACCCAGGCAAAGCCCCCAAACTCATGGGCTGGAGTGGATTGGGGAAATCTAT GATTTATGATGTCAGTAATCGGCCCTCAGCATACTGGGAGCACCAACTACAACCCG GGGTTTCTAATCGCTTCTCTGGCTCCAAGTTCCCTCAAGAGTCGAGTCACCATATCA CTGGCAACACGGCCTCCCTGACCATCTCTGTAGACAAGTCCAAGAACCAGTTCTCC GGGCTCCAGGCTGAGGACGAGGCTGATTCTGAAGCTGAGCTCTGTGACCGCCGC ATTACTGCAACTCATATACAAGCAGCAGCAGGACACGGCCGTGTATTACTGTGTGAG CTCGAGTCTTCGGAACTGGGACCAAGGTCAGATGGAGGACGACCCGGGGATGCTT ACCGTCCTAG TTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG C110 V-C010 CAGGTACAGCTGCAGCAGTCTGGAGC 253GACATCCAGATGACCCAGTCTCCTTCCAC 254 AGAGGTGAAAAAGCCCGGGGAGTCTCCCTGTCTGCATCTGTAGGAGACAGAGTCA TGAAGATCTCCTGTAAGGGTTCTGGATCCATCACTTGCCGGGCCAGTCAGAGTATT ACAGCTTTACCAGCTACTGGATCGGCTAGTTACTGGTTGGCCTGGTATCAGCAGAA GGGTGCGCCAGATGCCCGGGAAAGGCACCAGGGAAAGCCCCTAAGCTCCTGATCT CTGGAGTGGATGGGGATCATCTATCCTATCAGGCGTCTAGTTTAGAAAGTGGGGTC GGTGACTCTGATACCAGATACAGCCCGCCGTCAAGGTTCAGCGGCAGTGAGTCTGG TCCTTCCAAGGCCAGGTCACCATCTCAGACAGAATTCACTCTCACCATCAGCAGCC GCCGACAAGTCCATCAGCACCGCCTACTGCAGCCTGATGATTTTGCAACTTATTACT ATGCAGTGGAGCAGCCTGAAGGCCTCGCCAACAGTATAATAGTTACCCGTACACTT GGACACCGCCATGTATTACTGTGCGAGTTGGCCAGGGGACCAAGCTGGAGATCAAAC ATCGTTCCGGGACGACCCCCGTATAGCAGTGGCTGGCCCGGCTGATGCTTTTGA TATCTGGGGCCAAGGGACAATGGTCAC CGTCTCTTCAG C112V-C012 CAGGTGCAGCTGGTGGAGTCTGGGGG 255 CAGTCTGCCCTGACTCAGCCTGCCTCCGT 256AGGCGTGGTCCAGCCTGGGAGGTCCC GTCTGGGTCTCCTGGACAGTCGATCACCATGAGACTCTCCTGTGCAGCCTCTGGAT TCTCCTGCACCGGAACCAGCAGTGACGTTTCACCTTCAGTAGCCATGCTATGCACT GGTGGTTATAACTATGTCTCCTGGTACCAAGGGTCCGCCAGGCTCCAGGCAAGGGG CAACACCCAGGCAAAGCCCCCAAACTCATCTGGAGTGGGTGGCAGTTATATCATAT GATTTATGATGTCAGTAATCGGCCCTCAGGATGGAAGCAATAAATACTACGCAGAC GGGTTTCTAATCGCTTCTCTGGCTCCAAGTTCCGTGAAGGGCCGATTCACCATCTCC CTGGCAACACGGCCTCCCTGACCATCTCTAGAGACAATTCCAAGAACACGCTGTAT GGGCTCCAGGCTGAGGACGAGGCTGATTCTGCAAATGAACAGCCTGAGAGCTGAG ATTACTGCAGCTCATATACAAGCAGCAGCAGACACGGCTGTGTATTACTGTGCGAGA CTTGGGTGTTCGGCGGAGGGACCAAGCTGAGGATTACTATGATAGTAGTGGTTCTT GACCGTCCTAG TTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C113 V-C013 CAGGTGCAGCTGGTGGAGTCTGGGGG 257GACATCCAGATGACCCAGTCTCCTTCCAC 258 AGGCGTGGTCCAGCCTGGGAGGTCCCCCTGTCTGCATCTGTAGGAGACAGAGTCA TGAGACTCTCCTGTGCAGCCTCTGGATCCATCACTTGCCGGGCCAGTCAGAGTATG TCACCTTCAGTAACTTTGGCATGCACTAGTAGCTGGTTGGCCTGGTATCAGCAGAA GGGTCCGCCAGGCTCCAGGCAAGGGGACCAGGGAACGCCCCTAAGCTCCTGATCT CTGGAGTGGGTGGCAGTTATATGGTATATAAGGCGTCTAGTTTAGAAAGTGGGGTC GATGGAAGTAATAAATACTATGCAGACCCATCAAGGTTCAGCGGCAGTGGATCTGG TCCGTGAAGGGCCGATTCACCATCTCCGACAGAATTCACTCTCACCATCAGCAGCC AGAGACAATTCCAAGAACACGCTGTATTGCAGCCTGATGATTTTGCAACTTATTACT CTGCAAATGAACAGCCTGAGAGCCGAGCCAACAGCATAATAGTTCCCCGCTCACTT GGACACGGCTGTGTATTACTGTGCGAGTCGGCGGAGGGACCAAGGTGGAGATCAA AGGAGTAAACCCCGACGATATTTTGAC ACTGGCGTAGATGCTTTTGATATCTGGGG CCAAGGGACAATGGTCACCGTCTCTTC AG C114 V-C014CAGGTGCAGCTGGTGGAGTCTGGAGG 259 CAGTCTGTGCTGACTCAGCCGCCCTCAGT 260AGGGTTGATCCAGCCTGGGGGGTCCC GTCTGGGGCCCCAGGGCAGAGGGTCACCTGAAACTCTCCTGTGTAGTCTCTGGGT ATCTCCTGCACTGGGACCAGTTCCAACATTCACCGTCAGTAAGAACTACATCAGTT CGGGGCAGGTTATGATGTGCACTGGTACCGGGTCCGCCAGGCTCCAGGCAAGGGG AGCAACTTCCTGGAAGAGCCCCCAAAGTCCTGGAATGGGTCTCAGTTATTTTTGCC CTCATCTCTGGAAACAACATTCGGCCCTCAGGTGGTAGTACATTCTACGCAGACTCC GAGGTCCCTGACCGATTCTCTGGCTCCAGGTTAAGGGCCGATTCGCCATCTCCAGA GTCTGGCACCTCAGCCTCCCTGGCCATCAGACAACTCCAACAACACGCTGTTTCTT CTAGTCTCCAGCCTGAGGATGAGGCTCAACAAATGAACAGCCTGAGAGTCGAGGAC TATTACTGTCAGTCTTATGACAGCAGTCTCACGGCCATTTATTACTGTGCGAGAGGG TATGCGGTGTTCGGCGGAGGGACCAAGCTGACGGGGAGTTATTCTTTGACCAATGG GACCGTCCTA GGCCAGGGAACCCTGGTCACCGTCTC CTCAGC115 V-C015 CAGGTGCAGCTGGTGGAGTCTGGGGG 261GATATTGTGATGACTCAGTCTCCACTCTCC 262 AGGCTTGATAAAGCCAGGGCGGTCCCCTGTCCGTCACCCCTGGAGAGCCGGCCTC TGAGACTCTCTTGTACAGCCTCTGGATCATCTCCTGCAGGTCTAGTCAGAGCCTCC TCACCTTTGGTGATTATGCTATGACCTGTGCATAGTAATGGAAACAACTATTTCGATT GTTCCGCCAGGCTCCAGGGAAGGGGCGGTACCTGCAGAAGCCAGGGCAGTCTCCA TGGAGTGGGTAGGTTTCATTAGAAGTACAGCTCCTGATCTATTTGGGTTCTAATCGG AAGCTTATGGTGGGACAACAGGATACGGCCTCCGGGGTCCCTGACAGGTTCAGTG CCGCGTCTGTGAAATACAGATTTACCAGCAGTGGATCAGGCACAGATTTTACACTG TCTCAAGAGATGATTCCAAAAGCATCGAAGATCAGCAGAGTGGAGGCTGAGGATGT CCTATCTGCAAATGGACAGCCTGAAAATGGGGTTTATTACTGCATGCAAGTTCTACA CCGAGGACACAGCCGTGTATTACTGTAAATTCCGTACACTTTTGGCCAGGGGACCA CTAGGTGGGACGGGTGGAGTCAACAT AGCTGGAGATCAAACGACTATTGGGGCCAGGGAACCCTGGT CACCGTCTCCTCAG C116 V-C016CAGGTGCAGCTGGTGGAGTCTGGGGG 263 AATTTTATGCTGACTCAGCCCCACTCTGTG 264AGGCGTGGTCCAGCCTGGGAGGTCCC TCGGAGTCTCCGGGGAAGACGGTAACCATTGAGACTCTCCTGTGCAGCCTCTGGAT CTCCTGCACCGGCAGCAGTGGCAGCATTGTCACCTACAGTACCTATGCTATGCACT CCAGCAACTATGTGCAGTGGTACCAGCAGGGGTCCGCCAGGCTCCAGGCAAGGGG CGCCCGGGCAGTGCCCCCACCACTGTGACTGGAGTGGGTGGCATTTATATCATAT TCTATGAGGATAACCAAAGACCCTCTGGGGATGGAAGCAATAAATACTACGCAGAC GTCCCTGATCGGTTCTCTGGCTCCATCGATCCGTGAAGGGCCGATTCACCATCTCC CAGGTCCTCCAACTCTGCCTCCCTCACCAAGAGACAATTCCAAGAACACGCTGTAT TCTCTGGACTGAAGACTGAGGACGAGGCTCTGCAAATGAACAGCCTGAGAGCTGAG GACTACTACTGTCAGTCTTATGATAGCGGCGACACGGCTGTGTATTACTGTGCGAGA AATCATTGGGTGGTATTCGGCGGAGGGACGATTTCTACCATAACTGGTTCGACCCC CAGGCTGACCGTCCTAG TGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C117 V-C017 CAGGTGCAGCTGGTGGAGTCTGGGGG 265CAGTCTGTGCTGACTCAGCCGCCCTCAGT 266 AGGCGTGGTCCAGCCTGGGAGGTCCCGTCTGCGGCCCCAGGACAGAAGGTCACC TGAGACTCTCCTGTGCAGCCTCTGGATATCTCCTGCTCTGGAAGCAGCTCCAACATT TCACCTTCAGTACCTATGCTATGCACTGGGAATAATTTGGTATCCTGGTACCAGCA GGGTCCGCCAGGCTCCAGGCGAGGGGCTCCCAGGAACAGCCCCCAAACTCCTCA GCTGGAGTGGGTGGCAGTTATTTCATATCTATGAAAATAATAAGCGACCCTCAGGGA TGATGGAAGCAATACATACTACGCAGATTCCTGACCGATTCTCTGGCTCCAAGTCTG CTCCGTGAAGGGCCGATTCACCATCTCGCACGTCAGCCACCCTGGGCATCACCGG CAGAGACAATTCCAAGAACACGCTGTAACTCCAGACTGGGGACGAGGCCGATTATT TCTGCAAATGAACAGCCTGAGAGCTGAACTGCGGAGCATGGGATAGCAGCCTGAGT AGACACGGCTGTGTATTACTGTGCGAGGCTGGCGGGGTTTATGTCTTCGGAACTGG AGATCCCATATGGTTCGGGGAGTTATTGACCAAGGTCACCGTCCTAG ATCTCCTCCTTTTGTTCACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGT CTCCTCAG C118 V-C018CAGGTGCAGCTGGTGGAGTCTGGGGG 267 CAGCCTGTGCTGACTCAATCGCCCTCTGC 268AGGCGTGGTCCAGCCTGGGAGGTCCC CTCTGCCTCCCTGGGAGCCTCGGTCAAGCTGAGACTCTCCTGTGCAGCCTCTGGAT TCACCTGCACTCTGAGCAGTGGGCACAGCTCACCTTCAGTAACTATGCTATGCACTG AGCTACGCCATCGCATGGCATCAGCAGCAGGTCCGCCAGGCTCCAGGCAAGGGGC GCCAGAGAAGGGCCCTCGGTACTTGATGATGGAGTGGGTGGCAGTTATATCATATG AGCTTAACACTGATGGCAGCCACAGCAAGATGGAAGCAATAAATACTACGCAGACT GGGGACGGGATCCCTGATCGCTTCTCAGGCCGTGAAGGGCCGATTCACCATCTCCA CTCCAGCTCTGGGGCTGAGCGCTACCTCAGAGACAATTCCAAGAACACGCTGTATC CCATCTCCAGCCTCCAGTCTGAGGATGAGTGCAAATGAACAGCCTGAGAGCTGAGG GCTGACTATTACTGTCAGACCTGGGGCACACACGGCTATTTATTACTGTGCGAGTG TGGCATTCTCGTATTCGGCGGAGGGACCAGATATACTGGCTACGATTATTTTGTGCG AGCTGACCGTCCTAG GGGGGACTACTACGGTCTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC TCCTCA C119 V-C019 CAGGTCCAGCTGGTACAGTCTGGGGC269 CAGTCTGCCCTGACTCAGCCTGCCTCCGT 270 TGAGGTGAAGAAGCCTGGGGCCTCAGGTCTGGGTCTCCTGGACAGTCGATCACCA TGAAGGTTTCCTGCAAGGCATCTGGATTCTCCTGCACTGGAACCAGCAGTGACGTT ACACCTTCACCAGCTACTATATGCACTGGTGGTTATAAGTATGTCTCCTGGTACCAA GGGTGCGACAGGCCCCTGGACAAGGGCGGCACCCAGGCAAAGCCCCCAAACTCAT CTTGAGTGGATGGGAATAATCAACCCTGATATATGATGTCAGTAATCGGCCCTCAG AGTGGTGGTAGCACAAGCTACGCACAGGGTTTCTAATCGCTTCTCTGGCTCCAAGT GAAGTTACAGGGCAGAGTCACCATGACCTGGCAACACGGCCTCCCTGACCATCTCT CAGGGACACGTCCACGAGCACAGTCTGGGCTCCAGGCTGAGGACGAGGCTGATT ACATGGAGCTGAGCAGCCTGAGATCTGATTACTGCAGCTCATACACAAGCAGCAGC AGGACACGGCCGTGTATTACTGTGCGAACTTCTGTGGTGTTCGGCGGAGGGACCCA GAGCCAATCATGAAACAACTATGGACA GCTGACCGTCCTAGCTTACTACTACTACTACTACATGGACGT CTGGGGCAAAGGGACCACGGTCACCG TCTCCTCA C120V-C020 GAGGTGCAGCTGGTGGAGTCTGGAGG 271 GCCATCCGGATGACCCAGTCTCCATCCTC 272AGGCTTGATCCAGCCTGGGGGGTCCC CCTGTCTGCATCTGTAGGAGACACAGTCATGAGACTCTCCTGTGCAGCCTCTGGGT CCATCACTTGCCAGGCGAGTCAGGACATTTCACCGTCAGTAGCAACTACATGACCT AGCAAGTATTTAAATTGGTATCAGCAGAAAGGGTCCGCCAGGCTCCAGGGAAGGGG CCAGGGAAAGCCCCTAAGCTCCTGATCTACTGGAGTGGGTCTCACTTATTTATCCC CGATGCATCCAATTTGGAAACAGGGGTCCGGTGGTAGCACATACTACGCAGACTCC CATCAAGGTTCAGTGGAAGTGGATCTGGGGTGAAGGGCCGATTCACCATCTCCAGA ACAGATTTTACTTTCACCATCAGCAGCCTGGACAATTCCAAGAACACGCTGTATCTT CAGCCTGAAGATATTGCAACATATTACTGTCAAATGAACAGCCTGAGAGCCGAGGA CAACAGTATGATAATCTCCCTCAGACTTTCCACGGCCGTCTATTACTGTGCGAGAGA GGCGGAGGGACCAAGGTGGAGATCAAACGGGTATGGGTATGGCAGCAGCTGGTA CGTGGGGCCAGGGAACCCTGGTCACC GTCTCCTCAG C121V-C021 CAGGTGCAGCTGGTGCAGTCTGGGGC 273 CAGTCTGCCCTGACTCAGCCTGCCTCCGT 274TGAGGTGAAGAAGCCTGGGGCCTCAG GTCTGGGTCTCCTGGACAGTCGATCACCATGAAGGTCTCCTGCAAGGCTTCTGGAT TCTCCTGCACTGGAACCAGCAGTGATGTTACACCTTCACCGGCTACTATATGCACT GGGAGTTATAACCTTGTCTCCTGGTACCAAGGGTGCGACAGGCCCCTGGACAAGGG CAGCACCCAGGCAAAGCCCCCAAACTCATCTTGAGTGGATGGGATGGATCAGCCCT GATTTATGAGGGCAGTAAGCGGCCCTCAGGTCAGTGGTGGCACAAACTATGCACAG GGGTTTCTAATCGCTTCTCTGGCTCCAAGTAAGTTTCAGGGCAGGGTCACCATGACC CTGGCAACACGGCCTCCCTGACAATCTCTAGGGACACGTCCATCAGCACAGCCTAC GGACTCCAGGCTGAGGACGAGGCTGATTAATGGAGCTGAGCAGGCTGAGATCTGA TTACTGCTGCTCATATGCAGGTAGTAGCACCGACACGGCCGTGTATTACTGTGCGAG TTTGGTATTCGGCGGAGGGACCAAGCTGAAGCCCCACTGTTCCCCACAGGGGTGC CCGTCCTAG TAGCTGGGGACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACG GTCACCGTCTCCTCA C122 V-C022GAGGTGCAGCTGGTGGAGTCTGGAGG 275 GACATCCAGTTGACCCAGTCTCCATCCTTC 276AGGCTTGATCCAGCCTGGGGGGTCCC CTGTCTGCATCTGTAGGAGACAGAGTCACTGAGACTCTCCTGTGCAGCCTCTGGGC CATCACTTGCCGGGCCAGTCAGGGCATTATCACCGTCAGTAGCAACTACATGAGCT GCAGTTATTTAGCCTGGTATCAGCAAAAACGGGTCCGCCAGGCTCCAGGGAAGGGG CAGGGAAAGCCCCTAAGCTCCTGATCTATCTGGAGTGGGTCTCAGTTCTTTATAGC GCTGCATCCACTTTGCAAAGTGGGGTCCCGGTGGTAGCTCATTCTACGCAGACTCC ATCAAGGTTCAGCGGCAGTGGATCTGGGAGTGAAGGGCCGATTCACCATCTCCAGA CAGAATTCACTCTCACAATCAGCAGCCTGGACAATTCCAAGAACACGCTGTATCTT CAGCCTGAAGATTTTGCAACTTATTACTGTCAAATGAACAGCCTGAGAGCCGAAGAC CAACAGCTTAATAGTGACTCGTACACTTTTACGGCCGTGTATTACTGTGCGAGAGAA GGCCAGGGGACCAAGCTGGAGATCAAACAGTGGGGATACAACTATGGCCTTTGAC TACTGGGGCCAGGGAACCCTGGTCAC CGTCTCCTCAG C123V-C023 GAGGTGCAGCTGGTGGAGTCTGGAGG 277 GACATCCAGTTGACCCAGTCTCCATCCTTC 278AGGCTTGATCCAGCCTGGGGGGTCCC CTGTCTGCATCTGTAGGAGACAGAGTCACTGAGACTCTCCTGTGCAGCCTCTGGGG CATCACTTGCCGGGCCAGTCAGGGCATTATCACCGTCAGTAGGAACTACATGAGCT GCAGTTATTTAGCCTGGTATCAGCAAAAACGGGTCCGCCAGGCTCCAGGGAAGGGG CAGGGAAAGCCCCTAAGCTCCTGATCTATCTGGAGTGGGTCTCAGTTATTTATAGC GCTGCATCCACTTTGCAAAGTGGGGTCCCGGTGGTAGCACATACTACGCAGACTCC ATCAAGGTTCAGCGGCAGTGGATCTGGGAGTGAAGGGCCGATTCACCATCTCCAGA CAGAATTCACTCTCACAATCAGCAGCCTGGACAATTCCAAGAACACGCTGTATCTT CAGCCTGAAGATTTTGCAACTTATTACTGTCAAATGAACAGCCTGAGAGCCGAGGA CAACAGCTTAATAGTTACCCTCCAGCCTTCCACGGCCGTGTATTACTGTGCGAGAGA GGCCAAGGGACACGACTGGAGATTAAACTCTATCTGCTGCTTTTGATATCTGGGG CCAAGGGACAATGGTCACCGTCTCTTC AG C124 V-C024GAGGTGCAGCTGGTGGAGTCTGGGGG 279 GAAATTGTGTTGACACAGTCTCCAGCCAC 280AGGCTTGGTACAGCCTGGGGGGTCCC CCTGTCTTTGTCTCCAGGGGAAAGAGCCATGAGACTCTCCTGTGCAGCCTCTGGAT CCCTCTCCTGCAGGGCCAGTCAGAGTTTTTCACCTTCAGTGGCTATAGCATGAACT AGCAGCTACTTAGCCTGGTACCAACAGAAGGGTCCGCCAGGCTCCAGGGAAGGGG ACCTGGCCAGGCTCCCAGGCTCCTCATCTCCGGAGTGGGTTTCATACATTAGTAGG ATGATGCATCCAACAGGGCCACTGGCATCAGTAGTAGTACCATATACTACGCAGAC CCAGCCAGGTTCAGTGGCAGTGGGTCTGTCTGTGAAGGGCCGATTCACCATCTCC GGACAGACTTCACTCTCACCATCAGCAGCAGAGACAATGCCAAGAACTCACTGTAT CTAGAGCCTGAAGATTTTGCAGTTTATTACCTGCAAATGAACAGCCTGAGAGACGAG TGTCAGCAGCGTAACAACTGGCCTCCCGAGACACGGCTGTGTATTACTGTGCGAGA GTGGACGTTCGGCCAAGGGACCAAGGTGGAAGGGGCTAGAGTGGGAGCTACATA GAAATCAAAC TGACACGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC AG C125 V-C025 CAGGTGCAGCTGGTGCAGTCTGGGCC281 GAAATTGTGTTGACGCAGTCTCCAGGCAC 282 TGAGGTGAAGAAGCCTGGGACCTCAGCCTGTCTTTGTCTCCAGGGGAAAGAGCCA TGAAGGTCTCCTGCAAGGCTTCTGGATCCCTCTCCTGCAGGGCCAGTCAGAGTGTT TCACCTTTACTAGCTCTGCTGTGCAGTAGCAGCAGCTACTTAGCCTGGTACCAGCA GGGTGCGACAGGCTCGTGGACAACGCGAAACCTGGCCAGGCTCCCAGGCTCCTCA CTTGAGTGGATAGGATGGATCGTCGTTTCTATGGTGCATCCAGCAGGGCCACTGGC GGCAGTGGTAACACAAACTACGCACAGATCCCAGACAGGTTCAGTGGCAGTGGGTC AAGTTCCAGGAAAGAGTCACCATTACCTGGGACAGACTTCACTCTCACCATCAGCA AGGGACATGTCCACAAGCACAGCCTACGACTGGAGCCTGAAGATTTTGCAGTGTATT ATGGAGCTGAGCAGCCTGAGATCCGAACTGTCAGCAGTATGGTAGCTCACCGTGG GGACACGGCCGTGTATTACTGTGCGGACGTTCGGCCAAGGGACCAAGGTGGAAAT CACCTTATTGTAGTGGTGGTAGCTGCT CAAACCTGATGCTTTTGATATCTGGGGCCAAG GGACAATGGTCACCGTCTCTTCAG C126 V-C026CAGGTGCAGCTGCAGGAGTCGGGCCC 283 AATTTTATGCTGACTCAGCCCCACTCTGTG 284AGGACTGGTGAAGCCTTCGGAGACCC TCGGAGTCTCCGGGGAAGACGGTAACCATTGTCCCTCTCCTGCGCTGTCTCTGGTG CTCCTGCACCGGCAGCAGTGGCAGCATTGGCTCCATCGGTAGTTACTTCTGGAGCT CCAGCAACTATGTGCAGTGGTACCAGCAGGGATCCGGCAGCCCCCAGGGAAGGGA CGCCCGGGCAGTGCCCCCACCACTGTGACTGGAGTGGATTGGATATCTCCATTAC TCAATGAAGATAACCAAAGACCCTCTGGGAGTGGGAGCACCAACTACAACCCCTCC GTCCCTGATCGGTTCTCTGGCTCCATCGACTGAAGAGTCGAGTCACCATATCAGTA CAGCTCCTCCAACTCTGCCTCCCTCACCAGACACGTCCAAGAATCAGTTCTCCCTG TCTCTGGACTGAAGACTGAGGACGAGGCTAAGCTGAGCTCTGTGACCGCTGCGGA GACTACTACTGTCAGTCTTATGATAGCAGCCACGGCCGTGTATTACTGTGCGAGATT AATTTGGTATTCGGCGGAGGGACCAAGCTGCAGTGGCTACGCGGAGCTTTTGATAT GACCGTCCTAG CTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG C127 V-C027 CAGGTGCAGCTGGTGCAGTCTGGGGC 285CAGTCTGTGCTGACTCAGCCACCCTCAGC 286 TGAGGTGAAGAAGCCTGGGGCCTCAGGTCTGGGACCCCCGGGCAGAGGGTCACC TGAAGGTCTCCTGCAAGGCTTCTGGATATCTCTTGTTCTGGAAGCAGCTCCAACATC ACACCTTCACCGGCTACTATATGCACTGGAAGTAATACTGTAAACTGGTACCAGCA GGGTGCGACAGGCCCCTGGACAAGGGGCTCCCAGGAACGGCCCCCAAACTCCTCA CTTGAGTGGATGGGATGGATCAACCCTTCTATAGTAATAATCAGCGGCCCTCAGGG AACAGTGGTGGCACAAACTATGCACAGGTCCCTGACCGATTCTCTGGCTCCAAGTC AAGTTTCAGGGCAGGGTCACCATGACCTGGCACCTCAGCCTCCCTGGCCATCAGTG AGGGACACGTCCATCAGCACAGCCTACGGCTCCAGTCTGAGGATGAGGCTGATTAT ATGGAGCTGAGCAGGCTGAGATCTGATACTGTGCAGCATGGGATGACAGCCTGAA CGACACGGCCGTGTATTACTGTGCGACTGGCGTGGTATTCGGCGGAGGGACCAAG GGCGCACCCCCGGAGGATCCAAGGGG CTGACCGTCCTAGTATTTTTTTTGGGGCCGGGCGTCTGGG GCCAAGGGACCACGGTCACCGTCTCC TCA C128 V-C028GAGGTGCAGCTGTTGGAGTCTGGGGG 287 GAAATTGTGTTGACGCAGTCTCCAGGCAC 288AGGCTTGGTACAGCCTGGGGGGTCCC CCTGTCTTTGTCTCCAGGGGAAAGAGCCATGAGACTCTCCTGTGCAGCCTCTGGAT CCCTCTCCTGCAGGGCCAGTCAGAGTGTTTCACCTTTAGCACCTATGCCATGAGTT AACAGCAGGCAGTTAGCCTGGTACCAGCAGGGTCCGCCAGGCTCCAGGGAAGGGG GAAACCTGGCCAGGCTCCCAGGCTCCTCACTGGAGTGGGTCTCAACTATTACTGGT TCTATGGTGCGTCCAGCAGGGCCACTGGCAGTGGTCGTGACACATACTACGCAGAC ATCCCAGAGAGGTTCAGTGGCAGTGGATCTCCGTGAAGGGCCGGTTCACCATCTCC TGGGACAGACTTCACTCTCACCATCAGCAAGAGACAATTCCAAGAACACGCTGTTT GACTGGAGTCTGAAGATTTTGCAGTGTATCCTGCAACTGAACAGCCTGAGAGCCGA ACTGTCAGCAATATGGTAGCTCAAGGGCGGGACGCGGCCGTGTATTCCTGTGCGA CTCACTTTCGGCGGAGGGACCAAGGTGGAACCACCCTCTGGCATCAGGCGACGACT GATCAAAC ACTACCACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCC TCA C129 V-C029 CAGGTGCAGCTGGTGGAGTCTGGGGG289 GACATCCAGATGACCCAGTCTCCATCCTC 290 AGGCGTGGTCCAGCCTGGGAGGTCCCCCTGTCTGCATCTGTAGGAGACAGAGTCA TGAGACTCTCCTGTGCAGCCTCTGGATCCATCACTTGCCAGGCGAGTCAGGACATT TCACCTTCAGTAGCTATGGCATGAACTAGCAACTATTTAAATTGGTATCAGCAGAAA GGGTCCGCCAGGCTCCAGGCAAGGGGCCAGGGAAAGCCCCTAAGCTCCTGATCTA CTGGAGTGGGTGGCAGTTATATCATATCGATGCATCCAATTTGGAAACAGGGGTCC GATGGAAGTAATACATACTATACAGACTCATCAAGGTTCAGTGGAAGTGAATCTGGG CCGTGAAGGGCCGATTCACCATCTCCAACAGATTTTACTTTCACCATCAGCAGCCTG GAGACAATTCCAAGAACACGCTGTATCCAGCCTGAAGATATTGCAACATATTACTGT TGCAAATGAACAGCCTGAGAGTTGACGCAACAGTATGATAATCTCCCGATCACCTTC ACACGGCTACATATTACTGTGCGAAAGGGCCAAGGGACACGACTGGAGATTAAAC GGCCCCGGTTTGGCTGGAGCTATAGAGGGGGGTCTGGTTTTGATATCTGGGG CCAAGGGACAATGGTCACCGTCTCTTC AG C130 V-C030CAGGTGCAGCTGGTGCAGTCTGGGGC 291 TCCTATGAGCTGACACAGCCACCCTCAGT 292TGAGGTGAAGAAGCCTGGGGCCTCAG GTCAGTGGCCCCAGGAAAGACGGCCAGGTGAAGGTTTCCTGCAAGGCATCTGGAT ATTACCTGTGGGGGAAACAACATTGGAAGACACCTTCACCAACTACTATATGCACTG TAAAAGTGTGCACTGGTACCAGCAGAAGCGGTGCGACAGGCCCCTGGACAAGGGC CAGGCCAGGCCCCTGTGCTGGTCATCTATTTGAGTGGATGGGAATAATCAACCCTA TATGATAGCGACCGGCCCTCAGGGATCCCGTGGTGGTAGCACAGGCTACGCACAG TGAGCGATTCTCTGGCTCCAACTCTGGGAAAGTTCCAGGGCAGAGTCACCATGACC ACACGGCCACCCTGACCATCAGCAGGGTCAGGGACACGTCCACGAGCACAGTCTA GAAGCCGGGGATGAGGCCGACTATTACTGCATGGAGCTGAGCAGCCTGAGATCTGA TCAGGTGTGGGATAGTAGTAGTGATCATCGGACACGGCCGTGTATTACTGTGCGA CGGGGGTGGTATTCGGCGGAGGGACCAAGATCCCGACCGACTCCTGACTGGTACT GCTGACCGTCCTAG TCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCCTCAG C131 V-C031 CAGGTGCAGCTGGTGCAGTCTGGGTC 293GAAATAGTGATGACGCAGTCTCCAGCCAC 294 TGAGGTGAAGAAGCCTGGGTCCTCGGCCTGTCTGTGTCTCCAGGGGAAAGAGCCA TGAAGGTCTCCTGCAAGGCTTCTGGAGCCCTCTCCTGCAGGGCCAGTCAGAGTGTT GCACCTTCAGCAGCTATGCTTTCAGCTAGCAGCAACTTAGCCTGGTACCAGCAGAA GGGTGCGACAGGCCCCTGGACAAGGGACCTGGCCAGGCTCCCAGGCTCCTCATCT CTTGAGTGGATGGGAAGGATCATCCCTATGGTGCATCCACCAGGGCCACTGGTATC ATCCTTGCTTTAGCAAACTACGCACAGCCAGCCAGGTTCAGTGGCAGTGGGTCTG AAGTTCCAGGGCAGAGTCACGATTACCGGACAGAGTTCACTCTCACCATCAGCAGC GCGGACAAATCCACGAGCACAGCCTACTGCAGTCTGAAGATTTTGCAGTTTATTAC CATGGAGCTGAGCAGCCTGAGATCTGATGTCAGCAGTATAATAACTGGCCGATCAC GGACACGGCCGTGTATTACTGTGCGACTTCGGCCAAGGGACACGACTGGAGATTA GAGTCAATCAAGCAGTAACTACTCCCT AACTCTCCATGGACGTCTGGGGCCAAGGG ACCACGGTCACCGTCTCCTCA C132 V-C032CAGGTGCAGCTGCAGGAGTCGGGCCC 295 CAGTCTGCCCTGACTCAGCCTGCCTCCGT 296AGGACTGGTGAAGCCTTCGGGGACCC GTCTGGGTCTCCTGGACAGTCGATCACCATGTCCCTCACCTGCGCTGTCTCTGGTG TCTCCTGCACTGGAACCAGCAGTGACGTTGCTCCATCAGCAGTAATAACTGGTGGA GGTGGTTATAACTATGTCTCCTGGTACCAAGTTGTGTCCGCCAGCCCCCAGGGAAG CAACACCCAGGCAAAGCCCCCAAACTCATGGGCTGGAGTGGATTGGGGAAATCTAT GATTTATGATGTCAGTAATCGGCCCTCAGCATAGTGGGAGCACCAACTACAACCCG GGGTTTCTAATCGCTTCTCTGGCTCCAAGTTCCCTCAAGAGTCGAGTCACCATATCA CTGGCAACACGGCCTCCCTGACCATCTCTGTAGACAAGTCCAAGAACCAGTTCTCC GGGCTCCAGGCTGAGGACGAGGCTGATTCTGAAGCTGAGCTCTGTGACCGCCGC ATTACTGCAGCTCATATACAAGCAGCAGCAGGACACGGCCGTGTATTACTGTGCGA CTCTTTTGTTCGGCGGAGGGACCAAGCTGGAGGGGGGGATACAGCTATGGGCCCC ACCGTCCTAG GAATACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C133 V-C033 CAGGTGCAGCTGGTGGAGTCTGGGGG 297GACATCCAGATGACCCAGTCTCCATCCTC 298 AGGCGTGGTCCAGCCTGGGAGGTCCCCCTGTCTGCATCTGTAGGAGACAGAGTCA TGAGACTCTCCTGTGCAGCCTCTGGATCCATCACTTGCCGGGCAAGTCAGAGCATT TCACCTTCAGTAGCTATGCTATGCACTAGCAGCTATTTAAATTGGTATCAGCAGAAA GGGTCCGCCAGGCTCCAGGCAAGGGGCCAGGGAAAGCCCCTAAGCTCCTGATCTA CTGGAGTGGGTGGCAGTTATATTATATTGCTGCATCCAGTTTGCAAAGTGGGGTCC GATGGAAGCAATAAATACTACGCAGACCATCAAGGTTCAGTGGCAGTGGATCTGGG TCCGTGAAGGGCCGATTCACCATCTCCACAGATTTCACTCTCACCATCAGCAGTCTG AGAGACAATTCCAAGAACACGCTGTATCAACCTGAAGATTTTGCAACTTACTACTGT CTGCAAATGAACAGCCTGAGAGCTGAGCAACAGAGTTACAGTACCCCTCCGTGGAC GACACGGCTGTGTATTACTGTGCGAGAGTTCGGCCAAGGGACCAAGGTGGAAATCA GATTCGGACGTAGATACATCTATGGTT AACACTTGGTTCGACTACTGGGGCCAGGG AACCCTGGTCACCGTCTCCTCAG C134 V-C034GAGGTGCAGCTGTTGGAGTCTGGGGG 299 TCCTATGAGCTGACACAGCCACCCTCAGT 300AGGCTTGGTACAGCCTGGGGGGTCCC GTCAGTGGCCCCAGGAAAGACGGCCAGGTGAGACTCTCCTGTGCAGCCTCTGGAT ATTACCTGTGGGGGAAACAACATTGGAAGTCACCTTTAGCAACTATGCCATGAGCT TAAAAGTGTGCACTGGTACCAGCAGAAGCGGGTCCGCCAGGCTCCAGGGAAGGGG CAGGCCAGGCCCCTGTGCTGGTCATCTATCTGGAGTGGGTCTCAGCTATTAGTGGT TATGATAGCGACCGGCCCTCAGGGATCCCAGTGATGGTAGCACATACTACGCAGGC TGAGCGATTCTCTGGCTCCAACTCTGGGATCCGTGAAGGGCCGGTTCACCATCTCC ACACGGCCACCCTGACCATCAGCAGGGTCAGAGACAATTCCAAGAACACACTGTAT GAAGCCGGGGATGAGGCCGAATATCACTGCTGCAAATGAACAGCCTGAGAGCCGA TCAGGTGTGGGATAGTAGTAGTGATCGTCGGACACGGCCGTATATTACTGTGCGAA CGGGGGTGGTTTTCGGCGGAGGGACCAAAGATCCCCTTATAACTGGACCTACCTAT GCTGACCGTCCTAG CAATACTTTCACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C135 V-C035 CAGGTGCAGCTGGTGGAGTCTGGGGG 301GACATCCAGATGACCCAGTCTCCTTCCAC 302 AGGCGTGGTCCAGCCTGGGAGGTCCCCCTGTCTGCATCTGTAGGAGACAGAGTCA TGAGACTCTCCTGTGCAGCCTCTGGATCCATCACTTGCCGGGCCAGTCAGAGTATT TCACCTTCAGTAGCTATGCTATGCACTAGTAACTGGTTGGCCTGGTTTCAGCAGAA GGGTCCGCCAGGCTCCAGGGAAGGGGACCAGGGAAAGCCCCTAAGCTCCTGATCT CTGGAGTGGGTGGCAGTTATACCATTTATGAGGCGTCTAGTTTAGAAAGTGGGGTC GATGGAAGAAATAAGTACTACGCAGACCCATCAAGGTTCAGCGGCAGTGGATCTGG TCCGTGACGGGCCGATTCACCATCTCCGACAGAATTCACTCTCACCATCAGCAGCC AGAGACAATTCCAAGAACACACTGTATTGCAGCCTGATGATTTTGCAACTTATTACT CTGCAAATGAACAGCCTGAGAGCTGAGGCCAACAGTATAATAGTTATCCGTGGACGT GACACGGCTGTGTATTACTGTGCGAGTTCGGCCAAGGGACCAAGGTGGAGATCAAAC AGTAGTGGTTATCTTTTCCACTCTGACTACTGGGGCCAGGGAACCCTGGTCACC GTCTCCTCAG C138 V-C038GAGGTGCAGCTGGTGGAGTCTGGGGG 303 AATTTTATGCTGACTCAGCCCCACTCTGTG 304AGGCTTGGTCCAGCCTGGGGGGTCCC TCGGAGTCTCCGGGGAAGACGGTAACCATTGAGACTCTCCTGTGCAGCCTCTGGAT CTCCTGCACCGGCAGCAGTGGCAGCATTGTCACCTTTAGTACCTATTGGATGAGCT CCAGCAACTATGTGCAGTGGTACCAGCAGGGGTCCGCCAGCCTCCAGGGAAGGGG CGCCCGGGCAGTGCCCCCACCACTGTGACTGGAGTGGGTGGCCAACATAAAGCAA TCTATGAGGATAACCAAAGACCCTCTGGGGATGGAAGTGAGAAATACTATGTGGAT GTCCCTGATCGGTTCTCTGGCTCCATCGATCTGTGAAGGGCCGATTCACCATCTCC CAGCTCCTCCAACTCTGCCTCCCTCACCAAGAGACAACGCCAAGAACTCACTGTAT TCTCTGGACTGAAGACTGAGGACGAGGCTCTGCAAATGAACAGCCTGAGAGCCGAC GACTACTACTGTCAGTCTTATGATAGCAGCGACACGGCCGTGTATTACTGTGCCGG AATTGGGTGTTCGGCGGAGGGACCAAGCTGGGGACATGGCTACGATCCTCTTTTGA GACCGTCCTA CTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C139 V-C039 GAGGTGCAGCTGGTGGAGTCTGGGGG 305GACATCCAGATGACCCAGTCTCCATCCTC 306 AGGCGTGGTCCAGCCTGGGAGGTCCCCCTGTCTGCATCTGTAGGAGACAGAGTCA TGAGACTCTCCTGTGCAGCCTCTGGATCCATCACTTGCCAGGCGAGTCAGGACATT TCACCTTCAGTAGCTATGCCATGCACTAGCAACTATTTAAATTGGTATCAGCAGAAA GGGTCCGCCAGGCTCCAGGCAAGGGGCCAGGGAAAGCCCCTAAGCTCCTGATCTA CTGGAGTGGGTGGCAGTTATATCATATCGATGCATCCAATTTGGAAACAGGGGTCC GATGGAAGTAATAAATACTCTGCAGACCATCAAGGTTCAGTGGAAGTGGATCTGGG TCCGTGAAGGGCCGATTCACCATCTCCACAGATTTTACTTTCACCATCAGCAGCCTG AGAGACAATTCCAAGAACACGCTGTATCAGCCTGAAGATATTGCAACATATTACTGT CTGCAAATGAACAGCCTGAGAGCTGAGCAACAGTATGATAATCTCCCGCTCACTTTC GACACGGCTGTGTATTACTGTGCGAAAGGCGGAGGGACCAAGGTGGAAATCAAAC GGGGGGGCCTACAGCTACTACTACTACATGGACGTCTGGGGCAAAGGGACCAC GGTCACCGTCTCCTCA C140 V-C040GAGGTGCAGCTGGTGGAGTCTGGGGG 307 GACATCCAGTTGACCCAGTCTCCATCCTTC 308AGGCTTGGTCCAGCCTGGGGGGTCCC CTGTCTGCATCTGTAGGAGACAGAGTCACTGAGACTCTCCTGTGCAGCCTCTGGAG CATCACTTGCCGGGCCAGTCAGGGCATTATCACCGTCAGTAGCAACTACATGAGCT GCAGTTATTTAGCCTGGTATCAGCAAAAACGGGTCCGCCAGCCTCCAGGGAAGGGG CAGGGAAAGCCCCTAAGCTCCTGATCTATCTGGAGTGGGTCTCACTTATTTATAGC GCTGCATCCACTTTGCAAAGTGGGGTCCCGGTGGTAGCACATTCTACGCAGACTCC ATCAAGGTTCAGCGGCAGTGGATCTGGGAGTGAAGGGCAGATTCACCATCTCCAGA CAGAATTCACTCTCACAATCAGCAGCCTGGACAATTCCGAGAACACGCTGTATCTT CAGCCTGAAGATTTTGCAACTTATTACTGTCAAATGAACACCCTGAGAGCCGAGGA CAACAGCTTAATAGTTACTCTTACACTTTTCACGGCTGTGTATTACTGTGCGAGAGA GGCCAGGGGACCAAGCTGGAGATCAAACTCTGTATTACTACGGTATGGACGTCTG GGGCCAAGGGACCACGGTCACCGTCT CCTCA C141 V-C041GAGGTGCAGCTGGTGGAGTCTGGGGG 309 AATTTTATGCTGACTCAGCCCCACTCTGTG 310AGGCGTGGTCCAGCCTGGGAGGTCCC TCGGAGTCTCCGGGGAAGACGGTAACCATTGAGACTCTCCTGTGCAGCCTCTGGAT CTCCTGCACCGGCAGCAGTGGCAGCATTGTCACCTTCAGTAGCTATGCTATGTTCTG CCAGCAACTATGTGCAGTGGTACCAGCAGGGTCCGCCAGGCTCCGGGCAAGGGGC CGCCCGGGCAGTGCCCCCACCACTGTGATGGAGTGGGTGGCAGTTATATCATATG TCTATGAGGATAACCAAAGACCCTCTGGGATGGAAGCAATAAATACTACGCAGACT GTCCCTGATCGGTTCTCTGGCTCCATCGACCGTGAAGGGCCGATTCACCATCTCCA CAGCTCCTCCAACTCTGCCTCCCTCACCAGAGACAATTCCAAGAACACGCTGTATC TCTCTGGACTGAAGACTGAGGACGAGGCTTGCAAATGAACAGCCTGAGAGCTGAGG GACTACTACTGTCAGTCTTATGATAGCAGCACACGGCTGTGTATTACTGTGCGAGGG AATTGGGTGTTCGGCGGAGGGACCAAGCTCGGATTTAGGATATTGTACTAATGGTGT GACCGTCCTAG ATGCTATGTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA C143 V-C043 GAGGTGCAGCTGGTGGAGTCTGGGGG 311CAGTCTGCCCTGACTCAGCCTGCCTCCGT 312 AGGCTTGGTCCAGCCGGGGGGGTCCCGTCTGGGTCTCCTGGACAGTCGATCACCA TGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTGCACTGGAACCAGCAATGATGTT TCAGTGTCAGCACCAAGTACATGACATGGGAGTTATACCCTTGTCTCCTGGTACCA GGGTCCGTCAGGCTCCAGGGAAGGGGACAGTACCCAGGCAAAGCCCCCAAACTCT CTGGAGTGGGTCTCAGTTCTTTACAGCTAATTTTTGAGGGCACTAAGCGGTCCTCA GGTGGTAGTGATTACTACGCAGACTCCGGGATTTCTAATCGCTTCTCTGGTTCCAAG GTGAAGGGCAGATTCACCATCTCCAGATCTGGCAACACGGCCTCCCTGACAATCTC GACAATTCCAAGAACGCTTTATATCTTCTGGGCTCCAGGGTGAAGACGAGGCTGATT AAATGAACAGCTTGAGAGTCGAGGACAATTATTGCTGCTCATATGCAGGTGCTAGCA CGGGTGTTTATTACTGTGCCAGAGACTCTTTCGTGTTCGGCGGAGGGACCAAGCTG CGTCGGAAGTCCGTGACCACCCCGGG ACCGTCCTAGCACCCAGGGCGCTCGGTGGGGGCTTT TGATATCTGGGGCCAAGGGACAATGGT CACCGTCTCTTCAGC144 V-C044 GAGGTGCAGCTGGTGGAGTCTGGAGG 313 CAGTCTGCCCTGACTCAGCCTGCCTCCGT314 AGGCTTGATCCAGCCTGGGGGGTCCC GTCTGGGTCTCCTGGACAGTCGATCACCATGAGACTCTCCTGTGCAGCCTCTGGGT TCTCCTGCACTGGAACCAGCAGTGACGTTTCACCGTCAGTAACAACTACATGAGCT GGTGGTTATAACTATGTCTCCTGGTACCAAGGGTCCGCCAGGCTCCAGGGAAGGGG CAACACCCAGGCAAAGCCCCCAAACTCATCTGGAGTGGGTCTCAGTTATTTATAGC GATTTATGATGTCAGTAATCGGCCCTCAGGGTGGTAGCACATACTACGCAGACTCC GGGTTTCTAATCGCTTCTCTGGCTCCAAGTGTGAAGGGCCGATTCACCATCTCCAGA CTGGCAACACGGCCTCCCTGACCATCTCTGACAAATCCAAGAACACGCTGTATCTT GGGCTCCAGGCTGAGGACGAGGCTGATTCAAATGAACAGGCTGAGAGCCGAGGA ATTACTGCAGCTCATATACAAGCAGCAGCACACGGCCGTGTATTATTGTGCGAGAGA CTCGAGTCTTCGGAACTGGGACCAAGGTCAGGGGAGGTAGAAGGGTATAACGATTT ACCGTCCTAG TTGGAGTGGTTATTCTAGAGACCGTTACTACTTTGACTACTGGGGCCAGGGAAC CCTGGTCACCGTCTCCTCAG C145 V-C045GAGGTGCAGCTGGTGGAGTCTGGAGG 315 CAGTCTGCCCTGACTCAGCCTGCCTCCGT 316AGGCTTGATCCAGCCTGGGGGGTCCC GTCTGGGTCTCCTGGACAGTCGATCACCATGAGACTCTCCTGTGCAGCCTCTGGGT TCTCCTGCACTGGAACCAGCAGTGACGTTTCAGCGTCAGTAGCAACTACATGAGCT GGTGGTTATAACTATGTCTCCTGGTACCAAGGGTCCGCCAGGCTCCAGGGAAGGGG CAACACCCAGGCAAAGCCCCCAAACTCATCTGGAGTGGGTCTCAGTTATTTATAGC GATTTATGATGTCAGTAATCGGCCCTCAGGGTGGTAGTACATACTACGCAGACTCC GGGTTTCTAATCGCTTCTCTGGCTCCAAGTGTGAAGGGCCGATTCACCATCTCCAGA CTGGCAACACGGCCTCCCTGACCATCTCTGACAATTCCAAGAACACGCTGTATCTT GGGCTCCAGGCTGAGGACGAGGCTGATTCAAATGAACAGCCTGAGAGCCGAGGA ATTACTGCAGCTCATATACAAGCAGCACCACACGGCCGTGTATTACTGTGCGAGAGA CTCGAGTCTTCGGAACTGGGACCAGGGTCAGGGGAGGTAGAAGGGTATTACGATTT ACCGTCCTAG TTGGAGTGGTTATTCTAGAGACCGTTACTACTTTGACTACTGGGGCCAGGGAAC CCTGGTCACCGTCTCCTCAG C146 V-C046GAGGTGCAGCTGGTGGAGTCTGGGGG 317 CAGTCTGCCCTGACTCAGCCTGCCTCCGT 318AGGCCTGGTCAAGCCTGGGGGGTCCC GTCTGGGTCTCCTGGACAGTCGATCACCATGAGACTCTCCTGTGCAGCCTCTGGAC TCTCCTGCACTGGAACCAGCAGTGACATTTCACCTTCACTGCCTATAGAATGAATTG GGTGTTTATAACTATATCTCCTGGAGCCAAGGTCCGCCAGGCTCCAGGGAAGGGGC CAACACCCAGGCAAAGCCCCCAAAGTCATTGGAGTGGCTCTCATCAATTAGTAATA GATTTATGATGTCACTAATCGGCCCTCAGGCAAATGGCGACATATACTATGCAGACT GGTTTCTAATCGCTTCTCTGGCTCCAAGTCCAGTGAAGGGCCGATTCACCATCTCCA TGGCAACACGGCCTCCCTGACCATCTCTGGAGACAACGCCAAGAATTCTCTGTATC GGCTCCAGGCTGAGGACGAGGCTGATTATTGCAAATGAACAGCCTGAGGGCCGAC TATTGCAGCTCATATAGAGGCAGCAGCACGACACGGCTGTATATTACTGTGCGAGA TCCCTATGTCTTCGGAACTGGGACCAAGGGATGTTGCATCTAACTACGCTTACTTTG TCACCGTCCTAG ACCTTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C147 V-C047 GAGGTGCAGCTGGTGCAGTCTGGAGC 319CAGGCTGTGGTGACCCAGGAGCCCTCACT 320 AGAGGTGAAAAAGCCCGGGGAGTCTCGACTGTGTCCCCAGGAGGGACAGTCACTC TGAAGATCTCCTGTAAGGGTTCTGGATTCACCTGTGGCTCCAGCACTGGAGCTGTC ACAGATTTACCAACTACTGGATCGGCTACCAGTGGTCATTATCCCTACTGGTTCCAG GGGTGCGCCAGATGCCCGGGAAAGGCCAGAAGTCTGGCCAAGCCCCCAGGACACT CTGGAGTGGATGGGGATCATCTATCCTGATTTATGAAACAAGCATCAAACACTCCTG GGTGACTCTGATACCAGATACAGCCCGGACCCCTGCCCGGTTCTCAGGCTCCCTCC TCCTTCCAAGGCCAGGTCACCATCTCATTGGGGGCAAAGCTGCCCTGACCCTTTCG GCCGACAAGTCCATCACCACCGCCTACGGTGCGCAGCCTGAGGATGAGGCTGATTA CTGCAGTGGAGCAGCCTGAAGGCCTCTTACTGCTTGCTCTCCTATAGTGGTGCTCG GGACACCGCCATGTATTACTGTGCGAGGCCGGTGTTCGGCGGAGGGACCAAGCTG ACTCAGTGACCGCTGGTACAGTCCGTT ACCGTCCTAGCGACCCCTGGGGCCAGGGAACCCTGG TCACCGTCTCCTCAG C148 V-C048GAGGTGCAGCTGGTGGAGTCTGGGGG 321 GAAATAGTGATGACGCAGTCTCCAGCCAC 322AGGCTTGGTCCAGCCTGGGGGGTCCC CCTGTCTGTGTCTCCAGGGGAAAGAGCCAAGAGACTCTCCTGTGCAGCCTCTGGAT CCCTCTCCTGCAGGGCCAGTCAGAGTGTTTCACCGTCAGTAGCAATTACATGAGCT AGCAGCCACTTAGCCTGGTACCAGCAGAAGGATCCGCCAGGCTCCAGGGAAGGGG ACCTGGCCAGGCTCCCAGGCTCCTCATCTCTGGAGTGGGTCTCAGTTATTTATAGC ATGGTGCATCCACCAGGGCCACTGGTATCGGTGGTAGCGCATACTACGTAGACTCC CCAACCAGGTTCAGTGGCAGTGGGTCTGGGTGAAGGGCAGATTCACCATCTCCAGA GACAGAGTTCACTCTCACCATCAGCAGCCGACAATTCCAAGAACACCCTGTATCTT TGCAGTCTGAAGATTTTGCAGTTTATTACTCAAATGAACAGCCTGAGACCCGAGGA GCCAGCAGTATAATAACTGGCCTCCGCTCCACGGCTGTGTATTACTGTGCGAGAAT ACTTTCGGCGGAGGGACCAAGGTGGAGATCGCAAACTACATGGACGTCTGGGGCAA CAAAC AGGGACCACGGTCACCGTCTCCTCA C149 V-C049CAGGTGCAGCTGGTGGAGTCTGGGGG 323 GACATCCAGATGACCCAGTCTCCATCCTC 324AGGCGTGGTCCAGCCTGGGAGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCGGGCAAGTCAGAGCATTTCACCTTCAGTACCTATGGCATGCACT AGCAGTTATTTAAATTGGTATCAGCAGAAAGGGTCCGCCAGGCTCCAGGCAAGGGG CCAGGGAAAGTCCCTAAGCTCCTGATCTACTGGAGTGGGTGGCCGTTATATCATAT TGCTGCATCCAGTTTGCAAAGTGGGGTCCGATGGAAGTAATAAATACTTTGCAGACT CATCAAGGTTCAGTGGCAGTGGATCTGGGCCGTGAAGGGCCGATTCACCATCTCCA ACAGACTTCACTCTCACCATCAGCAGTCTGGAGACAATTCCAAGAACACGCTTTATC CAACCTGAAGATTTTGCAACTTACTACTGTTGCAAATGAACAGCCTGAGACCTGAGG CAACAGAGTTACAGAACCCCGCTCACTTTACACGGCTGTATATTACTGTGCGAAAG CGGCGGAGGGACCAAGGTGGAGATCAAACTGGGGATGGAGTACAGCAGTGGCTGG TACGGGGAAGAAATTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C150 V-C050 GAGGTGCAGCTGGTGGAGTCCGGGGG 325CAGTCTGCCCTGACTCAGCCTGCCTCCGT 326 AGGCTTAGTTCAGCCTGGGGGGTCCCGTCTGGGTCTCCTGGACAGTCGATCACCA TGAGACTCTCCTGTGTAGCCTCTGGATTCTCCTGCACTGGAACCAGCAGTGACGTT TCACCTTCAGTAGCTACTGGATGCACTGGTTATTATAACTTTGTCTCCTGGTACCAA GGGTCCGCCAAGTCCCAGGGAAGGGGCAACACCCAGGCAAAGCCCCCAAACTCAT CCGGTGTGGGTCTCACATATTAACAGTGATTTATGAGGTCAGTAATCGGCCCTCTG GAAGGGAGTAGCACAAACTACGCGGAGGGTTTCTAATCGCTTCTCTGGCTCCAAGT CTCCGTGAGGGGCCGATTCACCATCTCCTGGCAACACGGCCTCCCTGATCATCTCT CAGAGACAACGCCAAGGACACGCTATAGGGCTCCAGGCTGAGGACGAGGCTGATT TCTTCAAATGAACAATCTGAGAGCCGAATTACTGCAGCTCATATAGAAGCAGCAGC GGACACGGCTGTATATTACTGTGCAAGACTCTGGTGTTCGGCGGGGGGACCAAGC ACCGACGGCTGTAGCAGCAGCTGGCA TGACCGTCCTAGATTACTTCTACTACTACGGTATGGACGT CTGGGGCCAAGGGACCACGGTCACCG TCTCCTCA C151V-C051 CAGGTGCAGCTGGTGGAGTCTGGGGG 327 AATTTTATGCTGACTCAGCCCCACTCTGTG 328AGGCCTGGTCAAGCCTGGGGGGTCCC TCGGAGTCTCCGGGGAAGACGGTAACCATTGAGACTCTCCTGTGCAGCCTCTGGAT CTCCTGCACCGGCAGCAGTGGCAGCATTGTCACCTTCAGTAGCTATAACATGAACTG CCAGCAACTATGTGCAGTGGTACCAGCAGGGTCCGCCAGGCTCCAGGGAAGGGGC CGCCCGGGCAGTGCCCCCACCACTGTGATGGAGTGGGTCTCATGCATTAGTAGTA TCTATGAGGATAACCAAAGACCCTCTGGGGTAGTAGTTACATATACTACGCAGACT GTCCCTGATCGGTTCTCTGGCTCCATCGACAGTGAAGGGCCGATTCACCATCTCCA CAGCTCCTCCAACTCTGCCTCCCTCACCAGAGACAACGCCAAGAACTCACTGTATC TCTCTGGACTGAAGACTGAGGACGAGGCTTGCAAATGAACAGCCTGAGAGCCGAG GACTACTACTGTCAGTCTTATGATAGCAGCGACACGGCTGTGTATTACTGTGCGAGA AATTATTGGGTGTTCGGCGGAGGGACCAAGAGAGGGGGTATGACGGTGGTAAAAC GCTGACCGTCCTAG CCCCCCATTTCTTGGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C152 V-C052 CAGGTTCAGCTGGTGCAGTCTGGAGCT 329GACATCCAGATGACCCAGTCTCCATCCTC 330 GAGGTGAAGAAGCCTGGGGCCTCAGTCCTGTCTGCATCTGTAGGAGACAGAGTCA GAAGGTCTCCTGCAAGGCTTCTGGTTACCATCACTTGCCGGGCGAGTCAGGGCATA CACCTTTACCAGCTACGGTATCAGCTGAGCAATTACTTAGCCTGGTATCAGCAGAG GGTGCGACAGGCCCCTGGACAAGGGCACCAGGGAAAGTTCCTAAGCTCCTGATCTT TTGAGTGGATGGGATGGATCAGCGCTTTGCTGCATCCACTTTGCAATCAGGGGTCC ACAATGGTAACACAAACTATGCACAGACATCTCGGTTCAGTGGCAGTGGATCTGGG AGCTCCAGGGCAGAGTCACCATGACCACAGATTTCACTCTCACCATCAGCAGCCTG ACAGACACATCCACGAGCACAGCCTACCAGCCTGAAGATGTTGCAACTTATTACTGT ATGGAGCTGAGGAGCCTGAGATCTGACAAAAGTATAACAGTGCCCCTCGGACGTT CGACACGGCCGTGTTTTACTGTGCGAGCGGCCAAGGGACCAAGGTGGAAATCAAAC AGATCGGGGGGGGCACGATTTTTGGAGTGGTTATGGGTTCTACTACTACTACG GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA C153 V-C053 GAGGTGCAGCTGGTGGAGTCTGGAGG 331CAGTCTGCCCTGACTCAGCCTGCCTCCGT 332 AGGCTTGATCCAGCCTGGGGGGTCCCGTCTGGGTCTCCTGGACAGTCGATCACCA TGAGACTCTCCTGTGCAGCCTCTGGGTTCTCCTGCACTGGAACCAGCAGTGATGTT TCACCGTCAGTAGCAACTACATGAGCTGGGAGTTATAACCTTGTCTCCTGGTACCAA GGGTCCGCCAGGCTCCAGGGAAGGGGCAGCACCCAGGCAAAGCCCCCAAACTCAT CTGGAGTGGGTCTCAGTTATTTATAGCGATTTATGAGGGCAGTAAGCGGCCCTCAG GGTTATAGCACATACTACGTAGACTCCGGGTTTCTAATCGCTTCTCTGGCTCCAAGT GTGAAGGGCCGATTCACCATCTCCAGACTGGCAACACGGCCTCCCTGACAATCTCT GACAATTCCAAGAACACGCTGTATCTTGGGCTCCAGGCTGAGGACGAGGCTGATT CAAATGAACAGCCTGAGAGCCGAGGAATTACTGCTGCTCATATGCAGGTAGTAGCA CACGGCCGTGTATTACTGTGCGAGAGTCTTGGGTGTTCGGCGGAGGGACCAAGCT GGGGGGAGCACATAGTGGCTACGACG GACCGTCCTAGGATCCTTTGACTACTGGGGCCAGGGAA CCCTGGTCACCGTCTCCTCAG C154 V-C054CAGGTGCAGCTGGTGGAGTCTGGGGG 333 GACATCCAGATGACCCAGTCTCCATCCTC 334AGGCGTGGTCCAGCCTGGGAGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCAGGCGAGTCAGGGCATTTCACCTTCAGTCGCTATGGCATGCACT AGCAACTATTTAAATTGGTATCAGCAGAAAGGGTCCGCCAGGCTCCAGGCAAGGGG CCAGGGAAAGCCCCTAAGCTCCTGATCTACTGGAGTGGGTGGCAGTTATGTCATAT CGATGCATCCAATTTGGAAACAGGGGTCCGATGGAAGTAGTAAATACTATGCAGAC CATCAAGGTTCAGTGGAAGTGGATCTGGGTCCGTGAAGGGCCGATTCACCATCTCC ACAGATTTTACTTTCACCATCAGCAGCCTGAGAGACAATTCCAAGAACACGCTGTGT CAGCCTGAAGATATTGCAACATATTACTGTCTGCAAATGAACAGCCTGAGAGCTGAG CAACAGTATGATAATCTCCCGATCACCTTCGACACGGCTGTGTATTACTGTGCGAAA GGCCAAGGGACACGACTGGAGATTAAACCAGGCGGGCCCATATTGTAGTGGTGG TAGCTGCTACTCCGCGCCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG TCTCCTCAG C155 V-C055GAGGTGCAGCTGGTGGAGTCTGGAGG 335 GAAATAGTGATGACGCAGTCTCCAGCCAC 336AGGCTTGATCCAGCCTGGGGGGTCCC CCTGTCTGTGTCTCCAGGGGAAAGAGCCATGAGACTCTCCTGTGCAGCCTCTGGGT CCCTCTCCTGCAGGGCCAGTCAGAGTGTTTCATCGTCAGTAGCAACTACATGAGCT AGCAGCAACTTAGCCTGGTACCAGCAGAAGGGTCCGCCAGGCTCCAGGGAAGGGC ACCTGGCCAGGCTCCCAGGCTCCTCATCTCTGGAGTGGGTCTCAGTTATTTATAGC ATGGTGCATCCACCAGGGCCACTGCTATCGGTGGTAGCACATTCTACGCAGACTCC CCAGCCAGGTTCAGTGGCAGTGGGTCTGGTGAAGGGCCGATTCACCATCTCCAGA GGACAGAGTTCACTCTCACCATCAGCAGCGACAATTCCAAGAACACGCTGTATCTT CTGCAGTCTGAAGATTTTGCAGTTTATTACCAAATGAACAGCCTGAGAGCCGAGGA TGTCAGCAGTATAATAACTGGCCTCGGACCACGGCCGTGTATTACTGTGCGAGAGA GTTCGGCCAAGGGACCAAGGTGGAGATCATTTTGGAGAGTTCTACTTTGACTACTGG AAC GGCCAGGGAACCCTGGTCACCGTCTC CTCAG C156V-C056 CAGGTGCAGCTGGTGGAGTCTGGGGG 337 TCCTATGAGCTGACTCAGCCACCCTCGGT 338AGGCGTGGTCCAGCCTGGGAGGTCCC GTCAGTGGCCCCAGGACAGACGGCCAGGTGAGACTCTCCTGTGCAGCCTCTGGAT ATTTCCTGTGGGGGAAACAACATTGGAAGTCACCTTCAGTAACTATGGCATGCACT TAAAAATGTGCACTGGTACCAGCAGAAGCGGGTCCGCCAGGCTCCAGGCAAGGGG CAGGCCAGGCCCCTGTGCTGGTCGTCTATCTGGAGTGGGTGGCAGTTATATCATAT GATGATAGCGACCGGCCCTCAGGGATCCCGATGGAAATAATAAATACTATGCAGACT TGAGCGATTCTCTGGCTCCAACTCTGGGACCGTGAAGGGCCGATTCACCATCTCCA ACACGGCCACCCTGACCATCAGCAGGGTCGAGACAATTCCAAGAACACGCTGTATC GAAGCCGGGGATGAGGCCGACTATTACTGTGCAAATGAACAGCCTGAGAGCTGAGG TCAGGTGTGGGATAGTAGTAGTGATCCTTACACGGCTGTGTATTACTGTGCGAAAG GGGTGTTCGGCGGAGGGACCAAGCTGACATCCTTTCCCCTTAGCAGTGGCTGGGA CGTCCTAG CGGGCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C160 V-C060 CAGGTTCAGCTGGTGCAGTCTGGAGCT 339TCCTATGAGCTGACACAGCCACCCTCGGT 340 GAGGTGAAGAAGCCTGGGGCCTCAGTGTCAGTGTCCCCAGGACAGACGGCCAGG GAAGGTCTCCTGCAAGGCTTCTGGTTAATCACCTGCTCTGGAGATGCATTGCCAAA CACCTTTACCAGCTACGGTATCAGCTGGCAATATGCTTATTGGTACCAGCAGAAGC GGTGCGACAGGCCCCTGGACAAGGGCCAGGCCAGGCCCCTGTGCTGGTGATATAT TTGAGTGGATGGGATGGATCAGCGCTTAAAGACAGTGAGAGGCCCTCAGGGATCCC ACAATGGTAACACAAACTATGCACAGATGAGCGATTCTCTGGCTCCAGCTCAGGGA AGCTCCAGGGCAGAGTCACCATGACCCAACAGTCACGTTGACCATCAGTGGAGTC ACAGACACATCCACGAGCACAGCCTACCAGGCAGAAGACGAGGCTGACTATTACTG ATGGAGCTGAGGAGCCTGAGATCTGATCAATCAGCAGACAGCAGTGGTACTCTTT CGACACGGCCGTGTATTACTGTGCGAGGGGTGTTCGGCGGAGGGACCAAGCTGAC AGTTCCCGCCTCGTACGGTGACGACG CGTCCTAGATTACTACTACTACTACGGTATGGACGT CTGGGGCCAAGGGACCACGGTCACCG TCTCCTCA C161V-C061 CAGGTGCAGCTACAGCAGTGGGGCGC 341 GAAATTGTGTTGACGCAGTCTCCAGGCAC 342AGGACTGTTGAAGCCTTCGGAGACCCT CCTGTCTTTGTCTCCAGGGGAAAGAGCCAGTCTCTCACCTGCGCTGTCTCTGGTGG CCCTCTCCTGCAGGGCCAGTCAGACTCTTGTCACTCAGTGGTTTCTACTGGACCTG ACCGCCAACTACTTAGCCTGGTACCAGCAGATCCGCCAGCCCCCCGGAAAGGGGC GAAACCTGGCCAGGCTCCCAGACTCCTCATGGAGTGGATTGGGGAAACCAATCATT TCTATGGTGCATCCAAGAGGGCCACTGGCTTGGAAGCACCGACTACAAGCCGTCCC ATCCCAGACAGGTTCAGTGGCAGTGGGTCTCAAGAGTCGAGTCACCATATCAGTAG TGGGACAGACTTCACTCTCAGCATCAGCAACATGTCCAGGAACCAATTTTCCCTGA GACTGGAGCCTGAAGATTTTGCAGTGTATTTTATGACCTCTGTGACCGCCGCGGACA ACTGTCAGCAGTATGGTACTACACCTCGGCGGCTGTGTATTACTGTGCGAGAAAGA ACTTTCGGCGGAGGGACCAAGGTGGAAATCCCTCCTCTTCAGTGACTTTTCTCCTG CAA GTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG C162 V-C062 CAGGTGCAGCTACAGCAGTGGGGCGC 343GAAATTGTGTTGACGCAGTCTCCAGGCAC 344 AGGACTGTTGAAGCCTTCGGAGACCCTCCTGTCTTTGTCTCCAGGGGAAAGAGCCA GTCCCTCACCTGCGCTGTCTCTGGTGGCCCTCTCCTGCAGGGCCAGTCAGACTCTT GTCACTCAGTGGTTTCTACTGGACCTGACCGCCAACTACTTAGCCTGGTACCAGCA GATCCGCCAGCCCCCAGGAAAGGGGCGAAACCTGGCCAGGCTCCCAGACTCCTCA TGGAGTGGATTGGGGAAACCAATCATTTCTATGGTGCATCCAAGAGGGCCGCTGGC TTGGAAGCACCGACTACAAGGCGTCCCATCCCAGACAGGTTCAGTGGCAGTGGGTC TCAAGAGTCGAGTCACCATATCAGTAGTGGGACAGACTTCACTCTCAGCATCACCA GCATGTCCAGGAACCAATTTTCCCTGAGACTGGAGCCTGAAGATTTTGCAGTGTATT AGGTGACTTCTCTGACCGCCGCGGACACTGTCAGCAGTATCATACTACACCTCGGA ACGGCTGTGTATTACTGCGCGAGAAAGCTTTCGGCGGAGGGACCAAGGTGGAGAT CCCCTCCTCTACAGTGACTTTTCTCCT CAAGGTGCTTTTGATGTCTGGGGCCAAGG GACAATGGTCACCGTCTCTTCAG C163 V-C063CAGGTGCAGCTACAGCAGTGGGGCGC 345 GAAATTGTGTTGACGCAGTCTCCAGGCAC 346AGGACTGTTGAAGCCTTCGGAGACCCT CCTGTCTTTGTCTCCAGGGGAAAGAGCCAGTCCCTCACCTGCGCTGTCTCTGGTGG CCCTCTCCTGCAGGGCCAGTCAGACTGTTGTCACTCAGTGGTTTCTACTGGACCTG TCCGCCAACTACTTAGCCTGGTACCAGCAGATCCGCCAGCCCCCAGGAAAGGGGC GAAAGCTGGCCAGGCTCCCAGACTCCTCATGGAGTGGATTGGGGAAACCAATCATT TCTATGGTGCATCCAAGAGGGCCACTGGCTTGGAAGCACCGACTACAAGCCGTCCC ATCCCAGACAGGTTCAGTGGCAGTGGGTCTCAAGAGTCGAGTCACCATATCAGTAG TGGGACAGACTTCACTCTCAGCATCAGCAACATGTCCAGGAACCAGTTCTCCCTGA GACTGGAGCCTGAAGATTTTGCTGTGTATTAGGTGACCTCTGTGACCGCCGCGGAC ACTGTCAGCAGTATGTTACTACACCTCGGAACGGCTGTTTATTACTGTGCGAGAAAG CTTTCGGCGGAGGGACCAAGGTGGAAATCCCCCTCCTCCACAGTGACTTATCTCCT AA GGTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG C164 V-C064 GAGGTGCAGCTGGTGGAGTCTGGGGG 347CAGTCTGCCCTGACTCAGCCTGCCTCCGT 348 AGGCTTGGTCCAGCCGGGGGGGTCCCGTCTGGGTCTCCTGGACAGTCGATCACCA TGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTGCACTGGAACCAGCAATGATGTT TCAGTGTCAGCACCAAGTACATGACATGGGAGTTATACCCTTGTCTCCTGGTACCA GGGTCCGTCAGGCTCCAGGGAAGGGGACAGTACCCAGGCAAAGCCCCCAAGCTCT CTGGAGTGGGTCTCAGTTCTTTACAGCTAATTTTTGAGGTCACTAAGCGGTCCTCAG GGTGGTAGTGATTACTACGCAGACTCCGGATTTCTAATCGCTTCTCTGGTTCCAAGT GTGAAGGGCAGATTCACCATCTCCAGACTGGCAACACGGCCTCCCTGACAATCTCT GACAATTCCAAGAACGCTTTATATCTTCGGGCTCCAGGGTGAAGACGAGGCTGATTA AAATGAACAGCTTGAGAGTCGAGGACATTATTGCTGCTCATATGCAGGTGCTAGCAC CGGGTGTTTATTACTGTGCCAGAGACTTTTCGTGTTCGGCGGAGGGACCAAGCTGA CGTCGGAAGTCCGTGACCACCCCGGG CCGTCCTAGCACCCAGGGCGCTCGGTGGGGGCTTT TGATATCTGGGGCCAAGGGACAATGGT CACCGTCTCTTCAGC165 V-C065 CAGGTGCAGCTGGTGCAGTCTGGGGC 349 GAAATTGTGTTGACGCAGTCTCCAGGCAC350 TGAGGTGAAGAAGCCTGGGTCGTCGG CCTGTCTTTGTCTCCAGGGGAAAGAGCCATGAAGGTCTCCTGCAAGGCTTCTGGAG CCCTCTCCTGCAGGGCCAGTCAGAGTGTTGCACCTTCAGTAGCTATGCTATCAACT AGCAGCACCTACTTAGCCTGGTACCAGCAGGGTGCGACAGGCCCCTGGACAAGGG GAAACCTGGCCAGGCTCCCAGGCTCCTCACTTGAGTGGATGGGAAGGATCATCCCT TCTATGGTGCATCCAGCAGGGCCACTGGCATCGTTGGTATAGCAAACTACGCACAG ATCCCAGACAGGTTCAGTGGCAGTGGGTCAAGTTCCAGGGCAGAGTCACGATTACG TGGGACAGACTTCACTCTCACCATCAGCAGCGGACAAATCCTCGAGCACAGCCTAC GACTGGAGCCTGAAGATTTTGCAGTGTATTATGGAGCTGAGCAGCCTGAGATCTGA ACTGTCAGCAGTATGGTAGCTCACCGTGGGGACACGGCCGTGTATTACTGTGCGA ACGTTCGGCCAAGGGACCAAGGTGGAAATGAGATCTCCTGGACCCCCAGCTAGATG CAAAC ATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG C201 M-C001 GAAGTGCAGCTGGTGGAGTCTGGGGG 351CATCCGGATGACCCAGTCTCCATCTTCTGT 352 AGGCTTGGTACAGCCTGGCAGGTCCCGTCTGCATCTGTAGGAGACAGAGTCACCA TGAGACTCTCCTGTGCAGCCTCTGGATTCACTTGTCGGGCGAGTCAGGGTATTAGC TCACCTTTGATGATTATGCCATGCACTGAGCTGGTTAGCCTGGTATCAGCAGAAACC GGTCCGGCAAGCTCCAGGGAAGGGCCAGGGAAAGCCCCTAAGCTCCTGATCTATG TGGAGTGGGTCTCAGGTATTAGTTGGATTGAATCCAGTTTGCAAAGTGGGGTCCCA ATAGTGGTAGTATAGGCTATGCGGACTTCAAGGTTCAGCGGCAGTGGATCTGGGAC CTGTGAAGGGCCGATTCACCATCTCCAAGATTTCACTCTCACTATCAGCAGCCTGCA GAGACAACGCCAAGAACTCCCTGTATCGCCTGAAGATTTTGCAACCTACTATTGTCA TGCAAATGAACAGTCTGAGAGCTGAGGACAGGCTAACAGTTTCCCTCTCACTTTCGG AC CGGAGGGACCAAGGTGGAAATCAAACACGGCCTTGTATTACTGTGTAAAAGGG GTCGAGTATAGCAGCTCGAGCAACTTTGACTACTGGGGCCAGGGAACCCTGGT CACCGTCTCCTCAG C202 M-C002GAGGTGCAGCTGGTGGAGTCTGGGGG 353 GACATCCAGTTGACCCAGTCTCCATCCTC 354AGGCTTGGTCCAGCCTGGGGGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATAAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCAGGCGAGTCAGGACATTTCACCGTCAGTAGCAACTACATGAGCT AGCAACTATTTAAATTGGTATCAGCAGAAAGGGTCCGCCAGGCTCCAGGGAAGGGG CCAGGGAAAGCCCCTAAGCTCCTGATCTACTGGAGTGGGTCTCACTTATTTATAGC CGATGCATCCAATTTGGAAACAGGGGTCCGGTGGTAGCACATACTACGCAGACTCC CATCAAGGTTCAGTGGAAGTGGATCTGGGGTGAAGGGCCGATTCACCATCTCCAGA ACAGATTTTACTTTCACCATCAGCAGCCTGGACAATTCCAAGAACACGCTGTATCTT CAGCCTGAAGATATTGCAACATATTACTGTCAAATGAACAGCCTGAGAGCTGAGGAC CAACAGTATGATAATCTCCCTCGGAGTTTTACGGCTGTGTATTACTGTGCGAGAGAT GGCCAGGGGACCAAGCTGGAGATCAAACACCCTTGGTAGGGGGGGCGACTACTG GGGCCAGGGAACCCTGGTCACCGTCT CCTCAG C204 M-C004GAGGTGCAGCTGTTGGAGTCTGGGGG 355 GACATCCAGTTGACCCAGTCTCCATCCTC 356AGGCTTGGAACAGCCTGGGGGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCGGGCAAGTCAGAGCATTTCACTTTTAGCACCTATGCCATGAGCT AGCAGCTATTTAAATTGGTATCAGCAGAAAGGGTCCGCCAGGCTCCAGGGAAGGGG CCAGGGAAAGCCCCTAAGCTCCTGATCTACTGGAGTGGGTCTCAGCTATTAGTGGT TGCTGCATCCAGTTTGCAAAGTGGGGTCCAGTGGTGCTGGCACATTCTACGCAGAC CATCAAGGTTCAGTGGCAGTGGATCTGGGTCCGTGAAGGGCCGGTTCACCATCTCC ACAGATTTCACTCTCACCATCAGCAGTCTGAGAGACAATTCCAAGAACACGCTGTAT CAACCTGAAGATTTTGCAACTTACTACTGTCTGCAAATGAACAGCCTGAGAGCCGA CAACAGAGTTACAGTACCCCTCCGTGGACGGACACGGCCGTATATTACTGTGCGAG GTTCGGCCAGGGGACCAAGGTGGAAATCAAGAGAGCGATTGTGGTAGTACCAGCTG AAC CTATCAAGTCGGGTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCT CCTCAG C205 M-C005 CAGGTGCAGCTGGTGCAGTCTGGGGC357 GAAATTGTGTTGACGCAGTCTCCAGGCAC 358 TGAGGTGAAGAAGCCTGGGGCCTCAGCCTGTCTTTGTCTCCAGGGGAAAGAGCCA TGAAGGTTTCCTGCAAGGCATCTGGACCCCTCTCCTGCAGGGCCAGTCAGAGTGTT ACACCTTCACCAGCTACTATATGCACTAGCAGCAGCTACTTAGCCTGGTACCAGCA GGGTGCGACAGGCCCCTGGACAAGGGGAAACCTGGCCAGGCTCCCAGGCTCCTCA CTTGAGTGGATGGGAATCATCAACCCTTCTATGGTGCATCCAGCAGGGCCACTGGC AGTGGTGGTAGCACAAGCTACGCACAATCCCAGACAGGTTCAGTGGCAGTGGGTC GAAGTTCCAGGGCAGAGTCACCATGACTGGGACAGACTTCACTCTCACCATCAGCA CAGGGACACGTCCACGAGCACAGTCTGACTGGAGCCTGAAGATTTTGCAGTGTATT ACATGGAGCTGAGCAGCCTGAGATCTGACTGTCAGCAGTATGTTAGCTCACCGTGG AGGACACGGCTGTGTATTACTGTGCTAACGTTCGGCCAAGGGACCAAGGTGGAGAT GGGGGCCGGAACGGGGTATAGTGGGA CAAACGCTACTGACTACTTTGACTACTGGGGC CAGGGAACCCTGGTCACCGTCTCCTCAG C207 M-C007GAGGTGCAGCTGTTGGAGTCTGGGGG 359 GAAATTGTGTTGACACAGTCTCCAGCCAC 360AGGCTTGGTACAGCCTGGGGGGTCCC CCTGTCTTTGTCTCCAGGGGAAAGAGCCATGAGACTCTCCTGTGCAGCCTCTGGAT CCCTCTCCTGCAGGGCCAGTCAGAGTGTTTCACCTTTAGCAGCTATGCCATGAGCT AGCAGCTACTTAGCCTGGTACCAACAGAAGGGTCCGCCAGGCTCCAGGGAAGGGG ACCTGGCCAGGCTCCCAGGCTCCTCATCTCTGGAGTGGGTCTCAGCTATTAGTGGT ATGATGCATCCAACAGGGCCACTGGCATCAGTGGTGGTAGCACATACTACGCAGAC CCAGCCAGGTTCAGTGGCAGTGGGTCTGTCCGTGAAGGGCCGGTTCACCATCTCC GGACAGACTTCACTCTCACCATCAGCAGCAGAGACAATTCCAAGAACACGCTGTAT CTAGAGCCTGAAGATTTTGCAGTTTATTACCTGCAAATGAACAGCCTGAGAGCCGA TGTCAGCAGCGTAGCAACTGGCCCCGGGGGACACGGCCGTATATTACTGTGCGAA GGTTCGGCCAAGGGACCAAGGTGGAGATAGAACCCATCGGCCAGCCACTGCTATG CAAAC GTGGGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C208 M-C008 GAGGTGCAGCTGGTGCAGTCTGGAGC 361GAAATTGTGTTGACGCAGTCTCCAGGCAC 362 AGAGGTGAAAAAGCCCGGGGAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCA TGAAGATCTCCTGTAAGGGTTCTGGATCCCTCTCCTGCAGGGCCAGTCAGAGTGTT ACAGCTTTACCAGCTACTGGATCGGCTAGCGGCAGCTACTTAGCCTGGTACCAGCA GGGTGCGCCAGATGCCCGGGAAAGGCGAGACCTGGCCAGGCTCCCAGGCTCCTCA CTGGAGTGGATGGGGATCATCTATCCTTCTATGGTGCTTCCAGCAGGGCCACTGGC GGTGACTCTGATACCAGATACAGCCCGATCCCAGACAGGTTCAGTGGCAGTGGGTC TCCTTCCAAGGCCAGGTCACCATCTCATGGGACAGACTTCACTCTCACCATCAGCA GCCGACAAGTCCATCAGCACCGCCTACGACTGGAGCCTGAAGATTTTGCAGTGTATT CTGAAGTGGAGCAGCCTGAAGGCCTCACTGTCAGCAGTATGGTAGCTCGCTCACT GGACAGCGCCATGTATTACTGTGCGAGTTCGGCGGGGGGACCAAGGTGGAGATCA GGGGCCCAACCTCCAGAACTGGTTCG AACACCCCTGGGGCCAGGGAACCCTGGTC ACCGTCTCCTCAG C209 M-C009CAGGTGCAGCTGGTGCAGTCTGGGGC 363 TCCTATGAGCTGACACAGCCACCCTCGGT 364TGAGGTGAAGAAGTCTGGGGCCTCAG GTCAGTGGCCCCAGGAAAGACGGCCAGGTGAAGGTCTCCTGCAAGGCTTCTGGAT ATTACCTGTGGGGGAAACAACATTGGAAGACACCTTCACCAGTTATGATATCAACTG CAAAAGTGTGCACTGGTACCAGCAGAAGCGGTGCGACAGGCCACTGGACAAGGGC CAGGCCATGCCCCTGTACTGGTCGTCTATTTGAGTGGATGGGATGGATGAACCCTA GATGATAGCGACCGGCCCTCAGGGATCCCACAGTGGTAACACAGGCTATGCACAGA TGAGCGATTCTCTGGCTCCAACTCTGGGAAGTTCCAGGGCAGAGTCACCATGACCA ACACGGCCACCCTGACCATCAGCAGGGTCGGAACACCTCCATAAGCACAGCCTACA GAAGCCGGGGATGAGGCCGACTATTACTGTGGANCTGAGCAGCCTGANATCTGANG TCAGGTGTGGGATAGTACTGGTGGTCATCANACGGCCGTGTATTACTGTGCGANAG CCGATGTGGTGTTCGGCGGAGGGACCAAGGTTCAGCCTGACTTGGTACTTCGATC GCTGACCGTCCTAG TCTGGGGCCGTGGNNCCCTGGTCACCGNCTCCTCAG C210 M-C010 GAGGTGCAGCTGGTGGAGTCTGGAGG 365GACATCCAGTTGACCCAGTCTCCATCCTTC 366 AGGCTTGATCCAGCCTGGGGGGTCCCCTGTCTGCATCTGTAGGAGACAGAGTCAC TGAGACTCTCCTGTGCAGCCTCTGGGTCATCACTTGCCGGGCCAGTCAGGGCATTA TCACCGTCAGTAGCAACTACATGAGCTGCAGTTATTTAGCCTGGTATCAGCAAAAAC GGGTCCGCCAGGCTCCAGGGAAGGGGCAGGGAAAGCCCCTAAGCTCCTGATCTAT CTGGAGTGGGTCTCAGTTATTTATAGCGCTGCATCCACTTTGCAAAGTGGGGTCCC GGTGGTAGTACATTCTACGCAGACTCCATCAAGGTTCAGCGGCAGTGGATCTGGGA GTGAAGGGCCGATTCACCTTCTCCAGACAGAATTCACTCTCACAATCAGCAGCCTG GACAATTCCAAGAACACGCTGTATCTTCAGCCTGAAGATTTTGCAACTTATTACTGT CAAATGAACAGCCTGAGAGCCGAGGACAACAGCTTAATAGTTACCCTCAGGGCACT CACGGCCGTGTATTACTGTGCGAGAGATTCGGCGGAGGGACCAAGGTGGAAATCAA TTTGATGGCCTACGGTATGGACGTCTG ACGGGCCAAGGGACCACGGTCACCGTCT CCTCAG C211 M-C011 GAGGTGCAGCTGGTGGAGTCTGGGGG367 GAAATAGTGATGACGCAGTCTCCAGCCAC 368 AGGCTTGGTCCAGCCTGGGGGGTCCCCCTGTCTGTGTCTCCAGGGGAAAGAGCCA TGAGACTCTCCTGTGCAGCCTCTGAATCCCTCTCCTGCAGGGCCAGTCAGAGTGTT TCACCGTCAGTAGCAACTACATGAGCTAGCAGCAACTTAGCCTGGTACCAGCAGAA GGGTCCGCCAGGCTCCAGGGAAGGGGACCTGGCCAGGGTCCCAGGCTCCTCATCT CTGGAGTGGGTCTCAGTTATTTATAGCATGGTGCATCCACCAGGGCCACTGGTATC GGTGGTAGCACATTCTACGCAGACTCCCCAGCCAGGTTCAGTGGCAGTGGGTCTG GTGAAGGGCCGATTCACCATCTCCAGAGGACAGAGTTCACTCTCACCATCAGCAGC GACAATTCCAAGAACACGCTGTATCTTCTGCAGTCTGAAGATTTTGCAGTTTATTAC CAAATGAACAGCCTGAGACCTGAGGACTGTCAGCAGTATAATAACTGGCCCCGGAC ACGGCTGTGTATTACTGTGCGAGAGACGTTCGGCCAAGGGACCAAGGTGGAGATCA TACGGTGACTTCTACTTTGACTTCTGG AACGGCCAGGGAACCCTGGTCACCGTCTC CTCAG C212 M-C012 CAGGTGCAGCTGGTGCAGTCTGGGGC369 CTGACTCAGCCTGCCTCCGTGTCTGGGTC 370 TGAGGTGAAGAAGCCTGGGGCCTCAGTCCTGGACAGTCGATCACCATCTCCTGCA TGAAGGTCTCCTGCAAGGCTTCTGGATCTGGAACCAGCAGTGATGTTGGGAGTTAT ACACCGTCACCGGCTATTATATACACTAACCTTGTCTCCTGGTACCAACAGCACCC GGGTGCGACAGGCCCCTGGACAAGGGAGGCAAAGCCCCCAAACTCATGATTTATGA CTTGAGTGGATGGGATGGATCAGCCCTGGACAGTAAGCGGCCCTCAGGGGTTTCTA AACAGTGGTGGCACAAACTATGCACAGATCGCTTCTCTGGCTCCAAGTCTGGCAAC AAGTTTCAGGGCTGGGTCACCATGACCACGGCCTCCCTGACAATCTCTGGGCTCCA AGGGACATGTCCATCACCACAGCCTACGGCTGAGGACGAGGCTGATTATTACTGCT ATGGAGCTGAGTAGACTGAGATCTGACGCTCATATGCAGGTAGTAGCACTCGGCTA GACACGGCCGTGTATTACTGTGCGAGTTCGGCGGAGGGACCAAGCTGACCGTCCT GGAACGATATTTTGACTTGGGTGGTAT AGGGACGTCTGGGGCCAAGGGACCACGG TCACCGTCTCCTCAG C214 M-C014CAGGTGCAGCTGGTGGAGTCTGGGGG 371 GACATCCAGTTGACCCAGTCTCCATCCTC 372AGGCGTGGTCCAGCCTGGGAGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCGTCTGGAT CCATCACTTGCCGGGCAAGTCAGAGCATTTCACCTTCAGTAGCTATGGCATGCACT AGCAGCTATTTAACTTGGTATCAGCAGAAAGGGTCCGCCAGGCTCCAGGCAAGGGG CCAGGGAAAGCCCCTAAGCTCCTGATCTACTGGAGTGGGTGGCAGCTATATGGTAT TGCTGCATCCAGTTTGCAAAGTGGGGTCCGATGGAAGTAATAAACACTATGCAGAC CATCAAGGTTCAGTGGCAGTGGATCTGGGTCCGTGAAGGGCCGATTCACCATCTCC ACAGATTTCACTCTCACCATCAGCAGTCTGAGAGACAATTCCAAGAACACGCTGTAT CAACCTGAAGATTTTGCAACTTACTACTGTCTGCAAATGAACAGCCTGAGAGCCGA CAACAGAGTTACAGTACCCCTCCGTGGACGGACACGGCTGTGTATTACTGTGCGAG GTTCGGCCAAGGGACCAAGGTGGAGATCAAGATGTAGGGCGGGTGACGACCTGGT AAC TCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG C215 M-C015 GAGGTGCAGCTGTTGGAGTCTGGGGG 373GACATCCAGTTGACCCAGTCTCCATCCTC 374 AGGCTTGGTACAGCCTGGGGGGTCCCCCTGTCTGCATCTGTAGGAGACAGAGTCA TGAGACTCTCCTGTGCAGCCTCTGGATCCATCACTTGCCGGGCAAGTCAGAGCATT TCACCTTTAGCAGCTATGCCATGAGCTAGCAGCTATTTAAATTGGTATCAGCAGAAA GGGTCCGCCAGGCTCCAGGGAAGGGGCCAGGGAAAGCCCCTAAGCTCCTGATCTA CTGGAGTGGGTCTCAGCTATTACTGATTGCTGCATCCAGTTTGCAAAGTGGGGTCC AGTGGTGATGGCACATTCTACGCAGACCATCAAGGTTCAGTGGCAGTGGATCTGGG TCCGTGAAGGGCCGGTTCACCATCTCCACAGATTTCACTCTCACCATCAGCAGTCTA AGAGACAATTCCAAGAACACGCTGTATCAACCTGAAGATTTTGCAACTTACTACTGT CTGCAAATGAACAGCCTGAGAGCCGACAACAGAGTTACAGTACCCCTCCGTGGAC GGACACGGCCGTTTATTACTGTGCGTCGTTCGGCCAAGGGACCAAGGTGGAAATCA CGAAGAGGACTACAGTAACTACGTGGG AACGTGGTTCGACCCCTGGGGCCAGGGAA CCCTGGTCACCGTCTCCTCAG C216 M-C016GAGGTGCAGCTGGTGGAGTCTGGGGG 375 GACATCCAGTTGACCCAGTCTCCATCCTC 376AGGCTTGGTACAGCCTGGGGGGTCCC CCTGTCTGCATCTGTAGGAGACAGAGTCATGAGACTCTCCTGTGCAGCCTCTGGAT CCATCACTTGCCGGGCAAGTCAGAGCATTTCACCTTCAGTAGCTACGACATGCACT AGCAGCTATTTAAATTGGTATCAGCAGAAAGGGTCCGCCAAGCTACAGGAAAAGGT CCAGGGAAAGCCCCTAAGCTCCTGATCTACTGGAGTGGGTCTCAGCTATTGGTACT TGTTGCATCCAGTTTGCAAAGTGGGGTCCGCTGGTGACACATACTATCCAGACTCC CATCAAGGTTCAGTGGCAGTGGATCTGGGGTGAAGGGCCGATTCACCATCTCCAGA ACAGATTTCACTCTCACCATCAGCAGTCTGGAAAATGCCAAGAACTCCTTGTATCTTC CAACCTGAAGATTTTGCAACTTACTACTGTAAATGAACAGCCTGAGAGCCGGGGAC CAACAGAGTTACAGTACCCCCCCGATCACACGGCTGTGTATTACTGTGCAAGAGAT CTTCGGCCAAGGGACACGACTGGAGATTACGGGGAAGCAGTGGCTGGTACGGCTG AAC GTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCCTCAG

TABLE 6 Effective and inhibitory concentrations of the monoclonalantibodies SARS- SARS- CoV-2 CoV Participant Antibody SARS-CoV-2SARS-CoV-2 SARS-CoV-2 SARS-CoV RB RBD ID ID IC50 ng/ml IC80 ng/ml IC90ng/ml IC50 ng/ml EC50 ng/ml EC50 ng/ml COV21 C002 8.88 21.95 37.61 NT3.14 >1000 COV21 C003 313.79 992.62 >1000 NT 6.37 >1000 COV21 C004 10.6741.08 91.71 NT 2.39 >1000 COV21 C005 60.49 130.65 205.20 NT 4.41 >1000COV21 C006 321.51 >1000 >1000 NT 1.81 >1000 COV21 C008625.46 >1000 >1000 NT 4.63 >1000 COV21 C009 4.82 14.54 29.34 NT1.80 >1000 COV21 C010 >1000 >1000 >1000 >1000 5.44 >1000 COV21 C01342.48 360.59 >1000 NT 2.59 >1000 COV21 C016 >1000 >1000 >1000 NT7.41 >1000 COV21 C017 72.67 256.18 543.87 NT 1.63 >1000 COV21C018 >1000 >1000 >1000 NT 1.53 >1000 COV21 C019 >1000 >1000 >1000 NT11.85 >1000 COV21 C021 >1000 >1000 >1000 NT 1.25 >1000 COV21 C022 73.57314.71 736.87 168.15 2.40 5.99 COV21 C027 >1000 >1000 >1000 >1000 2.65696.05 COV21 C029 >1000 >1000 >1000 NT 4.13 >1000 COV21C030 >1000 >1000 >1000 >1000 2.89 >1000 COV21 C031 >1000 >1000 >1000 NT22.69 >1000 COV57 C032 >1000 >1000 >1000 NT 99.31 NT COV57C036 >1000 >1000 >1000 NT 64.10 NT COV57 C037 155.78 488.45 >1000 NT1.93 NT COV57 C038 >1000 >1000 >1000 NT 4.69 NT COV57C040 >1000 >1000 >1000 NT 11.10 NT COV107 C101 8.20 30.15 65.30 NT1.51 >1000 COV107 C102 34.03 84.21 143.23 NT 4.54 >1000 COV107 C103 4.3812.58 23.59 NT 3.77 >1000 COV107 C104 23.31 72.12 140.28 NT 8.31 >1000COV107 C105 26.09 72.24 133.70 NT 5.20 >1000 COV107C106 >1000 >1000 >1000 >1000 19.03 106.75 COV107 C107 >1000 >1000 >1000NT 11.55 >1000 COV107 C108 480.69 >1000 >1000 NT 5.32 >1000 COV107 C11018.44 45.11 77.28 NT 7.29 >1000 COV107 C112 111.79 701.99 >1000 NT3.38 >1000 COV107 C113 >1000 >1000 >1000 NT 6.93 >1000 COV107C114 >1000 >1000 >1000 NT 9.51 >1000 COV107 C115 198.33 958.18 >1000 NT3.40 >1000 COV107 C116 >1000 >1000 >1000 NT 37.56 >1000 COV107 C117348.00 >1000 >1000 NT 5.38 >1000 COV107 C118 103.69 417.76 >1000 138.363.45 3.82 COV107 C119 9.12 39.45 97.78 NT 3.57 >1000 COV107 C120 13.2626.73 40.30 NT 1.41 >1000 COV107 C121 6.73 14.31 22.33 NT 2.85 >1000COV107 C122 22.80 57.77 100.12 NT 2.67 >1000 COV107 C123 149.22 355.47595.51 NT 1.92 >1000 COV107 C124 341.82 937.26 >1000 NT 2.23 >1000COV107 C125 43.32 92.54 144.26 NT 1.87 >1000 COV107C126 >1000 >1000 >1000 NT 4.78 >1000 COV107 C127 68.74 190.96 347.31 NT2.62 >1000 COV072 C128 101.22 263.35 460.73 NT 1.95 >1000 COV072 C12910.85 31.48 59.47 NT 1.16 NT COV072 C130 >1000 >1000 >1000 NT 2.05 >1000COV072 C131 30.52 178.90 759.11 NT 1.67 >1000 COV072 C132708.67 >1000 >1000 NT 2.92 >1000 COV072 C133 >1000 >1000 >1000 NT1.98 >1000 COV072 C134 >1000 >1000 >1000 NT 1.57 >1000 COV072 C135 16.6132.81 48.90 NT 1.80 >1000 COV072 C138 >1000 >1000 >1000 NT 2.94 >1000COV072 C139 >1000 >1000 >1000 NT 1.89 >1000 COV072 C140 23.88 66.24120.69 NT 2.19 >1000 COV072 C141 >1000 >1000 >1000 >1000 1.71 >1000COV047 C143 >1000 >1000 >1000 NT 3.66 >1000 COV047 C144 6.91 17.28 29.66NT 3.24 >1000 COV047 C145 3.04 14.51 36.79 NT 3.86 >1000 COV047C146 >1000 >1000 >1000 NT >1000 >1000 COV047 C147 >1000 >1000 >1000NT >1000 >1000 COV047 C148 >1000 >1000 >1000 NT 64.69 >1000 COV047 C14945.42 139.99 271.02 NT 1.79 NT COV047 C150 >1000 >1000 >1000 NT8.11 >1000 COV047 C151 31.79 363.97 >1000 NT 4.30 >1000 COV047 C15222.27 122.06 330.67 NT 1.88 NT COV047 C153 70.71 490.08 >1000 NT3.17 >1000 COV047 C154 435.50 >1000 >1000 >1000 2.92 10.65 COV047 C15511.00 35.75 77.01 NT 3.30 >1000 COV047 C156 >1000 >1000 >1000 NT3.32 >1000 COV047 C160 >1000 >1000 >1000 NT 2.54 NT COV107 C161 42.32232.17 581.63 NT 1.63 NT COV107 C162 14.44 59.81 138.75 NT 1.18 NTCOV107 C163 9.65 29.45 57.97 NT 1.77 NT COV047 C164 239.15 865.40 >1000NT 2.06 >1000 COV072 C165 40.81 138.66 297.38 NT 4.25 >1000 COV96C201 >1000 >1000 >1000 NT 2.98 >1000 COV96 C202 >1000 >1000 >1000 NT3.40 >1000 COV96 C204 >1000 >1000 >1000 >1000 3.73 9.41 COV96C205 >1000 >1000 >1000 NT >1000 >1000 COV96 C207 158.52 960.39 >1000 NT1.87 >1000 COV96 C208 >1000 >1000 >1000 NT >1000 >1000 COV96C209 >1000 >1000 >1000 NT 3.79 >1000 COV96 C210 50.73 155.24 298.90 NT2.83 >1000 COV96 C211 12.79 34.87 62.89 NT 2.82 >1000 COV96C212 >1000 >1000 >1000 NT >1000 >1000 COV96 C214 >1000 >1000 >1000 NT5.75 >1000 COV96 C215 >1000 >1000 >1000 >1000 5.33 17.94 COV96C216 >1000 >1000 >1000 NT 9.53 >1000 NT = not tested

TABLE 7 Anti-SARS-CoV-2 IgG antibodies from COV20 SEQ SEQ SEQUENCE_IDID NOS aa ID NOS cdr3_aa COVD20_P1_HC_B6-1369 377EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 378 TRDDSSWMHWVRQAPGKGLVWVSRINSDGSRRAYA WPHFF TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV DNYYCTRDDSSWPHFFDNWGQGTLVTVSS COVD20_P1_HC_D9-1369 381EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 382 TRDDSSWMHWVRQAPGKGLVWVSRISSDGSRRAYAT WPHFF SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY DNYCTRDDSSWPHFFDNWGQGTLVTVSS COVD20_P1_HC_D12-1369 385EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 386 TRDDSSWMHWVRQAPGKGLVWVSRINSDGSRRAYA WPHFF TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV DNYYCTRDDSSWPHFFDNWGQGTLVTVSS COVD20_P1_HC_E3-1369 389EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 390 TRDDSSWMHWVRQAPGKGLVWVSRISSDGSRRAYAT WPHFF SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY DNYCTRDDSSWPHFFDNWGQGTLVTVSS COVD20_P1_HC_G12-1369 393EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 394 TRDDSSWMHWVRQAPGKGLVWVSRINSDGSRRAYA WPHFF TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV DNYYCTRDDSSWPHFFDNWGQGTLVTVSS COVD20_P1_HC_H3-1369 397EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 398 TRDDSSWMHWVRQAPGKGLVWVSRISSDGSRRAYAT WPHFF SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY DNYCTRDDSSWPHFFDNWGQGTLVTVSS COVD20_P1_HC_H6-1369 401EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 402 TRDDSSWMHWVRQAPGKGLVWVSRINSDGSRRAYA WPHFF TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV DNYFCTRDDSSWPHFFDNWGQGTLVTVSS COVD20_P1_HC_H7-1369 405EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 406 TRDDSSWMHWVRQAPGKGLVWVSRINTDGSRRAYA WPHFF TSVKGRFTISRDNAKNTVHLQMDSLRDEDTAV DNYFCTRDDSSWPHFFDNWGQGTLVTVSS COVD20_P1_HC_H10-1369 409EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 410 TRDDSSWMHWVRQAPGKGLVWVSRISSDGSRRAYAT WPHFF SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY DNYCTRDDSSWPHFFDNWGQGTLVTVSS COVID020_Plate2_HC_19- 413EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 414 TRDDSS P1369WMHWVRQAPGKGLVWVSRINTDGSRRAYA WPHFF TSVKGRFTISRDNAKNTVHLQMDSLRDEDTAV DNYFCTRDDSSWPHFFDNWGQGTLVTVSS COVID020_Plate2_HC_24- 417EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 418 TRDDSS P1369WMHWVRQAPGKGLVWVSRINSDGSRRAYA WPHFF TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV DNYYCTRDDSSWPHFFDNWGQGTLVTVSS COVID020_Plate2_HC_36- 421EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 422 TRDDSS P1369WMHWVRQAPGKGLVWVSRISSDGSRRAYAT WPHFF SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY DNYCTRDDSSWPHFFDNWGQGTLVTVSS COVID020_Plate2_HC_71- 425EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 426 TRDDSS P1369WMHWVRQAPGKGLVWVSRINSDGSRRAYA WPHFF TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV DNYFCTRDDSSWPHFFDNWGQGTLVTVSS HEAVY COVD20_P1_HC_F7-1369 429EVQLVESGGGLVQPGGSLRLSCAASGFTFSNY 430 ARGRGDMHWVRQVTGEGLEWVSAIGTAGDTYYPGS HCSSIS VKGRFTISRENAKNSVFLQMNSLRAGDTAVYYCLHSW CARGRGHCSSISCLHSWFDSWGQGTLVTVSS FDS COVID020_Plate2_HC_48- 433EVQLVESGGGLVQPGGSLRLSCAASGFTFSNY 434 ARGRG P1369DMHWVRQATGEGLEWVSAIGTAGDTYYPGS HCSSIS VKGRFTISRENAKNSVFLQMNSLRAGDTAVYYCLHSW CARGRGHCSSISCLHSWFDSWGQGTLVTVSS FDS COVID020_Plate2_HC_63- 437EVQLVESGGGLIQPGGSLRLSCAASGFTFNNY 438 ARGRG P1369DIHWVRQATGEGLEWVSAIGTAGDTYYPGSV HCSSIS KGRFTISRENAKNSVFLQMNSLRAGDTAVYYCCLHSW ARGRGHCSSISCLHSWFDSWGQGTLVTVSS FDS COVID020_Plate2_HC_66- 441EVQLVESGGGLVQPGGSLRLSCAASGFTFSNY 442 ARGRG P1369DIHWVRQATGEGLEWVSAIGTAGDTYYPGSV HCSSIS KGRFTISRENAKNSVFLQMNSLRAGDTAVYYCCLHSW ARGRGHCSSISCLHSWFDSWGQGTLVTVSS FDS COVD20_P1_HC_A5-1369 445EVQLVESGGGLVQPGRSLRLSCAASGFTFDDY 446 AKSGPYAMHWVRQAPGKGLEWVSGISWNSGSIGYAD PWAVY SVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYYYGMD CAKSGPYPWAVYYYGMDVWGQGTTVTVSS V COVD20_P1_HC_E10-1369 449EVQLVESGGGLVQPGRSLRLSCAASGFTFDDY 450 AKSGPYAMHWVRQAPGKGLEWVSGISWNSGSIGYAD PWAVY SVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYYYGMD CAKSGPYPWAVYYYGMDVWGQGTTVTVSS V COVID020_Plate2_HC_79- 453EVQLVESGGGLVQPGRSLRLSCAASGFTFDDY 454 AKSGPY P1369AMHWVRQAPGKGLEWVSGISWNSGSIGYAD PWAVY SVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYYYGMD CAKSGPYPWAVYYYGMDVWGQGTTVTVSS V COVD20_P1_HC_H8-1369 457QVQLVQSGAEVKKPGASVKVSCKASGYTFTGY 458 ARDLTYYVHWVRQAPGQGLEWMGWINPNSGGTNYT GTVFY QKFQGRVTMTRDRSISTAYMELSGLRSDDTAVGMDV YYCARDLTYGTVFYGMDVWGQGTTVTVSS COVD20_P1_HC_B7-1369 461QVQLVESGGGLVKPGGSLRLSCAASGFTFSDY 462 ARGKWYMSWIRQAPGKGLEWVSSISSSGSTIYYADSVK LRGSFDGRFTISRDNAKTSLYLQMNSLRAEDTAVYYCA Y RGKWLRGSFDYWGQGTLVTVSSCOVID020_Plate2_HC_33- 3186 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDY 466 ARGPSSP1369 YMSWIRQAPGKGLEWVSYISSSSPYTNYADSV THESRPKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC RPFDY ARGPSSTHESRPRPFDYWGQGTLVTVSSCOVID020_Plate2_HC_23- 3187 EVQLVESGGGLVKPGGSLRVSCAASGFTFTNA 470 TTSRGP1369 WMSWVRQAPGKGLEWVGRIKSKTDGGTTDY GDWPAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTA VTDY VYYCTTSRGGDWPVTDYWGQGTLVTVSSCOVID020_Plate2_HC_41- 469 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 474 AKDLEYP1369 MSWVRQAPGKGLEWVSVISGSGGSTYYADSV YDSSGYKGRFTISRDNFKNTLYLQMNSLRAEDTAVYYC PRPSEY AKDLEYYDSSGYPRPSEYFQHWGQGTLVTVSSFQH COVID020_Plate2_HC_16- 3188 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 478AKGGP P1369 MSWVRQAPGKGLEWVSGISGSGGSTYYADSV DYYDSSKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC GYIRSK AKGGPDYYDSSGYIRSKPEYFQHWGQGTLVTVPEYFQ SS H COVID020_Plate2_HC_64- 473 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY482 AKPTH P1369 GMHWVRQAPGKGLEWVAVILYDGSNKYYAD PGPSSESVKGRFTISRDNAKNTLYLQMNSLRAEDTAVY YFQH YCAKPTHPGPSSEYFQHWGQGTLVTVSSCOVD20_P1_HC_E1-1369 477 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY 486 AKPTHGMHWVRQAPGKGLEWVAVISYDGSNKYYAD PGPSSE SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYYFQH CAKPTHPGPSSEYFQHWGQGTLVTVSS COVD20_P1_HC_H5-1369 481QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY 490 AKKGGGMHWVRQAPGKGLEWVAVISYDGSNKYYAD LYGDYL SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYNWFDP CAKKGGLYGDYLNWFDPWGQGTLVTVSS COVD20_P1_HC_G1-1369 485QLQLQESGSGLVKPSQTLSLTCAVXGGSISSGG 3189 ARGPPIYSWSWIRQPPGKGLEWIGYIYHSGSTYYNPSL EGWLR KSRVTISVDRSKNQFSLKLSSVTAADTAVYYCALGLGG RGPPIEGWLRLGLGGGDWYFDLWGRGTLVTV GDWYF SS DL COVID020_Plate2_HC_83-489 EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYW 3190 ARHDE P1369ISWVRQMPGKGLEWMGRIDPSDYYTNYSPSF VDTAA QGHVTISADKSISTAYLQWSSLKASDTAMYYCGGY ARHDEVDTAAGGYWGQGTLVTVSS SEQ SEQ SEQUENCE_ID ID NOS aa ID NOScdr3_aa COVD20_P1_K_B6-1389 379 DIQMTQSPSSLSAFVGDRVTITCRASQ 380 QQSVANYLNWYQQKPGKAPKLLIYSASSL SFIT QSGVPSRFSGSGSGTDFSLTISSLQPED PWTATYYCQQSFITPWTFGQGTKVEIK T COVD20_P1_K_D9-1389 383DIQMTQSPSSLSAFVGDRVTITCRASQ 384 QQ SVANYLNWYQQKPGKAPKLLIYSASSL SFITQSGVPSRFSGGGSGTDFSLTISSLQPED PW TATYYCQQSFITPWTFGQGTKVEIK TCOVD20_P1_K_D12-1389 387 DIQMTQSPSSLSAFVGDRVTITCRASQ 388 QQSVANYLNWYQQKPGKAPKLLIYSASSL SFIT QSGVPSRFSGSGSGTDFSLTISSLQPED PWTATYYCQQSFITPWTFGQGTKVEIK T COVD20_P1_K_E3-1389 391DIQMTQSPSSLSAFVGDRVTITCRASQ 392 QQ SVANYLNWYQQKPGKAPKLLIYSASSL SFITQSGVPSRFSGGGSGTDFSLTISSLQPED PW TATYYCQQSFITPWTFGQGTKVEIK TCOVD20_P1_K_G12-1389 395 DIQMTQSPSSLSAFVGDRVTITCRASQ 396 QQSVANYLNWYQQKPGKAPKLLIYSASSL SFIT QSGVPSRFSGSGSGTDFSLTISSLQPED PWTATYYCQQSFITPWTFGQGTKVEIK T COVD20_P1_K_H3-1389 399DIQMTQSPSSLSAFVGDRVTITCRASQ 400 QQ SVANYLNWYQQKPGKAPKLLIYSASSL SFITQSGVPSRFSGGGSGTDFSLTISSLQPED PW TATYYCQQSFITPWTFGQGTKVEIK TCOVD20_P1_K_H6-1389 403 DIQMTQSPSSLSASVGDRVTITCRASQ 404 QQSVANYLNWYQQKPGKAPKLLIYSASSL SFIT QSGVPSRFSGSGSGTDFSLTISSLQPED PWTATYYCQQSFITPWTFGQGTKVEIK T COVD20_P1_K_H7-1389 407DIQMTQSPSSLSASVGDRVTITCRASQ 408 QQ SVANYLNWYQQKPGKAPKLLIYSASSL SFITQSGVPSRFSGSGSGTDFSLTISSLQPED PW TATYYCQQSFITPWTFGQGTKVEIK TCOVD20_P1_K_H10-1389 411 DIQMTQSPSSLSAFVGDRVTITCRASQ 412 QQSVANYLNWYQQKPGKAPKLLIYSASSL SFIT QSGVPSRFSGGGSGTDFSLTISSLQPED PWTATYYCQQSFITPWTFGQGTKVEIK T COVID020_Plate2_Kappa_19- 415DIQMTQSPSSLSASVGDRVTITCRASQ 416 QQ P1389 SVANYLNWYQQKPGKAPKLLIYSASSLSFIT QSGVPSRFSGSGSGTDFSLTISSLQPED PW TATYYCQQSFITPWTFGQGTKVEIK TCOVID020_Plate2_Kappa_24- 419 DIQMTQSPSSLSASVGDRVTITCRASQ 420 QQ P1389SVANYLNWYQKKPGKAPKLLIYSASSL SFIT QSGVPSRFSGSGSGTDFSLTISSLQPED PWTATYYCQQSFITPWTFGQGTKVEIK T COVID020_Plate2_Kappa_36- 423DIQMTQSPSSLSAFVGDRVTITCRASQ 424 QQ P1389 SVANYLNWYQQKPGKAPKLLIYSASSLSFIT QSGVPSRFSGGGSGTDFSLTISSLQPED PW TATYYCQQSFITPWTFGQGTKVEIK TCOVID020_Plate2_Kappa_71- 427 DIQMTQSPSSLSASVGDRVTITCRASQ 428 QQ P1389SVANYLNWYQQKPGKAPKLLIYSASSL SFIT QSGVPSRFSGSGSGTDFSLTISSLQPED PWTATYYCQQSFITPWTFGQGTKVEIK T LAMBDA COVD20_P1_L_F7-1409 431QSVLTQPPSVSGAPGQRVTISCTGSSS 432 QSY NIGAGSDVHWYQKLPGIAPKVLIYGYS DTSNRPSGVPDRFSGSKSGTSASLAITGLQA LRV EDEADYYCQSYDTSLRVVFGGGTKLTV VCOVID020_Plate2_Lambda_48- 435 QSVLTQPPSVSGAPGQRVTISCTGSSS 436 QSY P1409NIGAGSDVHWYQKLPGTAPKVLIYGYS DTS NRPSGVPDRFSGSKSGTSASLAITGLQA LRVEDEADYYCQSYDTSLRVVFGGGTKLTV V COVID020_Plate2_Lambda_63- 439QSVLTQPPSVSGAPGQRVTISCTGSSS 440 QSY P1409 NIGAGSDVHWYQKLPGTAPKVLIYGYSDTS NRPSGVPDRFSGSKSGTSASLAITGLQA LRV EDEADYYCQSYDTSLRVVFGGGTKLTV VCOVID020_Plate2_Lambda_66- 443 QSVLTQPPSVSGAPGQRVTISCTGSSS 444 QSY P1409NIGAGSDVHWYQKLPGTAPKVLIYGY DTS NNRPSGVPDRFSGSKSGTSASLAITGL LRVQAEDEADYYCQSYDTSLRVVFGGGTKL V TV COVD20_P1_L_A5-1409 447QSALTQPASVSGSPGQSITISCTGTSSD 448 SSY VGGYNYVSWYQQHPGKAPKLMIYEVS TSSNRPSGVSNRFSGSKSGNTASLTISGLQ STV AEDEADYYCSSYTSSSTVFGGGTKLTVLCOVD20_P1_L_E10-1409 451 QSALTQPASVSGSPGQSITISCTGTSSD 452 SSYVGGYNYVSWYQQHPGKAPKLMIYEVS TSS NRPSGVSNRFSGSKSGNTASLTISGLQ STVAEDEADYYCSSYTSSSTVFGGGTKLTVL COVID020_Plate2_Lambda_79- 455QSALTQPASVSGSPGQSITISCTGTSSD 456 SSY P1409 VGGYNYVSWYQQHPGKAPKLMIYEVSTSS NRPSGVSNRFSGSKSGNTASLTISGLQ STV AEDEADYYCSSYTSSSTVFGGGTKLTVLCOVD20_P1_L_H8-1409 459 QSVLTQPPSVSGAPGQRVTISCTGSSS 460 QSYNIGAGSDVHWYQKLPGTAPKVLIYGYS DTS NRPSGVPDRFSGSKSGTSASLAITGLQA LRVEDEADYYCQSYDTSLRVVFGGXXQAG V PS KAPPA COVD20_P1_K_B7-1389 463EIVLTQSPATLSLSPGERATLSCRASQSV 464 QQ SSYLAWYQQKPGQAPRLLIYDASNRAT RSNGIPARFSGSGSGTDFTLTISSLEPEDFAV G YYCQQRSNGFGGGTKVEIKCOVID020_Plate2_Kappa_33- 467 DIMTQSPSTLSASVGDRVTITCRASQ 468 QQ P1389SISSWLAWYQQKPGKAPKLLIYKASSLE YNS SGVPSRFSGSGSGTEFTLTISSLQPDDF YSPATYYCQQYNSYSPGIFTFGQGTRLEIK GIF T LAMBDA COVID020_Plate2_Lambda_23- 471QSVLTQPPSVSEAPRQRVTISCSGSSSN 472 AA P1409 IGNNAVNWYQQLPGKAPKLLIYYDDLL WDPSGVSDRFSGSKSGTSASLAISGLQSED DSL EADYYCAAWDDSLNVWVFGGGTKLT NV VL WVCOVID020_Plate2_Lambda_41- 475 QSVLTQPPSVSGAPGQRVTISCTGSSS 476 QSY P1409NIGAGYDVHWYQQLPGTAPKLLIYGN DSS SNRPSGVPDRFSGSKSGTSASLAITGLQ LSGAEDEADYYCQSYDSSLSGYVFGTGTKV YV TVL COVID020_Plate2_Lambda_16- 479QSVLTQPPSVSGAPGQRVTISCTGSSS 480 QSY P1409 NIGAGYDVHWYQQLPGTAPKLLIYGN DSSSNRPSGVPDRFSGSKSGTSASLAITGLQ LSV AEDEADYYCQSYDSSLSVVFGGGTKLT V VL KAPPACOVID020_Plate2_Kappa_64- 483 AIQLTQSPSSLSASVGDRVTITCRASQG 484 QQ P1389ISSALAWYQQKPGKAPKLLIYDASSLES FNS GVPSRFSGSGSGTDFTLTISSLQPEDFA YPLTYYCQQFNSYPLTFGGGTKVEIK T COVD20_P1_K_E1-1389 487AIQLTQSPSSLSAFVGDRVTITCRASQG 488 QQ ISSALAWYQQKPGKAPKLLIYDASSLES FNYGVPSRFSGSGSGTDFTLTISSLQPEDFA YPL TYYCQQFNYYPLTFGGGTKVEIK TCOVD20_P1_K_H5-1389 491 DIQMTQSPSSLSASVGDRVTITCQASQ 492 QQDISNYLNWYQQKPGKAPKLLIYDASNL YD ETGVPSRFSGSGSGTDFTFTISSLQPEDI NLPATYYCQQYDNLPLTFGGGTKVEIK LT LAMBDA COVD20_P1_L_G1-1409 495QSALTQPASVSGSPGQSITISCTGTSSD 496 SSY VGGYNYVSWYQQHPGKAPKLMIYDV TSSSNRPSGVSNRFSGSKSGNTASLTISGLQ STV AEDEADYYCSSYTSSSTVVFGGGTKLTV v LCOVID020_Plate2_Lambda_83- 499 QSALTQPASVSGSPGQSITISCTGTSSD 500 SSYP1409 VGGYNYVSWYQQHPGKAPKLMIYEVS TSS NRPSGVSNRFSGSKSGNTASLTISGLQ SSYAEDEADYYCSSYTSSSSYVFGTGTKVTV V L

TABLE 8 Anti-SARS-CoV-2 IgG antibodies from COV21 SEQ SEQ ID IDSEQUENCE_ID NOS aa NOS cdr3_aa HEAVY COVD21_P2_HC_A4- 501QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 502 AKEGRPS p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P2_HC_B5- 505 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 506 AKEGRPS p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P2_HC_C12- 509 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 510 AKEGRPSp1369 MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P2_HC_E4- 513 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 514 AKEGRPS p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P2_HC_F1- 517 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 518 AKEGRPS p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P1_HC_B7- 521 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 522 AKEGRPS p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P1_HC_B9- 525 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 526 AKEGRPS p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P1_HC_E1- 529 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 530 AKEGRPS p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P1_HC_E11- 533 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 534 AKEGRPSp1369 MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P1_HC_F6- 537 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 538 AKEGRPS p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P3_HC_A6- 541 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 542 AKEGRPS p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P3_HC_B12- 545 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 546 AKEGRPSp1369 MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P3_HC_B12- 549 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG 550 AKEGRPSp1369 MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DIVVVVAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KEGRPSDIVVVVAFDYWGQGTLVTVSSCOVD21_P2_HC_C8- 553 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 554 ASPASRG p1369MHWVRQAPGQGLEWMGWINPISGGTNYAQ YSGYDHG KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYYYYYMDV CASPASRGYSGYDHGYYYYMDVWGKGTTVTVS S COVD21_P2_HC_F12- 557QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 558 ASPASRG p1369MHWVRQAPGQGLEWMGWINPISGGTNYAQ YSGYDHG KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYYYYYMDV CASPASRGYSGYDHGYYYYMDVWGKGTTVTVS S COVD21_P1_HC_H9- 561QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 562 ASPASRG p1369MHWVRQAPGQGLEWMGWINPISGGTNYAQ YSGYDHG KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYYYYYMDV CASPASRGYSGYDHGYYYYMDVWGKGTTVTVS S COVD21_P1_HC_E5- 565QVQLVESGGGLVKPGGSLRLSCAASGFIFSDYC 566 ARRGDGS p1369MSWIRRAPGKGLEWLSYISNSGTTRYYADSVKG SSIYYYNYRFTISRDNGRNSLYLQMDSLSAEDTAVYYCARR MDV GDGSSSIYYYNYMDVWGKGTTVTVSSCOVD21_P1_HC_F8- 569 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYC 570 ARRGDGS p1369MSWIRQAPGKGLEWLSYISNSGTTRYYADSVK SSIYYYNYGRFTISRDNGRNSLYLQMNSLSAEDTAVYYCAR MDV RGDGSSSIYYYNYMDVWGKGTTVTVSSCOVD21_P1_HC_G5- 573 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYC 574 ARRGDGS p1369MSWIRQAPGKGLEWLSYISNSGTTRYYADSVK SSIYYYNYGRFTISRDNGRNSLYLQMNSLSAEDTAVYYCAR MDV RGDGSSSIYYYNYMDVWGKGTTVTVSSCOVD21_P2_HC_A11- 577 QVQLVESGGGVVQPGRSLRLSCAASGFTYSGYA 578 ARDGIVDp1369 MHWVRQAPGKGLEWVAVILDDGSNKYYADSV TAMVTWKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY RDGIVDTAMVTWFDYWGQGTLVTVSSCOVD21_P2_HC_D1- 581 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 582 ARDQGM p1369MHWVRQAPGKGLEWVAVILYDGSNKYYADSV ATTYFDYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RDQGMATTYFDYWGQGTLVTVSSCOVD21_P2_HC_H7- 585 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 586 ARDGIVD p1369MHWVRQAPAKGLEWVAVILYDGSGKYYADSV TALVTWFKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA DY RDGIVDTALVTWFDYWGQGTLVTVSSCOVD21_P1_HC_B5- 589 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 590 ARDSPFS p1369MHWVRQAPGQGLEWMGWINPNSGGTNYA GLGASND QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY YYCARDSPFSGLGASNDYWGQGTLVTVSS COVD21_P3_HC_B5- 593QVQLVQSGAEVKKPGASVKVSCMASGYTFTGY 594 ARDSPFS p1369YMHWVRQAPGQGLEWMGWINPNSGGTNYA ALGASND QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYY YCARDSPFSALGASNDYWGQGTLVTVSS COVD21_P2_HC_F9- 597QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA 598 AAPHCSG p1369VQWVRQARGQRLEWIGWIVVGSGNTNYAQK GSCLDAFFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCA DI APHCSGGSCLDAFDIWGQGTMVTVSSCOVD21_P1_HC_F10- 601 QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA 602 AAPHCSGp1369 VQWVRQARGQRLEWIGWIVVGSGNTNYAQK GSCYDAFFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCA DI APHCSGGSCYDAFDIWGQGTMVTVSSCOVD21_P2_HC_E9- 605 EVQLVESGGDLVKPGGSLRLSCAASGFTFNNA 606 TTGPHYD p1369WMSWVRQAPGKGLEWVGRIKDKSDGETTDY SSGYSYT AAPVQGRFTVSRDDSKNTLYLQMNSLKTEDTAVDS VYYCTTGPHYDSSGYSYTVDSWGQGTLVTVSS COVD21_P2_HC_G2- 609EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW 610 TTGPHYD p1369MNWVRQAPGKGLEWVGRIKDKSDGGTIDYAA DSGYSYTPVQGRFTISRDDSKNTLYLQMNSLKTEDTAVYY VDY CTTGPHYDDSGYSYTVDYWGQGTLVTVSSCOVD21_P2_HC_G4- 613 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 614 AKASGIY p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV CSGGDCYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA SYYFDY KASGIYCSGGDCYSYYFDYWGQGTLVTVSSCOVD21_P1_HC_B2- 617 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 618 AKASGIY p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV CSGGNCYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA SYYFDY KASGIYCSGGNCYSYYFDYWGQGTLVTVSSCOVD21_P2_HC_F2- 621 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 622 AKGRVVY p1369MHWVRQAPGKGLEWVSGTSWNSGTIGYADS AIDPDSV VKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCSPFDY AKGRVVYAIDPDSVSPFDYWGQGTLVTVSS COVD21_P1_HC_E2- 625EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 626 AKPRKRG p1369MHWVRQAPGKGLEWVSGISWNSGSIGYADSV DYYGSGSKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCA YDY KPRKRGDYYGSGSYDYWGQGTLVTVSSCOVD21_P2_HC_B10- 629 QLQLQESGPGLVKPSETLSVTCTVSGGSISSSRYY 630 ARHAAAYp1369 WGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR YDRSGYYVTISVDTSKNQFSLKLSSVTAADTAVYYCARHAA FIEYFQH AYYDRSGYYFIEYFQHWGQGTLVTVSSCOVD21_P2_HC_H11- 633 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSNYY 634 ARHAAAYp1369 WGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR YDRSGYYVTISVDTSKNQFSLKVSSVTAADTAVYYCARHAA FIEYFQH AYYDRSGYYFIEYFQHWGXGTLVTVSSCOVD21_P3_HC_E4- 637 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNY 638 ARTDGTP p1369GISWVRQAPGQGLEWMGWNSAYNGNTNYA AEYFQY QKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTDGTPAEYFQYWGQGTLVTVSS COVD21_P2_HC_G7- 641QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 642 ARGGQD p1369MHWVRQAPGQGLEWMGWINPNSGGTNYA ELTGAFDI QKFQGRVTMTRDTSISTAYMELSRLTSDDTAVYYCARGGQDELTGAFDIWGQGTMVTVSS COVD21_P1_HC_D10- 645QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 646 AKSPYYY p1369MHWVRQAPGQGLEWMGWINPISGGTNSAQ DSSGYLG KFQGRVTMTRDTSITTAYMELSSLRSDDTAVYHGFDY CAKSPYYYDSSGYLGGFDYWGQGTLVTVSS COVD21_P1_HC_C7- 649QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 650 ARDLGYS p1369MHWVRQAPGQGLEWMGWINPNSGGRNYTQ YVQGYFD KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYY CARDLGYSYVQGYFDYWGXGTLVTVSS COVD21_P2_HC_B12- 653QVQLVQSGAEVKKPGASVKVSCKASGYIFTGYY 654 ARDLGFS p1369MHWVRQAPGQGLEWMGWINPNSGGTNYA RLQFLFD QKFQGRVTMTRDTSISTVYMELSRLRSDDTAVY YYCARDLGFSRLQFLFDYWGQGTLVTVSS COVD21_P1_HC_F4- 657QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 658 ASTGYYIL p1369MHWVRQAPGQGLEWMGWINPNSGGTNYA TGYEFGA QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYMDV YCASTGYYILTGYEFGAMDVWGQGTTVTVSS COVD21_P1_HC_D7- 661QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYY 662 ARDRPL p1369LHWVRQAPGQGLEWMGWINPTSGGTKYAQK WFGVEY FQGRVTMTRDTSITTAYMEVNRLRSDDTAVYYGMDV CARDRPLWFGVEYGMDVWGQGTTVTVSS COVD21_P1_HC_C1- 665QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 666 ATTEGQQ p1369MHWVRQAPGQGLEWMGWINPNSGGTNYA LPHPPYY QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYYYYYMD YCATTEGQQLPHPPYYYYYYYMDVWGKGTTVT V VSS COVD21_P2_HC_G5- 669QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY 670 ARDRAET p1369MHWVRQAPGQGLEWIVIGIINPSGGSTTYAQK EGSETYYYFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYC DSSGYYLLARDRAETEGSETYYYDSSGYYLLGYWGQGTLVT GY VSS COVD21_P1_HC_D3- 673QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY 674 ARSSVTG p1369MHWVRQAPGQGLEWIVIGIINPSGGSTSYAQKF TPPFDYQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA RSSVTGTPPFDYWGQGTLVTVSSCOVD21_P2_HC_G8- 677 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY 678 ARVPREG p1369MHWVRQAPGQGLEWMGIINPSGGSTSYAQKF TPGFDP QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARVPREGTPGFDPWGQGTLVTVSS COVD21_P1_HC_E4- 681QVQLVQSGAEVKKPGASVKVSCKAXGYTFTRX 682 LVGISTIV p1369HMQWVGQAPGQGLEWMGIINXSGGSTSYAQ VVRPAV KFQGRVTMARDTSTSSVXMELSSLRXRTRPCITWTS VLVGISTIVVVRPAVWTSGAKGPRSPXX COVD21_P1_HC_F12- 685QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA 686 ARVLYYY p1369ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ DSSGYPNGRVTITADESTSTAYMELSSLRSEDTAVYYCARV LEYFQH LYYYDSSGYPNLEYFQHWGQGTLVTVSSCOVD21_P2_HC_B3- 689 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA 690 ARGNRLL p1369ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ YCSSTSCYGRVTITADESTSTAYMELSSLRSEDTAVYYCARG LDAVRQGNRLLYCSSTSCYLDAVRQGYYYYYYMDVWGKG YYYYYYM TTVTVSS DV COVD21_P2_HC_B3- 693QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA 694 ARGNRLL p1369ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ YCSSTSCYGRVTITADESTSTAYMELSSLRSEDTAVYYCARG LDAVRQGNRLLYCSSTSCYLDAVRQGYYYYYYMDVWGKG YYYYYYM TTVTVSS DV COVD21_P3_HC_C11-697 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA 698 ARVGYYY p1369ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ DRSGFPRGRVTITADKSTSTAYMELSSLRSEDTAVCYCARV TEDYFDY GYYYDRSGFPRTEDYFDYWGQGTLVTVSSCOVD21_P1_HC_G6- 701 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA 702 ARDEGYC p1369ISWVRQAPGQGLEWMGGIIPIFYTANYAQKFQ SGGSCYGGRVTITADKSTSTAYMELSSLRSEDTAVYYCARD YYYGMD EGYCSGGSCYGYYYGMDVWGQGTTVTVSSV COVD21_P2_HC_B2- 705 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA 706 ARGNRLLp1369 ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ YCSSTSCYGRVTITADESTSTAYMELSSLRSEDTAVYYCARG LDAVRQGNRLLYCSSTSCYLDAVRQGYYYYYYMDVWGKG YYYYYYM TTVTVSS DV COVD21_P1_HC_D2- 709QVQLVESGGGLVKPGGSLRLSCAASGFIFSDYY 710 ARGLVYT p1369MSWIRQAPGKGLEWVSYISSSASTIYYADSVKG PYRFGYRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG LVYTPYRFGYWGQGTLVTVSS COVD21_P3_HC_B4-713 QVQLVESGGGLVKPGGSLRLSCAASGFTFIDYY 714 ARGRTW p1369MSWIRQAPGKGLEWVSYISSSGSTIYYADSVKG ELVDYRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG RTWELVDYWGQGTLVTVSS COVD21_P1_HC_A12-717 QVQLVESGGGLVKPGGSLRLSCAASGFTFIDYY 718 ARGKWL p1369MSWIRQAPGKGLEWVSYISSSGSTIYYADSVKG RGSFDYRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG RTWELVDYWGQGTLVTVSS COVD21_P2_HC_A10-721 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYD 722 ARVGYDS p1369MHWVRQATGKGLEWVSAIGTAGDTYYPGSVK SGYSGW GRFTISRENAKNSLYLQMNSLRAGDTAVYYCARYFDL VGYDSSGYSGWYFDLWGRGTLVTVSS COVD21_P3_HC_A2- 725EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYD 726 ARGGGET p1369MHWVRQATGKGLEWVSAIGTAGDTYYPDSVK ITTVFDYGRFTISRENAKNSLYLQMNSLRAGDTAVYYCAR GGGETITTVFDYWGQGTLVTVSSCOVD21_P2_HC_D3- 729 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYD 730 ARGSYSN p1369MHWVRQATGKGLEWVSIIGTAGDTYYPGSVK YVGYMD GRFTISRENAKNSLYLQMNSLRAGDTAVYYCARV GSYSNYVGYMDVWGKGTTVTVSS COVD21_P2_HC_D10- 733EVQLVESGGGLVKPGGSLRLSCAASGFTFSDAW 734 TTDQIYG p1369MSWVRQAPGKGLEWVGRLKSKTDGGTTDYAA DYLRMPVPVKGRFTISRDDSKNTLSLQMNSLKTEDTAVYYC PFDY TTDQIYGDYLRMPVPFDYWGQGTLVTVSSCOVD21_P3_HC_H6- 737 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW 738 TTGPQYD p1369MNWVRQAPGKGLEWIGRIKSNSDGGTTDYAA DNGYSYTPVQGRFTILRDDSKNTLYLQMTSLRTEDTAVYFC VDY TTGPQYDDNGYSYTVDYWGRGTLVTVSSCOVD21_P3_HC_D12- 741 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS 742 AREVKRVp1369 MNWVRQAPGKGLEWVSSISSSSSYIYYADSVKG VAAPEYYRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARE FDY VKRVVAAPEYYFDYWGQGXLVTVSSCOVD21_P3_HC_D11- 745 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS 746 AREVKRVp1369 MNWVRQAPGKGLEWVSSISSSSSYIYYADSVKG VAAPEYYRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARE FDY VKRVVAAPEYYFDYWGQGTLVTVSSCOVD21_P2_HC_C3- 749 EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYN 750 ARDRNRY p1369MNWVRQAPGKGLEWVSSITSSSSYIYYADSVK DFWSGYYGRFTISRDNAENSLYLQMNSLRAEDTAVYYCAR RLVGFDP DRNRYDFWSGYYRLVGFDPWGQGTLVTVSSCOVD21_P1_HC_F11- 753 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 754 AKVWSISp1369 MSWVRQAPGKGLEWVSGISDSGVSTYNADSV LDAFDIKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA KVWSISLDAFDIWGQGTMVTVSSCOVD21_P2_HC_C4- 757 EVQLLESGGGLVQPGGSLRLSCAASGFTFNSYA 758 AKDGGR p1369MSWVRQAPGKGLEWVSGISGSGDSTYYADSV QWLVELLKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCA DY KDGGRQWLVELLDYWGHGTLVTVSSCOVD21_P2_HC_G9- 761 EVQLLESGGGLVQPGGSLRLSCAASRFTFSNYA 762 AKDRAAA p1369MSWVRQAPGKGLEWVSTISGSGGSTYYADSVK HWATDYGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK DRAAAHWATDYWGQGTLVTVSSCOVD21_P1_HC_F7- 765 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 766 AKDDSSG p1369MSWVRQAPGKGLEWVSAISGSGGSTYYADSV YHYYFDYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA KDDSSGYHYYFDYWGQGTLVTVSSCOVD21_P1_HC_D1- 769 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 770 AKDSGTA p1369MSWVRQAPGKGLEWVSAISGSGDITYYADSVK MVEIFDYGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK DSGTAMVEIFDYWGQGTLVTVSSCOVD21_P3_HC_E1- 773 EVQLLESGGDLVQPGGSLRLSCAASGFTFSSYA 774 AKDLRST p1369MSWVRQAPGKGLEWVSAISGSGGSTYYADSV TFYVYYFKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAK DY DLRSTTFYVYYFDYWGQGTLVTVSSCOVD21_P2_HC_F8- 777 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 778 AKVPIHY p1369MSWVRQAPGKGLEWVSAISGSGGTTYYADSV CSNGVCYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY KVPIHYCSNGVCYFDYWGQGTLVTVSSCOVD21_P3_HC_D4- 781 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 782 AKVVGSG p1369MSWVRQAPGKGLEWVSAISGSGDSTYFADSVK TPPDYYYGRFTISRDNSKNTLYLHMNSLRAEDTAVYYCAK YYYMDV VVGSGTPPDYYYYYYMDVWGKGTTVTVSSCOVD21_P1_HC_D4- 785 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYG 786 ARATCSG p1369MHWVRQAPGKGLEWVAVISYDGSNKYFADSV GSCLFGQKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA NAFDI RATCSGGSCLFGQNAFDIWGQGTMVTVSSCOVD21_P1_HC_G9- 789 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 790 ARDYGSS p1369MHWVRQAPGKGLEWVAVISYDGSSKFYADSV WYQVPD KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAY RDYGSSWYQVPDYWGQGTLVTVSS COVD21_P2_HC_H9- 793QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 794 AREFGDP p1369MHWVRQAPGKGLEWVTVISYDGRNKYYADSV EWYFDY KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREFGDPEWYFDYWGQGTLVTVSS COVD21_P1_HC_G8- 797QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 798 AKNQNSY p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV GYLSYFDKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA Y KNQNSYGYLSYFDYWGQGTLVTVSSCOVD21_P1_HC_E12- 801 QVQLVESGGGVVQPGRSLRLSCAASGFTFRRYG 802 AKASGEYp1369 IHWVRQAPGKGLEWVAVISYDGSNKYYADSVK CGGGSCYGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK RGVFDY ASGEYCGGGSCYRGVFDYWGQGTLVTVSSCOVD21_P3_HC_H4- 805 QVQLVESGGGVVQPGRSLRLSCATSGFTFSSYG 806 AKVMGP p1369LHWVRQAPGKGLEWVALISYDGSDKYYADSVK YCSGGSCGRFTISRDTSKNTLFLQMNSLRAEDTAVYYCAKV YSGYFDY MGPYCSGGSCYSGYFDYWGQGTLVTVSSCOVD21_P1_HC_C4- 809 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 810 AKAGGPY p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV CSGGSCYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA SSYFDY KAGGPYCSGGSCYSSYFDYWGQGTLVTVSSCOVD21_P1_HC_G2- 813 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 814 ARDCGG p1369MHWVRQAPGKGLEWVAVISYDGSNKYSADSV DCYPTTDKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA AFDI RDCGGDCYPTTDAFDIWGQGTMVTVSSCOVD21_P2_HC_H10- 817 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 818 ARDHDY p1369MHWVRQAPGKGLEWVAVISYDGSSKYYADSV GEIVDAFKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA DI RDHDYGEIVDAFDIWGQGTMVTVSSCOVD21_P1_HC_B1- 821 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 822 ARDSEDC p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV SSTSCYLDKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA Y RDSEDCSSTSCYLDYWGQGTLVTVSSCOVD21_P3_HC_E6- 825 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYV 826 ARGPGW p1369MNWVRQAPGKGLAWVAVISFDGSNKYYADSV QWPELD KGRFTVSRDNSKNTLYLQMNSLRAEDTALYYCAY RGPGWQWPELDYWGQGTLVTVSS COVD21_P3_HC_A5- 829QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 830 ATEDYYD p1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV SSGSFDYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA TEDYYDSSGSFDYWGQGTLVTVSSCOVD21_P3_HC_C12- 833 QVQLVESGGGVVQPERSLRLSCAASGFTFSSYA 834 ARSKSYTSp1369 MHWVRQAPGKGLEWVAVISYDGSNKYYADSV WGYYHMKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA DV RSKSYTSWGYYHMDVW COVD21_P1_HC_D8-837 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 838 ARDGTSI p1369IHWVRQAPGKGLEWVAVIWYDGSNKYYADSV TLITEGDAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDI RDGTSITLITEGDAFDIWGQGTMVTVSSCOVD21_P2_HC_B11- 841 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 842 ARDPSVVp1369 MHWVRQAPGKGLEWVAVIWHDGSNKYYADS VTAIDFDVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYC Y ARDPSVWTAIDFDYWGQGTLVTVSSCOVD21_P2_HC_C9- 845 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 846 AREHTPT p1369MHWVRQAPGKGLEWVAVIWYDGSNKYYADS DIVVVNV VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCEY AREHTPTDIVVVNVEYWGQGTLVTVSS COVD21_P3_HC_H8- 849QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYC 850 AREKDIV p1369MHWVRQAPGKGLEWVAVIWYDGNNKYYADS ATDFDY VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREKDIVATDFDYWGQGTLVTVSS COVD21_P1_HC_E10- 853QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 854 AREYFYD p1369IHWVRQAPGKGLEWVAVIWYDGSNKYYADSV SSDYYFEYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA YFDY REYFYDSSDYYFEYYFDYWGQGTLVTVSSCOVD21_P1_HC_A4- 857 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 858 ARDHSLG p1369MHWVRQAPGKGLEWVAVIWYDGSNKYYADS VRGDGY VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCGMDV ARDHSLGVRGDGYGMDVWGQGTTVTVSS COVD21_P1_HC_G11- 861QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 862 ARDGAV p1369MHWVRQAPGKGLEWVAVIWYDGSNKYYADS VRFLEWP VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTVGYYYY ARDGAVVRFLEWPTVGYYYYYMDVWGKGTTV YMDV TVSS COVD21_P3_HC_G10- 865QVQLVESGGGVVQPGRSLRLSCAASGFTFTSYG 866 ARDMMI p1369MHWVRQAPGKGLEWVAVIWYDGSNKYYADS RGVAWY VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCYYMDV ARDMMIRGVAWYYYMDVWGKGTTVTVSS COVD21_P2_HC_H2- 869EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYS 870 ARDSGG p1369MNWVRQAPGKGLEWVSYISSSSSTIYYADSVK DIVVIPAVGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR NGFDY DSGGDIVVIPAVNGFDYWGQGTLVTCOVD21_P2_HC_A8- 873 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYS 874 AREAHD p1369MNWVRQAPGKGLEWVSYISSSSSTIYYADSVK GALTDYGGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR DYLNWF EAHDGALTDYGDYLNWFDPWGQGTLVTVSSDP COVD21_P1_HC_A3- 877 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 878 ARDLYSSp1369 MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK GGTDIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DLYSSGGTDIWGQGTMVTVSS COVD21_P3_HC_G1-881 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 882 ARDLYSS p1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK GGTDI GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLYSSGGTDIWGQGTMVTVSS COVD21_P1_HC_A2- 885EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 886 ARGYGDY p1369MTWVRQAPGKGLEWVSLIYSGGSTFYADSVKG YFDY RFTISRDSSKNTLYLQMNSLRAEDTAVYYCARGYGDYYFDYWGQGTLVTVSS COVD21_P2_HC_F7- 889EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 890 ARDYGDF p1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK YFDY GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGDFYFDYWGQGTLVTVSS COVD21_P1_HC_C8- 893EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 894 ARDWGD p1369MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG YYFDY RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDWGDYYFDYWGQGTLVTVSS COVD21_P1_HC_A10- 897EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 898 ARDYGDF p1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK YFDY GRFTISRDNSKNTLYLQMNSLRAGDTAVYYCARDYGDFYFDYWGQGTLVTVSS COVD21_P1_HC_B12- 901EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 902 ARDLSVF p1369MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG GMDV RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLSVFGMDVWGQGTTVTVSS COVD21_P3_HC_C9- 905EVQLVESGGGLIQPGGSLRVSCAASGFTVSSNY 906 ARDLGER p1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK GMDV GRFTISRDNSKNTLSLQMNSLRAEDTAVYYCARDLGERGMDVWGQGTTVTVSS COVD21_P1_HC_H7- 909EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 910 ARYCSGG p1369MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV SCHPPGQKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA WLSDAF RYCSGGSCHPPGQWLSDAFDIWGQGTMVTVSDI S COVD21_P1_HC_F1- 913 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 914 ARLRWLRp1369 MSWVRQAPGKGLEWVTNIKLDGSEKYYVDSVK ADFDYGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR LRWLRADFDYWGQGTLVTVSSCOVD21_P1_HC_C10- 917 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 918 ARYYDILTp1369 MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV GYYVDYYKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA YMDV RYYDILTGYYVDYYYMDVWGXGTTVTVSSCOVD21_P3_HC_H10- 921 EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH 922 TRDDSS p1369WMHWVRQAPGKGLVWVSRINSDGSRRAYAT WPHFFD SVKGRFTISRDNAKNTLYLQMDSLRDEDTAVYYN CTRDDSSWPHFFDNWGQGTLVTVSS COVD21_P2_HC_D8- 925EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 926 ARAWAM p1369MHWVRQAPGKGLVWVSRINSDGSSTSYADSV RQTTLTPKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA EWIDY RAWAMRQTTLTPEWIDYWGQGTLVTVSSCOVD21_P2_HC_D9- 929 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 930 ARAWAM p1369MHWVRQAPGKGLVWVSRINSDGSSTSYADSV RQTTLTPKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA EWIDY RAWAMRQTTLTPEWIDYWGQGTLVTVSSCOVD21_P3_HC_G3- 933 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 934 AKGGEGF p1369MHWVRQAPGKGLEWVSGVTWNSGSIGYADS RNWNDG VKGRFIISRDNAKNSLYLQMNSLRAEDTALYYCALDYFDY KGGEGFRNWNDGLDYFDYWGQGTLVTVSS COVD21_P1_HC_A5- 937EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 938 AKDGRSG p1369MHWVRQAPGKGLEWVSGISWNSGTIGYADSV DQWPEL KGRFTISRDNAKNSLHLHMRSLRAEDTALYYCAYYFDY KDGRSGDQWPELYYFDYWGQGTLVTVSS COVD21_P2_HC_E10- 941EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 942 AKAGVR p1369MHWVRQAPGKGLEWVSGISWNSGTIGYADSV GIAAAGPKGRFTISRDNAKNSLYLQMNSLRAEDTAFYYCA DLNFDH KAGVRGIAAAGPDLNFDHWGQGTLVTVSSCOVD21_P3_HC_F9- 945 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 946 AKGSSSS p1369MHWVRQAPGKGLEWVSGITWNSGSIAYADSV YHNWFD KGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAP KGSSSSYHNWFDPWGQGTLVTVSS COVD21_P1_HC_D6- 949EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 950 AKDGAG p1369MHWVRQAPGKGLEWVSGISWNSVSIDYADSV TENWFD KGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAP KDGAGTENWFDPWGQGTLVTVSS COVD21_P2_HC_G3- 953EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 954 AKDMLG p1369MHWVRQAPGKGLEWVSGISWNSGSIGYAHSV NYYYYAMKGRFTISRDNAKNSLYLHMNSLRAEDTALYYCA VV KDMLGNYYYYAMVVWGQGTTVTVSSCOVD21_P1_HC_E6- 957 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY 958 ARTMYYYp1369 YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS DSSGSFDRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTM Y YYYDSSGSFDYWGQGTLVTVSSCOVD21_P1_HC_G1- 961 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY 962 ASGELSAp1369 YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLES FGELFPHRVTISVDTSKNQFSLKLSSVTAADTAVYYCASGE DY LSAFGELFPHDYWGXGTLVTVSSCOVD21_P3_HC_G7- 965 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY 966 ARVHVVRp1369 YWSWIRQHPGKGLEWIGYIYYSGSPYYNPSLKS GVANYPYRVTISIDTSKNQFSLKLSSVTAADTAVYYCARVH FDY VVRGVANYPYFDYWGQGTLVTVSSCOVD21_P1_HC_D5- 969 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY 970 ARGSYSNp1369 YWGWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS YNGGLDYRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGS YSNYNGGLDYWGQGTLVTVSSCOVD21_P2_HC_A9- 973 QVQLQESGPGLVKPSQTLSLTCTVSGGSFSSGG 974 ARVATDY p1369YYWHWIRQHPGKGLEWIGYIYYSGSTYYNPSLK GDSFDYSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARV ATDYGDSFDYWGQGTLVTVSSCOVD21_P3_HC_A8- 977 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 978 ARAPPGDp1369 SWIRQPAGKGLEWIGRIYTSGSTKYNPSLKSRVT FYDSSGYMSVDTSKNQFSLKLSSVTAADTAVYYCARAPPG FSAFDI DFYDSSGYFSAFDIWGQGTMVTVSSCOVD21_P1_HC_B6- 981 QVQLQESGPGLVKPSETLSLTCTVSGGSISAYYW 982 ARDNGY p1369SWIRQPAGKGLEWIGRIYTSGSTIYNPSLKSRVT VWGSYRMSVDTSKNQFSLKLSSVTAADTAVYYCARDNGY PDAFDI VWGSYRPDAFDIWGQGTMVTVSSCOVD21_P1_HC_B6- 985 QVQLQESGPGLVKPSETLSLTCTVSGGSISAYYW 986 ARDNGY p1369SWIRQPAGKGLEWIGRIYTSGSTIYNPSLKSRVT VWGSYRMSVDTSKNQFSLKLSSVTAADTAVYYCARDNGY PDAFDI VWGSYRPDAFDIWGQGTMVTVSSCOVD21_P2_HC_D4- 989 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 990 ARVVGYSp1369 SWIRQPAGKGLEWIGRIYTSGSTNYNPSLESRVT SRGANYYMSVDTSKNQFSLKLSSVTAADTAVYYCARVVGY MDV SSRGANYYMDVWGKGTTVTVSSCOVD21_P1_HC_H5- 993 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 994 ARVPSVGp1369 SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT DCSSTSCLISVDTSKNQFSLKLSSVTAADTAVYYCARVPSVG YWYFDL DCSSTSCLYWYFDLWGRGTLVTVSSCOVD21_P2_HC_F4- 997 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 998 ARYGMG p1369SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT ELLTLRSEISVDTSKNQFSLKLSSVTAADTAVYYCARYGMG YYFDY ELLTLRSEYYFDYWGQGTLVTVSSCOVD21_P3_HC_C4- 1001 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 1002 ARSYDSSp1369 SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT GLSYNWFISVDTSKNQFSLKLSSVTAADTAVYYCARSYDSS DP GLSYNWFDPWGQGTLVTVSSCOVD21_P2_HC_E2- 1005 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 1006 ARGGYYYp1369 SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT DSSGYEYISVDTSKNQFSLKLSSVTAADTAVYYCARGGYYY YYYYGM DSSGYEYYYYYGMDVWGQGTTVTVSS DVCOVD21_P1_HC_C5- 1009 QVQLQESGPGLVKPSETLSLTCAVSGGSVSSGN 1010 ARETYYYp1369 YYWNWIRQPPGKGLEWIGYIYYSGSTNYNPSLK DSSGYYISSRVTISVDTSKNQFSLKLNSVTAADTAVYHCARE DAFDI TYYYDSSGYYISDAFDIWGQGTMVTVSSCOVD21_P2_HC_H4- 1013 EVQLVQSGAEVKKPGESLKISCKGSGYSFSSYCIG 1014 ARQWRGp1369 WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG YYDRSGYQVTISVDKSISTAYLQWSSLKASDTAMYYCARQ YHFDAFD WRGYYDRSGYYHFDAFDIWGQGTMVTVSSI COVD21_P1_HC_C6- 1017 EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYCIG 1018 ARHWYYp1369 WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG GDYGNYSQVTISADKSISTAYLQWSSLKASDTAMYYCARH YYYLDV WYYGDYGNYSYYYLDVWGKGTTVTVSS SEQSEQ ID ID SEQUENCE_ID NOS aa NOS cdr3_aa KAPPA COVD21_P1_K_A4- 503DIQMTQSPSSLSASVGDRVTITCRASQSI 504 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSGYST VPSRFSGSGSGTDFTLTISSLQPEDFATY PRT YCQQSYSTPRTFGQGTKVEIKCOVD21_P1_K_B5- 507 DIQMTQSPSSLSASVGDRVTITCRASQSI 508 QQS p1389SSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PRTYCQQSYSTPRTFGQGTKVEIK COVD21_P1_K_C12- 511 DIQMTQSPSSLSASVGDRVTITCRASQSI512 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATY PRT YCQQSYSTPRTFGQGTKVEIK COVD21_P1_K_E4-515 DIQMTQSPSSLSASVGDRVTITCRASQSI 516 QQS p1389SSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PRTYCQQSYSTPRTFGQGTKVEIK COVD21_P1_K_F1- 519 DIQMTQSPSSLSASVGDRVTITCRASQSI520 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATY PRT YCQQSYSTPRTFGQGTKVEIK COVD21_P2_K_B7-523 DIQMTQSPSSLSASVGDRVTITCRASQSI 524 QQS p1389SSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PRTYCQQSYSTPRTFGQGTKVEIK COVD21_P2_K_B9- 527 DIQMTQSPXSLSASVGDRVTITCRASQS528 QQS p1389 ISSYLNWYQQKPGKAPKLLIYAASSLQS YSTGVPSRFSGSGSGTDFTLTISSLQPEDFAT PRT YYCQQSYSTPRTFGQGTKVEIK COVD21_P2_K_E1-531 DIQMTQSPSSLSASVGDRVTITCRASQSI 532 QQS p1389SSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PRTYCQQSYSTPRTFGQGTKVEIK COVD21_P2_K_E11- 535 DIQMTQSPSSLSASVGDRVTITCRASQSI536 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATY PRT YCQQSYSTPRTFGQGTKVEIK COVD21_P2_K_F6-539 DIQMTQSPSSLSASVGDRVTITCRASQSI 540 QQS p1389SSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PRTYCQQSYSTPRTFGQGTKVEIK COVD21_P3_K_A6- 543 DIQMTQSPSSLSASVGDRVTITCRASQSI544 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATY PRT YCQQSYSTPRTFGQGTKVEIK COVD21_P3_K_B12-547 DIQMTQSPSSLSASVGDRVTITCRASQSI 548 QQS p1389SSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PRTYCQQSYSTPRTFGQGTKVEIK COVD21_P3_K_B12- 551 DIQMTQSPSSLSASVGDRVTITCRASQSI552 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATY PRT YCQQSYSTPRTFGQGTKVEIK COVD21_P1_K_C8-555 DIQMTQSPSSLSASVGDRVTITCQASQD 556 QQY p1389ISNYLNWYQQKPGKAPKLLIYDASNLET DNL GVPSRFSGSGSGTDFTFTISSLQPEDIAT PITYYCQQYDNLPITFGQGTRLEIK COVD21_P1_K_F12- 559 DIQMTQSPSSLSASVGDRVTITCQASQD560 QQY p1389 ISNYLNWYQQKPGKAPKLLIYDASNLET DNLGVPSRFSGSGSGTDFTFTISSLQPEDIAT PIT YYCQQYDNLPITFGQGTRLEIK COVD21_P2_K_H9-563 DIQMTQSPSSLSASVGDRVTITCQASQD 564 QQY p1389ISNYLNWYQQKPGKAPKLLIYDASNLET DNL GVPSRFSGSGSGTDFTFTISSLQPEDIAT PITYYCQQYDNLPITFGQGTRLEIK LAMBDA COVD21_P2_L_E5- 567QSVLTQPPSASGTPGQRVTVSCSGSSSN 568 AA p1409 IGSNTVNWYQQLPGTAPKLLIYSNNQR WDPSGVPDRFSGSKSGTSASLAISGLQSEDE DSL ADYFCAAWDDSLNGPVFGGGTKLTVX NGP VCOVD21_P2_L_F8- 571 QSVLTQPPSASGTPGQRVTVSCSGSSSN 572 AA p1409IGSNTVNWYQQLPGTAPKLLIHSNNQR WD PSGVPDRFSGSKSGTSASLAISGLQSEDE DSLADYYCAAWDDSLNGPVFGGGTKLTVL NGP V COVD21_P2_L_G5- 575QSVLTQPPSASGTPGQRVTVSCSGSSSN 576 AA p1409 IGSNTINWYQQLPGTAPKLLIYSNNQRPWD SGVPDRFSGSKSGTSASLAISGLQSEDEA DSL NYYCAAWDDSLNGPVFGGGTKLTVL NGP VKAPPA COVD21_P1_K_A11- 579 DIQMTQSPSSLSASVGDRVTITCRASQSI 580 QQS p1389SSYLNWYHQKPGKAPKLLIYTASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PPYCQQSYSTPPWTFGQGTKVEIK WT COVD21_P1_K_D1- 583DIQMTQSPSSLSASVGDRVTITCRASQSI 584 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSGYNT VPSRFSGSGSGTDFTLTISSLQPEDFATY PP FCQQSYNTPPWTFGQGTKVEIK WTCOVD21_P1_K_H7- 587 DIQMTQSPSSLSASVGDRVTITCRASQSI 588 QQS p1389STYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PPYCQQSYSTPPWTFGQGTKVEIK WT LAMBDA COVD21_P2_L_B5- 591QSVLTQPPSASGSPGQSVTISCTGTSSD 592 SSD p1409 VGGYNYVSWYQQHPGKAPKLMIYEVSAGS KRPSGVPDRFSGSKSGNTASLTVSGLQA NNV EDEADYYCSSDAGSNNVVFGGGTKLTV V LCOVD21_P3_L_B5- 595 QSALTQPPSASGSPGQSVTISCTGTSSD 596 SSD p1409VGGYNYVSWYQQHPGKAPKLMIYEVS AGS KRPSGVPDRFSGSKSGNTASLTVSGLQA NNVEDEAEYYCSSDAGSNNVVFGGGTKLTVL V KAPPA COVD21_P1_K_F9- 599EIVLTQSPGTLSLSPGERATLSCRASQSV 600 QQY p1389 RSSYLAWYQQKPGQAPRLLIYGASSRATGSS GIPDRFSGSGSGTDFTLTISRLEPEDFAV PW YYCQQYGSSPWTFGQGTKVEIK TCOVD21_P2_K_F10- 603 EIVLTQSPXSLSLSPGERATLSCRASQSVS 604 QQY p1389SSYLAWYQQKPGQAPRLLIYGASSRATG GSS IPDRFSGSGSGTDFTLTISRLEPEDFAVYY PWCQQYGSSPWTFGQGTKVEIK T COVD21_P1_K_E9- 607 DIVMTQSPLSLPVXPGEPASISCRSSQSL608 MQ p1389 LHSNGFHFLEWYLQKPGQSPQLLIYSGS GLQNRASGVPDRFSGSGSGTHFTLKISRVEA TPL EDVGVYYCMQGLQTPLTFGGGTKVEIK TCOVD21_P1_K_G2- 611 DIVMTQSPLSLPVTPGEPASISCRSSQSL 612 MQ p1389LHSNGFHFLDWYLQKPGQTPQLLIYVG ALQ SNRASGVPDRFSGSGSGTDFTLKISRVE TPLAEDVGVYYCMQALQTPLTFGGGTKVEI T K COVD21_P1_K_G4- 615DIQMTQSPSTLSASVGDRVTITCRASQSI 616 QQY p1389 SSWLAWYQQKPGKAPKLLIYKASSLESGNSY VPSRFSGSGSGTEFTLTISSLQPDDFATY ST YCQQYNSYSTFGQGTKVEIKCOVD21_P2_K_B2- 619 DIQMTQSPSTLSASVGDRVTITCRASQSI 620 QQY p1389SSWLAWYQQKPGKAPKLLIYKASSLESG NSY VPSRFSGSGSGTEFTLTISSLQPDDFATY STYCQQYNSYSTFGQGTKVEIK LAMBDA COVD21_P1_L_F2- 623QSVLTQPASVSGSPGQSITISCTGTSSGV 624 SSY p1409 GGYNFVSWYQQHPGKAPKLMIYDVSNTSR RPSGVSNRFSGSKSGNTASLTISGLQAE STL DEADYHCSSYTSRSTLGVFGGGTKLTVL GVCOVD21_P2_L_E2- 627 QSVLTQPASVSGSPGQSITISCTGTSSDV 628 SSY p1409GGYNYVSWYQQHPGKAPKLMIYDVSN TSSS RPSGVSNRFSGSKSGNTASLTISGLQAE TVVDEADYYCSSYTSSSTVVFGGGTKLTVL KAPPA COVD21_P1_K_B10- 631DIQMTQSPSTLSASVGDSVTITCRASQSI 632 QQY p1389 SSWLAWYQQKPGKAPKLLIYKASSLESGNNY VPSRFSGSGSGTEFTLTISSLQPDDFATY RYT YCQQYNNYRYTFGQGTKLEIKCOVD21_P1_K_H11- 635 DIQMTQSPSTLSASVGDRVTITCRASQSI 636 QKY p1389SSWLAWYQQKPGKAPKLLIYKASSLESG NSY VPSRFSGSGSGTEFTLTISSLQPDDFATY RYTYCQKYNSYRYTFGQGTKLEIK LAMBDA COVD21_P3_L_E4- 639QSVLTQPASVSGSPGQSITISCTGTSSDI 640 SSY p1409 GVYNYISWSQQHPGKAPKVMIYDVTNRGS RPSGVSNRFSGSKSGNTASLTISGLQAE STP DEADYYCSSYRGSSTPYVFGTGTKVTVL YVCOVD21_P1_L_G7- 643 SYVLTQPPSVSVAPGKTARITCGGNSIGS 644 QV p1409KSVHWYQQKPGQAPVLVIYYDSDRPSG WD IPERFSGSNSGNTATLTISRVEAGDEADF SGHCQVWDSGWVFGGGTKLTVL WV COVD21_P2_L_D10- 647QSVLTQPASESGSPGQSITISCTGTSSDV 648 CSY p1409 GTYNLVSWYQQHPGKAPKLMIYEGSKRAAS PSGVSNRFSGSKSGNTASLTISGLQAED STY EADYYCCSYAASSTYVFGTGTKVTVL VCOVD21_P2_L_C7- 651 QSALTQPASESGSPGQSITISCTGTSSDV 652 CSY p1409GSYNLVSWYQQHPGKAPKLMIYEGSKR AGS PSGVSNRFSGSKSGNTASLTISGLQAED NTEADYYCCSYAGSNTWVFGGGTKLTVL WV COVD21_P1_L_B12- 655QSVLTQPASVSGSPGQSITISCTGTSSDV 656 CSY p1409 GSYNLVSWYQQHPGKAPKLMIYEVSKRAGS PSGVSNRFSGSKSGNTASLTISGLQAED SIVV EADYYCCSYAGSSIVVFGGGTKLTVLCOVD21_P2_L_F4- 659 QSALTQPASVSGSPGQSITISCTGTSSDV 660 SSY p1409GGYNYVSWYQQHPGKAPKLMIYDVSN TSSS RPSGVSNRFSGSKSGNTASLTISGLQAE TVDEADYYCSSYTSSSTVFGTGTKVTVL COVD21_P2_L_D7- 663QSVLTQPASVSGSPGQSITISCTGTNSD 664 SSY p1409 VGGYNYVSWYQQHPGKAPKLMIYDVGTSSS NRPSGVSNRFSGSKSGNTASLTISGLQA TLV EDEADYYCSSYTSSSTLVFGGGTKLTVLCOVD21_P2_L_C1- 667 QSVLTQPASVSGSPGQSITISCTGTSSDV 668 SSY p1409GGYNYVSWYQQHPGKAPKLMIYDVSN TSSS RPSGVSNRFSGSKSGNTASLTISGLQAE TYVDEADYYCSSYTSSSTYVFGTGTKVTVL KAPPA COVD21_P1_K_G5- 671DIQMTQSPSSLSASVGDRVTITCRASQSI 672 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSGYST VPSRFSGSGSGTDFTLTISSLQPEDFATY PPS YCQQSYSTPPSFGQGTKVEIK LAMBDACOVD21_P2_L_D3- 675 SYVLTQPPSVSVAPGKTARITCGGNNIG 676 QV p1409SKSVHWYQQKPGQAPVLVIYYDSDRPS WD GIPERFSGSNSGNTAILTISRVEAGDEAD SSSYYCQVWDSSSDHVVFGGGTKLTVL DHV V COVD21_P1_L_G8- 679SYVLTQPPSVSVAPGKTARITCGENNIGS 680 QV p1409 KSVHWYQQKPGQAPVLVIYYDSDRPSGWD IPERFSGSNSGNTATLTINRVEAGDEAD SSS YYCQVWDSSSDHVVFGGGTKLTVL DHV VCOVD21_P2_L_E4- 683 QSVLTQPSSHSASSGASVRLTCMLSSGF 684 GT p1409SVGDFWIRWYQQKPGNPPRYLLYYHSD WH SNKGQGSGVPSRFSGSNDASANAGILRI SNSSGLQPEDEADYYCGTWHSNSRVFGGG RV TKLTVL KAPPA COVD21_P2_K_F12- 687DIQMTQSPSSLSASVGDRVTITCQASQD 688 QQY p1389 ISNYLNWYQQKPGKAPKLLIYDASNLEADNL GVPSRFSGSGSGTDFTFTISSLQPEDIAT PSF YYCQQYDNLPSFTFGPGTXVDIK TCOVD21_P1_L_B3- 691 QSVLTQPPSASGTPGQRVTISCSGSSSNI 692 AS p1409GSNSVNWFQQLPGTAPKLLIYSNNQRP WD SGVPDRFSGSKSGASASLAISGLQSEDE DSLADYYCASWDDSLNGPLFGGGTKLTVL NGP L COVD21_P1_L_B3- 695QSVLTQPPSASGTPGQRVTISCSGSSSNI 696 AS p1409 GSNSVNWFQQLPGTAPKLLIYSNNQRPWD SGVPDRFSGSKSGASASLAISGLQSEDE DSL ADYYCASWDDSLNGPLFGGGTKLTVL NGP LCOVD21_P3_L_C11- 699 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 700 QSY p1409GAGYDVHWYQQLPGTAPKLLIYGNSNR DSS PSGVPDRFSGSKSGTSASLAITGLQAED LSGEADYYCQSYDSSLSGVVFGGGTKLTVL VV COVD21_P2_K_G6- 703DIQMTQSPSSLSASVGDRVTITCQASQD 704 QQY p1389 ISNYLNWYQQKPGKAPKLLIYDASNLETDNL GVPSRFSGSGSGTDFTFTISSLQPEDIAT PMY YYCQQYDNLPMYTFGQGTKLEIK TCOVD21_P1_K_B2- 707 EIVLTQSPATLSLSPGERATLSCRASQSV 708 QQ p1389SSYLAWYQQKPGQAPRLLIYDASNRAT RSN GIPARFSGSGSGTDFTLTISSLEPEDFAVY WPLYCQQRSNWPLTFGGGTKVEIK T COVD21_P2_K_D2- 711 DIQMTQSPSSLSASVGDRVTITCQASQD712 QQ p1389 ISNYLNWYQQKPGKAPKLLIYDASNLET HDGVPSRFSGSGSGTDFTFTISSLQPEDIAT NVV YYCQQHDNVVTFGPGTKVEIK T LAMBDACOVD21_P3_L_B4- 715 QSVLTQPASVSGSPGQSITISCTGTSSDI 716 SSY p1409GVYNYISWSQQHPGKAPKVMIYDVTN RGS RPSGVSNRFSGSKSGNTASLTISGLQAE STPDEADYYCSSYRGSSTPYVFGTGTKVTVL YV COVD21_P2_L_A12- 719NFMLTQPHSVSESPGKTVTISCTGSSGSI 720 QSY p1409 ASNYVQWYQQRPGSAPTTVIYEDNQRDSS PSGVPDRFSGSIDSSSNSASLTISGLKTED NH EADYYCQSYDSSNHWVFGGGTKLTVL WVKAPPA COVD21_P1_K_A10- 723 DIQMTQSPSSLSASVGDRVTITCRASQSI 724 QQS p1389SSYLNWYQQKPGKAPKVLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PPLYCQQSYSTPPLTFGGGTKVEIK T LAMBDA COVD21_P3_L_A2- 727QSVLTQPASVSGSPGQSITISCTGTSSDI 728 SSY p1409 GVYNYISWSQQHPGKAPKVMIYDVTNRGS RPSGVSNRFSGSKSGNTASLTISGLQAE STP DEADYYCSSYRGSSTPYVFGTGTKVTVL YVKAPPA COVD21_P1_K_D3- 731 DIQMTQSPSSLSASVGDRVTITCRASQSI 732 QQS p1389SSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY PGLYCQQSYSTPGLTFGGGTKVEIK T LAMBDA COVD21_P1_L_D10- 735QSVLTQPPSASGTPGQRVTISCSGSSSNI 736 AT p1409 GSNYVYWYQQLPGTAPKLLIYRNNQRPWD SGVPDRFSGSKSGTSASLAISGLRSEDEA DSL DYYCATWDDSLSGPVFGGGTKLTVL SGP VCOVD21_P3_L_H6- 739 QSALTQPASVSGSPGQSITISCTGTSSDI 740 SSY p1409GVYNYISWSQQHPGKAPKVMIYDVTN RGS RPSGVSNRFSGSKSGNTASLTISGLQAE STPDEADYYCSSYRGSSTPYVFGTGTKVTVL YV COVD21_P3_L_D12- 743QSVLTQPPSASGTPGQRVTISCSGISSNL 744 AE p1409 GSNTVNWFQQLPGTAPKLLIYNSNRRPWD SGVPDRFSGSKSGTSASLAISGLQSEDEG DSL DYYCAEWDDSLSTWVFGGGTHLTVL STW VCOVD21_P3_L_D11- 747 QSVLTQPASVSGSPGQSITISCTGTSSDI 748 SSY p1409GVYNYISWSQQHPGKAPKVMIYDVTN RGS RPSGVSNRFSGSKSGNTASLTISGLQAE STPDEADYYCSSYRGSSTPYVFGTGTKVTVL YV COVD21_P1_L_C3- 751QSVLTQPPSASGSPGQSVTISCTGTSSD 752 SSY p1409 VGGYKYVSWYQQHPGKAPKLMIYEVSKAGS RPSGVPDRFSGSKSGNTASLTVSGLQAE NN DEADYYCSSYAGSNNHVFGGGTKLTVL HVCOVD21_P2_L_F11- 755 SYVLTQPPSVSVAPGKTARITCGGNNIG 756 QV p1409SKSVHWYQQKPGQAPVLVIYYDSDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEA SSSDYYCQVWDSSSDLFGGGTKLTVL DL KAPPA COVD21_P1_K_C4- 759DIQMTQSPSSLSASVGDRVTITCRASQSI 760 QQS p1389 ASYLNWFQQKPGKAPKLLIYAASSLQSGYSS VPSRFSGSGSGTDFTLTISSLQPEDFATY PPT CCQQSYSSPPTFGQGTKLEIKCOVD21_P1_K_G9- 763 DIQMTQSPXXLSASVGDRVTITCQASQ 764 QQY p1389DISNYLNWYQQKPGKAPKLLIYDASNLE DNR TGVPSRFSGSGSGTDFTFTISSLQPEDIA LFTTYYCQQYDNRLFTFGPGTKVDIK COVD21_P2_K_F7- 767DIQMTQSPSSLSASVGDRVTITCRASQSI 768 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSGYNT VPSRFSGSGSGTDFTLTISSLQPEDFATY PPIT YCQQSYNTPPITFGPGTKVDIKCOVD21_P2_K_D1- 771 DIQMTQSPXSLSASVGDRVTITCRASQS 772 QQS p1389ISSYLNWYQQKPGKAPKLLIYAASSLQS YSS GVPSRFSGSGSGTDFTLTISSLQPEDFAT TLTYFCQQSYSSTLTFGGGTKVEIK LAMBDA COVD21_P3_L_E1- 775QSALTQPASVSGSPGQSITISCTGTSSDV 776 SSY p1409 GGYNYVSWYRQHPGKAPKLMIYDVSNTSSS RPSGVSNRFSGSKSGNTASLTISGLQAE TPD DEADYYCSSYTSSSTPDVFGSGTKVTVL VCOVD21_P1_L_F8- 779 NFMLTQPHSVSESPGKTVTISCTGSSGSI 780 QSY p1409ASNYVQWYQQRPGSAPTTVIYEDNQR DSS PSGVPDRFSGSIDSSSNSASLTISGLKTED NREADYYCQSYDSSNRWVFGGGTKLTVL WV COVD21_P3_L_D4- 783QSALTQPASVSGSPGQSITISCTGTSSDI 784 SSY p1409 GVYNYISWSQQHPGKAPKVMIYDVTNRGS RPSGVSNRFSGSKSGNTASLTISGLQAE STP DEADYYCSSYRGSSTPYVFGTGTKVTVL YVKAPPA COVD21_P2_K_D4- 787 DVVMTQSPLSLPVTLGQPASISCRSSQS 788 MQ p1389LVYSDGNTYLNWFQQRPGQSPRRLIYK GTH VSNRDSGVPDRFSGSGSGTDFTLKISRV WPEAEDVGVYYCMQGTHWPPYTFGQGTK PYT LEIK COVD21_P2_K_G9- 791DIQMTQSPSSLSASVGDRVTITCRASQSI 792 QQS p1389 SSYLNWYQQKPGKAPKLLIYAASSLQSGYST VPSRFSGSRSGTDFTLTISSLQPEDFATY PPL YCQQSYSTPPLTFGGGTKVEIK TCOVD21_P1_K_H9- 795 DIQMTQSPSTLSASVGDRVTITCRANQS 796 QQY p1389ISSWLAWYQQKPGKAPKLLIYKASSLES NSY GVPSRFSGSGSGTEFTLTISSLQPDDFAT WTYYCQQYNSYWTFGQGTKVEIK COVD21_P2_K_G8- 799 DIQMTQSPSSLSASVGDRVTITCQASQD800 QQY p1389 INNYLNWYQQKPGKAPKLLIYDASNLET DNLGVPSRFSGSGSGTDFAFTISSLQPEDIAT PRT YYCQQYDNLPRTFGQGTKVEIKCOVD21_P2_K_E12- 803 DIQMTQSPSSLSASVGDRVTITCQASQD 804 QQY p1389ISNYLNWYQQKPGKAPELLIYDASNLET DNL GVPSRFSGSGSGTDFTFTISSLQPEDIAT PLTYYCQQYDNLPLTFGGGTKVEI COVD21_P3_K_H4- 807 EIVLTQSPATLSLSPGERATLSCRASQSV808 QQ p1389 SSYLAWYQQKPGQAPRLLIYDASNRAT RSNGIPARFSGSGSGTDFTLTISSLEPEDFAVY WPL YCQQRSNWPLTFGGGTKVEIK TCOVD21_P2_K_C4- 811 EIVLTQSPXXLSLSPGERATLSCRASQSVS 812 QQY p1389SRNLAWYQQKPGQAPRLLIDGASSRAT GSS GIPDRFSGSGSGTDFTLTISRLEPEDFAV PAITYYCQQYGSSPAITFGQGTRLEIK COVD21_P2_K_G2- 815DIQMTQSPSSLSASVGDRVTITCRASQSI 816 QQS p1389 SSYLNWYQQKPGIAPKLLIYAASSLQSGYST VPSRFSGIGSGTDFTLTISSLQPEDFATYY PW CQQSYSTPWTFGQGTKVEIK TCOVD21_P1_K_H10- 819 DIQMTQSPSSLSASVGDRVTITCRASQSI 820 QQS p1389SSYLNWYQQRPGKAPKLLIYAASSLQSG YSTL FPSRFSGSGSGTDFTLTISSLQPEDFATYY MYTCQQSYSTLMYTFGQGTKLEI COVD21_P2_K_B1- 823 DIVMTQSPXSLAVSLGERATINCKSSQS824 QQY p1389 VLYSSNNKNYLAWYQQKPGQPPKLLIY YSTWASTRESGVPDRFSGSGSGTDFTLTISSL PFT QAEDVAVYYCQQYYSTPFTFGPGTKVDI KCOVD21_P3_L_E6- 827 QSVLTQPPSASGTPGQRVTISCSGSSSNI 828 AA p1409GSNTVNWYQQLPGTGPKLLIYSNNERP WD SGVPDRFSGSKSGTSASLAISGLQPEDEA DSLDYYCAAWDDSLNGPVFGTGTKVTVL NGP V COVD21_P3_L_A5- 831QSVLTQPRSVSGSPGQSVTISCTGTSSD 832 CSY p1409 VGGYNYVSWYQQHPGKAPKLMIYDVSAGS KRPSGVPDRFSGSKSGNTASLTISGLQA FW EDEADYYCCSYAGSFWVFGGGTKLTVL VCOVD21_P3_L_C12- 835 QSVLTQPASVSGSPGQSITISCAGTSSDV 836 SSY p1409GAYNYVSWYQQHPGKAPKLMIYDVSN TSSS RPSGVSNRFSGSKSGNTASLTISGLQAE TWDEADYYCSSYTSSSTWVFGGGTKLTVL V COVD21_P2_K_D8- 839DIQMTQSPSSVSASVGDRVTITCRASQ 840 QQ p1389 GISSWLAWYQQKPGKAPKLLIYAASSLQANS SGVPSRFSGSGSGTDFTLTISSLQPEDFA LPLT TYYCQQANSLPLTFGGGTKVEIKCOVD21_P1_K_B11- 843 DVVMTQSPLSLPVTLGQPASISCRSSQS 844 MQ p1389LVFSDGNTYLNWFQQRPGQSPRRLIYK GTH VSNRDSGVPDRFSGSGSGTDFTLKISRV WPEAEDVGVYFCMQGTHWPWTFGQGTK WT VEIK COVD21_P1_K_C9- 847DVVMTQSPLSLPVTLGQPASISCRSSQS 848 MQ p1389 LVYIDGNTYLNWFQQRPGQSPRRLIYKVGTH SNRDSGVPDRFSGSGSGTDFTLKISRVE WP AEDVGVYYCMQGTHWPYTFGQGTKLE YT IKLAMBDA COVD21_P3_L_H8- 851 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 852 QSY p1409GAGYDVHWYQQLPGTAPKLLIYGNSNR DSS PSGVPDRFSGSKSGTSASLAITGLQAED LSGEADYYCQSYDSSLSGPYVFGTGTKVTVL PYV COVD21_P2_L_E10- 855QSVLTQPRSVSGSPGQSVTISCTGTSSD 856 CSY p1409 VGGYNYVSWYQQHPGKAPKLMIYDVSAGS KRPSGVPDRFSGSKSGNTASLTISGLQA YTY EDEADYYCCSYAGSYTYVFGTGTKVTVL VKAPPA COVD21_P2_K_A4- 859 AIQLTQSPSSLSASVGDRVTITCRASQGI 860 QQF p1389SSALAWYQQKPGKAPKFLIYDASSLESG NNY VPSRFSGSGSGTDFTLTISSLQPEDFATY PLTYCQQFNNYPLTFGGGTKVEIK COVD21_P2_K_G11- 863 DIVMTQSPLSLPVTPGEPASISCRSSQSL864 MQ p1389 LHSNGYNYLDWYLQKPGQSPQLLIYLGS ALQNRASGVPDRFSGSGSGTDFTLKISRVEA TPIT EDVGVYYCMQALQTPITFGQGTRLEIK LAMBDACOVD21_P3_L_G10- 867 QSVLTQPASVSGSPGQSITISCTGTSSDV 868 SSYI p1409GGYNYVSWYQQHPGKAPKLIIYNVSNR SSN PSGVSNRFSGSKSGNTASLTISGLQAED TVEADYYCSSYISSNTVFGGGTKLTVL COVD21_P1_L_H2- 871SYVLTQPPSVSVSPGQTARITCSGDALP 872 QSA p1409 NQYAYWYQQKPGQAPVLVIYKDSERPSDSR GIPERFSGSSSGTTVTLTISGVQAEDEAD GV YYCQSADSRGVFGGGTKLTVLCOVD21_P1_L_A8- 875 SYVLTQPPSVSVAPGKTARITCGGNNIG 876 QV p1409SKSVHWYQQKPGQAPVLVIYYDSDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEA SSSDYYCQVWDSSSDHLYWVFGGGTKLTV DHL L YW V KAPPA COVD21_P2_K_A3- 879EIVLTQSPVSLSLSPGERATLSCRASQSVS 880 QQY p1389SSYLAWYQQKPGQAPRLLIYGASSRATG GSS IPDRFSGSGSGTDFTLTISRLEPEDFAVYY PGTCQQYGSSPGTFGQGTKVEIK LAMBDA COVD21_P3_L_G1- 883QSVLTQPASVSGSPGQSITISCTGTSSDI 884 SSY p1409 GVYNYISWSQQHPGKAPKVMIYDVTNRGS RPSGVSNRFSGSKSGNTASLTISGLQAE STP DEADYYCSSYRGSSTPYVFGTGTKVTVL YVKAPPA COVD21_P2_K_A2- 887 DIQLTQSPSFLSASVGDRVTITCRASQGI 888 QHL p1389SSYLAWYQQKPGKAPKLLIYAASTLQSG NG VPSRFSGSGSGTEFTLTISSLQPEDSATYYCQHLNGFGPGTKVDIK COVD21_P1_K_F7- 891 DIQMTQSPSSLSASVGDRVTITCRASQG 892QQY p1389 ISNSLAWYQQKPGKAPKLLLYAASRLES YST GVPSRFSGSGSGTDYTLTINSLQPEDFATPRT FYCQQYYSTPRTFGQGTKVEIK COVD21_P2_K_C8- 895EIVLTQSPGTLSLSPGERATLSCRASQSV 896 QQY p1389 SSSYLAWYQQKPGQAPRLLIYGASSRATGSS GIPDRFSGSGSGTDFTLTISRLEPEDFAV PRT YYCQQYGSSPRTFGQGTKVEIKCOVD21_P2_K_A10- 899 EIVLTQSPGTLSLSPGERATLSCRASQSV 900 QQY p1389SSTYLAWYQQKPGQAPRLLIYGASSRAT GSS GIPDRFSGSGSGTDFTLTISRLEPEDFAV PRTYYCQQYGSSPRTFGQGTKLEIK COVD21_P2_K_B12- 903 DIQLTQSPSFLSASVGDRVTVTCRASQG904 QQ p1389 ISSYLAWYQQKPGKAPKLLIYAASTLQSG VNSVPSRFSGSGSGTEFTLTISSLQPEDFATXY YSH CQQVNSYSHFGGGSKAEI LAMBDACOVD21_P3_L_C9- 907 QSVLTQPASVSGSPGQSITISCTGTSSDI 908 SSY p1409GVYNYISWSQQHPGKAPKVMIYDVTN RGS RPSGVSNRFSGSKSGNTASLTISGLQAE STPDEADYYCSSYRGSSTPYVFGTGTKVTVL YV KAPPA COVD21_P2_K_H7- 911DIQMTQSPXSLSASVGDRVTITCRASQS 912 QQS p1389 ISSYLNWYQQKPGKAPKLLIYAASSLQSYST GVPSRFSGSGSGTDFTLTISSLQPEDFAT WT YYCQQSYSTWTFGQGTKVEIK LAMBDACOVD21_P2_L_F1- 915 NFMLTQPHSVSESPGKTVTISCTGSSGSI 916 QSY p1409ASNYVQWYQQRPGSAPTTVIYEDNQR DSG PSGVPDRFSGSIDSSSNSASLTISGLKTED NVVEADYYCQSYDSGNVVFGGGTKLTVL COVD21_P2_L_C10- 919SYVLTQPPSVSVSPGQTARITCSGDALP 920 QSA p1409 KQYAFWYQQKPGQAPVLVIYKDSERPSDSS GIPERFSGSSSGTTVTLTISGVQAEDEAD GTY YYCQSADSSGTYVVFGGGTRLTVL VV KAPPACOVD21_P3_K_H10- 923 DIQMTQSPSSLSASVGDRVTITCRASQSI 924 QQS p1389SSYLNWYQQKPGKAPKLLIYVASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATY RTYCQQSYSTRTFGQGTKVEIK COVD21_P1_K_D8- 927 EIVLTQSPGTLSLSPGERATLSCRASQSV928 QQY p1389 SSSYLAWYQQKPGQAPRLLIYGASSRAT GSSGIPDRFSGSGSGTDFTLTISRLEPEDFAV PYT YYCQQYGSSPYTFGQGTKLEIK LAMBDACOVD21_P1_L_D9- 931 SYVLTQPPSVSVSPGQTARITCSGDALP 932 QSA p1409KQYAYWYQQKPGQAPVLVIYKDSERPS DSR GIPERFSGSSSGTTVTLTISGVQAEDEAD KVVYYCQSADSRKVVFGGGTKLTVL COVD21_P3_L_G3- 935 QSVLTQPPSASGTPGQRVTISCSGSSSNI936 AA p1409 GSNTVNWYQQLPGTAPKLLIYSNNQRP WDSGVPDRFSGSKSGTSASLAISGLQSEDEA DSL DYYCAAWDDSLNGYVFGTGTKVTVL NGY VCOVD21_P2_L_A5- 939 SYVLTQPPSVSVAPGKTARITCGGNDIG 940 QV p1409SNGVYWYQQKPGQAPVLVIYYDSDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEA SSSDYYCQVWDSSSDHVVFGGGTKLTVL DHV V KAPPA COVD21_P1_K_E10- 943EIVLTQSPATLSLSPGERATLSCRASQSV 944 QQ p1389 SSYLAWYQQKPGQAPRLLIYDASNRATRIT GIPARFSGSGSGTDFTLTISSLEPEDFAVY YCQQRITFGQGTRLEIK LAMBDACOVD21_P3_L_F9- 947 QSALTQPASVSGSPGQSITISCTGTSSDI 948 SSY p1409GVYNYISWSQQHPGKAPKVMIYDVTN RGS RPSGVXNRFSGSKSGNTASLTISGLQAE STPDEADYYCSSYRGSSTPYVFGTGTKVTVL YV COVD21_P2_L_D6- 951SYVLTQPPSVSVAPGKTARITCGGNNIG 952 QV p1409 SKSVHWYQQKPGQAPLLVIYYDSDRPS WDGIPERFSGSNSGNTATLTISRVEAGDETD SSS YYCQVWDSSSDPHVVFGGGTKLTV DPH VVCOVD21_P1_L_G3- 955 QSALTQPASVSGSPGQSITISCTGTSSDV 956 SSY p1409GGYNYVSWYQHHPGKAPKLMIYDVSN TSSS RPSGVSNRFSGSKSGNTASLTISGLQAE TLEDEADYYCSSYTSSSTLEGVFGGGTKLTVL GV KAPPA COVD21_P2_K_E6- 959DIVMTQSPLSLPVTPGEPASISCRSSQSL 960 MQ p1389 LHSNGYNYLDWYLQKPGQSPQLLIYLGSALQ NRASGVPDRFSGSGSGTDFTLKISRVEA TPH EDVGVYYCMQALQTPHTFGGGTKVEIK TCOVD21_P2_K_G1- 963 EIVLTQSPATLSLSPGERATLSCRASQSV 964 QQ p1389STYLAWYQQKPGQAPRLLIYDASNRAT RSN GIPARFSGSGSGTDFTLTISSLEPEDFAVY WLFYCQQRSNWLFTFGPGTKVDIK T COVD21_P3_L_G7- 967 QSXXTQPRSVSGSPGQSVTISCTGTSSD968 CSY p1409 VGGYNCVSWYQQHPGKAPKLMIYDVS AGSKRPSGVPDRFSGSKSGNTASLTISGLQA YTP EDEADYYCCSYAGSYTPWVFGGGTKLT WV VLCOVD21_P2_L_D5- 971 QSVLTQPPSASGSPGQSVTISCTGTSSD 972 SSY p1409VGGYNYVSWYQQHPGKAPKLMIYEVS AGS KRPSGVPDRFSGSKSGNTASLTVSGLQA NNEDEADYYCSSYAGSNNWVFGGGTKLTV WV L COVD21_P1_L_A9- 975QSVLTQEPSLTVSPGGTVTLTCASSTGA 976 LLYY p1409 VTSGYYPSWFQQKPGQAPRALIYSTSNGGA KHSWTPARFSGSLLGGKAALTLSGVQP WV EDEADYYCLLYYGGAWVFGGGTKLTVLCOVD21_P3_L_A8- 979 QSALTQPASVSGSPGQSITISCTGTSSDI 980 SSY p1409GVYNYISWSQQHPGKAPKVMIYDVTN RGS RPSGVSNRFSGSKSGNTASLTISGLQAE STPDEADYYCSSYRGSSTPYVFGTGTKVTVL YV COVD21_P2_L_B6- 983NFMLTQPHSVSESPGKTVTISCTGSSGSI 984 QSY p1409 ASNYVQWYQQRPGSAPTTVIYEDNQRDSR PSGVPDRISGSIDSSSNSASLTISGLKTED NVV EADYYCQSYDSRNVVFGGGTRLTVLCOVD21_P2_L_B6- 987 NFMLTQPHSVSESPGKTVTISCTGSSGSI 988 QSY p1409ASNYVQWYQQRPGSAPTTVIYEDNQR DSR PSGVPDRISGSIDSSSNSASLTISGLKTED NVVEADYYCQSYDSRNVVFGGGTRLTVL COVD21_P1_L_D4- 991QSVLTQPPSVSGAPGQRVTISCTGSSSNI 992 QSY p1409 GAGYDVHWYQQLPGTAPKLLIYGNSNRDSS PSGVPDRFSGSKSGTSASLAITGLQAED LSD EADYYCQSYDSSLSDSLFGGGTKLTVL SLCOVD21_P2_K_H5- 995 DIQMTQSPVSLSASVGDRVTITCRASQS 996 QQY p1389ISSWLAWYQQKPGKAPKLLIYKASSLES NSY GVPSRFSGSGSGTEFTLTISSLQPDDFAT STYYCQQYNSYSTFGQGTKVEIK LAMBDA COVD21_P1_L_F4- 999QSVLTQPRSVSGSPGQSVTISCTGTSSD 1000 YSY p1409 VGGYNYVSWYQQHPGKAPKLMIYDVSAGS KRPSGVPDRFSGSKSGNTASLTISGLQA YTF EDEADYYCYSYAGSYTFVFGGGTKLTVL VCOVD21_P3_L_C4- 1003 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1004 QSY p1409GAGYDVHWYQQLPGTAPKLLIYGNSNR DSS PSGVPDRFSGSKSGTSASLAITGLQAED LSGEADYYCQSYDSSLSGYVVFGGGTKLTVL YVV COVD21_P1_L_E2- 1007QSVLTQPPSASGTPGQRVTISCSGSSSNI 1008 AA p1409 GSNYVYWYQQLPGTAPKLLIYRNNQRPWD SGVPDRFSGSKSGTSASLAISGLRSEDEA DSL DYYCAAWDDSLSGYWVFGGGTKLTVL SGY WVKAPPA COVD21_P2_K_C5- 1011 DIQMTQSPSTLSASVGDRVTITCRASQSI 1012 QQY p1389SSWLAWYQQKPGKAPKLLIYKASSLESG NSF VPSRFSGSGSGTEFTLTISSLQPDDFATY SYTYCQQYNSFSYTFGQGTKLEIK COVD21_P1_K_H4- 1015 EIVMTQSPATLSVSPGERATLSCRASQS1016 QQY p1389 VSSNLAWYQQKSGQAPRLLIYGASTRA NNTGIPARFSGSGSGTEFTLTISSLQSEDFAV WL YYCQQYNNWLGTFGQGTKVEFK GTCOVD21_P2_K_C6- 1019 EIVMTQSPATLSVSPGERATLSCRASQS 1020 QQY p1389VSSNLAWYQQKPGQAPRLLIYGASTRA NN TGIPARFSGSGSGTEFTLTISSLQSEDFAV WPLYYCQQYNNWPLTFGGGTKVEIK T

TABLE 9 Anti-SARS-CoV-2 IgG antibodies from COV47 SEQ SEQ ID IDSEQUENCE_ID NO aa NO cdr3_aa HEAVY COV047_P3_IgG_43- 1021EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNY 1022 AREGEV P1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG EGYNDFRFTISRDKSKNTLYLQMNRLRAEDTAVYYCAREG WSGYSREVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSS DRYYFDY COV047_P4_IgG_57- 1025EVQLVESGGGLIQPGGSLRLSCAASGFSVSSNY 1026 AREGEV P1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG EGYYDFRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG WSGYSREVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS DRYYFDY COV047_P4_IgG_58- 1029EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNY 1030 AREGEV P1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSLKG EGYYDFRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG WSGYSREVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS DRYYFDY COV047_P5_IgG_26- 1033EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 1034 AREGDV P1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG EGYYDFRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG WSGYSRDVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS DRYYFDY COV047_P5_IgG_41- 1037EVQLVESGGGLIQPGGSLRLSCAASGFTVRNNY 1038 AREGEV P1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG EGYYDFRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG WSGYSREVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS DRYYFDY COV047_P5_IgG_49- 1041EVQLVESGGGLIQPGGSLRLSCAASGFSVSSNY 1042 AREGEV P1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG EGYYDFRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG WSGYSREVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS DRYYFDY COV047_P3_IgG_16- 1045EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY 1046 ARDSSEV P1369MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK RDHPGH GRFTISRDNSKNALYLQMNSLRVEDTGVYYCARPGRSVG DSSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS AFDI COV047_P4_IgG_12- 1049EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY 1050 ARDSSEV P1369MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK RDHPGHGRFTISRDNSKNALYLQMSSLRVEDTGIYYCARD PGRSVGSSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS AFDI COV047_P4_IgG_65- 1053EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY 1054 ARDSSEV P1369MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK RDHPGHGRFTISRDNSKNALYLQMSSLRVEDTGIYYCARD PGRSVGSSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS AFDI COV047_P5_IgG_57- 1057EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY 1058 ARDSSEV P1369MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK RDHPGH GRFTISRDNSKNALYLQMNSLRVEDTGVYYCARPGRSVG DSSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS AFDI COV047_P3_IgG_10- 1061QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGI 1062 ARDRGG P1369SWVRQAPGQGLEWMGWISAYNGNTNYAQKL HDFWSG QGRVTMTTDTSTSTAYMELRSLRSDDTAVFYCAYGFYYYY RDRGGHDFWSGYGFYYYYGMDVWGQGTTVT GMDV VSS COV047_P5_IgG_95- 1065QVQLVQSGAEVKKPGASVKVSCKASGYNFTSYG 1066 ARDRGG P1369ISWVRQAPGQGLEWMGWISGYNGNTNYGQK HNFWSG FQGGVTMTTDTSTSTAYMELRSLRSDDTAVYYCYGYYYYY ARDRGGHNFWSGYGYYYYYGMDVWGQGTTV GMDV TVSS COV047_P4_IgG_34- 1069EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM 1070 ARERGY P1369NWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF YGGKTPTISRDNAKNSLYLQMNSLRAEDTAVYYCARERG PFL YYGGKTPPFLGGQGTLVTVSSCOV047_P5_IgG_24- 1073 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYN 1074 ARERGYP1369 MNWVRQAPGKGLEWVSCISSSSSYIYYADSVKG DGGKTPRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARER PFL GYDGGKTPPFLGGQGTLVTVSSCOV047_P4_IgG_91- 1077 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 1078 AKNVGTP1369 MHWVRQAPGKGLEWVAVTSYDGTNKYYADSV GYNVMYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAK YFDY NVGTGYNVMYYFDYWGQGTLVTVSSCOV047_P5_IgG_87- 1081 QVQLVESGGGVVQPGRSLRLSCAASGFTFSRYG 1082 AKQAGPP1369 MHWVRQAPGKGLEWVAVMSYDGSSKYYADS YCSGGSCVKGRFTISRDNSKNTLCLQMNSLRAEDTAVYYC YSAPFDYAKQAGPYCSGGSCYSAPFDYWGQGTLVTVSS COV047_P4_IgG_69- 1085QVQLVESGGGVVQPGRSLRLSCTASGFTFSSYG 1086 AKVGLG P1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV YSSGWYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK GEEIDY VGLGYSSGWYGEEIDYWGQGTLVTVSSCOV047_P5_IgG_68- 1089 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYG 1090 AKVGMEP1369 MHWVRQAPGKGLEWVAVISYDGSNKYFADSV YSSGWYKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCAK GEEIDF VGMEYSSGWYGEEIDFWGQGTLVTVSSCOV047_P3_IgG_64- 1093 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYG 1094 AKDPFPLP1369 MHWVRQAPGKGLEWVAVISYDGNNKYYADSV AVAGTGKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK YFDY DPFPLAVAGTGYFDYWGQGTLVTVSSCOV047_P5_IgG_77- 1097 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 1098 AKDPWEP1369 MHWVRQAPGKGLEWVAVISYDGSNKHYADSV LRQGNYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK FDY DPWELRQGNYFDYWGQGTLVTVSSCOV047_P3_IgG_65- 1101 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 1102 ARDYGDP1369 MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG YYFDYRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDY GDYYFDYWGQGTLVTVSS COV047_P5_IgG_27-1105 EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM 1106 ARDFGE P1369SWVRQAPGKGLEWVSVIYSGGSTFYADSVKGR FYFDY FTISRDNSKNTLYLQMNSLRAEDTAVYYCARDFGEFYFDYWGQGTLVTVSS COV047_P4_IgG_3- 1109EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY 1110 ARDSSEV P1369MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK RDHPGH GRFTISRDNSKNALYLQMNSLRVEDTGVYYCARPGRSVG DSSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS AFDI COV047_P5_IgG_90- 1113EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY 1114 ARDSSEV P1369MTWVRQAPGKGLEWVSALYSGGSDYYADSVK RDHPGHGRFTISRDNSKNTLYLQMSSLRVEDTGVYYCARD PGRSVGSSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS AFDI COV047_P3_IgG_24- 1117EVQLVESGGGLVQPGGSQRLSCAASGFTVSSNY 1118 ARIANY P1369MSWIRQAPGKGLEWVSVIYSGGSAYYVDSVKG MDV RFTISRDNSKNTLYLQMNSLRPEDTAVYYCARIANYMDVWGKGTTVTVSS COV047_P5_IgG_94- 1121EVQLVESGGGLVQPGGSQRLSCAASGFTVSSNY 1122 ARIANY P1369MSWIRQAPGKGLEWVSVIYSGGSAYYVDSVKG MDV RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIANYMDVWGKGTTVTVSS COV047_P3_IgG_8- 1125EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWI 1126 ARLSDR P1369GWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ WYSPFDGQVTISADKSITTAYLQWSSLKASDTAMYYCARL P SDRWYSPFDPWGQGTLVTVSSCOV047_P3_IgG_91- 1129 EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWI 1130 ARLSDRP1369 GWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ WYSPFDGQVTISADKSITTAYLQWSSLKASDTAMYYCARL P SDRWYSPFDPWGQGTLVTVSSCOV047_P3_IgG_77- 1133 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYN 1134 ARVPRGP1369 ITWVRQAPGQGLEWVGWISAYNGNTNYAQKF YYDRSGYQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA YYLPHYLRVPRGYYDRSGYYYLPHYLDYWGQGTLVTVSS DY COV047_P5_IgG_78- 1137QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGI 1138 ARDSAYS P1369SWVRQAPGQGLEWMGWISAYNGNTNYAQKL GYDFFEA QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAPRDY RDSAYSGYDFFEAPRDYWGQGTLVTVSS COV047_P5_IgG_21- 1141QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDI 1142 ARPSSSL P1369SWVRQAPGQGLEWMGWINAYNGNTNYAQKL TSYFDY QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAARVPASY RPSSSLTSYFDYWGQGTLVTVSS COV047_P3_IgG_53- 1145QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGI 1146 GDDDYY P1369SWVRQAPGQGLEWMGWISAYNGNTNYAQKL YYYGMD QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAV RVPASYGDDDYYYYYGMDVWGQGTTVTVSS COV047_P4_IgG_27- 1149QVQLVQSGAEVKKPGASVKVSCKASGYIFTDYS 1150 ARGPLF P1369MHWVRQAPGQGLEWIGWVNPNSGGTNYAQ HRLVYDF KFQGWVTMARDTSITTVYMELSRLKSDDTAVYFWSGYHD CARGPLFHRLVYDFWSGYHDGFDMWGQGTM GFDM VTVSS COV047_P5_IgG_10- 1153QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 1154 ARTPRVY P1369LHWVRQAPGQGLEWMGWINPNSGGTNYAQK DPTLPN FQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCQWLVGE ARTPRVYDPTLPNQWLVGEYYCDYWGQGTLVT YYCDY VSS COV047_P4_IgG_60- 1157QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 1158 ARGTEY P1369IHWVRQAPGQGLEWMGWINPNSGGTKYAQK NWNSA FQGWVTMTRDTSITTVYMELSRLRSDDTAVYYCHFDP ARGTEYNWNSAHFDPWGQGTLVTVSS COV047_P5_IgG_29- 1161QVQLVQSGAEVKKPGASVKVSCMASGYTLTAY 1162 VRGGTW P1369YIHWVRQAPGQGLESLGWINPRTGGTTILQKFQ NYVGGEGWVTMTRDTSINTVYLELPRVTLADTAVYYCVR V GGTWNYVGGEVWGQGTAVTVSSCOV047_P3_IgG_61- 1165 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHY 1166 ASSSSTPP1369 MHWVRQAPGQGLEWMGIINPSGGGTSYAQK DYYGMDFQGRVTMTRDTSMSTVYMELSSLRSEDTAVYYC V ASSSSTPDYYGMDVWGQGTTVTVSSCOV047_P4_IgG_48- 1169 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYI 1170 ARASTSTP1369 HWVRQAPGQGLEWMGIINPSDGGTSYAQKFQ TNWNDGRVTMTRDTSTSTVYMELSSLRSEDTAVYSCAR ALSLGC ASTSTTNWNDALSLGCWGQGTLVTVSSCOV047_P3_IgG_78- 1173 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYY 1174 ARGGSSP1369 MHWVRQAPGQGLEWMGIINPSGGSTSYAQKF RYCSSTSQGRVTMTRDTSTSTVYMELNSLRSEDTAVYYCA CYSFGVDRGGSSRYCSSTSCYSFGVDNFDYWGQGTLVTVS NFDY S COV047_P4_IgG_43- 1177QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAI 1178 ARVGYG P1369SWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ YYFDY GRVTITADESTSTAYMELSSLRSEDTAVYYCARVGYGYYFDYWGQGTLVTVSS COV047_P4_IgG_89- 1181QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSDA 1182 ARDLRYC P1369ISWVRQAPGQGLEWMGGIMPIFGTANYAQKF SGGRCLQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR WWFDP DLRYCSGGRCLWWFDPWGQGTLVTVSSCOV047_P5_IgG_15- 1185 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNY 1186 ARYTYYYP1369 AISWVRQAPGQGLEWMGGIIPIFGTANYAQKL DRSGYYQGRVTITTDESTSTAYMELSSLRSEDTAVYYCAR RPDYFDY YTYYYDRSGYYRPDYFDYWGQGTLVTVSSCOV047_P3_IgG_54- 1189 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSAW 1190 TTTNDYP1369 MSWVRQAPGKGLEWVGRIKTKTDGGTKDYAA GDYSPAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYC Y TTTNDYGDYSPAYWGQGTLVTVSSCOV047_P5_IgG_72- 1193 EVQLVESGGGLVKPGGSLRLSCAVSGFTFSNVW 1194 TSQVWLP1369 MRWVRQAPGKGXEWVGRIKSKTDGGTTXYAA RGPGDYPVKGRFTXSRDDSKNTLYLQMNSLKTEDTAVYY CTSQVWLRGPGDYWGQGTLVTVSSCOV047_P4_IgG_17- 1197 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYIM 1198 AREAEWP1369 NWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF EAFDITISRDNAKNSLYLQMNSLRAEDTAVYYCAREAE WEAFDIWGQGTMVTVSS COV047_P5_IgG_84-1201 EVQLVESGGGLVKPGGSLRLSCAASGLTFTAYR 1202 ARDVAS P1369MNWVRQAPGKGLEWLSSISNTNGDIYYADSVK NYAYFDLGRFTISRDNAKNSLYLQMNSLRADDTAVYYCAR DVASNYAYFDLWGQGTLVTVSSCOV047_P4_IgG_67- 1205 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM 1206 ARERYGP1369 NWVRQAPGKGLEWVSSISSSTSYIYYADSVKGR DNFTISRDNAKNSLYLQMNSLRAEDTAVYYCARERY GDNWGQGTLVTVSS COV047_P3_IgG_84- 1209EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYSM 1210 ARVVAN P1369NWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF WFDPTISRDNAKNSLYLQMNSLRAEDTAVYYCARVVA NWFDPWGQGTLVTVSS COV047_P3_IgG_40-1213 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM 1214 AREAAR P1369NWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF RYDFWSTISRDNAKNSLYLQMNSLRAEDTAVYYCAREAA GLNWFD RRYDFWSGLNWFDPWGQGTLVTVSS PCOV047_P4_IgG_36- 1217 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 1218 AKSGGRP1369 MSWVRQAPGKGLEWVSAISGSGGSTYYADSVK HYYDSSGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKS GYYRLPLGGRHYYDSSGYYRLPLDDAFDIWGQGTMVTVS DDAFDI S COV047_P4_IgG_52- 1221QVQLVESGGGVVQPGRSLRLSCADSGFTFSTYG 1222 ARAEWL P1369MHWVRQAPGKGLEWVALISYDGSNKYYADSV RGAFDI KGRFTISGDNSKNTLYLQMNSLRAEDTAVYYCARAEWLRGAFDIWGQGTMVTVSS COV047_P3_IgG_70- 1225QVQLVESGGGVVQPGRSLRLSCAASGFTFNNY 1226 ARAGWE P1369GMHWVRQAPGKGLEWVAVISYDGNNKYYADS LLRIRYYFVKDRFTISRDNSKNTLYLQMNNLRAEDTAMYYC DF ARAGWELLRIRYYFDFWGQGTLVTVSSCOV047_P4_IgG_31- 1229 QVQLVESGGGVVQPGRSLRLSCAASGLTFSFYAI 1230 YALFERGP1369 HWVRQAPGKGLEWVAYISYEGSDKYYADSVKG NWNDARFTISRANSKSTLYLQMNSLRAEDTAVYYCYALFE EY RGNWNDAEYWGQGTLVTVSSCOV047_P5_IgG_30- 1233 QVQLVESGGGVVQPGRSLRLSCAASGFTFSGYD 1234 AKDLGSSP1369 IHWVRQAPGKGLEWVAVISYDGSSKFYADSVK LYYDAFDGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK I DLGSSLYYDAFDIWGQGTMVTVSSCOV047_P4_IgG_20- 1237 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 1238 AKVDGSP1369 MHWVRQAPGKGLEWVAVISYDGSNKYYADSV YYYYYYGKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK MDV VDGSYYYYYYGMDVWGQGTTVTVSSCOV047_P4_IgG_22- 1241 QVQLVESGGGVVQPGRSLRLSCAASGFTFRTYA 1242 AREQEAP1369 MHWVRQAPGKGLEWVAVILSDGNNKYYADSV NYYDISGKGRFTISRDNSKNTLYLQMNSLRAEDTAIFYCAR YYHWGEEQEANYYDISGYYHWGESLGYWGQGTLVTVPS SLGY COV047_P4_IgG_70- 1245QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 1246 ARGGRY P1369MHWVRQAPGKGLEWVAVIWYDGSNKYYADS YDSSGY VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNGTYEF ARGGRYYDSSGYNGTYEFDYWGQGTLVTVSS DY COV047_P4_IgG_50- 1249QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 1250 ARDRKYS P1369MHWVRQAPGKGLEWVAVIWYDGSNKYYADS SGWSVV VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNFDY ARDRKYSSGWSVVNFDYWGQGTLVTVSS COV047_P5_IgG_59- 1253QVQLVESGGGVVQPGRSLRLSCAASGFMFSSY 1254 ARDGLN P1369GMHWVRQAPGKGLEWVAVIWYDGSNKYYAD WNVPHY SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCGMDV ARDGLNWNVPHYGMDVWGQGTTVTVSS COV047_P5_IgG_58- 1257EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 1258 ARVGGA P1369MSWVRQAPGKGLEWVSVIYSGYSTYYVDSVKG HSGYDGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARV SFDY GGAHSGYDGSFDYWGQGTLVTVSSCOV047_P5_IgG_8- 1261 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 1262 ARDRVIYP1369 MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG GMDVRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD RVIYGMDVWGQGTTVTVSS COV047_P4_IgG_11-1265 EVQLVETGGGLIQPGGSLRLSCAASGFTVSSNY 1266 ARAISES P1369MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG PRYGVYRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAI SESPRYGVYWGQGTLVTVSSCOV047_P3_IgG_14- 1269 EVQLVETGGGLIQPGGSLRLSCAASEFTVSSNYM 1270 ARVLPFGP1369 SWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRF DYFDYTISRDNSKNTLYLQMNSLRAEDTAVYYCARVLPF GDYFDYWGQGTLVTVSS COV047_P5_IgG_91-1273 EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY 1274 ARDSSEV P1369MTWVRQAPGKGLEWVSALYSGGSDYYADSVK RDHPGHGRFTISRDNSKNTLYLQMSSLRVEDTGVYYCARD PGRSVG SSEVRDHPGHPGRSVGAFDIWGQGTMVAFDI COV047_P4_IgG_51- 1277 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNY 1278 P1369MSWVRQAPGKGLEWVSVIYSGGSAYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSTPGYGDYISGQGTLVTVSS COV047_P3_IgG_47- 1281EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNY 1282 ARDYGD P1369MSWVRQAPGKGLEWVSVIYSGGSAYYADSVKG FYFDYRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDY GDFYFDYWGQGTLVTVSS COV047_P5_IgG_71-1285 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNY 1286 ARDLRD P1369MSWVRQAPGKGLEWVSVIYSGGSAYYADSVKG QDGYSYRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDL GAFDY RDQDGYSYGAFDYWGQGTLVTVSSCOV047_P5_IgG_16- 1289 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 1290 ASAFWQP1369 MHWVRQAPGKGLVWVSHINGDGSSTSYADSV RGNFDYKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA SAFWQRGNFDYWGQGTLVTVSSCOV047_P3_IgG_25- 1293 EVQLVESGGGLVQPGGSLRLSCVASGFTFSSYW 1294 ARPTAVP1369 MHWVRQVPGKGPVWVSHINSEGSSTNYADSV AAAGNYRGRFTISRDNAKDTLYLQMNNLRAEDTAVYYCA FYYYGM RPTAVAAAGNYFYYYGMDVWGQGTTVTVSSDV COV047_P4_IgG_86- 1297 QLQLQESGSRLVKPSQTLSLTCAVSGGSISSGGYS 1298ARFTNP P1369 WSWIRQPPGKGLQWIGYIYHSGSTYYNPSLKSR NYYDSSVTISVDRSKNQFSLKLSSVTAADTAVYYCARFTN GYYGFD PNYYDSSGYYGFDYWGQGTLVTVSS YCOV047_P4_IgG_39- 1301 QVQLQESGPGLVKPSQTLSLTCAVSGDSIRSGGY 1302 ARVKGWP1369 YWSWVRQHPGRGLEWIGYIYFSGTTYYNPSLKS LRGYFDYRVTISVDTSEKQFSLKLTSVTDADTAVYFCARVK GWLRGYFDYWGQGAPVTVSACOV047_P4_IgG_83- 1305 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSN 1306 ARVAAFLP1369 WWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLK DYSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARV AAFLDYWGQGTLVTVSS COV047_P3_IgG_38-1309 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSN 1310 ARTWIQ P1369WWSWVRQPPGKGLEWIGEIYHSGTTNYNPSLK PHNWFDSRVTISVDKSKNQFSLKLSSVTAADTAVYYCART P WIQPHNWFDPWGQGTLVTVSSCOV047_P4_IgG_72- 1313 QVQLQESGPGLVKPSETLSLTCTVSGGSISNYYW 1314 ARGPPRLP1369 SWIRQPPGKGLEWIGYIYTSGSTNYNPSLKSRVTI LWFGESSVDTSKNQFSLKLSSVTAADTAVYYCARGPPRLL PPTYWY WFGESPPTYWYFNLWGRGTLVTVSS FNLCOV047_P4_IgG_38- 1317 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 1318 ARYQLAP1369 SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTI PGSGSYYSVDTSKNQFSLKLSSVTAADTAVYYCARYQLAPG NWGGY SGSYYNWGGYPRESEYYFDYWGQGTLVTVSSPRESEYY FDY COV047_P3_IgG_5- 1321 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW1322 ARHDTIF P1369 SWIRQPPGKGLEWIGYIYYSRSTNYNPSLKSRVTI GVGQYYSVDTSKNQFSLKLSSVTAADTAVYYCARHDTIFG FDY VGQYYFDYWGQGTLVTVSSCOV047_P3_IgG_35- 1325 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 1326 ARHSWLP1369 SWIRQPPGKGLEWIGYIYTSGSTNYNPSLKSRVTI RGMADYSVDTSKNQFSLKLSSVTAADTAVYYCARHSWLR GMADYWGQGTLVTVSS COV047_P3_IgG_49-1329 QVQLQESGPGLVKPSETLSLTCTVSGDSMSSYF 1330 ARLKQQ P1369WTWIRQPPGKGLECIGYFYPSGSTNYNPSLKSR LVGFGWVTISIDTSKNQFSLKLSSVTAADTAVYYCARLKQQ FDP LVGFGWFDPWGQGTLVTVSSCOV047_P4_IgG_23- 1333 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNTA 1334 ARDILRDP1369 AWNWIRQSPSRGLEWLGRTYYRSKWYNDYAV TSWPHDSVISRIIINPDTSKNQFSLQLKSVTPEDTAVYYCAR AFDI DILRDTSWPHDAFDIWGQGTMVTVSS SEQSEQ ID ID SEQUENCE_ID NO aa NO cdr3_aa LAMBDA COV047_P3_Lambda_43- 1023QSVLTQPASVSGSPGQSITISCTGTSSDV 1024 SSY P1409 GGYNYVSWYQQHPGKAPKLMIYDVSNTSS RPSGVSNRFSGSKSGNTASLTISGLQAED STR EADYYCSSYTSSSTRVFGTGTKVTVL VCOV047_P4_Lambda_57- 1027 QSVLTQPASVSGSPGQSITISCTGTSSDV 1028 SSY P1409GGYNYVSWYQQHPGKAPKLMIYDVSN TSS RPSGVSNRFSGSKSGNTASLTISGLQAED TTREADYYCSSYTSSTTRVFGTGTRVTVL V COV047_P4_Lambda_58- 1031QSALTQPASVSGSPGQSITISCTGTSSDV 1032 SSY P1409 GGYNYVSWYQQHPGKAPKLMIYDVSNTSIS RPSGVSNRFSGSKSGNTASLTISGLQAED TRV EADYYCSSYTSISTRVFGTGTKVTVLCOV047_P5_Lambda_26- 1035 QSALTQPASVSGSPGQSITISCTGTSSDV 1036 SSY P1409GGYNYVSWYQQHPGKAPKLMIYDVSN TSS RPSGVSNRFSGSKSGNTASLTISGLQAED STREADYYCSSYTSSSTRVFGTGTKVTVL V COV047_P5_Lambda_41- 1039QSALTQPASVSGSPGQSITISCTGTSSDV 1040 SSY P1409 GGYNYVSWYQQHPGKAPKLMIYDVSNTSS RPSGVSNRFSGSKSGNTASLTISGLQAED STR EADYYCSSYTSSSTRVFGTGTKVTVL VCOV047_P5_Lambda_49- 1043 QSVLTQPASVSGSPGQSITISCTGTSSDV 1044 SSY P1409GGYNYVSWYQQHPGKAPKLMIYDVSN TSS RPSGVSNRFSGSKSGNTASLTISGLQAED TTREADYYCSSYTSSTTRVFGTGTRVTVL V COV047_P3_Lambda_16- 1047QSVLTQPASVSGSPGQSITISCTGTSNDV 1048 CSY P1409GSYTLVSWYQQYPGKAPKLLIFEGTKRSS AGA GISNRFSGSKSGNTASLTISGLQGEDEAD STFYYCCSYAGASTFVFGGGTKLTVL V COV047_P4_Lambda_12- 1051QSVLTQPASVSGSPGQSITISCTGTSNDV 1052 CSY P1409GSYTLVSWYQQYPGKAPKLLIFEGTKRSS AGA GISNRFSGSKSGNTASLTISGLQGEDEAD STFYYCCSYAGASTFVFGGGTKLTVL V COV047_P4_Lambda_65- 1055QSALTQPASVSGSPGQSITISCTGTSNDV 1056 CSY P1409GSYTLVSWYQQYPGKAPKLLIFEGTKRSS AGA GISNRFSGSKSGNTASLTISGLQGEDEAD STFYYCCSYAGASTFVFGGGTKLTVL V COV047_P5_Lambda_57- 1059QSVLTQPASVSGSPGQSITISCTGTSNDV 1060 CSY P1409GSYTLVSWYQQYPGKAPKLLIFEGTKRSS AGA GISNRFSGSKSGNTASLTISGLQGEDEAD STFYYCCSYAGASTFVFGGGTKLTVL V KAPPA COV047_P3_Kappa_10- 1063DIQMTQSPSSLSASVGDRVTITCRASQGI 1064 QKY P1389SNYLAWYQQRPGKVPKLLIFAASTLQSG NSA VPSRFSGSGSGTDFTLTISSLQPEDVATY PRTYCQKYNSAPRTFGQGTKVEIK COV047_P5_Kappa_95- 1067DIQMTQSPSSLXASVGDRVTITCRASQG 1068 QKY P1389ISNYLAWYQQKPGKVPKLLIYAASTLQSG NSA VPSRFSGSESGTDFTLTISSLQPEDVATYY PRTCQKYNSAPRTFGQGTKVEIK LAMBDA COV047_P4_Lambda_34- 1071NFMLTQPHSVSESPGKTVTISCTGSSGSI 1072 QSY P1409 ASNYVQWYQQRPGSAPTTVIYEDNQRPDSS SGVPDRFSGSIDSSSNSASLTISGLKTEDE NY ADYYCQSYDSSNYWVFGGGTKLTVL WVCOV047_P5_Lambda_24- 1075 NFMLTQPHSVSESPGKTVTISCTGSSGSI 1076 QSY P1409ASNYVQWYQQRPGSAPTTVIYEDNQRP DSS SGVPDRFSGSIDSSSNSASLTISGLKTEDE NYADYYCQSYDSSNYWVFGGGTKLTVL WV KAPPA COV047_P4_Kappa_91- 1079DIQMTQSPSSLSASVGDRVTITCQASQD 1080 QQ P1389 ISNYLNWYQQKPGKAPKLLIYDTSNLERYDN GVPSRFSGSGSGSDFTFTISSLQPEDIATY LPIT YCQQYDNLPITFGQGTRLEIKCOV047_P5_Kappa_87- 1083 DIQMTQSPSSLSASVGDRVTITCQASQG 1084 QQ P1389ISNYLNWYQQKPGKAPKLLIYDASNLET YDN GVPSRFSGSGSGTDFTFTISSLQPEDIATY LPITYCQQYDNLPITFGQGTRLEIK COV047_P4_Kappa_69- 1087DIQMTQSPSSLSASVGDRVTITCRASQSI 1088 QQS P1389SSFLNWYQQKPGKAPNLLIYAASSLQSG YRT VPSRFSGSGSGTDFTLTISSLQPEDFATYY PLTCQQSYRTPLTFGGGTKVEIK COV047_P5_Kappa_68- 1091DIQMTQSPSSLSASVGDRVTITCRASQSI 1092 QQS P1389SSYLNWYQQKPGKVPKLLIYAASSLQSG YRT VPSRFSGSGSGTDFTLTISSLQPEDFATYY PLTCQQSYRTPLTFGGGTKVEIK LAMBDA COV047_P3_Lambda_64- 1095SYVLTQPPSVSVAPGQTARISCGGNNIG 1096 QV P1409 SKNVHWYQQKPGQAPVLVVYDDSDRP WDSGIPERFSGSNSGNTATLTISRVEAGDEA SSS DYYCQVWDSSSDPWVFGGGTKLTVL DP WVCOV047_P5_Lambda_77- 1099 SYVLTQPPSVSVAPGQTARITCGGNNIG 1100 QV P1409SKNVHWYQQKPGQAPVLVVYDDSDRP WD SGIPERFSGSNSGTTATLTISRVEAGDEA SSSDYYCQVWDSSSDPWVFGGGTKLTVL DP WV KAPPA COV047_P3_Kappa_65- 1103EIVMTQSPATLSVSPGERATLSCRASQSV 1104 QQ P1389 SSNLAWYQQKPGQAPRLLIYGASTRATYNN GIPARFSGSGSGTEFTLTISSLQSEDFAVY WP YCQQYNNWPRTFGQGTKVEIK RTCOV047_P5_Kappa_27- 1107 EIVMTQSPATLSVSPGERATLSCRASQSV 1108 QQ P1389SSNLAWYQQKPGQAPRLLIYGASTRATA YNN IPARFSGSGSGTEFTLTISSLQSEDFAVYY WPCQQYNNWPRTFGQGTKVEIK RT LAMBDA COV047_P4_Lambda_3- 1111QSVLTQPASVSGSPGQSITISCTGTSNDV 1112 CSY P1409GSYTLVSWYQQYPGKAPKLLIFEVTKRSS AGA GISNRFSGSKSGNTASLTISGLQGEDEAD STFYYCCSYAGASTFVFGGGTKLTVL V COV047_P5_Lambda_90- 1115QSALTQPASVSGSPGQSITISCTGTSNDV 1116 CSY P1409GSYTLVSWYQQYPGKAPKLLIFEDTKRSS AGT GISNRFSGSKSGNTASLTISGLQGEDEAD STFYYCCSYAGTSTFVFGGGTKLTVL V KAPPA COV047_P3_Kappa_24- 1119EIVMTQSPATLSVSPGERATLSCRASQSV 1120 QQ P1389 SSHLAWYQQKPGQAPRLLIYGASTRATGYNN IPTRFSGSGSGTEFTLTISSLQSEDFAVYY WP CQQYNNWPPLTFGGGTKVEIK PLTCOV047_P5_Kappa_94- 1123 EIVMTQSPATLSVSPGERATLSCRASQSV 1124 QQ P1389SSHLAWYQQKPGQAPRLLIYGASTRATG YNN IPTRFSGSGSGTEFTLTISSLQSEDFAVYY WPCQQYNNWPPLTFGGGTKVEIK PLT LAMBDA COV047_P3_Lambda_8- 1127QSVLTQEPSLTVSPGGTVTLTCGSSTGA 1128 LLSY P1409VTSGHYPYWFQQKSGQAPRTLIYETSIK SGA HSWTPARFSGSLLGGKAALTLSGAQPED RPVEADYYCLLSYSGARPVFGGGTKLTVL COV047_P3_Lambda_91- 1131QSVLTQEPSLTVSPGGTVTLTCGSSTGA 1132 LLSY P1409VTSGHYPYWFQQKSGQAPRTLIYETSIK SGA HSWTPARFSGSLLGGKAALTLSGAQPED RPVEADYYCLLSYSGARPVFGGGTKLTVL KAPPA COV047_P3_Kappa_77- 1135DIQMTQSPSSLSASVGDRVTITCQASQD 1136 QQ P1389 ISNYLNWYQQKPGKPPKLLIYDASNLETYDS GVPSRFSGSGSGTDFIFSISSLQPEDIATY LPG YCQQYDSLPGCSFGQGTKLEIK CSCOV047_P5_Kappa_78- 1139 DIQMTQSPSSLSASVGDRVTITCRASQSI 1140 QQS P1389SSFLNWYQQKPGKAPKLLIYAASSLHSG YRT VPSRFSGSGSGTDFTLTISSLQPEDFATYY PPLCQQSYRTPPLFGGGTKVEI LAMBDA COV047_P5_Lambda_21- 1143SYVLTQPPSVSVAPGQTARITCGGNNIG 1144 QV P1409 SKNVHWYQQKPGQAPVLVVYDDSDRP WDSGIPERFSGSNSGNTATLTISRVEAGDEA SSS DYYCQVWDSSSDRHWVFGGGTKLTVL DRH WVCOV047_P3_Lambda_53- 1147 SYVLTQPPSVSVSPGQTARITCSGDALPK 1148 QSA P1409QYAYWYQQKPGQAPVLVIYKDSERPSGI DSS PERFSGSSSGTTVTLTISGVQAEDEADYY GTLCQSADSSGTLWVFGGGTKLTVL WV COV047_P4_Lambda_27- 1151QSVLTQPASVSGSPGQSITISCTGTSSDV 1152 NSY P1409 GGYKFVSWYQQHPGKAPKLMIYEVSNRTSS PSGVSNRFSGSKSGNTASLTISGLQAEDE ST ADYYCNSYTSSSTWVFGGGTKLTVL WVCOV047_P5_Lambda_10- 1155 QSALTQPRSVSGSPGQSVTISCTGTSSDV 1156 CSY P1409GGYNYVSWYQQHPGKAPKLMIYDVSK AGS RPSGVPDRFSGSKSGNTASLTISGLQAED YTEADYYCCSYAGSYTWVFGGGTKLTVL WV COV047_P4_Lambda_60- 1159QSALTQPASVSGSPGQSITISCTGTSSDV 1160 SSY P1409 GGYNYVSWYQQHPGKAPKLMIYEVSNTSS RPSGVSNRFSGSKSGNTASLTISGLQAED STS EADYYCSSYTSSSTSWVFGGGTKLTVL WVCOV047_P5_Lambda_29- 1163 QSALTQPASVSGSPGQSITVSCAGSSTD 1164 TSF P1409VGGYNFVSWYQHHPGRVPKLIIYEVNN TSS RPSGVSVRFSGSKSGNTASLTISGLQAED SDSEADYYCTSFTSSSDSWIFGGGTKLTVL WI KAPPA COV047_P3_Kappa_61- 1167DIQLTQSPSFLSASVGDRVTITCRASQGIS 1168 QQL P1389SYLAWYQQKPGKAPKLLIYGASTLQSGV NSY PSRFSGSGSGTEFTLTISSLQPEDFATYYC PLCQQLNSYPLCSFGQGTKLEIK S LAMBDA COV047_P4_Lambda_48- 1171QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1172 QSY P1409 GAGYDVHWYQQLPGTAPKLLIYGNSNRDSG PSGVPDRFSGSKSGTSASLAITGLOAEDE LSG ADYYCQSYDSGLSGSGVVFGGGTKLTVL SGV VCOV047_P3_Lambda_78- 1175 SYVLTQPPSVSVAPGQTARITCGGNNIG 1176 QV P1409SKSVHWYQQKPGQAPVLVVYDDGDRP WD SGIPERFSGSNSGNTATLTISRVEAGDEA SSSDYYCQVWDSSSDHYYVFGTGTKVTVL DHY YV KAPPA COV047_P4_Kappa_43- 1179EIVLTQSPATLSLSPGERATLSCRASQSVS 1180 QQ P1389SYLAWYQQKPGQAPRLLIYDASNRATGI RSN PARFSGSGSGTDFTLTISSLEPEDFAVYYC WPQQRSNWPSFGQGTKLEIK S COV047_P4_Kappa_89- 1183DIQMTQSPSSLSASVGDRVTITCRASQSI 1184 QQS P1389NNYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PRTCQQSYSTPRTFGPGTKVDIK COV047_P5_Kappa_15- 1187AIQLTQSPSSLSASVGDRVTITCRASQGIS 1188 QQF P1389TVLAWYQQKPGKTPKLLIYDASSLESGA NSY PSRFSGSGSGTDFTLTISSLQPEDFATYYC QLTQQFNSYQLTFGGGTKVEIK COV047_P3_Kappa_54- 1191DIQMTQSPSSLSASVGDRVTITCRASQSI 1192 QQS P1389SSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTAFTLTISSLQPEDFATYY PLTCQQSYSTPLTFGGGTKVEIK LAMBDA COV047_P5_Lambda_72- 1195NFMLTQPHSVSESPGKTVTISCTGSSGSI 1196 QSY P1409 ASNYVQWYQQRPGSAPTTVIYEDNQRPDSS SGVPDRFSGSIDSSSNSASLTISGLKTEDE LN ADYYCQSYDSSLNWVFGGGTKLTVL WVCOV047_P4_Lambda_17- 1199 QSVLTQPRSVSGSPGQSVTISCTGTSSDV 1200 CSY P1409GGYNYVSWYQQHPGKAPKLMICDVSK AGS RPSGVPDRFSGSKSGNTASLTISGLOAED YTEADYYCCSYAGSYTWVFGGGTKLTVL WV KAPPA COV047_P5_Kappa_84- 1203DIQMTQSPSSLSASVGDRVTITCRASQSI 1204 QQS P1389SSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PPLCQQSYSTPPLTFGGGTKVEIK T LAMBDA COV047_P4_Lambda_67- 1207QLVLTQSPSASASLGASVKLTCTLSSGHS 1208 QT P1409 SYAIAWHQQQPEKGPRYLMSLNSDGSHWG SKGDGIPDRFSGSSSGAERYLTISSLQSED PW EADYYCQTWGPWVFGGGTKLTVL V KAPPACOV047_P3_Kappa_84- 1211 DIVMTQSPDSLAVSXGERATINCKSSQS 1212 QQ P1389VLYSSNNKNYLAWYQQKPGQPPKLLIY YYS WASTRESGVPDRFSGSGSGTDFTLTISSL TPQQAEDVAVYYCQQYYSTPQPSWTFGQG PS TKVEIK WT COV047_P3_Kappa_40- 1215DIVMTQSPDSLAVSXGERATINCKSSQS 1216 QQ P1389 VLYSSNNKNYLAWYQQKPGQPPKLLIYYYS WASTRESGVPDRFSGSGSGTDFTLTISSL TML QAEDVAVYYCQQYYSTMLTFGGGTKVE T IKLAMBDA COV047_P4_Lambda_36- 1219 QSVLTQPPSVSGAPGQRVTISCTGSSSSI 1220 QSYP1409 GAGYDVHWYQQLPGTAPKLLIYGNSNR DSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSGADYYCQSYDSSLSGSWVFGGGTKLTVL SW V COV047_P4_Lambda_52- 1223NFMLTQPHSVSESPGKTVTISCTGSSGSI 1224 QSY P1409 ASNYVQWYQQRPGSAPTTVIYEDNQRPDST SGVPDRFSGSIDSSSNSASLTISGLKTEDE NH ADYYCQSYDSTNHWVFGGGTKLTVL WV KAPPACOV047_P3_Kappa_70- 1227 DIQMTQSPSSLSASVGDRVTITCQASQD 1228 QQ P1389ISNYLNWYQQKPGKAPKFLIYGASNLET YDN GVPPRFSGSGSGTDFTFIISSLQPEDIATY LPPYCQQYDNLPPTFGGGTKVEIK T COV047_P4_Kappa_31- 1231DVVMTQSPLSLPVTLGQPASISCRSSQSL 1232 MQ P1389 VHSDGNIYLSWYQQRPGQSPRRLIYKVSGTH NRDSGVPDRFSASGSGTDFTLRISRVEAE WP DVGVYYCMQGTHWPRTFGQGTKLEIK RTCOV047_P5_Kappa_30- 1235 DIQMTQSPSSLSASVGDRLTITCRASQSI 1236 QQS P1389TSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PPCQQSYSTPPWTFGQGTKVEIK WT LAMBDA COV047_P4_Lambda_20- 1239QSVLTQPASVSGSPGQSITISCTGTSSDV 1240 SSY P1409 GAYNYVSWYQQHPGKAPKLMIYEVSNRTSS PSGVSNRFSGSKSGNTASLTISGLQAEDE STA ADYYCSSYTSSSTAWVFGGGTKLTVL WVKAPPA COV047_P4_Kappa_22- 1243 DIQLTQSPSFLSASVGDRVTITCRASQGIS 1244 QKVP1389 SYLAWYQQKPGKAPKLLIYGASTLQSGV NSH PSRFSGSGSGTEFTLTISSLQPEDFASYYCPPG QKVNSHPPGLTFGGGTKVEI LT COV047_P4_Kappa_70- 1247EIVMTQSPATLSVSPGERATLSCRASQSV 1248 QQ P1389 SSNLAWYQQKPGQAPRLLIYGASTRATYNN GIPARFSGSGSGTEFTLTISSLQSEDFAVY WP YCQQYNNWPPVTFGPGTKVDIK PVT LAMBDACOV047_P4_Lambda_50- 1251 QSVLTQPPSVSEAPRQRVTISCSGSSSNI 1252 AA P1409GNNAVNWYQQLPGKAPKLLIYYDDLLP WD SGVSDRFSGSKSGTSASLAISGLQSEDEA DSLDYYCAAWDDSLNGWVFGGGTKLTVL NG WV KAPPA COV047_P5_Kappa_59- 1255DIQMTQSPSSVSASVGDRVTITCRASQG 1256 QQ P1389 ISSWLAWYQQKPGKAPKLLIYAASSLQSANS GVPSRFSGSGSGTDFTLTISSLQPEDFAT FPP YYCQQANSFPPLTFGGGTKVEIK LT LAMBDACOV047_P5_Lambda_58- 1259 QSALTQPASVSGSPGQSITISCTGTSSDV 1260 CSY P1409GSYNLVSWYQQHPGKAPKLMIYEGSKR AGS PSGVSNRFSGSKSGNTASLTISGLQAEDE STADYYCCSYAGSSTWVFGGGTKLTVL WV KAPPA COV047_P5_Kappa_8- 1263DIQMTQSPSSLSASVGDRVTITCQASQD 1264 QQ P1389 ISNYLNWYQQKPGKAPKLLIYDASNLETYDN GVPSRFSGSGSGTDFTFTISSLQPEDIATY LPQ YCQQYDNLPQTFGGGTKVEIK TCOV047_P4_Kappa_11- 1267 DIQMTQSPSSLSASVGDRVTITCQASQD 1268 QQ P1389ISNYLNWYQQKPGKAPKLLIYDASNLET YDN GVPSRFSGSGSGTDFTFTISSLQPEDIATY LPLYCQQYDNLPLTFGQGTRLEIK T LAMBDA COV047_P3_Lambda_14- 1271QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1272 QSY P1409 GAGYDVHWCQQLPGTAPKLLIYGYSNRDIN PSGVPDRFSGSKSGTSASLAITGLOAEDE LSA ADYYCQSYDINLSAWVFGGGTRLTXL WVKAPPA COV047_P5_Kappa_91- 1275 DIVMTQSPDSLAVSXGERATINCKSSQS 1276 QQP1389 VLYSSNNKNYLAWYQQKPGQPPKLLIY YYS WASTRESGVPDRFSGSGSGTDFTLTISSL TPLQAEDVAVYYCQQYYSTPLTFGGGTKVEI T K COV047_P4_Kappa_51- 1279DIQMTQSPSSLSASVGDRVTITCQASQD 1280 QQ P1389 ISNYLNWYQQKPGKAPKLLIYDASNLETYDN GVPSRFSGSGSGTDFTFTISSLQPEDIATY LPIT YCQQYDNLPITFGQGTRLEIKCOV047_P3_Kappa_47- 1283 EIVMTQSPATLSVSPGERATLSCRASQSV 1284 QQ P1389SSNLAWYQQKPGQAPRLLIYGASTRAT YNN GIPARFSGSGSGTEFTLTISSLQSEDFAVY WPYCQQYNNWPRTFGQGTKVEIK RT LAMBDA COV047_P5_Lambda_71- 1287QSALTQPASVSGSPGQSITISCTGTSSDV 1288 SSY P1409 GGYNYVSWYQQHPGKAPKLMIYDVSNTSS RPSGVSNRFSGSKSGNTASLTISGLQAED SSW EADYYCSSYTSSSSWVFGGGTKLTVL VCOV047_P5_Lambda_16- 1291 NFMLTQPHSVSESPGKTVTISCTGSSGSI 1292 QSY P1409ASNYVQWYQQRPGSAPTTVIYEDNQRP DSSI SGVPDRFSGSIDSSSNSASLTISGLKTEDE LWADYYCQSYDSSILWVFGGGTKLTVL V COV047_P3_Lambda_25- 1295QSVLTQPASVSGSPGQSITISCTGTSSDV 1296 SSY P1409 GYYNFVSWYQQHPGKAPKLMIYEVSNRRSS PSGVSNRFSGSKSGNTASLIISGLQAEDE STL ADYYCSSYRSSSTLVFGGGTKLTVL VCOV047_P4_Lambda_86- 1299 QSVLTQPPSASGSPGQSVTISCTGTSSDV 1300 TSY P1409GGYNYVSWYQQHPGKAPKLMIYEVSKR AGS PSGVPDRLSGSKSGNTASLTVSGLQAED NNEADYYCTSYAGSNNWVFGGGTKLTVL WV COV047_P4_Lambda_39- 1303NFMLTQSHSVSESPGKTVTISCTGSSGNI 1304 QSY P1409VNNYVQWYQQRPGSAPIIVIYEDTQRPS DSG GVPDRFSGSIDTSSNSASLTISGLKTEDEA SHVDYYCQSYDSGSHVVFGGGTKLTV V KAPPA COV047_P4_Kappa_83- 1307DIQMTQSPSSLSASVGDRVTITCRASQGI 1308 QQ P1389 SNSLAWYQQKPGKAPKLLLYAASRLESGYYS VPSRFSGSGSGTDYTLTISSLQPEDFATYY TRT CQQYYSTRTFGQGTKVEIKCOV047_P3_Kappa_38- 1311 DIQMTQSPSSLSASVGDRVTITCRASQGI 1312 QQ P1389SNYLAWFQQKPGKAPKSLIYAASSLQSG YNS VPSKFSGSGSGTDFTLTISSLQPEDFATYY YPLCQQYNSYPLFTFGPGTKVDIK FT COV047_P4_Kappa_72- 1315DIVMTQSPDSLAVSXGERATINCKSSQS 1316 QQ P1389 VLYSSNNKNYLAWYQQKPRQPPKLLIYYYS WASTRESGVPDRISGSGSGTDFTLTISSL TPL QAEDVAVYYCQQYYSTPLTFGGGTKVEI T KLAMBDA COV047_P4_Lambda_38- 1319 QSVLTQPRSVSGSPGQSVTISCTGTSSDV 1320 CSYP1409 GGYNYVSWYQQHPGKAPKLMIYDVSK AGS RPSGVPDRFSGSKSGNTASLTISGLQAED YTEADYYCCSYAGSYTWVFGGGTKLTVL WV COV047_P3_Lambda_5- 1323QSVLTQPASVSGSPGQSVTISCTGTSSD 1324 CSY P1409 VGSYNLVSWYQQHPGKAPKVMIYEDSKAGS RPSGVSNRFSGSKSGNTASLTISGLQAED ST EADYYCCSYAGSSTWVFGGGTKLTVL WVCOV047_P3_Lambda_35- 1327 NFMLTQPHSVSESPGKTVTISCTGSSGSI 1328 QSY P1409ASNYVQWYQQRPGSAPTTVIYEDNQRP DSSI SGVPDRFSGSIDSSSNSASLTISGLKTEDE WVADYYCQSYDSSIWVFGGGTKLTVL COV047_P3_Lambda_49- 1331QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1332 QSY P1409 GADYDVHWYQQFPGTAPKVLIYANTNRDHS PSGVPERFSGSKSGTSASLAITGLQAEDE LN ADYYCQSYDHSLNWVFGGGTKLTVL WVCOV047_P4_Lambda_23- 1335 QSVLTQPASVSGSPGQSITISCTGTSSDV 1336 SSY P1409GGYNYLSWYQQHPGKAPKLMIYEVSNR TSS PSGVSNRFSGSKSGNTASLTISGLQAEDE STPADYYCSSYTSSSTPFYVFGTGTKVTVL FYV

TABLE 10 Anti-SARS-CoV-2 IgG antibodies from COV57 SEQ SEQ ID IDSEQUENCE_ID NO aa NO cdr3_aa HEAVY COVD57_P1_HC_B4- 1337EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 1338 ARGVA 1369WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ VDWYFVTISADKSISTAYLQWSSLKASDTAMYYCARGVAV DL DWYFDLWGRGTLVTVSSCOVD57_P1_HC_F6- 1341 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 1342 ARGVA1369 WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ VDWYFVTISADKSISTAYLQWSSLKASDTAMYYCARGVAV DL DWYFDLWGRGTLVTVSSCOVD57_P1_HC_G8- 1345 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 1346 ARGVA1369 WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ VDWYFVTISADKSISTAYLQWSSLKASDTAMYYCARGVAV DL DWYFDLWGRGTLVTVSSCOVD57_P2_HC_A2- 1349 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 1350 ARGVA1369 WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ VDWYFVTISADKSISTAYLQWSSLKASDTAMYYCARGVAV DL DWYFDLWGRGTLVTVSSCOVD57_P2_HC_B2- 1353 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWTG 1354 ARGVA1369 WVRQMPGKGLEWMGIIYPGDSDTRYRPAFQGQ VDWYFVTISADKSISTAYLQWSSLKASDTAMYYCARGVAV DL DWYFDLWGRGTLVTVSSCOVD57_P2_HC_B12- 1357 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 1358 ARGVA1369 WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ VDWYFVTISADKSISTAYLQWSSLKASDTAMYYCARGVAV DL DWYFDLWGRGTLVTVSSCOVD57_P2_HC_C10- 1361 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 1362 ARGVA1369 WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ VDWYFVTISADKSISSAYLQWSSLKASDTAMYYCARGVAV DL DWYFDLWGRGTLVTVSSCOVD57_P2_HC_D10- 1365 EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWIG 1366 ARGVA1369 WVRQMPGKGLEWMGIIYPADSDTRYSPSFQGQ VDWYFVTISADKSISTAYLQWSSLKASDTAMYYCARGVAV DL DWYFDLWGRGTLVTVSSCOVD57_P2_HC_E1- 1369 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 1370 ARGVA1369 WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ VDWYFVTISADKSISTAYLQWSSLKASDTAMYYCARGVAV DL DWYFDLWGRGTLVTVSSCOVD57_P1_HC_F3- 1373 QVQLQESGPGLVKPSETLSLTCTVSGASINSYYWT 1374 AREVV1369 WIRQPPGKGLEWIGYIHDSGNTNYNPALRSRVTI VQSAKSLDTSKNQFSLKVRSVTAADTAVYYCAREVVVQS DWSHY AKDWSHYYYYMDVWGKGTTVSVSS YYYMDV COVD57_P2_HC_A6- 1377 QVQLQESGPGLVKPSETLSLTCTVSGGSMTSYYW 1378 AREVV1369 NWIRHTPGKDLEWIGYIDYSGNTNYNPSLRSRGTI VSSPKDSVDTSKNQFSLRVTSVTAADTAVYYCAREVVVSSP WSHYY KDWSHYYYYMDVWGKGTTVTVSS YYMDVCOVD57_P2_HC_B11- 1381 QVQLQESGPGLVKPSETLSLTCTVSGASINSYYWT 1382 AREVV1369 WIRQPPGKGLEWIGYIHDSGNTNYNPALRSRVTI VQSAKSLDTSKNQFSLKVRSVTAADTAVYYCAREVVVQS DWSHY AKDWSHYYYYMDVWGKGTTVSVSS YYYMDV COVD57_P2_HC_D11- 1385 QVQLQESGPGLVKPSETLSLTCTVSGASINSYYWT 1386 AREVV1369 WIRQPPGKGLEWIGYIHDSGNTNYNPALRSRVTI VQSAKSLDTSKNQFSLKVRSVTAADTAVYYCAREVVVQS DWSHY AKDWSHYYYYMDVWGKGTTVSVSS YYYMDV COVD57_P2_HC_F10- 1389 QVQLQESGPGLVKPSETLSLTCTVSGASINSYYWT 1390 AREVV1369 WIRQPPGKGLEWIGYIHDSGNTNYNPALRSRVTI VQSAKSLDTSKNQFSLKVRSVTAADTAVYYCAREVVVQS DWSHY AKDWSHYYYYMDVWGKGTTVSVSS YYYMDV COVD57_P1_HC_B11- 1393 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS 1394 ARDSEY1369 WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV SSSWYSTITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS RGYYG SWYSRGYYGMDVWGQGTTVTVSS MDVCOVD57_P2_HC_A11- 1397 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS 1398 ARDSEY1369 WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV SSSWYSTITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS RGYYG SWYSRGYYGMDVWGQGTTVTVSS MDVCOVD57_P2_HC_E2- 1401 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS 1402 ARDSEY1369 WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV SSSWYSTITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS RGYYG SWYSRGYYGMDVWGQGTTVTVSS MDVCOVD57_P1_HC_B7- 1405 EVQLVESGGGLVQPGGSLRLSCAASGFIFSSYWM 1406 ARQPES1369 TWVRQAPGKGLEWVASIKYNGNERNYVDSVKG TIWYYFRFTISRDNARNSLFLQLNNLGAEDTAVYYCARQPE DY STIWYYFDYWGQGTLVTVSSCOVD57_P1_HC_F5- 1409 EVQLVESGGGLVQPGGSLRLSCAASGFIFSSYWM 1410 ARQPES1369 TWVRQAPGKGLEWVASIKYNGNERNYVDSVKG TIWYYFRFTISRDNARNSLFLQLNNLGAEDTAVYYCARQPE DY STIWYYFDYWGQGTLVTVSSCOVD57_P1_HC_H2- 1413 EVQLVESGGGLVQPGGSLRLSCAASGFIFSSYWM 1414 ARQPES1369 TWVRQAPGKGLEWVASIKYNGNERNYVDSVKG TIWYYFRFTISRDNARNSLFLQLNNLGAEDTAVYYCARQPE DY STIWYYFDYWGQGTLVTVSSCOVD57_P1_HC_D12- 1417 QVQLQQWGAGLLKPSETLSRTCAVFGGSFTNYY 1418 ARRRSF1369 WSWIRQSPGKGLEWIGEINDSGITNYNPSLKSRV SRPSSITISVDTSKNQFSLSLRSVTAADTAVYYCARRRSFSR DY PSSIDYWGQGTLVTVSSCOVD57_P2_HC_B6- 1421 QVQLQQWGAGLLKPSETLSRTCAVFGGSFTNYY 1422 ARRRSF 1369WSWIRQSPGKGLEWIGEINDSGITNYNPSLKSRV SRPSSITISVDTSKNQFSLSLRSVTAADTAVYYCARRRSFSR DY PSSIDYWGQGTLVTVSSCOVD57_P2_HC_H7- 1425 QVQLQQWGAGLLKPSETLSRTCAVFGGSFTNYY 1426 ARRRSF 1369WSWIRQSPGKGLEWIGEINDSGITNYNPSLKSRV SRPSSITISVDTSKNQFSLSLRSVTAADTAVYYCARRRSFSR DY PSSIDYWGQGTLVTVSSCOVD57_P2_HC_H7- 1429 QVQLQQWGAGLLKPSETLSRTCAVFGGSFTNYY 1430 ARRRSF 1369WSWIRQSPGKGLEWIGEINDSGITNYNPSLKSRV SRPSSITISVDTSKNQFSLSLRSVTAADTAVYYCARRRSFSR DY PSSIDYWGQGTLVTVSSCOVD57_P1_HC_E6- 1433 QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA 1434 AANHC 1369MQWVRQARGQRLEWIGWIVVGSGNTNYAQKF SGGSCYQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAN DGFDI HCSGGSCYDGFDIWGQGTMVTVSSCOVD57_P2_HC_H6- 1437 QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA 1438 AAPYCS 1369MQWVRQARGQRLEWIGWIVVGSGNTNYAQKF GGSCNQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAP DAFDI YCSGGSCNDAFDIWGQGTMVTVSSCOVD57_P2_HC_A10- 1441 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW 1442 TTDPH 1369MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP CSSTSCVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT PIFYYYYDPHCSSTSCPIFYYYYMDVWGKGTTVTVSS MDV COVD57_P2_HC_C4- 1445EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW 1446 TTDPH 1369MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP CSSTSCVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT PIFYYYYDPHCSSTSCPIFYYYYMDVWGKGTTVTVSS MDV COVD57_P2_HC_C4- 1449EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW 1450 TTDPH 1369MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP CSSTSCVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT PIFYYYYDPHCSSTSCPIFYYYYMDVWGKGTTVTVSS MDV COVD57_P1_HC_E9- 1453QVQLVESGGGVVOPGRSLRLSCAASGFTFNRIAM 1454 AKSPM 1369YWVRQAPGKGLEWVAVISFDGSYEYYAESVKGRF GYCTNAISRDNSKNTLYLQMNSLRAEDTAVYYCAKSPMG GVCYP YCTNGVCYPDSWGQGTLVTVSS DSCOVD57_P2_HC_G5- 1457 QVQLVESGGGVVQPGRSLRLSCAASGFTFNRIAM 1458 AKSPM 1369YWVRQAPGKGLEWVAVISFDGSYEYYAESVKGRF GYCTNAISRDNSKNTLYLQMNSLRAEDTAVYYCAKSPMG GVCYP YCTNGVCYPDSWGQGTLVTVSS DSCOVD57_P2_HC_G5- 1461 QVQLVESGGGVVQPGRSLRLSCAASGFTFNRIAM 1462 AKSPM 1369YWVRQAPGKGLEWVAVISFDGSYEYYAESVKGRF GYCTNAISRDNSKNTLYLQMNSLRAEDTAVYYCAKSPMG GVCYP YCTNGVCYPDSWGQGTLVTVSS DSCOVD57_P1_HC_F10- 1465 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYY 1466 ARAGF 1369WSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRV GVVITYTISVDTSKNQFSLKLSSVTAADTAVYYCARAGFGV GSGTD VITYGSGTDPLFDYWGQGTLVTVSSPLFDY COVD57_P1_HC_H3- 1469 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYY 1470 ARAGF1369 WSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRV GVVITYTISVDTSKNQFSLKLSSVTAADTAVYYCARAGFGV GSGTD VITYGSGTDPLFDYWGQGTLVTVSSPLFDY COVD57_P1_HC_A5- 1473 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 1474AREYLE 1369 MHWVRQAPGQGLEWMGRINPNSGGTNYAQKF RYFDGQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAR GQRWIEYLERYFDGGQRWISYYYMDVWGKGTAVTVSS SYYYM DV COVD57_P1_HC_A9- 1477QVQLVQSGAEVKKPGASVKVSCKASGYTFSNYYI 1478 AREIPDI 1369HWVRQAPGKGLEWMGMINPNGGTTRYPLKFQ LEVVAAGRVTMTRDTSTRTVYMELNSLRSEDTALYFCAREI TGSLDD PDILEVVAATGSLDDWGQGSLVTVSCOVD57_P1_HC_A11- 1481 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS 1482 ARDSEY1369 WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV SSSWYSTITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS RGYYG SWYSRGYYGMDVWGQGTTVTVSS MDVCOVD57_P2_HC_B1- 1485 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTIS 1486 ARDSG1369 WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV YSGYGSTITADKSTSTAYMELSSLRSEDTAVYYCARDSGYSG TYYMD YGSTYYMDVWGKGTTVTVSS VCOVD57_P1_HC_F11- 1489 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS 1490 ARDSEY1369 WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV SSSWYSTITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS RGYYG SWYSRGYYGMDVWGQGTTVTVSS MDVCOVD57_P2_HC_G11- 1493 EVQLVQSGPVLVKPGPSVKISCKASGFTFTDYYM 1494 ARSGP1369 HWVKQSHGKSLEWIGLVYPYNGGTSYNQKFKGK DYFDYATLTVDTSSSTAYMELNSLTSEDSAVYYCARSGPD YFDYWGQGTTLTVSS COVD57_P2_HC_C12-1497 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM 1498 ARGTTF 1369HWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRF NHYYYTISRENAKNSLYLQMNSLRAGDTAVYYCARGTTF MDV NHYYYMDVWGKGTTVTVSSCOVD57_P2_HC_C3- 1501 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW 1502 TTDVG 1369MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP ADSSSAVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT YYYYY DVGADSSSAYYYYYMDVWGKGTTVTVSSMDV COVD57_P2_HC_E11- 1505 EVQLVESGGGLVKPGGSLRLSCAASGLTFTAYRM 1506 ARDVA1369 NWVRQAPGKGLEWLSSISNTNGDIYYADSVKGR SNYAYFFTISRDNAKNSLYLQMNSLRADDTAVYYCARDVA DL SNYAYFDLWGQGTLVTVSSCOVD57_P2_HC_H12- 1509 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMS 1510 AKDTG1369 WVRQAPGKGLEWVSGMSGSGGITYYADSVKGR SMIVELFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDTGS LGY MIVELLGYWGQGTLVTVSSCOVD57_P2_HC_H12- 1513 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMS 1514 AKDTG1369 WVRQAPGKGLEWVSGMSGSGGITYYADSVKGR SMIVELFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDTGS LGY MIVELLGYWGQGTLVTVSSCOVD57_P1_HC_B8- 1517 EVQLVESGGGLVKPGRSLRLSCTASGFTFGDYAM 1518 TRARSV1369 SWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVK TMVWGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCTRAR YRYYM SVTMVWYRYYMDVWGKGTTVTVSS DVCOVD57_P2_HC_C2- 1521 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAM 1522 AREGPF1369 HWVRQAPGKGLEYVSVISSNGGSTYYANSVKGRF LPSLYSSTISRDNSKNTLYLQMGSLRAEDMAVYYCAREGPF SRDAF LPSLYSSSRDAFDIWGQGTMVTVSS DICOVD57_P1_HC_C8- 1525 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAM 1526 ARGPIA1369 HWVRQAPGKGLEYVSGISSNGGSPYYANSVKGR AAGSYFFTISRDNSKNTLYLQMGSLRAEDMAVYYCARGPI DY AAAGSYFDYWGQGTLVTVSSCOVD57_P1_HC_F9- 1529 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM 1530 ARDLA 1369SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFT VYGMDISRDNSKNTLYLQMNSLRAEDTAVYHCARDLAVY V GMDVWGQGTTVTVSS COVD57_P1_HC_C3-1533 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM 1534 ARDGE 1369SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFT GQRETISRDNSKNTLYLQMNSLRAEDTAVYYCARDGEGQ DY RETDYWGQGTLVTVSS COVD57_P1_HC_G3-1537 EVQLVESGGGLVQPGGSLRLSCAASGFNFSTHW 1538 TRDDSS 1369MHWVRQAPGKGLVWVSRINSDGSRRAYATSVK WPHFFGRFTISRDNAKNTLYLQMDSLRDEDTAVYYCTRD DN DSSWPHFFDNWGQGTLVTVSSCOVD57_P2_HC_B7- 1541 EVQLVESGGGLVQPGGSLRLSCAASGFNFSTHW 1542 TRDDSS 1369MHWVRQAPGKGLVWVSRINSDGSRRAYATSVK WPHFFGRFTISRDNAKNTLYLQMDSLRDEDTAVYYCTRD DN DSSWPHFFDNWGQGTLVTVSSCOVD57_P1_HC_H10- 1545 QVQLQQWGAGLLKPSETLSRTCGVYGGSFRDYY 1546 ARAYVS1369 WSWIRQSPGKGLEWIGEINHSGSTNYNPSLLGRV SVSEDYTISVDTSKNQFSLRLTSVTAADTAVYYCARAYVSSV FDY SEDYFDYWGQGTLVTVSSCOVD57_P1_HC_B9- 1549 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYY 1550 ARHW 1369WSWIRQPPGKGLEWIGEVNHSGSTNYNPSLKSR MPRDYVTISVDTSKNQFFLKLSSVTAADTAVYYCARHWM YYYGM PRDYYYYGMDVWGQGTTVTVSS DVCOVD57_P2_HC_E3- 1553 QVQLQQWGAGLLKPSETLSRTCAVYGGSFTDYY 1554 ARGAK 1369WSWIRQSPGKGLEWIGEINHSGSTNYNPFLKSRV GDSDWTLSVDTSKNQFSLKLDSLTVADTAIYYCARGAKGD YFDL SDWYFDLWGRGTLVTVSSCOVD57_P2_HC_F8- 1557 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWS 1558 ARHYDI1369 WIRQPPGKGLEWIGYIHYSGSTNYNPSLKSRVTIS LTALSWVDTSKNQFSLKLSSVTAADTAVYYCARHYDILTALS FDP WFDPWGQGTLVTVSSCOVD57_P2_HC_H11- 1561 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWS 1562 ARLLST1369 WIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISV EWLFNDTSKNQFSLKLSSVTAADTAVYYCARLLSTEWLFN WFDP WFDPWGQGTLVTVSSCOVD57_P2_HC_A9- 1565 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 1566 ARGIAV1369 WVRQMPGKGLEWVGIIYPGDSDTRYSPSFQGQV DWYFDTISADKSISTAYLQWSSLKASDTAMYYCARGIAVD L WYFDLWGRGTLVTVSS SEQ SEQ ID IDSEQUENCE_ID NO aa NO cdr3_aa LAMBDA COVD57_P1L_B4- 1339QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1340 QSY _1409 GAGYDVHWYQQLPGTAPKLLIYGNSNRDSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSAL ADYYCQSYDSSLSALYVFGTGTKVTVL YVCOVD57_P1_L_F6- 1343 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1344 QSY 1409GAGYDVHWYQQLPGTAPKLLIYGNSNR DSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSALADYYCQSYDSSLSALYVFGTGTKVTVL YV COVD57_P1_L_G8- 1347QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1348 QSY 1409 GAGYDVHWYQQLPGTAPKLLIYGNSNRDSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSAL ADYYCQSYDSSLSALYVFGTGTKVTVL YVCOVD57_P2_L_A2- 1351 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1352 QSY 1409GAGYDVHWYQQLPGTAPKLLIYGNSNR DSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSALADYYCQSYDSSLSALYVFGTGTKVTVL YV COVD57_P2_L_B2- 1355QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1356 QSY 1409 GAGYDVHWYQQLPGTAPKLLIYGNSNRDSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSAL ADYYCQSYDSSLSALYVFGTGTKVTVL YVCOVD57_P2_L_B12- 1359 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1360 QSY 1409GAGYDVHWYQQLPGTAPKLLIYGNSNR DSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSALADYYCQSYDSSLSALYVFGTGTKVTVL YV COVD57_P2_L_C10- 1363QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1364 QSY 1409 GAGYDVHWYQQLPGTAPKLLIYGNSNRDSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSVL ADYYCQSYDSSLSVLYVFGTGTKVTVL YVCOVD57_P2_L_D10- 1367 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1368 QSY 1409GAGYDVHWYQQLPGTAPKLLIYGYTNR DSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSALADYYCQSYDSSLSALYVFGTGTKVTVL YV COVD57_P2_L_E1- 1371QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1372 QSY 1409 GAGSDVHWYQQLPGTAPKLLIYGNSNRDSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSAL ADYYCQSYDSSLSALYVFGTGTKVTVL YVKAPPA COVD57_P1_K_F3- 1375 EIVLTQSPATLSLSPGERASLSCRASQSVG 1376 QQ 1389TYLAWYQQKVGQPPRLLIYDASNRATGI RSS PARFSGSGSGTDFTLTISSLDPEDFAVYYC WFQQRSSWFVTFGQGTRLEIK VT COVD57_P2_K_A6- 1379EIVLTQSPATLSLSPGERATLSCRASQSVS 1380 QQ 1389 TYLTWYQQKPGQAPRLLIYDASNRATGIRST PARFSGSGSGTDFTLTITSLEPEDFALYYC WF QQRSTWFVTFGQGTRLEIK VTCOVD57_P2_K_Bl1- 1383 EIVLTQSPATLSLSPGERASLSCRASQSVG 1384 QQ 1389TYLAWYQQKVGQPPRLLIYDASNRATGI RSS PARFSGSGSGTDFTLTISSLDPEDFAVYYC WFQQRSSWFVTFGQGTRLEIK VT COVD57_P2_K_D11- 1387EIVLTQSPATLSLSPGERASLSCRASQSVG 1388 QQ 1389 TYLAWYQQKVGQPPRLLIYDASNRATGIRSS PARFSGSGSGTDFTLTISSLDPEDFAVYYC WF QQRSSWFVTFGQGTRLEIK VT COVD_K_F10-1391 EIVLTQSPATLSLSPGERASLSCRASQSVG 1392 QQ 1389TYLAWYQQKVGQPPRLLIYDASNRATGI RSS PARFSGSGSGTDFTLTISSLDPEDFAVYYC WFQQRSSWFVTFGQGTRLEIK VT COVD57_P1_K_B11- 1395DIVMTQSPLSLPVTPGEPASISCRSSQSLL 1396 MQ 1389 HSNGYNYLDWYLQKPGQSPQLLIYLGSNALQ RASGVPDRFSGSGSGTDFTLKISRVEAED TPP VGVYYCMQALQTPPTFGGGTKVEIK TCOVD57_P2_K_A11- 1399 DIVMTQSPLSLPVTPGEPASISCRSSQSLL 1400 MQ 1389HSNGYNYLDWYLQKPGQSPQLLIYLGSN ALQ RASGVPDRFSGSGSGTDFTLKISRVEAED TPPVGVYYCMQALQTPPTFGGGTKVEIK T COVD57_P2_K_E2- 1403DIVMTQSPLSLPVTPGEPASISCRSSQSLL 1404 MQ 1389 HSNGYNYLDWYLQKPGQSPQLLIYLGSNALQ RASGVPDRFSGSGSGTDFTLKISRVEAED TPP VGVYYCMQALQTPPTFGGGTKVEIK T LAMBDACOVD57_P1_LB7- 1407 SYELTQPPSVSVSPGQTARVTCSGHALP 1408 QSA 1409DQYTYWYQQRPGRAPVLVIYVNNQRPS DSS GIPDRFSATTSGTTVTLTISGVQAEDEAD GSYYYCQSADSSGSYVVFGGGTKLTVL VV COVD57_P1_LF5- 1411SYVLTQPPSVSVSPGQTARVTCSGHALP 1412 QSA 1409 DQYTYWYQQRPGRAPVLVIYVNNQRPSDSS GIPDRFSATTSGTTVTLTISGVQAEDEAD GSY YYCQSADSSGSYVVFGGGTKLTVL VVCOVD57_P1_L_H2- 1415 SYELTQPPSVSVSPGQTARVTCSGHALP 1416 QSA 1409DQYTYWYQQRPGRAPVLVIYVNNQRPS DSS GIPDRFSATTSGTTVTLTISGVQAEDEAD GSYYYCQSADSSGSYVVFGGGTKLTVL VV KAPPA COVD57_P1_K_D12- 1419DIVMTQSPLSLPVTPGEPASISCRSSQSLL 1420 MQ 1389 HRNGYNYLDWYLQKPGQSPQLLIYLGSALQ NRASGVPDRFRGSGSGTDFTLKISRVEAE TLT DVGVYYCMQALQTLTFGQGTRLEIKCOVD57_P2_K_B6- 1423 DIVMTQSPLSLPVTPGEPASISCRSSQSLL 1424 MQ 1389HRNGYNYLDWYLQKPGQSPQLLIYLGS ALQ NRASGVPDRFRGSGSGTDFTLKISRVEAE TLTDVGVYYCMQALQTLTFGQGTRLEIK COVD57_P2_K_H7- 1427DIVMTQSPLSLPVTPGEPASISCRSSQSLX 1428 MQ 1389 HRNGYNYLDWYLQKPGQSPQLLIYLGSALQ NRASGVPDRFRGSGSGTDFTLKISRVEAE TLT DVGVYYCMQALQTLTFGQGTRLEIKCOVD57_P2_K_H7- 1431 DIVMTQSPLSLPVTPGEPASISCRSSQSLX 1432 MQ 1389HRNGYNYLDWYLQKPGQSPQLLIYLGS ALQ NRASGVPDRFRGSGSGTDFTLKISRVEAE TLTDVGVYYCMQALQTLTFGQGTRLEIK COVD57_P1_K_E6- 1435EIVLTQSPGTLSLSPGERATLSCRASQSVS 1436 QQY 1389SSYLAWYQQRPGQAPRLLIYGASSRATG GSS IPDRFSGSGSGTDFTLTISRLEPEDFAVYY PWCQQYGSSPWMFGQGTKVEIK M COVD57_P2_K_H6- 1439EIVLTQSPGTLSLSPGERATLSCRASQSVS 1440 QQY 1389SSYLAWYQQKPGQAPRLLIYGASSRATG GSS IPDRFSGSGSGTDFTLTISRLEPEDFAVYY PWCQQYGSSPWTFGQGTKVEIK T LAMBDA COVD57_P2_L_A10- 1443SYVLTQPPSVSVAPGQTARITCGGNNIG 1444 QV 1409 SKSVHWYQQKPGQAPVLVVYDDSDRPS WDGIPERFSGSNSGNTATLTISRVEAGDEAD SSS YYCQVWDSSSDQGVFGGGTKLTVL DQ GVCOVD57_P2_L_C4- 1447 SYVLTQPPSVSVAPGQTARITCGGNNIG 1448 QV 1409SKSVHWYQQKPGQAPVLVVYDDSDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEAD SSSYYCQVWDSSSDQGVFGGGTKLTVL DQ GV COVD57_P2_L_C4- 1451SYVLTQPPSVSVAPGQTARITCGGNNIG 14 QV 1409 SKSVHWYQQKPGQAPVLVVYDDSDRPS 52WD GIPERFSGSNSGNTATLTISRVEAGDEAD SSS YYCQVWDSSSDQGVFGGGTKLTVL DQ GVCOVD57_P1_L_E9- 1455 NFMLTQPHSVSESPGKTVTISCTGSSGSI 1456 QSY 1409ASNYVQWYQQRPGSAPTTVIYEDTQRP DIN SGVPDRFSGSIDSSSNSASLTISGLKTEDE SRADYYCQSYDINSRWVFGGGTKLTVL WV COVD57_P2_L_G5- 1459NFMLTQPHSVSESPGKTVTISCTGSSGSI 1460 QSY 1409 ASNYVQWYQQRPGSAPTTVIYEDTQRPDIN SGVPDRFSGSIDSSSNSASLTISGLKTEDE SR ADYYCQSYDINSRWVFGGGTKLTVL WVCOVD57_P2_L_G5- 1463 NFMLTQPHSVSESPGKTVTISCTGSSGSI 1464 QSY 1409ASNYVQWYQQRPGSAPTTVIYEDTQRP DIN SGVPDRFSGSIDSSSNSASLTISGLKTEDE SRADYYCQSYDINSRWVFGGGTKLTVL WV COVD57_P1_L_F10- 1467QSVLTQPPSVSGAPGQRVTISCTGSNSNI 1468 QSY 1409 GAGYDVHWYQQLPGTAPKLLIYGNSNRDSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSG ADYYCQSYDSSLSGSRVFGGGTKLTVL SRVCOVD57_P1_L_H3- 1471 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1472 QSY 1409GAGYDVHWYQQLPGTAPKLLIYGNSNR DSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSGADYYCQSYDSSLSGSRVFGGGTKLTVL SRV COVD57_P1_L_A5- 1475QSVLTQPASVSGSPGQSITISCTGTSSDV 1476 SSY 1409 GGYNYVSWYQQHPGKAPKLMIYDVSNTPN RPSGVSNRFSGSKSGNTASLTISGLQAED STL EADYYCSSYTPNSTLVVFGGGTKLTVL WCOVD57_P1_L_A9- 1479 QSVLTQPPSASGSPGQSVTISCTGTRSDV 1480 SSY 1409GGYNYVSWYQQHPGKAPKLIIYEVTKRP AGI SGVPDRFSGSKSGDTASLTVSGLQADDE TNLADYFCSSYAGITNLVFGGGTKLTV V COVD57_P1_L_A11- 1483QSVLTQPPSASGSPGQSVTISCTGTSSDV 1484 YSY 1409 GGYNYVSWYQHHPGKAPKLMIFEVTKRGG PSGVPDRFSGSKSGNTASLTVSGLQAED NN EADYYCYSYGGNNNAVFGGGTKLTVL NAVCOVD57_P2_L_B1- 1487 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1488 QSY 1409GAGYDVHWYQQLPGTAPKLLIYGNSNR DSS PSGVPDRFSGSKSGTSASLAITGLQAEDE LSGADYYCQSYDSSLSGSVFGTVTKVTVL SV KAPPA COVD57_P1_K_F11- 1491DIVMTQSPLSLPVTPGEPASISCRSSQSLL 1492 MQ 1389 HSNGYNYLDWYLQKPGQSPQLLIYLGSNALQ RASGVPDRFSGSGSGTDFTLKISRVEAED TPP VGVYYCMQALQTPPTFGGGTKVEIK TCOVD57_P2_K_G11- 1495 EIVMTQSPATLSVSPGERATLSCRASQSV 1496 QQY 1389SSNLAWYQQKPGQAPRLLIYGASTRATG NN IPARFSGSGSGTEFTLTISSLQSEDFAVYY WPCQQYNNWPRTFGGGTKVEIK RT COVD57_P2_K_C12- 1499DIQMTQSPSSLSASVGDRVXITCRASQSI 1500 QQS 1389 SSYLNWYQQKPGKAPKLLIYAASSLQSGYST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PP CQQSYSTPPWTFGQGTKVEIK WTCOVD57_P2_K_C3- 1503 EIVLTQSPXSLSLSPGERATLSCGASQSVS 1504 QQY 1389SSYLAWYQQKPGLAPRLLIYDASSRATGI GSS PDRFSGSGSGTDFTLTISRLEPEDFAVYYC PYTQQYGSSPYTFGQGTKLEIK COVD57_P2_K_E11- 1507 EIVMTQSPATLSLSPGERATLSCRASQSV1508 QQY 1389 SSNLAWYHQKPGQAPRLLIYGASTRATG DNIPARFSGSGSGTEFTLTISSLQSEDFAVYY WPL CQQYDNWPLFGQGTRLEIK LAMBDACOVD57_P2_L_H12- 1511 QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1512 QSY 1409GAGSDVHWYQKLPGTAPKVFIYGYNNR DTS PSGVPDRFSGSKSGTSASLAITGLQAEDE LRVADYYCQSYDTSLRVVFGGGTKLTV V COVD57_P2_L_H12- 1515QSVLTQPPSVSGAPGQRVTISCTGSSSNI 1516 QSY 1409 GAGSDVHWYQKLPGTAPKVFIYGYNNRDTS PSGVPDRFSGSKSGTSASLAITGLQAEDE LRV ADYYCQSYDTSLRVVFGGGTKLTV V KAPPACOVD57_P1_K_B8- 1519 DIVMTQTPLSLSVTPGQPASISCKSSQSL 1520 MQ 1389LHSDGKTYLYWYLQKPGQPPQLLIYEVS SIQL NRFSGVPDRFSGSGSGTDFTLKISRVEAE PYTDVGVYYCMQSIQLPYTFGQGTKLEIK LAMBDA COVD57_P2_L_C2- 1523SYVLTQPPSVSVAPGQTARITCGGNNIG 1524 QV 1409 SKSVHWYQQKPGQAPVLVVYDDSDRPS WDGIPERFSGSNSGDTATLTISRVEAGDEAD SSS YYCQVWDSSSDPHYVFGTGTKVTV DPH YVCOVD57_P1_L_C8- 1527 SYVLTQPPSVSVAPGQTARITCGGNNIG 1528 QV 1409SKNVHWYQQKPGQAPVLVVYDDSDRP WD SGIPERFSGSNSGNTATLTISRVEAGDEA SSSDYYCQVWDSSSDPHWVFGGGTKLTVL DPH WV KAPPA COVD57_P1_K_F9- 1531DIQLTQSPSFLSASVGDRVTITCRASQGIS 1532 QQL 1389SYLAWYQQKPGKAPKLLIYAASTLQSGV NSY PSRFSGSGSGTEFTLTISSLQPEDFATYYC PPVQQLNSYPPVTFGQGTRLEIK T COVD57_P1_K_C3- 1535 DIQMTQSPSSLSASVGDRVTITCQASQD1536 QQY 1389 ISNYLNWYQQKPGKAPKLLIYDASNLET DNLGVPSRFSGSGSGTDFTFTISSLQPEDIATY PRT YCQQYDNLPRTFGQGTKVEIK COVD57_P1_K_G3-1539 DIQMTQSPSSLSASVGDRVTITCRASQSII 1540 QQS 1389NYLNWYQQKPGKAPKLLIYTASSLQSGV YSS PSRFSGSGSGTDFTLTISSLQPEDFATYFC PLWQQSYSSPLWTFGQGTKVEIK T COVD57_P2_K_B7- 1543EIVMTQSPATLSVSPGERATLSCRASQSV 1544 QQY 1389 SSNLAWYHQKPGQAPRLLIYGASTRATGDN IPARFSGSGSGTEFTLTISSLQSEDFAVYY WPL CQQYDNWPLFGQGTRLEIKCOVD57_P1_K_H10- 1547 DIQMTQSPSSLSASVGDRVTITCRASQSI 1548 QQS 1389STYLNWYQQKPGKAPELLIYAASSFQSG YTT VPSRFSGSGSGTDFTLTIRSLEPEDSATYY PYTCQQSYTTPYTFGQGTKLEIK COVD57_P1_K_B9- 1551 DIQMTQSPSSLSASVGDRVTITCRASQSI1552 QQS 1389 SSYLNWYQQKPGKAPKLLIYAASSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATYY PRT CQQSYSTPRTFGQGTKVEIK COVD57_P2_K_E3-1555 EIVLTQSPATLSLSPGERATLSCRASQSVS 1556 GD 1389NYLAWYQQKPGQAPRLLISDASNRATG NW VPDRFSGSGSGTDFTLTINSLEPEDFAVY PRYCQQGDNWPRMYTFGQGTKLQIK MYT LAMBDA COVD57_P2_L_F8- 1559QSVLTQPPSVSAAPGQKVTISCSGSSSNI 1560 WD 1409 GNNYVSWYQQLPGTAPKLLIYDNNKRPSSLS SGIPDRFSGSKSGTSATLGITGLQTGDEA AY DYYCGTWDSSLSAYWVFGGGTKLTVL WVCOVD57_P2_L_H11- 1563 SYVLTQPPSVSVSPGQTASITCSGDKLGD 1564 QA 1409KYACWYQQKPGQSPVLVIYQDSKRPSGI WD PERFSGSNSGNTATLTISGTQAMDEADY SSTYCQAWDSSTAYVFGTGTKVTVL AYV COVD57_P2_L_A9- 1567QSVLTQPASVSGSPGQSITISCTGTSSDIG 1568 SSY 1409 VYNYISWSQQHPGKAPKVMIYDVTNRPRGS SGVSNRFSGSKSGNTASLTISGLQAEDEA STP DYYCSSYRGSSTPYVFGTGTKVTVL YV

TABLE 11 Anti-SARS-CoV-2 IgG antibodies from COV72 SEQ SEQ ID IDSEQUENCE_ID NO aa NO cdr3_aa HEAVY COV072_P3_HC_50- 1733EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYA 1734 ANHPLA P1369MSWVRQAPGKGLEWVSTITGSGGFTYYADSV SGDEYY KGRFTISRDNSKNTLFLQMNSLRAEDAAVYYCAYYYMDV NHPLASGDEYYYYYMDVWGKGTTVTVSS COV072_Plate2_HC_24- 1737EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYA 1738 ANHPLA P1369MSWVRQAPGKGLEWVSTITGSGRDTYYADSV SGDDYYKGRFTISRDNSKNTLFLQLNSLRAEDAAVYSCAN HYYMD HPLASGDDYYHYYMDVWGKGTTVTVSS VCOV072_Plate2_HC_66- 1741 EVQLLESGGGLVQPGGSLRLSCVASRFTFSNYA 1742 ANSPCSP1369 MSWVRQAPGKGLEWVSTITGTGDHTYYADSV SASCKSKGRFTISRDNSKNTLYLQMNSLRAEDTAIFYCA GYYYYY NSPCSSASCKSGYYYYYMDVWGKGTTVTVSSMDV COV072_P3_HC_17- 1745 QVQLVQSGSEVKKPGSSVKVSCKASGGTFSSYA 1746 ARVNQP1369 FSWVRQAPGQGLEWIVIGRIIPILALANYAQKFQ AVTTPFGRVTITADKSTSTAYMELSSLRSEDTAVYYCARV SMDV NQAVTTPFSMDVWGQGTTVTVSSCOV072_P3_HC_21- 1749 QVQLVQSGAEVKKPGSSVKVSCKASGDTFSSSA 1750 ARANQ P1369LSWVRQAPGQGLEWIVIGRIIPILGITNYAQKFQ PVTTPFSGRVTITADKSTSTAYMELNSLRSEDTAVYYCARA MDV NQPVTTPFSMDVWGQGTTVTVSSCOV072_P3_HC_53- 1753 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 1754 ARDSDVP1369 MHWVRQAPGKGLEWVAVILYDGSNKYYADSV DTSMVTKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA WFDY RDSDVDTSMVTWFDYWGQGTLVTVSSCOV072_Plate2_HC_83- 1757 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYA 1758 ARDSDVP1369 MHWVRQAPGKGLEWVAVISYDGTNKFYADSV DTAMVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCA TWFDY RDSDVDTAMVTWFDYWGQGTLVTVSSCOV072_P3_HC_80- 1761 EVQLVESGGGLVQPGGSLRLSCAASGITVSSNY 1762 ARDLGDP1369 MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK YGMDVGRVTISRDNSKNTLYLQMNSLRVEDTAVYYCAR DLGDYGMDVWGQGTTVTVSSCOV072_Plate2_HC_36- 1765 EVQLVESGGGLVQPGGSLRLSCAASGVTVSSNY 1766 ARDLYYP1369 MSWVRQAPGKGLEWVSLIYSGGSTFYADSVKG YGMDVRFTISRDNSENTLYLQMNTLRAEDTAVYYCARD LYYYGMDVWGQGTTVTVSS COV072_P3_HC_49-1769 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNY 1770 ARSRPT P1369YMHWVRQAPGQGLEWMGIINPSGGSTGYAQ PDWYF KFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYDL CARSRPTPDWYFDLWGRGTLVTVSS COV072_Plate2_HC_81- 1773QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHY 1774 AKSRPT P1369IHWVRQAPGQGLEWMGIINPSGGSTSYAQKF PDWYF QGRVTMTRDTSTTTLYMDLSSLRSEDTAVYYCADL KSRPTPDWYFDLWGRGTLVTVSS COV072_P3_HC_51- 1777EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYA 1778 AKDPLIT P1369MSWVRQAPGKGLEWVSAISGSDGSTYYAGSV GPTYQY KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAFHY KDPLITGPTYQYFHYWGQGTLVTVSS COV072_Plate2_HC_93- 1781EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYA 1782 AKDPLIT P1369MSWVRQAPGKGLEWVSAISGSDGSTYYAGSV GPTYQY KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAFHY KDPLITGPTYQYFHYWGQGTLVTVSS COV072_P3_HC_12- 1785EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 1786 ARALQG P1369MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV PWLGA KGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCADY RALQGPWLGADYWGQGTLVTVSS COV072_Plate2_HC_33- 1789EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYW 1790 AGGTW P1369MSWVRQPPGKGLEWVANIKQDGSEKYYVDSV LRSSFDYKGRFTISRDNAKNSLYLQMNSLRADDTAVYYCA GGTWLRSSFDYWGQGTLVTVSSCOV072_P3_HC_25- 1793 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSNN 1794 ARGGDTP1369 WWSCVRQPPGKGLEWIGEIYHSGSTNYNPSLK AMGPESRVTISVDKSKNQFSLKLSSVTAADTAVYYCARG YFDY GDTAMGPEYFDYWGQGTLVTVSSCOV072_Plate2_HC_53- 1797 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSNN 1798 AKGGDRP1369 WWSWVRQPPGKGLEWIGEIYHSGSTNYNPSL AMGPEKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCAK YFDY GGDRAMGPEYFDYWGQGTLVTVSSCOV072_P3_HC_44- 1801 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYG 1802 ARVLGIIP1369 ISWVRQAPGQGLEWMGWISAYNGNTKYAQK VAGSLNLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYFC ARVLGIIVAGSLNWGQGTLVTVSSCOV072_P3_HC_40- 1805 QVQLVQSGAEVKKPGASVKVSCKASGYTFSSNY 1806 ARDLGYP1369 MHWVRQAPGQGLEWMGIINPSGGSTTYAQK IPASDAFFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYC DI ARDLGYIPASDAFDIWGQGTMVTVSCOV072_P3_HC_77- 1809 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYT 1810 ARFSNYP1369 1SWVRQAPGHGLEWMGRIIPILGIANYAQKFQ CTSTSCYGRVTITADKSTSTAYMELSSLRSEDTAVYYCARF DY SNYCTSTSCYDYWGQGTLVTVSSCOV072_Plate2_HC_9- 1813 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYG 1814 ARDGITP1369 ISWVRQAPGQGLEWMGWISAYNGNTNYAQK GTIEYYFLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYC DY ARDGITGTIEYYFDYWGQGTLVTVSSCOV072_P3_HC_34- 1817 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELS 1818 ATNAEIP1369 MHWVRQAPGKGLEWIVIGGFDPEDGETIYVQK AARKGGFQGRATMTEHTSTETAYMELSSLRSEDTAVYYC MDV ATNAEIAARKGGMDVWGQGTTVTVSSCOV072_P3_HC_10- 1821 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY 1822 ARDIALP1369 IHWVRQAPGQGLEWMGIINPSAGSTSYAQKF VPAAMQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA GLDY RDIALVPAAMGLDYWGQGTLVTVSSCOV072_P3_HC_42- 1825 QMQLVQSGPEVKKPGTSVKVSCKASGFTFTNS 1826 AAVDC P1369AVQWVRQSRRQRLEWIGWIVVGSGNTNYAQ NSTSCY KFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCDAFDI AAVDCNSTSCYDAFDIWGQGTMVTVSS COV072_P3_HC_31- 1829QVQLVQSGAEVKKPGSSVKVSCKASGGTVNNY 1830 AKVSLTL P1369AINWVRQAPGQGLEWMGGIVPIFGTPNYAQK PIAAAPFQGRVTITADESTSTAYMELSSLRSEDTAVYYCA RFWFDS KVSLTLPIAAAPRFWFDSWGQGTLVTVSSCOV072_P3_HC_30- 1833 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA 1834 ARGWA P1369ISWVRQAPGQGLEWMGRIIPMLVIATYARKFQ ATPGNFGRVTITADKSTSTAYMELSSLRSEDTAVYYCARG DI VVAATPGNFDIWGQGTMVTVSSCOV072_P3_HC_48- 1837 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA 1838 ARDLLDP1369 INWVRQAPGQGLEWMGRIIPIVGIANYAQKFQ PQLDDAGRVTITADKSSSTAYMELSSLRSEDTAVYYCARD FDI LLDPQLDDAFDIWGQGTMVTVSSCOV072_Plate2_HC_40- 1841 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA 1842 ARGGYSP1369 INWVRQAPGQGLEWMGRIIPILDISNYAQKFQ YGQLYYGRVTITADKSTSIAYMELSSLRSEDTAVYYCARG FDY GYSYGQLYYFDYWGQGTLVTVSSCOV072_P3_HC_58- 1845 QVQLVESGGGLVKPGGSLRLSCAASGFTFSHYN 1846 ARDRGYP1369 MIWIRQAPGKGLEWVSYISSSSSYTNCSDSVRG SGYGLDRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARD RFDY RGYSGYGLDRFDYWGQGTLVTVSSCOV072_P3_HC_64- 1849 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYY 1850 ARDNITP1369 MTWIRQAPGKGLEWVSYITTSSSYTNYADSVK MVRGVIGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR VRPND DNITMVRGVIVRPNDGGYYYALDVWGQGTTVGGYYYA TVSS LDV COV072_P3_HC_5- 1853 EVQLLESGGGLVQPGGSLRLSCTASGFTFSTYA1854 AKSKTV P1369 MSWVRQAPGKGLEWVSAISDSGGSTYYADSV ERLPYCKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA GGDCFSKSKTVERLPYCGGDCFSAIDYWGQGTLVTVSS AIDY COV072_Plate2_HC_92- 1857EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 1858 AKAGPA P1369MSWVRQAPGKGLEWISAISGSGGRTYNADSV AAYGW KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYYYYMD KAGPAAAYGWYYYYMDVWGKGTTVTASS V COV072_Plate2_HC_15- 1861QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 1862 AKGPRF P1369MHWVRQAPGKGLEWVAVISYDGTDSVKGRFT GWSYR ISRDTSKNMLYLQMNSLRAEDTAVYYCAKGPRFGGPGFD GWSYRGGPGFDIWGQGTMVTVSS I COV072_P3_HC_45- 1865QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 1866 ASSSGYL P1369MHWVRQAPGKGLEWVAVIPFDGRNKYYADS FHSDY VTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPRF ASSSGYLFHSDYWGQGTLVTVSS COV072_Plate2_HC_31- 1869QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 1870 GWSYR P1369MNWVRQAPGKGLEWVAVISYDGSNTYYTDSV GGSGFD KGRFTISRDNSKNTLYLQMNSLRVDDTATYYCAI KGPRFGWSYRGGSGFDIWGQGTMVTVSS COV072_P3_HC_3- 1873QVQLVESGGGVVQPGRSLRLSCAVSGFTFSSYG 1874 AKQLGL P1369MHWVRQAPGKGLEWVAVISYDGSNKHYADS YCSGGN VKGRFTISRDNSKNTLYVQMNSLRAEDTAMYYCYSGAL CAKQLGLYCSGGNCYSGALDYWGQGTLVTVSS DY COV072_P3_HC_37- 1877QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 1878 AKQNGL P1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV YCSGGS KGRFTISRDNSKNMLYLQMNSLRAEDTAVYYCCYLGYF AKQNGLYCSGGSCYLGYFDYWGQGTLVTVSS DY COV072_Plate2_HC_63- 1881QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 1882 AKGGAY P1369MHWVRQAPGKGLEWVAVISYDGSNKYSADSV SYYYYM KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCADV KGGAYSYYYYMDVWGKGTTVTVSS COV072_P3_HC_69- 1885QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYT 1886 ARDSDT P1369MHWVRQAPGKGLEWVAVISYDGSIKYYADSV AMVDY KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAFDY RDSDTAMVDYFDYWGQGTLVTVSS COV072_P3_HC_74- 1889QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 1890 AKVDLK P1369MHWVRQAPGKGLEWVAVISYDGSNKYYADSV YSYGLYYKGRCTISRDNSKNTLFLQMNSLRPEDTAVYYCA FDY KVDLKYSYGLYYFDYWGQGTLVTVSSCOV072_Plate2_HC_12- 1893 QVQLVESGGGVVQPGRSLRLSCAASGFTFSHYA 1894 ASSSGYLP1369 MHWVRQAPGKGLEWVAVIPFDGSNKYYADSV FHFDYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA SSSGYLFHFDYWGQGTLVTVSSCOV072_Plate2_HC_23- 1897 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNY 1898 ARVRLGP1369 AMHWVRQAPGKGLEWVAVISYDGSKKYSADS AYYNYFVKGRFTISRDNSKNTLYLQMNSLRPVDTAVYYC GMDV ARVRLGAYYNYFGMDVWGQGTTVTVSSCOV072_P3_HC_68- 1901 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 1902 AKKGQPP1369 MHWVRQAPGKGLEWVAVISYDGSNKYYADSV YCGGDCKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA YFYYFDY KKGQPYCGGDCYFYYFDYWGQGTLVTVSSCOV072_Plate2_HC_72- 1905 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 1906 ARDGTGP1369 MHWVRQAPGKGLEWVAVIWYDGSNKYYADS IAAAGTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ANPPFD ARDGTGIAAAGTANPPFDYWGQGTLVTVSSY COV072_Plate2_HC_25- 1909 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYG 1910ATSLFGI P1369 MHWVRQAPGKGLEWVAVIWYDGNNKYYADS ISLDYVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ATSLFGIISLDYWGQGTLVTVSSCOV072_Plate2_HC_54- 1913 QVQLVESGGGVVQPGRSLRLSCAASGFTFNNY 1914 ARDWEIP1369 GMHWVRQAPGKGLEWVAVIWYDGSNKYYAD WAGMSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYY DV CARDWEIVVAGMDVWGQGTTVTVSSCOV072_Plate2_HC_78- 1917 EVQLVESGGVVVQPGGSLRLSCAASGFTFDDH 1918 AKGLNYP1369 TMHWVRQAPGKGLEWVSLISWDAGSTYYADS RPQYYYVKGRFTISRDNRKNFLYLQMNSLRTEDTALYYC YYGMD AKGLNYRPQYYYYYGMDVWGQGTTVTVSS VCOV072_P3_HC_26- 1921 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 1922 ARSFYFP1369 MSWVRQAPGKGLEWISVIYSGGSTFYADSVKG DAFDIRFTISRDNSKDTLYLQMNRLRAEDTAVYYCARS FYFDAFDIWGQGTMVTVSS COV072_P3_HC_67-1925 EVQLVESGGGLIQPGGSLRLSCAASGFIVSRNY 1926 TRDPVP P1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK GRGDAY GRFTISRDNSKNTLYLQMNSLRADDTAVYYCTRDPVPGRGDAYWGQGTLVTVSS COV072_Plate2_HC_89- 1929EVQLVETGGGLIQPGGSLRLSCAASGITVSSNY 1930 ARDLYY P1369MSWVRQAPGKGLEWVSIIYSGGSTFYADSVKG YGMDV RFTISRDNPKNTLYLQMNSLRAEDTAVYYCARDLYYYGMDVWGQGTTVTVS COV072_P3_HC_22- 1933EVQLVESGGGLVQPGGSLRLSCSASGFTFSSYA 1934 VKDITM P1369MHWVRQAPGKGLEYVSAISSNGGSTYYADSVK IVDVFEYGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCVK DITMIVDVFEYWGQGTLVTVSSCOV072_P3_HC_47- 1937 EVQLVESGGGLVQPGGSLRLSCAASEFIVSRNY 1938 ARDIAGP1369 MSWVRQAPGKGLEWVSLIYSGGSTYYADSVKG RLDYRFTISRDNSKNTLYLQMNSLRAEDTAMYYCARD IAGRLDYWGQGTLVTVSS COV072_P3_HC_59-1941 EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNY 1942 ARDLW P1369MSWVRQAPGKGLEWVSILYSGGSTYYADSVKG YGADY RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGADYWGQGTLVTVSS COV072_Plate2_HC_16- 1945EVQLVESGGDLVQPGGSLRLSCAASGLTVSSNY 1946 ARDLOY P1369MSWVRQAPGKGLEWVSVIYSGGSTFYADSVK YGMDV GRFTISRDNSQNTLYLQMNSLRAEDTAVYYCARDLQYYGMDVWGQGTTVTVSS COV072_Plate2_HC_37- 1949EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 1950 ARDQVS P1369MSWVRQAPGKGLEWVANIKQDGSVKYYVDSV WYNLD KGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAAFDI RDQVSWYNLDAFDIWGQGTMVTVSS COV072_Plate2_HC_86- 1953QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDY 1954 VRWM P1369SWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKS SGIAAARVTISVDTSKNQFSLKLSSVTAADTAVYYCVRVV GQNDY MSGIAAAGQNDYWGQGTLVTVSSCOV072_Plate2_HC_32- 1957 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDY 1958 ARTYYYP1369 YWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKS DSSGYYRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTY FQYYFD YYDSSGYYFQYYFDCWGQGTLVTVSS CCOV072_Plate2_HC_67- 1961 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY 1962 ATNYDDP1369 YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS YVPAEYRVTISVDTSKKQFSLKLSSVTAADTAVYYCATNY FQD DDYVPAEYFQDWGQGTLVTVSSCOV072_Plate2_HC_88- 1965 QVQLQESGPGLVKPSQTLSLTCTFSGGSISSGGH 1966 ARSCSSP1369 YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS TSCPFDRVIISVDTSKNQFSLRLSSVTAADTAVYYCARSCS Y STSCPFDYWGQGTLVTVSSCOV072_Plate2_HC_74- 1969 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYY 1970ARRPPG P1369 WGWIRQSPGKGLEWIGSIYYSGSTYYNPSLKSR DYYYMVTISVDTSKNQFSLKLSSVTAADTAVYYCARRPP DV GDYYYMDVWGKGTTVTVSSCOV072_P3_HC_4- 1973 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNS 1974 ARSGSY P1369TAWNWIRQSPSRGLEWLGRTYYRSKWYNHYA YISHGMLSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYC DV ARSGSYYISHGMDVWGQGTTVTVSSCOV072_P3_HC_54- 1977 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 1978 ARNDGSP1369 MHWVRQAPGKGLEWVAVISYDGSNKYYADSV SGWYPEKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RGGGFD RNDGSSGWYPERGGGFDYWGQGTLVTVSS YCOV072_P3_HC_94- 1981 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 1982 ARALSFIP1369 IHWVRQAPGKGLEWVAVISNDGSNKYYEDSVK AVAGIDGRFTFSRDNSKNTLYLQMNSLRAEDTAVYYCAR Y ALSFIAVAGIDYWGRGTLVTVSSCOV072_P3_HC_91- 1985 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 1986 ARADLGP1369 MFWVRQAPGKGLEWVAVISYDGSNKYYADSV YCTNGVKGRFTISRDNSKNTLYLQI\/INSLRAEDTAVYYCA CYVDY RADLGYCTNGVCYVDYWGQGTLVTVSSCOV072_Plate2_HC_14- 1989 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNY 1990 ASHLMPP1369 MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK DAFDIGRFTISRDNSKNTLYLHMNSLRAEDTAVFYCAS HLMPDAFDIWGQGTMVTVSS COV072_P3_HC_1-1993 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 1994 ARWGY P1369MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK DFWSG GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYDGGYF VVGYDFWSGYDGGYFDYWGQGTLVTVSS DY COV072_P3_HC_71- 1997QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYG 1998 ARGEW P1369MHWVRQAPGKGLEWVAVIWYDGSNKYYADS DSGSYQ VKGRFTISRDNSKNTLYLKMNSLRAEDTAVYYCYYDYYM ARGEWDSGSYQYYDYYMDVWGKGTTVTVSS DV COV072_Plate2_HC_5- 2001EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 2002 ARDTGR P1369MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV ITFGGG KGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCADDAFDI RDTGRITFGGGDDAFDIWGQGTMVTVSS COV072_Plate2_HC_71- 2005QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY 2006 ARGVVL P1369YWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS ITDYYFDRVTISVDTSQNQFSLRLSSVTAADTAVYYCARG Y VVLITDYYFDYWGQGTLVTVSSCOV072_P3_HC_73- 2009 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYS 2010 AREGAVP1369 WSWIRQPPGKGLEWIGEINHGGSTNYNASLKS AGGDFRVTISADTSKNLFSLKLSSVTAADTAVYYCAREG DY AVAGGDFDYWGQGTLVTVSSCOV072_Plate2_HC_76- 2013 QVQLQESG PG LVKPS ETLS LTCTVSGGS1SSYYW 2014ARGRGL P1369 SWIRQPPGKGLEWIGYIYYSGSTRYNPSLKSRVT PPWFDPISVDTSKNQFSLKLSSVTAADTAVFYCARGRGLP PWFDPWGQGTLVTVSS COV072_P3_HC_18-2017 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 2018 ARPDM P1369SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT SSSSSPHISVDTSKNQFSLKLSSVTAADTAVYYCARPDMSS YWYFDL SSSPHYWYFDLWGRGTLVTVSSCOV072_P3_HC_84- 2021 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWI 2022 ARRGGSP1369 VWVRQMPGKGLERMGIIYPGDSDTRYSPSFQG YYNNGDQVTISADKSISTAYLQWSSLKASDTAMYYCARR GMDV GGSYYNNGDGMDVWGQGTTVTVSSCOV072_P3_HC_55- 2025 EVQLVESGGGLVKPGGSLRLSCAAASGFTISNA 2026 TTDYSIRP1369 WMSWVRQAPGKGLEWVGRIKSKTDGGTTDY YYYGMAAPVKGRFTISRDNSKNTLYLQMNSLKTEDTAV DV YYCTTDYSIRYYYGMDVWGQGTTVTVSSCOV072_P3_HC_38- 2029 EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYS 2030 ARAKLEIP1369 MNWVRQAPGKGLEWVSSISSSSNYIYYADSVK AHYGGSGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR PGFDY AKLEIAHYGGSPGFDYWGQGTLVTVSSCOV072_P3_HC_36- 2033 EVQLVESGGGLVKPGGSLRLSCAASGFSFRSYS 2034 ARMGLEP1369 MNWVRQAPGKGLEWVSSISSSSSYIYYADSVK LPGLDYGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR GMDV MGLELPGLDYGMDVWGQGTTVTVSSCOV072_Plate2_HC_94- 2037 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYA 2038 AKVDYGP1369 MTWVRQAPGKGLEWVSAISGSGGRTYYADSV EYVFSNKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA AFDI KVDYGEYVFSNAFDIWGQGTMVSVSSCOV072_P3_HC_56- 2041 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNY 2042 AKAGGR P1369GMHWVRQAPGKGLEWVAVLSYEGSSTYYADS DYYDSS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCGYYLLD AKAGGRDYYDSSGYYLLDHYYGMDVWGQGTT HYYGM VTVSS DV SEQ SEQ ID IDSEQUENCE_ID NO aa NO cdr3_aa KAPPA COV072_Plate3_Kappa_50- 1735EIVLTQSPGTLSLSPGERATLSCRASQSV 1736 QQY P1389 NSRQLAWYQQKPGQGPRLLIYGASSRGSS ATGIPDRFSGSGSGTDFTLTISRLEPEDF RAL AVYYCQQYGSSRALTFGGGTKVEIK TCOV072_Plate2_Kappa_24- 1739 EIVLTQSPGTLSLSPGERATLSCRASQSV 1740 QQYP1389 NSRQLAWYQQKPGQAPRLLIYGASSR GSS ATGIPERFSGSGSGTDFTLTISRLESEDF RALAVYHCQQYGSSRALTFGGGTKVEIK T COV072_Plate2_Kappa_66- 1743EIVLTQSPGTLSLSPGERATLFCRASQSV 1744 QQY P1389 TSSHLAWYQQKAGQAPRLLIYGASSRAGSS TGIPDRFSGSGSGTDFTLTISRLEPEDFA RSLT VYYCQQYGSSRSLTFGGGTKVEIKCOV072_Plate3_Kappa_17- 1747 EIVMTQSPATLSVSPGERATLSCRASQS 1748 QQY P1389VSSNLAWYQQKPGQAPRLLIYGASTRA NN TGIPARFSGSGSGTEFTLTISSLQSEDFA WPIVYYCQQYNNWPITFGQGTRLEIK T COV072_Plate3_Kappa_21- 1751EIVMTQSPATLSVSPGERATLSCRASQS 1752 QQY P1389 VSSNLAWYQQKPGQAPRLLIYAASTRANN TGIPARFSGSGSGTEFTLTISSLQSEDFA WPI VYYCQQYNNWPITFGQGTRLEIK TCOV072_Plate3_Kappa_53- 1755 DIQMTQSPSSLSASVGDRVTITCRASQS 1756 QQS P1389ISSYLNWYQQKPGKAPKLLIYAASSLQS YSTP GVPSRFSGSGSGTDFTLTISSLQPEDFA PWTTYYCQQSYSTPPWTFGQGTKVEIK COV072_Plate2_Kappa_83- 1759DIQMTQSPSSLSASVGDRVTITCRASQS 1760 QQS P1389 ISSYLNWYQHKPGKAPKLLIYASSSLQSYSTP GVPSRFSGSGSGTDFTLTISSLQPEDFA PWT TYYCQQSYSTPPWTFGQGTKVEIKCOV072_Plate3_Kappa_80- 1763 DIQLTQSPSFLSASVGDRVTITCRASQGI 1764 QQLP1389 SSYLAWYQQKPGKAPKLLIYAASTLQSG NSY VPSRFSGSGSGTEFTLTISSLQPEDFATY PPYYCQQLNSYPPYTFGQGTKLEIK T COV072_Plate2_Kappa_36- 1767DIQLTQSPSFLSASVGDRVTITCRASQGI 1768 QQL P1389SSYLAWYQQKPGKAPKLLIYAASTLQSG NSY VPSRFSGSGSGTEFTLTISSLQPEDFATY SYTYCQQLNSYSYTFGQGTKLEIK LAMBDA COV072_Plate3_Lambda_49- 1771SYVLTQPPSVSVAPGKTARITCGGNNIG 1772 QV P1409 SKSVHWYQQKPGQAPVLVIYYDSDRPSWDS GIPERFSGSNSGNTATLTISRVEAGDEA SSD DYYCQVWDSSSDHPGVVFGGGTKLTV HPG L WCOV072_Plate2_Lambda_81- 1775 SYVLTQPPSVSVAPGKTARITCGGNNIG 1776 QV P1409SKSVHWYQQKPGQAPVLVIYYDNDRP WD SGIPERFSGSNSGNTATLTISRVEAGDE GGSADYYCQVWDGGSDHPGVVFGGGTKL DHP TVL GW COV072_Plate3_Lambda_51- 1779SYVLTQPPSVSVAPGKTARITCGGNNIG 1780 QV P1409 SKSVHWYQQKPGQAPVLVIYYDSDRPSWDS GIPERFSGSNSGNTATLTISRVEAGDEA SSD EYHCQVWDSSSDRPGVVFGGGTKLTV RPG L WCOV072_Plate2_Lambda_93- 1783 SYVLTQPPSVSVAPGKTARITCGGNNIG 1784 QV P1409SKSVHWYQQKPGQAPVLVIYYDSDRPS WDS GIPERFSGSNSGNTATLTISRVEAGDEA SSDEYHCQVWDSSSDRPGVVFGGGTKLTV RPG L W COV072_Plate3_Lambda_12- 1787NFMLNQPPCEXESPGKTVTISCTGSSG 1788 QSY P1409 SIASNYDQWYQQRPGSAPTTVIYEDKQDSS RTSGVLDWFSGSXARSSNSPSLTIXGRK KGV REDEADXYCQSYDSSKGVFGGGTKLTV LCOV072_Plate2_Lambda_33- 1791 NFMLTQPHSVSESPGKTVTISCTGSSGS 1792 QSYP1409 IASNYVQWYQQRPGSAPTTVIYEDNQ DSS RPSGVPDRFSGSIDSSSNSASLTISGLKT NWEDEADYYCQSYDSSNWVFGGGTKLTV V L COV072_Plate3_Lambda_25- 1795QSVLTQPASVSGSPGQSITISCTGTSSD 1796 SSYT P1409 VGGYNYVSWYQQH PGKAPKLMIYDVSSSST NRPSGVSNRFSGSKSGNTASLTISGLQA LL EDEADYYCSSYTSSSTLLFGGGTKLTVLCOV072_Plate2_Lambda_53- 1799 QSVLTQPASVSGSPGQSITISCTGTSSD 1800 SSFTP1409 VGGYNYVSWYQQH PGKAPKLMIYDVS SSST NRPSGVSNRFSGSKSGNTASLTISGLQA LLEDEADYYCSSFTSSSTLLFGGGTRLTVL COV072_Plate3_Lambda_44- 1803NFVLTQPHSVSESPGKTVTISCTGSSGSI 1804 QSY P1409 ASNYVQWYQQRPGSAPTTVIYEDNQRDSS PSGVPDRFSGSIDSSSNSASLTISGLKTE TWV DEADYYCQSYDSSTWVFGGGTKLTVLCOV072_Plate3_Lambda_40- 1807 QSVLTQPRSVSGSPGQSVTISCTGTSSD 1808 CSYP1409 FGGYNYVSWYQQHPGKAPKLIVIIYDVS KRPSGVPDRFSGSKSGNTASLTISGLQA AGSEDEADYYCCSYAGSYTRYVFGTGTKVT YTR VL YV COV072_Plate3_Lambda_77- 1811QSVLTQPPSVSGAPGQRVTISCTGSNS 1812 QSY P1409 NIGAGYDVHWYQQLPGTAPKLLIYVNSDSSL NRPSGVPDRFSGSKSGTSASLAITGLQA SGS EDEADYSCQSYDSSLSGSVFGTGTKVTV V LKAPPA COV072_Plate2_Kappa_9- 1815 EIVLTQSPATLSLSPGERATLSCRASQSV 1816 QQRP1389 SSYLAWYQQKPGQAPRLLIYDASNRAT SNW GIPARFSGSGSGTDFTLTISSLEPEDFAV PPGYYCQQRSNWPPGVTFGQGTRLEIK VT COV072_Plate3_Kappa_34- 1819DIVMTQSPLSLPVTPGEPASISCRSSQSL 1820 MQ P1389 LYSNGYNYLDWYLQKPGQSPQLLIYLGALQ SNRASGVPDRFSGSGSGTDFTLKISRVE TPW AEDVGVYYCMQALQTPWTFGQGTKV T EIKCOV072_Plate3_Kappa_10- 1823 DIQMTQSPSSLSASVGDRVTITCRASQS 1824 QQS P1389SSRYLNWYQQKPGKAPKLLIYAASSLQS YRT GVPSRFSGSGSGTDFTLTISSLQPEDFA RLTTYYCQQSYRTRLTFGGGTKVEIK COV072_Plate3_Kappa_42- 1827EIVLTQSPGTLSLSPGERATLSCRASQSF 1828 QQY P1389 RSSYLAWYQQKPGQAPRLLIYGASSRADISP TGIPDRFSGSGSGSDFTLTISRLEPEDFA WT VYYCQQYDISPWTFGQGTKVEIKCOV072_Plate3_Kappa_31- 1831 EIVMTQSPATLSVSPGERATLSCRASQS 1832 QQY P1389VSSHLAWYQQKPGQAPRLLIYGASTRA HN TGIPARFSGSGSGTEFTLTISSLQSEDFA WPPVYYCQQYHNWPPALTFGGGTKVEIK ALT COV072_Plate3_Kappa_30- 1835EIVMTQSPATLSVSPGERATLSCRASQS 1836 QQY P1389 VSSNLAWYQQKPGQAPRLLIYGASTRANNG TGIPARFSGSGSGTEFTLTISSLQSEDFA LT VYYCQQYNNGLTFGGGTKVEIKCOV072_Plate3_Kappa_48- 1839 EIVLTQSPGTLSLSPGERATLSCRASQSV 1840 QQYP1389 SSTYLAWYQQKPGQAPRLLIYGASSRA GSS TGIPDRFSGSGSGTDFTLTISRLEPEDFA PWTVYYCQQYGSSPWTFGQGTKVEIK COV072_Plate2_Kappa_40- 1843EIVLTQSPGTLSLPPGERATLSCRASQSV 1844 QQY P1389 SSSYLAWYQQKPGQAPRLLIYGASSRAANS TGIPDRFSGSGSGTDFTLTISRLEPEDFA RT VYYCQQYANSRTFGQGTKVEIKCOV072_Plate3_Kappa_58- 1847 DIQMTQSPSSLSASVGDRVTITCQASQ 1848 QQY P1389DISNYLNWYQQKPGKAPKLLIYDASHL DNL ETGVPSRFSGSGSGTDFTFTISSLQPEDI PLTATYYCQQYDNLPLTFGGGTKVEIK COV072_Plate3_Kappa_64- 1851DIQMTQSPSSLSASVGDRVTITCRASQS 1852 QQS P1389 ISSYLNWYQEKPGKAPKLLIYAASSLQSYSTR GVPSRFSGSGSGTDFTLTISSLQPEDFA ALT TYYCQQSYSTRALTFGGGTKVEIKCOV072_Plate3_Kappa_5- 1855 DIQMTQSPSSLSASVGDRVTITCQASQ 1856 QQY P1389DISNYLNWYQQKPGKAPKLLIYDASNL DNL ETGVPSRFSGSGSGTDFTFTISSLQPEDI PPFTATYYCQQYDNLPPFTFGPGTKVHIK COV072_Plate2_Kappa_92- 1859DIQMTQSPSSLSASVGDRVTITCRASQ 1860 QKY P1389 GISNYLAWYQQKPGKVPKLLIYAASTLQNSA SGVPSRFSGSGSGTDFTLTISSLQPEDVS LGFT TYYCQKYNSALGFTFGPGTKVDIKCOV072_Plate2_Kappa_15- 1863 DIQMTQSPSSLSASVGDRVTITCQASQ 1864 QQY P1389DISNYLNWYQQKPGKAPKLLIYDASNL DNL ETGVPSRFSGSGSGTDFTFTISSLQPEDI PITATYYCQQYDNLPITFGQGTRLEIK COV072_Plate3_Kappa_45- 1867DIQMTQSPSTLSASVGDRVTITCRASQS 1868 QQY P1389 ISNWLAWFQQKPGKAPKLLIYEAXSLESNSY GVPSRFSGSGSGTEFTLTISSLQPDDFA PWT TYYCQQYNSYPWTFGQGTKVEIKCOV072_Plate2_Kappa_31- 1871 DIQMTQSPSSLSASVGDRVTITCQASQ 1872 QQY P1389DISNYLNWYQQKPGKAPKLLIYDASNL DNL ETGVPSRFSGSESGTDFTFTISSLQPEDI PITATYYCQQYDNLPITFGQGTRLEIK COV072_Plate3_Kappa_3- 1875DIQMTQSPSSLSASVGDRVTITCQASQ 1876 QQY P1389 DISNYLNWYQQKPGKAPKLLIYDASNLDNL ETGVPSRFSGSGSGTDFTFTISSLQPEDI PFT ATYYCQQYDNLPFTFGPGTKVDIKCOV072_Plate3_Kappa_37- 1879 DIQMTQSPSSLSASVGDRVTITCQASQ 1880 LOY P1389DISNYLNWFQQKPGKAPKLLIYAASDLE DNL TGVPSRFSGSGSGTDFTFTISSLQPEDIA PLTSYYCLQYDNLPLTFGGGTKVEIK COV072_Plate2_Kappa_63- 1883DIQMTQSPSSLSASVGDRVTITCQASQ 1884 QQY P1389 DISNYLNWYQQKPGKAPKLLIYDASNLDNL ETGVPSRFSGSGSGTDFTFTISSLQPEDI PLT ATYYCQQYDNLPLTFGGGTKVEIKCOV072_Plate3_Kappa_69- 1887 DIQMTQSPSSLSASVGDRVTITCRASQS 1888 QQS P1389ISSYLNWYQQKAGKAPKLLIYAASSLQS YSTF GVPSRFSGSGSGTDFTLTISSLQPEDFA MYTTYYCQQSYSTFMYTFGQGTKLEIK COV072_Plate3_Kappa_74- 1891DIQMTQSPSSLSASVGDRVTITCRASQS 1892 QQT P1389 ISSYLNWYQQKPGKAPKLLIYAASSLQSYITP GVPSRFSGSGSGTDFTLTISSLQPEDFA PS TYYCQQTYITPPSFGPGTKVDIKCOV072_Plate2_Kappa_12- 1895 DIQMTQSPSTLSASVGDRVTITCRASQS 1896 QQY P1389ISSWLAWYQQKPGKAPKLLIYKASSLES NSY GVPSRFSGSGSGTEFTLTISSLQPDDFA PWTTYYCQQYNSYPWTFGQGTKVEIK COV072_Plate2_Kappa_23- 1899DIVMTQSPLSLPVTPGEPASISCRSSQSL 1900 MQ P1389 LHSNGYNYLDWYLQKPGQSPQLLIYLGALQ SNRASGVPDRFSGSGSGTDFTLKISRVE TFT AEDVGVYYCMQALQTFTFGPGTKVDIKCOV072_Plate3_Kappa_68- 1903 DIQMTQSPSSLSASLGDRVTITCQASQ 1904 QQY P1389DISNYLNWYQQKPGKAPKLLIYDASNL DNL ETGVPSRFSGSGSGTDFTFTISSLQPEDI PPITATYYCQQYDNLPPITFGQGTRLEIK COV072_Plate2_Kappa_72- 1907DIQMTQSPSSLSASVGDRVTITCQASQ 1908 QQY P1389 DISNYLNWYQQKPGKAPKLLIYDASNLDNL ETGVPSRFSGSGSGTDFTFTISSLQPEDI PYT ATYYCQQYDNLPYTFGQGTKLEIKCOV072_Plate2_Kappa_25- 1911 AIQMTQSPSSLSASVGDRVTITCRAGQ 1912 LOD P1389GIRNDLGWYQQKPGKAPKLLIYAASSL YNY QSGVPSRFSGSGSGTDFTLTISSLQPED PYTFATYYCLQDYNYPYTFGQGTKLEIK COV072_Plate2_Kappa_54- 1915DVVMTQSPLSLPVTLGQPASISCRSSQS 1916 MQ P1389 LVYNDGNTYLNWFQQRPGQSPRRLIYGTH KVSNRDSGVPDRFSGSGSGTDFTLKISR CPFT VEAEDVGVYYCMQGTHCPFTFGPGTK VDIKCOV072_Plate2_Kappa_78- 1919 DIVMTQSPLSLPVTPGEPASISCRSSQSL 1920 MQ P1389LHSNGYNYLDWYLQKPGQSPQLLIYLG ALQ SNRASGVPDRFSGSGSGTDFTLKISRVE TPWAEDVGVYYCMQALQTPWTFGQGTKV T EIK COV072_Plate3_Kappa_26- 1923DIQLTQSPSFLSASVGDRVTITCRASQGI 1924 QQL P1389SSYLAWYQQKPGKAPKLLIYAASTLQSG NSY VPSRFSGSGSGTEFTLTISSLQPEDFATY PLLTYCQQLNSYPLLTFGGGTKVEIK COV072_Plate3_Kappa_67- 1927DIQMTQSPSSLSASVGDRVTITCQASQ 1928 QQY P1389 DISNYLNWYQQKPGKAPKLLIYDASNLDNL ETGVPSRFSGSGSGTDFTFTISTLQPEDI PIT ATYYCQQYDNLPITFGGGTKVEIKCOV072_Plate2_Kappa_89- 1931 DIQLTQSPSFLSASVGDRVTITCRASQGI 1932 QQLP1389 SSYLAWYQQKPGKAPKLLIYAASTLQSG NSY VPSRFSGSGSGTEFTLTISSLQPEDFATY PTYCQQLNSYPTFGQGTKLEIK COV072_Plate3_Kappa_22- 1935DIQMTQSPSSLSASVGDRVTITCRASQS 1936 QQS P1389 ISNYLNWYQQKPGKAPKLLIYAASSLQSYTTP AVPSRFSGSGSGTDFTLTISSLQPEDFAT YT YFCQQSYTTPYTFGQGTKLEIKCOV072_Plate3_Kappa_47- 1939 DIQMTQSPSSLSASVGDRVTITCQASQ 1940 QHY P1389DISKYLNWYQQKPGKAPKLLIYDASNLE DSLS TGVPSRFSGSGSGTDFTFTISSLQPEDF RLTATYYCQHYDSLSRLTFGGGTKVEIK COV072_Plate3_Kappa_59- 1943DIQLTQSPSFLSASVGDRVTITCRASQGI 1944 QQL P1389SSYLAWYQQKPGKAPKLLIYAASTLQSG NSY VPSRFSGSGSGTEFTLTISSLQPEDFATY PPPYCQQLNSYPPPFGGGTKVEIK COV072_Plate2_Kappa_16- 1947DIQLTQSPSFLSASVGDRVTITCRASQGI 1948 QQP P1389SSYLAWYQQKPGKAPKLLIYAASTLQSG DSF VPSRFSGSGSGTEFTLTISSLQPEDFATY TYCQQPDSFTFGPGTKVDIK COV072_Plate2_Kappa_37- 1951DVVMTQSPLSLPVTLGQPASISCRSSQS 1952 MQ P1389 LVYSDGDTYLNWFQQRPGQSPRRLIYKGTH VSNRDSGVPDRFSGSGSGTDFTLKISRV WPK EAEDVGVYYCMQGTHWPKTFGQGTK T LEIKCOV072_Plate2_Kappa_86- 1955 DIQMTQSPSSLSASVGDRVTITCQASQ 1956 QQY P1389DISSYLNWYQQKPGKAPKLLIYDASNLE DILP TGVPSRFSGSGSGTDFTFTISSLQPEDIA PMYTYYCQQYDILPPMYTFGQGTKLEIK T COV072_Plate2_Kappa_32- 1959EIVLTQSPGTLSLSPGERATLSCRASLSV 1960 QQY P1389 SSSYLAWYQQKPGQAPRLLIYGASSRAGSS TGIPDRFSGSGSGTDFTLTISRLEPEDFA PLT VYYCQQYGSSPLTFGGGTKVEIKCOV072_Plate2_Kappa_67- 1963 EIVLTQSPATLSLSPGERATLSCRASQSV 1964 QQRP1389 SSYLAWYQQKPGQAPRLLIYDASNRAT SNW GIPARFSGSGSGTDFTLTISSLEPEDFAV PPLTYYCQQRSNWPPLTFGGGTKVEIK COV072_Plate2_Kappa_88- 1967DIQMTQSPSSLSASVGDRVTITCQASQ 1968 QQY P1389 DISNSLNWYQQKPGKAPKVLIYDASNLDNL ETGVPSRFSGSGSGTDFTFTISSLQPEDF PFT ATYYCQQYDNLPFTFGPGTKVDIKCOV072_Plate2_Kappa_74- 1971 DIQMTQSPSSLSASVGDRVTITCRASQS 1972 QQS P1389ISSYLNWYQQKPGKAPKLLIYAASSLQS YSIP GVPSRFSGSGSGTDFTLTISSLQPEDFA QITTYYCQQSYSIPQITFGQGTRLEIK COV072_Plate3_Kappa_4- 1975EIVMTQSPATLSVSPGERATLSCRASQS 1976 QQY P1389 VSSNLAWYQQRPGQAPRLLIYGASTRANN TGIPARFSGSGSGTEFTLTISSLQSEDFA WPP VYYCQQYNNWPPWTFGQGTKVEIK WT LAMBDACOV072_Plate3_Lambda_54- 1979 QSVLTQPPSVSGAPGQRVTISCTGSSS 1980 QSY P1409NIGAGYDVKWYQQLPGTAPKLLIYGNS DSSL NRPSGVPDRFSGSKSGTSASLAITGLQA SGLEDEADYYCQSYDSSLSGLWVFGGGTKL WV TVL COV072_Plate3_Lambda_94- 1983NFMLTQPHSVSESPGKTVTISCTGSSGS 1984 QSY P1409 IASNYVQWYQQRPGSAPTIVIYEDNQRDST PSGVPDRFSGSIDSSSNSASLTISGLKTE THV DEADYYCQSYDSTTHVVFGGGTKLIVL VCOV072_Plate3_Lambda_91- 1987 NFMLTQPHSVSESPGKTVTISCTGSSGS 1988 QSYP1409 IASNYVQWYQQRPGSAPTTVIYEDNQ DSS RPSGVPDRFSGSIDSSSNSASLTISGLKT NWEDEADYYCQSYDSSNWVFGGGTKLTV V L COV072_Plate2_Lambda_14- 1991QSVLTQPASVSGSPGQSITISCTGTSSD 1992 CSY P1409 VGSYNLVSWYQQHPGKAPKLMIYEVSGGS KRPSGVSNRFSGSKSGNTASLTISGLQA STSF EDEADYYCCSYGGSSTSFYVFGTGTKVT YV VLCOV072_Plate3_Lambda_1- 1995 QSALTQPASVSGSPGQSITISCTGTSSD 1996 CSY P1409VGSYNLVSWYQQHPGKAPKLMIYEVS AGS KRPSGVSNRFSGSKSGNTASLTISGLQA STWEDEADYYCCSYAGSSTWVFGGGTKLTV V L COV072_Plate3_Lambda_71- 1999QSVLTQEPSFSVSPGGTVTLTCGLSSGS 2000 VLY P1409 VSTSYYPSWYQQTPGQPPRTLIYITNTRMGS SSGVPDRFSGSILGNKAALTITGAQADD SNW ESDYYCVLYMGSSNWVFGGGTKLTVL VCOV072_Plate2_Lambda_5- 2003 SYVLTQPPSVSVAPGKTARITCGGNNIG 2004 QV P1409SKSVHWYQQKPGQAPVLVIYYDSDRPS WDS GIPERFSGSKSGNTATLTISRVEAGDEA SSDDYYCQVWDSSSDHRVFGGGTKLTVL HRV COV072_Plate2_Lambda_71- 2007SYVLTQPPSVSVSPGQTARITCSGDTLP 2008 QSA P1409 KQYVYWYQQKPGQAPALVIYKDSERPSDSS GIPERLSGSSSGTTATLTISGVQAEDEA GTR DYYCQSADSSGTRFGGGTKLTVLCOV072_Plate3_Lambda_73- 2011 SYVLTQPPSVSVAPGKTARITCGGNNIG 2012 QV P1409SKSVHWYQQKPGQAPVLVIYYDSDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEA GTSDYYCQVWDGTSDHPGWVFGGGTKLT DHP VL GW V COV072_Plate2_Lambda_76- 2015NFMLTQPHSVSESPGKTVTISCTGSSGS 2016 QSY P1409 IASNYVQWYQQRPGSAPTTVIYEDNQDSS RPSGVPDRFSGSIDSSSNSASLTISGLKT NVV EDEADYYCQSYDSSNVVFGGGTKLTVLCOV072_Plate3_Lambda_18- 2019 SYVLTQPPSVSVAPGKTARITCGGNNIG 2020 QV P1409SKNVHWYQQKPGQAPVLVVYYDSDR WDS PSGIPERFSGSNSGNTATLTISRVEAGD SSGEADYYCQVWDSSSGHFHVVFGGGTKL HFH TVL W COV072_Plate3_Lambda_84- 2023SYVLTQPPSVSVSPGQTASITCFGDKLG 2024 QA P1409 DKYACWYQQKPGQSPVLVIYQDSKRPWDS SGIPERFSGSNSGNTATLTISGTQAMDE STP ADYYCQAWDSSTPHVVFGGGTKLTVL HVVCOV072_Plate3_Lambda_55- 2027 SYVLTQPPSVAVSPGQTARITCSGDALP 2028 QSAP1409 KQYAYWYQQKPGQAPVLVIYKDSERPS DSS GIPERFSGSSSGTTVTLTISGVQAEDEA GTYDYYCQSADSSGTYEVFGGGTKVTVL EV COV072_Plate3_Lambda_38- 2031SYELTQPPSVSVSPGQTASITCSGDKLG 2032 QA P1409 DKYTCWYQQKPGQSPVLVIYQDTQRPWDS SGIPERFSGSNSGNTATLTISGTQAMDE STG ADYYCQAWDSSTGVVFGGGTKVTVL WCOV072_Plate3_Lambda_36- 2035 QSVLTQPPSVSEAPRQRVTISCSGSSSN 2036 AA P1409IGNNAVNWYQQLPGKAPKLLIYYDDLL WD PSGVSDRFSGSKSGTSASLAISGLQSED DSFEADYYCAAWDDSFNGPVFGGGTKLTV NGP L V COV072_Plate2_Lambda_94- 2039QSVLTQPASVSGSPGQSITISCTGTSSD 2040 CSY P1409 VGSYNLVSWYQQHPDKAPKLMIYEVSAGT KRPSGVSNRFSGSKSGNTASLTISGLQA STYV EDEADYYCCSYAGTSTYVFGTGTKLTVLCOV072_Plate3_Lambda_56- 2043 QSVLTQPPSVSGAPGQRVTISCTGSSS 2044 QSY P1409NIGAGYDVHWYQQLPGTAPKLLIYGNS DSSL NRPSGVPDRFSGSKSGTSASLAITGLQA SGFEDEADYYCQSYDSSLSGFYVFGTGTKVT YV VL

TABLE 12 Anti-SARS-CoV-2 IgG antibodies from COV96 SEQ SEQ ID IDSEQUENCE_ID NO aa NO cdr3_aa HEAVY COV096_HC_100-pl369 2045EVQLLESGGGLEQPGGSLRLSCAASGFTFSTYAM 2046 ARESDCGSWVRQAPGKGLEWVSAISGSGAGTFYADSVKGR STSCYQVFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESD GWFDP CGSTSCYQVGWFDPWGQGTLVTVSSCOV096_HC_164-pl369 2049 EVQLLESGGGLVQPGTSLRLSCAASGFTFSSYAMS 2050ATERIAVA WVRQAPGKGLEWVSAISSSGGSTYYADSVKGRF GTRMYNTISRDNSKNTLYLHMNSLRAEDTAVYYCATERIAV WFDP AGTRMYNWFDPWGQGTLVTVSSCOV096_HC_25-pl369 2053 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAM 2054 ASEEDYSSWVRQAPGKGLEWVSAITDSGDGTFYADSVKGR NYVGWFFTISRDNSKNTLYLQMNSLRAEDTAVYYCASEEDY DP SNYVGWFDPWGQGTLVTVSSCOV096_HC_91-pl369 2057 EVQLLESGGGLEQPGGSLRLSCAASGFTFSTYAM 2058 ARESDCGSWVRQAPGKGLEWVSAISGSGAGTFYADSVKGR STSCYQVFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESD GWFDP CGSTSCYQVGWFDPWGQGTLVTVSSCOV096_HC_91-pl369 2061 EVQLLESGGGLEQPGGSLRLSCAASGFTFSTYAM 2062 ARESDCGSWVRQAPGKGLEWVSAISGSGAGTFYADSVKGR STSCYQVFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESD GWFDP CGSTSCYQVGWFDPWGQGTLVTVSSCOV096_HC_115-pl369 2065 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM 2066 ARDTLGRSWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFT GGDYISRDNSKNTLYLQMNSLRAEDTAVYYCARDTLGR GGDYWGQGTLVTVSS COV096_HC_133-pl3692069 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM 2070 ARDTFGRSWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFT GGDYISRDNSKNTLYLQMNSLRAEDTAVYYCARDTFGR GGDYWGQGTLVTVSS COV096_HC_34-pl3692073 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM 2074 ARDTLGRSWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFT GGDYISRDNSKNTLYLQMNTLRAEDTAVYYCARDTLGR GGDYWGQGTLVTVSS COV096_HC_34-pl3692077 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM 2078 ARDTLGRSWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFT GGDYISRDNSKNTLYLQMNTLRAEDTAVYYCARDTLGR GGDYWGQGTLVTVSS COV096_HC_106-pl3692081 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2082 AKGVEYSMHWVRQAPGKGLEWVSGISWNSDSIGYADSVK SSSNFDYGRFTISRDNAKNSLYLQMNSLTAEDTALYYCAKG VEYSSSSNFDYWGQGTLVTVSSCOV096_HC_132-pl369 2085 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2086 VKGVEYSMHWVRQAPGKGLEWVSGISWNSGSIGYADSVK SSSNFDYGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVKG VEYSSSSNFDYWGQGTLVTVSSCOV096_HC_6-pl369 2089 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2090 VKGVEYSMHWVRQAPGKGLEWVSGISWNSGSIGYADSVK SSSNFDYGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVKG VEYSSSSNFDYWGQGTLVTVSS HEAVYCOV096_HC_116-pl369 2093 QVQLVQSGAEVKKPGASVKVSCKASGYTVTGYYI 2094ARERYFDL HWVRQAPGQGLEWMGWISPNSGGTNYAQKF GGMDVQGWVTMTRDMSITTAYMELSRLRSDDTAVYYCA RERYFDLGGMDVWGQGTTVTVSSCOV096_HC_77-pl369 2097 QVQLVQSGAEVKKPGASVKVSCKASGYTVTGYYI 2098 AREPYFDLHWVRQAPGQGLEWMGWISPNSGGTNYAQKF GGMDV QGWVTMTRDMSITTAYMELSRLRSDDTAVYYCAREPYFDLGGMDVWGQGTTVTVSS COV096_HC_138-pl369 2101QVQLVQSGAEVKKSGASVKVSCKASGYTFTSYDI 2102 ARGFSLTNWVRQATGQGLEWMGWMNPNSGNTGYAQK WYFDL FQGRVTMTRNTSISTAYMDLSSLRSEDTAVYYCARGFSLTWYFDLWGRGTLVTVSS COV096_HC_176-pl369 2105QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDV 2106 ARGFSLTNWVRQATGQGLEWMGWMNPNSGSAGYAQK WYFDL FQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARGFSLTWYFDLWGRGTLVTVSS COV096_HC_104-pl369 2109EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM 2110 ARVQVGANWVRQAPGKGLEWVSFISSRSSYIYYADSVKGRF RGWVDYTISRDNAKNSLYLQMNSLRAEDTAVYYCARVQVG ARGWVDYWGQGTLVTVSSCOV096_HC_111-pl369 2113 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM 2114 ARVQVGANWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF RGWVDYTISRDNAKNSLYLQMNSLRAEDTAVYYCARVQVG ARGWVDYWGQGTLVTVSS HEAVYCOV096_HC_158-pl369 2117 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAM 2118 AKEPIGQSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGR PLLWWDFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEPIG Y QPLLWWDYWGQGTLVTVSSCOV096_HC_78-pl369 2121 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAM 2122 AKEPIGQSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGR PLLWWDFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEPIG Y QPLLWWDYWGQGTLVTVSSCOV096_HC_130-pl369 2125 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2126 AKGSSSGMHWVRQVPGKGLEWVSGISWNSASIGYADSVK WTRPLDYGRFTISRDNAKNSLYLQMNSLRPEDMAFYYCAKG SSSGWTRPLDYWGQGTLVTVSSCOV096_HC_44-pl369 2129 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2130 AKGSSSGMHWVRQVPGKGLEWVSGISWNSASIGYADSVK WTRPLDYGRFTISRDNAKNSLYLQMNSLRPEDMAFYYCAKG SSSGWTRPLDYWGQGTLVTVSS HEAVYCOV096_HC72-pl369 2133 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGI 2134 ARRPRDYSWVRQAPGQGLEWMGWISAYNGNTNYAQKL YDRSGYYQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR YVPGYFDRPRDYYDRSGYYYVPGYFDYWGQGTLVTVSS Y COV096_HC_4-pl369 2137QVQLVQSGAEVKKPGASVKVSCKASGSTFTGYY 2138 AREKVATMHWVRQAPGQGLEWMGWINPNSGGTNYAQ MFALPPY KFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCGMDV AREKVATMFALPPYGMDVWGQGTTVTVSS COV096_HC_127-pl369 2141QVQLVQSGAEVKKPGASVKVSCKASGYTFTYYY 2142 ARPLLPGEMHWVRQAPGQGLEWMGIINPSGGSTSYAQKF TGSLNRLQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR DY PLLPGETGSLNRLDYWGQGTLVTVSSCOV096_HC_113-pl369 2145 QVQLVQSGAEVKKPGASVKVSCKASGHTFTSYY 2146 ARGPERGMHWVRQAPGQGLEWMGIINPSGGSTSYAQKF IVGATDYFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR DY GPERGIVGATDYFDYWGQGTLVTVSSCOV096_HC_153-pl369 2149 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNAI 2150 ASEWEIFSWVRQAPGQGLEWMGGITPIFGTVNYAQKFQG GFDYRVTITADESTSTAYMELSSLRSEDTAVYYCASEWEI FGFDYWGQGTLVTVSS COV096_HC_55-pl3692153 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS 2154 TSGQGAGWVRQAPGQGLEWMGGIIPIFGTTNHAQKFQGR VNRGVVIVTITADESTSTAYMELSSLRSEDTAVYYCTSGQGA TTLGY GVNRGVVITTLGYWGQGTLVTVSSCOV096_HC_42-pl369 2157 QVQLVQSGAEVKKPGSSVKVSCKASGGTISSYAIS 2158 ARDDGQWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGR QLWSYFDVTITADESTSTAYMELSSLRSEDTALYYCARDDGQ Y QLWSYFDYWGQGTLVTVSSCOV096_HC_156-pl369 2161 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYM 2162 ARDLPPRSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFT RFDIISRDNAKNSLYLQMNSLRAEDTAVYYCARDLPPR RFDIWGQGTMVTVSS COV096_HC_137-pl3692165 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM 2166 ARGDSGSHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGR YLGVWYFFTISRENAKNSLYLQMNSLRAGDTAVYYCARGDS DL GSYLGVWYFDLWGRGTLVTVSSCOV096_HC_75-pl369 2169 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM 2170 ARDRGSSHWVRQATGKGLEWVSAIGTAGDTYYPDSVKGR GWYGWYFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRG FDL SSGWYGWYFDLWGRGTLVTVSSCOV096_HC_123-pl369 2173 EVQLVESGGGLVQPGGSLRLSCAASGFIFSSYDM 2174 ARGDYNIHWVRQATGKGLEWVSTIGTAGDTYYPDSVKGRF LTGYYFDYTISRENAKNSLYLQMNSLRAGDTAVYYCARGDYN ILTGYYFDYWGQGTLVTVSSCOV096_HC_65-pl369 2177 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM 2178 ARDRDSSHWVRQATGKGLQWVSAIGTAGDTYYPDSVKGR WSFDYFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRD SSWSFDYWGQGTLVTVSS COV096_HC_81-pl3692181 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM 2182 ARGTFFYHWVRQASGKGLEWVSAIGTSGDTYYPGSVKGRF GSGSYNTISRENAKNSLYLQMNSLRAGDTAVYYCARGTFF WFDP YGSGSYNWFDPWGQGTLVTVSSCOV096_HC_166-pl369 2185 EVQLVESGGGLVKPGGSLRVSCAASGFSFSYAW 2186 TTLSDYGMSWVRQAPGKGLEWVGRIKSKTDGGTTDCAAP DLSSVYVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT LSDYGDLSSVYWGQGTLVTVSSCOV096_HC_140-pl369 2189 EVQLVESGGGLVKPGGSLRLSCAASGFTVRSYSM 2190 AKEEYYGNWVRQAPGKGLEWVSCMTSSGSYLYYADSVKG MDV RFTISRDNAKNSLYLQMNSLRDEDTAVYYCAKEEYYGMDVWGQGATVTVSS COV096_HC_43-pl369 2193QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 2194 AKQLYYYMHWVRQAPGKGLEWVAVISYDGSNKYYADSVK GSGSYVFGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKQ DY LYYYGSGSYVFDYWGQGTLVTVSSCOV096_HC_21-pl369 2197 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 2198 AKDTPGGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVK DDILTGWGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKD GLYGMD TPGGDDILTGWGLYGMDVWGQGTTVTVSSV COV096_HC_122-pl369 2201 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYG 2202ARDMGTL MHWVRQAPGKGLEWVAVIWYDGSNKHYADSV VTHFDYKGRFTISRDNSKNTLYLQMNSLRAEDTAEYYCAR DMGTLVTHFDYWGQGTLVTVSSCOV096_HC_98-pl369 2205 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 2206 ARDVGRVMHWVRQAPGKGLEWVAAIWYDGSNKHYADSV TTWFDPKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DVGRVTTWFDPWGQGTLVTVSSCOV096_HC_48-pl369 2209 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSM 2210 ARASGLRNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRF SYYYYGMTISRDNAKNSLYLQMNSLRDEDTAVYYCARASGL DV RSYYYYGMDVWGQGTTVTVSSCOV096_HC_79-pl369 2213 EVQLVESGGGLVQPGGSLRLSCAASGFTFTNYN 2214 ARVVGSGMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKG SYYYYGMRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARVV DV GSGSYYYYGMDVWGQGTTVTVSSCOV096_HC_3-pl369 2217 EVQLVESGGGLVQPGRSLRLSCTASGFTFGDYAM 2218 TRDLSYYYNWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVR DSSGRGSGRFTISRDDSESIAYLQMNSLKTEDTAVYYCTRDL HLFDY SYYYDSSGRGSHLFDYWGQGTLVTVSSCOV096_HC_3-pl369 2221 EVQLVESGGGLVQPGRSLRLSCTASGFTFGDYAM 2222 TRDLSYYYNWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVR DSSGRGSGRFTISRDDSESIAYLQMNSLKTEDTAVYYCTRDL HLFDY SYYYDSSGRGSHLFDYWGQGTLVTVSSCOV096_HC_134-pl369 2225 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYM 2226 ARDLMAYSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRF GMDV TFSRDNSKNTLYLQMNSLRAEDTAVYYCARDLMAYGMDVWGQGTTVTVSS COV096_HC_68-pl369 2229EVQLVESGGGLIQPGGSLRLSCAASGVIVSSNYM 2230 ARDGGHYSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRF GMDVTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGH YGMDVWGQGTTVTVSS COV096_HC_183-pl3692233 EVQLVESGGGLIQPGGSLRLSCAASGLTVSRNYM 2234 ARESYGMNWVRQAPGKGLEWVSVMYSGGSTFYADSVKGR DV FTISRDNSKNTLYLQMNSLRAEDTAVYYCARESYGMDVWGQGTTVTVSS COV096_HC_74-pl369 2237EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNYM 2238 ARDYGDFSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRF YFDYTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGD FYFDYWGQGTLVTVSS COV096_HC_45-pl3692241 EVQLVESGGGLVQPGGSLRLSCAASGFNFSTHW 2242 TRDDSSWMHWVRQAPGKGLVWVSRINSDGSRRAYATSVK PHFFDNGRFTISRDNAKNTLYLQMDSLRDEDTAVYYCTRD DSSWPHFFDNWGQGTLVAVSSCOV096_HC_126-pl369 2245 EVQLVESGGGLVQPGGSLRLSCAASGFNFSTHW 2246 TRDDSSWMHWVRQAPGKGLVWVSRINSDGSRRAYATSVK PHFFDNGRFTISRDNAKNTLYLQMDSLRDEDTAVYYCTRD DSSWPHFFDNWGQGTLVTVSSCOV096_HC_8-pl369 2249 EVQLVQSGAEVKKPGESLKISCKGSGYTFTSYWIG 2250 ARPVTYDWVRQMPGKGLEWMGFIYPGDSDTRYSPSFQG WYFDLQVTISADKSISTAYLQWSSLKASDTAMYYCARPVT YDWYFDLWGRGTLVTVSSCOV096_HC_124-pl369 2253 EVQLVQSGAEVKKPGESLKISCKVSGYTFTNYWIG 2254ARVPSSS WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ DYGDYGGVTISADKSIITAYLQWSSLKASDTAMYYCARVPSSS FEY DYGDYGGFEYWGQGTLVTVSSCOV096_HC_28-pl369 2257 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 2258 ARMVTSGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ TYYYDNSVTISADKSISTAYLQWSSLKASDTAMYYCARMVT GYSSSGPFSGTYYYDNSGYSSSGPFDYWGQGTLVTVSS DY COV096_HC_12-pl369 2261EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWI 2262 ARLSDRWGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG YSPFDPQVTISADKSITTAYLQWSSLKASDTAMYYCARLSD RWYSPFDPWGQGTLVTVSS HEAVYCOV096_HC_90-pl369 2265 QVQLVQSGAELKKPGASVKVSCKASGYTFNSYGI 2266 ARRVEDNSWVRQAPGQGLEWMGGISAYNGNTNYAQKLO GDDGGDGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARR YYYYYGMVEDNGDDGGDYYYYYGMDVWGQGTTVTVSS DV COV096_HC_71-pl369 2269QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYS 2270 ARDLEYCSMHWVRQAPGQGLEWMGWINPNSGGTNYAQ STSCYTSTKFQGRVTMTRDTSISTAYMELSRLGSDDTAVYYC TFDY ARDLEYCSSTSCYTSTTFDYWGQGTLVTVSSCOV096_HC52-pl369 2273 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYY 2274 ASGIGHNMHWVRQAPGQGLEWMGWINPNSGGTNYAQ WNYVSTP KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCNGMDV ASGIGHNWNYVSTPNGMDVWGQGTTVTVSS COV096_HC_10-pl369 2277QVQLVQSGAEVKKPGASVRVSCKASGYTFTGYYI 2278 ARDFAMHWVRQAPGQGLEWMGWINPMSGGTNYTQKF GTVTGTF QGWVTMTRDTSINTAYMELSRLRSDDTAVYYCAVY RDFAMGTVTGTFVYWGQGTLVTVSS COV096_HC_2-pl369 2281QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY 2282 AREGVGGMHWVRQAPGQGLEWMGIINPSGGSTRYAQKF TSYFDYQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR EGVGGTSYFDYWGQGTLVTVSSCOV096_HC_30-pl369 2285 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS 2286 ARDGLSGWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGR HFPHNWVTITADESTSTAYMELSSLRSEDTAVYYCARDGLS FDP GHFPHNWFDPWGQGTLVTVSSCOV096_HC_136-pl369 2289 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS 2290ARREAYG WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGR PRDYYYYYVTITADESTSTAYMELSSLRSEDTAVYYCARREAY GMDV GPRDYYYYYGMDVWGQGTTVTVSSCOV096_HC_99-pl369 2293 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS 2294 ARVLGYYWGRQAPGQGLEWMGGIIPILGTVNYAQKFQGR DSSGSNDVTITADKSTSTAYMELSSLRSEDTAVYYCARVLGY AFDI YDSSGSNDAFDIWGQGTMVTVSSCOV096_HC_152-pl369 2297 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDI 2298 ARGGRYCNWVRQATGQGLEWMGWMNPNSGNTGYAQK SDVSCYSFQGRVTITRDTSISTAYMELSSLRXEDTAVYYCAR GTGFDY GGRYCSDVSCYSGTGFDYWGQGTLVTVSSCOV096_HC_50-pl369 2301 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW 2302 TTDLGYCSMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP STNCYYYYVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT DLGYCSSTNCYYYYWGQGTLVTVSSCOV096_HC_92-pl369 2305 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW 2306 TTDDPGSMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP YYYGMDVVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT DDPGSYYYGMDVWGQGTTVTVSSCOV096_HC_40-pl369 2309 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 2310 ARAGTTNMHWVRQAPGKGLEWVALISYDGSNKHYADSVK SDYFDYGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARA GTTNSDYFDYWGQGTLVTVSSCOV096_HC_149-pl369 2313 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 2314 AKGGYSYMHWVRQAPGKGLEWVAVISYDGSNKYYADSVK GYSLYYFDGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKG Y GYSYGYSLYYFDYWGQGTLVTVSSCOV096_HC_157-pl369 2317 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 2318 AKAQYSYMHWVRQAPGKGLEWVAVISYDGSNKYYADSVK GYVVYYFGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKA DY QYSYGYWYYFDYWGQGALVTVSSCOV096_HC_121-pl369 2321 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYM 2322 ARSLWLRSWVRQAPGKGLEWVSVISSGGGTFYADSVKGRF GSFQHTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLWL RGSFQHWGQGTLVTVSS COV096_HC_27-pl3692325 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 2326 ARGDYDFMSWVRQAPGKGLEWVATIKQDGSEKYYVDSVK WSGYYDYGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG DYDFWSGYYDYWGQGTLVTVSSCOV096_HC_142-pl369 2329 EVQLVESGGGLVQPGGSLRLSCAASRFTFSSYW 2330 ATAPWLRMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVK GGFDYGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATA PWLRGGFDYWGQGTLVTVSSCOV096_Hc_1-pl369 2333 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2334 AKIADIVRMHWVRQAPGKGLEWVSGVSWNSGTIGYADSV AYDFWSGKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKI QHFDAFDADIVRAYDFWSGQHFDAFDIWGQGTMVTVSS I COV096_HC_15-pl369 2337EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2338 AKDGGSGMHWVRQAPGKGLEWVSGISWNSGIIGYADSV TTEYEAYYMGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAK FDY DGGSGTTEYEAYYFDYWGQGTLVTVSSCOV096_HC_20-pl369 2341 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2342 AKDMGRMHWVRQAPGKGLEWVSGISWNSGTIGYADSV DDSSGSLLQGRFIISRDNAKNSLYLQMNSLRAEDTALYYCAK FDY DMGRDDSSGSLLFDYWGQGTLVTVSSCOV096_HC_159-pl369 2345 EVQLVESGGGLIQPGRSLRLSCAASGFTFDDYAM 2346AKDIGSKR HWVRQAPGKGLEWVSGTSWNSGTIGYADSVKG STSENYGRFTISRDNAKNSLYLQMNRLRAEDTALYHCAKDI MDV GSKRSTSENYGMDVWGQGTTVTVSSCOV096_HC_103-pl369 2349 QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYY 2350ASLRGAY WGWIRQPPGKGLEWIGTIYYGGSTYYNPSLKSRV YDFWSGPTISVDTSKNQISLKLSSVTAADTAVYYCASLRGAYY RDGGWF DFWSGPRDGGWFDPWGQGTLVTVSS DPCOV096_HC_23-pl369 2353 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGSYY 2354 AREIPSTWSWIRQPAGKGLEWIGHIYTSGSTNYNPSLKSRV WYFDLTISVDTSKNQFSLKLSSVTAADTAVYYCAREIPST WYFDLWGRGTLVTVSS COV096_HC_101-pl3692357 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGNYY 2358 ARDIPPTLTWIRQPAGKGLEWIGHIYTSGSTNYNPSLKSRVT WYFDLISVDTSMNQFSLKLSSVTAADTAVYYCARDIPPT WYFDLWGRGTLVTVSS COV096_HC_174-pl3692361 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSHWIG 2362 ARLPSGRWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ YNWFDPVTISADKSISTAYLQWSSLKASDTAMYYCARLPSG RYNWFDPWGQGTLVTVSSCOV096_HC_189-pl369 2365 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG 2366ARLPQEE WVRQMPGKGLEWMGIIYPGDSDTTYSPSFQGQ 66 KRFLEWLVTISADKSVTTAYLQWSSLKASDTAMYYCARLPQ PPANVRKEEKRFLEWLPPANVRKQIPYYYGMDVWGQGTT QIPYYYG VTVSS MDV KAPPACOV096_KC_100-pl389 2047 DIQMTQSPSSLSASVGDRVTITCRASQSI 2048 QQSSSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PPWCQQSYSTPPWTFGQGTKVEIK T COV096_KC_164-pl389 2051DIQMTQSPSSLSASVGDRVTLTCRASQSI 2052 QQS SSYLNWYQQKPGKAPNLLIYAASSLQSG YSAVPSRFSGSGSGTDFTLTISSLQPEDFATYY PPW CQQSYSAPPWTFGQGTKVEIK TCOV096_KC_25-pl389 2055 DIQMTQSPSSLSASVGDRVTITCRASQSI 2056 QQSSSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PPWCQQSYSTPPWTFGQGTKVEIK T COV096_KC_91-pl389 2059DIQMTQSPSSLSASVGDRVTITCRASQSI 2060 QQS SSYLNWYQQKPGKAPKLLIYAASSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATYY PPW CQQSYSTPPWTFGQGTKVEIK TCOV096_KC_91-pl389 2063 DIQMTQSPSSLSASVGDRVTITCRASQSI 2064 QQSSSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PPWCQQSYSTPPWTFGQGTKVEIK T COV096_KC_115-pl389 2067DIQMTQSPSSLSASVGDRVTITCQASQDI 2068 QQY SNYLNWYQQKPGKAPKLLIYDASNLETG DNLVPSRFSGSGSGTDFTFTISSLQPEDIATYY PRS CQQYDNLPRSFGQGTKLEIKCOV096_KC_133-pl389 2071 DIQMTQSPSSLSASVGDRVTITCQASQDI 2072 QQYSNYLNWYQQKPGKAPKLLIYDASNLETG DNL VPSRFSGSGSGTDFTFTISSLQPEDIATYY PRSCQQYDNLPRSFGQGTKLEIK COV096_KC_34-pl389 2075DIQMTQSPSSLSASVGDRVTITCQASQDI 2076 QQY SNYLNWYQQKPGKAPKVLIYDASNLETG DNLVPSRFSGSGSGTDFTFTISSLQPEDIATYF PRS CQQYDNLPRSFGQGTKLEIKCOV096_KC_34-pl389 2079 DIQMTQSPSSLSASVGDRVTITCQASQDI 2080 QQYSNYLNWYQQKPGKAPKVLIYDASNLETG DNL VPSRFSGSGSGTDFTFTISSLQPEDIATYF PRSCQQYDNLPRSFGQGTKLEIK COV096_KC_106-pl389 2083DIQMTQSPSSVSASVGDRVTITCRASQGI 2084 QQT SSWLAWYQQKPGKAPKLLIYTASGLQSG NSFVPSRFSGSGSETDFTLTISSLQPEDFATYY PLT CQQTNSFPLTFGGGTKVEICOV096_KC_132-pl389 2087 DIQMTQSPSSVSASVGDRVTITCRASQGI 2088 QQTSSWLAWYQQKPGKAPKLLIYTASGLQSG NSF VPSRFSGSGSETDFTLTISSLQPEDFATYY PLTCQQTNSFPLTFGGGTKVEI COV096_KC_6-pl389 2091 DIQMTQSPSSVSASVGDRVTITCRASQGI2092 QQA SSWLAWYQQKPGKAPKLLIYVESSLQSG NSF VPSRFSGSGSGTDFTLTISSLQPEDFATYYPLT CQQANSFPLTFGGGTKVEIK LAMBDA COV096_LC_116-pl409 2095QSALTQPASVSGSPGQSITISCTGTSSDV 2096 CSY GSYNLVSWYQQHPGKAPKLMIYEDSKR AGSPSGVSNRFSGSKSGNTASLTISGLQAEDE STRL ADYYCCSYAGSSTRLFGGGTKLTVLCOV096_LC_77-pl409 2099 QSXLTQPASVSGSPGQSITISCTGTSSDV 2100 CSYGSYNLVSWYQQHPGKAPKLMIYEGSKR AGS   PSGVSNRFSGSKSGNTASLTISGLQAEDE   STRADYYCCSYAGSSTRVFGGGTKLTVL V COV096_LC_138-pl409 2103SYXLTQPPSVSVAPGKTARITCGGNNIGS 2104 QV KSVHWYQQKPGHAPVLVVYDDSDRPSG WDIPERFSGSNSGNTATLTISRVEAGDEADY STG YCQVWDSTGGHPDVVFGGGTKLTVL GHP DVVCOV096_LC_176-pl409 2107 SYXLTQPPSVSVAPGKTARITCGGNNIGS 2108KSVHWYQQKPGQAPVLVVYDDSDRPS QV GIPERFSGSNSGNTATLTISRVEAGDEAD WDYYCQVWDSTSDHPDVVFGGGTKLTVL STS DHP DVV COV096_LC_104-pl409 2111NFMLTQPHSVSESPGKTVTISCTRSSGSI 2112 QSY ASNYVQWYQQRPGSAPTTVIYEDNQRP DSISGVPDRFSGSIDSSSNSASLTISGLKTEDE NW ADYYCQSYDSINWVFGGGTKLTVL VCOV096_LC_111-pl409 2115 NFMLTQPHSVSESPGKTVTISCTRSSGSI 2116 QSYASNYVQWYQQRPGSAPTTVIYEDNERP DRI SGVPDRFSGSIDSSSNSASLTISGLKTEDE NWADYYCQSYDRINWVFGGGTKLTVL V KAPPA COV096_KC_158-pl389 2119EIVLTQSPATLSLSPGERATLSCRASQSVS 2120 QQR SYLAWYQQKPGQAPRLLIYDASNRATGI SNPARFSGSGSGTDFTLTISSLEPEDFAVYYC WP QQRSNWPRGFGQGTKVEIK RGCOV096_KC_78-pl389 2123 EIVLTQSPATLSLSPGERATLSCRASQSVS 2124 QQRSYLAWYQQKPGQAPRLLIYDASNRATGI SN PARFSGSGSGTDFTLTISSLEPEDFAVYYC WPQQRSNWPRGFGQGTKVEIK RG COV096_LC_130-pl409 2127SYXLTQPPSVSVAPGKTARITCGGNNIGS 2128 QV KSVHWYQQKPGQAPVLVVYDDSDRPS WDGIPERFSGSNSGNTATLTISRVEAGDEAD SSS YYCQVWDSSSDPVVFGGGTKLTVL DPV VCOV096_LC_44-pl409 2131 SYVLTQPPSVSVAPGKTARITCGGNNIGS 2132 QVKSVHWYQQKPGQAPVLVVYDDSDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEAD SSSYYCQVWDSSSDPVVFGGGTKLTVL DPV V KAPPA COV096_KC_72-pl389 2135DIQMTQSPSSLSASVGDRVTITCQASQDI 2136 QQY SNYLNWYQQKPGKAPKLLIYDASNLETG DNLVPSRFSGSGSGTDFTFTISSLQPEDIATYY PLT CQQYDNLPLTFGGGTKVEIKCOV096_KC_4-pl389 2139 EIVLTQSPATLSLSPGERATLSCRASQSVS 2140 QQRSYLAWYQQKPGQTPRLLIYDASNRATGI SN PARFSGSGSGTDFTLTISSLEPEDFAVYYC WPPQQRSNWPPIAFGQGTRLEIK IA COV096_KC_127-pl389 2143DIQMTQSPSSLSASVGDRVTITCRASQSI 2144 QQS SSYLNWYQQKPGKAPKLLIYAASSLQSG YSTLVPSRFSGSGSGTDFTLTISSLQPEDFATYY WT CQQSYSTLWTFGQGTKVEIKCOV096_KC_113-pl389 2147 EIVLTQSPGTLSLSPGERATLSCRASQSVS 2148 QQYSSYLAWYQQKPGQAPRLLIYGASSRATGI VSS PDRFSGSGSGTDFTLTISRLEPEDFAVYYC PWTQQYVSSPWTFGQGTKVEIK COV096_KC_153-pl389 2151DIQMTQSPSSLSASVGDRVTITCRASQSI 2152 QQS SRYLNWYQQKSGKAPKLLIYAASSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATYY PWT CQQSYSTPWTFGQGTKVEIKCOV096_KC_55-pl389 2155 DIVMTQSPDSLAVSLGERATINCKSSQSV 2156 QQYLYSSNNKNYLAWYQQKPGQPPKLLIYW YST ASTRESGVPDRFSGSGSGTDFTLTISSLQ PCSAEDVAVYYCQQYYSTPCSFGQGTKLEIK COV096_KC_42-pl389 2159DIVMTQSPDSLAVSLGERATINCKSSQSV 2160 QQY LYSSNNKSYLAWYQQKPGQPPKLLIYWA YSTLSTRESGVPDRFSGSGSGTDFTLTISSLQAE PLT DVAVYYCQQYYSTLPLTFGGGTKVEIKCOV096_KC_156-pl389 2163 DIQMTQSPSSLSASVGDRVTITCQASQDI 2164 QQFSNYLNWYQQKPGKAPKLLIYDASNLETG DNL VPSRFSGSGSGTDFTFTISSLQPEDIATYY PITCQQFDNLPITFGQGTRLEIK COV096_KC_137-pl389 2167DIQMTQSPSSLSASVGDRVTITCRASQSI 2168 QQS SSYLNWYQQKPGKAPKLLIYAASSLQSG YSSPVPSRFSGSGSGTDFTLTISSLQPEDFATYY PIT CQQSYSSPPITFGPGTKVDIKCOV096_KC_75-pl389 2171 DIQMTQSPSSLSASVGDRVTITCRASQSI 2172 QQSSSYLNWYQQKPGKAPKLLIYVASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PPITCQQSYSTPPITFGQGTRLEIK COV096_KC_123-pl389 2175DIQMTQSPSSLSASVGDRVTITCRASQSI 2176 QQS SSYLNWYQQKPGKAPNLLIYAASSLQSG YNTVPSRFSGSGSGTDFTLTISSLQPEDFATYY PQV CQQSYNTPQVTFGGGTKVESK TCOV096_KC_65-pl389 2179 DIQMTQSPSSLSASVGDRVTITCRASQSI 2180 QQSSSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGGGSGADFTLTISSLQPEDFATY PPITYCQQSYSTPPITFGQGTRLEIK COV096_KC_81-pl389 2183DIQMTQSPSSLSASVGDRVTITCRASQSI 2184 QQS   SSYLNWYQQKPGKAPKLLIYAASSLQSGYST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PPW CQQSYSTPPWTFGQGTKVEIK TCOV096_KC_166-pl389 2187 DIQMTQSPSSLSASVGDRVTITCRASQSI 2188 QQSSSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PLTCQQSYSTPLTFGGGTKVEIK COV096_KC_140-pl389 2191DIQMTQSPSSLSASVGDRVTITCRASQDI 2192 QQA SSWLAWYQQKPGKAPKLLIYAASNLQSG NRFVPSRFSGSGSGTHFTLTISSLQPEDFVTYY PIT CQQANRFPITFGQGTRLEIKCOV096_KC_43-pl389 2195 DIQMTQSPSSLSASVGDRVTITCQASQDI 2196 QQYRNFLNWYQQKPGKAPKLLIYDASNLETG DNL VPSRFSGSGSGTDFTFTISSLQPEDIATYY PLTCQQYDNLPLTFGGGTKVEIK COV096_KC_21-pl389 2199DIQMTQSPSSLSASVGDRVTITCRASQSI 2200 QQS SSYLNWYQQKPGKAPKLLIYAAFSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATYY PWT CQQSYSTPWTFGQGTKVEIKCOV096_KC_122-pl389 2203 DIQMTQSPSSLSASVGDRVTITCRASQSI 2204 QQSSSYLNWYQQKPGKAPKLLIYAASNLQSG YSSP VPSRFSGSGSGTDFTLTISSLQPEDFATYY PWTCQQSYSSPPWTFGQGTKVEIK COV096_KC_98-pl389 2207DIQMTQSPSSLSASVGDRVTITCRASQSI 2208 QQS SSYLTWYQQKPGKAPKLLIYAASSLQSGV YSTPSRFSGSGSGTDFTLTISSLQPEDFATYYC PPW QQSYSTPPWTFGQGTKVEIK TCOV096_KC_48-pl389 2211 DIQMTQSPSSLSASVGDRVTITCRASQSI 2212 QQSSSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PATCQQSYSTPATFGQGTKVEIK COV096_KC_79-pl389 2215DIQMTQSPSSLSASVGDRVTITCRASQSI 2216 QQS SSYLNWYQQKPGKAPKLLIYGASSLQSG YSTVPSRFSGSGSGTDFTLTISSLQPEDFATYY PAT CQQSYSTPATFGQGTKLEIKCOV096_KC_3-pl389 2219 EIVMTQSPATLSVSPGERATLSCRASQSV 2220 QQYSSNLAWYQQKPGQAPRLLIYGASTRATG NN IPARFSGSGSGTEFTLTISSLQSEDFAVYY WWCQQYNNWWTFGQGTKVEIK T COV096_KC_3-pl389 2223EIVMTQSPATLSVSPGERATLSCRASQSV 2224 QQY SSNLAWYQQKPGQAPRLLIYGASTRATG NNIPARFSGSGSGTEFTLTISSLQSEDFAVYY WW CQQYNNWWTFGQGTKVEIK TCOV096_KC_134-pl389 2227 DIQLTQSPSFLSASVGDRVTITCRASQGIS 2228 QQLSYLAWYQQKPGKAPKLLIYAASTLQSGV NSY PSRFSGSGSGTEFTLTISSLQPEDFATYYC PQGQQLNSYPQGTFGGGTKVEIK T COV096_KC_68-pl389 2231DIQLTQSPSFLSASVGDRVTITCRASQGIS 2232 QQL SYLAWYQQKPGKAPKLLIYAASTLQSGV NSYPSRFSGSGSGTEFTLTISSLQPEDFATYYC PPA QQLNSYPPAFGQGTRLEIKCOV096_KC_183-pl389 2235 EIVLTQSPGTLSLSPGERATLSCRASQSFS 2236 QQYSTYLAWYQQKPGQAPRLLIYGASSRATGI VTS PDRFSGSGSGTDFTLTISRLEPEDFAVYYC PWTQQYVTSPWTFGQGTKVEIK COV096_KC_74-pl389 2239EIVMTQSPATLSVSPGERATLSCRASQSV 2240 QQY SSNLAWYQQKPGQAPRLLIYGASTRATG NNIPARFSGSGSGTEFTLTISSLQSEDFAVYY WP CQQYNNWPRTFGQGTKVEIK RTCOV096_KC_45-pl389 2243 DIQMTQSPSSLSASVGDRVTITCQASQDI 2244 QQYSNYLNWYQQKPGKAPKLLIYDASNLETG DNL VPSRFSGSGSGTDFTFTISSLQPEDIATYY PPKCQQYDNLPPKLTFGGGTKVEIK LT COV096_KC_126-pl389 2247DIQMTQSPSSLSASVGDRVTIPCRASQNI 2248 QQS DNYLNWYQQKPGKAPKLLIFAASGLQDE YISPAPSRFSGVGSGTDFTLTISSLQPEDSATYY YT CQQSYISPYTFGRGTKLEIK COV096_KC_8-pl3892251 DIQMTQSPSSVSASLGDRVTITCRASQGI 2252 QQA SSWLAWYQQKPGKAPKVLIYAASSLQSGNSF VPSRFSGSGSGTDFTLTISSLQPEDFATYY PIT CQQANSFPITFGQGTRLEIKCOV096_KC_124-pl389 2255 DIQMTQSPSSLSASVGDRVTITCRASQSI 2256 QQSSSYLNWYQQKPGKAPKLLIYAASSLQSG YST VPSRFSGSGSGTDFTLTISSLQPEDFATYY PCSCQQSYSTPCSFGQGTKLEIK COV096_KC_28-pl389 2259AIQLTQSPSSLSASVGDRVTITCRASQGIS 2260 QQF SALAWYQQKPGKAPKLLIYDASSLESGVP NNSRFSGSGSGTDFTLTISSLQPEDFATYYCQ QFNNFGPGTKVDIK COV096_KC_12-pl389 2263EIVMTQSPATLSVSPGERATLSCRASQSV 2264 QQY SSNLAWYQQKPGQAPRLLIYGASTRATG NNIPARFSGSGSGTEFTLTISSLQSEDFAVYY WPP CQQYNNWPPGGFTFGPGTKVDIK GGF T LAMBDACOV096_LC_90-pl409 2267 SYVLTQPPSVSVSPGQTARITCSGEALPK 2268 QSAQYAYWYQQKPGQAPVMVIYKDSERPSG DSS IPERFSGSSSGTTVTLTISGVQAEDDADYY GTLCQSADSSGTLVVFGGGTKLTVL VV COV096_LC_71-pl409 2271SYVLTQPPSVSVAPGKTARITCGGNNIGS 2272 QV KSVHWYQQKPGQAPVLVVYDDSDRPS WDGIPERFSGSNSGNTATLTISRVEAGDEAD YGV YYCQVWDYGVVFAGGTKLTVL VCOV096_LC_52-pl409 2275 NFMLTQPHSVSESPGKTVTISCTRSSGSI 2276 QSYASNYVQWYQQRPGSAPTTVIYEDYQRP DSG SGVPDRFSGSIDSSSNSASLTISGLKTEDE VVADYYCQSYDSGVVFGGGTKLTVL COV096_LC_10-pl409 2279QXXLTQPPSASGSPGQSVTISCTGTSSDV 2280 SSY GGYNYVSWYQQHPGKAPKLMIYEVSKR AGSPSGVPDRFSGSKSGNTASLTVSGLQAED NN EADYYCSSYAGSNNWVFGTGTKVTVL WVCOV096_LC_2-pl409 2283 SYVLTQPPSVSVAPGKTARITCGGNNIGS 2284 QVKSVHWYQQKPGQAPVLVVYDDSDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEAD SSSYYCQVWDSSSDPYVFGTGTKVTVL DPY V COV096_LC_30-pl409 2287QSVLTQPPSVSGAPGQRVTISCTGSSSNI 2288 QSY GAGYDVHWYQQLPGTAPKLLIYGNSNR DSSPSGVPDRFSGSKSGTSASLAITGLQAEDE LRG ADYYCQSYDSSLRGVFGGGTKLTVL VCOV096_LC_136-pl409 2291 QSXXTQPPSASASLGASVTLTCTLSSGYS 2292 GADNYKVDWYQQRPGKGPRFVMRVGTGGI QGS VGSKGDGIPDRFSVLGSGLNRYLTIKNIQ GSNEEDESDYHCGADQGSGSNFVGVFGGGT FVG KLTVL V COV096_LC_99-pl409 2295QSXXTQPPSVSGAPGQRVTISCTGSSSNI 2296 QSY GAGYDVHWYQQLPGTAPKLLIYANINRP DSSSGVPDRFSGSKSGTSASLAITGLQAEDEA LSG DYYCQSYDSSLSGSVFGGGTKLTVL SVCOV096_LC_152-pl409 2299 QSVLTQPPSASGTPGQRVTISCSGSSSNI 2300 AAGSNYVYWYQQLPGTAPKLLIYRNNQRPS WD GVPDRFSGSKSGTSASLAISGLRSEDEAD DSLYYCAAWDDSLSGYWVFGGGTKLTVL SGY WV COV096_LC_50-pl409 2303SYVLTQPPSVSVAPGKTARITCGGNNIGS 2304 QV KSVHWYQQKPGQAPVLVIYYDSDRPSGI WDPERFSGSNSGNTATLTISRVEAGDEADYY SSS CQVWDSSSDHPVFGGGTKLTVL DHP VCOV096_LC_92-pl409 2307 QSVLTQEPSLTVSPGGTVTLTCGSSTGAV 2308 LLSYTSGHYPYWFQQKPGQAPRTLIYDTSNKH SGA SWTPARFSGSLLGGKGALTLSGAQPEDE RVAEYYCLLSYSGARVFGGGTKLTVL COV096_LC_40-pl409 2311SYVLTQPPSVSVAPGKTARITCGGNNIGS 2312 QV KSVHWYQQKPGQAPVLVIYYDTDRPSGI WDPERFSGSNSGNTATLTISRVEAGDEADYY SSS CQVWDSSSALWVFGGGTKLTVL ALW VCOV096_LC_149-pl409 2315 QXXXTQPASVSGSPGQSITISCTGTSSDV 2316 SSYTGGYNYVSWHQQHPGKAPKLMIYDVSN SSST RPSGVSNRFSGSKSGNTASLTISGLQAED LVEADYYCSSYTSSSTLVFGGGTKLTVL COV096_LC_157-pl409 2319NFMLTQPHSVSESPGKTVTISCTRSSGSI 2320 QSY ASNYVQWYQQRPGSSPTMYEDNQRPS DSSGVPDRFSGSIDSSSNSASLTISGLKTEDEA NVV DYYCQSYDSSNVVFGGGTKLTVLCOV096_LC_121-pl409 2323 NFMLTQPHSVSESPGKTVTISCTRSSGSI 2324 QSYASNYVQWYQQRPGSSPTTVIYEDNQRP DSS SGVPDRFSGSIDSSSNSASLTISGLKTEDE SWVADYYCQSYDSSSWVFGGGTKLTVL COV096_LC_27-pl409 2327SYXLTQPPSVSVSPGQTARITCSGDAFPN 2328 QSA QYAYWYQQKPGQAPVLVIYKDSERPSGI DSSPERFSGSSSGTTVTLTISGVQAEDEADYY SWV CQSADSSSWVFGGGTKLTVLCOV096_LC_142-pl409 2331 NFMLTQPHSVSESPGKTVTISCTRSSGSI 2332 QSFASNYVQWYQQRPGSSPTTVIYEDSQRPS DST GVPDRFSGSIDSSSNSASLTISGLKTEDEA NLDYYCQSFDSTNLWVFGGGTKLTVL WV COV096_LC_1-pl409 2335QSALTQPPSASGTPGQRVTISCSGSSSNI 2336 AA GSNTVNWYQQLPGTAPKLLIYSNNQRPS WDGVPDRFSGSKSGTSASLAISGLQSEDEAD DSL YYCAAWDDSLVVFGGGTKLTVL VVCOV096_LC_15-pl409 2339 QSVLTQPPSASGTPGQRVTISCSGSSSNI 2340 AAGSNTVNWYQQLPGTAPKLLIYSNNQRPS WD GVPDRFSGSKSGTSASLAISGLQSEDEAD DSLYYCAAWDDSLNGVVFGGGTKLTVL NGV V COV096_LC_20-pl409 2343SYVLTQPPSVSVAPGKTARITCGGNNIGS 2344 QV KSVHWFQQKPGQAPVLVVYDDSDRPSG WDIPERFSGSNSGNTATLTISRVEAGDEADY SSS YCQVWDSSSDHVVFGGGTKLTVL DHV VCOV096_LC_159-pl409 2347 SYVLTQPPSVSVAPGKTARITCGGNNIGS 2348 QVKSVHWYQQKPGQAPVLVVYDDSDRPS WD GIPERFSGSNSGNTATLTISKVEAGDEAD SSSYYCQVWDSSSDSVVFGGGTKLTVL DSV V COV096_LC_103-pl409 2351QXXXTQPASVSGSPGQSITISCTGTSSDV 2352 CSY GSYNLVSWYQQHPGKAPKLMIYEDSKR AGSPSGVSNRFSGSKSGNTASLTISGLQAEDE SLW ADYYCCSYAGSSLWVFGGGTKLTVL VCOV096_LC_23-pl409 2355 QSVLTQPPSASGTPGQRVTISCSGSSSNI 2356 AAGSNYVYWYQQLPGTAPKLLIYRNNQRPS WD GVPDRFSGSKSGTSASLAISGLRSEDEAD DSLYYCAAWDDSLSGYWVFGGGTKLTVL SGY WV COV096_LC_101-pl409 2359SYVLTQPPSVSVAPGKTARITCGGNNIGS 2360 QV KNVHWYQQKPGQAPVLVVYDDSDRPS WDGIPERFSGSNSGNTATLTISRVEAGDEAG STS YYCQVWDSTSDHLFWVFGGGTKLTVL DHL FWVCOV096_LC_174-pl409 2363 QSXXTQPPSASGTPGQRVTISCSGSSSNI 2364 AAGSNTVNWYQQLPGTAPKLLIYSNNQRPS WD GVPDRFSGSKSGTSASLAISGLQSEDEAD DSLYYCAAWDDSLNGHVVFGGGTKLTVL NGH VV COV096_LC_189-pl409 2367QSXLTQPPSVSGAPGQRVTISCTGSSSNI 2368 QSY GADYDVHWYQQLPGTAPKLLIYGNSNR DSSPSGVPDRFSGSKSGTSASLAITGLQAEDE LSG ADYYCQSYDSSLSGPYWVFGGGTKLTVL PYW V

TABLE 13 Anti-SARS-CoV-2 IgG antibodies from COV107 SEQ SEQ ID IDSEQUENCE_ID NO aa NO cdr3_aa HEAVY COV107_Plate1_HC_9-P1369 2721EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 2369 ARDWGMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG EYYFDYRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD WGEYYFDYWGQGTLVTVSSCOV107_Plate1_HC_36-P1369 2725 EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM 2373ARDYGD SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGR YYFDYFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDY GDYYFDYWGQGTLVTVSSCOV107_Plate1_HC_40-P1369 2729 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 2377ARDWG MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG EYYFDYRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD WGEYYFDYWGQGTLVTVSSCOV107_Plate2_HC_13-P1369 2733 EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM 2381ARDYGD SWVRQAPGKGLEWVSVIYSGGSTFYADSVKGR YYFDYFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDY GDYYFDYWGQGTLVTVSSCOV107_Plate2_HC_93-P1369 2737 EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM 2385VRDYGD SWVRQAPGKGLEWVSVIYSGGSTFYTDSVKGR FYFDYFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRDY GDFYFDYWGQGTLVTVSSCOV107_Plate1_HC_11-P1369 2741 QVQLQQWGAGLLKPSETLSLTCAVSGGSLSGFY 2389ARKPLLY WTWIRQPPGKGLEWIGETNHFGSTDYKASLKS SDFSPGRVTISVGMSRNQFSLKVTSLTAADTAVYYCARK AFDI PLLYSDFSPGAFDIWGQGTMIVVSSCOV107_Plate1_HC_42-P1369 2745 QVQLQQWGAGLLKPSETLSLSCAVYGGSLSGYY 2393ARKPLLY WSWIRQPPGKGLEWIGEINHFGSTGYNPSLKSR SNLSPGVTISVDTSKSQFSVKLSSVTAADTAVYYCARKPLL AFDI YSNLSPGAFDIWGQGTMVTVSSCOV107_Plate1_HC_84-P1369 2749 QVQLQQWGAGLLKPSETLSLTCAVSGGSLSGFY 2397ARKTLLF WTWIRQPPGKGLEWIGETNHFGSTDYKPSLKS SDFSPGRVTISVDMSRNQFSLIMTSVTAADTAVYYCARK AFDI TLLFSDFSPGAFDIWGQGTMVVVSSCOV107_Plate2_HC_31-P1369 2753 QVQLQQWGAGLLKPSETLSLTCAVSGGSLSGFY 2401ARKPLL WTWIRQPPGKGLEWIGETNHFGSTDYKPSLKS HSDLSPRVTISVDMSRNQFSLKVTSVTAADTAVYYCARK GAFDI PLLHSDLSPGAFDIWGQGTMVAVSSCOV107_Plate2_HC_53-P1369 2757 QVQLQQWGAGLLKPSETLSLTCAVSGGSLSGFY 2405ARKPLLY WTWIRQPPGKGLEWIGETNHFGSTGYKPSLKS SDFSPGRVTISVDMSRNQFSLKVTSVTAADTAVYYCARK AFDI PLLYSDFSPGAFDIWGQGTMVAVSS HEAVYCOV107_Plate1_HC_29-P1369 2761 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 2409ARGEG MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK WDLPYGRFTISRDNSKNTLYLQMHSLRAEDTAVYYCAR DY GEGWDLPYDYWGQGTLVTVSSCOV107_Plate1_HC_35-P1369 2765 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 2413ARGEG MSWVRQAPGKGLEWVSVIYTGGSTFYADSVK WDLPYGRFTISRDNSKNTLYLQMNSLRAEDTAMYYCAR DY GEGWDLPYDYWGQGTLVTVSSCOV107_Plate2_HC_4-P1369 2769 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 2417ARGEG MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK WELPYDGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR Y GEGWELPYDYWGQGTLVTVSSCOV107_Plate1_HC_63-P1369 2773 QVQLVQSGAEVKKPGASVRVSCKASGYTFTSYG 2421ARGEAV FSWVRQAPGQGLEWMGWISAYNGNTNFAQK AGTTGFLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYC FDY ARGEAVAGTTGFFDYWGQGTLVTVSSCOV107_Plate1_HC_68-P1369 2777 QVQLVQSGAEVKKPGASVRVSCKASGYTFTSYG 2425ARGEAV FSWVRQAPGQGLEWMGWISAYNGNTNFAQK AGTTGFLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYC FDY ARGEAVAGTTGFFDYWGQGTLVTVSSCOV107_Plate1_HC_13-P1369 2781 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYY 2429ARDVIV IHWVRQAPGQGLEWMGWINPNSGGTNYAQK SMVRGFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYC VIFRMD ARDVIVSMVRGVIFRMDVWGQGTTVTVSS VCOV107_Plate1_HC_27-P1369 2785 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 2433ATAHPR MHWVRQAPGQGLEWMGWINPNSGGTNYA RIQGVFQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY FLGPGV YCATAHPRRIQGVFFLGPGVWGQGTTVTVSSCOV107_Plate1_HC_79-P1369 2789 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY 2437ARANHE MHWVRQAPGQGLEWMGIINPSGGSTSYAQKL TTMDTYQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA YYYYYM RANHETTMDTYYYYYYMDVWGKGTTVTVSSDV COV107_Plate1_HC_91-P1369 2793 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY 2441ARANHE MHWVRQAPGQGLEWMGIINPSGGSTSYAQKL TTMDTYQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA YYYYYM RANHETTMDTYYYYYYMDVWGKGTTVTVSSDV HEAVY COV107_Plate1_HC_53-P1369 2797QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA 2445 AAPHCSVQWVRQARGQRLEWIGWIVVGSGNTNYVQK STSCFD FQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAFDI APHCSSTSCFDAFDIWGQGTMVTVSS COV107_Plate2_HC_81-P1369 2801QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA 2449 AAPYCSVQWVRQARGQRLEWIGWIVVGSGNTNYAQK GGSCSD FQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAFDI APYCSGGSCSDAFDIWGQGTMVTVSS HEAVY COV107_Plate2_HC_42-P1369 2805QVQLVESGGGLVQPGRSLRLSCAASGFTFSTYA 2453 ARDPIWMHWVRQAPGKGLKWVAVISYDGGNKYYADS FGELLSP VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCPFVHFD ARDPIWFGELLSPPFVHFDYWGQGTLVTVSS Y COV107_Plate2_HC_89-P1369 2809QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYA 2457 ARDPIWMHWVRQAPGEGLEWVAVISYDGSNTYYADSV FGELLSPKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA PFVHFD RDPIWFGELLSPPFVHFDYWGQGTLVTVSSY COV107_Plate1_HC_22-P1369 2813 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSHA 2461AREDYY MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DSSGSFKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA DY REDYYDSSGSFDYWGQGTLVTVSSCOV107_Plate2_HC_88-P1369 2817 QVQLVESGGGVVQPGRSLRLSCAASGFTFSRHA 2465AREDYY MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DSSGSFKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA DY REDYYDSSGSFDYWGQGTLVTVSSCOV107_Plate2_HC_49-P1369 2821 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYA 2469ASGYTG MHWVRQAPGKGLEWVAVISYDGSNXYYADSV YDYFVRKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCAS GDYYGL GYTGYDYFVRGDYYGLDVWGQGTTVTVSSDV COV107_Plate2_HC_84-P1369 2825 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 2473ASGYTG MHWVRQAPGKGLEWVAVISYDGSNKYYADSV YDYFVGKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA GDYYG SGYTGYDYFVGGDYYGMDVWGQGTTVTVSSMDV HEAVY COV107_Plate1_HC_19-P1369 2829QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFG 2477 ARGVNPMHWVRQAPGKGLEWVAVIWYDGSNKYYADS DDILTG VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVDAFDI ARGVNPDDILTGVDAFDIWGQGTMVTVSS COV107_Plate1_HC_38-P1369 2833QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFG 2481 ARGVNPMHWVRQAPGKGLEWVAVIWYDGSNKYYADS DDILTG VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVDAFDI ARGVNPDDILTGVDAFDIWGQGTMVTVSS COV107_Plate2_HC_15-P1369 2837EVQLVESGGGLIKPGRSLRLSCTASGFTFGDYA 2485 TRWDGMTWFRQAPGKGLEWVGFIRSKAYGGTTGYAA WSQHDSVKYRFTISRDDSKSIAYLQMDSLKTEDTAVYYCT Y RWDGWSQHDYWGQGTLVTVSSCOV107_Plate2_HC_69-P1369 2841 EVQLVESGGGLIKPGRSLRLSCTASGFTFGDYA 2489TRWDG MTWFRQAPGKGLEWVGFIRSKAYGGTTGYAA WSQHDSVRYRFTISRDDSSGIAYLQMDSLKTEDTAVYYC Y TRWDGWSQHDYWGQGTLVTVSSCOV107_Plate2_HC_32-P1369 2845 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 2493AREGM MTWVRQAPGKGLEWVSLIYPGGSTYYADSVKG GMAAARFTISRDNSKNTLYLQMNSLRAEDTAVYYCARE GT GMGMAAAGTWGQGTLVTVSSCOV107_Plate2_HC_73-P1369 2849 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 2497AREGM MSWVRQAPGKGLEWVSLIYPGGSTYFADSVKG GIAAAGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARE T GMGIAAAGTWGQGTLVTVSS HEAVYCOV107_Plate1_HC_62-P1369 2853 EVQLVESGGGLIQPGGSLKLSCVVSGFTVSKNYI 2501ARGDGE SWVRQAPGKGLEWVSVIFAGGSTFYADSVKGR LFFDHFAISRDNSNNTLFLQMNSLRVEDTAIYYCARGD GELFFDHWGQGTLVTVSSCOV107_Plate1_HC_73-P1369 2857 EVQLVESGGGLIQPGGSLKLSCVVSGFTVSKNYI 2505ARGDGE SWVRQAPGKGLEWVSVIFAGGSTFYADSVKGR LFFDQFAISRDNSNNTLFLQMNSLRVEDTAIYYCARGD GELFFDQWGQGTLVTVSSCOV107_Plate1_HC_46-P1369 2861 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSTN 2509VRDGGR WWSWVRQPPGKGLEWIGEIYHTGSTNYNPSL PGDAFDKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCVR I DGGRPGDAFDIWGQGTMVTVSSCOV107_Plate2_HC57-P1369 2865 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSTN 2513VRDGGR WWSWVRQPPGKGLEWIGEIYHTGSTNYNPSL PGDAFDKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCVR I DGGRPGDAFDIWGQGTMVTVSSCOV107_Plate2_HC_36-P1369 2869 QVQLQESGPGLVKPSETLSLTCTVSGGSISNYYW 2517ARVED SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT WGYCSSISVDTSKNQFSLKLSSVTAADTAVYYCARVEDW TNCYSG GYCSSTNCYSGAFDIWGQGTMVTVSS AFDICOV107_Plate2_HC71-P1369 2873 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 2521ARVED SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT WGYCSSISVDTSKNQFSLKLSSVTAADTAVYYCARVEDW TNCYSG GYCSSTNCYSGAFDIWGQGTMVTVSS AFDICOV107_Plate1_HC_77-P1369 3220 QVQLQESGPGLVKPSETLSLTCTVSGASVSSGSY 2525ARERPG YWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKS GTYSNTRVTISVDTSKNQFSLKLSSVTAADTAVYYCARER WYTPTDPGGTYSNTWYTPTDTNWFDTWGQGTLVTVSS TNWFD T COV107_Plate2_HC_72-P1369 3221QVQLQESGPGLVKPSETLSLTCTVSGASVSSGSY 2529 ARERPGYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKS GTYSNTRVTISVDTSKNQFSLKLSSVTAADTAVYYCARER WYTPTDPGGTYSNTWYTPTDTNWFDTWGQGTLVTVSS TNWFD T HEAVY COV107_Plate1_HC_75-P13693222 EVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWI 2533 ARSFRDGWVRQMPGKGLEWMGIIYPGDSDATYSPSFQ DPRIAV GQVTISADRSISTAYLQWSSLKASDTAMYYCARAGPADA SFRDDPRIAVAGPADAFDIWGQGTMVTVSS FDI COV107_Plate2_HC_90-P1369 3223EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWI 2537 ARSFRDGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ DPRIAV GQVTISADKSISTAYMQWSSLKASDTAMYYCAAGPADA RSFRDDPRIAVAGPADAFDIWGQGTMVTVSS FDI HEAVYCOV107_Plate1_HC_52-P1369 3224 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYG 2541ARAIAV FSWVRQAPGQGLEWLGWISAYNGNTNYAQKL AGTSGEQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA FDY RAIAVAGTSGEFDYWGQGTLVTVSSCOV107_Plate1_HC_58-P1369 3225 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYG 2545ARSQG ISWVRQAPGQGLEWMGWISAYNGNTNYAQK WLQLNLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYC DY ARSQGWLQLNDYWGQGTLVTVSSCOV107_Plate2_HC_45-P1369 3226 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 2549ARGHDY MHWVRQAPGQGLEWMGWINPNSGGTKYAQ VWGSYKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYY RYHNV CARGHDYVWGSYRYHNVWGQGTLVTVSSCOV107_Plate1_HC_60-P1369 3227 QVQLVQSGAEVKKPGASVMLSCKASGYTFTGY 2553ARDLAF YMHWVRQAPGQGLEWMGWINPNSGGTNYA SMVRAPQKFQGRVTMTRDTSITTTYMELSRLRSDDTAVY GDY YCARDLAFSMVRAPGDYWGQGTLVTVSSCOV107_Plate1_HC_5-P1369 3228 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYS 2557ARELIAV MHWVRQAPGQGLEWMGWINPNSGGTNYA AGIFDYQKFQGRVTMTRDTSISTAYMELNRLRSDDTAV YYCARELIAVAGIFDYWGQGTLVTVSSCOV107_Plate2_HC_94-P1369 3229 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 2561ARAPLF MHWVRQAPGQGLEWMGWISPVSGGTNYAQ PTGVLAKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYY GDYYYY CARAPLFPTGVLAGDYYYYGMDVWGQGTTVTGMDV VSS COV107_Plate1_HC_83-P1369 3230QVQLVQSGAEVKKPGASVKVSCKASGYILTDYFI 2565 ARYKGTHWVRQAPGQGLEWMGWINPNSGGTNYAQK TVNTNY FQGRVTMTRDTSISTAYMELSRLRSDDTAVYHCYYGMD ARYKGTTVNTNYYYGMDVWGQGTTVTVSS V COV107_Plate2_HC_40-P1369 3231QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYY 2569 ARDPSPIMHWVRQAPGQGLEWMGIINPSGGSTSYAQKF IARPGM QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAGYWFD RDPSPIIARPGMGYWFDPWGQGTLVTVSS P COV107_Plate1_HC_28-P1369 3232QVQLVQSGAEVKKPGSSVKVSCKASGGTFRSYA 2573 ARDSSGISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQ YYYVSNGRVTITADESTSRAYMELSSLRSEDTAVYYCARD WFDP SSGYYYVSNWFDPWGQGTLVTVSSCOV107_Plate2_HC_92-P1369 2929 QVQLLESGGGLVKPGGSLRLSCAASGFTFSDYY 2577ATYRSYL MSWIRQAPGKGLEWVSYISSRSSYTNYADSVKG PLVQVDRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATY Y RSYLPLVQVDYWGQGTLVTVSSCOV107_Plate2_HC_55-P1369 2933 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS 2581ARGQLL MNWVRQAPGKGLEWVSSISSSSSYIYYADSVKG PFADYRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG QLLPFADYWGQGTLVTVSSCOV107_Plate2_HC_47-P1369 2937 EVQLVESGGGLVKPGGSLRVSCAASGFTFSSYS 2585TRGSRG MNWVRQAPGKGLEWVSSISSSKNYIYYADSVK YYDRSGGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTR YYTPLDPGSRGYYDRSGYYTPLDPYYGMDVWGQGTTVT YYGMD VSS V COV107_Plate1_HC_49-P13692941 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 2589 AKEEVLMSWVRQAPGKGLEWVSGISDSGGSTYYADSV PAVEYF KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAQH KEEVLPAVEYFQHWGQGTLVTVSS COV107_Plate2_HC_22-P1369 2945QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 2593 AKGGYYMHWVRQAPGKGLEWVAVISYDGSNKYYADSV YYNSDS KGRFTISRDNSKNTLDLQMNSLRAEDTAVYYCAYQAEID KGGYYYYNSDSYQAEIDYWGQGTLVTVSS Y COV107_Plate2_HC_91-P1369 2949QVQLVESGGGVVQPGRSLRLSCAASGFTFSSSG 2597 AKDPLPMHWVRQAPGKGLEWVAIISYDGSNKYYADSV FRDFFYYKGRFTISRDNSKNTLSLQMNSLRAEDTAVYYCA YMDV KDPLPFRDFFYYYMDVWGKGTTVTVSSCOV107_Plate2_HC_35-P1369 2953 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 2601ARETQG MHWVRQAPGKGLEWVAVISYDGSNKYYADSV GYYGSGKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA SYYASPFRETQGGYYGSGSYYASPFDPWGQGTLVTVSS DP COV107_Plate2_HC_24-P1369 2957QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 2605 ARDFYHMHWVRQAPGKGLEWVAVISYDGSNKYYADSV NWFDP KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDFYHNWFDPWGQGTLVTVSS COV107_Plate2_HC_34-P1369 2961QVQLVESGGGVVQPGRSLRLSCAASGLTFSSYG 2609 ARDRGLMHWVRQAPGKGLEWVAVIWYDGINKYYADS RLGGPK VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCYYFDY ARDRGLRLGGPKYYFDYWGQGTLVTVSS COV107_Plate1_HC_41-P1369 2965EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYY 2613 ARDPQRMNWVRQAPGKGLEWVSYISSSSSTIYYADSVK DPADYFGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR DY DPQRDPADYFDYWGQGTLVTVSSCOV107_Plate2_HC_46-P1369 2969 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW 2617AIQLWL MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV RGGYDYKGRFTISGDNAKNSLYLHMNSLRAEDTAVYYCAI QLWLRGGYDYWGQGTLVTVSSCOV107_Plate1_HC_32-P1369 2973 EVQLVESGGGLVQPGGSLRLSCADSGFTFSSYW 2621AVQLW MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV LRGNFDKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA Y VQLWLRGNFDYWGQGTLVTVSSCOV107_Plate2_HC_25-P1369 2977 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2625AKDDRE MHWVRQAPGKGLEWVSGISWNSGSRGYADS GFGDYFVKGRFTISRDNAKNSLYLLMNSLRAEDTAFYYCA DY KDDREGFGDYFDYWGQGTLVTVSSCOV107_Plate2_HC_54-P1369 2981 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 2629AKDSLV MHWVRQAPGKGLEWVSGISWNSGSIGYADSV RRNFYYKGRFTISRDNAKSSLYLQMKSLRVEDTALYYCAK YYMDV DSLVRRNFYYYYMDVWGKGTTVTVSSCOV107_Plate2_HC_20-P1369 2985 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYY 2633AGMYY WGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR DILTGYSVTISVDTSKNQFSLKLSSVTAADTAVYYCAGMYY EGAFDI DILTGYSEGAFDIWGQGTMVTVSSCOV107_Plate1_HC_25-P1369 2989 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYY 2673AGGTNP WGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR QWLDSVTISVDTSKNQFSLKLSSVTAADTAVYYCAGGTN TFDY PQWLDSTFDYWGQGTLVTVSSCOV107_Plate1_HC_64-P1369 2993 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSHY 2641ASAPYL WGWIRQPPGKGLEWIGTIYYSGSTYYNPSLKSR NWNDVTISVDTSKNQFSLRLSSVTAADTAVYYCASAPYL WIFDY NWNDWIFDYWGQGTLVTVSSCOV107_Plate2_HC_28-P1369 2997 QVQLQESGPGLVKPSETLSLSCAVSGGSIGSYF 2645ARLQWL WSWIRQPPGKGLEWIGYLHYSGSTNYNPSLKSR RGAFDIVTISVDTSKNQFSLKLSSVTAADTAVYYCARLQ WLRGAFDIWGQGTMVTVSSCOV107_Plate2_HC_58-P1369 3001 QVQLQESGPGLVKPSETLSLTCTVSGGSISGYYW 2649ARYGW SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT GYDSSGISVDTSKNQFSLKLSSVTAADTAVYYCARYGWG YYFDY YDSSGYYFDYWGQGTLVTVSSCOV107_Plate2_HC_2-P1369 3005 QVQLQESGPRLVKPSENLSLTCTVSGGSISSYYW 2653ARATTP SWIRQPPGKGLEWIGYIYYTGSTKYNPSLKSRVTI FSGVDYSVDTSKNQFSLKLSSVTAADTAVFYCARATTPFS GVDYWGQGTLVTVSSCOV107_Plate2_HC_10-P1369 3009 QVQLQESGPGLVKPSETLSLTCTVSGGSISNYYW 2657ARILRGV SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT AENWFISVDTSKNQFSLKLTSVTAADTAVYYCARILRGV DP AENWFDPWGQGTLVTVSSCOV107_Plate1_HC_48-P1369 3013 QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGSY 2661ATRGGY YWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKS YDSSGYRVTISVDTSKNQFSLKLSSVTAADTAVYYCATRG YALAFDI GYYDSSGYYALAFDIWGQGTMVTVSSCOV107_Plate2_HC_87-P1369 3017 EVQLVQSGAEVKQPGESLKISCKALGYTFTTSWI 2665ATETNS SWVRQMPGKGLEWMGRIDPSDSYTKYSPSFQ ETTDMFGHVTISVDKSITTAYLQWSSLKASDSAVYYCATE TGYSFD TNSETTDMFTGYSFDPWGQGTLVTVSS PCOV107_Plate2_HC_1-P1369 3021 EVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWI 2669ARGGPP AWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ GGVKLEGQVTISADQSISTAYLQWSSLKASDTAMYYCAR LTDY GGPPGGVKLELTDYWGQGALVTVSSCOV107_Plate1_HC_92-P1369 3025 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWI 2673ARLHPT GWVRQMPGKGLEWMGILYPGDSDTTYSPSFQ YYDILTGGQVTISADKSISTAYLQWSSLKASDTAMYYCARL YYIDY HPTYYDILTGYYIDYWGQGTLVTVSSCOV107_Plate1_HC_26-P1369 3029 EVQLVQSGAEVKKPGESLKISCKGSGYSFISYWI 2677ARRPSS GWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ YSGWFGQVTISADKSISTAYLQWSSLKASDTAMYYCAR DP RPSSYSGWFDPWGQGTLVTVSS HEAVYCOV107_Plate2_HC_18-P1369 3033 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY 2681AREPQI MHWVRQAPGQGLEWMGWINPNSGGTNYA NPYYDILQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY TGYRAFYCAREPQINPYYDILTGYRAFDYWGQGTLVTVS DY S COV107_Plate1_HC_21-P1369 3037QVQLVQSGAEVVRPGASVKVSCKASGYTFTTHY 2685 ARGPRSMHWVRQAPGQGLEWMGIINPSVGSTSYAQKF PSDWCS QGRVTMTRDTSTSTVYMELSSLISEDTAMYYCAGGSCYD RGPRSPSDWCSGGSCYDDQNWFDPWGQGTL DQNWF VTVSS DPCOV107_Plate1_HC_24-P1369 3041 QVQLVQSGAEVMKPGASVKVSCKASGYTFTSY 2689ARDFEL YMHWVRQAPGQGLEWMGIINPTAGSTSYAQK WFGELRFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYC GWFDP ARDFELWFGELRGWFDPWGQGTLVTVSSCOV107_Plate2_HC_17-P1369 3045 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSIYAI 2693ASFHVA SWVRQAPGQGLEWMGGIIPILGTANYAQKFQ YGDYIPFGRVTITADESTSTAYMELSSLRSEDTAVYYCASF DY HVAYGDYIPFDYWGQGTLVTVSSCOV107_Plate1_HC_78-P1369 3049 QVQLVQSGAEVKKSGSSVKVSCKASGGTFSSYG 2697ARAGLL ISWVRQAPGQGLEWMGGIIPIIGTANYAQKFQ TKNIVAGRVTITADESMSTAYMELSSLRSEDTAVYYCAR TIGCFDP AGLLTKNIVATIGCFDPWGQGTLVTVSSCOV107_Plate1_HC_95-P1369 3053 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYD 2701ARGGRY INWVRQATGQGLEWMGWMNPNSGNTGYA CSSTSCYQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVY SHVGFDYCARGGRYCSSTSCYSHVGFDPWGQGTLVTVS P S COV107_Plate2_HC_38-P1369 3057EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYD 2705 ARVRYDMHWVRQATGRGLEWVSTIGTAGDTYYPGSVK SSGYFW GRFTISRENAKNSLYLQMNSLRAGDTALYYCARSLDY VRYDSSGYFWSLDYWGQGTLVTVSS COV107_Plate2_HC_61-P1369 3061EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYD 2709 ARGVSGMHWVRQATGKGLEWVSTIGTAGDTYYPGSVK VVRGVI GRFTISRENAKNSLYLQMNSLRAGDTAVYFCARRSFYYY GVSGVVRGVIRSFYYYGLDVWGQGTTVTVSS GLDV COV107_Plate1_HC_80-P13693065 EVQLLESGGGLVQPGGSLRLSCAASGITFSSYAM 2713 VETNLWTWVRQAPGKGLEWVSTISGSGGGTYYADSVKG FGEDNYRFTISRDNSKNTLYLOMNSLRAEDTAVYYCVET YYYYGM NLWFGEDNYYYYYGMDVWGQGTTVTVSS DVCOV107_Plate2_HC_68-P1369 3069 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 2717ATGGGS MHWVRQAPGKGLEWVAVISYDGSNKYYADSV YFSPRIYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA FDY TGGGSYFSPRIYFDYWGQGTLVTVSSCOV107_Plate2_HC_51-P1369 3073 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 3191AKQAGP MHWVRQAPGKGLEWVAVISYDGSNKYYADSV YCSGGTKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA CYPGTL KQAGPYCSGGTCYPGTLDYWGQGTLVTVSSDY COV107_Plate1_HC_43-P1369 3077 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 3192AKAGYS MHWVRQAPGKGLEWVAVISYDGSNKYYADSV YGYPQQKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA YFDY KAGYSYGYPQQYFDYWGQGTLVTVSSCOV107_Plate2_HC_3-P1369 3081 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 3193AKSLGP MHWVRQAPGKGLEWVAVILYDGSNKYYADSV YCSGGNKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA CYSSYFD KSLGPYCSGGNCYSSYFDYWGQGTLVTVSSY COV107_Plate2_HC_44-P1369 3085 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 3194AKKGGG MHWVRQAPGKGLEWVAVISYDGSNKYYGDSV AYCGGDKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA CYLGEF KKGGGAYCGGDCYLGEFDYWGQGTLVTVSSDY COV107_Plate2_HC_76-P1369 3089 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 3195AKSWW MHWVRQAPGKGLEWVAVISDDGSNKYYADSV LSENWFKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA DP KSWWLSENWFDPWGQGTLVTVSSCOV107_Plate1_HC_16-P1369 3093 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYG 3196AKGGLY MHWVRQAPGKGLEWVAVISYDGSNKYYADSV DSSGYYKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA PHYGM KGGLYDSSGYYPHYGMDVWGQGTTVTVSS DVCOV107_Plate1_HC_10-P1369 3097 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA 3197ARDQDL MHWVRQAPGKGLEWVAVILYDGSNKYYADSV DTAMVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA TLFDY RDQDLDTAMVTLFDYWGQGTLVTVSSCOV107_Plate1_HC_65-P1369 3101 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAI 3198ARDSPS HWVRQAPGKGLEWVAVISYDGSNKYYADSVK QIVVVPGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAR VFDY DSPSQIVVVPVFDYWGQGTLVTVSSCOV107_Plate1_HC_2-P1369 3105 EVQLVESGGGLVQPGGSLRLSCAASGFTFSGYS 3199AREGAR MNWVRQAPGKGPEWVSYISRSSSTIYYADSVK VGATYDGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR TYYFDY EGARVGATYDTYYFDYWGQGTLVTVSSCOV107_Plate2_HC_64-P1369 3109 EVQLVESGGDLVQPGGSLRLSCAASGFTFSSYS 3200ARVAIR MNWVRQAPGKGLEWVSYISISSSTIYYADSVKG WVPSARFTISRDNAKNSLYLQMNSLRDEDTAVYYCARV TYYFDY AIRVVVPSATYYFDYWGQGTLVTVSSCOV107_Plate2_HC_11-P1369 3113 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYS 3201ARDQGY MNWVRQAPGKGLEWVSYISTSSSTIYYADSVQ CSSTSCYGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR DGYYYY DQGYCSSTSCYDGYYYYMDVWGKGTTVTVSSMDV COV107_Plate1_HC_44-P1369 3117 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY3202 ARDLRG MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG PGTFDIRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDL RGPGTFDIWGQGTMVTVSSCOV107_Plate1_HC_88-P1369 3121 EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNY 3203AREVAA MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG FDIRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARE VAAFDIWGQGTMVTVSSCOV107_Plate1_HC_18-P1369 3125 EVQLVESGGGLIQPGGSLRLSCAASGVTVSRNY 3204ARDLSA MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK AFDIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DLSAAFDIWGQGTMVTVSSCOV107_Plate1_HC_59-P1369 3129 EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM 3205ARTMD SWVRQAPGKGLEWVSIIYSGGSTFYADSVKGRF GDYFDYTISRDNSKNTLYLOMNSLRAEDTAVYYCARTMD GDYFDYWGQGTLVTVSSCOV107_Plate1_HC_30-P1369 3133 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 3206ARTDIV MSWVRQAPGKGLEWVSLIYSGGSTYYADSVKG WPAARRFTISRDNSKNTLYLOMNSLRAEDTAVYYCART GFYFDY DIVVVPAARGFYFDYWGQGTLVTVSSCOV107_Plate1_HC_15-P1369 3137 EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNY 3207ARESGD MSWVRQAPGKGLEWVSVLYSGGSSFYADSVK TTMAFDGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR Y ESGDTTMAFDYWGQGTLVTVSSCOV107_Plate2_HC_23-P1369 3141 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 3208ARDLGT MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG GLFDYRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD LGTGLFDYWGQGTLVTVSSCOV107_Plate1_HC_82-P1369 3145 EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM 3209ARDYGD SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGR FYFDYFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDY GDFYFDYWGQGTLVTVSSCOV107_Plate2_HC_95-P1369 3149 EVQLVESGGGLIQPGGSLRLSCAASGFTVSYNY 3210ARDYGD MSWVRQAPGKGLEWVSIIYSGGSTYYADSVKG LYFDYRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARDY GDLYFDYWGQGTLVTVSSCOV107_Plate1_HC_86-P1369 3153 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 3211ATDLTS 53 MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK 11 GRGPGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAT DLTSGRGPWGQGTLVTVSSCOV107_Plate2_HC_78-P1369 3157 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY 3212ARDLW MTWVRQAPGKGLEWVSVIYSGGTTYYADSVK WGMDGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR V DLVVWGMDVWGQGTTVTVSSCOV107_Plate2_HC_9-P1369 3161 EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSA 3213TKPHAH MHWVRQASGKGLEWVGRIRSKANSYATTYAA CGGDCYSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYY SRDWF CTKPHAHCGGDCYSRDWFDPWGQGTLVTVSSDP COV107_Plate2_HC_50-P1369 3165 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAI3214 AKGLIAE HWVRQAPEKGLEWVSGINWSSGSIVYADSVKG LVGGGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGL WYFDY IAELVGGGWYFDYWGQGTLVTVSSCOV107_Plate1_HC_74-P1369 3169 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA 3215AKALSST MHWVRQAPGKGLEWVSGVSWNSGSIGYADS GFLVVYVRGRFTISRDNAKNSLYLQMNSLRAEDTALYYC FDY AKALSSTGFLVVYFDYWGRGTLVTVSSCOV107_Plate1_HC_93-P1369 3173 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY 3216AWRYSS YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS SWYTVDRVTISVDTXKNQFSLKLSSVTAADTAVYYCAWR NKKGDY YSSSWYTVDNKKGDYYFDYWGQGTLVTVSSYFDY COV107_Plate1_HC_45-P1369 3177 EVQLVQSGAEVKKPGESLRISCKGSAYIFTTYWIS3217 ARHISS WVRQMPGKGLEWMGRIDPSDSYTNYSPSFQG GWYDYHVTISADKSISTAYLQWSSLKASDTAMYYCARHI SSGWYDYWGQGTLVTVSSCOV107_Plate1_HC_39-P1369 3181 EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYYIS 3218ARHRHP WVRQMPGKGLEWMGRIDPSDSYTNYSPSFQG GITMIVHVTISADKSISAAYLQWSSLKASDTAMYYCARH ALDY RHPGITMIVALDYWGQGTLVTVSSCOV107_Plate1_HC_37-P1369 3185 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWI 3219ALTTVTT GWVRQMPGKDLEWMGIIYPGDSDTRYSPSFO GRWFDGQVTISADKSISTAYLQWSSLKASDTAMYYCALT P TVTTGRWFDPWGQGTLVTVSS KAPPACOV107_Plate1_Kappa_9-P1389 2370 EIVLTQSPGTLSLSPGERATLSCRASQSV 2411 QQYTSYLAWYQQKPGQAPRLLIYGASSRAT GSS GIPDRFSGSGSGTDFTLTISRLDPEDFAV PRTYYCQQYGSSPRTFGQGTKVEIK COV107_Plate1_Kappa_36-P1389 2374EIVLTQSPGTLSLSPGERATLSCRASQSV 2415 QQY SSSYLAWYQQKPGQAPRLLIYGAFSRA GSSTGIPDRFSGSGSGTDFTLTISRLEPEDFA PRT VYYCQQYGSSPRTFGQGTKVEIKCOV107_Plate1_Kappa_40-P1389 2378 EIVLTQSPGTLSLSPGERATLSCRASQSV 2419 QQYTSYLAWYQQKPGQAPRLLIYGASSRAT GSS GIPDRFSGSGSGTDFTLTISRLDPEDFAV PRTYYCQQYGSSPRTFGQGTKVEIK COV107_Plate2_kappa_13-P1389 2382EIVLTQSPGTLSLSPGERATLSCRASQSV 2423 QQY SSSYLAWYQQKPGQAPRLLIYGASSRA GSSTGIPDRFSGSGSGTDFTLTISRLEPEDFA PRT VYYCQQYGSSPRTFGQGTKVEIKCOV107_Plate2_kappa_93-P1389 2386 EIVLTQSPGTLSLSPGERATLSCRASQSV 2427 QQYSSSYLAWYQQKPGQAPRLLIYGASSRA GSS TGIPDRFSGGGSETDFTLTISRLEPEDCA PRTVYYCQQYGSSPRTFGQGTKVEIK COV107_Plate1_Kappa_11-P1389 2390EIVLTQSPGTLSLSPGERATLSCRASQTL 2431 QQY TANYLAWYQQKPGQAPRLLIYGASKRA HTTAGIPDRFSGSGSGTDFTLSITRLEPEDFA PRT VYYCQQYHTTPRTFGGGTKVEICOV107_Plate1_Kappa_42-P1389 2394 EIVLTQSPGTLSLSPGERATLSCWASQS 2435 QQYVSASYLAWYQQKPGQAPRLLIYGASSR GTT ATGIPDRFSGSGSGTDFTLTISRLEPEDF PRTAVYYCQQYGTTPRTFGGGTKVEIK COV107_Plate1_Kappa_84-P1389 2398EIVLTQSPGTLSLSPGERATLSCRASQTL 2439 QQY TANYLAWYQQKPGQAPRLLIYGASKRA GTTTGIPDRFSGSGSGTDFTLSISRLEPEDFA PRT VYYCQQYGTTPRTFGGGTKVEICOV107_Plate2_kappa_31-P1389 2402 EIVLTQSPGTLSLSPGERATLSCRASQTV 2443 QQYSANYLAWYQQKAGQAPRLLIYGASKRA VTT TGIPDRFSGSGSGTDFTLSISRLEPEDFA PRTVYYCQQYVTTPRTFGGGTKVEI COV107_Plate2_kappa_53-P1389 2406EIVLTQSPGTLSLSPGERATLSCRASQTV 2447 QQY TANYLAWYQQKPGQAPRLLIYGASKRA TTTTGIPDRFSGSGSGTDFTLSISRLEPEDFA PRT VYYCQQYTTTPRTFGGGTKVEI LAMBDACOV107_Plate1_Lambda_29-P1409 2410 QSALTQPPSASGSPGQSVTISCTGTSSD 2451 SSYVGGYNYVSWYQQHPGKAPKLMIYEVS AGS KRPSGVPDRFSGSKSGNTASLTVSGLQ NNFAEDEADYYCSSYAGSNNFVVFGGGTKL VV TVL COV107_Plate1_Lambda_35-P1409 2414QSVLTQPPSASGSPGQSVTISCTGTSSD 2455 SSY VGGYNYVSWYQQHPGKAPKLMIYEVR AGSKRPSGVPDRFSGSKSGNTASLTVSGLQ NNF AEDEADYYCSSYAGSNNFVLFGGGTKL VL TVLCOV107_Plate2_lambda_4-P1409 2418 QSVLTQPPSASGSPGQSVTISCTGTSSD 2459 SSYEVGGYKYVSWYQQHPGKAPKLMIYEVS GSN KRPSGVPDRFSGSKSGNTASLTVSGLQ NFVAEDEADYYCSSYEGSNNFVVFGGGTKL V TVL COV107_Plate1_Lambda_63-P1409 2422QSVLTQPPSASGTPGQRVTISCSGSSSN 2463 AA IGSNYVYWYQQLPGTAPKLLIYRNNQR WDPSGVPDRFSGSKSGTSASLAISGLRSEDE DSL ADYYCAAWDDSLSGFVVFGGGTKLTVL SGF VVCOV107_Plate1_Lambda_68-P1409 2426 QSVLTQPPSASGTPGQRVTISCSGSSSN 2467 AAIGSNYVYWYQQLPGTAPKLLIYRNNQR WD PSGVPDRFSGSKSGTSASLAISGLRSEDE DSLADYYCAAWDDSLSGFVVFGGGTKLTVL SGF VV COV107_Plate1_Lambda_13-P1409 2430QSVLTQPPSASGTPGQRVTISCSGSSSN 2471 AA IGSNTVNWYQQLPGTAPKLLIYSNNQR WDPSGVPDRFSVSKSGTSASLAISGLQSED DSL EADYYCAAWDDSLNGVVFGGGTKLTV NGV L VCOV107_Plate1_Lambda_27-P1409 2434 QSVLTQPPSASGTPGQRVTISCSGSSSN 2475 AAIGSNTVNWYQQLPGTAPKLLIYSNNQR WD PSGVPDRFSGSKSGTSASLAISGLQSED DSLEADYYCAAWDDSLNGVVFGGGTKLTV NGV L V COV107_Plate1_Lambda_79-P1409 2438QSVLTQPASVSGSPGQSITISCTGTSSD 2479 SSYT VGGYKYVSWYQRHPGKAPKLMIYDVS SSSTNRPSGVSNRFSGSKSGNTASLTISGLQA SVV EDEADYYCSSYTSSSTSVVFGGGTQLTV LCOV107_Plate1_Lambda_91-P1409 2442 QSALTQPASVSGSPGQSITISCTGTSSD 2483SSYT VGGYKYVSWYQRHPGKAPKLMIYDVS SSST NRPSGVSNRFSGSKSGNTASLTISGLQA SVVEDEADYYCSSYTSSSTSVVFGGGTQLTV L KAPPA COV107_Plate1_Kappa_53-P1389 2446EIVLTQSPGTLSLSPGERATLSCRASQSV 2487 QQY SSSYLAWYQQKPGQAPRLLIYGASSRA GNSTGIPDRFSGSGSGTDFTLTISRLEPEDFA PWT VYYCQQYGNSPWTFGQGTKVEIKCOV107_Plate2_kappa_81-P1389 2450 EIVLTQSPGTLSLSPGERATLSCRASQSV 2491 QQYSSSYLAWYQQKPGQAPRLLIYGASSRA GSS TGIPDRFSGSGSGTDFTLTISRLEPEDFA 24 PWTVYYCQQYGSSPWTFGQGTKVEIK 91 LAMBDA COV107_Plate2_lambda_42-P1409 2454QSVLTQPPSVSAAPGQKVTISCSGSSSN 2495 GT IGNNYVSWYQQLPGTAPKLLIYENNKR WDPSGIPDRFSGSKSGTSATLGITGLQTGD SSLS EADYYCGTWDSSLSAGGVYVFGTGTTV AGG TVLVYV COV107_Plate2_lambda_89-P1409 2458 QSVLTQPPSVSAAPGQKVTISCSGSSSN 2499GA IGNNLVSWYQQLPGTAPKLLIYENNKR WD PSGIPDRFSGSKSGTSATLGITGLQTGD SSLSEADYYCGAWDSSLSAGGVYVFGTGTK AGG VTVL VYV COV107_Plate1_Lambda_22-P14092462 QSALTQPASVSGSPGQSITISCTGTSSD 2503 SSYT VGGYNYVSWYQQHPGKAPKLMIYDVSSSST NRPSGVSNRFSGSKSGNTASLTISGLQA WV EDEADYYCSSYTSSSTWVFGGGTKLTVLCOV107_Plate2_lambda_88-P1409 2466 QSVLTQPASVSGSPGQSITISCTGTSSD 2507SSYT VGGYNYVSWYQQHPGKAPKLMIYDVS SSST NRPSGVSNRFSGSKSGNTASLTISGLQA WVEDEADYYCSSYTSSSTWVFGGGTKLTVL COV107_Plate2_lambda_49-P1409 2470QSVLTQSPSASASLGASVKLTCTLSSGH 2511 QT SSYAIAWHQQQPEKGPRYLMKLNTDG WGSHSKGDGIPDRFSGSSSGAERYLTISSLQ TGIL SEDEADYYCQTWGTGILVFGGGTKLTV V LCOV107_Plate2_lambda_84-P1409 2474 QSVLTQSPSASASLGASVKLTCTLSSGH 2515 QTSSYAIAWHQQQPEKGPRYLMKLNSDG WG SHSKGDGIPDRFSGSSSGAERYLTISSLQ TGILSEDEADYYCQTWGTGILVFGGGTKLTV V L KAPPA COV107_Plate1_Kappa_19-P1389 2478DIQMTQSPSTLSASVGDRVTITCRASQS 2519 QQ MSSWLAWYQQKPGNAPKLLIYKASSLE HNSSGVPSRFSGSGSGTEFTLTISSLQPDDFA SPLT TYYCQQHNSSPLTFGGGTKVEIKCOV107_Plate1_Kappa_38-P1389 2482 DIQMTQSPSTLSASVGDRVTITCRASQS 2523 QQMSSWLAWYQQKPGNAPKLLIYKASSLE HNS SGVPSRFSGSGSGTEFTLTISSLQPDDFA SPLTTYYCQQHNSSPLTFGGGTKVEIK COV107_Plate2_kappa_15-P1389 2486DIVMTQSPLSLSVTPGEPASISCRSSQSL 2527 MQ LHSNGNNYFDWYLQKPGQSPQLLIYLG VLQISNRASGVPDRFSGSGSGTDFTLKISRVE PYT AEDVGVYYCMQVLQIPYTFGQGTKLEICOV107_Plate2_kappa_69-P1389 2490 DIVMTQSPLSLPVTPGEPASISCRSSQSL 2531 MQLQSNGNNYFDWYLQKPGQSPQLLIYLG VLQ SNRASGVPDRFSGSGSGTDFTLKISRVE VPYAEDVGVYYCMQVLQVPYTFGQGTNLE T I COV107_Plate2_kappa_32-P1389 2494DIQMTQSPSSLSASVGDTVTITCQASQ 2535 QQY DISKYLNWYQQKPGKAPKLLIYDASNLE DNLTGVPSRFSGSGSGTDFTFTISSLQPEDIA PQT TYYCQQYDNLPQTFGGGTKVEIKCOV107_Plate2_kappa_73-P1389 2498 DIQMTQSPSSLSASVGDTVTITCQASQ 2539 QQYDISKYLNWYQQKPGKAPKLLIYDASNLE DNL TGVPSRFSGSGSGTDFTFTISSLQPEDIA PQTTYYCQQYDNLPQTFGGGTKVEIK LAMBDA COV107_Plate1_Lambda_62-P1409 2502QSVLTQPPSVSGAPGQRVTISCTGTSS 2543 QSY NIGAGYDVHWYQQLPGRAPKVLISGN DSSNIRPSEVPDRFSGSRSGTSASLAITSLQP LYA EDEAQYYCQSYDSSLYAVFGGGTKLTVL VCOV107_Plate1_Lambda_73-P1409 2506 QSVLTQPPSVSGAPGQRVTISCTGTSS 2547 QSYNIGAGYDVHWYQQLPGRAPKVLISGN DSS NIRPSEVPDRFSGSRSGTSASLAITSLQP LYAEDEAQYYCQSYDSSLYAVFGGGTKLTVL V COV107_Plate1_Lambda_46-P1409 2510QSALTQPASVSGSPGQSITISCTGTSSD 2551 NSY VGGYNFVSWYQQHPGKAPKLMIYDVS TSSSNRPSGVSNRFSGSKSGNTASLTISGLQA TRV EDEADYYCNSYTSSSTRVFGTGTKVTVLCOV107_Plate2_lambda57-P1409 2514 QSVLTQPASVSGSPGQSITISCTGTSSD 2555 NSYVGGYNYVSWYQQHPGKAPKLMIYDVS TSSS NRPSGVSNRFSGSKSGNTASLTISGLQA TRVEDEADYYCNSYTSSSTRVFGTGTKVTVL COV107_Plate2_lambda_36-P1409 2518QSVLTQPPSVSEAPRQRVTISCSGSSSNI 2559 AA GNNAVNWYQQLPGKAPKLLIYYDDLLP WDSGVSDRFSGSKSGTSASLAISGLQSEDE DSL ADYYFAAWDDSLNGAWVFGGGTKLT NGA VL WVCOV107_Plate2_lambda71-P1409 2522 QSVLTQPPSVSEAPRQRVTISCSGSSSNI 2563 AAGNNAVNWYQQVPGKAPKLLIYYDDLL WD PSGVSDRFSGSKSGTSASLAISGLQSED DSLEADYYCAAWDDSLNGAWVFGGGTKL NGA TVL WV COV107_Plate1_Lambda_77-P1409 2526SYVLTQPPSVSVAPGKTARITCGGNNIG 2567 QV SKSVHWYQQKPGQAPVLVIYFDSDRPS WDGIPERFSGSNSGNTATLTISRVEAGDEA SSR DYYCQVWDSSRDHVVFGGGTKLTVL DHV VCOV107_Plate2_lambda_72-P1409 2530 SYVLTQPPSVSVAPGKTARITCGGNNIG 2571 QVSKSVHWYQQKPGQAPVLVIYFDSDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEA SSRDYYCQVWDSSRDHVVFGGGTKLTVL DHV V KAPPA COV107_Plate1_Kappa_75-P1389 2534DIQMTQSPSTLSASVGDRATITCRASQS 2575 QQY ISYWLAWYQQKPGKAPKLLIYKASSLES NSYGVPSRFSGSGSGTEFTLTISSLQPDDSAT PYT YYCQQYNSYPYTFGQGTKLEIKCOV107_Plate2_kappa_90-P1389 2538 DIQMTQSPSTLSASVGDRVTITCRASQS 2579 QQYISYWLAWYQQKPGKAPKLLIYQASSLES NSY GVPSRFSGSESGTEFTLTISSLQPDDFAT PYTYYCQQYNSYPYTFGQGTKLEIK LAMBDA COV107_Plate1_Lambda_52-P1409 2542QSVLTQPPSASGTPGQRVTISCSGSSSN 2583 AA IGSNTVNWYQQLPGTAPKLLIYSNNQR WDPSGVPDRFSGSKSGTSASLAISGLQSED DSL EADYYCAAWDDSLNGHVVFGGGTKLT NGH VL VVCOV107_Plate1_Lambda_58-P1409 2546 NFMLTQPHSVSESPGKTVTISCTGSSGS 2587 QSYIASNYVQWYQQRPGSAPTTMIYEDNQ DSS RPSGVPDRFSGSIDSSSNSASLTISGLKT TPNEDEADYYCQSYDSSTPNCVFGGGTKLT CV VL COV107_Plate2_lambda_45-P1409 2550QSVLTQPASVSGSPGQSITISCTGTSSD 2591 SSYT VGGYNYVSWYQQHPGKAPKVMIYDV SSSTSNRPSGVSNRFSGSKSGNTASLTISGLQ LL AEDEADYYCSSYTSSSTLLFGGGTKLTXLCOV107_Plate1_Lambda_60-P1409 2554 QSALTQPASVSGSPGQSITISCTGTSSD 2595 CSYVGSYNLVSWYQQHPGKAPKLMIYEGS AGS KRPSGVSNRFSGSKSGNTASLTISGLQA STWEDEADYYCCSYAGSSTWVFGGGTKLTV V L COV107_Plate1_Lambda_5-P1409 2558SYVLTQPPSVSVAPGKTARITCGGNNIG 2599 QV SKNVHWYQQKPGQAPVLVIYYDSDRP WDSGIPERFSGSNSGNTATLTISRVEAGDE SSW ADYYCQVWDSSWVFGGGTKLTVL VCOV107_Plate2_lambda_94-P1409 2562 QSVLTQPASVSGSPGQSITISCTGTSSD 2603 CSYVGSYNLVSWYQQHPGKAPKLMIYEGS AGS KRPSGVSNRFSGSKSGNTASLTISGLQA STLVEDEADYYCCSYAGSSTLVFGGGTKLTVL COV107_Plate1_Lambda_83-P1409 2566SYVLTQPPSVSVSPGQTASITCSGDKLG 2607 QA DKYACWYQQKAGQSPVLVIYQDSKRP WDSGIPERFSGSKSGNTATLTISGTQAMDE SST ADYYCQAWDSSTVVFGGGTKLTVL VVCOV107_Plate2_lambda_40-P1409 2570 QSVLTQPPSVSGAPGQRVTISCTGSSSN 2511 QSYIGAGYDVHWYQHLPGTAPKLLIYGNN DSS NRPSGVPDRFSGSRSGTSASLAITGLQA LSAEDEADYYCQSYDSSLSAVVFGGGTKLT VV VL COV107_Plate1_Lambda_28-P1409 2574QSVLTQPPSVSGAPGQRVTISCTGSSSN 2615 QSY IGAGYDVHWYQQLPGTAPNLLIYDNIN DSSRPSGVPDRFSGSKSGTSASLAITGLQAE LSG DEADYYCQSYDSSLSGVVFGGGTKLTV VV LCOV107_Plate2_lambda_92-P1409 2578 NFMLTQPHSVSESPGKTVTISCTGSSGS 2619 QSYIASNYVQWYQQRPGSAPTTVIYEDNQ DSS RPSGVPDRFSGSIDSSSNSASLTISGLKT KHAEDEADYYCQSYDSSKHAVFGGGTQLTV V L COV107_Plate2_lambda_55-P1409 2582NFMLTQPHSVSESPGKTVTISCAGSSGS 2623 QSY IASNYVQWYQQRPGSAPTTVIYEDNQ DSSRPSGVPDRFSGSIDSSSNSASLTISGLKT KSW EDEADYYCQSYDSSKSWVFGGGTKLTV V LCOV107_Plate2_lambda_47-P1409 2586 QSVLTQPPSVSGAPGQRVTISCTGSSSN 2627 QSYIGAGYDVHWYQQLPGTAPKLLIYGNSN DSS RPSGVPDRFSGSKSGTSASLAITGLQAE LSGDEADYYCQSYDSSLSGSYVFGTGTKVTV SYV L COV107_Plate1_Lambda_49-P1409 2590SYVLTQPPSVSVAPGKTARITCGGNNIG 2631 QV SKSVHWYQQKPGQAPVLVISYDSDRPS WDGIPERFSGSNSGNTATLTISRVEAGDAA GSS DYYCQVWDGSSDHHVVFGGGTKLTVL DHH VVCOV107_Plate2_lambda_22-P1409 2594 QSVLTQPPSVSAAPGQRVTISCSGSSSN 2635 GTIGNNYVSWYQQLPGTAPKLLIYENNKR WD PSGIPDRFSGSKSGTSATLGITGLQTGD SSLSEADYYCGTWDSSLSAFVFGTGTKVTVL AFV COV107_Plate2_lambda_91-P1409 2598QSALTQPASVSGSPGQSITISCTGTSSD 2639 SSYT VGGYNYVSWYQQHPGKAPKLMIYDVS SSSTNRPSGVSNRFSGSKSGNTASLTISGLQA LGV EDEADYYCSSYTSSSTLGVFGTGTKVTV LCOV107_Plate2_lambda_35-P1409 2602 SYVLTQPPSVSVAPGKTARITCGGNNIG 2643 QVSKSVHWYQQKPGQAPVLVIYYDSDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEA SSSDYYCQVWDSSSDHPVVFGGGTKLTVL DHP VV COV107_Plate2_lambda_24-P1409 2606NFMLTQPHSVSESPGKTVTISCTGSSGS 2647 QSY IASNYVQWYQQRPGSAPTTVIYEDNQ DSSRPSGVPDRFSGSIDSSSNSASLTISGLKT NQ EDEADYYCQSYDSSNQWVVFGGGTKL WV TVL VCOV107_Plate2_lambda_34-P1409 2610 QSVLTQPASVSGSPGQSITISCPGTSSD 2651SSYT VGGYNYVSWYQQHPGKAPKLMIYDVS SSS TRPSGVSNRFSGSKSGNTASLTISGLQA VVEDEADYYCSSYTSSSVVFGGGTKLTVL COV107_Plate1_Lambda_41-P1409 2614SYVLTQPPSVSVAPGKTARITCGGNNIG 2655 QV SKSVHWYQQKPGQAPVLVIYYDSDRPS WDGIPERFSGSNSGNTATLTISRVEAGDEA SSR DYYCQVWDSSRVFGGGTKLTVL VCOV107_Plate2_lambda_46-P1409 2618 QSVLTQPPSASGSPGQSVTISCTGTSSD 2659 SSYVGGYNYVSWYQQHPGKAPKLMIYEVT AGS KRPSGVPDRFSGSKSGNTASLTVSGLQ NNYAEDEADYYCSSYAGSNNYVVFGGGTKL VV TVL COV107_Plate1_Lambda_32-P1409 2622NFMLTQPHSVSESPGKTVTISCTGSSGS 2663 QSY IASNYVQWYQQRPGSAPTTVIYEDNQ DSSRPSGVPDRFSGSIDSSSNSASLAISGLKT NHV EDEADYYCQSYDSSNHVVFGGGTKLTV V LCOV107_Plate2_lambda_25-P1409 2626 SYVLTQPPSVSVAPGKTARITCGGNNIG 2667 QVSKSVHWYQQKPGQAPVLVIYYDSVRPS WD GIPERFSGSNSGNTATLTISRVEAGDEA SSSDYYCQVWDSSSDHYVFGTGTKVTVL DHY V COV107_Plate2_lambda_54-P1409 2630QSVLTQPPSVSGAPGQRVTISCTGSSSN 2671 QSY IGAGYDVHWYQQLPGTAPKLLIYGNSD DSSRPSGVPDRFSGSKSGTSASLAITGLQAE LSG DEADYYCQSYDSSLSGVVFGGGTKLTXL VVCOV107_Plate2_lambda_20-P1409 2634 QSVLTQPASVSGSPGQSITISCTGTSSD 2675 CSYVGSYNLVSWYQQHPGKAPKLMIYEGS AGS KRPSGVSNRFSGSKSGNTASLTISGLQA STWEDEADYYCCSYAGSSTWVFGGGTKLTV V L COV107_Plate1_Lambda_25-P1409 2638QSALTQPASVSGSPGQSITISCTGTSSD 2679 SSYT VGGYNYVSWYQQHPGKAPKLMIYDVS SSSTNRPSGVSNRFSGSKSGNTASLTISGLOA YV EDEADYYCSSYTSSSTYVFGTGTKVTVLCOV107_Plate1_Lambda_64-P1409 2642 QSVLTQPASVSGSPGQSITISCTGTSSD 2683SSYT VGGYNYVSWYQQHPGEAPKLMIHDV SSST SNRPSGVSNRFSGSKSGNTASLTISGLQ LVAEDEADYYCSSYTSSSTLVFGGGTKLTV L COV107_Plate2_lambda_28-P1409 2646NFMLTQPHSVSESPGKTVTISCTGSSGS 2687 QSY IASNYVQWYQQRPGSAPTTVINEDNQ DSSRPSGVPDRFSGSIDSSSNSASLTISGLKT NLV EDEADYYCQSYDSSNLVFGGGTKLTVLCOV107_Plate2_lambda_58-P1409 2650 QSVLTQPASVSGSPGQSITISCTGTSSD 2691 CSYVGSYNLVSWYQEHPGKAPKLMIYEGSK AGS RPSGVSNRFSGSKSGNTASLTISGLOAE STWDEADYYCCSYAGSSTWVFGGGTKLTVL V COV107_Plate2_lambda_2-P1409 2654NFMLTQPHSVSESPGKTVTISCTGSSGS 2695 QSY IASNYVQWYQQRPGSAPTTVIYEDNQ DTSRPSGVPDRFSGSIDSSSNSASLTISGLKT NW EDEADYYCQSYDTSNWVFGGGTKLTV V LCOV107_Plate2_lambda_10-P1409 2658 SYVLTQPPSVSVAPGKTARITCGGNNIG 2699 QVSKSVHWYQQKPGQAPVLVIYYDTDRPS WD GIPERFSGSNSGNTATLTISRVEAGDEA NNSDYYCQVWDNNSDHRGVFGGGTRLTV DHR L GV COV107_Plate1_Lambda_48-P1409 2662QSALTQPASVSGSPGQSITISCTGTSSD 2703 SSYT VGGYNYVSWYQQHPGKAPKLMIYDVS SSSTNRPSGVSNRFSGSKSGNTASLTISGLOA VW EDEADYYCSSYTSSSTVWVFGGGTKLT V VLCOV107_Plate2_lambda_87P1409- 2666 QSVLTQPPSASGTPGQRVTIACSGSSSN 2707 AAIGSSPVKWYKQLPGTGPKLLIYSSNQRP WD SGVPDRFSGSKSGTSASLAISGLQSEDE DSLADYYCAAWDDSLSGYVFGTGTKVTVL SGY V COV107_Plate2_lambda_1-P1409 2670QSVLTQPPSASGTPGQRVTISCSGSSSN 2711 AA IGSNTVNWYQQLPGTAPQLLIYNNYQR WDPSGVPDRFSGSKSGTSASLAISGLQSED DSL EADYYCAAWDDSLNGPVVFGGGTKLT NGP VL VVCOV107_Plate1_Lambda_92-P1409 2674 QSALTQPASVSGSPGQSITISCTGTSSD 2715 CLYVGSYNLVSWYQQHPGKAPKLMIYEGS AFS KRPSGVSNRFSGSKSGNTASLTISGLQA SIVEDEADYYCCLYAFSSIVFGGGTKLTVL COV107_Plate1_Lambda_26-P1409 2678QSVLTQPPSASGTPGQRVTISCSGSSSN 2719 AA IGSNTVNWYQQLPGTAPKLLIYNNNQR WDPSGVPDRFSGSKSGTSASLAISGLQSED DSL EADYYCAAWDDSLNGLVFGGGTKLTV NGL L VKAPPA COV107_Plate2_kappa_18-P1389 2682 EIVLTQSPGTLSLSPGERATLSCRASQSV2723 QQY SSSYLAWYQQKPGQAPRLLIYGASSRA GSS TGIPDRFSGSGSGTDFTLTISRLEPEDFALT VYYCQQYGSSLTFGQGTRLEIK COV107_Plate1_Kappa_21-P1389 2686DIQMTQSPSSLSASVGDRVTITCRASQS 2727 QQS ISSYLNWYQQKPGKAPKLLIYSASSLQS YSTLGVPSRFSGSGSGTDFTLTISSLQPEDFAT IT YYCQQSYSTLITFGQGTRLEIKCOV107_Plate1_Kappa_24-P1389 2690 EIVMTQSPATLSVSPGERATLSCRASQS 2731 QQYVSSNLAWYQQKPGQAPTLLIYGASTRA NN TGIPARFSGSGSGTEFTLTISSLQSEDFA WPPVYYCQQYNNWPPITFGQGTRLEIK IT COV107_Plate2_kappa_17-P1389 2694EIVLTQSPGTLSLSPGERATLSCRASQSV 2735 QQY SSSYLAWYQQKPGQAPRLLIYGASSRA GRSTGIPDRFSGSGSGTDFTLTISRLEREDFA PTW VYYCQQYGRSPTWTFGQGTKVEIK TCOV107_Plate1_Kappa_78-P1389 2698 DIVMTQSPDSLAVSXGERATINCKSSQS 2739 QQYVLYSSNNKNYLAWYQQKPGQPPKLLIY YST WASTRESGVPDRFSGSGSGTDFTLTISS PLTLQAEDVAVYYCQQYYSTPLTFGGGTKV EIK COV107_Plate1_Kappa_95-P1389 2702DIQLTQSPSFLSASVGDRVTITCRASQGI 2743 QQL SSYLAWFQQKPGKAPKLLIYAASTLQTG NSYVPSRFSGSGSGTEFTLTISSLQPEDFATY PIT YCQQLNSYPITFGQGTRLEIKCOV107_Plate2_kappa_38-P1389 2706 DIQMTQSPSSLSASVGDRVTITCRASQS 2747 QQSISRYLNWYQQKPGKAPKLLIYAASSLQS YST GVPSRFSGSGSGTDFTLTISGLQPEDFA PQYTYYCQQSYSTPQYTFGQGTKLEIK T COV107_Plate2_kappa_61-P1389 2710DIQMTQSPSSLSASVGDRVTITCRASQS 2751 QQS ISSYLNWYQQKPGKAPKLLIYAASSLQS YITPGVPSRFSGSGSGTDFTLTISSLQPEDFAT GW YYCQQSYITPGWTFGQGTKVEIK TCOV107_Plate1_Kappa_80-P1389 2714 EIVLTQSPGTLSLSPGERATLSCRASQSV 2755 QQYRSSYLAWYQQKPGQAPRLLIYGASSRA GSS TGIPDRFSGSGSGTDFTLTISRLEPEDFA PPWVYYCQQYGSSPPWTFGQGTKVEIK T COV107_Plate2_kappa_68-P1389 2718DIQMTQSPSSLSASVGDRVTITCQASQ 2759 QQY DISNYLNWYQQKPGKAPKLLIYDASNL DNLETGVPSRFSGSGSGTDFTFTISSLQPEDI PPY ATYYCQQYDNLPPYTFGQGTKLEIK TCOV107_Plate2_kappa_51-P1389 2722 DIQMTQSPSSLSASVGDRVTITCQASQ 2763 QQYDISNYLNWYQQKPGKAPKLLIYDASNL DNV ETGVPSRFSGSGSGTDFTFTISSLQPEDI PLTATYYCQQYDNVPLTFGPGTKVDIK COV107_Plate1_Kappa_43-P1389 2726DIQMTQSPSTLSASVGDRVTITCRASQS 2767 QQY ISSWLAWYQQKPGKAPKLLISEASSLES NSYGVPSRFSGSGSGTEFTLTISSLQPDDFAT SYT YYCQQYNSYSYTFGQGTKLEIKCOV107_Plate2_kappa_3-P1389 2730 DIQMTQSPSTLSASVGDRVTITCRASQS 2771 QQYISSWLAWYQQKPGKAPKLLIYEASSLES NSY GVPSRFSGSGSGTEFTLTISSLQPDDFAT STYYCQQYNSYSTFGPGTKVDIK COV107_Plate2_kappa_44-P1389 2734EIVLTQSPGTLSLSPGERATLSCRASQSV 2775 QQY SSSYLAWYQQKPGQAPRLLIYGASSRA GTSTGIPDRFSGSGSGTDFTLTISRLEPEDFA PST VFYCQQYGTSPSTFGQGTKVESKCOV107_Plate2_kappa_76-P1389 2738 EIVMTQSPATLSVSPGERATLSCRASQS 2779 QQYVSSNLAWYQQKPGQAPRLLIYGASTRA NN TGIPARFSGTGSGTEFTLTISSLQSEDFA WPLVYYCQQYNNWPLTFGGGTKVEIK T COV107_Plate1_Kappa_16-P1389 2742DIQMTQSPSSLSASVGDRVTITCQASQ 2783 QQY DINNYLNWYQQKPGKAPKVLIYDASNL DNLETGVPSRFSGSGSGTDFTFTISSLQPEDF PLA ATYYCQQYDNLPLAFGGGTKVEIKCOV107_Plate1_Kappa_10-P1389 2746 DIQMTQSPSSLSASVRDRVTITCRASQS 2787 QQSISSYLNWYQQKPGKAPKLLIYAASSLQS YST GVPSRFSGSGSGTDFTLTISSLQPEDLAT PPWYYCQQSYSTPPWTFGQGTKVEIK T COV107_Plate1_Kappa_65-P1389 2750DIQMTQSPSSLSASVGDRVTITCRASQS 2791 QQS ISRYLNWYQQKPGKAPNLLIYAASSLQS YSTLGVPSRFSGSGSGTDFTLIISSLQPEDFAT ALT YYCQQSYSTLALTFGGGTKVEIKCOV107_Plate1_Kappa_2-P1389 2754 EIVLTQSPATLSLSPGERATLSCRASQSF 2795 QQRSSYLAWYQQKPGQAPRLLIYDASNRAT NN GIPARFSGSGSGTDFTLTISSLEPEDFAV WPPYYCQQRNNWPPEWTFGQGTKVEIK EWT COV107_Plate2_kappa_64-P1389 2758EIVLTQSPATLSLSPGERATLSCRASQSF 2799 QQR SSYLAWYQQKPGQAPRLLIYDASNRAT SNGIPARFSGSGSGTDFTLTISSLEPEDFAF WP YYCQQRSNWPQGFTFGPGTKVDIK QGF TCOV107_Plate2_kappa_11-P1389 2762 DIQMTQSPSSLSASVGDRVTITCRASQS 2803 QQSISSYLNWYQQKPGKAPKLLIYAASSLHS YSA GVPSRFSGSGSGTDFTLTISSLQPEDFAT PWTYYCQQSYSAPWTFGQGTKVEIK COV107_Plate1_Kappa_44-P1389 2766DIQMTQSPSSLSASVGDRVTITCQASQ 2807 QQY DISNYLNWYQQKPGKAPKLLIYDASNL DNLETGVPSRFSGSGSGTDFTFTISSLQPEDI PRV ATYYCQQYDNLPRVTFGPGTKVDIK TCOV107_Plate1_Kappa_88-P1389 2770 DIQLTQSPSFLSASVGDRVTITCRASQGI 2811 QQLSSYLAWYQQKPGKAPKLLIYAASTLQSG NSY VPSRFSGSGSGTEFTLTISSLQPEDFATY PPGYCQQLNSYPPGFGQGTKVEIK COV107_Plate1_Kappa_18-P1389 2774DIQLTQSPSFLSASVGDRVTITCRASQGI 2815 QQL SSYLAWYQQKPGKAPKLLIYAASTLQSG NSYVPSRFSGSGSGTEFTLTISSLQPEDFATY PPA YCQQLNSYPPAFGQGTRLEIKCOV107_Plate1_Kappa_59-P1389 2778 DIQMTQSPSSLSASVGDRVTITCRASQ 2819 QKYDINNYLAWYQQKPGKVPKLLIYAASTL NSA QSGVPSRFSGSGSGTDFTLTISSLQPED PLTVATFYCQKYNSAPLTFGGGTKVEIK COV107_Plate1_Kappa_30-P1389 2782DIQMTQSPSTLSASVGDRVTITCRASQS 2823 QQY ISSWLAWYQQKPGKAPKLLIYKASSLES NSYGVPSRFSGSGSGTEFTLTISSLQPDDFAT GT YYCQQYNSYGTFGQGTKVEIKCOV107_Plate1_Kappa_15-P1389 2786 DIQLTQSPSFLSASVGDRVTITCRASQGI 2827 QQLSSYLAWYQQKPGKAPKLLIYAASTLQSG NSD VPSRFSGSGSGTEFTLTISSLQPEDFATY SYTYCQQLNSDSYTFGQGTKLEIK COV107_Plate2_kappa_23-P1389 2790DIQLTQSPSFLSASVGDRVTITCRASQGI 2831 QQL SSYLAWYQQKPGKAPKLLIYAASTLQSG DSYVPSRFSGSGSGTEFTLTISSLQPEDFATY PPG YCQQLDSYPPGTFGPGTKVDIK TCOV107_Plate1_Kappa_82-P1389 2794 EIVMTQSPATLSVSPGERATLSCRASQS 2835 QQYVSSNLAWYQQKPGQAPRLLIYGASTRA YN TGIPARFSGSGSGTEFTLTISSLQSEDFA WPVYYCQQYYNWPRTFGQGTKVEIK RT COV107_Plate2_kappa_95-P1389 2798EIVLTQSPGTLSLSPGERATLSCRASQSV 2839 QQY SSSYLAWYQQKPGQAPRLLIYGASSRA GSSTGIPDRFSGSGSGTDFTLTISRLEPEDFA PRT VYYCQQYGSSPRTFGQGTRLEIKCOV107_Plate1_Kappa_86-P1389 2802 AIQMTQSPSSLSASVGDRVTITCRASQ 2843 LQDGIRNDLGWYQQKPGKAPKLLIYAASSL YNY QSGVPSRFSGSGSGTDFTLTISSLQPED PKTFATYYCLQDYNYPKTFGQGTKVEIK COV107_Plate2_kappa_78-P1389 2806DIQLTQSPSFLSASVGDRVTITCRASQGI 2847 QLL SSYLAWYQQKPGKAPKLLIYAASTLQSG NSYVPSRFSGSGSGTEFTLTISSLQPEDFATY PYT YCQLLNSYPYTFGQGTKLEIKCOV107_Plate2_kappa_9-P1389 2810 DIQMTQSPSSLSASVGDRVTITCRASQS 2851 QQSISSYLYWYQQKPGKAPKLLIYAASSLQS YST GVPSRFSGSGSGTDFTLTISSLQPEDFAT PPFYYCQQSYSTPPFTFGPGTKVDIK T COV107_Plate2_kappa_50-P1389 2814EIVLTQSPATLSLSPGERATLSCRASQSV 2855 QQR SSYLAWYQQKPGQAPRLLIYDASNRAT SNGIPARFSGGGSGTDFTLTISSLEPEDFAV WPP YYCQQRSNWPPLTFGQGTKVEIK LTCOV107_Plate1_Kappa_74-P1389 2818 EIVMTQSPATLSVSPGERATLSCRASQS 2859 QQYVSSNLAWYQQKPGQAPRLLIYGASTRA NN TGIPARFSGSGSGTEFTLTISSLQSEDFA WLSVYYCQQYNNWLSLTFGGGTKVEIK LT COV107_Plate1_Kappa_93-P1389 2822DIVMTQSPLSLPVTPGEPASISCRSSESL 2863 MQ LHSNGYNYLDWYLQKPGQSPQLLIYLG ALQSNRASGVPDRFSGSGSGTDFTLKISRVE TPR AEDVGVYYCMQALQTPRTFGQGTKLEI T KCOV107_Plate1_Kappa_45-P1389 2826 DIQMTQSPSSLSASVGDRVTITCQASQ 2867 QQYDISNYLNWYQQKPGKAPKLLIYDASNL DNL ETGVPSRFSGSKSGTDFTFTISSLQPEDI PYTATYYCQQYDNLPYTFGQGTKVEI COV107_Plate1_Kappa_39-P1389 2830DIQMTQSPSSLSASVGDRVTITCQASQ 2871 QQY DISNYLNWYQQKPGKAPKLLIYDASYLE DNVTGVPSRFTGSASGTDFTFTISSLQPEDIA PL TYYCQQYDNVPLFGPGTKVDICOV107_Plate1_Kappa_37-P1389 2834 DVVMTQSPLSLPVTLGQPASISCRSSQS 2875 MQLVYSDGNTYLNWFQQRPGQSPRRLIYQ GTH VSNRDSGVPDRFSGSGSGTDFTLKISRV WLEAEDVGVYYCMQGTHWLWTFGQGTK WT VEIK

TABLE 14Additional representative sequences of the example antibodies as disclosedSEQ ID Anti- NO body Sequence Notes 2876 C135QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSVH KNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSS 2877QVQLVESGGG VVQPGRSLRL SCAASGFTFS HFW1 2878 SYAMH HCDR1 2879WVRQAPGKGL EWVA HFW2 2880 VIPFDGRNKY YADSVTG HCDR2 2881RFTISRDNSK NTLYLQMNSL RAEDTAVYYC AS HFW3 2882 SSGYLFHSDY HCDR3 2883WGQGTLVTVS S HFW4 2884 TVSS VH end 2885ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVTIGHCVPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTPEVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKALPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPVLDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHSHYT QKSLSLSPG 2886QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSHCKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP(contain-EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCing M428LPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLand N434STVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES(LS;  NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGhigh- lighted  in bold) according  to EU  numbering) 2887MRAWIFFLLCLAGRALAQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNHC (with KYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSSASTKGPSVFPLAPSSKN-terminal STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVSignalDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKsequence)TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT(contain-CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLing M428L SPG and N434S (LS;  high- lighted  in bold) according  to EU numbering) 2888DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQVL PDDFATYYCQQYNSYPWTFGQGTKVEIK 2889 DIQMTQSPST LSASVGDRVT ITC LFWI 2890RASQSISNWL A LCDRI 2891 WFQQKPGKAP KLLIY LFW2 2892 EASSLES LCDR2 2893GVPSRFSGSG SGTEFTLTIS SLQPDDFATY YC LFW3 2894 QQYNSYPWT LCDR3 2895FGQGTKVEIK LFW4 2896 KVEIK VL end 2897RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD SKDSTYSLSSIGLC TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC 2898DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQLCPDDFATYYCQQYNSYPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 2899MRAWIFFLLCLAGRALADIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRLC (with FSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYN-terminal PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSignal sequence) 2900 C144'EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYIVISWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNTVH LYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSS 2901EVQLVESGGG LIQPGGSLRL SCAASGFTVS HFWI 2902 NNYMS HCDRI 2903WVRQAPGKGL EWVS HFW2 2904 VIYSGGSTYY ADSVKG HCDR2 2905RFTISRDKSK NTLYLQMNSL RAEDTAVYYC AR HFW3 2906 EGEVEGYNDF WSGYSRDRYY FDYHCDR3 2907 WGQGTLVTVS S HFW4 2908 TVSS VH end 2909ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVTIGHCVPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTPEVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKALPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPVLDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHSHYT QKSLSLSPG 2910EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYIVISWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNTHCLYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT(contain-AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPing M428LKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEand N434SQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF(LS; YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGhigh- lighted  in bold) according  to EU  numbering) 2911MRAWIFFLLCLAGRALAEVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYIVISWVRQAPGKGLEWVSVIYSGGSTYYHC (withADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSSASTKN-terminal GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICSignalNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWsequence)YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ.DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS(contain-REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEing M428L ALHSHYTQKSLSLSPG and N434S (LS;  high- lighted  in bold)according  to EU  numbering) 2912QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISVL GLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL 2913 QSALTQPASV SGSPGQSITI SC LFW12914 TGTSSDVGGY NYVS LCDRI 2915 WYQQHPGKAP KLMIY LFW2 2916 DVSNRPS LCDR22917 GVSNRFSGSK SGNTASLTIS GLQ.AEDEADY YC LFW3 2918 SSYTSSSTRV LCDR32919 FGTGTKVTVL LFW4 2920GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADSSPVK AGVETTTPSK QSNNKYAASSIGLC YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS 2921QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISLCGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS 2922MRAWIFFLLCLAGRALAQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVLC (with SNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCN-terminalLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSSignal sequence) 2923 C135ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGAGAGCGCTCGCACAGGTGCAGCTGGTGGAGTCTGHC (with GGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATN-terminalGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATACCATTTGATGGAAGASignalAATAAGTACTACGCAGACTCCGTGACGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTsequence)GCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGTAGTAGTGGTTATC1111CCACTCTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGCTGCATGAGGCTCTGCACAGCCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA 2924 C135ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGCGCGCCTTGGCCGACATCCAGATGACCCAGTCTCCTLC (with TCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTAGTAACTGGTTN-terminalGGCCTGGTTTCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAGGCGTCTAGTTTAGAAAGTGGGSignalGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGAsequence)TTTTGCAACTTATTACTGCCAACAGTATAATAGTTATCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG 2925 C144'ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGAGAGCGCTCGCAGAGGTGCAGCTGGTGGAGTCTGHC (with GAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAACAACN-terminalTACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCASignalCATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAAATCCAAGAACACGCTGTATCTTCAAsequence)ATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTATTGTGCGAGAGAAGGGGAGGTAGAAGGGTATAACGATTTTTGGAGTGGTTATTCTAGAGACCGTTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGCTGCATGAGGCTCTGCACAGCCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA 2926 C144'ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGCGCGCCTTGGCCCAGTCTGCCCTGACTCAGCCTGCCLC (with TCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAAN-terminalCTATGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTAATCGGCCCTCSignalAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAsequence)GGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGCAGCACCCGAGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTTACCCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCATAG CDR sequences are identified basedon the IMGT Kabat method.

TABLE 15Additional sequence information for the disclosed anti-SARS-CoV-2 antibodiesHEAVY CHAIN LIGHT CHAIN sequence     miniprep  original nt  ID minipreporiginal nt sequence ID ALICE AbsID sequence sequence (plate/well)sequence sequence (plate/well) COV21_P2 A-C003 TACACATACGATTTAGGTGGAGGTGCTCTTGGAGGAGG COV21_P2 TACACATACGATTTAGGT CGATTGGAGGGCGTTATCCACOV21_P2 A10 ACACTATAGAATAACATCC GTGCCAGGGGGAAGACCGA A10GACACTATAGAATAACA CCTTCCACTGTACTTTGGCC A10 ACTTTGCCTTTCTCTCCACATGGGCCCTTGGTGGAGGCT TCCACTTTGCCTTTCTCT TCTCTGGGATAGAAGTTATTGGTGTCCACTCCCAGGTCC GAGGAGACGGTGACCAGGG CCACAGGTGTCCACTCCCCAGCAGGCACACAACAGAG AACTGCACCTCGGTTCTATC TTCCCTGGCCCCAGTAGTCAAGGTCCAACTGCACCTC GCAGTTCCAGATTTCAACTG GATTGAATTCCACCATGGGAAGTAGAAGTCACCGTAAT GGTTCTATCGATTGAATT CTCATCAGATGGCGGGAAGATGGTCATGTATCATCCTTT CCCTCGCACAGTAATACAC CCACCATGGGATGGTCAATGAAGACAGATGGTGCAG TTCTAGTAGCAACTGCAAC GGCCGTGTCCCCGGCTCTCTGTATCATCCTTTTTCTA CCACAGTTCGTTTGATCTCC CGGTGTACATTCTGAGGTGAGGCTGTTCATTTGAAGAT GTAGCAACTGCAACCGG AGCTTGGTCCCCTGGCCAAACAGCTGGTGGAGTCTGGAG ACAGCGTGTTCTTGGAATT TGTACATTCAGAAATTGTAGTCCTAGGTGAGCTACCAT GAGGCTTGATCCAGCCTGG GTCTCTGGAGATGGTGAATGTTGACGCAGTCTCCAG ACTGCTGACAGTAATACACT GGGGTCCCTGAGACTCTCCCGGCCCTTCACGGAGTCTG GCACCCTGTCTTTGTCTC GCAAAATCTTCAGGCTCCAGTGTGCAGCCTCTGGGTTCAC CGTAGTATGTGCTACCACC CAGGGGAAAGAGCCACCTCTGCTGATGGTGAGAGTGA CGTCAGTAGCAACTACATG GCTATAAATAACTGAGACCCTCTCCTGCAGGGCCAGT AGTCTGTCCCAGACCCACTG AGCTGGGTCCGCCAGGCTCCACTCCAGCCCCTTCCCTGG CAGAGTGTTAGCAGCAC CCACTGAACCTGTCTGGGATCAGGGAAGGGGCTGGAGTG AGCCTGGCGGACCCAGCTC CTACTTAGCCTGGTACCAGCCAGTGGCCCTGCTGGATG GGTCTCAGTTATTTATAGCG ATGTAGTTGCTACTGACGGGCAGAAACCTGGCCAGG CACCATAGATGAGGAGCCT GTGGTAGCACATACTACGCTGAACCCAGAGGCTGCACA CTCCCAGGCTCCTCATCT GGGAGCCTGGCCAGGTTTCTAGACTCCGTGAAGGGCCGA GGAGAGTCTCAGGGACCCC ATGGTGCATCCAGCAGGGCTGGTACCAGGCTAAGTA TTCACCATCTCCAGAGACA CCAGGCTGGATCAAGCCTCGCCACTGGCATCCCAGA GGTGCTGCTAACACTCTGAC ATTCCAAGAACACGCTGTACTCCAGACTCCACCAGNCT CAGGTTCAGTGGCAGTG TGGCCCTGCAGGAGAGGGTTCTTCAAATGAACAGCCTG GCAC (SEQ ID NO:  GGTCTGGGACAGACTTCGGCTCTTTCCCCTGGAGACA AGAGCCGGGGACACGGCCG 3243) ACTCTCACCATCAGCAGAAGACAGGGAGACTGGA TGTATTACTGTGCGAGGGA ACTGGAGCCTGAAGATT(SEQ ID NO: 3245) TTACGGTGACTTCTACTTTG TTGCAGTGTATTACTGTCACTACTGGGGCCAGGGAAC AGCAGTATGGTAGCTCA CCTGGTCACCGTCTCCTCAGCCTAGGACTTTTGGCCAG CGTCGACCAAGGGCCCATC GGGACCAAGCTGGAGATGGTCTTCCCCCTGGCACCCT CAAACGTACGGTGGCTG CCTCCAAGAGCACCTCTGGCACCATCTGTCTTCATCT GGGCACAGCGGCCCTGGGC TCCCGCCATCTGATGAGCTGCCTGGTCAAGGACTACT AGTTGAAATCTGGAACT TCCCCGAACCTGTGACGGTGCCTCTGTTGTGTGCCTG CTCGTGGAACTCAGGCGCC CTGAATAACTTCTATCCCCTGACCAGCGGCGTGCACA AGAGAGGCCAAAGTACA CCTTCCCGGCTGTCCTACAGGTGGAAGGTGGATAACG TCCTCANGACTCTACTCCCT CCCTCCAATCGGGTAACTCAGCAGCGTGGTGACCGTG CCCAGGAGAGTGTCACA CCCTCCAGCAGCTTGGGCAGAGCAGGACAGCAAGGA CCCAGACCTACATCTGCAA CAGCACCTACAGCCTCACGTGAATCACAAGCCCAGC GCAGCACCCTGACGCTG AACACCNANGTGGACAAGAAGCAAAGCAGACTACGA GAGTTGAGCCCAAATCTTG GAAACACAAAGTCTACGTGACAAAACTCACACATGC CCTGCGAAGTCACCCAT CCACCGTGCCCAGCACCTG C (SEQ ID NO: AACT (SEQ ID NO:  3244) 3242) COV21_P1 A-C007 TACACATACGATTTAGGTGNGAGGTGCTCTTGGAGGAG COV21_P1 TACACATACGATTTAGGT CGATTGGAGGGCGTTATCCACOV21_P1 G2 ACACTATAGAATAACATCC GGTGCCAGGGGGAAGACCG G2 GACACTATAGAATAACACCTTCCACTGTACTTTGGCC G2 ACTTTGCCTTTCTCTCCACA ATGGGCCCTTGGTGGAGGCTCCACTTTGCCTTTCTCT TCTCTGGGATAGAAGTTATT GGTGTCCACTCCCAGGTCCTGAGGAGACGGTGACCAGG CCACAGGTGTCCACTCCC CAGCAGGCACACAACAGAGAACTGCACCTCGGTTCTATC GTTCCCTGGCCCCAGTAGTC AGGTCCAACTGCACCTCGCAGTTCCAGATTTCAACTG GATTGAATTCCACCATGGG AACAGTGTACGAATAACCAGGTTCTATCGATTGAATT CTCATCAGATGGCGGGAAG ATGGTCATGTATCATCCTTTGAATCATCATAGTGAGGGC CCACCATGGGATGGTCA ATGAAGACAGATGGTGCAGTTCTAGTAGCAACTGCAAC CTGTGGTACAGTAATACAC TGTATCATCCTTTTTCTACCACAGTTCGTTTGATCTCC CGGTGTACATTCTGAGGTG GGCTGTGTCCTCGGTTTTCAGTAGCAACTGCAACCGG ACCTTGGTCCCTCCGCCGAA CAGCTGGTGGAGTCTGGGGGGCTGTTCATTTGCAGATAC TGTACATGGGGATATTGT AGTGAGGGGAGTTTGTAGAGAGGCTTGGTAAAGCCTGG AGCGTGTTTTTTGAATCATC GATGACTCAGTCTCCACTGCTTGCATGCAGTAATAAAC GGGGTCCCTTAGACTCTCCT TCTTGAGATGGTGAATCTGCTCCCTGCCCGTCACCCC CCCAACATCCTCAGCCTCCA GTGCAGCCTCTGGATTCACTCCTTGCACGGGTGCAGCGT TGGAGAGCCGGCCTCCA CTCTGCTGATTTTCAATGTATTCAGTAACGCCTGGATGA AGTCTATTGTCCCACCATCA TCTCCTGCAGGTCTAGTCAAATCTGTGCCTGATCCACT ACTGGGTCCGCCAGGCTCC GATTTGTCTTTAATACGGCCAGAGCCTCCTGCATAGT GCCACTGAACCTGTCAGGG AGGGAAGGGGCTGGAGTGGAACCCACTCCAGCCCCTTCC AATGGATTCCACTTTTTG ACCCCGGAGGCCCGATTAGGTTGGCCGTATTAAAGACA CTGGAGCCTGGCGGACCCA GATTGGTACCTGCAGAAAACCCACATAGATCAGGAG AATCTGATGGTGGGACAAT GTTCATCCAGGCGTTACTGGCCAGGGCAGACTCCAC CTGTGGAGTCTGCCCTGGCT AGACTACGCTGCACCCGTGAAAGTGAATCCAGAGGCTG AGCTCCTGATCTATGTGG TCTGCAGGTACCAATCCAAACAAGGCAGATTCACCATCT CACAGGAGAGTCTAAGGGA GTTCTAATCGGGCCTCCGAAGTGGAATCCATTACTATG CAAGAGATGATTCAAAAAA CCCCCCAGGCTTTACCAAGGGGTCCCTGACAGGTTC CAGGAGGCTCTGACTAGAC CACGCTGTATCTGCAAATGCCTCCCCCAGACTCCACCA AGTGGCAGTGGATCAGG CTGCAGGAGATGGAGGCCGAACAGCCTGAAAACCGAGG GCTGCACNT (SEQ ID  CACAGATTTTACATTGAAGCTCTCCAGGGGTGACGGG ACACAGCCGTGTATTACTG NO: 3247) AATCAGCAGAGTGGAGGCAGGGAGANTGGA (SEQ  TACCACAGGCCCTCACTAT CTGAGGATGTTGGGGTTT ID NO: 3249)GATGATTCTGGTTATTCGTA ATTACTGCATGCAAGCTC CACTGTTGACTACTGGGGCTACAAACTCCCCTCACTT CAGGGAACCCTGGTCACCG TCGGCGGAGGGACCAAGTCTCCTCAGCGGTCGACCA GTGGAGATCAAACGTAC AGGGCCCATCGGTCTTCCCGGTGGCTGCACCATCTGT CCTGGCACCCTCCTCCAAG CTTCATCTTCCCGCCATCAGCACCTCTGGGGGCACAG TGATGAGCAGTTGAAAT CGGCCCTGGGCTGCCTGGTCTGGAACTGCCTCTGTTG CAAGGACTACTTCCCCGAA TGTGCCTGCTGAATAACTCCTGTGACGGTCTCGTGGA TCTATCCCAGAGAGGCC ACTCANGCGCCCTGACCAGAAAGTACAGTGGAAGGT CGGCGTGCACACCTTCCCG GGATAACGCCCTCCAATGCTGTCCTACAGTCCTCAN CGGGTAACTCCCAGGAG GACTCTACTCCCTCAGCAGAGTGTCACAGAGCAGGA CGTGGTGACCGTGCCCTCC CAGCAAGGACAGCACCTAGCAGCTTGGGCACCCAGA ACAGCCTCAGCAGCACC CCTACATCTGCAACGTGAACTGACGCTGAGCAAAGC TCACAAGCCCAGCAACACC AGACTACGAGAAACACA AA (SEQ ID NO: AAGTCTACGCCTGCGAA 3246) GTCACCCAT (SEQ ID NO: 3248) COV21_P1 A-C008TACACATACGATTTAGGTG CGCTGTGCCCCNGAGGTGC COV21_P1 TACACATACGATTTAGGTTGGGANTACCCGATTGGAG COV21_P1 H9 ACACTATAGAATAACATCC TCTTGGAGGAGGGTGCCAGH9 GACACTATAGAATAACA GGCGTTATCCACCTTCCACT H9 ACTTTGCCTTTCTCTCCACAGGGGAAGACCGATGGGCCC TCCACTTTGCCTTTCTCT GTACTTTGGCCTCTCTGGGAGGTGTCCACTCCCAGGTCC TTGGTGGAGGCTGAGGAGA CCACAGGTGTCCACTCCCTAGAAGTTATTCAGCAGGCA AACTGCACCTCGGTTCTATC CGGTGACCAGGGTTCCCTGAGGTCCAACTGCACCTC CACAACAGAGGCAGTTCCA GATTGAATTCCACCATGGGGCCCCAGTAGTCAAAGTAC GGTTCTATCGATTGAATT GATTTCAACTGCTCATCAGAATGGTCATGTATCATCCTTT CACTCGGGGTCACCGAATT CCACCATGGGATGGTCATGGCGGGAAGATGAAGACA TTCTAGTAGCAACTGCAAC CTCTCGCACAGTAATACACTGTATCATCCTTTTTCTA GATGGTGCAGCCACAGTTCG CGGTGTACATTCTGAGGTGAGCCGTGTCCTCAGCTCTCA GTAGCAACTGCAACCGG TTTGATTTCCACCTTGGTCCCAGCTGGTGGAGTCTGGGG GGCTGTTCATTTGCAGATAC TGTACATTCTGACATCCACTTGGCCGAACGTCCAATAA GAGGCGTGGTCCAGCCTGG AGCGTGTTCTTGGAGTTGTCGATGACCCAGTCTCCTTC CTATTATACTGTTGGCAGTA GAGGTCCCTGAGACTCTCCTCTGGAGATGGTGAATCGG CACCCTGTCTGCATCTGT ATAAGTTGCAAAATCATCAGTGTGCAGCCTCTGGATTCAC CCCTTCACGGAGTCTGCAT AGGAGACAGAGTCACCAGCTGCAGGCTGCTGATGGTG CTTCAGTAGCTATGGCATG AGTATTTATTCCTTCCATCATCACTTGCCGGGCCAATC AGAGTGAATTCTGTCCCAGA CACTGGGTCCGCCAGGCTCTATGAAATAACTGTCACCC AGAGTATTAGTAGCTGG TCCACTGCCGCTGAACCTTGCAGGCAAGGGGCTGGAGTG ACTCCAGCCCCTTGCCTGG TTGGCCTGGTATCAGCAATGGGACCCCACTTTCTAAA GGTGACAGTTATTTCATATG AGCCTGGCGGACCCAGTGCGAAACCAGGGAAAGCCC CTAGACGCCTTATAGATCAG ATGGAAGGAATAAATACTAATGCCATAGCTACTGAAGG CTAAGCTCCTGATCTATA GAGCTTAGGGGCTTTCCCTGTGCAGACTCCGTGAAGGGC TGAATCCAGAGGCTGCACA AGGCGTCTAGTTTAGAAGTTTCTGCTGATACCAGGCC CGATTCACCATCTCCAGAG GGAGAGTCTCAGGGACCTCAGTGGGGTCCCATCAAG AACCAGCTACTAATACTCTG ACAACTCCAAGAACACGCTCCAGGCTGGACCACGCCTC GTTCAGCGGCAGTGGAT ATTGGCCCGGCAAGTGATGGTATCTGCAAATGAACAGC CCCCAGACTCCACCAGCTG CTGGGACAGAATTCACTGTGACTCTGTCTCCTACAGA CTGAGAGCTGAGGACACGG CACCTANNANGNAAACCCTCACCATCAGCAGCCT TGCAGACAGGGNGANTGNA CTGTGTATTACTGTGCGAG(SEQ ID NO: 3251) GCAGCCTGATGATTTTGC NNNNGGGGTCAT (SEQAGAATTCGGTGACCCCGAG AACTTATTACTGCCAACA ID NO: 3253) TGGTACTTTGACTACTGGGGTATAATAGTTATTGGAC GCCAGGGAACCCTGGTCAC GTTCGGCCAAGGGACCACGTCTCCTCAGCGTCGACC AGGTGGAAATCAAACGT AAGGGCCCATCGGTCTTCCACGGTGGCTGCACCATC CCCTGGCACCCTCCTCCAA TGTCTTCATCTTCCCGCCGAGCACCTCTGGGGGCACA ATCTGATGAGCAGTTGA GCGGCCCTGGGCTGCCTGGAATCTGGAACTGCCTCTG TCAAGGACTACTTCCCCGA TTGTGTGCCTGCTGAATAACCTGTGACGGTCTCGTGG ACTTCTATCCCAGAGAG AACTCNGCGCCCTGACCAGGCCAAAGTACAGTGGAA CGGCGTGCACACCTTCCCG GGTGGATAACGCCCTCCGCTGTCCTACAGTCCTCNN AATCGGGTAACTCCCAG ACTCTACTCCCTCAGCAGCGAGAGTGTCACAGAGCA GTGGTGACCGTGCCCTCCA GGACAGCAAGGACAGCAGCAGCTTGGGCACCCAGAC CCTACAGCCTCAGCAGC CTACATCTGCAACGTGAATACCCTGACGCTGANCAA CACAAGCCCAGCAACACCA AGCAGACTACGAGAAACAGNTGGANAGAGAGTTGAG ACAAAGTCTACGCCTGC CCCAAATCTTGTGAC  GAAGTCACCCATCNGGN(SEQ ID NO: 3250) CTGAGCTCGCCCGTCAC AAAGAGCTTCAAC  (SEQ ID NO: 3252)COV21_P1 A-C010 TACACATACGATTTAGGTG GAGGTGCTCTTGGAGGAGG COV21_P1TACACATACGATTTAGGT CGATTGGAGGGCGTTATCCA COV21_P1 H7 ACACTATAGAATAACATCCGTGCCAGGGGGAAGACCGA H7 GACACTATAGAATAACA CCTTCCACTGTACTTTGGCC H7ACTTTGCCTTTCTCTCCACA TGGGCCCTTGGTGGAGGCT TCCACTTTGCCTTTCTCTTCTCTGGGATAGAAGTTATT GGTGTCCACTCCCAGGTCC GAGGAGACGGTGACCAGGGCCACAGGTGTCCACTCCC CAGCAGGCACACAACAGAG AACTGCACCTCGGTTCTATCTTCCCTGGCCCCAGTAGTCA AGGTCCAACTGCACCTC GCAGTTCCAGATTTCAACTGGATTGAATTCCACCATGGG AACCACGTAACCAGAGCTG GGTTCTATCGATTGAATTCTCATCAGATGGCGGGAAG ATGGTCATGTATCATCCTTT TATCCACGATCCCGTCTCTCCCACCATGGGATGGTCA ATGAAGACAGATGGTGCAG TTCTAGTAGCAACTGCAACGCACAGTAATACACAGCCG TGTATCATCCTTTTTCTA CCACAGTTCGTTTGATTTCCCGGTGTACATTCTGAGGTG TGTCCTCAGCTCTCAGGCTG GTAGCAACTGCAACCGGACCTTGGTCCCTTGGCCGAA CAGCTGGTGGAGTCTGGGG TTCATTTGCAGATACAACGTTGTACATTCAGACATCCA CGTCCACGGAGGGGTACTGT GAGGCGTGGTCCAGCCTGGGTTCTTGGAATTGTCTCTGG GTTGACCCAGTCTCCATC AACTCTGTTGACAGTAGTAAGAGGTCCCTGAGACTCTCC AGATGGTGAATCGGCCCTT CTCCCTGTCTGCATCTGTGTTGCAAAATCTTCAGGTTG TGTGCAGCCTCTGGATTCAC CACGGAGTCTGCGTAGTATAGGAGACAGAGTCACCA CAGACTGCTGATGGTGAGA CTTCAGTAGCTATGCTATGCTTACCGCTTCCATCATATAA TCACTTGCCGGGCAAGT GTGAAATCTGTCCCAGATCCACTGGGTCCGCCAGGCTCC TATAACTGCCACCCACTCC CAGAGCATTAGCACCTAACTGCCACTGAACCTTGATG AGCCAAGGGGCTGGAGTGG AGCCCCTTGGCTGGAGCCTTTTAAATTGGTATCAGCA GGACCCCACTTTGCAAACTG GTGGCAGTTATATTATATGGGCGGACCCAGTGCATAGC GAAACCAGGGAAAGCCC GATGCAGCATAGATCAGGAATGGAAGCGGTAAATACTA ATAGCTACTGAAGGTGAAT CTAAGCTCCTGATCTATGGCTTAGGGGCTTTCCCTGGT CGCAGACTCCGTGAAGGGC CCAGAGGCTGCACAGGAGACTGCATCCAGTTTGCAAA TTCTGCTGATACCAATTTAA CGATTCACCATCTCCAGAGGTCTCAGGGACCTCCCAGG GTGGGGTCCCATCAAGG ATAGGTGCTAATGCTCTGACACAATTCCAAGAACACGTT CTGGACCACGCCTCCCCCA TTCAGTGGCAGTGGATCTTTGCCCGGCAAGTGATGGTG GTATCTGCAAATGAACAGC GACTCCACCAGGCTGCACCGGGACAGATTTCACTCTC ACTCTGTCTCCTACAGATGC CTGAGAGCTGAGGACACGGT (SEQ ID NO: 3255) ACCATCAGCAGTCTGCA AGACAGGGAG (SEQ ID CTGTGTATTACTGTGCGAG ACCTGAAGATTTTGCAA NO: 3257) AGACGGGATCGTGGATACACTTACTACTGTCAACAGA GCTCTGGTTACGTGGTTTGA GTTACAGTACCCCTCCGTCTACTGGGGCCAGGGAACC GGACGTTCGGCCAAGGG CTGGTCACCGTCTCCTCAGCACCAAGGTGGAGATCAA GTCGACCAAGGGCCCATCG ACGTACGGTGGCTGCACGTCTTCCCCCTGGCACCCTC CATCTGTCTTCATCTTCC CTCCAAGAGCACCTCTGGGCGCCATCTGATGAGCAG GGCACAGCGGCCCTGGGCT TTGAAATCTGGAACTGCGCCTGGTCAAGGACTACTT CTCTGTTGTGTGCCTGCT CCCCGAACCTGTGACGGTCGAATAACTTCTATCCCAG TCGTGGAACTCNNCGCCCT AGAGGCCAAAGTACAGTGACCAGCGGCGTGCACACC GGAAGGTGGATAACGCC TTCCCGGCTGTCCTACAGTCCTCCAATCGGGTAACTCC CTCNNNCTCTACTCCCTCAG CAGGAGAGTGTCACAGACAGCGTGGTGACCGTGCCC GCAGGACAGCAAGGACA TCCAGCAGCTTGGGCACCCGCACCTACAGCCTCAGC AGACCTACATCTGCAACGT AGCACCCTGACGCTGAGGAATCACAAGCCCAGCAAC CAAAGCAGACTACGAGA ACCAAG (SEQ ID NO: AACACAAAGTCTACGCC 3254) TGCGAAGTCACCCATCN GGCCNTGAGCTCGCCCGTCACAAAGAGCTTCAAC AGGGGAGAGTGTTAGAA GCTTGGCCGCCATGGCC CAACTTGTTTATTGCAGCTTAT (SEQ ID NO:  3256) COV21_P2 A-C001 TACACATACGATTTAGGTGCNCTGTGCCCCAGAGGTGC COV21_P2 TACACATACGATTTAGGT ATTGGAGGGCGTTATCCACCCOV21_P2 B7 ACACTATAGAATAACATCC TCTTGGAGGAGGGTGCCAG B7 GACACTATAGAATAACATTCCACTGTACTTTGGCCTC B7 ACTTTGCCTTTCTCTCCACA GGGGAAGACCGATGGGCCCTCCACTTTGCCTTTCTCT TCTGGGATAGAAGTTATTCA GGTGTCCACTCCCAGGTCCTTGGTGGAGGCTGAGGAGA CCACAGGTGTCCACTCCC GCAGGCACACAACAGAGGCAACTGCACCTCGGTTCTATC CGGTGACCAGGGTTCCCTG AGGTCCAACTGCACCTCAGTTCCAGATTTCAACTGCT GATTGAATTCCACCATGGG GCCCCAGTAGTCAAAGGCCGGTTCTATCGATTGAATT CATCAGATGGCGGGAAGAT ATGGTCATGTATCATCCTTTACCACCACTACAATATCAG CCACCATGGGATGGTCA GAAGACAGATGGTGCAGCCTTCTAGTAGCAACTGCAAC ATGGTCTCCCCTCTTTCGCA TGTATCATCCTTTTTCTAACAGTTCGTTTGATTTCCAC CGGTGTACATTCTGAGGTG CAGTAATACACAGCCGTGTGTAGCAACTGCAACCGG CTTGGTCCCTTGGCCGAACG CAGCTGGTGGAGTCTGGGGCCTCAGCTCTCAGGCTGTTC TGTACATTCAGACATCCA TCCGAGGGGTACTGTAACTCGAGGCGTGGTCCAGCCTGG ATTTGCAGATACAGCGTGT GTTGACCCAGTCTCCATCTGTTGACAGTAGTAAGTTGC GAGGTCCCTGAGACTCTCC TCTTGGAATTGTCTCTGGAGCTCCCTGTCTGCATCTGT AAAATCTTCAGGTTGCAGAC TGTGCAGCCTCTGGATTCACATGGTGAATCGGCCCTTCA AGGAGACAGAGTCACCA TGCTGATGGTGAGAGTGAACTTCAGTATCTATGGCATGC CGGAGTCTGCATAGTATTT TCACTTGCCGGGCAAGTATCTGTCCCAGATCCACTGC ACTGGGTCCGCCAGGCTCC ATTACTTCCATCATATGATACAGAGCATTAGCAGCTA CACTGAACCTTGATGGGACC AGGCAAGGGGCTGGAGTGGTAACTGCCACCCACTCCAG TTTAAATTGGTATCAGCA CCACTTTGCAAACTGGATGCGTGGCAGTTATATCATATG CCCCTTGCCTGGAGCCTGG GAAACCAGGGAAAGCCCAGCATAGATCAGGAGCTTA ATGGAAGTAATAAATACTA CGGACCCAGTGCATGCCATCTAAGCTCCTGATCTATG GGGGCTTTCCCTGGTTTCTG TGCAGACTCCGTGAAGGGCAGATACTGAAGGTGAATCC CTGCATCCAGTTTGCAAA CTGATACCAATTTAAATAGCCGATTCACCATCTCCAGAG AGAGGCTGCACAGGAGAGT GTGGGGTCCCATCAAGGTGCTAATGCTCTGACTTGCC ACAATTCCAAGAACACGCT CTCAGGGACCTCCCAGGCTTTCAGTGGCAGTGGATCT CGGCAAGTGATGGTGACTCT GTATCTGCAAATGAACAGCGGACCACGCCTCCCCCAGA GGGACAGATTTCACTCTC GTCTCCTACAGATGCAGACACTGAGAGCTGAGGACACGG CTCCACCAGCTGCA (SEQ ACCATCAGCAGTCTGCAGGGAGANTGGAG (SEQ ID CTGTGTATTACTGTGCGAA ID NO: 3259) ACCTGAAGATTTTGCAANO: 3261) AGAGGGGAGACCATCTGAT CTTACTACTGTCAACAGA ATTGTAGTGGTGGTGGCCTTGTTACAGTACCCCTCGG TGACTACTGGGGCCAGGGA ACGTTCGGCCAAGGGACACCCTGGTCACCGTCTCCTC CAAGGTGGAAATCAAAC AGCGTCGACCAAGGGCCCAGTACGGTGGCTGCACCA TCGGTCTTCCCCCTGGCACC TCTGTCTTCATCTTCCCGCTCCTCCAAGAGCACCTCT CCATCTGATGAGCAGTT GGGGGCACAGCGGCCCTGGGAAATCTGGAACTGCCT GCTGCCTGGTCAAGGACTA CTGTTGTGTGCCTGCTGACTTCCCCGAACCTGTGACG ATAACTTCTATCCCAGAG GTCTCGTGGAACTCANGCGAGGCCAAAGTACAGTGG CCCTGACCAGCGGCGTGCA AAGGTGGATAACGCCCTCACCTTCCCGGCTGTCCTAC CCAATCGGGTAACTCCC AGTCCTC (SEQ ID NO: AGGAGAGTGTCACAGAG 3258) CAGGACAGCAAGGACAG GCACCCTGACGCTGAGCAAAGCAGACTACGAGAA ACACAAAGTCTACGCCT GCGAAGTCACCCATCAG GGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACN GGGGAGAGTGTTAGAAG CTTGGCCGCCATGGCCC AACTTGTTTATTGCAGCTTATAAT (SEQ ID NO: 3260) COV21_P2 A-C002 TACACATACGATTTAGGTGGCTNNGCNCCNNANGTGCT COV21_P2 TACACATACGATTTAGGT CNGGGANTTACCCGATTGGCOV21_P2 F6 ACACTATAGAATAACATCC CTTGGAGGNNGGTGCCAGG F6 GACACTATAGAATAACAAGGGCGTTATCCACCTTCCA F6 ACTTTGCCTTTCTCTCCACA GGGAAGACCGATGGGCCCTTCCACTTTGCCTTTCTCT CTGTACTTTGGCCTCTCTGG GGTGTCCACTCCCAGGTCCTGGTGGAGGCTGAGGAGAC CCACAGGTGTCCACTCCC GATAGAAGTTATTCAGCAGAACTGCACCTCGGTTCTATC GGTGACCAGGGTTCCCTGG AGGTCCAACTGCACCTCGCACACAACAGAGGCAGTT GATTGAATTCCACCATGGG CCCCAGTAGTCAAAGGCCAGGTTCTATCGATTGAATT CCAGATTTCAACTGCTCATC ATGGTCATGTATCATCCTTTCCACCACTACAATATCAGA CCACCATGGGATGGTCA AGATGGCGGGAAGATGAAGTTCTAGTAGCAACTGCAAC TGGTCTCCCCTCTTTCGCAC TGTATCATCCTTTTTCTAACAGATGGTGCAGCCACAG CGGTGTACATTCTGAGGTG AGTAATACACAGCCGTGTCGTAGCAACTGCAACCGG TTCGTTTGATTTCCACCTTG CAGCTGGTGGAGTCTGGGGCTCAGCTCTCAGGCTGTTCA TGTACATTCAGACATCCA GTCCCTTGGCCGAACGTCCGGAGGCGTGGTCCAGCCTGG TTTGCAGATACAGCGTGTTC GTTGACCCAGTCTCCATCAGGGGTACTGTAACTCTGTT GAGGTCCCTGAGACTCTCC TTGGAATTGTCTCTGGAGATCTCCCTGTCTGCATCTGT GACAGTAGTAAGTTGCAAA TGTGCAGCCTCTGGATTCACGGTGAATCGGCCCTTCACG AGGAGACAGAGTCACCA ATCTTCAGGTTGCAGACTGCCTTCAGTATCTATGGCATGC GAGTCTGCATAGTATTTATT TCACTTGCCGGGCAAGTTGATGGTGAGAGTGAAATCT ACTGGGTCCGCCAGGCTCC ACTTCCATCATATGATATAACAGAGCATTAGCAGCTA GTCCCAGATCCACTGCCACT AGGCAAGGGGCTGGAGTGGCTGCCACCCACTCCAGCCC TTTAAATTGGTATCAGCA GAACCTTGATGGGACCCCACGTGGCAGTTATATCATATG CTTGCCTGGAGCCTGGCGG GAAACCAGGGAAAGCCCTTTGCAAACTGGATGCAGCA ATGGAAGTAATAAATACTA ACCCAGTGCATGCCATAGACTAAGCTCCTGATCTATG TAGATCAGGAGCTTAGGGG TGCAGACTCCGTGAAGGGCTACTGAAGGTGAATCCAGA CTGCATCCAGTTTGCAAA CTTTCCCTGGTTTCTGCTGATCGATTCACCATCTCCAGAG GGCTGCACAGGAGAGTCTC GTGGGGTCCCATCAAGGACCAATTTAAATAGCTGCTA ACAATTCCAAGAACACGCT AGGGACCTCCCAGGCTGGATTCAGTGGCAGTGGATCT ATGCTCTGACTTGCCCGGCA GTATCTGCAAATGAACAGCCCACGCCTCCCCCAGACTC GGGACAGATTTCACTCTC AGTGATGGTGACTCTGTCTCCTGAGAGCTGAGGACACGG CACCAGCCTGCAC (SEQ  ACCATCAGCAGTCTGCACTACAGATGCAGACAGGGA CTGTGTATTACTGTGCGAA ID NO: 3263) ACCTGAAGATTTTGCAAGANTGGANNNTGGG (SEQ  AGAGGGGAGACCATCTGAT CTTACTACTGTCAACAGA ID NO: 3265)ATTGTAGTGGTGGTGGCCTT GTTACAGTACCCCTCGG TGACTACTGGGGCCAGGGAACGTTCGGCCAAGGGAC ACCCTGGTCACCGTCTCCTC CAAGGTGGAAATCAAACAGCGTCGACCAAGGGCCCA GTACGGTGGCTGCACCA TCGGTCTTCCCCCTGGCACCTCTGTCTTCATCTTCCCG CTCCTCCAAGAGCACCTCT CCATCTGATGAGCAGTTGGGGGCACAGCGGCCCTGG GAAATCTGGAACTGCCT GCTGCCTGGTCAAGGACTACTGTTGTGTGCCTGCTGA CTTCCCCGAACCTGTGACG ATAACTTCTATCCCAGAGGTCTCGTGGAACTCANGCG AGGCCAAAGTACAGTGG CCCTGACCAGCGGCGTGCAAAGGTGGATAACGCCCT CACCTTCCCGGCTGTCCTAC CCAATCGGGTAACTCCCAGTCCTCNNACTCTACTCCC AGGAGAGTGTCACAGAG TCAGCAGCGTGGTGACCGTCANGACAGCAAGGACAG GCCCTCCAGCAGCTTGGGC CACCTACAGCCTCAGCAACCCAGACCTACATCTGCA GCACCCTGACGCTGAGC ACGTGAATCACAAGCCCAGAAAGCAGACTACGAGAA CAACACCNAAGGTGGACAA ACACAAAGTCTACGCCTGAGAGTTGAGCCCAAATCT GCGAAGTCACCCATC TGTGACAAACTCACACATG(SEQ ID NO: 3264) CCCACCGTGCCCAGCACCT GAACTCCTGGGGGGACCGTCAGTCTT (SEQ ID NO:  3262) COV21_P1 A-C004 TACACATACGATTTAGGTGGCTGTGCCCCAGAGGTGCT COV21_P1 TACACATACGATTTAGGT CNNGGANTTNCCCGATTGGCOV21_P1 F12 ACACTATAGAATAACATCC CTTGGAGGANGGTGCCAGG F12GACACTATAGAATAACA AGGGCGTTATCCACCTTCCA F12 ACTTTGCCTTTCTCTCCACAGGGAAGACCGATGGGCCCT TCCACTTTGCCTTTCTCT CTGTACTTTGGCCTCTCTGGGGTGTCCACTCCCAGGTCC TGGTGGAGGCTGAGGAGAC CCACAGGTGTCCACTCCCGATAGAAGTTATTCAGCAG AACTGCACCTCGGTTCTATC GGTGACCGTGGTCCCTTTGCAGGTCCAACTGCACCTC GCACACAACAGAGGCAGTT GATTGAATTCCACCATGGGCCCAGACGTCCATGTAGTA GGTTCTATCGATTGAATT CCAGATTTCAACTGCTCATCATGGTCATGTATCATCCTTT GTAGTACCCATGATCGTAG CCACCATGGGATGGTCAAGATGGCGGGAAGATGAAG TTCTAGTAGCAACTGCAAC CCACTATATCCACGTGATGTGTATCATCCTTTTTCTA ACAGATGGTGCAGCCACAG CGGTGTACATTCCCAGGTGCTGGGCTCGCACAGTAATA GTAGCAACTGCAACCGG TTCGTTTAATCTCCAGTCGTCAGCTGGTGCAGTCTGGGG CACGGCCGTGTCGTCAGAT TGTACATTGTGCCATCCGGTCCCTTGGCCGAAGGTGAT CTGAGGTGAAGAAGCCTGG CTCAGCCTGCTCAGCTCCATGATGACCCAGTCTCCATC AGGGAGATTATCATACTGTT GGCCTCAGTGAAGGTCTCCGTAGGCTGTGCTGATGGAC CTCCCTGTCTGCATCTGT GACAGTAATATGTTGCAATATGCAAGGCTTCTGGATACA GTGTCCCTGGTCATGGTGA AGGAGACAGAGTCACCATCTTCAGGCTGCAGGCTGCT CCTTCACCGGCTACTATATG CCCTGCCCTGAAACTTCTGTTCACTTGCCAGGCGAGT GATGGTGAAAGTAAAATCT CACTGGGTGCGACAGGCCCGCATAGTTTGTGCCACCACT CAGGACATTAGCAACTA GTCCCAGATCCACTTCCACTCTGGACAAGGGCTTGAGTG GATAGGGTTGATCCATCCC TTTAAATTGGTATCAGCAGAACCTTGATGGGACCCCTG GATGGGATGGATCAACCCT ATCCACTCAAGCCCTTGTCCGAAACCAGGGAAAGCCC TTTCCAAATTGGATGCATCG ATCAGTGGTGGCACAAACTAGGGGCCTGTCGCACCCAG CTAAGCTCCTGATCTACG TAGATCAGGAGCTTAGGGGATGCACAGAAGTTTCAGGG TGCATATAGTAGCCGGTGA ATGCATCCAATTTGGAACTTTCCCTGGTTTCTGCTGAT CAGGGTCACCATGACCAGG AGGTGTATCCAGAAGCCTTACAGGGGTCCCATCAAG ACCAATTTAAATAGTTGCTA GACACGTCCATCAGCACAGGCAGGAGACCTTCACTGAG GTTCAGTGGAAGTGGAT ATGTCCTGACTCGCCTGGCACCTACATGGAGCTGAGCAG GCCCCAGGCTTCTTCACCTC CTGGGACAGATTTTACTTAGTGATGGTGACTCTGTCTC GCTGAGATCTGACGACACG AGCCCCAGACTGCACCAGCTCACCATCAGCAGCCTG CTACAGATGCAGACAGGGN GCCGTGTATTACTGTGCGATGCACCT (SEQ ID NO:  CAGCCTGAAGATATTGC G (SEQ ID NO: 3269)GCCCAGCATCACGTGGATA 3267) AACATATTACTGTCAAC TAGTGGCTACGATCATGGGAGTATGATAATCTCCCTA TACTACTACTACATGGACG TCACCTTCGGCCAAGGGTCTGGGGCAAAGGGACCAC ACACGACTGGAGATTAA GGTCACCGTCTCCTCAGCGTACGTACGGTGGCTGCAC CGACCAAGGGCCCATCGGT CATCTGTCTTCATCTTCCCTTCCCCCTGGCACCCTCCT CGCCATCTGATGAGCAG CCAAGAGCACCTCTGGGGGTTGAAATCTGGAACTGC CACAGCGGCCCTGGGCTGC CTCTGTTGTGTGCCTGCTCTGGTCAAGGACTACTTCC GAATAACTTCTATCCCAG CCGAACCTGTGACGGTCTCAGAGGCCAAAGTACAGT GTGGAACTCAGGCGCCCTG GGAAGGTGGATAACGCCACCAGCGGCGTGCACACCT CTCCAATCGGGTAACTCC TCCCGGCTGTCCTACAGTCCCAGGAGAGTGTCACAGA TCAGGACTCTACTCCCTCAG GCAGGACAGCAAGGACACAGCGTGGTGACCGTGCCC GCACCTACAGCCTCAGC TCCAGCAGCTTGGGCACCCAGCACCCTGACGCTGAG AGACCTACATCTGCAACGT CAAAGCAGACTACGAGAGAATCACAAGCCCAGCAAC AACACAAAGTCTACGCC ACCAAGGTGGACAAGAGAGTGCGAAGTCACCCATCA TTGAGCCCAAATCTTGTGA GGGCCTGAGCTCGCCCGCAAAAC (SEQ ID NO: TCACAAAGAGCTTCAAC 3266) AGGGGAGAGTGTTAGAAGCTTGGCCGCCATGGCC CAACTTGTTTATTGCAGC TTATAATGGTTACAAATA AA (SEQ ID NO:3268) COV21_P1 A-C005 TACACATACGATTTAGGTG NGAGGTGCTCTTGGAGGAG COV21_P1TACACATACGATTTAGGT ANTTACCCGATTGGAGGGC COV21_P1 F9 ACACTATAGAATAACATCCGGTGCCAGGGGGAAGACCG F9 GACACTATAGAATAACA GTTATCCACCTTCCACTGTA F9ACTTTGCCTTTCTCTCCACA ATGGGCCCTTGGTGGAGGC TCCACTTTGCCTTTCTCTCTTTGGCCTCTCTGGGATAG GGTGTCCACTCCCAGGTCC TGAAGAGACGGTGACCATTCCACAGGTGTCCACTCCC AAGTTATTCAGCAGGCACAC AACTGCACCTCGGTTCTATCGTCCCTTGGCCCCAGATATC AGGTCCAACTGCACCTC AACAGAGGCAGTTCCAGATGATTGAATTCCACCATGGG AAAAGCATCAAGGCAGCTA GGTTCTATCGATTGAATTTTCAACTGCTCATCAGATGG ATGGTCATGTATCATCCTTT CCACCGCTACAATGGGGAGCCACCATGGGATGGTCA CGGGAAGATGAAGACAGAT TTCTAGTAGCAACTGCAACCCGCACAGTAATACACGGC TGTATCATCCTTTTTCTA GGTGCAGCCACAGTTCGTTTCGGTGTACATTCCCAGGTG CGTGTCCTCGGATCTCAGG GTAGCAACTGCAACCGGGATTTCCACCTTGGTCCCTT CAGCTGGTGCAGTCTGGGC CTGCTCAGCTCCATGTAGGTGTACATTCAGAAATTGT GGCCGAACGTCCACGGTGA CTGAGGTGAAGAAGCCTGGCTGTGCTTGTGGACATGTCC GTTGACGCAGTCTCCAG GCTACCATACTGCTGACAGTGACCTCAGTGAAGGTCTCC CTGGTAATGGTGACTCTTTC GCACCCTGTCTTTGTCTCAATACACTGCAAAATCTTCA TGCAAGGCTTCTGGATTCA CTGGAACTTCTGTGCGTAGTCAGGGGAAAGAGCCACC GGCTCCAGTCTGCTGATGGT CCTTTACTAGCTCTGCTGTGTTGTGTTACCACTGCCAACG CTCTCCTGCAGGGCCAGT GAGAGTGAAGTCTGTCCCACAGTGGGTGCGACAGGCTC ACGATCCATCCTATCCACTC CAGAGTGTTAGAAGCAGGACCCACTGCCACTGAACCT GTGGACAACGCCTTGAGTG AAGGCGTTGTCCACGAGCCCTACTTAGCCTGGTACCA GTCTGGGATGCCAGTGGCCC GATAGGATGGATCGTCGTTTGTCGCACCCACTGCACAG GCAGAAACCTGGCCAGG TGCTGGATGCACCATAGATGGGCAGTGGTAACACAAACT CAGAGCTAGTAAAGGTGAA CTCCCAGGCTCCTCATCTAGGAGCCTGGGAGCCTGGC ACGCACAGAAGTTCCAGGA TCCAGAAGCCTTGCAGGAGATGGTGCATCCAGCAGG CAGGTTTCTGCTGGTACCAG AAGAGTCACCATTACCAGGACCTTCACTGAGGTCCCAG GCCACTGGCATCCCAGA GCTAAGTAGCTGCTTCTAACGACATGTCCACAAGCACAG GCTTCTTCACCTCAGGCCCA CAGGTTCAGTGGCAGTGACTCTGACTGGCCCTGCAGG CCTACATGGAGCTGAGCAG GACTGCACCAGCTGCACCTGGTCTGGGACAGACTTC AGAGGGTGGCTCTTTCCCCT CCTGAGATCCGAGGACACG(SEQ ID NO: 3271) ACTCTCACCATCAGCAG GGAGACAAAGACAGGGAGAGCCGTGTATTACTGTGCGG ACTGGAGCCTGAAGATT CTGGA (SEQ ID NO: CTCCCCATTGTAGCGGTGGT TTGCAGTGTATTACTGTC 3273) AGCTGCCTTGATGCTTTTGAAGCAGTATGGTAGCTCA TATCTGGGGCCAAGGGACA CCGTGGACGTTCGGCCAATGGTCACCGTCTCTTCAGC AGGGACCAAGGTGGAAA GTCGACCAAGGGCCCATCGTCAAACGTACGGTGGCT GTCTTCCCCCTGGCACCCTC GCACCATCTGTCTTCATCCTCCAAGAGCACCTCTGGG TTCCCGCCATCTGATGAG GGCACAGCGGCCCTGGGCTCAGTTGAAATCTGGAAC GCCTGGTCAAGGACTACTT TGCCTCTGTTGTGTGCCTCCCCGAACCTGTGACGGTC GCTGAATAACTTCTATCC TCGTGGAACTCANGCGCCCCAGAGAGGCCAAAGTAC TGACCAGCGGCGTGCACAC AGTGGAAGGTGGATAACCTTCCCGGCTGTCCTACAGT GCCCTCCAATCGGGTAA CCTCNNNCTCTACTCCCTCACTCCCAGGAGAGTGTCA GCAGCGTGGNGACCGTGCC CAGAGCNNACAGCAAGGCTCCAGCAGCTTGGGCACC ACAGCACCTACAGCCTC CAGACCTACATCTGCAACGAGCAGCACCCTGACGCT TGAATCACAAGCCCAGCAA GAGCAAAGCAGACTACGCACCA (SEQ ID NO:  AGAAACACAAAGTCTAC 3270) GCCTGCGAAGTCACCCATC (SEQ ID NO:  3272) COV21 P2 A-C006 TACACATACGATTTAGGTGGNNGCTGTNNNNNNGAGGT COV21 P2 TACACATACGATTTAGGT GNNAGCCTTGGGCTGACCTACOV21 P2 E5 ACACTATAGAATAACATCC GCTCTTGGAGGAGGGTGCC E5 GACACTATAGAATAACANGACGGTCAGCTTGGTCCCT E5 ACTTTGCCTTTCTCTCCACA AGGGGGAAGACCGATGGGCTCCACTTTGCCTTTCTCT CCGCCGAATACCGGACCATT GGTGTCCACTCCCAGGTCCCCTTGGTGGAGGCTGAGGA CCACAGGTGTCCACTCCC CAGGCTGTCATCCCATGCTGAACTGCACCTCGGTTCTATC GACGGTGACCGTGGTCCCT AGGTCCAACTGCACCTCCACAGAAATAATCAGCCTC GATTGAATTCCACCATGGG TTGCCCCAGACGTCCATGTGGTTCTATCGATTGAATT ATCCTCAGACTGGAGCCCAC ATGGTCATGTATCATCCTTTAGTTGTAGTAGTAGATCGA CCACCATGGGATGGTCA TGATGGCCAGGGAGGCTGATTCTAGTAGCAACTGCAAC GCTGCTACCGTCCCCCCTTC TGTATCATCCTTTTTCTAGGTGCCAGACTTGGAGCCA CGGTGTACATTCTCAGGTG TCGCACAGTAATAAACGGCGTAGCAACTGCAACCGG GAGAATCGGTCAGGGACCC CAGCTGGTGGAGTCTGGGGCGTGTCTTCGGCGCTCAGG TTCCTGGGCCCAGTCTGT CTGAGGGCCGCTGATTATTAGAGGCTTGGTCAAGCCTGG CTGTCCATTTGCAGATACA GCTGACTCAGCCACCCTCCTATAGATGAGGAGTTTGGG AGGGTCCCTGAGACTCTCC GTGAGTTCCTGCCGTTGTCCAGCGTCTGGGACCCCCG GGCCGTTCCTGGGAGCTGCT TGTGCAGCCTCTGGATTCATCTGGAGATGGTGAATCGGC GACAGAGGGTCACCGTC GGTACCAGTTTACAGTATTGCTTCAGTGACTACTGCATG CCTTCACAGAGTCTGCGTA TCTTGTTCTGGAAGCAGCCTTCCGATGTTGGAGCTGCT AGCTGGATCCGCCGGGCTC GTATCTGGTGGTACCACTATTCCAACATCGGAAGCAA TCCAGAACAAGAGACGGTG CAGGGAAGGGGCTGGAATGTACTAATATATGAAAGCCA TACTGTAAACTGGTACC ACCCTCTGTCCGGGGGTCCCGCTTTCATATATTAGTAATA TTCCAGCCCCTTCCCTGGAG AGCAGCTCCCAGGAACGAGACGCTGAGGGTGGCTGA GTGGTACCACCAGATACTA CCCGGCGGATCCAGCTCATGCCCCCAAACTCCTCATC GTCAGCACAGACTGGGCCC CGCAGACTCTGTGAAGGGCGCAGTAGTCACTGAAGATG TATAGTAATAATCAGCG NGGAACCGGTTGCNNNTNNCGATTCACCATCTCCAGGG AATCCAGAGGCTGCACAGG GCCCTCAGGGGTCCCTGCTTACTAGA (SEQ ID NO: ACAACGGCAGGAACTCACT AGAGTCTCAGGGACCCTCCACCGATTCTCTGGCTCCA 3277) GTATCTGCAAATGGACAGC AGGCTTGACCAAGCCTCCCAGTCTGGCACCTCAGCCT CTGAGCGCCGAAGACACGG CCAGACTCCACCAGCCTGCCCCTGGCCATCAGTGGG CCGTTTATTACTGTGCGAGA AC (SEQ ID NO: 3275)CTCCAGTCTGAGGATGA AGGGGGGACGGTAGCAGCT GGCTGATTATTTCTGTGCCGATCTACTACTACAACTA AGCATGGGATGACAGCC CATGGACGTCTGGGGCAAATGAATGGTCCGGTATTCG GGGACCACGGTCACCGTCT GCGGAGGGACCAAGCTGCCTCAGCCTCCACCAAGGG ACCGTCCTAGGTCAGCC CCCATCGGTCTTCCCCCTGGCAAGGCTGCCCCCTCGG CACCCTCCTCCAAGAGCAC TCACTCTGTTCCCACCCTCTCTGGGGGCACAGCGGCC CGAGTGAGGAGCTTCAA CTGGGCTGCCTGGTCAAGGGCCAACAAGGCCACACT ACTACTTCCCCGAACCTGTG GGTGTGTCTCATAAGTGACGGTCTCGTGGAACTCAG ACTTCTACCCGGGAGCC GCGCCCTGACCAGCGGCGTGTGACAGTGGCCTGGAA GCACACCTTCCCGGCTGTCC GGCAGATAGCAGCCCCGTACAGTCCTCNNNCTCTACT TCAAGGCGGGAGTGGAG CCCTCAGCAGCGTGGTGACACCACCACACCCTCCAA CGTGCCCTCCAGCAGCTTG ACAAAGCAACAACAAGTGGCACCCAGACCTACATCT ACGCGGCCAGCAGCTAC GCAACGTGAATCACAAGCCCTGAGCCTGACGCCTGA CAGCAACACCAAGNGGACN GCAGTGGAAGTCCCACAAGANAGTTGAGCCCAAATC GAAGCTACAGCTGCCAG TTGTGANAAACTCACNCATGTCACGCATGAAGGGAG GCCCACCGTGCCCAG (SEQ CACCGTGGAGAAGACAG ID NO: 3274)TGGCCCCTACAGAATGTT CATAGAAGCTTGGCCGC CATGGCCCAACTTGTTTATTGCAGCTTATAATGGTT ACAAATAAAGCAA (SEQ ID NO: 3276) COV21_P3 A-C009TACACATACGATTTAGGTG CAGAGGTGCTCTTGGAGGA COV21_P3 TACACATACGATTTAGGTTTGGGCTGACCTAGGACGGT COV21_P3 B5 ACACTATAGAATAACATCC GGGTGCCAGGGGGAAGACCB5 GACACTATAGAATAACA CAGCTTGGTCCCTCCGCCGA B5 ACTTTGCCTTTCTCTCCACAGATGGGCCCTTGGTGGAGG TCCACTTTGCCTTTCTCT ATACCACATTGTTGCTGCCTGGTGTCCACTCCCAGGTCC CTGAGGAGACGGTGACCAG CCACAGGTGTCCACTCCCGCATCTGAGCTGCAGTAATA AACTGCACCTCGGTTCTATC GGTTCCCTGGCCCCAGTAGAGGTCCAACTGCACCTC CTCAGCCTCATCCTCAGCCT GATTGAATTCCACCATGGGTCATTGGAGGCCCCTAAAG GGTTCTATCGATTGAATT GGAGCCCAGAGACGGTCAGATGGTCATGTATCATCCTTT CACTAAATGGGGAGTCTCT CCACCATGGGATGGTCAGGAGGCCGTGTTGCCAGACT TTCTAGTAGCAACTGCAAC CGCACAGTAATACACGGCCTGTATCATCCTTTTTCTA TGGAGCCAGAGAAGCGATC CGGTGTACATTCCCAGGTGGTGTCGTCAGATCTCAGCCT GTAGCAACTGCAACCGG AGGGACCCCTGAGGGCCGCCAGCTGGTGCAGTCTGGGG GCTCAGCTCCATGTAGGCT TTCCTGGGCCCAGTCTGCTTACTGACCTCATAAATCAT CTGAGGTGAAGAAGCCTGG GTGCTGATGGACGTGTCCCCCTGACTCAGCCTCCCTC GAGTTTGGGGGCTTTGCCTG GGCCTCAGTGAAGGTCTCCTGGTCATGGTGACCCTGCC CGCGTCCGGGTCTCCTGG GGTGCTGTTGGTACCAGGAGTGCATGGCTTCTGGATACA CTGAAACTTCTGTGCATAGT ACAGTCAGTCACCATCTCACATAGTTATAACCACCAAC CCTTCACCGGCTACTATATG TTGTGCCACCACTGTTAGGCTGCACTGGAACCAGCA GTCACTGCTGGTTCCAGTGC CACTGGGTGCGACAGGCCCGTTGATCCATCCCATCCACT GTGACGTTGGTGGTTATA AGGAGATGGTGACTGACTGCTGGACAAGGGCTTGAGTG CAAGCCCTTGTCCAGGGGC ACTATGTCTCCTGGTACCTCCAGGAGACCCGGACGCG GATGGGATGGATCAACCCT CTGTCGCACCCAGTGCATAAACAGCACCCAGGCAAA GAGGGAGGCTGAGTCAG AACAGTGGTGGCACAAACTTAGTAGCCGGTGAAGGTGT GCCCCCAAACTCATGATT (SEQ ID NO: 3281)ATGCACAGAAGTTTCAGGG ATCCAGAAGCCATGCAGGA TATGAGGTCAGTAAGCGCAGGGTCACCATGACCAGG GACCTTCACTGAGGCCCCA GCCCTCAGGGGTCCCTGGACACGTCCATCAGCACAG GGCTTCTTCACCTCAGCCCC ATCGCTTCTCTGGCTCCACCTACATGGAGCTGAGCAG AGACTGCACCAGCTGCACC AGTCTGGCAACACGGCCGCTGAGATCTGACGACACG TGNNANNGGGACNCCC TCCCTGACCGTCTCTGGGGCCGTGTATTACTGTGCGA (SEQ ID NO: 3279) CTCCAGGCTGAGGATGAGAGACTCCCCATTTAGTGCT GGCTGAGTATTACTGCA TTAGGGGCCTCCAATGACTGCTCAGATGCAGGCAGC ACTGGGGCCAGGGAACCCT AACAATGTGGTATTCGGGGTCACCGTCTCCTCAGCGT CGGAGGGACCAAGCTGA CGACCAAGGGCCCATCGGTCCGTCCTAGGTCAGCCC CTTCCCCCTGGCACCCTCCT AAGGCTGCCCCCTCGGTCCAAGAGCACCTCTGGGGG CACTCTGTTCCCGCCCTC CACAGCGGCCCTGGGCTGCGAGTGAGGAGCTTCAAG CTGGTCAAGGACTACTTCC CCAACAAGGCCACACTGCCGAACCTGTGACGGTCTC GTGTGTCTCATAAGTGAC GTGGAACTCANGCGCCCTGTTCTACCCGGGAGCCGT ACCAGCGGCGTGCACACCT GACAGTGGCCTGGAAGGTCCCGGCTGTCCTACAGTCC CAGATAGCAGCCCCGTC TCNNACTCTACTCCCTCAGCAAGGCGGGAGTGGAGAC AGCGTGGTGACCGTGCCCT CACCACACCCTCCAAACCCAGCAGCTTGGGCACCCA AAAGCAACAACAAGTAC GACCTACATCTGCAACGTGGCGGCCAGCAGCTACCT AATCACAAGCCCAGCAACA GAGCCTGACGCCTGAGCCCANNNGGANANAGAGTTG AGTGGAAGTCCCACAGA AGCCCAAATCTTGTGACAAAGCTACAGCTGCCAGGT AACTCACACATGCCCNCCG CACGCATGAAGGGAGCATGCCCAGC (SEQ ID NO: CCGTGGAGAAGACAGTG 3278) GCCCCTACAGAATGTTCATAGAAGCTTGGCCGCC ATGGCCCAACTTGTTTAT TGCAGCTTATAATGGTTA CAAA (SEQ ID NO:3280) COV21_P2 A-C012 TACACATACGATTTAGGTG GNNCGCTNNGNNNNNNNN COV21_P2TACACATACGATTTAGGT GNCAGCCTTGGGCTGACCTA COV21_P2 C7 ACACTATAGAATAACATCCGTGCTNTTGGANNNNGGTG C7 GACACTATAGAATAACA GGACGGTCAGCTTGGTCCCT C7ACTTTGCCTTTCTCTCCACA CCAGGGGGAAGACCGATGG TCCACTTTGCCTTTCTCTCCGCCGAACACCCAAGTGTT GGTGTCCACTCCCAGGTCC GCCCTTGGTGGAGGCTGAGCCACAGGTGTCCACTCCC ACTACCTGCATATGAGCAGC AACTGCACCTCGGTTCTATCGAGACGGTGACCAGGGTTC AGGTCCAACTGCACCTC AGTAATAATCAGCCTCGTCCGATTGAATTCCACCATGGG CCNGGCCCCAGTAGTCAAA GGTTCTATCGATTGAATTTCAGCCTGGAGCCCAGAGA ATGGTCATGTATCATCCTTT GTACCCTTGGACATAGCTGCCACCATGGGATGGTCA TTGTCAGGGAGGCCGTGTTG TTCTAGTAGCAACTGCCAATATCCGAGATCTCTCGCAC TGTATCATCCTTTTTCTA CCAGACTTGGAGCCAGAGACCGGTGTACATTCCCAGGT AGTAATATACGGCCGTGTC GTAGCAACTGCAACCGGAGCGATTAGAAACCCCTGA GCAGCTGGTGCAGTCTGGG GTCAGATCTCAGCCTGCTCTTCCTGGGCCCAGTCTGC GGGCCGCTTACTGCCCTCAT GCTGAGGTGAAGAAGCCTGAGCTCCATGTAGGCTGTGC CCTGACTCAGCCTGCCTC AAATCATGAGTTTGGGGGCTGGGCCTCAGTGAAGGTCTC TGATGGACGTGTCCCTGGT CGAGTCTGGGTCTCCTGGTTGCCTGGGTGCTGTTGGTA CTGCAAGGCTTCTGGATAC CATGGTGACCCTGCCCTGAACAGTCGATCACCATCTC CCAGGAGACAAGGTTATAA ACCTTCACCGGCTACTATATAACTTCTGTGTATAGTTTCT CTGCACTGGAACCAGCA CTCCCAACATCACTGCTGGTGCACTGGGTGCGACAGGCC GCCACCACTGTTAGGGTTG GTGATGTTGGGAGTTATTCCAGTGCAGGAGATGGTG CCTGGACAAGGGCTTGAGT ATCCATCCCATCCACTCAAAACCTTGTCTCCTGGTAC ATCGACTGTCCAGGAGACCC GGATGGGATGGATCAACCCGCCCTTGTCCAGGGGCCTG CAACAGCACCCAGGCAA AGACTCGGAGGCAGGCTGATAACAGTGGTGGCAGAAAC TCGCACCCAGTGCATATAG AGCCCCCAAACTCATGAGTCAGCACAGACTGGGACC TATACACAGAAGTTTCAGG TAGCCGGTGAAGGTGTATCTTTATGAGGGCAGTAAG AGGAACCGGTTGCNNNNGN GCAGGGTCACCATGACCAGCAGAAGCCTTGCAGGAGAC CGGCCCTCAGGGGTTTCT NNAACTAGA (SEQ ID NO:GGACACGTCCATCAGCACA CTTCACTGAGGCCCCAGGC AATCGCTTCTCTGGCTCC 3285)GCCTACATGGAGCTGAGCA TTCTTCACCTCAGCCCCAGA AAGTCTGGCAACACGGCGGCTGAGATCTGACGACAC CTGCACCAGCTGCACCTG CTCCCTGACAATCTCTGGGGCCGTATATTACTGTGCG (SEQ ID NO: 3283) GCTCCAGGCTGAGGACGAGAGATCTCGGATACAGCT AGGCTGATTATTACTGCT ATGTCCAAGGGTACTTTGAGCTCATATGCAGGTAGT CTACTGGGGCCAGGGAACC AACACTTGGGTGTTCGGCTGGTCACCGTCTCCTCAGC CGGAGGGACCAAGCTGA GTCGACCAAGGGCCCATCGCCGTCCTAGGTCAGCCC GTCTTCCCCCTGGCACCCTC AAGGCTGCCCCCTCGGTCTCCAAGAGCACCTCTGGG CACTCTGTTCCCACCCTC GGCACAGCGGCCCTGGGCTGAGTGAGGAGCTTCAAG GCCTGGTCAAGGACTACTT CCAACAAGGCCACACTGCCCCGAACCTGTGACGGTC GTGTGTCTCATAAGTGAC TCGTGGAACTCANGCGCCCTTCTACCCGGGAGCCGT TGACCAGCGGCGTGCACAC GACAGTGGCCTGGAAGGCTTCCCGGCTGTCCTACAGT CAGATAGCAGCCCCGTC CCTCNNNCTCTACTCCCTCAAAGGCGGGAGTGGAGAC GCAGCGTGGTGACCGTGCC CACCACACCCTCCAAACCTCCAGCAGCTTGGGCACC AAAGCAACAACAAGTAC CAGACCTACATCTGCAACGGCGGCCAGCAGCTACCT TGAATCACAAGCCCAGCAA GAGCCTGACGCCTGAGC CACCAAGGTGGACAGAAGTGGAAGTCCCACAGA (SEQ ID NO: 3282) AGCTACAGCTGCCAGGT CACGCATGAAGGGAGCACCGTGG (SEQ ID NO: 3284) COV21_P1 A-C013 TACACATACGATTTAGGTGGGNCGCNGTGCCCCAGAGG COV21_P1 TACACATACGATTTAGGT CGATTGGAGGGCGTTATCCACOV21_P1 B2 ACACTATAGAATAACATCC TGCTCTTGGAGGAGGGTGC B2 GACACTATAGAATAACACCTTCCACTGTACTTTGGCC B2 ACTTTGCCTTTCTCTCCACA CAGGGGGAAGACCGATGGGTCCACTTTGCCTTTCTCT TCTCTGGGATAGAAGTTATT GGTGTCCACTCCCAGGTCCCCCTTGGTGGAGGCTGAGG NNNNNGNGTCCACTCCC CAGCAGGCACACAACAGAGAACTGCACCTCGGTTCTATC AGACGGTGACCGTGGTCCC AGGTCCAACTGCACCTCGCAGTTCCAGATTTCAACTG GATTGAATTCCACCATGGG TTTGCCCCAGACGTCCATGTGGTTCTATCGATTGAATT CTCATCAGATGGCGGGAAG ATGGTCATGTATCATCCTTTAGTAGTAGTAGTAGTACCC CCACCATGGGATGGTCA ATGAAGACAGATGGTGCAGTTCTAGTAGCAACTGCAAC CTGCCTAACCGCATCTAGA TGTATCATCCTTTTTCTACCACAGTTCGTTTGATCTCC CGGTGTACATTCCCAGGTG TAGCAGCTGGTACTACTACGTAGCAACTGCAACCGG ACCTTGGTCCCTCCGCCGAA CAGCTGGTGCAGTCTGGGGAATAAAGTAGTCGATTCCC TGTACATTCAGAAATTGT AGTGAGGGGCCAGTTGCTACTGAGGTGAAGAAGCCTGG TCTCGCACAGTAATACACG GTTGACACAGTCTCCAGCGCTGCTGACAGTAATAAAC GTCCTCGGTGAAGGTCTCCT GCCGTGTCCTCAGATCTCACCACCCTGTCTTTGTCTC TGCAAAATCTTCAGGCTCTA GCAAGGCTTCTGGAGGCACGGCTGCTCAGCTCCATGTA CAGGGGAAAGAGCCACC GGCTGCTGATGGTGAGAGTCTTCAGCAGCTATGCTATCA GGCTGTGCTCGTGGATTCGT CTCTCCTGCAGGGCCAGTGAAGTCTGTCCCAGACCCAC GCTGGGTGCGACAGGCCCC CCGCGGTAATCGTGACTCTCAGAGTGTTAGCAGCTA TGCCACTGAACCTGGCTGGG TGGACAAGGGCTTGAGTGGGCCCTGGAACTTCTGTGCGT CTTAGCCTGGTACCAAC ATGCCAGTGGCCCTGTTGGAATGGGAGGGATCATCCCTA AGTTTGCTGTACCAAAGAT AGAAACCTGGCCAGGCTTGCATCATAGATGAGGAGC TCTTTGGTACAGCAAACTA AGGGATGATCCCTCCCATCCCCAGGCTCCTCATCTAT CTGGGAGCCTGGCCAGGTTT CGCACAGAAGTTCCAGGGCCACTCAAGCCCTTGTCCAG GATGCATCCAACAGGGC CTGTTGGTACCAGGCTAAGTAGAGTCACGATTACCGCGG GGGCCTGTCGCACCCAGCT CACTGGCATCCCAGCCAAGCTGCTAACACTCTGACTG ACGAATCCACGAGCACAGC GATAGCATAGCTGCTGAAGGGTTCAGTGGCAGTGGG GCCCTGCAGGAGAGGGTGG CTACATGGAGCTGAGCAGCGTGCCTCCAGAAGCCTTGC TCTGGGACAGACTTCACT CTCTTTCCCCTGGAGACAAACTGAGATCTGAGGACACGG AGGAGACCTTCACCGAGGA CTCACCATCAGCAGCCTGACAGGG (SEQ ID NO:  CCGTGTATTACTGTGCGAG CCCAGGCTTCTTCACCTCAGAGAGCCTGAAGATTTTG 3289) AGGGAATCGACTACTTTAT CCCCAGACTGCACCAGCTGCAGTTTATTACTGTCAGC TGTAGTAGTACCAGCTGCT GCACCT (SEQ ID NO:AGCGTAGCAACTGGCCC ATCTAGATGCGGTTAGGCA 3287) CTCACTTTCGGCGGAGGGGGGTACTACTACTACTAC GACCAAGGTGGAGATCA TACATGGACGTCTGGGGCAAACGTACGGTGGCTGCA AAGGGACCACGGTCACCGT CCATCTGTCTTCATCTTCCTCCTCAGCGTCGACCAAG CCGCCATCTGATGAGCA GGCCCATCGGTCTTCCCCCTGTTGAAATCTGGAACTG GGCACCCTCCTCCAAGAGC CCTCTGTTGTGTGCCTGCACCTCTGGGGGCACAGCGG TGAATAACTTCTATCCCA CCCTGGGCTGCCTGGTCAAGAGAGGCCAAAGTACAG GGACTACTTCCCCGAACCT TGGAAGGTGGATAACGCGTGACGGTCTCGTGGAACT CCTCCAATCGGGTAACTC CAGGCGCCCTGACCAGCGGCCAGGAGAGTGTCACAG CGTGCACACCTTCCCGGCT AGCNNACAGCAAGGACAGTCCTACAGTCCTCAGGAC GCACCTACAGCCTCAGC TCTACTCCCTCAGCAGCGTGAGCACCCTGACGCTGAN GTGACCGTGCCCTCCAGCA CAAAGCANACTACGAGAGCTTGGGCACCCAGACCTA AACACAAAGTCTACGCC CATCTGCAACGTGAATCACTGCGAAGTCACCCATCN AAGCCCAGCAACACCAA NNNCTGAGCTCGCCCGT (SEQ ID NO: 3286)CACAAAGAGCTTCAACA GGGGGANANTGTTANAA GCTTGGCCGCCATGGCC CAACTTGTTNATTGCAGCTTANATGGTTA (SEQ ID NO: 3288) COV21_P3 A-C014 TACACATACGATTTAGGTGGGGGCCACCGGTGTGCACA COV21_P3 TACACATACGATTTAGGT CTTGGGCTGACCTAGGACGGCOV21_P3 H10 ACACTATAGAATAACATCC GCAGTGGGGGAGGCTTGGT H10GACACTATAGAATAACA TCAGCTTGGTCCCTCCGCCG H10 ACTTTGCCTTTCTCTCCACAGCAACCTGGTGGCTCATTG TCCACTTTGCCTTTCTCT AATATCACATATCGAGAGTGGGTGTCCACTCCCAGGTCC CGCCTCAGCTGCGCGGCGT CCACAGGTGTCCACTCCCCTGCTGCTTGTATATGAGCT AACTGCACCTCGGTTCTATC CCGGCTTCAATTTTTCCACTAGGTCCAACTGCACCTC GCAGTAATAATCAGCCTCGT GATTGAATTCCACCATGGGCACTGGATGCATTGGGTCA GGTTCTATCGATTGAATT CCTCAGCCTGGAGCCCAGAATGGTCATGTATCATCCTTT GGCAAGCACCGGGAAAGG CCACCATGGGATGGTCAGATGGTCAGGGAGGCCGTG TTCTAGTAGCAACTGCAAC GCCTCGTGTGGGTATCTCGTGTATCATCCTTTTTCTA TTGCCAGACTTGGAGCCAGA CGGTGTGCACAGCAGTGGGGATTAACTCCGATGGCAGC GTAGCAACTGCAACCGG GAAGCGATTAGAAACCCCTGGAGGCTTGGTGCAACCTG AGAAGAGCCTACGCTACCT TTCCTGGGCCCAGTCTGTGAGGGCCGATTACTGACATC GTGGCTCATTGCGCCTCAG CAGTGAAAGGGAGGTTCACGCTGACTCAGCCTGCCTC ATAAATCATGAGTTTGGGGG CTGCGCGGCGTCCGGCTTCAATTTCACGGGATAACGCA CGTGTCTGGGTCTCCTGG CTTTGCCTGGGTGTTGTTGGAATTTTTCCACTCACTGGAT AAAAACACTCTCTATCTCC ACAGTCGATCACCATCTCTACCAGGAGACATAGTTATA GCATTGGGTCAGGCAAGCA AGATGGACTCACTCCGCGACTGCACTGGAACCAGCA ACCACCAACGTCACTGCTGG CCGGGAAAGGGCCTCGTGTCGAAGATACAGCTGTCTAT GTGACGTTGGTGGTTATA TTCCAGTGCAGGAGATGGTGGGGTATCTCGGATTAACTC TACTGTACTAGGGATGATA ACTATGTCTCCTGGTACCATCGACTGTCCAGGAGACCC CGATGGCAGCAGAAGAGCC GTTCTTGGCCGCATTTCTTCAACAACACCCAGGCAAA AGACACGGAGGCAGGCTGA TACGCTACCTCAGTGAAAGGACAACTGGGGTCAGGGGA GCCCCCAAACTCATGATT GTCAGCACAGACTGGGNCCGGAGGTTCACAATTTCACG CCTTGGTGACGGTCTCTAGC TATGATGTCAGTAATCGAGGAACCGGNT (SEQ ID GGATAACGCAAAAAACACT GCGTCGACGGCA (SEQ IDGCCCTCAGGGGTTTCTAA NO: 3293) CTCTATCTCCAGATGGACTC NO: 3291)TCGCTTCTCTGGCTCCAA ACTCCGCGACGAAGATACA GTCTGGCAACACGGCCTGCTGTCTATTACTGTACTAG CCCTGACCATCTCTGGGC GGATGATAGTTCTTGGCCGTCCAGGCTGAGGACGAG CATTTCTTCGACAACTGGG GCTGATTATTACTGCAGCGTCAGGGGACCTTGGTGAC TCATATACAAGCAGCAG GGTCTCTAGCGCGTCGACCCACTCTCGATATGTGATA AAGGGCCCATCGGTCTTCC TTCGGCGGAGGGACCAACCCTGGCACCCTCCTCCAA GCTGACCGTCCTAGGTC GAGCACCTCTGGGGGCACAAGCCCAAGGCTGCCCCC GCGGCCCTGGGCTGCCTGG TCGGTCACTCTGTTCCCGTCAAGGACTACTTCCCCGA CCCTCGAGTGAGGAGCT ACCTGTGACGGTCTCGTGGTCAAGCCAACAAGGCCA AACTCAGGCGCCCTGACCA CACTGGTGTGTCTCATAAGCGGCGTGCACACCTTCCC GTGACTTCTACCCGGGA GGCTGTCCTACAGTCCTCAGCCGTGACAGTGGCCTG GGACTCTACTCCCTCAGCA NAAGGCAGATAGCAGCCGCGTGGTGACCGTGCCCTC CCGTCAAGGCGGGAGTG CAGCAGCTTGGGCACCCAGGAGACCACCACACCCTC ACCTACATCTGCAACGTGA CAAACAAAGCAACAACAATCACAAGCCCAGCAACAC AGTACGCGGCCAGCAGC CAAGGTGGACAAGAGAGTTTACCTGAGCCTGACGCCT GAGCCCAAATCTTGTGACA GAGCAGTGGAAGTCCCAAAACTCACACATGCCCNNN CAGAAGCTACAGCTGCC CNNGNGNCCAGCACCTGAAAGGTCACGCATGAAGGA CTCCTGGGGGGACCGTC GCACCGTGGANAAGACA (SEQ ID NO: 3290)GTGGCCCCTACAGAATG TTCATAGAAGCTTGGCC GCCATGGCCCAACTTGTTTATTGCAGCTTAT (SEQ ID NO: 3292) COV21_P3 A-C015 TACACATACGATTTAGGTGGGGGCCACCGGTGTGCACA COV21_P3 TACACATACGATTTAGGT GGGNNNNNCTTGGGCTGACCOV21_P3 D12 ACACTATAGAATAACATCC GCGTCTGGAGGGGGCTTGG D12GACACTATAGAATAACA GTAGGACGGTCAGGTGGGT D12 ACTTTGCCTTTCTCTCCACATGAAACCTGGTGGTTCTCTT TCCACTTTGCCTTTCTCT CCCTCCACCGAACACCCAAGGGTGTCCACTCCCAGGTCC AGGCTGAGTTGCGCTGCGT CCACAGGTGTCCACTCCCTACTCAGGCTGTCATCCCAT AACTGCACCTCGGTTCTATC CAGGCTTTACCTTTTCTTCTAGGTCCAACTGCACCTC TCTGCACAGTAATAGTCACC GATTGAATTCCACCATGGGTATAGCATGAACTGGGTAC GGTTCTATCGATTGAATT CTCATCCTCAGACTGGAGCCATGGTCATGTATCATCCTTT GCCAAGCGCCGGGCAAAGG CCACCATGGGATGGTCACACTGATGGCCAGGGAGGC TTCTAGTAGCAACTGCAAC TCTCGAGTGGGTGTCCTCTATGTATCATCCTTTTTCTA TGAGGTGCCAGACTTGGAG CGGTGTGCACAGCGTCTGGTATCAAGTTCCAGTAGCTA GTAGCAACTGCAACCGG CCAGAGAATCGGTCAGGGAAGGGGGCTTGGTGAAACCT CATTTACTATGCTGACTCAG TTCCTGGGCCCAGTCTGTCCCCTGAGGGCCGCCGATTA GGTGGTTCTCTTAGGCTGA TCAAAGGCAGATTTACCATGCTGACTCAGCCACCCTC CTATTGTAAATGAGGAGTTT GTTGCGCTGCGTCAGGCTTTCAGCCGCGATAATGCCAAA AGCGTCTGGGACCCCCG GGGGGCCGTTCCTGGGAGCTACCTTTTCTTCTTATAGCAT AATTCACTCTATCTGCAAAT GACAGAGGGTCACCATCGCTGGAACCAGTTAACAGT GAACTGGGTACGCCAAGCG GAACTCTCTTCGCGCAGAGTCTTGTTCTGGAATCAGC ATTACTTCCGAGGTTGGAGC CCGGGCAAAGGTCTCGAGTGATACCGCTGTCTACTACTG TCCAACCTCGGAAGTAA TGATTCCAGAACAAGAGATGGGTGTCCTCTATATCAAGT TGCTAGGGAGGTGAAAAGA TACTGTTAACTGGTTCCAGGTGACCCTCTGTCCGGGGG TCCAGTAGCTACATTTACTA GTAGTAGCTGCCCCAGAGTGCAGCTCCCAGGAACGG TCCCAGACGCTGAGGGTGG TGCTGACTCAGTCAAAGGCACTACTTTGATTATTGGGGT CCCCCAAACTCCTCATTT CTGAGTCAGCACAGACTGGAGATTTACCATCAGCCGCG CAAGGGACACTTGTTACAG ACAATAGTAATCGGCGGGACCAGGAACCGGTTG (SEQ ATAATGCCAAAAATTCACT TCTCATCCGCGTCGACGGCCCCTCAGGGGTCCCTGA ID NO: 3297) CTATCTGCAAATGAACTCTC A (SEQ ID NO: 3295)CCGATTCTCTGGCTCCAA TTCGCGCAGAGGATACCGC GTCTGGCACCTCAGCCTCTGTCTACTACTGTGCTAGGG CCTGGCCATCAGTGGGC AGGTGAAAAGAGTAGTAGCTCCAGTCTGAGGATGAG TGCCCCAGAGTACTACTTTG GGTGACTATTACTGTGCAATTATTGGGGTCAAGGGAC GAATGGGATGACAGCCT ACTTGTTACAGTCTCATCCGGAGTACTTGGGTGTTCG CGTCGACCAAGGGCCCATC GTGGAGGGACCCACCTGGGTCTTCCCCCTGGCACCCT ACCGTCCTACGTCAGCCC CCTCCAAGAGCACCTCTGGAAGGCTGCCCCCTCGGT GGGCACAGCGGCCCTGGGC CACTCTGTTCCCACCCTCTGCCTGGTCAAGGACTACT GAGTGAGGAGCTTCAAG TCCCCGAACCTGTGACGGTCCAACAAGGCCACACTG CTCGTGGAACTCAGGCGCC GTGTGTCTCATAAGTGACCTGACCAGCGGCGTGCACA TTCTACCCGGGAGCCGT CCTTCCCGGCTGTCCTACAGGACAGTGGCCTGGAAGG TCCTCAGGACTCTACTCCCT CAGATAGCAGCCCCGTCCAGCAGCGTGGTGACCGTG AAGGCGGGAGTGGAGAC CCCTCCAGCAGCTTGGGCACACCACACCCTCCAAAC CCCAGACCTACATCTGCAA AAAGCAACAACAAGTACCGTGAATCACAAGCCCAGC GCGGCCAGCAGCTACCT AACACCAAGGTGGACAAGAGAGCCTGACGCCTGAGC GAGTTGAGCCCAAATCTTG AGTGGAAGTCCCACAGATGACAAAACTCACACATGC AGCTACAGCTGCCAGGT CCACCGTGCCCAGCACCCACGCATGAAGGGAGCA (SEQ ID NO: 3294) CCGTGGAGAAGACAGTG GCCCCTACAGAATGTTCATAGAAGCTTGGCCGCC ATGGCCCAACTTGTTTAT TGCAGCTTATAATGGTTACAAA (SEQ ID NO: 3296) COV21_P3 A-C016 TACACATACGATTTAGGTGGCTGTGNNNNAGAGGTGCT COV21_P3 TACACATACGATTTAGGT TNCCCGATTGGAGGGCGTTACOV21_P3 A4 ACACTATAGAATAACATCC CTTGGAGGAGGGTGCCAGG A4 GACACTATAGAATAACATCCACCTTCCACTGTACTTT A4 ACTTTGCCTTTCTCTCCACA GGGAAGACCGATGGGCCCTTCCACTTTGCCTTTCTCT GGCCTCTCTGGGATAGAAGT GGTGTCCACTCCCAGGTCCTGGTGGAGGCTGAGGAGAC CCACAGGTGTCCACTCCC TATTCAGCAGGCACACAACAACTGCACCTCGGTTCTATC GGTGACCAGGGTTCCCTGG AGGTCCAACTGCACCTCAGAGGCAGTTCCAGATTTCA GATTGAATTCCACCATGGG CCCCAGTAGTCAAAGTTACGGTTCTATCGATTGAATT ACTGCTCATCAGATGGCGGG ATGGTCATGTATCATCCTTTCTCCGTAGCAGCTACCACC CCACCATGGGATGGTCA AAGATGAAGACAGATGGTGTTCTAGTAGCAACTGCAAC ACTACAATAAGGGGCGGTC TGTATCATCCTTTTTCTACAGCCACAGTTCGTTTGATC CGGTGTACATTCTGAGGTG ACTTTCGCACAGTAATACAGTAGCAACTGCAACCGG TCCACCTTGGTCCCTCCGCC CAGCTGGTGGAGTCTGGGGCAGCCGTGTCCTCAGCTCTC TGTACATTGTGCCATCCG GAAAGTAGGAGGGAGATTAGAGGCGTGGTCCAGCCTGG AGGCTGTTCATTTGCAGAT GATGACCCAGTCTCCATCTCATACTGTTGACAGTAATA GAGGTCCCTGAGACTCTCC ACAGCGTGTTCTTGGAATTCTCCCTGTCTGCATCTGT TGTTGCAATATCTTCAGGCT TGTGCAGCCTCTGGATTCACGTCTCTGGAGATGGTGAAT AGGAGACAGAGTCACCA GCAGGCTGTTGATGGTGAACTTCAGTAGATATGGCATG CGGCCCTTCACGGAGTCTG TCACTTGCCAGGCGAGTAGTAAAATCTGTCCCAGATC CACTGGGTCCGCCAGGCTC CATAGTATTTATTACTTCCACAGGACATTAGCAACTA CACTTCCGCTGAACCTTGAT CAGGCAAGGGGCTGGAGTGTCATATGATATAACTGCCA TTTAAATTGGTATCAGCA GGGACCCCTGTTTCCAAATTGGTGGCAGTTATATCATAT CCCACTCCAGCCCCTTGCCT GAAACCAGGGAAAGCCCGGATGCATCGTAGATCAGG GATGGAAGTAATAAATACT GGAGCCTGGCGGACCCAGTCTAAGCTCCTGATCTACG AGCTTAGGGGCTTTCCCTGG ATGCAGACTCCGTGAAGGGGCATGCCATATCTACTGAA ATGCATCCAATTTGGAA TTTCTGCTGATACCAATTTACCGATTCACCATCTCCAGA GGTGAATCCAGAGGCTGCA ACAGGGGTCCCATCAAGAATAGTTGCTAATGTCCTGA GACAATTCCAAGAACACGC CAGGAGAGTCTCAGGGACCGTTCAGCGGAAGTGGAT CTCGCCTGGCAAGTGATGGT TGTATCTGCAAATGAACAGTCCCAGGCTGGACCACGCC CTGGGACAGATTTTACTT GACTCTGTCTCCTACAGATGCCTGAGAGCTGAGGACACG TCCCCCAGACTCCACCANN TCACCATCAACAGCCTGCAGACAGGGNG (SEQ ID GCTGTGTATTACTGTGCGA CTGCAC (SEQ ID NO: CAGCCTGAAGATATTGC NO: 3301) AAGTGACCGCCCCTTATTGT 3299) AACATATTACTGTCAACAGTGGTGGTAGCTGCTACG AGTATGATAATCTCCCTC GAGGTAACTTTGACTACTGCTACTTTCGGCGGAGGG GGGCCAGGGAACCCTGGTC ACCAAGGTGGAGATCAAACCGTCTCCTCAGCGTCGA ACGTACGGTGGCTGCAC CCAAGGGCCCATCGGTCTTCATCTGTCTTCATCTTCC CCCCCTGGCACCCTCCTCCA CGCCATCTGATGAGCAGAGAGCACCTCTGGGGGCAC TTGAAATCTGGAACTGC AGCGGCCCTGGGCTGCCTGCTCTGTTGTGTGCCTGCT GTCAAGGACTACTTCCCCG GAATAACTTCTATCCCAGAACCTGTGACGGTCTCGTG AGAGGCCAAAGTACAGT GAACTCANGCGCCCTGACCGGAAGGTGGATAACGCC AGCGGCGTGCACACCTTCC CTCCAATCGGGTAACTCCCGGCTGTCCTACAGTCCTCN CAGGAGAGTGTCACAGA NACTCTACTCCCTCAGCAGGCAGGACAGCAAGGACA CGTGGTGACCGTGCCCTCC GCACCTACAGCCTCAGCAGCAGCTTGGGCACCCAGA AGCACCCTGACGCTGAG CCTACATCTGCAACGTGAACAAAGCAGACTACGAGA TCACAAGCCCAGCAACACC AACACAAAGTCTACGCCA (SEQ ID NO: 3298) TGCGAAGTCACCCATCA GGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAAC AGGGGAGAGTGTTAGAA GCTTGGCCGCCATGGCC CAACTTGTTTATTGCAGCTTATAATGG (SEQ ID NO: 3300) COV21_P1 A-C017 TACACATACGATTTAGGTGGAGGTGCTCTTGGAGGAGG COV21_P1 TACACATACGATTTAGGT CCGATTGGAGGGCGTTATCCCOV21_P1 E10 ACACTATAGAATAACATCC GTGCCAGGGGGAAGACCGA E10GACACTATAGAATAACA ACCTTCCACTGTACTTTGGC E10 ACTTTGCCTTTCTCTCCACATGGGCCCTTGGTGGAGGCT TCCACTTTGCCTTTCTCT CTCTCTGGGATAGAAGTTATGGTGTCCACTCCCAGGTCC GAGGAGACGGTGACCAGGG CCACAGGTGTCCACTCCCTCAGCAGGCACACAACAGA AACTGCACCTCGGTTCTATC TTCCCTGGCCCCAGTGGTCGAGGTCCAACTGCACCTC GGCAGTTCCAGATTTCAACT GATTGAATTCCACCATGGGAAGTTGAGGTCGGGACCAG GGTTCTATCGATTGAATT GCTCATCAGATGGCGGGAAATGGTCATGTATCATCCTTT CTGCTGCTATACCCCTTACG CCACCATGGGATGGTCAGATGAAGACAGATGGTGCA TTCTAGTAGCAACTGCAAC CCCGCTTTTGCACAGTAATATGTATCATCCTTTTTCTA GCCACAGTTCGTTTAATCTC CGGTGTACATTCTGAAGTGAAAGGCCGTGTCCTCAGCT GTAGCAACTGCAACCGG CAGTCGTGTCCCTTGGCCGACAGCTGGTGGAGTCTGGGG CTCAGACTGTTCATTTGCAG TGTACATTCAGAAATTGTAGGTGATACGCTGCTGACA GAGGCTTGGTACAGCCTGG ATACAGGGAGTTCTTGGCGGTTGACACAGTCTCCAG GTAATAAACTGCAAAATCTT CAGGTCCCTGAGACTCTCCTTTGTCTCTGGAGATGGTGA CCACCCTGTCTTTGTCTC CAGGCTCTAGGCTGCTGATGGTGCAGCCTCTGGATTCAC ATCGGCCCTTCACAGAGTC CAGGGGAAAGAGCCACCGTGAGAGTGAAGTCTGTCCC CTTTGATGATTATGCCATGC CGCATAGCCTATGGTACCACTCTCCTGCAGGGCCAGT AGACCCACTGCCACTGAACC ACTGGGTCCGGCAAGCTCCCTATTCCAACTAATACCTGA CAGAGTGTTAGCAGCTA TGGCTGGGATGCCAGTGGCCAGGGAAGGGCCTGGAGTGG GACCCACTCCAGGCCCTTC CTTAGCCTGGTACCAACCTGTTGGATGCATCATAGAT GTCTCAGGTATTAGTTGGA CCTGGAGCTTGCCGGACCCAGAAACCTGGCCAGGCT GAGGAGCCTGGGAGCCTGG ATAGTGGTACCATAGGCTAAGTGCATGGCATAATCATC CCCAGGCTCCTCATCTAT CCAGGTTTCTGTTGGTACCATGCGGACTCTGTGAAGGGC AAAGGTGAATCCAGAGGCT GATGCATCCAACAGGGCGGCTAAGTAGCTGCTAACAC CGATTCACCATCTCCAGAG GCACAGGAGAGTCTCAGGGCACTGGCATCCCAGCCA TCTGACTGGCCCTGCAGGAG ACAACGCCAAGAACTCCCTACCTGCCAGGCTGTACCAA GGTTCAGTGGCAGTGGG AGGGTGGCTCTTTCCCCTGGGTATCTGCAAATGAACAGT GCCTCCCCCAGACTCCACN TCTGGGACAGACTTCACTAGACAAAGACAGGGAGACT CTGAGAGCTGAGGACACGG NNNTTGCAC (SEQ ID NO:CTCACCATCAGCAGCCT GGA (SEQ ID NO: 3305) CCTTTTATTACTGTGCAAAA 3303)AGAGCCTGAAGATTTTG GCGGGCGTAAGGGGTATAG CAGTTTATTACTGTCAGCCAGCAGCTGGTCCCGACCT AGCGTATCACCTTCGGCC CAACTTCGACCACTGGGGCAAGGGACACGACTGGAG CAGGGAACCCTGGTCACCG ATTAAACGTACGGTGGCTCTCCTCAGCGTCGACCAA TGCACCATCTGTCTTCAT GGGCCCATCGGTCTTCCCCCCTTCCCGCCATCTGATGA TGGCACCCTCCTCCAAGAG GCAGTTGAAATCTGGAACACCTCTGGGGGCACAGCG CTGCCTCTGTTGTGTGCC GCCCTGGGCTGCCTGGTCATGCTGAATAACTTCTATC AGGACTACTTCCCCGAACC CCAGAGAGGCCAAAGTATGTGACGGTCTCGTGGAAC CAGTGGAAGGTGGATAA TCAGGCGCCCTGACCAGCGCGCCCTCCAATCGGGTA GCGTGCACACCTTCCCGGC ACTCCCAGGAGAGTGTCTGTCCTACAGTCCTCAGGA ACAGAGCAGGACAGCAA CTCTACTCCCTCAGCAGCGTGGACAGCACCTACAGCC GGTGACCGTGCCCTCCAGC TCAGCAGCACCCTGACGAGCTTGGGCACCCAGACCT CTGAGCAAAGCAGACTA ACATCTGCAACGTGAATCACGAGAAACACAAAGTCT CAAGCCCAGCAACACCAA ACGCCTGCGAAGTCACC (SEQ ID NO: 3302)CATCNGGCCTGAGCTCG CCCGTCACAAAGAGCTT CAACAGGGGAGAGTGTT AGAAGCTTGGNCGCCATGGCCCAACTTGTTTATTG CAGCTTATNATGGNTAC AAATAAAGCAATAGCAT CACAAATTTCAC (SEQID NO: 3304) COV21_P3 A-C028 TACACATACGATTTAGGTG CTGTGCCCCAGAGGTGCTCCOV21_P3 TACACATACGATTTAGGT TACCCGATTGGAGGGCGTTA COV21_P3 E2ACACTATAGAATAACATCC TTGGAGGAGGGTGCCAGGG E2 GACACTATAGAATAACATCCACCTTCCACTGTACTTT E2 ACTTTGCCTTTCTCTCCACA GGAAGACCGATGGGCCCTTTCCACTTTGCCTTTCTCT GGCCTCTCTGGGATAGAAGT GGTGTCCACTCCCAGGTCCGGTGGAGGCTGAGGAGACG CCACAGGTGTCCACTCCC TATTCAGCAGGCACACAACAACTGCACCTCGGTTCTATC GTGACCAGGGTTCCCTGGC AGGTCCAACTGCACCTCAGAGGCAGTTCCAGATTTCA GATTGAATTCCACCATGGG CCCAGTAGTCAAAGTTGAGGGTTCTATCGATTGAATT ACTGCTCATCAGATGGCGGG ATGGTCATGTATCATCCTTTGTCGGGACCAGCTGCTGCT CCACCATGGGATGGTCA AAGATGAAGACAGATGGTGTTCTAGTAGCAACTGCAAC ATACCCCTTACGCCCGCTTT TGTATCATCCTTTTTCTACAGCCACAGTTCGTTTAATC CGGTGTACTTCTGAAGTGC TGCACAGTAATACAAGGCCGTAGCAACTGCAACCGG TCCAGTCGTGTCCCTTGGCC AGCTGGTGGAGTCTGGGGGGTGTCCTCAGCTCTCAGACT TGTACATTCAGAAATTGT GAAGGTGATACGCTGCTGAAGGCTTGGTACAGCCTGGC GTTCATTTGCAGATACAGG GTTGACACAGTCTCCAGCAGTAATAAACTGCAAAAT AGGTCCCTGAGACTCTCCT GAGTTCTTGGCGTTGTCTCTCCACCCTGTCTTTGTCTC CTTCAGGCTCTAGGCTGCTG GTGCAGCCTCTGGATTCACGGAGATGGTGAATCGGCCC CAGGGGAAAGAGCCACC ATGGTGAGAGTGAAGTCTGTCTTTGATGATTATGCCATGC TTCACAGAGTCCGCATAGC CTCTCCTGCAGGGCCAGTCCCAGACCCACTGCCACTGA ACTGGGTCCGGCAAGCTCC CTATGCTACCACTATTCCAACAGAGTGTTAGCAGCTA ACCTGGCTGGGATGCCAGTG AGGGAAGGGCCTGGAGTGGCTAATACCTGAGACCCACT CTTAGCCTGGTACCAAC GCCCTGTTGGATGCATCATAGTCTCAGGTATTAGTTGGA CCAGGCCCTTCCCTGGAGC AGAAACCTGGCCAGGCTGATGAGGAGCCTGGGAGCC ATAGTGGTAGCATAGGCTA TTGCCGGACCCAGTGCATGCCCAGGCTCCTCATCTAT TGGCCAGGTTTCTGTTGGTA TGCGGACTCTGTGAAGGGCGCATAATCATCAAAGGTGA GATGCATCCAACAGGGC CCAGGCTAAGTAGCTGCTAACGATTCACCATCTCCAGAG ATCCAGAGGCTGCACAGGA CACTGGCATCCCAGCCACACTCTGACTGGCCCTGCAG ACAACGCCAAGAACTCCCT GAGTCTCAGGGACCTGCCAGGTTCAGTGGCAGTGGG GAGAGGGTGGCTCTTTCCCC GTATCTGCAAATGAACAGTGGCTGTACCAAGCCTCCCC TCTGGGACAGACTTCACT TGGAGACAAAGACAGGGNGCTGAGAGCTGAGGACACGG CAGACTCCACCAGCTGCAC CTCACCATCAGCAGCCTACTGNNNNNGGGGGTCATA CCTTGTATTACTGTGCAAAA (SEQ ID NO: 3307)AGAGCCTGAAGATTTTG CCAATCTCGCANGT (SEQ GCGGGCGTAAGGGGTATAGCAGTTTATTACTGTCAGC ID NO: 3309) CAGCAGCTGGTCCCGACCT AGCGTATCACCTTCGGCCCAACTTTGACTACTGGGGC AAGGGACACGACTGGAG CAGGGAACCCTGGTCACCGATTAAACGTACGGTGGC TCTCCTCAGCGTCGACCAA TGCACCATCTGTCTTCATGGGCCCATCGGTCTTCCCCC CTTCCCGCCATCTGATGA TGGCACCCTCCTCCAAGAGGCAGTTGAAATCTGGAA CACCTCTGGGGGCACAGCG CTGCCTCTGTTGTGTGCCGCCCTGGGCTGCCTGGTCA TGCTGAATAACTTCTATC AGGACTACTTCCCCGAACCCCAGAGAGGCCAAAGTA TGTGACGGTCTCGTGGAAC CAGTGGAAGGTGGATAATCAGGCGCCCTGACCAGCG CGCCCTCCAATCGGGTA GCGTGCACACCTTCCCGGCACTCCCAGGAGAGTGTC TGTCCTACAGTCCTCAGGA ACAGAGCAGGACAGCAACTCTACTCCCTCAGCAGCGT GGACAGCACCTACAGCC GGTGACCGTGCCCTCCAGCTCAGCAGCACCCTGACG AGCTTGGGCACCCAGACCT CTGAGCAAAGCANACTAACATCTGCAACGTGAATCA CGAGAAACACAAAGTCT CAAGCCCAGCAACACCAANACGCCTGCGAAGTCACC GTGGACAAGAGAGTTGAGC CATCNGNCCTGAGCTCGCCAAATCTTGTGACAAAAC CCCGTCACAAAGAGCTT TCACACATGCCCACCGTGCCAACAGGGGAGAGTGTT CC (SEQ ID NO: 3306) AGAAGCTTGGCCGCCATGGNNCAACTTGTTTATTG CAGCTTATAATGGTTACA AATAAAGCAATAGCATC(SEQ ID NO: 3308) COV21_P3 A-C018 TACACATACGATTTAGGTGGCTGTGNNNNNGAGGTGCT COV21_P3 TACACATACGATTTAGGT GGNNNTNCNNGATTGGAGGCOV21_P3 B9 ACACTATAGAATAACATCC CTTGGAGGAGGGTGCCAGG B9 GACACTATAGAATAACAGCGTTATCCACCTTCCACTG B9 ACTTTGCCTTTCTCTCCACA GGGAAGACCGATGGGCCCTTCCACTTTGCCTTTCTCT TACTTTGGCCTCTCTGGGAT GGTGTCCACTCCCAGGTCCTGGTGGAGGCTGAGGAGAC CCACAGGTGTCCACTCCC AGAAGTTATTCAGCAGGCAAACTGCACCTCGGTTCTATC GGTGACCAGGGTTCCCTGG AGGTCCAACTGCACCTCCACAACAGAGGCAGTTCCA GATTGAATTCCACCATGGG CCCCAGTAGTCAAACGCCCGGTTCTATCGATTGAATT GATTTCAACTGCTCATCAGA ATGGTCATGTATCATCCTTTAGAACGAACTATCGTCAAA CCACCATGGGATGGTCA TGGCGGGAAGATGAAGACATTCTAGTAGCAACTGCAAC ATCTCTCGCACAGTAATAC TGTATCATCCTTTTTCTAGATGGTGCAGCCACAGTTCG CGGTGTACATTCTGAGGTG ACAGCCGTGTCCTCAGCTCTGTAGCAACTGCAACCGG TTTGATCTCCAGCTTGGTCC CAGCTGGTGGAGTCTGGGGCAGGCTGTTCATTTGCAGAT TGTACATTCAGACATCCA CCTGGCCAAAAGTGGCCGGGAGGCGTGGTCCAGCCTGG ACAGCGTGTTCTTGGAATT GTTGACCCAGTCTCCATCAGGGGTACTGTAACTCTGTT GAGGTCCCTGAGACTCTCC GTCTCTGGAGATGGTGAATCTCCCTGTCTGCGTCTGT GACAGTAGTAAGTTGCAAA TGTGCAGCCTCTGGATTCACCGGCCCTTCACGGAGTCTG AGGAGACAGAGTCACCA ATCATCAGGTTGCAGACTGCCTTCAGTAACTATGCTATAC CGTAGTATTTATTGCTTCCA TCACTTGCCGGGCAAGTTGATGGTGAGAGTGAAATCT ACTGGGTCCGCCAGGCTCC TCATATGATATAACTGCCACAGAGCATTCGCAGCTA GTCCCAGATCCACTGCCACT AGGCAAGGGGCTGGAGTGGCCCACTCCAGCCCCTTGCCT TTTAAATTGGTATCAACA GAACCTTGAAGGGACCCCAGTGGCAGTTATATCATATG GGAGCCTGGCGGACCCAGT GAAACCAGGGAAAGCCCCTTTGCAAACTGGATGCAGC ATGGAAGCAATAAATACTA GTATAGCATAGTTACTGAACTAAGCTCCTGATCTATG ATAGATCAGGAGCTTAGGG CGCAGACTCCGTGAAGGGCGGTGAATCCAGAGGCTGCA CTGCATCCAGTTTGCAAA GCTTTCCCTGGTTTCTGTTGCGATTCACCATCTCCAGAG CAGGAGAGTCTCAGGGACC GTGGGGTCCCTTCAAGGATACCAATTTAAATAGCTGC ACAATTCCAAGAACACGCT TCCCAGGCTGGACCACGCCTTCAGTGGCAGTGGATCT GAATGCTCTGACTTGCCCGG GTATCTGCAAATGAACAGCTCCCCCAGACTCCACCAGN GGGACAGATTTCACTCTC CAAGTGATGGTGACTCTGTCCTGAGAGCTGAGGACACGG CCTGCAC (SEQ ID  ACCATCAGCAGTCTGCATCCTACAGACGCAGACAGG CTGTGTATTACTGTGCGAG NO: 3311) ACCTGATGATTTTGCAACGNGG (SEQ ID NO:  AGATTTTGACGATAGTTCGT TTACTACTGTCAACAGA 3313)TCTGGGCGTTTGACTACTGG GTTACAGTACCCCTCCGG GGCCAGGGAACCCTGGTCACCACTTTTGGCCAGGGG CCGTCTCCTCAGCGTCGACC ACCAAGCTGGAGATCAAAAGGGCCCATCGGTCTTCC ACGTACGGTGGCTGCAC CCCTGGCACCCTCCTCCAACATCTGTCTTCATCTTCC GAGCACCTCTGGGGGCACA CGCCATCTGATGAGCAGGCGGCCCTGGGCTGCCTGG TTGAAATCTGGAACTGC TCAAGGACTACTTCCCCGACTCTGTTGTGTGCCTGCT ACCTGTGACGGTCTCGTGG GAATAACTTCTATCCCAGAACTCAGGCGCCCTGACCA AGAGGCCAAAGTACAGT GCGGCGTGCACACCTTCCCGGAAGGTGGATAACGCC GGCTGTCCTACAGTCCTCA CTCCAATCGGGTAACTCCGGACTCTACTCCCTCAGCA CAGGAGAGTGTCACAGA GCGTGGTGACCGTGCCCTCGCAGGACAGCAAGGACA CAGCAGCTTGGGCACCCAG GCACCTACAGCCTCAGCACCTACATCTGCAACGTGA AGCACCCTGACGCTGAG ATCACAAGCCCAGCAACACCAAAGCAGACTACGAGA CAANGTGGACAAGAGAGTT AACACAAAGTCTACGCCGAGCCCAAATCTTGTGACA TGCGAAGTCACCCATCA AAACTCACACATGCCCACCGGGCCTGAGCTCGCCCG GTGCCCAGCACCT (SEQ TCACAAAGAGCTTCAAC ID NO: 3310)AGGGGAGAGTGTTAGAA GCTTGGCCGCCATGGCC CAACTTGTTTATTGCAGC TTATAATGGTTACAAA(SEQ ID NO: 3312) COV21_P1 A-C019 TACACATACGATTTAGGTGGNCGCTGTNNNNNAGAGGT COV21_P1 TACACATACGATTTAGGT AGGGGGCCANCTTGGGCTGCOV21_P1 G8 ACACTATAGAATAACATCC GCTCTTGGAGGAGGGTGCC G8 GACACTATAGAATAACAACCTAGGACGGTCAGCTTGG G8 ACTTTGCCTTTCTCTCCACA AGGGGGAAGACCGATGGGCTCCACTTTGCCTTTCTCT TCCCTCCGCCGAATACCACA GGTGTCCACTCCCAGGTCCCCTTGGTGGAGGCTGAGGA CCACAGGTGTCCACTCCC TGATCACTACTACTATCCCAAACTGCACCTCGGTTCTATC GACGGTGACCAGGGTTCCC AGGTCCAACTGCACCTCCACCTGACAGTAATAGTCGG GATTGAATTCCACCATGGG TGGCCCCAGGGGTCGAACCGGTTCTATCGATTGAATT CCTCATCCCCGGCTTCGACC ATGGTCATGTATCATCCTTTCTGGGGTCCCCTCACGGGG CCACCATGGGATGGTCA CTGTTGATGGTCAGGGTGGCTTCTAGTAGCAACTGCAAC CACTCTAGCACAGTAATAC TGTATCATCCTTTTTCTACGTGTTCCCAGAGTTGGAGC CGGTGTACATTCCCAGGTG ACGGCCGTGTCCTCAGATCGTAGCAACTGCAACCGG CAGAGAATCGCTCAGGGAT CAGCTGGTGCAGTCTGGGGTCAGGCTGCTCAGCTCCAT TTCTGTGACCTCCTATGA CCCTGAGGGCCGGTCGCTATCTGAGGTGAAGAAGCCTGG GTAGACTGTGCTCGTGGAC GCTGACACAGCCACCCTCATAATAGATGACCAGCAC GGCCTCAGTGAAGGTTTCC GTGTCCCTGGTCATGGTGACAGTGTCAGTGGCCCCA AGGGGCCTGGCCTGGCTTCT TGCAAGGCATCTGGATACACTCTGCCCTGGAACTTCTGT GGAAAGACGGCCAGGAT GCTGGTACCAGTGCACACTTCCTTCACCAGTTACTATATG GCGTAGCTTGTGCTACCAC TACCTGTGGGGAAAACATTACTTCCAATGTTGTTTTCC CACTGGGTGCGACAGGCCC CACTAGGGTTGATTATTCCCACATTGGAAGTAAAAGT CCACAGGTAATCCTGGCCGT CTGGACAAGGGCTTGAGTGATCCACTCAAGCCCTTGTCC GTGCACTGGTACCAGCA CTTTCCTGGGGCCACTGACAGATGGGAATAATCAACCCT AGGGGCCTGTCGCACCCAG GAAGCCAGGCCAGGCCCCTGAGGGTGGCTGAGTCAG AGTGGTGGTAGCACAAGCT TGCATATAGTAACTGGTGACTGTGCTGGTCATCTATT CACAGACTGGGCCCAGGAA ACGCACAGAAGTTCCAGGGAGGTGTATCCAGATGCCTT ATGATAGCGACCGGCCC CCGGTTGCAGNNNNNTACTCAGAGTCACCATGACCAGG GCAGGAAACCTTCACTGAG TCAGGGATCCCTGAGCGAAAANNG (SEQ ID  GACACGTCCACGAGCACAG GCCCCAGGCTTCTTCACCTCATTCTCTGGCTCCAACTC NO: 3317) TCTACATGGAGCTGAGCAG AGCCCCAGACTGCACCAGCTGGGAACACGGCCACCC CCTGAGATCTGAGGACACG TGCACCTGNNA (SEQ IDTGACCATCAACAGGGTC GCCGTGTATTACTGTGCTAG NO: 3315) GAAGCCGGGGATGAGGCAGTGCCCCGTGAGGGGACC CGACTATTACTGTCAGGT CCAGGGTTCGACCCCTGGGGTGGGATAGTAGTAGTG GCCAGGGAACCCTGGTCAC ATCATGTGGTATTCGGCGCGTCTCCTCAGCGTCGACC GAGGGACCAAGCTGACC AAGGGCCCATCGGTCTTCCGTCCTAGGTCAGCCCAA CCCTGGCACCCTCCTCCAA GGCTGCCCCCTCGGTCACGAGCACCTCTGGGGGCACA TCTGTTCCCACCCTCGAG GCGGCCCTGGGCTGCCTGGTGAGGAGCTTCAAGCCA TCAAGGACTACTTCCCCGA ACAAGGCCACACTGGTGACCTGTGACGGTCTCGTGG TGTCTCATAAGTGACTTC AACTCAGGCGCCCTGACCATACCCGGGAGCCGTGAC GCGGCGTGCACACCTTCCC AGTGGCCTGGAAGGCAGGGCTGTCCTACAGTCCTCA ATAGCAGCCCCGTCAAG NGACTCTACTCCCTCAGCAGCGGGAGTGGAGACCAC GCGTGGTGACCGTGCCCTC CACACCCTCCAAACAAACAGCAGCTTGGGCACCCAG GCAACAACAAGTACGCG ACCTACATCTGCAACGTGAGCCAGCAGCTACCTGAG ATCACAAGCCCAGCAACAC CCTGACGCCTGAGCAGTC (SEQ ID NO: 3314) GGAAGTCCCACAGAAGC TACAGCTGCCAGGTCACGCATGAAAGGGAGCACC GTGGANAAGACAGTGGC CCCTACAGAATGTTCATA GAAGCTTGGCCGCCATGGCCCAACTTGTTTATTGC AGCTTATAATGG (SEQ ID NO: 3316) COV21_P3 A-C020TACACATACGATTTAGGTG GNCGCTGTNNNNNAGAGGT COV21_P3 TACACATACGATTTAGGTGGGGCCACCGGTGTACATTC COV21_P3 G5 ACACTATAGAATAACATCC GCTCTTGGAGGAGGGTGCCG5 GACACTTATAGAATAAC CCTCCCTGTCTGCATCTGTA G5 ACTTTGCCTTTCTCTCCACAAGGGGGAAGACCGATGGGC ATCCACTTTGCCTTTCTC GGAGACAGAGTCACCATCAGGTGTCCACTCCCAGGTCC CCTTGGTGGAGGCTGAGGA TCCACAGGTGTCCACTCCCTTGCCGGGCAAGTCAGAG AACTGCACCTCGGTTCTATC GACGGTGACCAGGGTTCCCCAGGTCCAACTGCACCT CATTAGCAGCTATTTAAATT GATTGAATTCCACCATGGGTGGCCCCAGTACCCCAATA CGGTTCTATCGATTGAAT GGTATCAGCAGAAACCAGGATGGTCATGTATCATCCTTT GGTAATAACCACTACTATC TCCACCATGGGANGGNCGAAAGCCCCTAAGCTCCTGA TTCTAGTAGCAACTGCAAC ATAGTAATACGTTTCCGATCATGTATCATCCTTTTTCT TCTATGCTGCATCCAGTTTG CGGTGTACATTCCCAGGTGCCTCGGTCTCGGCCCGATCT AGTAGCAACTGCAACCG CAAAGTGGGGTCCCATCAACAGCTGGTGCAGTCTGGGG CTAGCACAGTAATACACGG GTGTACATTCCCTCCCTGGGTTCAGTGGCAGTGGATCT CTGAGGTGAAGAAACCTGG CCGTGTCCTCAGATCTCAGTCTGCATCTGTAGGAGA GGGACAGATTTCACTCTCAC GGCCTCAGTGAAGGTTTCCGCTGCTCAGCTCCATGTAG CAGAGTCACCATCACTT CATCAGCAGTCTGCAACCTGTGCAAGGCATCTGGATACA ACTGTGCTCGTGGACGTGT GCCGGGCAAGTCAGAGCAAGATTTTGCAACTTACTAC CCTTCACCAGCTACTATATG CCCTGGTCATGGTGACTCTGATTAGCAGCTATTTAAAT TGTCAACAGAGTTACAGTAC CACTGGGTGCGACAGGCCCCCCTGGAACTTCTGTGCGTA TGGTATCAGCAGAAACC CCCACCGTCGTTCGGCCAAGCTGGACAAGGGCTTGAGTG GGTTGTGCTACCACCACTA AGGGAAAGCCCCTAAGCGGACCAAGGTGGAAATCAA GATGGGAATAATCAACCCT GGGTTGATTATTCCCATCCATCCTGATCTATGCTGCAT ACGGTGGAGGCACCAAGCT AGTGGTGGTAGCACAACCTCTCAAGCCCTTGTCCAGGG CCAGTTTGCAAAGTGGG GGAAATCAAACGTACGGGCACGCACAGAAGTTCCAGGG GCCTGTCGCACCCAGTGCA GTCCCATCAAGGTTCAGTA (SEQ ID NO: 3321) CAGAGTCACCATGACCAGG TATAGTAGCTGGTGAAGGTGGCAGTGGATCTGGGAC GACACGTCCACGAGCACAG GTATCCAGATGCCTTGCAGAGATTTCACTCTCACCAT TCTACATGGAGCTGAGCAG GAAACCTTCACTGAGGCCCCAGCAGTCTGCAACCTG CCTGAGATCTGAGGACACG CAGGTTTCTTCACCTCAGCCAAGATTTTGCAACTTACT GCCGTGTATTACTGTGCTAG CCAGACTGCACCAGCTGCAACTGTCAACAGAGTTAC AGATCGGGCCGAGACCGAG CCNNNGACANGACCCCAGTACCCCACCGTCGTTC GGATCGGAAACGTATTACT (SEQ ID NO: 3319)GGCCAAGGGACCAAGGT ATGATAGTAGTGGTTATTA GGAAATCAAACGGTGGACCTATTGGGGTACTGGGGC GGCACCAAGCTGGAAAT CAGGGAACCCTGGTCACCGCAAACGTACGGTGGCTG TCTCCTCAGCGTCGACCAA CACCATCTGTCTTCATCTGGGCCCATCGGTCTTCCCCC TCCCGCCATCTGATGAGC TGGCACCCTCCTCCAAGAGAGTTGAAATCTGGAACT CACCTCTGGGGGCACAGCG GCCTCTGTTGTGTGCCTGGCCCTGGGCTGCCTGGTCA CTGAATAACTTCTATCCC AGGACTACTTCCCCGAACCAGAGAGGCCAAAGTACA TGTGACGGTCTCGTGGAAC GTGGAAGGTGGATAACGTCAGGCGCCCTGACCAGCG CCCTCCAATCGGGTAACT GCGTGCACACCTTCCCGGCCCCAGGAGAGTGTCACA TGTCCTACAGTCCTCANGA GAGCAGGACAGCAAGGACTCTACTCCCTCAGCAGCGT CAGCACCTACAGCCTCA GGTGACCGTGCCCTCCAGCGCAGCACCCTGACGCTG AGCTTGGGCACCCAGACCT AGCAAAGCAGACTACGAACATCTGCAACGTGAATCA GAAACACAAAGTCTACG CAAGCCCAGCAACACCACCTGCGAAGTCACCCAT (SEQ ID NO: 3318) CAGGGCCTGAGCTCGCC CGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG AAGCTTGGCCGCCATGG CCCAACTTGTTTATTGCA GCTTATAATGGTTACAAATAAAGCAATAG (SEQ ID NO: 3320) COV21_P3 A-C021 TACACATACGATTTAGGTGGCTGTGNNNNNGAGGTGCT COV21_P3 TACACATACGATTTAGGT TNNCCGATTGGAGGGCGTTACOV21_P3 E7 ACACTATAGAATAACATCC CTTGGAGGAGGGTGCCAGG E7 GACACTATAGAATAACATCCACCTTCCACTGTACTTT E7 ACTTTGCCTTTCTCTCCACA GGGAAGACCGATGGGCCCTTCCACTTTGCCTTTCTCT GGCCTCTCTGGGATAGAAGT GGTGTCCACTCCCAGGTCCTGGTGGAGGCTGAGGAGAC CCACAGGTGTCCACTCCC TATTCAGCAGGCACACAACAACTGCACCTCGGTTCTATC GGTGACCAGGGTTCCCTGG AGGTCCAACTGCACCTCAGAGGCAGTTCCAGATTTCA GATTGAATTCCACCATGGG CCCCAGTAGTCAAAGGAACGGTTCTATCGATTGAATT ACTGCTCATCAGATGGCGGG ATGGTCATGTATCATCCTTTCACTACTATCATAGTATTGC CCACCATGGGATGGTCA AAGATGAAGACAGATGGTGTTCTAGTAGCAACTGCAAC CAAACTCTCGCACAGTAAT TGTATCATCCTTTTTCTACAGCCACAGTTCGTTTGATA CGGTGTACATTCCCAGGTG ACACGGCCGTGTCCGCGGCGTAGCAACTGCAACCGG TCCACTTTGGTCCCAGGGCC CAGCTGCAGGAGTCGGGCCAGTCACAGAGCTCAGCTTC TGTACATGGGGATATTGT GAAAGTGAATGGAGTTTGTCAGGACTGGTGAAGCCTTC AGGGAGAACTGGTTCTTAG GATGACTCAGTCTCCACTAGAGCTTGCATGCAGTAATA ACAGACCCTGTCCCTCACCT ACGTGTCTACTGATATGGTCTCCCTGCCCGTCACCCC AACCCCAACATCCTCAGCCT GCACTGTCTCTGGTGGCTCCAACTCGACTCTTGAGGGAC TGGAGAGCCGGCCTCCA CCACTCTGCTGATTTTCAGTATCAGCAGTGGTGGTTACT GGGTTGTAGTAGGTGCTCC TCTCCTGCAGGTCTAGTCGTAAAATCTGTGCCTGATCC ACTGGAGCTGGATCCGCCA CACTGTAATAGATGTACCCAGAGCCTCCTGCATAGT ACTGCCACTGAACCTGTCAG GCACCCAGGGAAGGGCCTGAATCCACTCCAGGCCCTTCC AATGGATACAACTATTT GGACCCCGGAGGCCCGATTGAGTGGATTGGGTACATCT CTGGGTGCTGGCGGATCCA GGATTGGTACCTGCAGAAGAACCCAAATAGATCAGG ATTACAGTGGGAGCACCTA GCTCCAGTAGTAACCACCAAGCCAGGGCAGTCTCCA AGCTGTGGAGACTGCCCTGG CTACAACCCGTCCCTCAAGCTGCTGATGGAGCCACCAG CAGCTCCTGATCTATTTG CTTCTGCAGGTACCAATCCAAGTCGAGTTACCATATCAG AGACAGTGCAGGTGAGGGA GGTTCTAATCGGGCCTCCAATAGTTGTATCCATTACTA TAGACACGTCTAAGAACCA CAGGGTCTGTGAAGGCTTCGGGGTCCCTGACAGGTT TGCAGGAGGCTCTGACTAG GTTCTCCCTGAAGCTGAGCTACCAGTCCTGGGCCCGACT CAGTGGCAGTGGATCAG ACCTGCAGGAGATGGAGGCCTGTGACTGCCGCGGACAC CCTGCAGCTGCACCT  GCACAGATTTTACACTGCGGCTCTCCAGGGGTGACG GGCCGTGTATTACTGTGCG (SEQ ID NO: 3323)AAAATCAGCAGAGTGGA GGCAGGGAGGATGGA (SEQ AGAGTTTGGCAATACTATGGGCTGAGGATGTTGGGG ID NO: 3325) ATAGTAGTGGTTCCTTTGAC TTTATTACTGCATGCAAGTACTGGGGCCAGGGAACCC CTCTACAAACTCCATTCA TGGTCACCGTCTCCTCAGCGCTTTCGGCCCTGGGACCA TCGACCAAGGGCCCATCGG AAGTGGATATCAAACGTTCTTCCCCCTGGCACCCTCC ACGGTGGCTGCACCATC TCCAAGAGCACCTCTGGGGTGTCTTCATCTTCCCGCC GCACAGCGGCCCTGGGCTG ATCTGATGAGCAGTTGACCTGGTCAAGGACTACTTC AATCTGGAACTGCCTCTG CCCGAACCTGTGACGGTCTTTGTGTGCCTGCTGAATA CGTGGAACTCANGCGCCCT ACTTCTATCCCAGAGAGGACCAGCGGCGTGCACACC GCCAAAGTACAGTGGAA TTCCCGGCTGTCCTACAGTCGGTGGATAACGCCCTCC CTCAGGACTCTACTCCCTCA AATCGGGTAACTCCCAGGCAGCGTGGTGACCGTGCC GAGAGTGTCACAGAGCA CTCCAGCAGCTTGGGCACCGGACAGCAAGGACAGCA CAGACCTACATCTGCAACG CCTACAGCCTCAGCAGCTGAATCACAAGCCCAGCAA ACCCTGACGCTGANCAA CACCAAGGTGGACAAGAGAAGCAGACTACGAGAAAC GTTGAGCCCAAATCTTGTG ACAAAGTCTACGCCTGCACAAAACTCACACATGCCC GAAGTCACCCATCNGGC ACCGTGCCCAGCACC  CTGAGCTCGCCCGTCAC(SEQ ID NO: 3322) AAAGANCTTCAACAGGG GANANTGTTANAAGCTT GGNCGCCATGGCCCAACTTGTTTATTGCAGCTTAT AATGG (SEQ ID NO:  3324) COV21_P2 A-C029TACACATACGATTTAGGTG GCTNNGCCCCAGAGGTGCT COV21_P2 TACACATACGATTTAGGTTTNCCCGATTGGAGGGCGTT COV21_P2 E6 ACACTATAGAATAACATCC CTTGGAGGAGGGTGCCAGGE6 GACACTATAGAATAACA ATCCACCTTCCACTGTACTT E6 ACTTTGCCTTTCTCTCCACAGGGAAGACCGATGGGCCCT TCCACTTTGCCTTTCTCT TGGCCTCTCTGGGATAGAAGGGTGTCCACTCCCAGGTCC TGGTGGAGGCTGAGGAGAC CCACAGGTGTCCACTCCCTTATTCAGCAGGCACACAAC AACTGCACCTCGGTTCTATC GGTGACCAGGGTTCCCTGGAGGTCCAACTGCACCTC AGAGGCAGTTCCAGATTTCA GATTGAATTCCACCATGGGCCCCAGTAGTCAAAGGAAC GGTTCTATCGATTGAATT ACTGCTCATCAGATGGCGGGATGGTCATGTATCATCCTTT CACTACTATCATAGTAATA CCACCATGGGATGGTCAAAGATGAAGACAGATGGTG TTCTAGTAGCAACTGCAAC CATTGTTCTCGCACAGTAATTGTATCATCCTTTTTCTA CAGCCACAGTTCGTTTGATC CGGTGTACATTCCCAGGTGACACGGCCGTGTCCGCGGC GTAGCAACTGCAACCGG TCCACCTTGGTCCCTCCGCCCAGCTGCAGGAGTCGGGCC AGTCACAGAGCTCAGCTTC TGTACATGGGGATATTGTGAAAGTGTGAGGAGTTTGT CAGGACTGGTGAAGCCTTC AGGGAGAACTGGTTCTTAGGATGACTCAGTCTCCACT AGAGCTTGCATGCAGTAATA ACAGACCCTGTCCCTCACCTACGTGTCTACTGATATGGT CTCCCTGCCCGTCACCCC AACCCCAACATCCTCAGCCTGCACTGTCTCTGGTGGCTCC AACTCGACTCTTGAGGGAC TGGAGAGCCGGCCTCCACCACTCTGCTGATTTTCAGT ATCAGCAGTGGTGGTTACT GGGTTGTAGTAGGTGCTCCTCTCCTGCAGGTCTAGTC GTAAAATCTGTGCCTGATCC ACTGGAGCTGGATCCGCCACACTGTAATAGATGTACCC AGAGCCTCCTGCATAGT ACTGCCACTGAACCTGTCAGGCACCCAGGGAAGGGCCTG AATCCACTCCAGGCCCTTCC AATGGATACAACTATTTGGACCCCGGAGGCCCGATT GAGTGGATTGGGTACATCT CTGGGTGCTGGCGGATCCAGGATTGGTACCTGCAGA AGAACCCAAATAGATCAGG ATTACAGTGGGAGCACCTAGCTCCAGTAGTAACCACCA AGCCAGGGCAGTCTCCA AGCTGTGGAGACTGCCCTGGCTACAACCCGTCCCTCAAG CTGCTGATGGAGCCACCAG CAGCTCCTGATCTATTTGCTTCTGCAGGTACCAATCCA AGTCGAGTTACCATATCAG AGACAGTGCAGGTGAGGGAGGTTCTAATCGGGCCTCC AATAGTTGTATCCATTACTA TAGACACGTCTAAGAACCACAGGGTCTGTGAAGGCTTC GGGGTCCCTGACAGGTT TGCAGGAGGCTCTGACTAGGTTCTCCCTGAAGCTGAGCT ACCAGTCCTGGGCCCGACT CAGTGGCAGTGGATCAGACCTGCAGGAGATGGAGGC CTGTGACTGCCGCGGACAC CCTGCAGCTTNNACC GCACAGATTTTACACTG CGGCTCTCCAGGGGTGACG GGCCGTGTATTACTGTGCG(SEQ ID NO: 3327) AAAATCAGCAGAGTGGA GGCAGGGAGANTGGAGNNTAGAACAATGTATTACTATG GGCTGAGGATGTTGGGG NNG (SEQ ID NO: ATAGTAGTGGTTCCTTTGAC TTTATTACTGCATGCAAG 3329) TACTGGGGCCAGGGAACCCCTCTACAAACTCCTCACA TGGTCACCGTCTCCTCAGCG CTTTCGGCGGAGGGACCTCGACCAAGGGCCCATCGG AAGGTGGAGATCAAACG TCTTCCCCCTGGCACCCTCCTACGGTGGCTGCACCAT TCCAAGAGCACCTCTGGGG CTGTCTTCATCTTCCCGCGCACAGCGGCCCTGGGCTG CATCTGATGAGCAGTTG CCTGGTCAAGGACTACTTCAAATCTGGAACTGCCTCT CCCGAACCTGTGACGGTCT GTTGTGTGCCTGCTGAATCGTGGAACTCAGGCGCCCT AACTTCTATCCCAGAGA GACCAGCGGCGTGCACACCGGCCAAAGTACAGTGGA TTCCCGGCTGTCCTACAGTC AGGTGGATAACGCCCTCCTCAGGACTCTACTCCCTCA CAATCGGGTAACTCCCA GCAGCGTGGTGACCGTGCCGGAGAGTGTCACAGAGC CTCCAGCAGCTTGGGCACC AGGACAGCAAGGACAGCCAGACCTACATCTGCAACG ACCTACAGCCTCAGCAG TGAATCACAAGCCCAGCAACACCCTGACGCTGANCA CACCAANGTGGACAAGAGA AAGCAGACTACGAGAAAGTTGAGCCCAAATCTTGTG CACAAAGTCTACGCCTG ACAAAACTCACACATGCCCCGAAGTCACCCATCNGG ACCGTGCCCAGCACC  NCTGAGCTCGCCCGTCA (SEQ ID NO: 3326)CAAAGAGCTTCAACNGG GGANAGTGTTAGAAGCT TGGCCGCCATGGCCCAA CTTGTTTATTGCAGCTTATAATGG (SEQ ID NO: 3328) COV21_P1 A-C022 TACACATACGATTTAGGTGGCTGTGCCCCAGAGGTGCT COV21_P1 TACACATACGATTTAGGT CTGGNNTTNCCCGATTGGAGCOV21_P1 B10 ACACTATAGAATAACATCC CTTGGAGGAGGGTGCCAGG B10GACACTATAGAATAACA GGCGTTATCCACCTTCCACT B10 ACTTTGCCTTTCTCTCCACAGGGAAGACCGATGGGCCCT TCCACTTTGCCTTTCTCT GTACTTTGGCCTCTCTGGGAGGTGTCCACTCCCAGGTCC TGGTGGAGGCTGAGGAGAC CCACAGGTGTCCACTCCCTAGAAGTTATTCAGCAGGCA AACTGCACCTCGGTTCTATC GGTGACCAGGGTGCCCTGGAGGTCCAACTGCACCTC CACAACAGAGGCAGTTCCA GATTGAATTCCACCATGGGCCCCAGTGCTGGAAGTATT GGTTCTATCGATTGAATT GATTTCAACTGCTCATCAGAATGGTCATGTATCATCCTTT CGATGAAATAATAACCACT CCACCATGGGATGGTCATGGCGGGAAGATGAAGACA TTCTAGTAGCAACTGCAAC TCTATCATAGTATGCTGCCGTGTATCATCCTTTTTCTA GATGGTGCAGCCACAGTTCG CGGTGTACATTCCCAGGTGCATGTCTCGCACAGTAATA GTAGCAACTGCAACCGG TTTGATCTCCAGCTTGGTCCCAGTTGCAGGAGTCGGGCC CACAGCCGTGTCTGCGGCG TGTACATTCTGACATCCACCTGGCCAAAAGTGTACCG CAGGACTGGTGAAGCCTTC GTCACAGAGCTCAGCTTCAGATGACCCAGTCTCCTTC GTAATTATTATACTGTTGGC GGAGACCCTGTCCGTCACTGGGAGAACTGGTTCTTGGA CACCCTGTCTGCATCTGT AGTAATAAGTTGCAAAATCTGCACTGTCTCTGGTGGCTC CGTGTCCACGGATATGGTG AGGAGACAGCGTCACCAATCAGGCTGCAGGCTGCTGA CATCAGCAGTAGTAGGTAC ACTCGACTCTTGAGGGACGTCACTTGCCGGGCCAGTC TGGTGAGAGTGAATTCTGTC TACTGGGGCTGGATCCGCCGGTTGTAGTAGGTGCTCCC AGAGTATTAGTAGCTGG CCAGATCCACTGCCGCTGAAAGCCCCCAGGGAAGGGGCT ACTATAATAGATACTCCCA TTGGCCTGGTATCAGCACCTTGATGGGACCCCACTTT GGAGTGGATTGGGAGTATC ATCCACTCCAGCCCCTTCCCGAAACCAGGGAAAGCCC CTAAACTAGACGCCTTATAG TATTATAGTGGGAGCACCTTGGGGGCTGGCGGATCCAG CTAAGCTCCTGATCTATA ATCAGGAGCTTAGGGGCTTTACTACAACCCGTCCCTCAA CCCCAGTAGTACCTACTACT AGGCGTCTAGTTTAGAACCCTGGTTTCTGCTGATACC GAGTCGAGTCACCATATCC GCTGATGGAGCCACCAGAGAGTGGGGTCCCATCAAG AGGCCAACCAGCTACTAAT GTGGACACGTCCAAGAACCACAGTGCAAGTGACGGACA GTTCAGCGGCAGTGGAT ACTCTGACTGGCCCGGCAAGAGTTCTCCCTGAAGCTGAG GGGTCTCCGAAGGCTTCAC CTGGGACAGAATTCACTTGATGGTGACGCTGTCTCCT CTCTGTGACCGCCGCAGAC CAGTCCTGGGCCCGACTCCCTCACCATCAGCAGCCT ACAGATGCAGACAGGG  ACGGCTGTGTATTACTGTGCNG (SEQ ID NO: 3331) GCAGCCTGATGATTTTGC (SEQ ID NO: 3333)GAGACATGCGGCAGCATAC AACTTATTACTGCCAACA TATGATAGAAGTGGTTATTGTATAATAATTACCGGT ATTTCATCGAATACTTCCAG ACACTTTTGGCCAGGGGCACTGGGGCCAGGGCACCC ACCAAGCTGGAGATCAA TGGTCACCGTCTCCTCAGCCACGTACGGTGGCTGCAC TCCACCAAGGGCCCATCGG CATCTGTCTTCATCTTCCTCTTCCCCCTGGCACCCTCC CGCCATCTGATGAGCAG TCCAAGAGCACCTCTGGGGTTGAAATCTGGAACTGC GCACAGCGGCCCTGGGCTG CTCTGTTGTGTGCCTGCTCCTGGTCAAGGACTACTTC GAATAACTTCTATCCCAG CCCGAACCTGTGACGGTCTAGAGGCCAAAGTACAGT CGTGGAACTCANGCGCCCT GGAAGGTGGATAACGCCGACCAGCGGCGTGCACACC CTCCAATCGGGTAACTCC TTCCCGGCTGTCCTACAGTCCAGGAGAGTGTCACAGA CTCAGGACTCTACTCCCTCA GCAGGACAGCAAGGACAGCAGCGTGGTGACCGTGCC GCACCTACAGCCTCAGC CTCCAGCAGCTTGGGCACCAGCACCCTGACGCTGAG CAGACCTACATCTGCAACG CAAAGCAGACTACGAGATGAATCACAAGCCCAGCAA AACACAAAGTCTACGCC CACCAANNGGACAAGAGATGCGAAGTCACCCATCA GTTGAGCCCAAATCTTGTG GGGCCTGAGCTCGCCCGAC (SEQ ID NO: 3330) TCACAAAGAGCTTCAAC NGGGGAGAGTGTTAGAAGCTTGGNCGCCATGGCC CAACTTGTTTATTGCAGC TTATAATGG (SEQ ID NO: 3332)COV21_P1 A-C027 TACACATACGATTTAGGTG GCTGNGCCCCAGAGGTGCT COV21_P1TACACATACGATTTAGGT CGATTGGAGGGCGTTATCCA COV21_P1 G4 ACACTATANAATAACATCCCTTGGAGGAGGGTGCCAGG G4 GACACTATAGAATAACA CCTTCCACTGTACTTTGGCC G4ACTTTGCCTTTCTCTCCACA GGGAAGACCGATGGGCCCT TCCACTTTGCCTTTCTCTTCTCTGGGATAGAAGTTATT GGTGTCCACTCCCAGGTCC TGGTGGAGGCTGAGGAGACCCACAGGTGTCCACTCCC CAGCAGGCACACAACAGAG AACTGCACCTCGGTTCTATCGGTGACCAGGGTTCCCTGG AGGTCCAACTGCACCTC GCAGTTCCAGATTTCAACTGGATTGAATTCCACCATGGG CCCCAGTAGTCAAAGTAGT GGTTCTATCGATTGAATTCTCATCAGATGGCGGGAAG ATGGTCATGTATCATCCTTT ATGAGTAGCAGTCTCCACCCCACCATGGGATGGTCA ATGAAGACAGATGGTGCAG TTCTAGTAGCAACTGCAACACTACAATAAATTCCACTT TGTATCATCCTTTTTCTA CCACAGTTCGTTTGATTTCCCGGTGTACATTCTGAGGTG GCTTTCGCACAGTAATACA GTAGCAACTGCAACCGGACCTTGGTCCCTTGGCCGAA CAGCTGGTGGAGTCTGGGG CAGCCGTGTCCTCAGCTCTCTGTACATTCTGACATCCA CGTCGAATAACTATTATACT GAGGCGTGGTCCAGCCTGGAGGCTGTTCATTTGCAGAT GATGACCCAGTCTCCTTC GTTGGCAGTAATAAGTTGCAGAGGTCCCTGAGACTCTCC ACAGCGTGTTCTTGGAATT CACCCTGTCTGCATCTGTAAATCATCAGGCTGCAGGCT TGTGCAGCCTCTGGATTCAC GTCTCTGGAGATGGTGAATAGGAGACAGAGTCACCA GCTGATGGTGAGAGTGAATT CTTCAGTAGCTATGGCATGCGGCCCTTCACGGAGTCTG TCACTTGCCGGGCCAGTC CTGTCCCAGATCCACTGCCGCACTGGGTCCGCCAGGCTC CATAGTATTTATTACTTCCA AGAGTATTAGTAGCTGGCTGAACCTTGATGGGACCCC CAGGCAAGGGGCTGGAGTG TCATATGATATAACTGCCATTGGCCTGGTATCAGCA ACTTTCTAAACTAGACGCCT GGTGGCAGTTATATCATATCCCACTCCAGCCCCTTGCCT GAAACCAGGGAAAGCCC TATAGATCAGGAGCTTAGGGATGGAAGTAATAAATACT GGAGCCTGGCGGACCCAGT CTAAGCTCCTGATCTATAGGCTTTCCCTGGTTTCTGCT ATGCAGACTCCGTGAAGGG GCATGCCATAGCTACTGAAAGGCGTCTAGTTTAGAA GATACCAGGCCAACCAGCT CCGATTCACCATCTCCAGAGGTGAATCCAGAGGCTGCA AGTGGGGTCCCATCAAG ACTAATACTCTGACTGGCCCGACAATTCCAAGAACACGC CAGGAGAGTCTCAGGGACC GTTCAGCGGCAGTGGATGGCAAGTGATGGTGACTCTG TGTATCTGCAAATGAACAG TCCCAGGCTGGACCACGCCCTGGGACAGAATTCACT TCTCCTACAGATGCAGACAG CCTGAGAGCTGAGGACACGTCCCCCAGACTCCACCAGC CTCACCATCAGCAGCCT GGNG (SEQ ID NO: GCTGTGTATTACTGTGCGA TGCA (SEQ ID NO:  GCAGCCTGATGATTTTGC 3337)AAGCAAGTGGAATTTATTG 3335) AACTTATTACTGCCAACA TAGTGGTGGAGACTGCTACGTATAATAGTTATTCGAC TCATACTACTTTGACTACTG GTTCGGCCAAGGGACCAGGGCCAGGGAACCCTGGTC AGGTGGAAATCAAACGT ACCGTCTCCTCAGCGTCGAACGGTGGCTGCACCATC CCAAGGGCCCATCGGTCTT TGTCTTCATCTTCCCGCCCCCCCTGGCACCCTCCTCCA ATCTGATGAGCAGTTGA AGAGCACCTCTGGGGGCACAATCTGGAACTGCCTCTG AGCGGCCCTGGGCTGCCTG TTGTGTGCCTGCTGAATAGTCAAGGACTACTTCCCCG ACTTCTATCCCAGAGAG AACCTGTGACGGTCTCGTGGCCAAAGTACAGTGGAA GAACTCANGCGCCCTGACC GGTGGATAACGCCCTCCAGCGGCGTGCACACCTTCC AATCGGGTAACTCCCAG CGGCTGTCCTACAGTCCTCAGAGAGTGTCACAGAGCA GNACTCTACTCCCTCAGCA GGACAGCAAGGACAGCAGCGTGGTGACCGTGCCCTC CCTACAGCCTCAGCAGC CAGCAGCTTGGGCACCCAGACCCTGACGCTGAGCAA ACCTACATCTGCAACGTGA AGCANACTACGAGAAACATCACAAGCCCAGCAACAC ACAAAGTCTACGCCTGC CAAGGTGGNANNAGAGAGTGAAGTCACCCATCNGGN TGAGCCCAAATCTTGTGAN CNTGANCTCGCCCGTCAAAAACTCACACATGCCC CAAAGAGCTTCAACAGG (SEQ ID NO: 3334) GGAGAGTGTTAGAAGCTTGGCCGCCATGGCCCAA CTTGTTTATTGCAGCTTA TAATGGNTACAAATAAA GCAATAGCATCA (SEQID NO: 3336) COV21_P2 A-C030 TACACATACGATTTAGGTG AGAGGTGCTCTTGGAGGAGCOV21_P2 TACACATACGATTTAGGT TTACCCGATTGGAGGGCGTT COV21_P2 B2ACACTATAGAATAACATCC GGTGCCAGGGGGAAGACCG B2 GACACTATAGAATAACAATCCACCTTCCACTGTACTT B2 ACTTTGCCTTTCTCTCCACA ATGGGCCCTTGGTGGAGGCTCCACTTTGCCTTTCTCT TGGCCTCTCTGGGATAGAAG GGTGTCCACTCCCAGGTCCTGAGGAGACGGTGACCAGG CCACAGGTGTCCACTCCC TTATTCAGCAGGCACACAACAACTGCACCTCGGTTCTATC GTTCCCTGGCCCCAGTAGTC AGGTCCAACTGCACCTCAGAGGCAGTTCCAGATTTCA GATTGAATTCCACCATGGG AAAGTAGTATGAGTAGCAGGGTTCTATCGATTGAATT ACTGCTCATCAGATGGCGGG ATGGTCATGTATCATCCTTTTTACCACCACTACAATATAT CCACCATGGGATGGTCA AAGATGAAGACAGATGGTGTTCTAGTAGCAACTGCAAC TCCACTTGCTTTCGCACAGT TGTATCATCCTTTTTCTACAGCCACAGTTCGTTTGATT CGGTGTACATTCTGAGGTG AATACACAGCCGTGTCCTCGTAGCAACTGCAACCGG TCCACCTTGGTCCCTTGGCC CAGCTGGTGGAGTCTGGGGAGCTCTCAGGCTGTTCATTT TGTACATTCTGACATCCA GAACGTCGAATAACTATTATGAGGCGTGGTCCAGCCTGG GCAGATACAGCGTGTTCTT GATGACCCAGTCTCCTTCACTGTTGGCAGTAATAAGTT GAGGTCCCTGAGACTCTCC GGAATTGTCTCTGGAGATGCACCCTGTCTGCATCTGT GCAAAATCATCAGGCTGCA TGTGCAGCCTCTGGATTCACGTGAATCGGCCCTTCACGG AGGAGACAGAGTCACCA GGCTGCTGATGGTGAGAGTCTTCAGTAGCTATGGCATG AGTCTGCATAGTATTTATTA TCACTTGCCGGGCCAGTCGAATTCTGTCCCAGATCCAC CACTGGGTCCGCCAGGCTC CTTCCATCATATGATATAACAGAGTATTAGTAGCTGG TGCCGCTGAACCTTGATGGG CAGGCAAGGGGCTGGAGTGTGCCACCCACTCCAGCCCCT TTGGCCTGGTATCAGCA ACCCCACTTTCTAAACTAGAGGTGGCAGTTATATCATAT TGCCTGGAGCCTGGCGGAC GAAACCAGGGAAAGCCCCGCCTTATAGATGAGGAGCT GATGGAAGTAATAAATACT CCAGTGCATGCCATAGCTACTAAGCTCCTCATCTATA TAGGGGCTTTCCCTGGTTTC ATGCAGACTCCGTGAAGGGCTGAAGGTGAATCCAGAGG AGGCGTCTAGTTTAGAA TGCTGATACCAGGCCAACCACCGATTCACCATCTCCAGA CTGCACAGGAGAGTCTCAG AGTGGGGTCCCATCAAGGCTACTAATACTCTGACTGG GACAATTCCAAGAACACGC GGACCTCCCAGGCTGGACCGTTCAGCGGCAGTGGAT CCCGGCAAGTGATGGTGACT TGTATCTGCAAATGAACAGACGCCTCCCCCAGACTCCA CTGGGACAGAATTCACT CTGTCTCCTACAGATGCAGACCTGAGAGCTGAGGACACG NNNNCTGCAC (SEQ ID CTCACCATCAGCAGCCTCAGGGAGACTGGAGNNNNG GCTGTGTATTACTGTGCGA NO: 3339) GCAGCCTGATGATTTTGCGGTCA (SEQ ID NO:  AAGCAAGTGGAATATATTG AACTTATTACTGCCAACA 3341)TAGTGGTGGTAACTGCTAC GTATAATAGTTATTCGAC TCATACTACTTTGACTACTGGTTCGGCCAAGGGACCA GGGCCAGGGAACCCTGGTC AGGTGGAAATCAAACGTACCGTCTCCTCAGCGTCGA ACGGTGGCTGCACCATC CCAAGGGCCCATCGGTCTTTGTCTTCATCTTCCCGCC CCCCCTGGCACCCTCCTCCA ATCTGATGAGCAGTTGAAGAGCACCTCTGGGGGCAC AATCTGGAACTGCCTCTG AGCGGCCCTGGGCTGCCTGTTGTGTGCCTGCTGAATA GTCAAGGACTACTTCCCCG ACTTCTATCCCAGAGAGAACCTGTGACGGTCTCGTG GCCAAAGTACAGTGGAA GAACTCANGCGCCCTGACCGGTGGATAACGCCCTCC AGCGGCGTGCACACCTTCC AATCGGGTAACTCCCAGCGGCTGTCCTACAGTCCTCN GAGAGTGTCACAGAGCA NNCTCTACTCCCTCAGCAGNGACAGCAAGGACAGCA CGTGGTGACCGTGCCCTCC CCTACAGCCTCAGCAGCAGCAGCTTGGGCACCCAGA ACCCTGACGCTGAGCAA CCTACATCTGCAACGTGAAAGCAGACTACGAGAAAC TCACAAGCCCAGCAACACC ACAAAGTCTACGCCTGCANNNGGACAAGANAGTTGA GAAGTCACCCATCNGNC GCCCAAATCTTGTGACAAACTGAGCTCGCCCGTCAC ACTCACACATGCCCACCG AAAGAGCTTCAACAGGG (SEQ ID NO: 3338)GANAGTGTTAGAAGCTT GGCCGCCATGGCCCAAC TTGTTTATTGCAGCTTAT AATGGTTACAAATAAAGCAATAGCATCAC (SEQ ID NO: 3340) COV21_P1 A-C031 TACACATACGATTTAGGTGCGCTGTGCCCCNGAGGTGC COV21_P1 TACACATACGATTTAGGT TACCCGATTGGAGGGCGTTACOV21_P1 A10 ACACTATAGAATAACATCC TCCTGGAGCAGGGCGCCAG A10GACACTATAGAATAACA TCCACCTTCCACTGTACTTT A10 ACTTTGCCTTTCTCTCCNCNGGGGAAGACCGATGGGCCC TCCACTTTGCCTTTCTCT GGCCTCTCTGGGATAGAAGTGGTGTCCACTCCCAGGTCC TTGGTGGAAGCTGAGGAGA CCACAGGTGTCCACTCCCTATTCAGCAGGCACACAAC AACTGCACCTCGGTTCTATC CAGTGACCAGGGTGCCACGAGGTCCAACTGCACCTC AGAGGCAGTTCCAGATTTCA GATTGAATTCCACCATGGGGCCCCAGAGATCGAAGTAC GGTTCTATCGATTGAATT ACTGCTCATCAGATGGCGGGATGGTCATGTATCATCCTTT CAGCCCGAATAACCACTAC CCACCATGGGATGGTCAAAGATGAAGACAGATGGTG TTCTAGTAGCAACTGCAAC TATCATACCCTACTCTTGCATGTATCATCCTTTTTCTA CAGCCACAGTTCGTTTGATC CGGTGTACATTCTGAGGTGCAGTAATACACAGCCGTGT GTAGCAACTGCAACCGG TCCACCTTGGTCCCTCCGCCCAGCTGGTGGAGTCTGGGG CCCCGGCTCTCAGGCTGTTC TGTACATTCTGACATCCAGAAAGTGAGCGGAGGGGTA GAGGCTTGGTACAGCCTGG ATTTGAAGATACAAGGAGTGATGACCCAGTCTCCATC CTGTAACTCTGTTGACAGTA GGGGTCCCTGAGACTCTCCTCTTGGCATTTTCTCTGGAG CTCCCTGTCTGCATCTGT GTAAGTTGCAAAATCTTCAGTGTGCAGCCTCTGGATTCAC ATGGTGAATCGGCCCTTCA AGGAGACAGAGTCACCAGTTGCAGACTGCTGATGGTG CTTCAGTAGCTACGACATG CGGAGCCTGGATAGTATGTTCACTTGCCGGGCAAGT AGAGTGAAATCTGTCCCAG CACTGGGTCCGCCAAGCTAGTCACCAGCAGTACCAATA CAGAGCATTAGCAGCTA ATCCACTGCCACTGAACCTTCAGGAAAAGGTCTGGAGTG GCTGAGACCCACTCCAGAC TTTAAATTGGTATCAGCAGATGGGACCCCACTTTGCAA GGTCTCAGCTATTGGTACTG CTTTTCCTGTAGCTTGGCGGGAAACCAGGGAAAGCCC ACTGGATGCAGCATAGATC CTGGTGACACATACTATCCACCCAGTGCATGTCGTAGC CTAAGGTCCTGATCTATG AGGACCTTAGGGGCTTTCCCAGGCTCCGTGAAGGGCCGA TACTGAAGGTGAATCCAGA CTGCATCCAGTTTGCAAATGGTTTCTGCTGATACCAAT TTCACCATCTCCAGAGAAA GGCTGCACAGGAGAGTCTCGTGGGGTCCCATCAAGG TTAAATAGCTGCTAATGCTC ATGCCAAGAACTCCTTGTAAGGGACCCCCCAGGCTGTA TTCAGTGGCAGTGGATCT TGACTTGCCCGGCAAGTGATTCTTCAAATGAACAGCCTG CCAAGCCTCCCCCAGACTC GGGACAGATTTCACTCTCGGTGACTCTGTCTCCTACAG AGAGCCGGGGACACGGCTG CACCAGCCTGCACCT ACCATCAGCAGTCTGCA ATGCAGACAGGGAG (SEQ TGTATTACTGTGCAAGAGT(SEQ ID NO: 3343) ACCTGAAGATTTTGCAA ID NO: 3345) AGGGTATGATAGTAGTGGTCTTACTACTGTCAACAGA TATTCGGGCTGGTACTTCGA GTTACAGTACCCCTCCGCTCTCTGGGGCCGTGGCACC TCACTTTCGGCGGAGGG CTGGTCACCGTCTCCTCAGCACCAAGGTGGAGATCAA GTCGACCAAGGGCCCATCG ACGTACGGTGGCTGCACGTCTTCCCCCTGGCACCCTC CATCTGTCTTCATCTTCC CTCCAAGAGCACCTCTGGGCGCCATCTGATGAGCAG GGCACAGCGGCCCTGGGCT TTGAAATCTGGAACTGCGCCTGGTCAAGGACTACTT CTCTGTTGTGTGCCTGCT CCCCGAACCTGTGACGGTCGAATAACTTCTATCCCAG TCGTGGAACTCANGCGCCC AGAGGCCAAAGTACAGTTGACCAGCGGCGTGCACAC GGAAGGTGGATAACGCC CTTCCCGGCTGTCCTACAGTCTCCAATCGGGTAACTCC CCTCAGGACTCTACTCCCTC CAGGAGAGTGTCACAGAAGCAGCGTGGTGACCGTGC GCANGACAGCAAGGACA CCTCCAGCAGCTTGGGCACGCACCTACAGCCTCAGC CCAGACCTACATCTGCAAC AGCACCCTGACGCTGAGGTGAATCACAAGCCCAGCA CAAAGCAGACTACGAGA CACC (SEQ ID NO: AACACAAAGTCTACGCC 3342) TGCGAAGTCACCCATCA GGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACN GGGGANANTGTTAGAAG CTTGGCCGCCATGGCCC AACTTGTTTATTGCAGCTTATNATGGNTACAAATA AAGCAATAGCA (SEQ  ID NO: 3344) COV21_P1 A-C042TACACATACGATTTAGGTG CGCTGTGCNNNNGAGGTGC COV21_P1 TACACATACGATTTAGGTANGGGGCNACCTTGGGCTG COV21_P1 F2 ACACTATAGAATAACATCC TCTTGGAGGAGGGTGCCAGF2 GACACTATAGAATAACA ACCTAGGACGGTCAGCTTGG F2 ACTTTGCCTTTCTCTCCACAGGGGAAGACCGATGGGCCC TCCACTTTGCCTTTCTCT TCCCTCCGCCGAATACCCCCGGTGTCCACTCCCAGGTCC TTGGTGGAGGCTGAGGAGA CCACAGGTGTCCACTCCCAGAGTGCTCCTGCTTGTATA AACTGCACCTCGGTTCTATC CGGTGACCAGGGTTCCCTGAGGTCCAACTGCACCTC TGAGCTGCAGTGATAGTCAG GATTGAATTCCACCATGGGGCCCCAGTAGTCAAACGGC GGTTCTATCGATTGAATT CCTCGTCCTCAGCCTGGAGCATGGTCATGTATCATCCTTT GAGACCGAGTCCGGGTCTA CCACCATGGGATGGTCACCAGAGATGGTCAGGGAGG TTCTAGTAGCAACTGCAAC TAGCATACACCACCCTGCCTGTATCATCCTTTTTCTA CCGTGTTGCCAGACTTGGAG CGGTGTACATTCTGAAGTGTTTTGCACAGTAATACAAG GTAGCAACTGCAACCGG CCAGAGAAGCGATTAGAAACAGCTGGTGGAGTCTGGGG GCCGTGTCCTCAGCTCTCAG TTCCTGGGCCCAGTCTGCCCCCTGAGGGCCGATTACTG GAGGCTTGGTACAGCCTGG ACTGTTCATTTGCAGATACACCTGACTCAGCCTGCCTC ACATCATAAATCATGAGTTT CAGGTCCCTGAGACTCTCCTGGGAGTTCTTGGCGTTGTCT CGTGTCTGGGTCTCCTGG GGGGGCTTTGCCTGGGTGTTGTGCAGCCTCTGGATTCAC CTGGAGATGGTGAATCGGC ACAGTCGATCACCATCTCGTTGGTACCAGGAGACAAA CTTTGATGATTATGCCATGC CCTTCACAGAGTCCGCATACTGCACTGGAACCAGCA GTTATAACCACCAACGCCAC ACTGGGTCCGGCAAGCTCCGCCTATGGTGCCACTATTCC GTGGCGTTGGTGGTTATA TGCTGGTTCCAGTGCAGGAGAGGGAAGGGCCTGGAGTGG AACTAGTGCCTGAGACCCA ACTTTGTCTCCTGGTACCATGGTGATCGACTGTCCAGG GTCTCAGGCACTAGTTGGA CTCCAGGCCCTTCCCTGGAAACAACACCCAGGCAAA AGACCCAGACACGGAGGCA ATAGTGGCACCATAGGCTAGCTTGCCGGACCCAGTGCA GCCCCCAAACTCATGATT GGCTGAGTCAGCACAGACTTGCGGACTCTGTGAAGGGC TGGCATAATCATCAAAGGT TATGATGTCAGTAATCGGGGACCAGGAACCGGTTGC CGATTCACCATCTCCAGAG GAATCCAGAGGCTGCACAGGCCCTCAGGGGTTTCTAA NNNTNNCCTACTAGAA  ACAACGCCAAGAACTCCCTGAGAGTCTCAGGGACCTGC TCGCTTCTCTGGCTCCAA (SEQ ID NO: 3349)GTATCTGCAAATGAACAGT CAGGCTGTACCAAGCCTCC GTCTGGCAACACGGCCTCTGAGAGCTGAGGACACGG CCCAGACTCCACCAGCCTG CCCTGACCATCTCTGGGCCCTTGTATTACTGTGCAAAA CACCTANNATG (SEQ ID TCCAGGCTGAGGACGAGGGCAGGGTGGTGTATGCTA NO: 3347) GCTGACTATCACTGCAG TAGACCCGGACTCGGTCTCCTCATATACAAGCAGGA GCCGTTTGACTACTGGGGC GCACTCTGGGGGTATTCCAGGGAACCCTGGTCACCG GGCGGAGGGACCAAGCT TCTCCTCAGCGTCGACCAAGACCGTCCTAGGTCAGC GGGCCCATCGGTCTTCCCCC CCAAGGCTGCCCCCTCGTGGCACCCTCCTCCAAGAG GTCACTCTGTTCCCACCC CACCTCTGGGGGCACAGCGTCGAGTGAGGAGCTTCA GCCCTGGGCTGCCTGGTCA AGCCAACAAGGCCACACAGGACTACTTCCCCGAACC TGGTGTGTCTCATAAGTG TGTGACGGTCTCGTGGAACACTTCTACCCGGGAGCC TCANGCGCCCTGACCAGCG GTGACAGTGGCCTGGAAGCGTGCACACCTTCCCGGC GGCAGATAGCAGCCCCG TGTCCTACAGTCCTCANGATCAAGGCGGGAGTGGAG CTCTACTCCCTCAGCAGCGT ACCACCACACCCTCCAAGGTGACCGTGCCCTCCAGC ACAAAGCAACAACAAGT AGCTTGGGCACCCAGACCTACGCGGCCAGCAGCTAC ACATCTGCAACGTGAATCA CTGAGCCTGACGCCTGACAAGCCCAGCAACACCAAN GCAGTGGAAGTCCCACA GTGGACAAGAGAGTTGAGCGAAGCTACAGCTGCCAG CCAAATCTTGTGACAAAAC GTCACGCATGAAGGGAGTCACACATGCCCACCG  CACCGTGGANAAGACAG (SEQ ID NO: 3346) TGGCCCTACAGAATGTTCATAGAAGCTTGGCCGCC ATGGNCCAACTTGTTTAT TGCAGCTTATAATGGTTA CNAATAAAGCA (SEQID NO: 3348) COV21_P1 A-C023 TACACATACGATTTAGGTG TGAGGAGACGGTGACCAGGCOV21_P1 TACACATACGATTTAGGT TGGGCTGACCCAGGACGGT COV21_P1 H8ACACTATAGAATAACATCC GTTCCCTGGCCCCAGGAGT H8 GACACTATAGAATAACACAGCTTGGTCCCTCCGCCGA H8 ACTTTGCCTTTCTCTCCACA CGAACCAACTATGCAAGCATCCACTTTGCCTTTCTCT ATACCACCCTCAGGCTGGTG GGTGTCCACTCCCAGGTCCGCTGATACTACTACAATGT CCACAGGTGTCCACTCCC TCATAGGACTGGCAGTAATAAACTGCACCTCGGTTCTATC CCCCGACCTCTTGCACAGT AGGTCCAACTGCACCTCATCAGCCTCATCCTCAGCCT GATTGAATTCCACCATGGG AATACACAGCCGTGTCCCCGGTTCTATCGATTGAATT GGAGCCCTGTGATGGCCAG ATGGTCATGTATCATCCTTTGGCTCTCAGGCTGTTCATTT CCACCATGGGATGGTCA GGAGGCTGAGGTGCCAGACTTCTAGTAGCAACTGCAAC GAAGAAACACGGAGTTCTT TGTATCATCCTTTTTCTATTGGAGCCAGAGAATCGGT CGGTGTACATTCTGAGGTG GGCATTTTCTCTGGAGATGGTAGCAACTGCAACCGG CAGGGACCCCTGAGGGCCG CAGCTGGTGGAGTCTGGGGGTGAATCGGCCCCTCACGG TTCCTGGGCCCAGTCTGT ATTGCTGTAACCATAGATGAGAGGCTTGGTACAGCCTGG AGCCTGGATAGTATGTGTC GCTGACGCAGCCGCCCTGGACTTTGGGGGCTGTTCCT GGGGTCCCTGAGACTCTCG ACCACCAGTACCAATTGCTCAGTGTCTGGGGCCCCA GGAAGTTTCTGGTACCAGTG TGTGCAGCCTCTGGATTCACGAGACCCACTCCAGACCTT GGGCAGAGGGTCACCAT TACATCAGAACCTGCCCCGACTTCAGTAACTACGACATTC CTCCTGTAGCTTGGCGGAC CTCCTGCACTGGGAGCATGTTGGAGCTGCTCCCAGTG ACTGGGTCCGCCAAGCTAC ACAGTGAATGTCGTAGTTAGCTCCAACATCGGGGCA CAGGAGATGGTGACCCTCTG AGGAGAAGGTCTGGAGTGGCTGAAGGTGAATCCAGAGG GGTTCTGATGTACACTGG CCCTGGGGCCCCAGACACTGGTCTCAGCAATTGGTACTG CTGCACACGAGAGTCTCAG TACCAGAAACTTCCAGGAGGGCGGCTGAGTCAGCAC GTGGTGACACATACTATCC GGACCCCCCAGGCTGTACCAACAGCCCCCAAAGTCC AGACTNGGCNCCNAGAANC AGGCTCCGTGAGGGGCCGAAAGCCTCCCCCAGACTCCA TCATCTATGGTTACAGCA GNNT (SEQ ID NO:TTCACCATCTCCAGAGAAA CCAGCTGCACCTANNATG ATCGGCCCTCAGGGGTC 3353)ATGCCAAGAACTCCGTGTT (SEQ ID NO: 3351) CCTGACCGATTCTCTGGCTCTTCAAATGAACAGCCTG TCCAAGTCTGGCACCTCA AGAGCCGGGGACACGGCTGGCCTCCCTGGCCATCACA TGTATTACTGTGCAAGAGG GGGCTCCAGGCTGAGGATCGGGGACATTGTAGTAGT TGAGGCTGATTATTACTG ATCAGCTGCTTGCATAGTTGCCAGTCCTATGACACCA GTTCGACTCCTGGGGCCAG GCCTGAGGGTGGTATTCGGAACCCTGGTCACCGTCT GGCGGAGGGACCAAGCT CCTCAGCGTCGACCAAGGGGACCGTCCTGGGTCAGC CCCATCGGTCTTCCCCCTGG CCAAGGCTGCCCCCTCGCACCCTCCTCCAAGAGCAC GTCACTCTGTTCCCGCCC CTCTGGGGGCACAGCGGCCTCGAGTGAGGAGCTTCA CTGGGCTGCCTGGTCAAGG AGCCAACAAGGCCACACACTACTTCCCCGAACCTGTG TGGTGTGTCTCATAAGTG ACGGTCTCGTGGAACTCAGACTTCTACCCGGGAGCC GCGCCCTGACCAGCGGCGT GTGACAGTGGCCTGGAAGCACACCTTCCCGGCTGTCC GGCAGATAGCAGCCCCG TACAGTCCTCANGACTCTATCAAGGCGGGAGTGGAG CTCCCTCAGCAGCGTGGTG ACCACCACACCCTCCAAACCGTGCCCTCCAGCAGCT ACAAAGCAACAACAAGT TGGGCACCCAGACCTACATACGCGGCCAGCAGCTAC CTGCAACGTGAATCACAAG CTGAGCCTGACGCCTGACCCAGCAACACCNAAGGTG GCAGTGGAAGTCCCACA GACNAGANAGTTGAGCCCAGAAGCTACAGCTGCCAG AATCTTGTGACAAAACTCA GTCACGCATGAAGGGAG CACATGCCCACCGT CACCGTGGAGAAGACAG (SEQ ID NO: 3350) TGGCCCCTACAGAATGTT CATAGAAGCTTGGCCGCCATGGCCCAACTTGTTTA TTGCAGCTTATAATGGTT ACAAA (SEQ ID NO: 3352) COV21_P1A-C024 TACACATACGATTTAGGTG CTGAGGAGACGGTGACCAG COV21_P1TACACATACGATTTAGGT TTGGGCTGACCCAGGACGGT COV21_P1 B2 ACACTATAGAATAACATCCGGTTCCCTGGCCCCAGGAG B2 GACACTATAGAATAACA CAGCTTGGTCCCTCCGCCGA B2ACTTTGCCTTTCTCTCCACA TCGAACCAGCTATGCAAGC TCCACTTTGCCTTTCTCTATACCACCCTCAGGCTGGTG GGTGTCCACTCCCAGGTCC AGCTGATACTACTACAATGCCACAGGTGTCCACTCCC TCATAGGACTGGCAGTAATA AACTGCACCTCGGTTCTATCTCCCCGACCTCTTGCACAGT AGGTCCAACTGCACCTC ATCAGCCTCATCCTCAGCCTGATTGAATTCCACCATGGG AATACACAGCCGTGTCCCC GGTTCTATCGATTGAATTGGAGCCCTGTGATGGCCAG ATGGTCATGTATCATCCTTT GGCTCTCAGGCTGTTCATTTCCACCATGGGATGGTCA GGAGGCTGAGGTGCCAGAC TTCTAGTAGCAACTGCAACGAAGAAACACGGAGTTCTT TGTATCATCCTTTTTCTA TTGGAGCCAGAGAATCGGTCGGTGTACATTCTGAGGTG GGCATTTTCTCTGGAGATG GTAGCAACTGCAACCGGCAGGGACCCCTGAGGGCCG CAGCTGGTGGAGTCTGGGG GTGAATCGGCCCTTCACGGTTCCTGGGCCCAGTCTGT ATTGCTGTAGCCATAGATGA GAGGCTTGGTACAGCCTGGAGCCTGGATAGTATGTGTC GCTGACGCAGCCGCCCT GGACTTTGGGGGCTATTCCTGGGGTCCCTGAGACTCTCG ACCAGCAGTACCAATTGCT CAGTGTCTGGGGCCCCAGGAAGTTTCTGGTACCAGTG TGTGCAGCCTCTGGATTCAC GAGACCCACTCCAGACCTTGGGCAGAGGGTCACCAT TACATCAGAACCTGCCCCGA CTTCAGTAACTACGACATGCTCCTGTAACTTGGCGGAC CTCCTGCACTGGGAGCA TGTTGGAGCTGCTCCCAGTGCACTGGGTCCGCCAAGTTA CCAGTGCATGTCGTAGTTA GCTCCAACATCGGGGCACAGGAGATGGTGACCCTCTG CAGGAGAAGGTCTGGAGTG CTGAAGGTGAATCCAGAGGGGTTCTGATGTACACTGG CCCTGGGGCCCCAGACACTG GGTCTCAGCAATTGGTACTCTGCACACGAGAGTCTCAG TACCAGAAACTTCCAGG AGGGCGGCTGAGTCAGCACGCTGGTGACACATACTATC GGACCCCCCAGGCTGTACC AATAGCCCCCAAAGTCCAGACTGGGACCNGGAACCG CAGGCTCCGTGAAGGGCCG AAGCCTCCCCCAGACTCCATCATCTATGGCTACAGCA GNN (SEQ ID NO:  ATTCACCATCTCCAGAGAACCAGCTGCACNNNACACTG ATCGGCCCTCAGGGGTC 3357) AATGCCAAGAACTCCGTGTNNACACC (SEQ ID  CCTGACCGATTCTCTGGC TTCTTCAAATGAACAGCCT NO: 3355)TCCAAGTCTGGCACCTCA GAGAGCCGGGGACACGGCT GCCTCCCTGGCCATCACAGTGTATTACTGTGCAAGAG GGGCTCCAGGCTGAGGA GTCGGGGACATTGTAGTAGTGAGGCTGATTATTACTG TATCAGCTGCTTGCATAGCT CCAGTCCTATGACACCAGGTTCGACTCCTGGGGCCA GCCTGAGGGTGGTATTC GGGAACCCTGGTCACCGTCGGCGGAGGGACCAAGCT TCCTCAGCGTCGACCAAGG GACCGTCCTGGGTCAGCGCCCATCGGTCTTCCCCCTG CCAAGGCTGCCCCCTCG GCACCCTCCTCCAAGAGCAGTCACTCTGTTCCCACCC CCTCTGGGGGCACAGCGGC TCGAGTGAGGAGCTTCACCTGGGCTGCCTGGTCAAG AGCCAACAAGGCCACAC GACTACTTCCCCGAACCTGTTGGTGTGTCTCATAAGTG GACGGTCTCGTGGAACTCA ACTTCTACCCGGGAGCCGGCGCCCTGACCAGCGGCG GTGACAGTGGCCTGGAA TGCACACCTTCCCGGCTGTCGGCAGATAGCAGCCCCG CTACAGTCCTCAGGACTCT TCAAGGCGGGAGTGGAGACTCCCTCAGCAGCGTGGT ACCACCACACCCTCCAA GACCGTGCCCTCCAGCAGCACAAAGCAACAACAAGT TTGGGCACCCAGACCTACA ACGCGGCCAGCAGCTACTCTGCAACGTGAATCACAA CTGAGCCTGACGCCTGA GCCCAGCAACACCAANGTGGCAGTGGAAGTCCCACA GACAAGAGAGTTGAGCCCA GAAGCTACAGCTGCCAGAATCTTGTGACAAAACTCA GTCACGCATGAAGGGAG CACATGCCCACCGTGCCCCACCGTGGAGAAGACAG (SEQ ID NO: 3354) TGGCCCCTACAGAATGTT CATAGAAGCTTGGCCGCCATGGCCCAACTTGTTTA TTGCAGCTTATAATGGTT ACAAATAAAGCAA (SEQ ID NO: 3356)COV21_P1 A-C025 TACACATACGATTTAGGTG GGTGACCAGGGTTNCCTGG COV21_P1TACACATACGATTTAGGT CTTGGGCTGACCCAGGACG COV21_P1 A12 ACACTATAGAATAACATCCCCCCAGGAGTCGAACCAGC A12 GACACTATAGAATAACA GTCAGCTTGGTCCCTCCGCC A12ACTTTGCCTTTCTCTCCACA TATGCAAGCAGCTGATACT TCCACTTTGCCTTTCTCTGAATACCACCCTCAGGCTGG GGTGTCCACTCCCAGGTCC ACTACAATGTCCCCGACCTCCACAGGTGTCCACTCCC TGTCATAGGACTGGCAGTAA AACTGCACCTCGGTTCTATCCTTGCACAGTAATACACAG AGGTCCAACTGCACCTC TAATCAGCCTCATCCTCAGCGATTGAATTCCACCATGGG CCGTGTCCCCGGCTCTCAG GGTTCTATCGATTGAATTCTGGAGCCCTGTGATGGCCA ATGGTCATGTATCATCCTTT GCTGTTCATTTGAAGAAACCCACCATGGGATGGTCA GGGAGGCTGAGGTGCCAGA TTCTAGTAGCAACTGCAACACGGAGTTCTTGGCATTTTC TGTATCATCCTTTTTCTA CTTGGAGCCAGAGAATCGGCGGTGTACATTCTGAGGTG TCTGGAGATGGTGAATCGG GTAGCAACTGCAACCGGTCAGGGACCCCCGAGGGCC CAGCTGGTGGAGTCTGGGG CCCTTCACGGAGCCTGGATTTCCTGGGCCCAGTCTGT GATTGCTGTAACCATAGATG GAGGCTTGGTACAGCCTGGAGTATGTGTCACCAGCAGT GCTGACGCAGCCGCCCT AGGACTTTGGGGGCTGTTCCGGGGTCCCTGAGACTCTCG ACCAATTGCTGAGACCCAC CAGTGTCTGGGGCCCCATGGAAGTTTCTGGTACCAGT TGTGCAGCCTCTGGATTCAC TCCAGACCTTCTCCTGTAGCGGGCAGAGGGTCACCAT GTACATCAGAACCTGCCCCG CTTCAGTAACTACGACATGTTGGCGGACCCAGTGCATG CTCCTGCACTGGGAGTA ATGTTGGAGCTACTCCCAGTCACTGGGTCCGCCAAGCTA TCGTAGTTACTGAAGGTGA GCTCCAACATCGGGGCAGCAGGAGATGGTGACCCTCT CAGGAGAAGGTCTGGAGTG ATCCAGAGGCTGCACACGAGGTTCTGATGTACACTGG GCCCTGGGGCCCCAGACACT GGTCTCAGCAATTGGTACTGAGTCTCAGGGACCCCCCA TACCAGAAACTTCCAGG GAGGGCGGCTGAGTCAGCAGCTGGTGACACATACTATC GGCTGTACCAAGCCTCCCC AACAGCCCCCAAAGTCCCAGACTGGGNCCAGGAACC CAGGCTCCGTGAAGGGCCG CAGACTCCACCANCTGCACTCATCTATGGTTACAGCA GGNN (SEQ ID NO:  ATTCACCATCTCCAGAGAACTANNATG (SEQ ID  ATCGGCCCTCGGGGGTC 3361) AATGCCAAGAACTCCGTGT NO: 3359)CCTGACCGATTCTCTGGC TTCTTCAAATGAACAGCCT TCCAAGTCTGGCACCTCAGAGAGCCGGGGACACGGCT GCCTCCCTGGCCATCACA GTGTATTACTGTGCAAGAGGGGCTCCAGGCTGAGGA GTCGGGGACATTGTAGTAG TGAGGCTGATTATTACTGTATCAGCTGCTTGCATAGCT CCAGTCCTATGACACCA GGTTCGACTCCTGGGGCCAGCCTGAGGGTGGTATTC GGGAACCCTGGTCACCGTC GGCGGAGGGACCAAGCTTCCTCAGCGTCGACCAAGG GACCGTCCTGGGTCAGC GCCCATCGGTCTTCCCCCTGCCAAGGCTGCCCCCTCG GCACCCTCCTCCAAGAGCA GTCACTCTGTTCCCACCCCCTCTGGGGGCACAGCGGC TCGAGTGAGGAGCTTCA CCTGGGCTGCCTGGTCAAGAGCCAACAAGGCCACAC GACTACTTCCCCGAACCTGT TGGTGTGTCTCATAAGTGGACGGTCTCGTGGAACTCA ACTTCTACCCGGGAGCC GGCGCCCTGACCAGCGGCGGTGACAGTGGCCTGGAA TGCACACCTTCCCGGCTGTC GGCAGATAGCAGCCCCGCTACAGTCCTCAGGACTCT TCAAGGCGGGAGTGGAG ACTCCCTCAGCAGCGTGGTACCACCACACCCTCCAA GACCGTGCCCTCCAGCAGC ACAAAGCAACAACAAGTTTGGGCACCCAGACCTACA ACGCGGCCAGCAGCTAC TCTGCAACGTGAATCACAACTGAGCCTGACGCCTGA GCCCAGCAACACCAANGTG NCAGTGGAAGTCCCACAGACAAGAGAGTTGAGCCCA GAAGCTACAGCTGCCAG AATCTTGTGACAAAACTCAGTCACGCATGAAGGGAG CACATGCCCACCGTGCCC CACCGTGGAGAAGACAG (SEQ ID NO: 3358)TGGCCCCTACAGAATGTT CATAGAAGCTTGGCCGC CATGGCCCAACTTGTTTATTGCAGCTTATAATGGTT ACAAATAAAGCAAT (SEQ ID NO: 3360) COV21_P1 A-C026TACACATACGATTTAGGTG CTGAGGAGANGGTGACCAG COV21_P1 TACACATACGATTTAGGTTTGGGCTGACCCAGGACGGT COV21_P1 D11 ACACTATAGAATAACATCCGGTTCCCTGGCCCCAGGAG D11 GACACTATAGAATAACA CAGCTTGGTCCCTCCGCCGA D11ACTTTGCCTTTCTCTCCACA TCGAACCAGCTATGCAAGC TCCACTTTGCCTTTCTCTATACCACCCTCAAACTGGTG GGTGTCCACTCCCAGGTCC AGCTGATACTACTACAATGCCACAGGTGTCCACTCCC TCATAGGACTGGCAGTAATA AACTGCACCTCGGTTCTATCTCCCCGACCTCTTGCACAGT AGGTCCAACTGCACCTC ATCAGCCTCATCCTCAGCCTGATTGAATTCCACCATGGG AATACACCGCCGTGTCCCC GGTTCTATCGATTGAATTGGAGCCCTGTGATGGCCAG ATGGTCATGTATCATCCTTT GGCTCTCAGGCTGTTCATTTCCACCATGGGATGGTCA GGAGGCTGAGGTGCCAGAC TTCTAGTAGCAACTGCAACGAAGAAACACGGAGTTCTT TGTATCATCCTTTTTCTA TTGGAGCCAGAGAATCGGTCGGTGTACATTCTGAGGTG GGCATTTTCTCTGGAGATG GTAGCAACTGCAACCGGCAGGGACCCCTGAGGGCCG CAGCTGGTGGAGTCTGGGG GTGAATCGGCCCTTCACGGTTCCTGGGCCCAGTCTGT ATTGTTGTAACCATAGATGA GAGGCTTGGTACAGCCTGGAGCCTGGATAGTATGTGTC GCTGACGCAGCCGCCCT GGACTTTGGGGGCTGTTCCTGGGGTCCCTGAGACTCTCG ACCAGCAGTACCAATTGCT CAGTGTCTGGGGCCCCAGGAAGTTTCTGGTACCAGTG TGTGCAGCCTCTGGATTCAC GAGACCCACTCCAGACCTTGGGCAGAGGGTCACCAT TACATCAGAACCTGCCCCGA CTTCAGTAACTACGACATACTCCTGTAGCCTGGCGGAC CTCCTGCACTGGGAGCA TGTTGGAGCTGCTCCCAGTGCACTGGGTCCGCCAGGCTA CCAGTGTATGTCGTAGTTAC GCTCCAACATCGGGGCACAGGAGATGGTGACCCTCTG CAGGAGAAGGTCTGGAGTG TGAAGGTGAATCCAGAGGCGGTTCTGATGTACACTGG CCCTGGGGCCCCAGACACTG GGTCTCAGCAATTGGTACTTGCACACGAGAGTCTCAGG TACCAGAAACTTCCAGG AGGGCGGCTGAGTCAGCACGCTGGTGACACATACTATC GACCCCCCAGGCTGTACCA AACAGCCCCCAAAGTCCAGACTGGGNNNNGGAACCG CAGGCTCCGTGAAGGGCCG AGCCTCCCCCAGACTCCACTCATCTATGGTTACAACA GNTGNNNNTG (SEQ ID  ATTCACCATCTCCAGAGAACAGCTGCACCTANNATG ATCGGCCCTCAGGGGTC NO: 3365) AATGCCAAGAACTCCGTGT(SEQ ID NO: 3363) CCTGACCGATTCTCTGGC TTCTTCAAATGAACAGCCTTCCAAGTCTGGCACCTCA GAGAGCCGGGGACACGGCG GCCTCCCTGGCCATCACAGTGTATTACTGTGCAAGAG GGGCTCCAGGCTGAGGA GTCGGGGACATTGTAGTAGTGAGGCTGATTATTACTG TATCAGCTGCTTGCATAGCT CCAGTCCTATGACACCAGGTTCGACTCCTGGGGCCA GTTTGAGGGTGGTATTCG GGGAACCCTGGTCACCGTCGCGGAGGGACCAAGCTG TCCTCAGCGTCGACCAAGG ACCGTCCTGGGTCAGCCGCCCATCGGTCTTCCCCCTG CAAGGCTGCCCCCTCGG GCACCCTCCTCCAAGAGCATCACTCTGTTCCCGCCCT CCTCTGGGGGCACAGCGGC CGAGTGAGGAGCTTCAACCTGGGCTGCCTGGTCAAG GCCAACAAGGCCACACT GACTACTTCCCCGAACCTGTGGTGTGTCTCATAAGTG GACGGTCTCGTGGAACTCA ACTTCTACCCGGGAGCCNGCGCCCTGACCAGCGGCG GTGACAGTGGCCTGGAA TGCACACCTTCCCGGCTGTCGGCAGATAGCAGCCCCG CTACAGTCCTCANGACTCT TCAAGGCGGGAGTGGAGACTCCCTCAGCAGCGTGGT ACCACCACACCCTCCAA GACCGTGCCCTCCAGCAGCACAAAGCAACAACAAGT TTGGGCACCCAGACCTACA ACGCGGCCAGCAGCTACTCTGCAACGTGAATCACAA CTGAGCCTGACGCCTGA GCCCAGCAACACCAAGGTGGCAGTGGAAGTCCCACA GACAGANAGTTGAGCCCAA GAAGCTACAGCTGCCAGATCTTGTGACAAAACTCAC GTCACGCATGAAGGGAG ACATGCCCACCGTGCCCCACCGTGGAGAAGACAG (SEQ ID NO: 3362) TGGCCCCTACAGAATGTT CATAGAAGCTTGGCCGCCATGGCCCAACTTGTTTA TTGCAGCTTATAATGGTT ACAAATAAAGCAAT (SEQ ID NO: 3364)COV57_P1 A-C032 TACACATACGATTTAGGTG GNNGCTGTGCCCCAGAGGT COV57_P1TACACATACGATTTAGGT CTTGGGCTGACCTAGGACGG COV57_P1 F6 ACACTATAGAATAACATCCGCTCTTGGAGGAGGGTGCC F6 GACACTATAGAATAACA TGACCTTGGTCCCAGTTCCG F6ACTTTGCCTTTCTCTCCACA AGGGGGAAGACCGATGGGC TCCACTTTGCCTTTCTCTAAGACATAAAGGGCACTCA GGTGTCCACTCCCAGGTCC CCTTGGTGGAGGCTGAGGACCACAGGTGTCCACTCCC GGCTGCTGTCATAGGACTGG AACTGCACCTCGGTTCTATCGACAGTGACCAGGGTGCCA AGGTCCAACTGCACCTC CAGTAATAATCAGCCTCATCGATTGAATTCCACCATGGG CGGCCCCAGAGATCGAAGT GGTTCTATCGATTGAATTCTCAGCCTGGAGCCCAGTGA ATGGTCATGTATCATCCTTT ACCAGTCCACTGCTACCCCTCCACCATGGGATGGTCA TGGCCAGGGAGGCTGAGGT TTCTAGTAGCAACTGCAACCTCGCACAGTAATACATGG TGTATCATCCTTTTTCTA GCCAGACTTGGAGCCAGAGCGGTGTACATTCCGAGGTG CGGTGTCCGAGGCCTTCAG GTAGCAACTGCAACCGGAATCGGTCAGGGACCCCTG CAGCTGGTGCAGTCTGGAG GCTGCTCCACTGCAGGTAGTTCCTGGGCCCAGTCTGT AGGGCCGATTGCTGTTACCA CAGAGGTGAAAAAGCCCGGGCGGTGCTGATGGACTTGT GCTGACTCAGCCGCCCTC TAGATGAGGAGTTTGGGGGGGAGTCTCTGAAGATCTCC CGGCTGAGATGGTGACCTG AGTGTCTGGGGCCCCAGCTGTTCCTGGAAGCTGCTGG TGTAAGGGTTCTGGATACA GCCTTGGAAGGACGGGCTGGGCAGAGGGTCACCATC TACCAGTGTACATCATAACC GCTTTACCAGCTACTGGATCTATCTGGTATCAGAGTCAC TCCTGCACTGGGAGCAG TGCCCCGATGTTGGAGCTGCGGCTGGGTGCGCCAGATGC CAGGATAGATGATCCCCAT CTCCAACATCGGGGCAGTCCCAGTGCAGGAGATGGT CCGGGAAAGGCCTGGAGTG CCACTCCAGGCCTTTCCCGGGTTATGATGTACACTGGT GACCCTCTGCCCTGGGGCCC GATGGGGATCATCTATCCTGCATCTGGCGCACCCAGCC ACCAGCAGCTTCCAGGA CAGACACTGAGGGCGGCTGGGTGACTCTGATACCAGAT GATCCAGTAGCTGGTAAAG ACAGCCCCCAAACTCCTAGTCAGCACAGACTGGGAC ACAGCCCGTCCTTCCAAGG CTGTATCCAGAACCCTTACCATCTATGGTAACAGCA CAGGAACCGGNTG (SEQ CCAGGTCACCATCTCAGCCAGGAGATCTTCAGAGACTC ATCGGCCCTCAGGGGTC ID NO: 3369) GACAAGTCCATCAGCACCGCCCGGGCTTTTTCACCTCTG CCTGACCGATTCTCTGGC CCTACCTGCAGTGGAGCAGCTCCAGACTGCACCAGCTG TCCAAGTCTGGCACCTCA CCTGAAGGCCTCGGACACCCAC (SEQ ID NO:  GCCTCCCTGGCCATCACT GCCATGTATTACTGTGCGA 3367)GGGCTCCAGGCTGAGGA GAGGGGTAGCAGTGGACTG TGAGGCTGATTATTACTGGTACTTCGATCTCTGGGGCC CCAGTCCTATGACAGCA GTGGCACCCTGGTCACCGTGCCTGAGTGCCCTTTATG CTCCTCAGCGTCGACCAAG TCTTCGGAACTGGGACCGGCCCATCGGTCTTCCCCCT AAGGTCACCGTCCTAGG GGCACCCTCCTCCAAGAGCTCAGCCCAAGGCCAACC ACCTCTGGGGGCACAGCGG CCACTGTCACTCTGTTCCCCCTGGGCTGCCTGGTCAA CACCCTCGAGTGAGGAG GGACTACTTCCCCGAACCTCTTCAAGCCAACAAGGC GTGACGGTCTCGTGGAACT CACACTGGTGTGTCTCATCAGGCGCCCTGACCAGCGG AAGTGACTTCTACCCGG CGTGCACACCTTCCCGGCTGAGCCGTGACAGTGGCC GTCCTACAGTCCTCAGGAC TGGAAGGCAGATAGCAGTCTACTCCCTCAGCAGCGTG CCCCGTCAAGGCGGGAG GTGACCGTGCCCTCCAGCATGGAGACCACCACACCC GCTTNNCACCCAGACCTAC TCCAAACAAAGCAACAAATCTGCAACGTGAATCACA CAAGTACGCGGCCAGCA AGCCCAGCAACACCAAGGTGCTACCTGAGCCTGACG GGACAAGAGAGTTGAGCCC CCTGAGCAGTGGAAGTCAAATCTTGTGACAAAACTC CCACAGAAGCTACAGCT ACACATGCCCACCGTGCCCGCCAGGTCACGCATGAA AGCACC (SEQ ID NO:  GGGAGCACCGTGGAGAA 3366)GACAGTGGCCCCTACAG AATGTTCATAGAAGCTT GGCCGCCATGGCCCAAC TTGTTTATTGCAGCTTATAAT (SEQ ID NO:  3368) COV57_P2 A-C033 TACACATACGATTTAGGTGAGAGGTGCTCTTGGAGGAG COV57_P2 TACACATACGATTTAGGT TACCGATTGGAGGGCGTTATCOV57_P2 F10 ACACTATAGAATAACATCC GGTGCCAGGGGGAAGACCG F10GACACTATAGAATAACA CCACCTTCCACTGTACTTTG F10 ACTTTGCCTTTCTCTCCACAATGGGCCCTTGGTGGAGGC TCCACTTTGCCTTTCTCT GCCTCTCTGGGATAGAAGTTGGTGTCCACTCCCAGGTCC TGAGGAGACGCTGACCGTG CCACAGGTGTCCACTCCCATTCAGCAGGCACACAACA AACTGCACCTCGGTTCTATC GTCCCTTTGCCCCAGACGTCAGGTCCAACTGCACCTC GAGGCAGTTCCAGATTTCAA GATTGAATTCCACCATGGGCATGTAGTAGTAGTAGTGA GGTTCTATCGATTGAATT CTGCTCATCAGATGGCGGGAATGGTCATGTATCATCCTTT GACCAATCTTTTGCAGATTG CCACCATGGGATGGTCAAGATGAAGACAGATGGTGC TTCTAGTAGCAACTGCAAC TACTACTACCTCTCTCGCACTGTATCATCCTTTTTCTA AGCCACAGTTCGTTTAATCT CGGTGTACATTCCCAGGTGAGTAATAGACGGCCGTGTC GTAGCAACTGCAACCGG CCAGTCGAGTCCCTTGGCCGCAGCTGCAGGAGTCGGGCC CGCAGCGGTCACAGACCTC TGTACATTCAGAAATTGTAAGGTGACGAACCAGCTGC CAGGACTAGTGAAGCCTTC ACCTTCAGGGAGAACTGATGTTGACACAGTCTCCAG TACGCTGCTGACAGTAATAA GGAGACCCTGTCCCTCACCTCTTCGACGTGTCTAGTGAT CCACCCTGTCTTTGTCTC ACTGCAAAATCTTCAGGGTCTGCACTGTCTCTGGTGCCTC ATGGTGACTCGACTCCTGA CAGGGGAAAGAGCCTCCTAGGCTGCTGATGGTGAGA CATCAATAGTTACTACTGG GGGCGGGGTTGTAGTTGGTCTCTCCTGCAGGGCCAGT GTGAAGTCTGTCCCAGACCC ACCTGGATCCGGCAGCCCCGTTCCCACTGTCATGGATAT CAGAGTGTTGGTACCTA ACTGCCACTGAACCTGGCTGCAGGGAAGGGACTGGAATG ATCCAATCCATTCCAGTCCC CTTAGCCTGGTACCAACGGATGCCAGTGGCCCTGTTG GATTGGATATATCCATGAC TTCCCTGGGGGCTGCCGGAAGAAAGTTGGCCAGCCT GACGCATCATAGATGAGGA AGTGGGAACACCAACTACATCCAGGTCCAGTAGTAACT CCCAGGCTCCTCATCTAT GCCTGGGAGGCTGGCCAACACCCCGCCCTCAGGAGTCG ATTGATGGAGGCACCAGAG GATGCGTCCAACAGGGCTTTCTGTTGGTACCAGGCTA AGTCACCATATCACTAGAC ACAGTGCAGGTGAGGGACACACTGGCATCCCAGCCA AGTAGGTACCAACACTCTGA ACGTCGAAGAATCAGTTCTGGGTCTCCGAAGGCTTCAC GGTTCAGTGGCAGTGGG CTGGCCCTGCAGGAGAGGGCCCTGAAGGTGAGGTCTGT TAGTCCTGGGCCCGACTCC TCTGGGACAGACTTCACTAGGCTCTTTCCCCTGGAGAC GACCGCTGCGGACACGGCC NGCAGCCTGCACCT CTCACCATCAGCAGCCT AAAGACAGGG (SEQ ID  GTCTATTACTGTGCGAGAG(SEQ ID NO: 3371) AGACCCTGAAGATTTTG NO: 3373) AGGTAGTAGTACAATCTGCCAGTTTATTACTGTCAGC AAAAGATTGGTCTCACTAC AGCGTAGCAGCTGGTTCTACTACTACATGGACGTCT GTCACCTTCGGCCAAGG GGGGCAAAGGGACCACGGTGACACGACTGGAGATTA CACCGTCTCCTCAGCGTCG AACGTACGGTGGCTGCAACCAAGGGCCCATCGGTCT CCATCTGTCTTCATCTTC TCCCCCTGGCACCCTCCTCCCCGCCATCTGATGAGCA AAGAGCACCTCTGGGGGCA GTTGAAATCTGGAACTGCAGCGGCCCTGGGCTGCCT CCTCTGTTGTGTGCCTGC GGTCAAGGACTACTTCCCCTGAATAACTTCTATCCCA GAACCTGTGACGGTCTCGT GAGAGGCCAAAGTACAGGGAACTCAGGCGCCCTGAC TGGAAGGTGGATAACGC CAGCGGCGTGCACACCTTCCCTCCAATCGGGTAACTC CCGGCTGTCCTACAGTCCTC CCAGGAGAGTGTCACAGAGGACTCTACTCCCTCAGC AGCAGGACAGCAAGGAC AGCGTGGTGACCGTGCCCTAGCACCTACAGCCTCAG CCAGCAGCTTGGGCACCCA CAGCACCCTGACGCTGAGACCTACATCTGCAACGTG GCAAAGCAGACTACGAG AATCACAAGCCCAGCAACAAAACACAAAGTCTACGC CCAAGGTGGACAAGAGAGT CTGCGAAGTCACCCATCTGAGCCCAAATCTTGTGAC ANGGCCTGAGCTCGCCC AAAACTCACACATGCCCAGTCACAAAGAGCTTCAA (SEQ ID NO: 3370) CAGGGGAGAGTGNNNNA AANCTTGGCCGCCATGGCCCAACTTGTTTATTGCA GCTTATAATGGTTACAA ATAAA (SEQ ID  NO: 3372) COV57_P1A-C036 TACACATACGATTTAGGTG GCTGTGCCNNGAGGTGCTC COV57_P1TACACATACGATTTAGGT TACCCGATTGGAGGGCGTTA COV57_P1 D12 ACACTATAGAATAACATCCTTGGAGGAGGGTGCCAGGG D12 GACACTATAGAATAACA TCCACCTTCCACTGTACTTT D12ACTTTGCCTTTCTCTCCACA GGAAGACCGATGGGCCCTT TCCACTTTGCCTTTCTCTGGCCTCTCTGGGATAGAAGT GGTGTCCACTCCCAGGTCC GGTGGAGGCTGAGGAGACGCCACAGGTGTCCACTCCC TATTCAGCAGGCACACAAC AACTGCACCTCGGTTCTATCGTGACCAGGGTTCCCTGGC AGGTCCAACTGCACCTC AGAGGCAGTTCCAGATTTCAGATTGAATTCCACCATGGG CCCAGTAGTCGATAGACGA GGTTCTATCGATTGAATTACTGCTCATCAGATGGCGGG ATGGTCATGTATCATCCTTT AGGACGAGAGAAGGACCTCCCACCATGGGATGGTCA AAGATGAAGACAGATGGTG TTCTAGTAGCAACTGCAACCTTCTGGCACAGTAATACA TGTATCATCCTTTTTCTA CAGCCACAGTTCGTTTAATCCGGTGTACATTCCCAGGTG CAGCCGTGTCCGCGGCGGT GTAGCAACTGCAACCGGTCCAGTCGTGTCCCTTGGCC CAGCTACAGCAGTGGGGCG CACAGACCTCAGGCTCAGGTGTACATGGGGATATTGT GAAGGTGAGAGTTTGTAGA CAGGACTGTTGAAGCCTTCGAGAACTGGTTCTTGGACG GATGACTCAGTCTCCACT GCTTGCATGCAGTAATAAACGGAGACCCTGTCCCGCACC TGTCTACTGAGATGGTGAC CTCCCTGCCCGTCACCCCCCCAACATCCTCAGCCTCCA TGCGCTGTCTTTGGTGGGTC TCGACTCTTGAGGGACGGGTGGAGAGCCGGCCTCCA CTCTGCTGATTTTCAGTGTG CTTCACTAATTACTACTGGATTGTAGTTGGTGATTCCACT TCTCCTGCAGGTCTAGTC AAATCTGTGCCTGATCCACTGTTGGATCCGCCAGTCCCC ATCATTGATTTCCCCAATCC AGAGCCTCCTGCATAGAGCCCCTGAACCTGTCAGGGA AGGGAAGGGGCTGGAGTGG ACTCCAGCCCCTTCCCTGGGAATGGATACAACTATTT CCCCGGAGGCCCGATTGGA ATTGGGGAAATCAATGATAGACTGGCGGATCCAACTCC GGATTGGTACCTGCAGA ACCCAAATAGATCAGGAGCGTGGAATCACCAACTACAA AGTAGTAATTAGTGAAGGA AGCCAGGGCAGTCTCCATGTGGAGACTGCCCTGGCTT CCCGTCCCTCAAGAGTCGA CCCACCAAAGACAGCGCAGCAGCTCCTGATCTATTTG CTGCAGGTACCAATCCAAAT GTCACCATCTCAGTAGACAGTGCGGGACAGGGTCTCCG GGTTCCAATCGGGCCTCC AGTTGTATCCATTTCTATGCCGTCCAAGAACCAGTTCTC AAGGCTTCAACAGTCCTGC GGGGTCCCTGACAGGTTAGGAGGCTCTGACTAGACCT CCTGAGCCTGAGGTCTGTG GCCCCACTGCTGTAGCTGCCAGGGGCAGTGGATCAG GCAGGAGATGGAGGCCGGC ACCGCCGCGGACACGGCTGAC (SEQ ID NO: 3375) GCACAGATTTCACACTG TCTCCAGGGGTGACGGGGCTGTATTACTGTGCCAGAAG AAAATCAGCAGAGTGGA AGGGAG (SEQ ID NO: GAGGTCCTTCTCTCGTCCTT GGCTGAGGATGTTGGGG 3377) CGTCTATCGACTACTGGGGTTTATTACTGCATGCAAG CCAGGGAACCCTGGTCACC CTCTACAAACTCTCACCTGTCTCCTCAGCGTCGACCA TCGGCCAAGGGACACGA AGGGCCCATCGGTCTTCCCCTGGAGATTAAACGTAC CCTGGCACCCTCCTCCAAG GGTGGCTGCACCATCTGTAGCACCTCTGGGGGCACAG CTTCATCTTCCCGCCATC CGGCCCTGGGCTGCCTGGTTGATGAGCAGTTGAAAT CAAGGACTACTTCCCCGAA CTGGAACTGCCTCTGTTGCCTGTGACGGTCTCGTGGA TGTGCCTGCTGAATAACT ACTCAGGCGCCCTGACCAGTCTATCCCAGAGAGGCC CGGCGTGCACACCTTCCCG AAAGTACAGTGGAAGGTGCTGTCCTACAGTCCTCAG GGATAACGCCCTCCAAT GACTCTACTCCCTCAGCAGCGGGTAACTCCCAGGAG CGTGGTGACCGTGCCCTCC AGTGTCACAGAGCAGGAAGCAGCTTGGGGCACCCAG CAGCAAGGACAGCACCT ACCTACATCTGCAACGTGAACAGCCTCAGCAGCACC ATCACAAGCCCAGCAACAC CTGACGCTGAGCAAAGCCAAGGTGGACAAGAGAGTT AGACTACGAGAAACACA GAGCCCAAATCTTGTGACAAAGTCTACGCCTGCGAA AAACTCACACATGCCCACC GTCACCCATCAGGGCCTGTGCCCAGCACCTGAAC GAGCTCGCCCGTCACAA (SEQ ID NO: 3374) AGAGCTTCAACANGGGNANAGTGTTAGAAGCTTG GCCGCCATGGCCCAACT TGTTTATT (SEQ ID  NO: 3376) COV57_P2A-C037 TACACATACGATTTAGGTG CGCTGTGCCCCNGAGGTGC COV57_P2TACACATACGATTTAGGT ATTGGAGGGCGTTATCCACC COV57_P2 H6 ACACTATAGAATAACATCCTCCTGGAGCAGGGCGCCAG H6 GACACTATAGAATAACA TTCCACTGTACTTTGGCCTC H6ACTTTGCCTTTCTCTCCACA GGGGAAGACCGATGGGCCC TCCACTTTGCCTTTCTCTTCTGGGATAGNNCNTAANN GGTGTCCACTCCCAGGTCC TTGGTGGAAGCTGAAGAGACCACAGGTGTCCACTCCC CAGCAGGCACACAACAGAG AACTGCACCTCGGTTCTATCCGGTGACCATTGTCCCTTGG AGGTCCAACTGCACCTC GCAGTTCCAGATTTCAACTGGATTGAATTCCACCATGGG CCCCAGATATCAAAAGCAT GGTTCTATCGATTGAATTCTCATCAGATGGCGGGAAG ATGGTCATGTATCATCCTTT CATTGCAGCTACCACCACTCCACCATGGGATGGTCA ATGAAGACAGATGGTGCAG TTCTAGTAGCAACTGCAACACAATATGGGGCCGCACAG TGTATCATCCTTTTTCTA CCACAGTTCGTTTGATTTCCCGGTGTACATTCCCAGGTG TAATACACGGCCGTGTCCT GTAGCAACTGCAACCGGACCTTGGTCCCTTGGCCGAA CAGCTGGTGCAGTCTGGGC CGGATCTCAGGCTGCTCAGTGTACATTCAGAAATTGT CGTCCACGGTGAGCTACCAT CTGAGGTGAAGAAGCCTGGCTCCATGTAGGCTGTGCTTG GTTGACGCAGTCTCCAG ACTGCTGACAGTAATACACTGACCTCAGTGAAGGTCTCC TGGACATGTCCCTGGTAAT GCACCCTGTCTTTGTCTCGCAAAATCTTCAGGCTCCAG TGCAAGGCTTCTGGATTCA GGTGACTCTTTCCTGGAACTCAGGGGAAAGAGCCACC TCTGCTGATGGTGAGAGTGA CCTTTACTAGCTCTGCTATGTCTGTGCGTAGTTTGTGTTA CTCTCCTGCAGGGCCAGT AGTCTGTCCCAGACCCACTGCAGTGGGTGCGACAGGCTC CCACTGCCAACGACGATCC CAGAGTGTTAGCAGCAGCCACTGAACCTGTCTGGGAT GTGGACAACGCCTTGAGTG ATCCTATCCACTCAAGGCGCTACTTAGCCTGGTACCA GCCAGTGGCCCTGCTGGATG GATAGGATGGATCGTCGTTTTGTCCACGAGCCTGTCGC GCAGAAACCTGGCCAGG CACCATAGATGAGGAGCCTGGCAGTGGTAACACAAACT ACCCACTGCATAGCAGAGC CTCCCAGGCTCCTCATCTGGGAGCCTGGCCAGGTTTCT ACGCACAGAAGTTCCAGGA TAGTAAAGGTGAATCCAGAATGGTGCATCCAGCAGG GCTGGTACCAGGCTAAGTA AAGAGTCACCATTACCAGGAGCCTTGCAGGAGACCTTC GCCACTGGCATCCCAGA GCTGCTGCTAACACTCTGACGACATGTCCACAAGCACAG ACTGAGGTCCCAGGCTTCTT CAGGTTCAGTGGCAGTGTGGCCCTGCAGGAGAGGGT CCTACATGGAGCTGAGCAG CACCTCAGGCCCAGACTGCGGTCTGGGACAGACTTC GGCTCTTTCCCCTGGAGACA CCTGAGATCCGAGGACACGNC (SEQ ID NO:  ACTCTCACCATCAGCAG AAGACAGGGNGANTGNAGAGCCGTGTATTACTGTGCGG 3379) ACTGGAGCCTGAAGATT NTGGGTC (SEQ ID NO:CCCCATATTGTAGTGGTGGT TTGCAGTGTATTACTGTC 3381) AGCTGCAATGATGCTTTTGAGCAGTATGGTAGCTCA ATATCTGGGGCCAAGGGAC CCGTGGACGTTCGGCCAAATGGTCACCGTCTCTTCAG AGGGACCAAGGTGGAAA CGTCGACCAAGGGCCCATCTCAAACGTACGGTGGCT GGTCTTCCCCCTGGCACCCT GCACCATCTGTCTTCATCCCTCCAAGAGCACCTCTGG TTCCCGCCATCTGATGAG GGGCACAGCGGCCCTGGGCCAGTTGAAATCTGGAAC TGCCTGGTCAAGGACTACT TGCCTCTGTTGTGTGCCTTCCCCGAACCTGTGACGGT GCTGAATAACTTCTATCC CTCGTGGAACTCAGGCGCCCAGAGAGGCCAAAGTAC CTGACCAGCGGCGTGCACA AGTGGAAGGTGGATAACCCTTCCCGGCTGTCCTACAG GCCCTCCAATCGGGTAA TCCTCAGGACTCTACTCCCTCTCCCAGGAGAGTGTCA CAGCAGCGTGGTGACCGTG CAGAGCAGGACAGCAAGCCCTCCAGCAGCTTGGGCA GACAGCACCTACAGCCT CCCAGACCTACATCTGCAACAGCAGCACCCTGACGC CGTGAATCACAAGCCCAGC TGAGCAAAGCAGACTACAACACCNAAGGTGGACAAG GAGAAACACAAAGTCTA AGAGTTGAGCCCAAATCTTCGCCTGCGAAGTCACCC GTGACAAAACTCACACATG ATCANGGCCTGAGCTCGCCCACCGTGCC (SEQ  CCCGTCACAAAGAGCTT ID NO: 3378) CAACAGGGGAGAGTGTTAGAAGCTTGGCCGCCAT GGCCCAACTTGTTTATTG CAGCTTATAATGGTTACA AA (SEQ ID NO: 3380) COV57_P1 A-C038 TACACATACGATTTAGGTG CTGTGCTCTCGGANGTGCTC COV57_P1TACACATACGATTTAGGT TGGGCTGGCTTAGGACGGTC COV57_P1 E9 ACACTATAGAATAACATCCCTGGAGCAGGGCGCCAGGG E9 GACACTATAGAATAACA AGCTTGGTCCCTCCGCCGAA E9ACTTTGCCTTTCTCTCCACA GGAAGACCGATGGGCCCTT TCCACTTTGCCTTTCTCTCACCCAACGACTGTTGATAT GGTGTCCACTCCCAGGTCC GGTGGAGGCTGAGGAGACGCCACAGGTGTCCACTCCC CATAAGACTGACAGTAGTA AACTGCACCTCGGTTCTATCGTGACCAGGGTTCCCTGGC AGGTCCAACTGCACCTC GTCAGCCTCGTCCTCAGTCTGATTGAATTCCACCATGGG CCCAGGAGTCAGGATAGCA GGTTCTATCGATTGAATTTCAGTCCAGAGATGGTGAG ATGGTCATGTATCATCCTTT TACACCATTAGTGCAATAACCACCATGGGATGGTCA GGAGGCAGAATTGGAGGAG TTCTAGTAGCAACTGCAACCCCATCGGACTTTTCGCACA TGTATCATCCTTTTTCTA CTGTCGATGGAGCCAGAGACGGTGTACATTCTGAGGTG GTAATAGACAGCCGTGTCC GTAGCAACTGCAACCGGACCGATCAGGGACCCCAGA CAGCTGGTGGAGTCTGGGG TCAGCTCTCAGGCTGTTCATTTCTTGGGCCAATTTTAT GGGTCTTTGGGTATCTTCAT GAGGCGTGGTCCAGCCTGGCTGTAGATACAGCGTGTTCT GCTGACTCAGCCCCACTC AGATCACAGTGGTGGGGGCGAGGTCCCTGAGACTCTCC TGGAATTGTCTCTGGAGAT TGTGTCGGAGTCTCCGGACTGCCCGGGCGCTGCTGGT TGTGCAGCCTCTGGATTCAC GGCGAACCGGCCCTTCACGGGAAGACGGTTACCATC ACCACTGCACATAGTTGCTG CTTCAATAGAATTGCCATGTGACTCTGCATAGTATTCATA TCCTGCACCGGCAGCAG GCAATGCTGCCACTGCTGCCACTGGGTCCGCCAGGCTCC ACTTCCATCAAATGATATA TGGCAGCATTGCCAGCAGGTGCAGGAGATGGTAACC AGGCAAGGGGCTGGAATGG ACTGCCACCCATTCCAGCCACTATGTGCAGTGGTAC GTCTTCCCCGGAGACTCCGA GTGGCAGTTATATCATTTGACCTTGCCTGGAGCCTGGCG CAGCAGCGCCCGGGCAG CACAGAGTGGGGCTGAGTCTGGAAGTTATGAATACTAT GACCCAGTACATGGCAATT TGCCCCCACCACTGTGATAGCACAGACTGGGACCAGG GCAGAGTCCGTGAAGGGCC CTATTGAAGGTGAATCCAGCTATGAAGATACCCAAA AACCGGNTG (SEQ ID  GGTTCGCCATCTCCAGAGAAGGCTGCACAGGAGAGTCT GACCCTCTGGGGTCCCTG NO: 3385) CAATTCCAAGAACACGCTGCAGGGACCTCCCAGGCTGG ATCGGTTCTCTGGCTCCA TATCTACAGATGAACAGCCACCACGCCTCCCCCAGACT TCGACAGCTCCTCCAATT TGAGAGCTGAGGACACGGCCCACCANNCTGCAC  CTGCCTCCCTCACCATCT TGTCTATTACTGTGCGAAA (SEQ ID NO: 3383)CTGGACTGAAGACTGAG AGTCCGATGGGTTATTGCA GACGAGGCTGACTACTACTAATGGTGTATGCTATCCT CTGTCAGTCTTATGATAT GACTCCTGGGGCCAGGGAACAACAGTCGTTGGGTGTT CCCTGGTCACCGTCTCCTCA CGGCGGAGGGACCAAGCGCGTCGACCAAGGGCCCAT TGACCGTCCTAAGCCAG CGGTCTTCCCCCTGGCACCCCCCAAGGCTGCCCCCTC TCCTCCAAGAGCACCTCTG GGTCACTCTGTTCCCACCGGGGCACAGCGGCCCTGGG CTCGAGTGAGGAGCTTC CTGCCTGGTCAAGGACTACAAGCCAACAAGGCCACA TTCCCCGAACCTGTGACGG CTGGTGTGTCTCATAAGTTCTCGTGGAACTCAGGCGC GACTTCTACCCGGGAGC CCTGACCAGCGGCGTGCACCGTGACAGTGGCCTGGA ACCTTCCCGGCTGTCCTACA AGGCAGATAGCAGCCCCGTCCTCAGGACTCTACTCCC GTCAAGGCGGGAGTGGA TCAGCAGCGTGGTGACCGTGACCACCACACCCTCCA GCCCTCCAGCAGCTTGGGC AACAAAGCAACAACAAGACCCAGACCTACATCTGCA TACGCGGCCAGCAGCTA ACGTGAATCACAAGCCCAGCCTGAGCCTGACGCCTG CAACACCNANGTGGACAAG AGCAGTGGAAGTCCCACAGAGTTGAGCCCAAATCTT AGAAGCTACAGCTGCCA GTGACAAAACTCACACATGGGTCACGCATGAAGGGA CCCACCGTGCCCA  GCACCGTGGAGAAGACA (SEQ ID NO: 3382)GTGGCCCCTACAGAATG TTCATAGAAGCTTGGGC CGCCATGGCCCAACTTGTTTATTGCAGCTTATAATG G (SEQ ID NO: 3384) COV57_P1 A-C039TACACATACGATTTAGGTG CGCTGTGNNNNNGAGGTGC COV57_P1 TACACATACGATTTAGGTTTGGGCTGACCTAGGACGGT COV57_P1 F10 ACACTATAGAATAACATCCTCTTGGAGGAGGGTGCCAG F10 GACACTATAGAATAACA CAGCTTGGTCCCTCCGCCAA F10ACTTTGCCTTTCTCTCCACA GGGGAAGACCGATGGGCCC TCCACTTTGCCTTTCTCTACACCCTCGAACCACTCAGG GGTGTCCACTCCCAGGTCC TTGGTGGAGGCTGAGGAGACCACAGGTGTCCACTCCC CTGCTGTCATAGGACTGGCA AACTGCACCTCGGTTCTATCCGGTGACCAGGGTTCCCTG AGGTCCAACTGCACCTC GTAATAATCAGCCTCATCCTGATTGAATTCCACCATGGG GCCCCAGTAGTCAAAAAGG GGTTCTATCGATTGAATTCAGCCTGGAGCCCAGTGAT ATGGTCATGTATCATCCTTT GGATCCGTTCCTGAACCATCCACCATGGGATGGTCA GGCCAGGGAGGCTGAGGTG TTCTAGTAGCAACTGCAACAGGTAATAACCACTCCAAA TGTATCATCCTTTTTCTA CCAGACTTGGAGCCAGAGACGGTGTACATTCCCAGGTG ACCAGCTCTCGCACAGTAA GTAGCAACTGCAACCGGATCGGTCAGGGACCCCTGA CAGCTACAGCAGTGGGGCG TACACAGCCGTGTCCGCGGTTCCTGGGCCCAGTCTGT GGGCCGATTGCTGTTACCAT CAGGACTGTTGAAGCCTTCCGGTCACAGAGCTCAGCTT GCTGACTCAGCCGCCCTC AGATGAGGAGTTTGGGGGCGGAGACCCTGTCCCTCACC CAGGGAGAACTGGTTCTTG AGTGTCTGGGGCCCCAGTGTTCCTGGAAGCTGCTGGT TGCGCTGTCTATGGTGGGTC GACGTGTCTACTGATATGGGGCAGAGGGTCACCATC ACCAGTGTACATCATAACCT CTTCAGTGGTTACTACTGGATGACTCGACTCTTGAGGGA TCCTGCACTGGGAGCAA GCCCCGATGTTGGAGTTGCTGCTGGATCCGCCAGCCCCC CGGGTTGTAGTTGGTGCTTC CTCCAACATCGGGGCAGCCCAGTGCAGGAGATGGTG AGGGAAGGGGCTGGAGTGG CACTATGATTGATTTCCCCAGTTATGATGTACACTGGT ACCCTCTGCCCTGGGGCCCC ATTGGGGAAATCAATCATAATCCACTCCAGCCCCTTCCC ACCAGCAGCTTCCAGGA AGACACTGAGGGCGGCTGAGTGGAAGCACCAACTACAA TGGGGGCTGGCGGATCCAG ACAGCCCCCAAACTCCTGTCAGCACAGACTGGGACC CCCGTCCCTCAAGAGTCGA CTCCAGTAGTAACCACTGACATCTATGGTAACAGCA AGGAACCGGNTG (SEQ ID GTCACCATATCAGTAGACAAGGACCCACCATAGACAGC ATCGGCCCTCAGGGGTC NO: 3389) CGTCCAAGAACCAGTTCTCGCAGGTGAGGGACAGGGTC CCTGACCGATTCTCTGGC CCTGAAGCTGAGCTCTGTGTCCGAAGGCTTCAACAGTC TCCAAGTCTGGCACCTCA ACCGCCGCGGACACGGCTGCTGCGCCCCACTGCTGTAG GCCTCCCTGGCCATCACT TGTATTACTGTGCGAGAGCCTGCACCTGGGA (SEQ ID GGGCTCCAGGCTGAGGA TGGTTTTGGAGTGGTTATTA NO: 3387)TGAGGCTGATTATTACTG CCTATGGTTCAGGAACGGA CCAGTCCTATGACAGCATCCCCTTTTTGACTACTGGG GCCTGAGTGGTTCGAGG GCCAGGGAACCCTGGTCACGTGTTTGGCGGAGGGAC CGTCTCCTCAGCGTCGACC CAAGCTGACCGTCCTAGAAGGGCCCATCGGTCTTCC GTCAGCCCAAGGCTGCC CCCTGGCACCCTCCTCCAACCCTCGGTCACTCTGTTC GAGCACCTCTGGGGGCACA CCGCCCTCGAGTGAGGAGCGGCCCTGGGCTGCCTGG GCTTCAAGCCAACAAGG TCAAGGACTACTTCCCCGACCACACTGGTGTGTCTCA ACCTGTGACGGTCTCGTGG TAAGTGACTTCTACCCGGAACTCAGGCGCCCTGACCA GAGCCGTGACAGTGGCC GCGGCGTGCACACCTTCCCTGGAAGGCAGATAGCAG GGCTGTCCTACAGTCCTCA CCCCGTCAAGGCGGGAGGGACTCTACTCCCTCAGCA TGGAGACCACCACACCC GCGTGGTGACCGTGCCCTCTCCAAACAAAGCAACAA CAGCAGCTTGGGCACCCAG CAAGTACGCGGCCAGCAACCTACATCTGCAACGTGA GCTACCTGAGCCTGACG ATCACAAGCCCAGCAACACCCTGAGCAGTGGAAGTC CAAGGTGGACAAGAGAGTT CCACAGAAGCTACAGCTGAGCCCAAATCTTGTGACA GCCAGGTCACGCATGAA AAACTCACACATGCCCACGGGAGCACCGTGGAGAA (SEQ ID NO: 3386) GACAGTGGCCCCTACAG AATGTTCATAGAAGCTTGGCCGCCATGGCCCAAC TTGTTTATTGCAGCTTAT AATGGTTACAAATAAA (SEQ ID NO: 3388)CO57_P2 A-C040 TACACATACGATTTAGGTG CGCTGTGNNNNNGAGGTGC CO57_P2TACACATACGATTTAGGT TTGGGCTGACCTAGGACGGT CO57_P2 A10 ACACTATAGAATAACATCCTCTTGGAGGAGGGTGCCAG A10 GACACTATAGAATAACA CAGCTTGGTCCCTCCGCCGA A10ACTTTGCCTTTCTCTCCACA GGGGAAGACCGATGGGCCC TCCACTTTGCCTTTCTCTATACCCCCTGATCACTACTA GGTGTCCACTCCCAGGTCC TTGGTGGAGGCTGAGGAGACCACAGGTGTCCACTCCC CTATCCCACACCTGACAGTA AACTGCACCTCGGTTCTATCCGGTGACCGTGGTCCCTTTG AGGTCCAACTGCACCTC ATAGTCGGCCTCATCCCCGGGATTGAATTCCACCATGGG CCCCAGACGTCCATGTAGT GGTTCTATCGATTGAATTCTTCGACCCTGCTGATGGTC ATGGTCATGTATCATCCTTT AGTAGTAAAAAATGGGGCACCACCATGGGATGGTCA AGGGTGGCCGTGTTCCCAGA TTCTAGTAGCAACTGCAACGCTGGTACTACTACAATGG TGTATCATCCTTTTTCTA GTTGGAGCCAGAGAATCGCCGGTGTACATTCTGAGGTG GGATCTGTGGTACAGTAAT GTAGCAACTGCAACCGGTCAGGGATCCCTGAGGGCC CAGCTGGTGGAGTCTGGGG ACACGGCTGTGTCCTCGGTTTTCTGTGACCTCCTATGA GGTCGCTATCATCATAGACG GAGGCTTGGTAAAGCCTGGTTCAGGCTGTTCATTTGCAG GCTGACTCAGCCACCCTC ACCAGCACAGGGGCCTGGCGGGGTCCCTTAGACTCTCCT ATACAGCGTGTTTTTTGAAT GGTGTCAGTGGCCCCAGCTGGCTTCTGCTGGTACCAG GTGCAGCCTCTGGATTCACT CATCTCTTGAGATGGTGAAGACAGACGGCCAGGATT TGCACACTTTTACTTCCAAT TTCAGTAACGCCTGGATGATCTGCCTTTCACGGGTGCAG ACCTGTGGGGGAAACAA gttgtttcccccAcAggtAAGCTGGGTCCGCCAGGCTCC CGTAGTCTGTTGTCCCACCA CATTGGAAGTAAAAGTGTCCTGGCCGTCTGTCCTGGG AGGGAAGGGGCTGGAGTGG TCAGTTTTGCTTTTAATACGTGCACTGGTACCAGCAG GCCACTGACACCGAGGGTG GTTGGCCGTATTAAAAGCAGCCAACCCACTCCAGCCCC AAGCCAGGCCAGGCCCC GCTGAGTCAGCACATACTGGAAACTGATGGTGGGACAAC TTCCCTGGAGCCTGGCGGA TGTGCTGGTCGTCTATGAGACCAGGAACCGGTTG  AGACTACGCTGCACCCGTG CCCAGCTCATCCAGGCGTTTGATAGCGACCGGCCCT (SEQ ID NO: 3393) AAAGGCAGATTCACCATCTACTGAAAGTGAATCCAGAG CAGGGATCCCTGAGCGA CAAGAGATGATTCAAAAAAGCTGCACAGGAGAGTCTAA TTCTCTGGCTCCAACTCT CACGCTGTATCTGCAAATGGGGACCCCCCAGGCTTTAC GGGAACACGGCCACCCT AACAGCCTGAAAACCGAGGCAAGCCTCCCCCAGACTCC GACCATCAGCAGGGTCG ACACAGCCGTGTATTACTGNNNNCTGCACC (SEQ ID AAGCCGGGGATGAGGCC TACCACAGATCCCCATTGT NO: 3391)GACTATTACTGTCAGGTG AGTAGTACCAGCTGCCCCA TGGGATAGTAGTAGTGATTTTTTACTACTACTACATG TCAGGGGGTATTCGGCG GACGTCTGGGGCAAAGGGAGAGGGACCAAGCTGACC CCACGGTCACCGTCTCCTCA GTCCTAGGTCAGCCCAAGCGTCGACCAAGGGCCCAT GGCTGCCCCCTCGGTCAC CGGTCTTCCCCCTGGCACCCTCTGTTCCCGCCCTCGAG TCCTCCAAGAGCACCTCTG TGAGGAGCTTCAAGCCAGGGGC_(A)C_(A)GCGGCCCTGGG ACAAGGCCACACTGGTG CTGCCTGGTCAAGGACTACTGTCTCATAAGTGACTTC TTCCCCGAACCTGTGACGG TACCCGGGAGCCGTGACTCTCGTGGAACTCAGGCGC AGTGGCCTGGAAGGCAG CCTGACCAGCGGCGTGCACATAGCAGCCCCGTCAAG ACCTTCCCGGCTGTCCTACA GCGGGAGTGGAGACCACGTCCTCANGACTCTACTCCC CACACCCTCCAAACAAA TCAGCAGCGTGGTGACCGTGCAACAACAAGTACGCG GCCCTCCAGCAGCTTGGGC GCCAGCAGCTACCTGAGACCCAGACCTACATCTGCA CCTGACGCCTGAGCAGT ACGTGAATCACAAGCCCAGGGAAGTCCCACAGAAGC CAACACCNANGTGGACAAG TACAGCTGCCAGGTCACAGAGTTGAGCCCAAATCTT GCATGAAGGGAGCACCG GTGACAAAAC (SEQ IDTGGAGAAGACAGTGGCC NO: 3390) CCTACAGAATGTTCATA GAAGCTTGGCCGCCATGGCCCAACTTGTTTATTGC AGCTTATAATGGTTACA AATAAAG (SEQ ID NO: 3392) CO57_P1A-C041 TACACATACGATTTAGGTG GNCGCTGTGNNNNNNAGGT CO57_P1TACACATACGATTTAGGT GANTTNCCCGATTGGAGGG CO57_P1 B9 ACACTATAGAATAACATCCGCTCTTGGAGGAGGGTGCC B9 GACACTATAGAATAACA CGTTATCCACCTTCCACTGT B9ACTTTGCCTTTCTCTCCACA AGGGGGAAGACCGATGGGC TCCACTTTGCCTTTCTCTACTTTGGCCTCTCTGGGATA GGTGTCCACTCCCAGGTCC CCTTGGTGGAGGCTGAGGACCACAGGTGTCCACTCCC GAAGTTATTCAGCAGGCAC AACTGCACCTCGGTTCTATCGACGGTGACCGTGGTCCCT AGGTCCAACTGCACCTC ACAACAGAGGCAGTTCCAGGATTGAATTCCACCATGGG TGGCCCCAGACGTCCATAC GGTTCTATCGATTGAATTATTTCAACTGCTCATCAGAT ATGGTCATGTATCATCCTTT CGTAGTAGTAGTAGTCCCTCCACCATGGGATGGTCA GGCGGGAAGATGAAGACAG TTCTAGTAGCAACTGCAACCGGCATCCAGTGTCTCGCA TGTATCATCCTTTTTCTA ATGGTGCAGCCACAGTTCGTCGGTGTACATTCCCAGGTG CAGTAATACACAGCCGTGT GTAGCAACTGCAACCGGTTGATTTCCACCTTGGTCCC CAGCTACAGCAGTGGGGCG CCGCGGCGGTCACAGAGCTTGTACATTCAGACATCCA TTGGCCGAACGTCCGAGGG CAGGACTGTTGAAGCCTTCCAGCTTCAGGAAGAACTGG GTTGACCCAGTCTCCATC GTACTGTAACTCTGTTGACAGGAGACCCTGTCCCTCACC TTCTTGGACGTGTCTACTGA CTCCCTGTCTGCATCTGTGTAGTAAGTTGCAAAATCTT TGCGCTGTCTATGGTGGGTC TATGGTGACTCGACTCTTGAAGGAGACAGAGTCACCA CAGGTTGCAGACTGCTGATG CTTCAGTGGTTACTACTGGAGGGACGGGTTGTAGTTGGT TCACTTGCCGGGCAAGT GTGAGAGTGAAATCTGTCCCGCTGGATCCGCCAGCCCCC GCTTCCACTATGATTGACTT CAGAGCATTAGCAGCTAAGATCCACTGCCACTGAACC AGGGAAGGGGCTGGAGTGG CCCCAATCCACTCCAGCCCTTTAAATTGGTATCAGCA TTGATGGGACCCCACTTTGC ATTGGGGAAGTCAATCATACTTCCCTGGGGGCTGGCGG GAAACCAGGGAAAGCCC AAACTGGATGCAGCATAGAGTGGAAGCACCAACTACAA ATCCAGCTCCAGTAGTAAC CTAAGCTCCTGATCTATGTCAGGAGCTTAGGGGCTTTC CCCGTCCCTCAAGAGTCGA CACTGAAGGACCCACCATACTGCATCCAGTTTGCAAA CCTGGTTTCTGCTGATACCA GTCACCATATCAGTAGACAGACAGCGCAGGTGAGGGAC GTGGGGTCCCATCAAGG ATTTAAATAGCTGCTAATGCCGTCCAAGAACCAGTTCTT AGGGTCTCCGAAGGCTTCA TTCAGTGGCAGTGGATCTTCTGACTTGCCCGGCAAGTG CCTGAAGCTGAGCTCTGTG ACAGTCCTGCGCCCCACTGGGGACAGATTTCACTCTC ATGGTGACTCTGTCTCCTAC ACCGCCGCGGACACGGCTGCTGTAGCTGCACCTNNNAA ACCATCAGCAGTCTGCA AGATGCAGACAGGGAGTGTATTACTGTGCGAGACA (SEQ ID NO: 3395) ACCTGAAGATTTTGCAA(SEQ ID NO: 3397) CTGGATGCCGAGGGACTAC CTTACTACTGTCAACAGATACTACTACGGTATGGACG GTTACAGTACCCCTCGG TCTGGGGCCAAGGGACCACACGTTCGGCCAAGGGAC GGTCACCGTCTCCTCAGCGT CAAGGTGGAAATCAAAGCGACCAAGGGCCCATCGGT TACGGTGGCTGCACCAT CTTCCCCCTGGCACCCTCCTCTGTCTTCATCTTCCCGC CCAAGAGCACCTCTGGGGG CATCTGATGAGCAGTTGCACAGCGGCCCTGGGCTGC AAATCTGGAACTGCCTCT CTGGTCAAGGACTACTTCCGTTGTGTGCCTGCTGAAT CCGAACCTGTGACGGTCTC AACTTCTATCCCAGAGAGTGGAACTCNGCGCCCTGA GGCCAAAGTACAGTGGA CCAGCGGCGTGCACACCTTAGGTGGATAACGCCCTC CCCGGCTGTCCTACAGTCCT CAATCGGGTAACTCCCACANGACTCTACTCCCTCAG GGAGAGTGTCACAGAGC CAGCGTGGTGACCGTGCCCAGGACAGCAAGGACAGC TCCAGCAGCTTGGGCACCC ACCTACAGCCTCAGCAGAGACCTACATCTGCAACGT CACCCTGACGCTGAGCA GAATCACAAGCCCAGCAACAAGCAGACTACGAGAAA ACCNANGTGGACAAGANAG CACAAAGTCTACGCCTGTTGAGCCCAAATCTTGTGA CGAAGTCACCCATCAGG CAAACTCACACATGCCCACGCCTGAGCTCGCCCGTC CGTGCCCAG (SEQ ID  ACAAAGAGCTTCAACAG NO: 3394)GGGAGAGTGTTAGAAGC TTGGNCGCCATGGCCCA ACTTGTTTATTGCAGCTT ATAATGGTTACAAATAAAGCAATAGCATCAC  (SEQ ID NO: 3396) V-C001 NNNNNNNNNNNNNGTATCAGAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNCNNATGTATC GAAATTGTGTTGACGCAGTCCOV107_ TACACATACGATTTAGGTG CTGGAGGAGGCTTGATCCA P2_H9 NTACACATACGATTTAGTCCAGGCACCCTGTCTTTGT P2_H9 ACACTATAGAATAACATCC GCCTGGGGGGTCCCTGAGAGTGACACTATAGAATAA CTCCAGGGGAAAGAGCCAC ACTTTGCCTTTCTCTCCACACTCTCCTGTGCAGCCTCTGG CATCCACTTTGCCTTTCT CCTCTCCTGCAGGGCCAGTCGGTGTCCACTCCCAGGTCC GTTCATCGTCAGTAGCAAC CTCCACAGGTGTCCACTCAGAGTGTTAGCAGCAGCTA AACTGCACCTCGGTTCTATC TACATGAGCTGGGTCCGCCCCAGGTCCAACTGCACC CTTAGCCTGGTACCAGCAGA GATTGAATTCCACCATGGGAGGCTCCAGGGAAGGGGCT TCGGTTCTATCGATTGAA AACCTGGCCAGGCTCCCAGATGGTCATGTATCATCCTTT GGAGTGGGTCTCAGTTATTT TTCCACCATGGGATGGTCGCTCCTCATCTATGGTGCAT TTCTAGTAGCAACTGCAAC ATAGCGGTGGTAGCACATTATGTATCATCCTTTTTCT CCAGCAGGGCCACTGGCAT CGGTGTACATTCTCAGGTGCTACACAGACTCCGTGAAG AGTAGCAACTGCAACCG CCCAGACAGGTTCAGTGGCCAGCTGGTGGAGTCTGGAG GGCCGATTCACCATCTCCA GTGTACATTCAGAAATTGGTGGGTCTGAGACAGACTT GAGGCTTGATCCAGCCTGG GAGACAATTCCAAGAACACGTGTTGACGCAGTCTCCA CACTCTCACCATCAGCAGAC GGGGTCCCTGAGACTCTCCTCTGTATCTTCAAATGAACA GGCACCCTGTCTTTGTCT TGGAGCCTGAAGATTGTGCATGTGCAGCCTCTGGGTTCAT GCCTGAGAGCCGAGGACAC CCAGGGGAAAGAGCCACGTGTATTACTGTCAGCAGTA CGTCAGTAGCAACTACATG GGCCGTGTATTACTGTGTGCCCTCTCCTGCAGGGCCA TGGTAGCTCACCCCGGACGT AGCTGGGTCCGCCAGGCTCGGGACTACGGTGACTTCTA GTCAGAGTGTTAGCAGC TCGGCCAAGGGACCAAGGTCAGGGAAGGGGCTGGAGTG CTTTGACTACTGGGGCCAG AGCTACTTAGCCTGGTACGGAAATCAAAC (SEQ  GGTCTCAGTTATTTATAGCG GGAACCCTGGTCACCGTCTCAGCAGAAACCTGGCCA ID NO: 3401) GTGGTAGCACATTCTACAC CCTCAG (SEQ ID GGCTCCCAGGCTCCTCAT AGACTCCGTGAAGGGCCGA NO: 3399) CTATGGTGCATCCAGCATTCACCATCTCCAGAGACA GGGCCACTGGCATCCCA ATTCCAAGAACACTCTGTAGACAGGTTCAGTGGCGG TCTTCAAATGAACAGCCTG TGGGTCTGAGACAGACTAGAGCCGAGGACACGGCCG TCACTCTCACCATCAGCA TGTATTACTGTGTGCGGGAGACTGGAGCCTGAAGAT CTACGGTGACTTCTACTTTG TGTGCAGTGTATTACTGTACTACTGGGGCCAGGGAAC CAGCAGTATGGTAGCTC CCTGGTCACCGTCTCCTCAGACCCCGGACGTTCGGCC CGTCGACCAAGGGCCCATC AAGGGACCAAGGTGGAAGGTCTTCCCCCTGGCACCCT ATCAAACGTACGGTGGC CCTCCAAGAGCACCTCTGGTGCACCATCTGTCTTCAT GGGCACAGCGGCCCTGGGC CTTCCCGCCATCTGATGATGCCTGGTCAAGGACTACT GCAGTTGAAATCTGGAA TCCCCGAACCTGTGACGGTCTGCCTCTGTTGTGTGCC CTCGTGGAACTCAGGCGCC TGCTGAATAACTTCTATCCTGACCAGCGGCGTGCACA CCAGAGAGGCCAAAGTA CCTTCCCGGCTGTCCTACAGCAGTGGAAGGTGGATAA TCCTCAGGACTCTACTCCCT CGCCCTCCAATCGGGTACAGCAGCGTGGTGACCGTG ACTCCCAGGAGAGTGTC CCCTCCAGCAGCTTGGGCAACAGAGCAGGACAGCAA CCCAGACCTACATCTGCAA GGACAGCACCTACAGCCCGTGAATCACAAGCCCAGC TCAGCAGCACCCTGACG AACACCNANNTGGACAAGACTGAGCAAAGCAGACTA GAGTTGAGCCCAAATCTTG CGAGAAACACAAAGTCTTGACAAAACTCACACATGC ACGCCTGCGAAGTCACC CCACCGTGCCCAGCACCTGCATCNGGNCNTGAGCTC AACTCCTGGGGGGACCGTC GCCCGTCACAAAGAGCTAGTCTTCCTCTTCCCCCCAA TCAACAGGGGAGAGTGT AACCCNAGGACACCCTCATTAGAAGCTTGGCCGCCA GATCTCCCNGACCCCNGAG TGGCCCAACTTGTTTATTTCACATGCGTGGNNGTGGN GCAGCTTATAATGGTTAC NGTGANCCACGAAGANCCTAAATAAAGCAATAGCAT GAGGTCAAGTTCAACTGGN CACAAATTTCACAAATA ACNNNGNNNNGNN AAGCATTTTTTTCACTGC (SEQ ID NO: 3398) ATTCTANTTGNNGTTNGTCCAAACTCATCANGTAT NTNNCATGTCTGGNTCG GGANTNNNGCGCAGCNC NTGCTGAANNNACNTCTGAANNAGANNNNGTTAG GTACCTTNNGNNNGNNN NNNN (SEQ ID  NO: 3400) V-C002NNNNNNNNNNNTNTGNNTC GAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNCNTATGTATCGAAATTGTGTTGACGCAGTC COV107_ NTACNCATACGATTTAGGT CTGGAGGAGGCTTGATCCAP2_b1 NTACACATACGATTTAG TCCAGGCACCCTGTCTTTGT P2_b1 GACACTATAGAATAACATCGCCTGGGGGGTCCCTGAGA GTGACACTATAGAATAA CTCCAGGGGAAAGAGCCACCACTTTGCCTTTCTCTCCAC CTCTCCTGTGCAGCCTCTGG CATCCACTTTGCCTTTCTCCTCTCCTGCAGGGCCAGTC AGGTGTCCACTCCCAGGTC GTTCATCGTCAGTAGCAACCTCCACAGGTGTCCACTC AGAGTGTTAGCAGCAGCTA CAACTGCACCTCGGTTCTATTACATGAGCTGGGTCCGCC CCAGGTCCAACTGCACC CTTAGCCTGGTACCAGCAGACGATTGAATTCCACCATGG AGGCTCCAGGGAAGGGGCT TCGGTTCTATCGATTGAAAACCTGGCCAGGCTCCCAG GATGGTCATGTATCATCCTT GGAGTGGGTCTCAGTTATTTTTCCACCATGGGATGGTC GCTCCTCATCTATGGTGCAT TTTCTAGTAGCAACTGCAAATAGCGGTGGTAGCACATT ATGTATCATCCTTTTTCT CCAGCAGGGCCACTGGCATCCGGTGTACATTCTCAGGT CTACGCAGACTCCGTGAAG AGTAGCAACTGCAACCGCCCAGACAGGTTCAGTGGC GCAGCTGGTGGAGTCTGGA GGCCGATTCACCATCTCCAGTGTACATTCAGAAATT AGTGGGTCTGGGACAGACTT GGAGGCTTGATCCAGCCTGGAGACAATTCCAAGAACAC GTGTTGACGCAGTCTCCA CACTCTCACCATCAGCAGACGGGGGTCCCTGAGACTCTC GCTGTATCTTCAAATGAAC GGCACCCTGTCTTTGTCTTGGAGCCTGAAGATTTTGCA CTGTGCAGCCTCTGGGTTCA AGCCTGAGAGCCGAGGACACCAGGGGAAAGAGCCAC GTCTATTACTGTCAGCAGTA TCGTCAGTAGCAACTACATCGGCCGTGTATTACTGTGC CCTCTCCTGCAGGGCCA TGGTAGCTCACCTCGGACGTGAGCTGGGTCCGCCAGGCT GAGGGACTACGGTGACTAC GTCAGAGTGTTAGCAGCTCGGCCAAGGGACCAAGGT CCAGGGAAGGGGCTGGAGT TACTTTGACTACTGGGGCCAGCTACTTAGCCTGGTAC GGAAATCAAAC (SEQ  GGGTCTCAGTTATTTATAGCAGGGAACCCTGGTCACCGT CAGCAGAAACCTGGCCA ID NO: 3405) GGTGGTAGCACATTCTACGCTCCTCAG (SEQ ID  GGCTCCCAGGCTCCTCAT CAGACTCCGTGAAGGGCCG NO: 3403)CTATGGTGCATCCAGCA ATTCACCATCTCCAGAGAC GGGCCACTGGCATCCCAAATTCCAAGAACACGCTGT GACAGGTTCAGTGGCAG ATCTTCAAATGAACAGCCTTGGGTCTGGGACAGACT GAGAGCCGAGGACACGGCC TCACTCTCACCATCAGCAGTGTATTACTGTGCGAGGG GACTGGAGCCTGAAGAT ACTACGGTGACTACTACTTTTTTGCAGTCTATTACTGT GACTACTGGGGCCAGGGAA CAGCAGTATGGTAGCTCCCCTGGTCACCGTCTCCTCA ACCTCGGACGTTCGGCC GCGTCGACCAAGGGCCCATAAGGGACCAAGGTGGAA CGGTCTTCCCCCTGGCACCC ATCAAACGTACGGTGGCTCCTCCAAGAGCACCTCTG TGCACCATCTGTCTTCAT GGGGCACAGCGGCCCTGGGCTTCCCGCCATCTGATGA CTGCCTGGTCAAGGACTAC GCAGTTGAAATCTGGAATTCCCCGAACCTGTGACGG CTGCCTCTGTTGTGTGCC TCTCGTGGAACTCAGGCGCTGCTGAATAACTTCTATC CCTGACCAGCGGCGTGCAC CCAGAGAGGCCAAAGTAACCTTCCCGGCTGTCCTACA CAGTGGAAGGTGGATAA GTCCTCAGGACTCTACTCCCCGCCCTCCAATCGGGTA TCAGCAGCGTGGTGACCGT ACTCCCAGGAGAGTGTCGCCCTCCAGCAGCTTGGGC ACAGAGCAGGACAGCAA ACCCAGACCTACATCTGCAGGACAGCACCTACAGCC ACGTGAATCACAAGCCCAG TCAGCAGCACCCTGACGCAACACCAAGGTGGACAAG CTGAGCAAAGCAGACTA AGAGTTGAGCCCAAATCTTCGAGAAACACAAAGTCT GTGACAAAACTCACACATG ACGCCTGCGAAGTCACCCCCACCGTGCCCAGCACCT CATCNGGNCCTGAGCTC GAACTCCTGGGGGGACCGTGCCCGTCACAAAGAGCT CAGTCTTCCTCTTCCCCCCA TCAACAGGGGAGAGTGTAAACCCAANGACACCCTCA TAGAAGCTTGGCCGCCA TGATCTCCCGGACCCCTGATGGNCCAACTTGTTTATT GGTCACATGCGTGGTGGTG GCAGCTTATAATGGNTAGACGTGAGCCACGAANANC CAAATAAAGCAATAGCA CTGANNCAAGTTCNACTGGTCACAAATTTCACAAAT NACGTGGNNGGCGTNNNGT AAAGCATTTTTTTCACTGGCATANGCCANANAAGCNG CATTCTAGTTGNGGNTTG CGGAGGAGCANTANANAGCTCCAAACTCATCAATGN ACGTACGNNNNGNCAGCGT ATNTNTCATGTCTGGNTCCCNNNNCNNCNGCNNNGAC GGGNATNATTCNNNGCA TNNNNANNNNNNNNANANGCACCNTGGNNTGAAAN NNCAGNCTCANAANCNNNC NACCTNNTGAANNNGNNCNNCCCCANCNANAAAANC CTNNGN (SEQ ID  NTNNNNNAGCNNANNNGN NO: 3404)NNNNCCCNNAN (SEQ  ID NO: 3402) V-C003 NNNNNNNNNNNNTGNNTCNCAGGTGCAGCTACAGCAGT COV107_ NNNNNNNNNNNATGTAT GAAATTGTGTTGACGCAGTCCOV107_ TACACATACGATTTAGGTG GGGGCGCAGGACTGTTGAA P2_E5 CNTACACATACGATTTATCCAGGCACCCTGTCTTTGT P2_E5 ACACTATAGAATAACATCC GCCTTCGGAGACCCTGTCCGGTGACACTATAGAATA CTCCAGGGGAAAGAGCCAC ACTTTGCCTTTCTCTCCACACTCACCTGCGCTGTCTCTGG ACATCCACTTTGCCTTTC CCTCTCCTGCAGGGCCAGTCGGTGTCCACTCCCAGGTCC TGGGTCACTCAGTGGTTTCT TCTCCACAGGTGTCCACTAGACTGTTACCGCCAACTAC AACTGCACCTCGGTTCTATC ACTGGACCTGGATCCGCCACCCAGGTCCAACTGCAC TTAGCCTGGTACCAGCAGAA GATTGAATTCCACCATGGGGCCCCCAGGAAAGGGGCTG CTCGGTTCTATCGATTGA ACCTGGCCAGGCTCCCAGACATGGTCATGTATCATCCTTT GAGTGGATTGGGGAAACCA ATTCCACCATGGGATGGTCCTCATCTATGGTGCATCC TTCTAGTAGCAACTGCAAC ATCATTTTGGAAGCACCGGTCATGTATCATCCTTTTT AAGAGGGCCACTGGCATCC CGGTGTACATTCCCAGGTGCTACAAGCCGTCCCTCAAG CTAGTAGCAACTGCAAC CAGACAGGTTCAGTGGCAGCAGCTACAGCAGTGGGGCG AGTCGAGTCACCATATCAG CGGTGTACATTCAGAAATGGGTCTGGGACAGACTTCA CAGGACTGTTGAAGCCTTC TAGACATGTCCAGGAACCATTGTGTTGACGCAGTCTC CTCTCAGCATCAGCAGACTG GGAGACCCTGTCCCTCACCGTTCTCCCTGAAGGTGACCT CAGGCACCCTGTCTTTGT GAGCCTGAAGATTTTGCAGTTGCGCTGTCTCTGGTGGGTC CTGTGACCGCCGCGGACAC CTCCAGGGGAAAGAGCCGTATTACTGTCAGCAGTATA ACTCAGTGGTTTCTACTGGA GGCTGTGTATTACTGTGCGACCCTCTCCTGCAGGGCC CTACTACACCTCGGACTTTC CCTGGATCCGCCAGCCCCCAGAAAGCCCCTCCTCTACA AGTCAGACTGTTACCGC GGCGGAGGGACCAAGGTGGAGGAAAGGGGCTGGAGTGG GTGACTTCTCTCCTGGTGCT CAACTACTTAGCCTGGTAAGATCAA (SEQ ID  ATTGGGGAAACCAATCATT TTTGATATCTGGGGCCAAGCCAGCAGAAACCTGGCC NO: 3409) TTGGAAGCACCGGCTACAA GGACAATGGTCGCCGTCTCAGGCTCCCAGACTCCTC GCCGTCCCTCAAGAGTCGA TTCAG (SEQ ID NO: ATCTATGGTGCATCCAA GTCACCATATCAGTAGACA 3407) GAGGGCCACTGGCATCCTGTCCAGGAACCAGTTCTC CAGACAGGTTCAGTGGC CCTGAAGGTGACCTCTGTGAGTGGGTCTGGGACAGA ACCGCCGCGGACACGGCTG CTTCACTCTCAGCATCAGTGTATTACTGTGCGAGAAA CAGACTGGAGCCTGAAG GCCCCTCCTCTACAGTGACTATTTTGCAGTGTATTACT TCTCTCCTGGTGCTTTTGAT GTCAGCAGTATACTACTATCTGGGGCCAAGGGACAA ACACCTCGGACTTTCGGC TGGTCACCGTCTCTTCAGCGGGAGGGACCAAGGTGGA TCGACCAAGGGCCCATCGG GATCAAACGTACGGTGGTCTTCCCCCTGGCACCCTCC CTGCACCATCTGTCTTCA TCCAAGAGCACCTCTGGGGTCTTCCCGCCATCTGATG GCACAGCGGCCCTGGGCTG AGCAGTTGAAATCTGGACCTGGTCAAGGACTACTTC ACTGCCTCTGTTGTGTGC CCCGAACCTGTGACGGTCTCTGCTGAATAACTTCTAT CGTGGAACTCAGGCGCCCT CCCAGAGAGGCCAAAGTGACCAGCGGCGTGCACACC ACAGTGGAAGGTGGATA TTCCCGGCTGTCCTACAGTCACGCCCTCCAATCGGGT CTCAGGACTCTACTCCCTCA AACTCCCAGGAGAGTGTGCAGCGTGGTGACCGTGCC CACAGAGCAGGACAGCA CTCCAGCAGCTTGGGCACCAGGACAGCACCTACAGC CAGACCTACATCTGCAACG CTCAGCAGCACCCTGACTGAATCACAAGCCCAGCAA GCTGAGCAAAGCAGACT CACCAAGGTGGACAAGAGAACGAGAAACACAAAGTC GTTGAGCCCAAATCTTGTG TACGCCTGCGAAGTCACACAAAACTCACACATGCCC CCATCAGGGCCTGAGCT ACCGTGCCCAGCACCTGAACGCCCGTCACAAAGAGC CTCCTGGGGGGACCGTCAG TTCAACAGGGGANAGTGTCTTCCTCTTCCCCCCAAAA TTAGAAGCTTGGNCGCC CCCAAGGACACCCTCATGAATGGNCCAACTTGTTTAT TCTCCCGGACCCCTGAGGT TGCAGCTTATAATGGNTTCACATGCGTGGNGGTGGNC ACNAATAAAGCAATAGC GTGAGCCACGAANACCCTGATCACAAATTTCACAAA ANNCAAGTTCAACTGGNAC TAAAGCATTTTTTTCACTNTGNNGGCNNNNNNGCATA GCATTCTAGTTGTGGNTN NGCCANGAANAAGCCNCGGGNCCAAACTCATCAATG NAGNANCANTANANNGCNC NATNTNATCATGTCTGGGTACNNNNNNNAGCNTCNN NTCGGNAATTAATTCGG NCNNNCNGCNCANNACTNNNGNNGCNNNNATGGNNT NNANNNNNNGNNNNNNNN GAANNACNNNNNGN NNNAGNNNCANNANNCNN(SEQ ID NO: 3408) NCCNNNNCCNTCNANNANN NTNNNNAANNNNAAGGGN NN (SEQ ID NO: 3406) V-C004 NNNNNNCNNATGTATCNTA CAGGTGCAGCTACAGCAGT COV107_NNNNNNNNNNNTATGNA GAAATTGTGTTGACGCAGTC COV107_ CACNTACGATTTAGGTGACGGGGCGCAGGACTGTTGAA P1_D6 TCNTACACATACGATTTA TCCAGGCACCCTGTCTTTGT P1_D6ACTATAGAATAACATCCAC GCCTTCGGAGACCCTGTCC GGTGACACTATAGAATACTCCAGGGGAAAGAGCCAC TTTGCCTTTCTCTCCACAGG CTCTCCTGCGCTGTCTATGGACATCCACTTTGCCTTTC CCTCTCCTGCTGGGCCAGTC TGTCCACTCCCAGGTCCAATGGGTCCCTCAGTGGTTACT TCTCCACAGGTGTCCACT AGAGTGTTAGCGCCAGCTACCTGCACCTCGGTTCTATCGA ACTGGAGCTGGATCCGCCA CCCAGGTCCAACTGCACTTAGCCTGGTACCAGCAGAA TTGAATTCCACCATGGGAT GCCCCCAGGGAAGGGGCTGCTCGGTTCTATCGATTGA ACCTGGCCAGGCTCCCAGGC GGTCATGTATCATCCTTTTTGAGTGGATTGGGGAGATCA ATTCCACCATGGGATGG TCCTCATCTATGGTGCATCCCTAGTAGCAACTGCAACCG ATCATTTTGGAAGCACCGG TCATGTATCATCCTTTTTAGCAGGGCCACTGGCATCC GTGTACATTCCCAGGTGCA CTACAACCCGTCCCTCAAGCTAGTAGCAACTGCAAC CAGACAGGTTCAGTGGCAG GCTACAGCAGTGGGGCGCAAGTCGAGTCACCATCTCCG CGGTGTACATTCAGAAA TGGGTCTGGGACAGACTTCAGGACTGTTGAAGCCTTCGG TGGACACGTCCAAGAGCCA TTGTGTTGACGCAGTCTCCTCTCACCATCAGTAGACTG AGACCCTGTCCCTCTCCTGC GTTCTCCGTGAAGCTGAGCCAGGCACCGTGTCTTTGT GAGCCTGAAGATTTTGCAGT GCTGTCTATGGTGGGTCCCTTCTGTGACCGCCGCGGACA CTCCAGGGGAAAGAGCC ATATTACTGTCAGCAGTACGCAGTGGTTACTACTGGAGC CGGCTGTCTATTACTGTGCG ACCCTCTCCTGCTGGGCCGTACTACACCTCGGACTTTC TGGATCCGCCAGCCCCCAG AGAAAGCCCCTCCTCTACAAGTCAGAGTGTTAGCGC GGCGGAGGGACCAAGGTGG GGAAGGGGCTGGAGTGGATGTAACTTATCCCCTGGTGCT CAGCTACTTAGCCTGGTA AGATCAAAC (SEQ ID TGGGGAGATCAATCATTTT TTTGATATCTGGGGCCAAG CCAGCAGAAACCTGGCC NO: 3413)GGAAGCACCGGCTACAACC GGACAATGGTCACCGTCTC AGGCTCCCAGGCTCCTCCGTCCCTCAAGAGTCGAGT TTCAG (SEQ ID NO:  ATCTATGGTGCATCCAGCCACCATCTCCGTGGACACG 3411) AGGGCCACTGGCATCCC TCCAAGAGCCAGTTCTCCGAGACAGGTTCAGTGGCA TGAAGCTGAGCTCTGTGAC GTGGGTCTGGGACAGACCGCCGCGGACACGGCTGTC TTCACTCTCACCATCAGT TATTACTGCGCGAGAAAGCAGACTGGAGCCTGAAGA CCCTCCTCTACAGTAACTTA TTTTGCAGTATATTACTGTCCCCTGGTGCTTTTGATAT TCAGCAGTACGGTACTA CTGGGGCCAAGGGACAATGCACCTCGGACTTTCGGCG GTCACCGTCTCTTCAGCGTC GAGGGACCAAGGTGGAGGACCAAGGGCCCATCGGTC ATCAAACGTACGGTGGC TTCCCCCTGGCACCCTCCTCTGCACCATCTGTCTTCAT CAAGAGCACCTCTGGGGGC CTTCCCGCCATCTGATGAACAGCGGCCCTGGGCTGCC GCAGTTGAAATCTGGAA TGGTCAAGGACTACTTCCCCTGCCTCTGTTGTGTGCC CGAACCTGTGACGGTCTCG TGCTGAATAACTTCTATCTGGAACTCAGGCGCCCTGA CCAGAGAGGCCAAAGTA CCAGCGGCGTGCACACCTTCAGTGGAAGGTGGATAA CCCGGCTGTCCTACAGTCCT CGCCCTCCAATCGGGTACAGGACTCTACTCCCTCAG ACTCCCAGGAGAGTGTC CAGCGTGGTGACCGTGCCCACAGAGCAGGACAGCAA TCCAGCAGCTTGGGCACCC GGACAGCACCTACAGCCAGACCTACATCTGCAACGT TCAGCAGCACCCTGACG GAATCACAAGCCCAGCAACCTGAGCAAAGCAGACTA ACCNANGTGGACAAGANAG CGAGAAACACAAAGTCTTTGAGCCCAAATCTTGTGA ACGCCTGCGAAGTCACC CAAAACTCACACATGCCCACATCAGGGCCTGAGCTC CCGTGCCCAGCACCTGANT GCCCGTCACAAAGAGCTCCTGGGGGGACCGTCAGTC TCAACAGGGGAGAGTGT TTCCTCTTCCCCCCAAAACCTAGAAGCTTGGCCGCCA CNAGGANACCCTCATGATC TGGCCCAACTTGTTTATTTCCNNNCCCNTGNNNCACA GCAGCTTATAATGGTTAC TGCGTGGNGNNNGNNGTGAAAATAAAGCAATAGCAT GCCACNANACCCTGAGTCA CACAAATTTCACAAATAAGTTCAACTGGNACNNNGN AAGCATTTTTTTCACTGC NNGGCGTNNNNGNTGCANNATTCTAGTTGTGGTTTGT NN (SEQ ID NO:  CCAAACTCATCAATGTAT 3410)CTTATCATGTCTGGATCG GGAATTAANTTCGNCGC AGCACNTGGCNTGAAAT NACCTCTGAAAGANGAACTTG (SEQ ID NO: 3412) V-C005 NNNNNNNNNNNATGTATCA GAGGTGCAGCTGGTGGAGTCOV107_ NNNNNNNNTATGTATCN CAGTCTGTGCTGACTCAGCC COV107_TACACATACGATTTAGGTG CTGGAGGAGGCTTGATCCA P2_A4 TACACATACGATTTAGGTTCCCTCCGCGTCCGGGTCTC P2_A4 ACACTATAGAATAACATCC GCCTGGGGGGTCCCTGAGAGACACTATAGAATAACA CTGGACAGTCAGTCACCATC ACTTTGCCTTTCTCTCCACACTCTCCTGTGCAGCCTCTGG TCCACTTTGCCTTTCTCT TCCTGCACTGGAACCAGCAGGGTGTCCACTCCCAGGTCC GTTCACCGTCAGTAGCAAC CCACAGGTGTCCACTCCCTGACGTTGGTGGTTATAAGT AACTGCACCTCGGTTCTATC TACATGAGCTGGGTCCGCCAGGTCCAACTGCACCTC ATGTCTCCTGGTACCAACAG GATTGAATTCCACCATGGGAGGCTCCAGGGAAGGGGCT GGTTCTATCGATTGAATT CACCCAGGCAAAGCCCCCAATGGTCATGTATCATCCTTT GGAGTGGGTCTCAGTTATTT CCACCATGGGATGGTCAAACTCATGATTTATGAGGTC TTCTAGTAGCAACTGCAAC ATAGCGGTGGTAGTACATATGTATCATCCTTTTTCTA AGTAAGCGGCCCTCAGGGG CGGTGTACATTCTCAGGTGCTACGCAGACTCCGTGAAG GTAGCAACTGCAACCGG TCCCTGATCGCTTCTCTGGCCAGCTGGTGGAGTCTGGAG GGCCGATTCACCATCTCCA TTCCTGGGCCCAGTCTGCTCCAAGTCTGGCAACACGGC GAGGCTTGATCCAGCCTGG GAGACAATTCCAAGAACACCCTGACTCAGCCTCCCTC CTCCCTGACCGTTTCTGGGC GGGGTCCCTGAGACTCTCCGCTGTATCTTCAAATGAAC CGCGTCCGGGTCTCCTGG TCCAGGCTGAGGATGAGGCTGTGCAGCCTCTGGGTTCAC AGCCTGAGAGCCGAGGACA ACAGTCAGTCACCATCTCTGATTATTACTGCAGCTCAT CGTCAGTAGCAACTACATG CGGCCGTGTATTACTGTGCCTGCACTGGAACCAGCA ATGAAGGCAGCAACAATTTT AGCTGGGTCCGCCAGGCTCGAGAGGCGAGGGGTGGGA GTGACGTTGGTGGTTATA GTGGTATTCGGCGGAGGGACAGGGAAGGGGCTGGAGTG GCTACCATACGACTACTGG AGTATGTCTCCTGGTACCCCAAGCTGACCGTCCTAG GGTCTCAGTTATTTATAGCG GGCCAGGGAACCCTGGTCAAACAGCACCCAGGCAAA (SEQ ID NO: 3417) GTGGTAGTACATACTACGCGCCCCCAAACTCATGATT AGACTCCGTGAAGGGCCGA CCGTCTCCTCAG (SEQ IDTATGAGGTCAGTAAGCG TTCACCATCTCCAGAGACA NO: 3415) GCCCTCAGGGGTCCCTGATTCCAAGAACACGCTGTA ATCGCTTCTCTGGCTCCA TCTTCAAATGAACAGCCTGAGTCTGGCAACACGGCC AGAGCCGAGGACACGGCCG TCCCTGACCGTTTCTGGGTGTATTACTGTGCGAGAGG CTCCAGGCTGAGGATGA CGAGGGGTGGGAGCTACCAGGCTGATTATTACTGCAG TACGACTACTGGGGCCAGG CTCATATGAAGGCAGCAGAACCCTGGTCACCGTCTC ACAATTTTGTGGTATTCG CTCAGCGTCGACCAAGGGCGCGGAGGGACCAAGCTG CCATCGGTCTTCCCCCTGGC ACCGTCCTAGGTCAGCCACCCTCCTCCAAGAGCACC CAAGGCTGCCCCCTCGG TCTGGGGGCACAGCGGCCCTCACTCTGTTCCCACCCT TGGGCTGCCTGGTCAAGGA CGAGTGAGGAGCTTCAACTACTTCCCCGAACCTGTGA GCCAACAAGGCCACACT CGGTCTCGTGGAACTCAGGGGTGTGTCTCATAAGTG CGCCCTGACCAGCGGCGTG ACTTCTACCCGGGAGCCCACACCTTCCCGGCTGTCCT GTGACAGTGGCCTGGAA ACAGTCCTCANGACTCTACGGCAGATAGCAGCCCCG TCCCTCAGCAGCGTGGTGA TCAAGGCGGGAGTGGAGCCGTGCCCTCCAGCAGCTT ACCACCACACCCTCCAA GGGCACCCAGACCTACATCACAAAGCAACAACAAGT TGCAACGTGAATCACAAGC ACGCGGCCAGCAGCTACCCAGCAACACCANNGTGGA CTGAGCCTGACGCCTGA CAAGANAGTTGAGCCCAAAGCAGTGGAAGTCCCACA TCTTGTGACAAAACTCACA GAAGCTACAGCTGCCAGCATGCCCACCGTGCCCAGC GTCACGCATGNAAGGGA ACCTGAACTCCTGGGGGGAGCACCGTGGNNAAGACA CCGTCAGTCTTCCTCNTCCC GTGGCCCCTACAGAATGCCCAAAACCCNNNCACCCN TTCATAGAAGCTTGGCC CATGATCTNCCNNACCCNGGCCATGGCCCAACTTGTT AGTCNNNNTGNNNNGGNGG TATTGCAGCTTATAATGGNNGNNGTGANCNNNNANA NTACNAATAAAGCATAG CCCTGNNNGTCAAGTTCAACATCACAAATTTCACAA NTGGNACNN (SEQ ID NO: ATAAAGCATTTTTTTCAC 3414)TGCATTCTANTTGTNGNT NGTCCAAACTCATCNAT GNNNCTTATCATGTCTGGNTCGGGAATTAANTNNG NNGCAGCNNCNNNGN (SEQ ID NO: 3416) V-C006NNNNNNNNNTATGNATCNT CAGGTGCAGCTGCAGGAGT COV107_ NNNNNNNNNNATGTATCTCCTATGTGCTGACTCAGCC COV107_ ACACATACGATTTAGGTGA CGGGCCCAGGACTGGTGAAP2_F12 NTACACATACGATTTAG ACCCTCAGTGTCAGTGGCCC P2_F12 CACTATAGAATAACATCCAGCCTTCGGAGACCCTGTCC GTGACACTATAGAATAA CAGGAAAGACGGCCAGGATCTTTGCCTTTCTCTCCACAG CTCACCTGCACTGTCTCTGG CATCCACTTTGCCTTTCTTACCTGTGGGGGAAACAAC GTGTCCACTCCCAGGTCCA TGCCTCCGTCAGCAGTGGTCTCCACAGGTGTCCACTC ATTGGAAGTAAAAGTGTGC ACTGCACCTCGGTTCTATCGAGTTACTACTGGAGCTGGA CCAGGTCCAACTGCACC ACTGGTACCAGCAGAAGCCATTGAATTCCACCATGGGA TCCGGCAGCCCCCAGGGAA TCGGTTCTATCGATTGAAAGGCCAGGCCCCTGTGCTGG TGGTCATGTATCATCCTTTT GGGACTGGAATGGATTGGGTTCCACCATGGGATGGTC TCATCTATTTTGATAGCGAC TCTAGTAGCAACTGCAACCTATATCTATTACAGTGGGA ATGTATCATCCTTTTTCT CGGCCCTCAGGGATCCCTGAGGTGTACATTCCCAGCTGC GCACCAACTACAACCCCTC AGTAGCAACTGCAACCGGCGATTCTCTGGCTCCAACT AGCTGCAGGAGTCGGGCCC CCTCAAGAGTCGAGTCACCGTTCTGTGACCTCCTATG CTGGGAACACGGCCACCCT AGGACTGGTGAAGCCTTCGATATCAGTGGACACGTCCA AGCTGACACAGCCACCC GACCATCAGCAGGGTCGAAGAGACCCTGTCCCTCACCT AGAACCAGTTCTCCCTGAA TCAGTGTCAGTGGCCCCGCCGGGGATGAGGCCGACT GCACTGTCTCTGGTGCCTCC GCTGAGCTCTGTGACCGCTAGGAAAGACGGCCAGGA ATTACTGTCAGGTGTGGGAT GTCAGCAGTGGTAGTTACTGCGGACACGGCCGTGTATT TTACCTGTGGGGGAAAC AGTAGTCGTGATCATGTGGTACTGGAGCTGGATCCGGCA ACTGTGCGAGAGAGCGGCC AACATTGGAAGTAAAAGATTCGGCGGAGGGACCAAG GCCCCCAGGGAAGGGACTG CGGTGGAACGTATAGCAACTGTGCACTGGTACCAGC CTGACCGTCCTAG (SEQ  GAATGGATTGGGTATATCTACCTGGTACACCCCAACCG AGAAGCCAGGCCAGGCC ID NO: 3421) ATTACAGTGGGAGCACCAAATACCAACTGGTTCGACAC CCTGTGCTGGTCATCTAT CTACAACCCCTCCCTCAAGCTGGGGCCAGGGAACCCTG TTTGATAGCGACCGGCC AGTCGAGTCACCATATCAGGTCACCGTCTCCTCAG  CTCAGGGATCCCTGAGC TGGACACGTCCAAGAACCA(SEQ ID NO: 3419) GATTCTCTGGCTCCAACT GTTCTCCCTGAAGCTGAGCTCTGGGAACACGGCCACC CTGTGACCGCTGCGGACAC CTGACCATCAGCAGGGTGGCCGTGTATTACTGTGCG CGAAGCCGGGGATGAGG AGAGAGCGGCCCGGTGGAACCGACTATTACTGTCAGG CGTATAGCAACACCTGGTA TGTGGGATAGTAGTCGTCACCCCAACCGATACCAAC GATCATGTGGTATTCGGC TGGTTCGACACCTGGGGCCGGAGGGACCAAGCTGAC AGGGAACCCTGGTCACCGT CGTCCTAGGTCAGCCCACTCCTCAGCGTCGACCAAG AGGCTGCCCCCTCGGTC GGCCCATCGGTCTTCCCCCTACTCTGTTCCCGCCCTCG GGCACCCTCCTCCAAGAGC AGTGAGGAGCTTCAAGCACCTCTGGGGGCACAGCGG CAACAAGGCCACACTGG CCCTGGGCTGCCTGGTCAATGTGTCTCATAAGTGACT GGACTACTTCCCCGAACCT TCTACCCGGGAGCCGTGGTGACGGTCTCGTGGAACT ACAGTGGCCTGGAAGGC CAGGCGCCCTGACCAGCGGAGATAGCAGCCCCGTCA CGTGCACACCTTCCCGGCT AGGCGGGAGTGGAGACCGTCCTACAGTCCTCANGAC ACCACACCCTCCAAACA TCTACTCCCTCAGCAGCGTGAAGCAACAACAAGTACG GTGACCGTGCCCTCCAGCA CGGCCAGCAGCTACCTGGCTTGGGCACCCAGACCTA AGCCTGACGCCTGAGCA CATCTGCAACGTGAATCACGTGGAAGTCCCACAGAA AAGCCCAGCAACACCAAGG GCTACAGCTGCCAGGTCTGGACAAGAGAGTTGAGCC ACGCATGAAGGGAGCAC CAAATCTTGTGACAAAACTCGTGGAGAAGACAGTGG CACACATGCCCACCGTGCC CCCCTACAGAATGTTCATCAGCACCTGAACTCCTGGG AGAAGCTTGGCCGCCAT GGGANCGTCAGTCTTCCTCTGGCCCAACTTGTTTATTG TCCCCCCAAAACCCAAGGA CAGCTTATAATGGTTACACACCCTCATGATCTCCCGG AATAAAGCAATAGCATC ACCCCTGAGTCACATGCGTACAAATTTCACAAATAA NNNNNGANGTGANCCACGA AGCATTTTTTTCACTGCAANACCCTGAGNCAAGTTCA TTCTANTTGTGGTTTGTC CTGGNACGTNNNNNNTNNNCAAACTCATCAATGTATC NNCATNANNCANNAANAA TTATCATGTCTGGATCGGGCNNNNGGANGANCANTN GAATTAATTCGNCGCAG NANNNNACNNNCNNNNNNCACCATGNNNTGAAATA NGNNAGCNTCNTNNCGNNC ACCTCTGAAAGAGNAACNNNNNCNNNNTNNNTNANN NN (SEQ ID NO: NNNGNNNNANNNNNNNNN 3420)NCNNNNNCCNNNCNNNNCC ATCNNNANCCNTNNNNNNA NNNNNN (SEQ ID ) NO: 3418 V-C007NNNNNNNNNATGTATCNTA CAGGTTCAGCTGGTGCAGT COV107_ NNNNNNNNNNNNNNNGCAGTCTGTGCTGACTCAGCC COV107_ CACATACGATTTAGGTGAC CTGGAGCTGAGGTGAAGAAP1_F3 NATCTACACNTACGATTT ACCCTCAGCGTCTGGGACCC P1_F3 ACTATAGAATAACATCCACGCCTGGGGCCTCAGTGAGG AGGTGACACTATAGAAT CCGGGCAGAGGGTCACCATTTTGCCTTTCTCTCCACAGG GTCTCCTGCAAGGCTTCTGG AACATCCACTTTGCCTTTCTCTTGTTCTGGAAGCAGCT TGTCCACTCCCAGGTCCAA TTACACCTTTACCAGCTATGCTCTCCACAGGTGTCCAC CCAACATCGGAAGTAATTAT CTGCACCTCGGTTCTATCGAGTTTCAGCTGGGTGCGACA TCCCAGGTCCAACTGCA GTATACTGGTACCAGCAGCTTTGAATTCCACCATGGGAT GGCCCCTGGACAAGGGCTT CCTCGGTTCTATCGATTGCCCAGGAACGGCCCCCAAA GGTCATGTATCATCCTTTTT GAGTGGATGGGATGGATCAAATTCCACCATGGGATG CTCCTCATCTATAGGAATAA CTAGTAGCAACTGCAACCGGCGCTTACAATGGTAACAC GTCATGTATCATCCTTTT TCAGCGGCCCTCAGGGGTCCGTGTACATTCCCAGGTTCA AAACTTTGCACAGAAGCTC TCTAGTAGCAACTGCAACTGACCGATTCTCTGGCTCC GCTGGTGCAGTCTGGAGCT CAGGGCAGAGTCACCATGACCGGTTCCTGGGCCCAGT AAGTCTGGCACCTCAGCCTC GAGGTGAAGAAGCCTGGGGCCACAGACACATCCACGAG CTGTGCTGACTCAGCCAC CCTGGCCATCAGTGGGCTCCCCTCAGTGAGGGTCTCCTG CACAGCCTACATGGAGCTG CCTCAGCGTCTGGGACCGGTCCGAGGATGAGGCTGA CAAGGCTTCTGGTTACACCT AGGAGCCTGAGATCTGACGCCCGGGCAGAGGGTCAC TTATTACTGTGCAGCATGGG TTACCAGCTATGGTTTCAGCACACGGCCGTGTATTACTG CATCTCTTGTTCTGGAAG ATGACAGCCTGAGTGGTTTTTGGGTGCGACAGGCCCCTG TGCGAGAGGGGAAGCAGTG CAGCTCCAACATCGGAAGTGGTATTCGGCGGAGGGA GACAAGGGCTTGAGTGGAT GCTGGTACAACCGGTTTTTTGTAATTATGTATACTGGT CCAAGCTGACCGTCCTAG GGGATGGATCAGCGCTTACTGACTACTGGGGCCAGGGA ACCAGCAGCTCCCAGGA (SEQ ID NO: 3425)AATGGTAACACAAACTTTG ACCCTGGTCACCGTCTCCTC ACGGCCCCCAAACTCCTCACAGAAGCTCCAGGGCAG AG (SEQ ID NO: 3423) CATCTATAGGAATAATCAGTCACCATGACCACAGAC AGCGGCCCTCAGGGGTC ACATCCACGAGCACAGCCTCCTGACCGATTCTCTGGC ACATGGAGCTGAGGAGCCT TCCAAGTCTGGCACCTCAGAGATCTGACGACACGGCC GCCTCCCTGGCCATCAGT GTGTATTACTGTGCGAGAGGGGCTCCGGTCCGAGGA GGGAAGCAGTGGCTGGTAC TGAGGCTGATTATTACTGAACCGGTTTTTTTGACTACT TGCAGCATGGGATGACA GGGGCCAGGGAACCCTGGTGCCTGAGTGGTTTTGTGG CACCGTCTCCTCAGCGTCG TATTCGGCGGAGGGACCACCAAGGGCCCATCGGTCT AAGCTGACCGTCCTAGG TCCCCCTGGCACCCTCCTCCTCAGCCCAAGGCTGCCC AAGAGCACCTCTGGGGGCA CCTCGGTCACTCTGTTCCCAGCGGCCCTGGGCTGCCT CGCCCTCGAGTGAGGAG GGTCAAGGACTACTTCCCCCTTCAAGCCAACAAGGC GAACCTGTGACGGTCTCGT CACACTGGTGTGTCTCATGGAACTCAGGCGCCCTGAC AAGTGACTTCTACCCGG CAGCGGCGTGCACACCTTCGAGCCGTGACAGTGGCC CCGGCTGTCCTACAGTCCTC TGGAAGGCAGATAGCAGAGGACTCTACTCCCTCAGC CCCCGTCAAGGCGGGAG AGCGTGGTGACCGTGCCCTTGGAGACCACCACACCC CCAGCAGCTTGGGCACCCA TCCAAACAAAGCAACAAGACCTACATCTGCAACGTG CAAGTACGCGGCCAGCA AATCACAAGCCCAGCAACAGCTACCTGAGCCTGACG CCNAAGGTGGACAAGANAG CCTGAGCAGTGGAAGTCTTGAGCCCAAATCTTGTGA CCACAGAAGCTACAGCT CAAAACTCACACATGCCCAGCCAGGTCACGCATGAA CCGTGCCCAGCACCTGAAC GGGAGCACCGTGGAGAATNCTGGGGGGACCGTCAGT GACAGTGGCCCCTACAG CTTCCTCTTCCCCCCNAAACAATGTTCATAGAAGCTT CCAAGGACANCCTCATGAT GGCCGCCATGGCCCAACNTNCCNGACCCNTGAGTCA TTGTTTATTGCAGCTTAT CATGNNGTNGTGGNGGNCGAATGGTTACAAATAAAG TGNNCCACNAANNACCNNG CAATAGCATCACAAATTNAGGTCAAGTTCAACNGGN TCACAAATAAAGCATTTT ACNNNGNNN (SEQ ID NO:TTTCACTGCATTCTAGTT 3422) GNGGNTTGTCCAAACTC ATCAATGTATCTNATCATGTCTGGNTCNGGGANTA ATTCNGCGCAGCACCAT GGCNTGAAANNACCTCT GAAAGAGNNTNNNNGNNCNNCTNNGNNNNNNNNT CNGNGANNNGNGNTCAN TNNNNNNGAAAGNCCCC NGNNNCCCNNCAGNNNANNNTGN (SEQ ID NO: 3424) V-C008 NNNNNNNCNTATGNATCNT CAGGTGCAGCTGCAGGAGTCOV107_ NNNNNNNNNTTATGTAT CAGTCTGTGCTGACTCAGCC COV107_ACACATACGATTTAGGTGA CGGGCCCAGGACTGGTGAA P2_E9 CNTACNCATACGATTTATGCCTCCGTGTCTGGGTCTC P2_E9 CACTATAGAATAACATCCA GCCTTCGGGGACCCTGTCCGGTGACACTATAGAATA CTGGACAGTCGATCACCATC CTTTGCCTTTCTCTCCACAGCTCACCTGCGCTGTCTCTGG ACATCCACTTTGCCTTTC TCCTGCACTGGAACCAGCAGGTGTCCACTCCCAGGTCCA TGGCTCCATCAGCAGTACT TCTCCACAGGTGTCCACTTGACGTTGGTGGTTATAACT ACTGCACCTCGGTTCTATCG AACTGGTGGAGTTGGGTCCCCCAGGTCCAACTGCAC ATGTCTCCTGGTACCAACAA ATTGAATTCCACCATGGGAGCCAGCCCCCAGGGAAGGG CTCGGTTCTATCGATTGA CACCCAGGCAAAGCCCCCATGGTCATGTATCATCCTTTT GCTGGAGTGGATTGGGGAA ATTCCACCATGGGATGGAACTCATGATTTATGATGTC TCTAGTAGCAACTGCAACC ATCTATCATACTGGGAGCATCATGTATCATCCTTTTT AGTAATCGGCCCTCAGGGGT GGTGTACATTCCCAGGTGCCCAACTACAACCCGTCCCT CTAGTAGCAACTGCAAC TTCTAATCGCTTCTCTGGCTAGCTGCAGGAGTCGGGCCC CAAGAGTCGAGTCACCATA CGGTTCCTGGGCCCAGTCCCAAGTCTGGCAACACGGC AGGACTGGTGAAGCCTTCG TCAGTAGACAAGTCCAAGATGCCCTGACTCAGCCTGC CTCCCTGACCATCTCTGGGC GGGACCCTGTCCCTCACCTACCAGTTCTCCCTGAAGCT CTCCGTGTCTGGGTCTCC TCCAGGCTGAGGACGAGGCGCGCTGTCTCTGGTGGCTCC GAGCTCTGTGACCGCCGCG TGGACAGTCGATCACCATGATTATTACTGCAACTCAT ATCAGCAGTACTAACTGGT GACACGGCCGTGTATTACTTCTCCTGCACTGGAACCA ATACAAGCAGCAGCACTCG GGAGTTGGGTCCGCCAGCCGTGTGAGAGATGGAGGACG GCAGTGACGTTGGTGGT AGTCTTCGGAACTGGGACCACCCAGGGAAGGGGCTGGAG ACCCGGGGATGCTTTTGAT TATAACTATGTCTCCTGGAGGTCACCGTCCTAG (SEQ TGGATTGGGGAAATCTATC ATCTGGGGCCAAGGGACAATACCAACAACACCCAGG ID NO: 3429) ATACTGGGAGCACCAACTA TGGTCACCGTCTCTTCAGCAAAGCCCCCAAACTCA CAACCCGTCCCTCAAGAGT (SEQ ID NO: 3427)TGATTTATGATGTCAGTA CGAGTCACCATATCAGTAG ATCGGCCCTCAGGGGTTTACAAGTCCAAGAACCAGTT CTAATCGCTTCTCTGGCT CTCCCTGAAGCTGAGCTCTCCAAGTCTGGCAACACG GTGACCGCCGCGGACACGG GCCTCCCTGACCATCTCTCCGTGTATTACTGTGTGAG GGGCTCCAGGCTGAGGA AGATGGAGGACGACCCGGGCGAGGCTGATTATTACTG GATGCTTTTGATATCTGGGG CAACTCATATACAAGCACCAAGGGACAATGGTCACC GCAGCACTCGAGTCTTC GTCTCTTCAGCGTCGACCAGGAACTGGGACCAAGGT AGGGCCCATCGGTCTTCCC CACCGTCCTAGGTCAGCCCTGGCACCCTCCTCCAAG CCAAGGCCAACCCCACT AGCACCTCTGGGGGCACAGGTCACTCTGTTCCCACCC CGGCCCTGGGCTGCCTGGT TCGAGTGAGGAGCTTCACAAGGACTACTTCCCCGAA AGCCAACAAGGCCACAC CCTGTGACGGTCTCGTGGATGGTGTGTCTCATAAGTG ACTCAGGCGCCCTGACCAG ACTTCTACCCGGGAGCCCGGCGTGCACACCTTCCCG GTGACAGTGGCCTGGAA GCTGTCCTACAGTCCTCAGGGCAGATAGCAGCCCCG GACTCTACTCCCTCAGCAG TCAAGGCGGGAGTGGAGCGTGGTGACCGTGCCCTCC ACCACCACACCCTCCAA AGCAGCTTGGGCACCCAGAACAAAGCAACAACAAGT CCTACATCTGCAACGTGAA ACGCGGCCAGCAGCTACTCACAAGCCCAGCAACACC CTGAGCCTGACGCCTGA AAGGTGGACAAGANAGTTGGCAGTGGAAGTCCCACA AGCCCAAATCTTGTGACAA GAAGCTACAGCTGCCAGAACTCACACATGCCCACCG GTCACGCATGAANGGGA TGCCCAGCACCTGAACTNCGCACCGTGGAGAAGACA TGGGGGGACCGTCAGTCTT GTGGCCCCTACAGAATGCCTCTTCCCCCAAANCCNA TTCATAGAAGCTTGGCC GGACACCCTCATGATCTNCGCCATGGNCCAACTTGTT CNGACCCTGAGTCACATGC TATTGCAGCTTATAATGGGTGGNNNNNNGTGAGCCAC TTACAAATAAAGCAATA NANANCCTGAGTCAGTTCAGCATCACAAATTTCACA ACTGGNACGNNGNNGGNN AATAAAGCATTTTTTTNANNGGNNGNNGCATNATGNN CTGCATTCTANTNGTGGT (SEQ ID NO: 3426)TNGTCCAANTCATCAAT GTATNNNTCATGTCTGG NTCGGGNATTAATTCGN CGCAGCACCANGGCCTGAANNNACCTCTNNAANN ANN (SEQ ID  NO: 3428) V-C009 NNNNNNNNNTTATGTATCNGAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNNNNNNNNTAT CAGTCTGTGCTGACTCAGCCCOV107_ TACACATACGATTTAGGTG CTGGGGGAGGCTTGGTCCA P2_D10 GTATCNTACACATACGATCCCTCCGCGTCCGGGTCTC P2_D10 ACACTATAGAATAACATCC GCCTGGGGGGTCCCTGAGATTTAGGTGACACTATAG CTGGACAGTCAGTCACCATC ACTTTGCCTTTCTCTCCACACTCTCCTGTGCAGCCTCTGG AATAACATCCACTTTGCC TCCTGCACTGGAACCAGCAGGGTGTCCACTCCCAGGTCC ATTCACCTTTAGTAGCTATT TTTCTCTCCACAGGTGTCTGACGTTGGTGGTTATAACT AACTGCACCTCGGTTCTATC GGATGAGCTGGGTCCGCCACACTCCCAGGTCCAACT ATGTCTCCTGGTACCAACAG GATTGAATTCCACCATGGGGGCTCCAGGGAAGGGGCTG GCACCTCGGTTCTATCGA CACCCAGGCAAAGCCCCCAATGGTCATGTATCATCCTTT GAGTGGGTGGCCAACATAA TTGAATTCCACCATGGGAACTCATGATTTATGAGGTC TTCTAGTAGCAACTGCAAC AGCAAGATGGAAGTGAGAAATGGTCATGTATCATCCT ACTAAGCGGCCCTCAGGGG CGGTGTACATTCTGAAGTGATACTATGTGGACTCTGTG TTTTCTAGTAGCAACTGC TCCCTGATCGCTTCTCTGGCCAGCTGGTGGAGTCTGGGG AAGGGCCGATTCACCATCT AACCGGTTCCTGGGCCCTCCAAGTCTGGCAACACGGC GAGGCTTGGTCCAGCCTGG CCGGAGACAACGCCAAGAAAGTCTGCCCTGACTCAGC CTCCCTGACCGTCTCTGGGC GGGGTCCCTGAGACTCTCCCTCACTGTATCTGCACATGA CTCCCTCCGCGTCCGGGT TCCAGGCTGAGGATGAGGCTGTGCAGCCTCTGGATTCAC ACAGCCTGAGAGCCGAGGA CTCCTGGACAGTCAGTCTGATTATTACTGCAGCTCAT CTTTAGTAGCTATTGGATGA CACGGCTGTGTATTACTGTGACCATCTCCTGCACTGGA ATGCAGGCAGCAACAATTA GCTGGGTCCGCCAGGCTCCCTATACAGCTATGGTTAAG ACCAGCAGTGACGTTGG TGTGGTATTCGGCGGAGGGAGGGAAGGGGCTGGAGTGG GGGGGGCTATGACTACTGG TGGTTATAACTATGTCTCACCAAGCTGACCGTCCTAG GTGGCCAACATAAAGCAAG GGCCAGGGAACCCTGGTCACTGGTACCAACAGCACC (SEQ ID NO: 3433) ATGGAAGTGAGAAATACTACCGTCTCCTCAG (SEQ CAGGCAAAGCCCCCAAA TGTGGACTCTGTGAAGGGC ID NO: 3431)CTCATGATTTATGAGGTC CGATTCACCATCTCCGGAG ACTAAGCGGCCCTCAGGACAACGCCAAGAACTCACT GGTCCCTGATCGCTTCTC GTATCTGCACATGAACAGCTGGCTCCAAGTCTGGCA CTGAGAGCCGAGGACACGG ACACGGCCTCCCTGACCCTGTGTATTACTGTGCTATA GTCTCTGGGCTCCAGGCT CAGCTATGGTTAAGGGGGGGAGGATGAGGCTGATTA GCTATGACTACTGGGGCCA TTACTGCAGCTCATATGCGGGAACCCTGGTCACCGTC AGGCAGCAACAATTATG TCCTCAGCGTCGACCAAGGTGGTATTCGGCGGAGGG GCCCATCGGTCTTCCCCCTG ACCAAGCTGACCGTCCTGCACCCTCCTCCAAGAGCA AGGTCAGCCCAAGGCTG CCTCTGGGGGCACAGCGGCCCCCCTCGGTCACTCTGT CCTGGGCTGCCTGGTCAAG TCCCGCCCTCGAGTGAGGACTACTTCCCCGAACCTGT GAGCTTCAAGCCAACAA GACGGTCTCGTGGAACTCAGGCCACACTGGTGTGTCT NGCGCCCTGACCAGCGGCG CATAAGTGACTTCTACCCTGCACACCTTCCCGGCTGTC GGGAGCCGTGACAGTGG CTACAGTCCTCANGACTCTCCTGNAAGGCAGATAGC ACTCCCTCAGCAGCGTGGT AGCCCCGTCAAGGCGGGGACCGTGCCCTCCAGCAGC AGTGGAGACCACCACAC TTGGGCACCCAGACCTACACCTCCAAACAAAGCAAC TCTGCAACGTGAATCACAA AACAAGTACGCGGCCAGGCCCAGCAACACCNANGTG CAGCTACCTGAGCCTGA GACAAGAGAGTTGAGCCCACGCCTGAGCAGTGGAAG AATCTTGTGACAAAACTCA TCCCACAGAAGCTACAGCACATGCCCACCGTGCCCA CTGCCAGGTCACGCATG GCACCTGAACTCCTGGGGGANGGAGCACCGTGGAGA GACCGTCAGTCTTCCTCTTC ANACAGTGGCCCCTACACCCCCAAAACCCAAGNANA GAATGTTCATAGAAGCT NCCTCATGATCTCCCNGACTGGCCGCCATGGCCCAA CCCTGAGTCACATGCGTGN CTTGTTTATTGCAGCTTANNNGACGTGAGCCACGANA TAATGGNTACNAATAAA CCCTGAGNCAAGTTCAACTGCAATAGCATCACAAAT GGNACNNNGNNGNNNNNN TTCNNAAANAAAGCATTGNNNGCATAATGNCANNAA tttttcactgcatnntan NAAAGCCNN (SEQ IDTNGNGGNTTNTCNNAAC NO: 3430) TCATCNATGNATCTTATC ATGTCTGGNTNGGAATTNATTCGGNNNNNN  (SEQ ID NO: 3432) V-C010 NNNNNNNNNNTGNNTCNTAGAGGTGCAGCTGGTGCAGT COV107_ NNNNNNNNNNNATGTAT GACATCCAGATGACCCAGTCCOV107_ CACATACGATTTAGGTGAC CTGGAGCAGAGGTGAAAAA P2_H6 CNTACACATACGATTTATCCTTCCACCCTGTCTGCAT P2_H6 ACTATAGAATAACATCCAC GCCCGGGGAGTCTCTGAAGGGTGACACTATAGAATA CTGTAGGAGACAGAGTCAC TTTGCCTTTCTCTCCACAGGATCTCCTGTAAGGGTTCTGG ACATCCACTTTGCCTTTC CATCACTTGCCGGGCCAGTCTGTCCACTCCCAGGTCCAA ATACAGCTTTACCAGCTACT TCTCCACAGGTGTCCACTAGAGTATTAGTTACTGGTTG CTGCACCTCGGTTCTATCGA GGATCGGCTGGGTGCGCCACCCAGGTCCAACTGCAC GCCTGGTATCAGCAGAAAC TTGAATTCCACCATGGGATGATGCCCGGGAAAGGCCTG CTCGGTTCTATCGATTGA CAGGGAAAGCCCCTAAGCTGGTCATGTATCATCCTTTTT GAGTGGATGGGGATCATCT ATTCCACCATGGGATGGCCTGATCTATCAGGCGTCTA CTAGTAGCAACTGCAACCG ATCCTGGTGACTCTGATACCTCATGTATCATCCTTTTT GTTTAGAAAGTGGGGTCCCG GTGTACATTCCCAGGTACAAGATACAGCCCGTCCTTCC CTAGTAGCAACTGCAAC TCAAGGTTCAGCGGCAGTGGCTGCAGCAGTCTGGAGCA AAGGCCAGGTCACCATCTC CGGTGTACATTCTGACATAGTCTGGGACAGAATTCACT GAGGTGAAAAAGCCCGGGG AGCCGACAAGTCCATCAGCCCAGATGACCCAGTCTC CTCACCATCAGCAGCCTGCA AGTCTCTGAAGATCTCCTGTACCGCCTACATGCAGTGGA CTTCCACCCTGTCTGCAT GCCTGATGATTTTGCAACTTAAGGGTTCTGGATACAGCT GCAGCCTGAAGGCCTCGGA CTGTAGGAGACAGAGTCATTACTGCCAACAGTATAAT TTACCAGCTACTGGATCGG CACCGCCATGTATTACTGTGACCATCACTTGCCGGGC AGTTACCCGTACACTTTTGG CTGGGTGCGCCAGATGCCCCGAGATCGTTCCGGGACGA CAGTCAGAGTATTAGTT CCAGGGGACCAAGCTGGAGGGGAAAGGCCTGGAGTGGA CCCCCGTATAGCAGTGGCT ACTGGTTGGCCTGGTATCATCAAAC (SEQ ID  TGGGGATCATCTATCCTGGT GGCCCGGCTGATGCTTTTGAGCAGAAACCAGGGAAA NO: 3437) GACTCTGATACCAGATACA ATATCTGGGGCCAAGGGACGCCCCTAAGCTCCTGATC GCCCGTCCTTCCAAGGCCA AATGGTCACCGTCTCTTCAGTATCAGGCGTCTAGTTTA GGTCACCATCTCAGCCGAC (SEQ ID NO: 3435)GAAAGTGGGGTCCCGTC AAGTCCATCAGCACCGCCT AAGGTTCAGCGGCAGTGACATGCAGTGGAGCAGCCT AGTCTGGGACAGAATTC GAAGGCCTCGGACACCGCCACTCTCACCATCAGCAG ATGTATTACTGTGCGAGAT CCTGCAGCCTGATGATTTCGTTCCGGGACGACCCCCG TGCAACTTATTACTGCCA TATAGCAGTGGCTGGCCCGACAGTATAATAGTTACC GCTGATGCTTTTGATATCTG CGTACACTTTTGGCCAGGGGGCCAAGGGACAATGGTC GGACCAAGCTGGAGATC ACCGTCTCTTCAGCGTCGACAAACGTACGGTGGCTGC CAAGGGCCCATCGGTCTTC ACCATCTGTCTTCATCTTCCCCTGGCACCCTCCTCCAA CCCGCCATCTGATGAGC GAGCACCTCTGGGGGCACAAGTTGAAATCTGGAACT GCGGCCCTGGGCTGCCTGG GCCTCTGTTGTGTGCCTGTCAAGGACTACTTCCCCGA CTGAATAACTTCTATCCC ACCTGTGACGGTCTCGTGGAGAGAGGCCAAAGTACA AACTCAGGCGCCCTGACCA GTGGAAGGTGGATAACGGCGGCGTGCACACCTTCCC CCCTCCAATCGGGTAACT GGCTGTCCTACAGTCCTCACCCAGGAGAGTGTCACA GGACTCTACTCCCTCAGCA GAGCANGACAGCAAGGAGCGTGGTGACCGTGCCCTC CAGCACCTACAGCCTCA CAGCAGCTTGGGCACCCAGGCAGCACCCTGACGCTG ACCTACATCTGCAACGTGA AGCAAAGCAGACTACGAATCACAAGCCCAGCAACAC GAAACACAAAGTCTACG CAAGGTGGANANAGAGTTGCCTGCGAAGTCACCCAT AGCCCAAATCTTGTGACAA CAGGGCCTGAGCTCGCCACTCACACATGCCCACCGT CGTCACAAAGAGCTTCA GCCCAGCACCTGAACTCCTACAGGGGAGAGTGTTAG GGGGGGACCGTCAGTCTTC AAGCTTGGCCGCCATGGCTCTTCCCCCCAAAACCCN CCCAACTTGTTTATTGCA NNNCACCCNCATGATCTCCGCTTATNATGGNTACNA CNNACCCNNGAGTCACATG ATAAAGCAATAGCATCACNTGGNGNNGGNNGTGNNC CAAATTTCACAAATAAA CNCNANACCCNGNANGTCAGCATTTTTTTCACTGCAT AGTNN (SEQ ID  TCTANTNNTGGTTTNTCC NO: 3434)AAACTCATCANNNNTCT TATCATGTCTGGNTCGGG AANTAANTCGNNNNNAG NNNNNTGGNNTGNAANNAACNNNNNNNNN (SEQ ID NO: 3436) V-011 NNNNNNNNNNNNNNNTATCAGGTGCAGCTGCAGGAGT COV107_ NNNNNNNNNNNATGNAT CAGTCTGTGCTGACTCAGCCCOV107_ GTATNNTACACATACGATT CGGGCCCAGGACTGGTGAA P2_F11 CNTACACATACGATTTAACCCTCGGTGTCTGAAGCCC P2_F11 TAGGTGACACTATAGAATA GCCTTCGGAGACCCTGTCCGGTGACACTATAGAATA CCAGGCAGAGGGTCACCAT ACATCCACTTTGCCTTTCTCCTCACCTGCACTGTCTCTGG ACATCCACTTTGCCTTTC CTCCTGTTCTGGAAGCAGCTTCCACAGGTGTCCACTCCC TGGCTCCATCAGTAGTTACT TCTCCACAGGTGTCCACTCCAACATCGGAAATAATGCT AGGTCCAACTGCACCTCGG ACTGGAGCTGGATCCGGCACCCAGGTCCAACTGCAC GTAAATTGGTACCAGCAGGT TTCTATCGATTGAATTCCACGCCCCCAGGGAAGGGACTG CTCGGTTCTATCGATTGA CCCAGGAAAGGCTCCCAAACATGGGATGGTCATGTATC GAGTGGATTGGGTATATCT ATTCCACCATGGGATGGCTCCTCATCTATTATGATGA ATCCTTTTTCTAGTAGCAAC ATTACAGTGGGAGCACCAATCATGTATCATCCTTTTT TCTGCTGCCCTCAGGGGTCT TGCAACCGGTGTACATTCCCTACAACCCCTCCCTCAAG CTAGTAGCAACTGCAAC CTGACCGATTCTCTGGCTCCCAGCTGCAGCTGCAGGAGT AGTCGAGTCACCATATCAG CGGTTCCTGGGCCCAGTCAAGTCTGGCACCTCAGCCTC CGGGCCCAGGACTGGTGAA TAGACACGTCCAAGAACCATGTGCTGACGCAGCCAC CCTGGCCATCAGTGGGCTCC GCCTTCGGAGACCCTGTCCGTTCTCCCTGAAGCTGAGCT CCTCGGTGTCTGAAGCCC AGTCTGAGGATGAGGCTGACTCACCTGCACTGTCTCTGG CTGTGACCGCTGCGGACAC CCAGGCAGAGGGTCACCTTATTACTGTGCAGCATGGG TGGCTCCATCAGTAGTTACT GGCCGTGTATTACTGTGCGATCTCCTGTTCTGGAAGC ATGACAGCCTGAATGGCGCT ACTGGAGCTGGATCCGGCAAGAGTAGAAGACTGGGGAT AGCTCCAACATCGGAAA TGGGTGTTCGGCGGAGGGAGCCCCCAGGGAAGGGACTG ATTGTAGTAGTACCAACTG TAATGCTGTAAATTGGTACCAAGCTGACCGTCCTAG GAGTGGATTGGGTATATCT CTATTCTGGTGCTTTTGATACCAGCAGGTCCCAGGAA (SEQ ID NO: 3441) ATTACAGTGGGAGCACCAATCTGGGGCCAAGGGACAAT AGGCTCCCAAACTCCTC CTACAACCCCTCCCTCAAGGGTCACCGTCTCTTCAG ATCTATTATGATGATCTG AGTCGAGTCACCATATCAG(SEQ ID NO: 3439) CTGCCCTCAGGGGTCTCT TAGACACGTCCAAGAACCAGACCGATTCTCTGGCTCC GTTCTCCCTGAAGCTGAGCT AAGTCTGGCACCTCAGCCTGTGACCGCTGCGGACAC CTCCCTGGCCATCAGTGG GGCCGTGTATTACTGTGCGGCTCCAGTCTGAGGATG AGAGTAGAAGACTGGGGAT AGGCTGATTATTACTGTGATTGTAGTAGTACCAACTG CAGCATGGGATGACAGC CTATTCTGGTGCTTTTGATACTGAATGGCGCTTGGGT TCTGGGGCCAAGGGACAAT GTTCGGCGGAGGGACCAGGTCACCGTCTCTTCAGCGT AGCTGACCGTCCTAGGT CGACCAAGGGCCCATCGGTCAGCCCAAGGCTGCCCC CTTCCCCCTGGCACCCTCCT CTCGGTCACTCTGTTCCCCCAAGAGCACCTCTGGGGG ACCCTCGAGTGAGGAGC CACAGCGGCCCTGGGCTGCTTCAAGCCAACAAGGCC CTGGTCAAGGACTACTTCC ACACTGGTGTGTCTCATACCGAACCTGTGACGGTCTC AGTGACTTCTACCCGGG GTGGAACTCAGGCGCCCTGAGCCGTGACAGTGGCCT ACCAGCGGCGTGCACACCT GGAAGGCAGATAGCAGCTCCCGGCTGTCCTACAGTCC CCCGTCAAGGCGGGAGT TCANGACTCTACTCCCTCAGGGAGACCACCACACCCT CAGCGTGGTGACCGTGCCC CCAAACAAAGCAACAACTCCAGCAGCTTGGGCACCC AAGTACGCGGCCAGCAG AGACCTACATCTGCAACGTCTACCTGAGCCTGACGC GAATCACAAGCCCAGCAAC CTGAGCAGTGGAAGTCCACCAAAGGTGGACAAGAGA CACAGAAGCTACAGCTG GTTGAGCCCAAATCTTGTGCCAGGTCACGCATGAAG ACAAAACTCACACATGCCC GGAGCACCGTGGNNAAGACCGTGCCCAGCACCTGAA ACAGTGGNCCCTACAGA CTCCTGGGGGGANCGTCAGATGTTCATAGAAGCTTG TCTTCCTCTTCCCCCCAAAA GCCGCCATGGCCCAACTCCCAAGGACACCNTCATGA TGTTTATTGCAGCTTATA TCTCCCNGNACCCCTGAGGATGGTTACAAATAAAGC TCNCNTGCGTGGNGGNNGN AATAGCATCACAAATTTNGTGANCCACGAAGANCCT CACAAATAANCATTTTTT GANGTCAAGTTNANTGNNNCACTGCATCTANTTGNGT CNNGGNNGNCNNNNNGTGC TNNTCCAANCTCATCAATATANNNNANANNAAGCNN GNATCTNNCATGTCTGG NGGANGANNAGTACAACN NTCGGGAAN (SEQ GCACGTNCNNNNNGNNAGC ID NO: 3440) NTCNNCACCNNCCNNNACC NNNNACNNGNNNNANN(SEQ ID NO: 3438) V-C012 NNNNNNNNNNNTATGNATC CAGGTGCAGCTGGTGGAGT COV107_NNNNNNNNNNNNNNNTG CAGTCTGCCCTGACTCAGCC COV107_ NTACACATACGATTTAGGTCTGGGGGAGGCGTGGTCCA P1_B10 NNTCNACACATACGATT TGCCTCCGTGTCTGGGTCTC P1_B10GACACTATAGAATAACATC GCCTGGGAGGTCCCTGAGA TAGGTGACACTATAGAACTGGACAGTCGATCACCATC CACTTTGCCTTTCTCTCCAC CTCTCCTGTGCAGCCTCTGGTAACATCCACTTTGCCTT TCCTGCACCGGAACCAGCA AGGTGTCCACTCCCAGGTCATTCACCTTCAGTAGCCATG TCTCTCCACAGGTGTCCA GTGACGTTGGTGGTTATAACCAACTGCACCTCGGTTCTAT CTATGCACTGGGTCCGCCA CTCCCAGGTCCAACTGCTATGTCTCCTGGTACCAACA CGATTGAATTCCACCATGG GGCTCCAGGCAAGGGGCTGACCTCGGTTCTATCGATT ACACCCAGGCAAAGCCCCC GATGGTCATGTATCATCCTTGAGTGGGTGGCAGTTATAT GAATTCCACCATGGGAT AAACTCATGATTTATGATGTTTTCTAGTAGCAACTGCAA CATATGATGGAAGCAATAA GGTCATGTATCATCCTTTCAGTAATCGGCCCTCAGGG CCGGTGTACATTCTCAGGT ATACTACGCAGACTCCGTGTTCTAGTAGCAACTGCA GTTTCTAATCGCTTCTCTGG GCAGCTGGTGGAGTCTGGGAAGGGCCGATTCACCATCT ACCGGTTCCTGGCCCAGT CTCCAAGTCTGGCAACACGGGGAGGCGTGGTCCAGCCTG CCAGAGACAATTCCAAGAA CTGCCCTGACTCAGCCTGCCTCCCTGACCATCTCTGGG GGAGGTCCCTGAGACTCTC CACGCTGTATCTGCAAATGCCTCCGTGTCTGGGTCTC CTCCAGGCTGAGGACGAGG CTGTGCAGCCTCTGGATTCAAACAGCCTGAGAGCTGAGG CTGGACAGTCGATCACC CTGATTATTACTGCAGCTCACCTTCAGTAGCCATGCTATG ACACGGCTGTGTATTACTGT ATCTCCTGCACCGGAACTATACAAGCAGCAGCACTTG CACTGGGTCCGCCAGGCTC GCGAGAGAGGATTACTATGCAGCAGTGACGTTGGTG GGTGTTCGGCGGAGGGACC CAGGCAAGGGGCTGGAGTGATAGTAGTGGTTCTTTTGAC GTTATAACTATGTCTCCT AAGCTGACCGTCCTAG GGTGGCAGTTATATCATAT TACTGGGGCCAGGGAACCC GGTACCAACAACACCCA(SEQ ID NO: 3445) GATGGAAGCAATAAATACT TGGTCACCGTCTCCTCAGGGCAAAGCCCCCAAACT ACGCAGACTCCGTGAAGGG (SEQ ID NO: 3443)CATGATTTATGATGTCAG CCGATTCACCATCTCCAGA TAATCGGCCCTCAGGGGGACAATTCCAAGAACACGC TTTCTAATCGCTTCTCTG TGTATCTGCAAATGAACAGGCTCCAAGTCTGGCAAC CCTGAGAGCTGAGGACACG ACGGCCTCCCTGACCATCGCTGTGTATTACTGTGCGA TCTGGGCTCCAGGCTGA GAGAGGATTACTATGATAGGGACGAGGCTGATTATT TAGTGGTTCTTTTGACTACT ACTGCAGCTCATATACAGGGGCCAGGGAACCCTGGT AGCAGCAGCACTTGGGT CACCGTCTCCTCAGCGTCGGTTCGGCGGAGGGACCA ACCAAGGGCCCATCGGTCT AGCTGACCGTCCTAGGTTCCCCCTGGCACCCTCCTCC CAGCCCAAGGCTGCCCC AAGAGCACCTCTGGGGGCACTCGGTCACTCTGTTCCC CAGCGGCCCTGGGCTGCCT ACCCTCGAGTGAGGAGCGGTCAAGGACTACTTCCCC TTCAAGCCAACAAGGCC GAACCTGTGACGGTCTCGTACACTGGTGTGTCTCATA GGAACTCAGGCGCCCTGAC AGTGACTTCTACCCGGGCAGCGGCGTGCACACCTTC AGCCGTGACAGTGGCCT CCGGCTGTCCTACAGTCCTCGGAAGGCAGATAGCAGC AGGACTCTACTCCCTCAGC CCCGTCAAGGCGGGAGTAGCGTGGTGACCGTGCCCT GGAGACCACCACACCCT CCAGCAGCTTGGGCACCCACCAAACAAAGCAACAAC GACCTACATCTGCAACGTG AAGTACGCGGCCAGCAGAATCACAAGCCCAGCAACA CTACCTGAGCCTGACGC CCAAGGTGGACAAGAGAGTCTGAGCAGTGGAAGTCC TGAGCCCAAATCTTGTGAC CACAGAAGCTACAGCTGAAAACTCACACATGCCCAC CCAGGTCACGCATGAAG CGTGCCCAGCACCTGAACTGGAGCACCGTGGAGAAG CCTGGGGGGACCGTCAGTC ACAGTGGCCCCTACAGATTCCTCTTCCCCCCAAAACC ATGTTCATAGAAGCTTG CAAGGACACCCTCATGATCGCCGCCATGGCCCAACT TCCCGGACCCCTGAGGTTA TGTTTATTGCAGCTTATACATGCGTGGNGGNGGNCGT ATGGNTACAAATAAAGC GAGCCACGAANACCCTGANAATAGCATCACAAATTT NCAGTTCANCTGGNACNNG CACAAATAAAGCATTTTTGNNGGCGTNNNNTGCATNA TTCACTGCATTCTANTTG TGNNANAANAAGCCNNNGTGGTTTGTCCAAACTCAT GGAGGANCAGTANANAGC CAATGTATCTTATCATGTACGTACCNNGNNNNAGCGT CTGGATCGGGAATTAAN CNCNCGTCNGCACANNACTTNNNGCANCACCATGNN GGNNNANGGNNAGNANTA NTGAANTAACCTCNGAANNANNNCNNGNNNNNCNN GANNACTTNNNNGNACC NNANNNNNN (SEQ  TTCNGAGNNNANNNNNNID NO: 3442) CTGNNNNNNNNGTCANT NGGNNNNNGNANGTCCC NNGNNCCCNNNAGGCANANNNNNCNAAGCATNCA TCTCANNNNNCANCANN ANNNNN (SEQ ID NO: 3444) V-C013NNNNNNCNNNNTGNATCNT CAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNNNNTATGNATGACATCCAGATGACCCAGTC COV107_ ACACNTACGATTTAGGTGA CTGGGGGAGGCGTGGTCCAP1_D2 CNTACACATACGATTTA TCCTTCCACCCTGTCTGCAT P1_D2 CACTATAGAATAACATCCAGCCTGGGAGGTCCCTGAGA GGTGACACTATAGAATA CTGTAGGAGACAGAGTCACCTTTGCCTTTCTCTCCACAG CTCTCCTGTGCAGCGTCTGG ACATCCACTTTGCCTTTCCATCACTTGCCGGGCCAGTC GTGTCCACTCCCAGGTCCA ATTCACCTTCAGTAACTTTGTCTCCACAGGTGTCCACT AGAGTATGAGTAGCTGGTTG ACTGCACCTCGGTTCTATCGGCATGCACTGGGTCCGCCA CCCAGGTCCAACTGCAC GCCTGGTATCAGCAGAAACATTGAATTCCACCATGGGA GGCTCCAGGCAAGGGGCTG CTCGGTTCTATCGATTGACAGGGAACGCCCCTAAGCT TGGTCATGTATCATCCTTTT GAGTGGGTGGCAGTTATATATTCCACCATGGGATGG CCTGATCTATAAGGCGTCTA TCTAGTAGCAACTGCAACCGGTATGATGGAAGTAATAA TCATGTATCATCCTTTTT GTTTAGAAAGTGGGGTCCCAGGTGTACATTCTCAGGTGC ATACTATGCAGACTCCGTG CTAGTAGCAACTGCAACTCAAGGTTCAGCGGCAGTG AGCTGGTGGAGTCTGGGGG AAGGGCCGATTCACCATCTCGGTGTACATTCTGACAT GATCTGGGACAGAATTCACT AGGCGTGGTCCAGCCTGGGCCAGAGACAATTCCAAGAA CCAGATGACCCAGTCTC CTCACCATCAGCAGCCTGCAAGGTCCCTGAGACTCTCCT CACGCTGTATCTGCAAATG CTTCCACCCTGTCTGCATGCCTGATGATTTTGCAACTT GTGCAGCGTCTGGATTCAC AACAGCCTGAGAGCCGAGGCTGTAGGAGACAGAGTC ATTACTGCCAACAGCATAAT CTTCAGTAACTTTGGCATGCACACGGCTGTGTATTACTGT ACCATCACTTGCCGGGC AGTTCCCCGCTCACTTTCGGACTGGGTCCGCCAGGCTCC GCGAGAGGAGTAAACCCCG CAGTCAGAGTATGAGTACGGAGGGACCAAGGTGGAG AGGCAAGGGGCTGGAGTGG ACGATATTTTGACTGGCGTGCTGGTTGGCCTGGTATC ATCAAAC (SEQ ID GTGGCAGTTATATGGTATGAGATGCTTTTGATATCTGGG AGCAGAAACCAGGGAAC NO: 3449) ATGGAAGTAATAAATACTAGCCAAGGGACAATGGTCAC GCCCCTAAGCTCCTGATC TGCAGACTCCGTGAAGGGC CGTCTCTTCAG TATAAGGCGTCTAGTTTA CGATTCACCATCTCCAGAG (SEQ ID NO: 3447)GAAAGTGGGGTCCCATC ACAATTCCAAGAACACGCT AAGGTTCAGCGGCAGTGGTATCTGCAAATGAACAGC GATCTGGGACAGAATTC CTGAGAGCCGAGGACACGGACTCTCACCATCAGCAG CTGTGTATTACTGTGCGAG CCTGCAGCCTGATGATTTAGGAGTAAACCCCGACGAT TGCAACTTATTACTGCCA ATTTTGACTGGCGTAGATGACAGCATAATAGTTCCC CTTTTGATATCTGGGGCCAA CGCTCACTTTCGGCGGAGGGACAATGGTCACCGTCT GGGACCAAGGTGGAGAT CTTCAGCGTCGACCAAGGGCAAACGTACGGTGGCTG CCCATCGGTCTTCCCCCTGG CACCATCTGTCTTCATCTCACCCTCCTCCAAGAGCAC TCCCGCCATCTGATGAGC CTCTGGGGGCACAGCGGCCAGTTGAAATCTGGAACT CTGGGCTGCCTGGTCAAGG GCCTCTGTTGTGTGCCTGACTACTTCCCCGAACCTGTG CTGAATAACTTCTATCCC ACGGTCTCGTGGAACTCAGAGAGAGGCCAAAGTACA GCGCCCTGACCAGCGGCGT GTGGAAGGTGGATAACGGCACACCTTCCCGGCTGTCC CCCTCCAATCGGGTAACT TACAGTCCTCAGGACTCTACCCAGGAGAGTGTCACA CTCCCTCAGCAGCGTGGTG GAGCAGGACAGCAAGGAACCGTGCCCTCCAGCAGCT CAGCACCTACAGCCTCA TGGGCACCCAGACCTACATGCAGCACCCTGACGCTG CTGCAACGTGAATCACAAG AGCAAAGCAGACTACGACCCAGCAACACCAAGGTGG GAAACACAAAGTCTACG ACAAGAGAGTTGAGCCCAACCTGCGAAGTCACCCAT ATCTTGTGACAAAACTCAC CAGGGCCTGAGCTCGCCACATGCCCACCGTGCCCAG CGTCACAAAGAGCTTCA CACCTGAACTCCTGGGGGGACAGGGGANAGTGTTAG ACCGTCAGTCTTCCTCTTCC AAGCTTGGCCGCCATGGCCCCAAAACCCAAGGACAC CCCAACTTGTTTATTGCA CCTCATGATCTCCCGGACCCGCTTATAATGGNTACAA CTGAGGTCACATGCGTGGN ATAAAGCAATAGCATCAGGNNNACGTGANCCACGAA CAAATTTCACNAATAAA GACCCTNAGGTCAAGTTCAGCATTTTTTTCACTGCAT ACTGGNACGTNNNGGCNTN TCTANTTGNGGNTTNTCCNNGTGCATNANGNCCAAGA AAACTCATNANNNATNT CNAAGCCGCGGNGANCAGTNNCATGTCTGGNTCGNN ACAACANCNNNTACCGTGN NNANTNGNGCAGCNCNTNGNNANNNTCNTCACCNNC GNNNGAANNNCNCTGAA NNNACCANNANTNNNTNANGAGANNNNNNNACTNTG NNNNGNNTNNNNNNCNNG AGNGAANANNTNNNNNNNNNNNNNAANNNCNTCCNA NGAATGNNNNNNTCANT NNNCCATNNNNN (SEQ IDNGGGNNNNNNAANTCCC NO: 3446) NNGNNNCCCCNNNNNNN (SEQ ID NO: 3448) V-C014NNNNNNNNNNNNTGTNTNN GAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNNNNNNNTATGCAGTCTGTGCTGACTCAGCC COV107_ ACACATACGATTTAGGTGA CTGGAGGAGGGTTGATCCAP1_G1 TATCATACACATACGATT GCCCTCAGTGTCTGGGGCCC P1_G1 CACTATAGAATAACATCCAGCCTGGGGGGTCCCTGAAA TAGGTGACACTATAGAA CAGGGCAGAGGGTCACCATCTTTGCCTTTCTCTCCACAG CTCTCCTGTGTAGTCTCTGG TAACATCCACTTTGCCTTCTCCTGCACTGGGACCAGTT GTGTCCACTCCCAGGTCCA GTTCACCGTCAGTAAGAACTCTCTCCACAGGTGTCCA CCAACATCGGGGCAGGTTAT ACTGCACCTCGGTTCTATCGTACATCAGTTGGGTCCGCC CTCCCAGGTCCAACTGC GATGTGCACTGGTACCAGCAATTGAATTCCACCATGGGA AGGCTCCAGGCAAGGGGCT ACCTCGGTTCTATCGATTACTTCCTGGAAGAGCCCCCA TGGTCATGTATCATCCTTTT GGAATGGGTCTCAGTTATTTGAATTCCACCATGGGAT AAGTCCTCATCTCTGGAAAC TCTAGTAGCAACTGCAACCTTGCCGGTGGTAGTACATTC GGTCATGTATCATCCTTT AACATTCGGCCCTCAGAGGTGGTGTACATTCTCAGGTGC TACGCAGACTCCGTTAAGG TTCTAGTAGCAACTGCACCCTGACCGATTCTCTGGCT AGCTGGTGGAGTCTGGAGG GCCGATTCGCCATCTCCAGACCGGTTCCTGGGCCCA CCAGGTCTGGCACCTCAGCC AGGGTTGATCCAGCCTGGGAGACAACTCCAACAACACG GTCTGTGCTGACTCAGCC TCCCTGGCCATCACTAGTCTGGGTCCCTGAAACTCTCCT CTGTTTCTTCAAATGAACAG GCCCTCAGTGTCTGGGGCCAGCCTGAGGATGAGGCT GTGTAGTCTCTGGGTTCACC CCTGAGAGTCGAGGACACGCCCCAGGGCAGAGGGTC CAATATTACTGTCAGTCTTA GTCAGTAAGAACTACATCAGCCATTTATTACTGTGCGAG ACCATCTCCTGCACTGGG TGACAGCAGTCTCTATGCGGGTTGGGTCCGCCAGGCTCC AGGGGACGGGGAGTTATTC ACCAGTTCCAACATCGGTGTTCGGCGGAGGGACCAA AGGCAAGGGGCTGGAATGG TTTGACCAATGGGGCCAGGGGCAGGTTATGATGTGC GCTGACCGTCCTA (SEQ GTCTCAGTTATTTTTGCCGGGAACCCTGGTCACCGTCTC ACTGGTACCAGCAACTT ID NO: 3453) TGGTAGTACATTCTACGCACTCAG (SEQ ID NO:  CCTGGAAGAGCCCCCAA GACTCCGTTAAGGGCCGAT 3451)AGTCCTCATCTCTGGAAA TCGCCATCTCCAGAGACAA CAACATTCGGCCCTCAGCTCCAACAACACGCTGTTTC AGGTCCCTGACCGATTCT TTCAAATGAACAGCCTGAGCTGGCTCCAGGTCTGGC AGTCGAGGACACGGCCATT ACCTCAGCCTCCCTGGCCTATTACTGTGCGAGAGGGG ATCACTAGTCTCCAGCCT ACGGGGAGTTATTCTTTGAGAGGATGAGGCTCAATA CCAATGGGGCCAGGGAACC TTACTGTCAGTCTTATGACTGGTCACCGTCTCCTCAGC CAGCAGTCTCTATGCGGT GTCGACCAAGGGCCCATCGGTTCGGCGGAGGGACCA GTCTTCCCCCTGGCACCCTC AGCTGACCGTCCTACGTCCTCCAAGAGCACCTCTGGG AGCCCAAGGCTGCCCCC GGCACAGCGGCCCTGGGCTTCGGTCACTCTGTTCCCA GCCTGGTCAAGGACTACTT CCCTCGAGTGAGGAGCTCCCCGAACCTGTGACGGTC TCAAGCCAACAAGGCCA TCGTGGAACTCAGGCGCCCCACTGGTGTGTCTCATAA TGACCAGCGGCGTGCACAC GTGACTTCTACCCGGGACTTCCCGGCTGTCCTACAGT GCCGTGACAGTGGCCTG CCTCAGGACTCTACTCCCTCNAAGGCAGATAGCAGCC AGCAGCGTGGTGACCGTGC CCGTCAAGGCGGGAGTGCCTCCAGCAGCTTGGGCAC GAGACCACCACACCCTC CCAGACCTACATCTGCAACCAAACAAAGCAACAACA GTGAATCACAAGCCCAGCA AGTACGCGGCCAGCAGCACACCAAGGTGGACAAGAG TACCTGAGCCTGACGCCT AGTTGAGCCCAAATCTTGTGAGCAGTGGAAGTCCCA GACAAAACTCACACATGCC CAGAAGCTACAGCTGCCCACCGTGCCCAGCACCTGA AGGTCACGCATGAAGGG ACTCCTGGGGGGANCGTCAAGCACCGTGNANAAGAC GTCTTCCTCTTCCCCCCAAA AGTGGCCCCTACAGAATCCCNAGGACACCCTCATGA GTTCATAGAAGCTTGGN TCTCCCGGACCCCTGANTCCGCCATGGCCCAACTTGT ACATGCGTGGTGGTGGACG TTATTGCAGCTTANNATGTGAGCCACGAAGACCCTGA GTTACAAANTAAAGCAA GTCAAGTTCANTGGNACNNTAGCATCACAAATTTCAC NGNNGGCNNNGNGGTGCAT AAATAAANNCATTTTTTTAATGCCANANNAAGCCNNN CACTGCATTCTANTTGNN GGANGANCANNANANAGCGTTNGNCCAAACTCNTC ACNTACCGNGNNNNAGCGT AATGNNTCTTATCATGNCCCTNNNCNNCNNNNCNGNC TGGATCGGNNANTNANT TGNNNANGNNNNNNACNN TCGGNNCAGCNNC NNNCANGGNNNCANCNAN (SEQ ID NO: 3452) CCNTNCCNNCNNCNNTCNANAAAANNANNNNNN (SEQ ID NO: 3450) V-C015 NNNNNNNNTATGTATNNTAGAGGTGCAGCTGGTGGAGT COV107_ NNNNNNCNNATGTATCN GATATTGTGATGACTCAGTCCOV107_ CACATACGATTTAGGTGAC CTGGGGGAGGCTTGATAAA P2_B3 TACACATACGATTTAGGTTCCACTCTCCCTGTCCGTCA P2_B3 ACTATAGAATAACATCCAC GCCAGGGCGGTCCCTGAGAGACACTATAGAATAACA CCCCTGGAGAGCCGGCCTCC TTTGCCTTTCTCTCCACAGGCTCTCTTGTACAGCCTCTGG TCCACTTTGCCTTTCTCT ATCTCCTGCAGGTCTAGTCATGTCCACTCCCAGGTCCAA ATTCACCTTTGGTGATTATG CCACAGGTGTCCACTCCCGAGCCTCCTGCATAGTAATG CTGCACCTCGGTTCTATCGA CTATGACCTGGTTCCGCCAAGGTCCAACTGCACCTC GAAACAACTATTTCGATTGG TTGAATTCCACCATGGGATGGCTCCAGGGAAGGGGCTG GGTTCTATCGATTGAATT TACCTGCAGAAGCCAGGGCGGTCATGTATCATCCTTTTT GAGTGGGTAGGTTTCATTA CCACCATGGGATGGTCAAGTCTCCACAGCTCCTGATC CTAGTAGCAACTGCAACCG GAAGTAAAGCTTATGGTGGTGTATCATCCTTTTTCTA TATTTGGGTTCTAATCGGGC GGTACATTCTCAGGTGCAGGACAACAGGATACGCCGCG GTAGCAACTGCAACCGG CTCCGGGGTCCCTGACAGGTCTGGTGGAGTCTGGGGGAG TCTGTGAAATACAGATTTA TGTACATGGGGATATTGTTCAGTGGCAGTGGATCAGG GCTTGATAAAGCCAGGGCG CCATCTCAAGAGATGATTCGATGACTCAGTCTCCACT CACAGATTTTACACTGAAGA GTCCCTGAGACTCTCTTGTACAAAAGCATCGCCTATCTG CTCCCTGTCCGTCACCCC TCAGCAGAGTGGAGGCTGACAGCCTCTGGATTCACCTTT CAAATGGACAGCCTGAAAA TGGAGAGCCGGCCTCCAGGATGTTGGGGTTTATTACT GGTGATTATGCTATGACCT CCGAGGACACAGCCGTGTATCTCCTGCAGGTCTAGTC GCATGCAAGTTCTACAAATT GGTTCCGCCAGGCTCCAGGTTACTGTACTAGGTGGGAC AGAGCCTCCTGCATAGT CCGTACACTTTTGGCCAGGGGAAGGGGCTGGAGTGGGTA GGGTGGAGTCAACATGACT AATGGAAACAACTATTTGACCAAGCTGGAGATCAA GGTTTCATTAGAAGTAAAG ATTGGGGCCAGGGAACCCTCGATTGGTACCTGCAGA (SEQ ID NO: 3457) CTTATGGTGGGACAACAGGGGTCACCGTCTCCTCAG AGCCAGGGCAGTCTCCA ATACGCCGCGTCTGTGAAA(SEQ ID NO: 3455) CAGCTCCTGATCTATTTG TACAGATTTACCATCTCAAGGTTCTAATCGGGCCTCC GAGATGATTCCAAAAGCAT GGGGTCCCTGACAGGTTCGCCTATCTGCAAATGGAC CAGTGGCAGTGGATCAG AGCCTGAAAACCGAGGACAGCACAGATTTTACACTG CAGCCGTGTATTACTGTACT AAGATCAGCAGAGTGGAAGGTGGGACGGGTGGAGTC GGCTGAGGATGTTGGGG AACATGACTATTGGGGCCATTTATTACTGCATGCAAG GGGAACCCTGGTCACCGTC TTCTACAAATTCCGTACATCCTCAGCGTCGACCAAGG CTTTTGGCCAGGGGACC GCCCATCGGTCTTCCCCCTGAAGCTGGAGATCAAACG GCACCCTCCTCCAAGAGCA TACGGTGGCTGCACCATCCTCTGGGGGCACAGCGGC CTGTCTTCATCTTCCCGC CCTGGGCTGCCTGGTCAAGCATCTGATGAGCAGTTG GACTACTTCCCCGAACCTGT AAATCTGGAACTGCCTCTGACGGTCTCGTGGAACTCA GTTGTGTGCCTGCTGAAT NGCGCCCTGACCAGCGGCGAACTTCTATCCCAGAGA TGCACACCTTCCCGGCTGTC GGCCAAAGTACAGTGGACTACAGTCCTCNNNCTCTAC AGGTGGATAACGCCCTC TCCCTCAGCAGCGTGGTGACAATCGGGTAACTCCCA CCGTGCCCTCCAGCAGCTT GGAGAGTGTCACAGAGCGGGCACCCAGACCTACATC AGGACAGCAAGGACAGC TGCAACGTGAATCACAAGCACCTACAGCCTCAGCAG CCAGCANNNCCNNNNNNNN CACCCTGACGCTGAGCAANANANTTGAGCCCNAATC AAGCAGACTACGAGAAA TNNTGANNAACTCANNCATCACAAAGTCTACGCCTG GCCCANCGNGCCCAGCACC CGAAGTCACCCATCNGGTGACTNCTGGGGGGANCGT NCNTGAGCTCGCCCGTC CAGTCTCNNTCCCCNNAANACAAAGAGCTTCAACNG CNNNNNNNCCNTCATGATN GGGANANTGTTAGAAGCNNCNNACCCTGAGTCACAT TTGGNCGCCATGGCCCA GNNNNGGTGGNNGANNTGACTTGTTTATTGCAGCTT ANCCNCNANANCCTGAGNC ATNATGGNTACAAATAAAGTCANTGNANNGNNNGGN AGCAATAGCATCACAAA NNGNNNNNNCNNNANGCNTTTCANAATAAAGCATTT NANNNANNNNNNGNNNNN TTTTCACTGCATNTANTNNNNNNTNCANNNNGCNNGT NGGNNNTCCAANCTCAT NCNNNNGTNNNNNNNNNCCNATGNATNTATCATGTC NGTNCNNNNNNNNNNTGGN TGGNTCNGNATTANTTCNNANGNNNNNNNNNNANN GNNNNAGCNNCANN NNNNNGNNNNNCNNNANN (SEQ ID NO: 3456)NNNCNNNNCCCCCNNNNNN NNA (SEQ ID NO:  3454) V-C016 NNNNNNNNNNATGTATCATCAGGTGCAGCTGGTGGAGT COV107_ NNNNCNTTATGNNTCNA AATTTTATGCTGACTCAGCCCOV107_ ACACNTACGATTTAGGTGA CTGGGGGAGGCGTGGTCCA P2_C6 CNCATACGATTTAGGTGCCACTCTGTGTCGGAGTCTC P2_C6 CACTATAGAATAACATCCA GCCTGGGAGGTCCCTGAGAACACTATAGAATAACAT CGGGGAAGACGGTAACCAT CTTTGCCTTTCTCTCCACAGCTCTCCTGTGCAGCCTCTGG CCACTTTGCCTTTCTCTC CTCCTGCACCGGCAGCAGTGGTGTCCACTCCCAGGTCCA ATTCACCTACAGTACCTATG CACAGGTGTCCACTCCCGCAGCATTGCCAGCAACTAT ACTGCACCTCGGTTCTATCG CTATGCACTGGGTCCGCCAAGGTCCAACTGCACCTC GTGCAGTGGTACCAGCAGC ATTGAATTCCACCATGGGAGGCTCCAGGCAAGGGGCTG GGTTCTATCGATTGAATT GCCCGGGCAGTGCCCCCACCTGGTCATGTATCATCCTTTT GAGTGGGTGGCATTTATAT CCACCATGGGATGGTCAACTGTGATCTATGAGGATAA TCTAGTAGCAACTGCAACC CATATGATGGAAGCAATAATGTATCATCCTTTTTCTA CCAAAGACCCTGTGGGGTCC GGTGTACATTCTCAGGTGCATACTACGCAGACTCCGTG GTAGCAATGCAACCGGT CTGATCGGTTCTCTGGCTCCAGCTGGTGGAGTCTGGGGG AAGGGCCGATTCACCATCT TCTTGGGCCAATTTTATGATCGACAGGTCCTCCAACTC AGGCGTGGTCCAGCCTGGG CCAGAGACAATTCCAAGAACTGACTCAGCCCCACTCT TGCCTCCCTCACCATCTCTG AGGTCCCTGAGACTCTCCTCACGCTGTATCTGCAAATG GTGTCGGAGTCTCCGGG GACTGAAGACTGAGGACGAGTGCAGCCTCTGGATTCAC AACAGCCTGAGAGCTGAGG GAAGACGGTAACCATCTGGCTGACTACTACTGTCAGT CTACAGTACCTATGCTATGC ACACGGCTGTGTATTACTGTCCTGCACCGGCAGCAGT CTTATGATAGCGGCAATCAT ACTGGGTCCGCCAGGCTCCGCGAGAGATTTCTACCATA GGCAGCATTGCCAGCAA TGGGTGGTATTCGGCGGAGAGGCAAGGGGCTGGAGTGG ACTGGTTCGACCCCTGGGG CTATGTGCAGTGGTACCGGACCAGGCTGACCGTCCTA GTGGCATTTATATCATATGA CCAGGGAACCCTGGTCACCAGCAGCGCCCGGGCAGT G (SEQ ID NO: 3461) TGGAAGCAATAAATACTACGTCTCCTCAG (SEQ ID GCCCCCACCACTGTGATC GCAGACTCCGTGAAGGGCC NO: 3459)TATGAGGATAACCAAAG GATTCACCATCTCCAGAGA ACCCTCTGGGGTCCCTGACAATTCCAAGAACACGCTG TCGGTTCTCTGGCTCCAT TATCTGCAAATGAACAGCCCGACAGGTCCTCCAACT TGAGAGCTGAGGACACGGC CTGCCTCCCTCACCATCTTGTGTATTACTGTGCGAGA CTGGACTGAAGACTGAG GATTTCTACCATAACTGGTTGACGAGGCTGACTACTA CGACCCCTGGGGCCAGGGA CTGTCAGTCTTATGATAGACCCTGGTCACCGTCTCCTC CGGCAATCATTGGGTGG AGCGTCGACCAAGGGCCCATATTCGGCGGAGGGACC TCGGTCTTCCCCCTGGCACC AGGCTGACCGTCCTAGGCTCCTCCAAGAGCACCTCT TCAGCCCAAGGCTGCCC GGGGGCACAGCGGCCCTGGCCTCGGTCACTCTGTTCC GCTGCCTGGTCAAGGACTA CGCCCTCGAGTGAGGAGCTTCCCCGAACCTGTGACG CTTCAAGCCAACAAGGC GTCTCGTGGAACTCAGGCGCACACTGGTGTGTCTCAT CCCTGACCAGCGGCGTGCA AAGTGACTTCTACCCGGCACCTTCCCGGCTGTCCTAC GAGCCGTGACAGTGGCC AGTCCTCANGACTCTACTCCTGGANGGCAGATAGCAG CTCAGCAGCGTGGTGACCG CCCCGTCAAGGCGGGAGTGCCCTCCAGCAGCTTGGG TGGAGACCACCACACCC CACCCAGACCTACATCTGCTCCAAACAAAGCAACNA AACGTGAATCACAAGCCCA CAAGTACGCNGNCNNNCGCAACACCAAGGTGGACAA ANN (SEQ ID NO: GAGAGTTGAGCCCAAATCT 3460)TGTGACAAAACTCACACAT GCCCACCGTGCCCAGCACC TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCC AAAACCCNNNNNNNCCTCA TGATCTCCCGGACCCCTGAGTCACATGCGTGNNNNNNG TGAGCCACGANANCCTGAG NCAGTTCAACTGGNACNNNGNNGGCNNGGNNNTGCAN NATGCCNAGACNNAAGCCN N (SEQ ID NO: 3458) V-C017NNNNNNNNNATGTATCNTA CAGGTGCAGCTGGTGGAGT COV107_ NNNNNNCNNATGTATCNCAGTCTGTGCTGACTCAGCC COV107_ CACATACGATTTAGGTGAC CTGGGGGAGGCGTGGTCCAP2_H5 TACACATACGATTTAGGT GCCCTCAGTGTCTGCGGCCC P2_H5 ACTATAGAATAACATCCACGCCTGGGAGGTCCCTGAGA GACACTATAGAATAACA CAGGACAGAAGGTCACCATTTTGCCTTTCTCTCCACAGG CTCTCCTGTGCAGCCTCTGG TCCACTTTGCCTTTCTCTCTCCTGCTCTGGAAGCAGCT TGTCCACTCCCAGGTCCAA ATTCACCTTCAGTACCTATGCCACAGGTGTCCACTCCC CCAACATTGGGAATAATTTG CTGCACCTCGGTTCTATCGACTATGCACTGGGTCCGCCA AGGTCCAACTGCACCTC GTATCCTGGTACCAGCAGCTTTGAATTCCACCATGGGAT GGCTCCAGGCGAGGGGCTG GGTTCTATCGATTGAATTCCCAGGAACAGCCCCCAAA GGTCATGTATCATCCTTTTT GAGTGGGTGGCAGTTATTTCCACCATGGGATGGTCA CTCCTCATCTATGAAAATAA CTAGTAGCAATGCAACCGGCATATGATGGAAGCAATAC TGTATCATCCTTTTTCTA TAAGCGACCCTCAGGGATTCTGTACATTCTCAGGTGCAG ATACTACGCAGACTCCGTG GTAGCAACTGCAACCGGCTGACCGATTCTCTGGCTCC CTGGTGGAGTCTGGGGGAG AAGGGCCGATTCACCATCTTTCCTGGGCCCAGTCTGT AAGTCTGGCACGTCAGCCAC GCGTGGTCCAGCCTGGGAGCCAGAGACAATTCCAAGAA GCTGACTCAGCCGCCCTC CCTGGGCATCACCGGACTCCGTCCCTGAGACTCTCCTGTG CACGCTGTATCTGCAAATG AGTGTCTGCGGCCCCAGAGACTGGGGACGAGGCCGA CAGCCTCTGGATTCACCTTC AACAGCCTGAGAGCTGAAGGACAGAAGGTCACCATC TTATTACTGCGGAGCATGGG AGTACCTATGCTATGCACTACACGGCTGTGTATTACTGT TCCTGCTCTGGAAGCAG ATAGCAGCCTGAGTGCTGGCGGGTCCGCCAGGCTCCAGG GCGAGAGATCCCATATGGT CTCCAACATTGGGAATAGGGGTTTATGTCTTCGGAAC CGAGGGGCTGGAGTGGGTG TCGGGGAGTTATTATCTCCTATTTGGTATCCTGGTACC TGGGACCAAGGTCACCGTCC GCAGTTATTTCATATGATGGCCTTTTGTTCACTTTGACTA AGCAGCTCCCAGGAACA TAG (SEQ ID NO:AAGCAATACATACTACGCA CTGGGGCCAGGGAACCCTG GCCCCCAAACTCCTCATC 3465)GACTCCGTGAAGGGCCGAT GTCACCGTCTCCTCAG (SEQ TATGAAAATAATAAGCGTCACCATCTCCAGAGACAA ID NO: 3463) ACCCTCAGGGATTCCTG TTCCAAGAACACGCTGTATACCGATTCTCTGGCTCCA CTGCAAATGAACAGCCTGA AGTCTGGCACGTCAGCCGAGCTGAAGACACGGCTGT ACCCTGGGCATCACCGG GTATTACTGTGCGAGAGATACTCCAGACTGGGGACG CCCATATGGTTCGGGGAGT AGGCCGATTATTACTGCTATTATCTCCTCCTTTTGTT GGAGCATGGGATAGCAG CACTTTGACTACTGGGGCCCCTGAGTGCTGGCGGGG AGGGAACCCTGGTCACCGT TTTATGTCTTCGGAACTGCTCCTCAGCGTCGACCAAG GGACCAAGGTCACCGTC GGCCCATCGGTCTTCCCCCTCTAGGTCAGCCCAAGGC GGCACCCTCCTCCAAGAGC CAACCCCACTGTCACTCTACCTCTGGGGGCACAGCGG GTTCCCACCCTCGAGTGA CCCTGGGCTGCCTGGTCAAGGAGCTTCAAGCCAACA GGACTACTTCCCCGAACCT AGGCCACACTGGTGTGTGTGACGGTCTCGTGGAACT CTCATAAGTGACTTCTAC CAGGCGCCCTGACCAGCGGCCGGGAGCCGTGACAGT CGTGCACACCTTCCCGGCT GGCCTGGAAGGCAGATAGTCCTACAGTCCTCAGGAC GCAGCCCCGTCAAGGCG TCTACTCCCTCAGCAGCGTGGGAGTGGAGACCACCAC GTGACCGTGCCCTCCAGCA ACCCTCCAAACAAAGCAGCTTGGGCACCCAGACCTA ACAACAAGTACGCGGCC CATCTGCAACGTGAATCACAGCAGCTACCTGAGCCT AAGCCCAGCAACACCNANG GACGCCTGAGCAGTGGATGGACAAGAGAGTTGAGCC AGTCCCACAGAAGCTAC CAAATCTTGTGACAAAACTAGCTGCCAGGTCACGCA CACACATGCCCACCGTGCC TGAAGGGAGCANCGTGNCAGCACCTGAACTCCTGGG NANANAGTNNCCCTACN GGGACCGTCAGTCTTCCTCTGAATGNTCATNNNANCT TCCCCCCAAAACCCNAGGA TGGNGCATGGCCCANTTNACCCTCATGATCTCCCNG GTTNANTGCAGCTTATA ACCCCNGAGTCACNNGCCGATGGTNCAANNAAGCAT NNGNNGGNGGACGTGAGCC AGCATCACAAANTTCAC NNGA (SEQ ID NO:AAATAAGCATTTTTTNNC 3462) TGCATCTANNNNGTTGN CNAACTCNTCANGNNNCTTANCATGNCNGNTCGG NANNNNGNNCANNNCNT NNNGAANNNACCNNTNA NNNANTNNNNNGNACTNNGANGNGAANANCNNN NNNNNNNGGNGNNANN NNGGNNNAAGNNNCCNN GNNCCNNNGNNANNNNNNNNNNNGNN (SEQ ID NO: 3464) V-C018 NNNNNNNNNNNNTGNATCNCAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNNNCNTATGNN CAGTCTGTGCTGACTCAGTCCOV107_ ACACATACGATTTAGGTGA CTGGGGGAGGCGTGGTCCA P2_E1 NNNACACNTACGATTTAGCCCTCTGCCTCTGCCTCCC P2_E1 CACTATAGAATAACATCCA GCCTGGGAGGTCCCTGAGAGGTGACACTATAGAATA TGGGAGCCTCGGTCAAGCTC CTTTGCCTTTCTCTCCACAGCTCTCCTGTGCAGCCTCTGG ACATCCACTTTGCCTTTC ACCTGCACTCTGAGCAGTGGGTGTCCACTCCCAGGTCCA ATTCACCTTCAGTAACTATG TCTCCACAGGTGTCCACTGCACAGCAGCTACGCCATC ACTGCACCTCGGTTCTATCG CTATGCACTGGGTCCGCCACCCAGGTCCAACTGCAC GCATGGCATCAGCAGCAGC ATTGAATTCCACCATGGGAGGCTCCAGGCAAGGGGCTG CTCGGTTCTATCGATTGA CAGAGAAGGGCCCTCGGTATGGTCATGTATCATCCTTTT GAGTGGGTGGCAGTTATAT ATTCCACCATGGGATGGCTTGATGAAGCTTAACACTG TCTAGTAGCAACTGCAACC CATATGATGGAAGCAATANTCATGTATCATCCTTTTT ATGGCAGCCACAGCAAGGG GGTGTACATTCTCAGGTGCATACTACGCAGACTCCGTG CTAGTAGCAACTGCAAC GGACGGGATCCCTGATCGCTAGCTGGTGGAGTCTGGGGG AAGGGCCGATTCACCATCT CGGTTCTCTCTCCCAGCCTCTCAGGCTCCAGCTCTGGG AGGCGTGGTCCAGCCTGGG CCAGAGACAATTCCAAGAATGTGCTGACTCAATCGCC GCTGAGCGCTACCTCACCAT AGGTCCCTGAGACTCTCCTCACGCTGTATCTGCAAATG CTCTGCCTCTGCCTCCCT CTCCAGCCTCCAGTCTGAGGGTGCAGCCTCTGGATTCAC AACAGCCTGAGAGCTGAGG GGGAGCCTCGGTCAAGCATGAGGCTGACTATTACTGT CTTCAGTAACTATGCTATGC ACACGGCTATTTATTACTGTTCACCTGCACTCTGAGCA CAGACCTGGGGCACTGGCA ACTGGGTCCGCCAGGCTCCGCGAGTGGATATACTGGCT GTGGGCACAGCAGCTAC TTCTCGTATTCGGCGGAGGGAGGCAAGGGGCTGGAGTGG ACGATTATTTTGTGCGGGG GCCATCGCATGGCATCAACCAAGCTGACCGTCCTAG GTGGCAGTTATATCATATG GGACTACTACGGTCTGGACGCAGCAGCCAGAGAAGG (SEQ ID NO: 3469) ATGGAAGCAATAAATACTAGTCTGGGGCCAAGGGACCA GCCCTCGGTACTTGATGA CGCAGACTCCGTGAAGGGCCGGTCACCGTCTCCTCA AGCTTAACACTGATGGC CGATTCACCATCTCCAGAG(SEQ ID NO: 3467) AGCCACAGCAAGGGGGA ACAATTCCAAGAACACGCTCGGGATCCCTGATCGCTT GTATCTGCAAATGAACAGC CTCAGGCTCCAGCTCTGGCTGAGAGCTGAGGACACGG GGCTGAGCGCTACCTCA CTATTTATTACTGTGCGAGTCCATCTCCAGCCTCCAGT GGATATACTGGCTACGATT CTGAGGATGAGGCTGACATTTTGTGCGGGGGGACTA TATTACTGTCAGACCTGG CTACGGTCTGGACGTCTGGGGCACTGGCATTCTCGTA GGCCAAGGGACCACGGTCA TTCGGCGGAGGGACCAACCGTCTCCTCAGCGTCGACC GCTGACCGTCCTAGGTC AAGGGCCCATCGGTCTTCCAGCCCAAGGCTGCCCCC CCCTGGCACCCTCCTCCAA TCGGTCACTCTGTTCCCGGAGCACCTCTGGGGGCACA CCCTCGAGTGAGGAGCT GCGGCCCTGGGCTGCCTGGTCAAGCCAACAAGGCCA TCAAGGACTACTTCCCCGA CACTGGTGTGTCTCATAAACCTGTGACGGTCTCGTGG GTGACTTCTACCCGGGA AACTCAGGCGCCCTGACCAGCCGTGACAGTGGCCTG GCGGCGTGCACACCTTCCC GAAGGCAGATAGCAGCCGGCTGTCCTACAGTCCTCA CCGTCAAGGCGGGAGTG GGACTCTACTCCCTCAGCAGAGACCACCACACCCTC GCGTGGTGACCGTGCCCTC CAAACAAAGCAACAACACAGCAGCTTGGGCACCCAG AGTACGCGGCCAGCAGC ACCTACATCTGCAACGTGATACCTGAGCCTGACGCCT ATCACAAGCCCAGCAACAC GAGCAGTGNAAGTCCCACAAGGTGGACAAGAGAGTT CAGAAGCTACAGCTGCC GAGCCCAAATCTTGTGACAAGGTCACGCATGAANGG AAACTCACACATGCCCACC AGCACCGTGGAGAAGACGTGCCCAGCACCTGAACTC AGTGGCCCCTACAGAAT CTGGGGGGACCGTCAGTCTGTTCATAGAAGCTTGGG TCCTCTTCCCCCCAAAACCC CCGCCATGGNCCAACTTAAGGACACCCTCATGATCT GTTTATTGCAGCTTATAA CCCGGACCCCTGAGGTNNCTGGTTACAAATAAAGCA ATGCGTGGNGGTGGNNGTG ATAGCATCACAAATTTCANCCACNANACCCTGANGT ACAAATAAAGCATTTTTT CAAGTTCAACTGGNACGTNTCACTGCATTCTANTTNG NNGGCGTGAAGGTGCATAA TGGNTTGTCCAAACTCATTGNCNANNANNANCCGCNG CAATGNATCTTATCATGT GNAGGAGCAGNANANNNNCTGGNTCGGGAANTAAT CNNNNNCNNGNNNNNCAN TCGNNGCANCANCATNNCNNCNTCNNCNNNNNNCAN NTGAAATACNTCTNAAN NNNNNTNNNNNNNNNNNNNAGNNNTGNNNGGTACC NANTACNANNNNAGNNNN TTCTGAGGNNNANGAANCANNAANNCNTCCCNNNCC CANCTNNGGNNNNNNNN NCATNNNNAAAANNCNTNNNNCANTNNGNNNNNNNN NNCAANN (SEQ ID  NCCCNNNNCCCNNNNCC NO: 3466)NNANNATGCAAAGCATG CATNTNNNNNNCNGNNN NNNNNNNNAANNNCNCA GNNNNCNCNNNNGGNNNANNNNNNNNAANNNN (SEQ ID NO: 3468) V-C019 NNNNNNNNNNNNNNNNTGCAGGTGCAGCTGGTGCAGT COV107_ NNNNNNNNNNNATGTAT CAGTCTGCCCTGACTCAGCCCOV107_ TATCNNCACNTACGATTTA CTGGGGCTGAGGTGAAGAA P1_H7 CNTACACATACGATTTATGCCTCCGTGTCTGGGTCTC P1_H7 GGTGACACTATAGAATAAC GCCTGGGGCCTCAGTGAAGGGTGACACTATAGAATA CTGGACAGTCGATCACCATC ATCCACTTTGCCTTTCTCTCGTTTCCTGCAAGGCATCTG ACATCCACTTTGCCTTTC TCCTGCACTGGAACCAGCAGCACAGGTGTCCACTCCCAG GATACACCTTCACCAGCTA TCTCCACAGGTGTCCACTTGACGTTGGTGGTTATAAGT GTCCAACTGCACCTCGGTTC CTATATGCACTGGGTGCGACCCAGGTCCAACTGCAC ATGTCTCCTGGTACCAACGG TATCGATTGAATTCCACCATCAGGCCCCTGGACAAGGGC CTCGGTTCTATCGATTGA CACCCAGGCAAAGCCCCCAGGGATGGTCATGTATCATC TTGAGTGGATGGGAATAAT ATTCCACCATGGGATGGAACTCATGATATATGATGTC CTTTTTCTAGTAGCAACTGC CAACCCTAGTGGTGGTAGCTCATGTATCATCCTTTTT AGTAATCGGCCCTCAGGGGT AACCGGTGTACATTCCCAGACAAGCTACGCACAGAAGT CTAGTAGCAACTGCAAC TTCTAATCGCTTCTCTGGCTGTCCAGCTGGTACAGTCTG TACAGGGCAGAGTCACCAT CGGTTCCTGGGCCCAGTCCCAAGTCTGGCAACACGGC GGGCTGAGGTGAAGAAGCC GACCAGGGACACGTCCACGTGCCCTGACTCAGCCTGC CTCCCTGACCATCTCTGGGC TGGGGCCTCAGTGAAGGTTAGCACAGTCTACATGGAGC CTCCGTGTCTGGGTCTCC TCCAGGCTGAGGACGAGGCTCCTGCAAGGCATCTGGAT TGAGCAGCCTGAGATCTGA TGGACAGTCGATCACCATGATTATTACTGCAGCTCAT ACACCTTCACCAGCTACTAT GGACACGGCCGTGTATTACTCTCCTGCACTGGAACCA ACACAAGCAGCAGCACTTCT ATGCACTGGGTGCGACAGGTGTGCGAGAGCCAATCATG GCAGTGACGTTGGTGGT GTGGTGTTCGGCGGAGGGACCCCTGGACAAGGGCTTGA AAACAACTATGGACACTTA TATAAGTATGTCTCCTGGCCCAGCTGACCGTCCTAG GTGGATGGGAATAATCAAC CTACTACTACTACTACATGGTACCAACGGCACCCAGG (SEQ ID NO: 3473) CCTAGTGGTGGTAGCACAAACGTCTGGGGCAAAGGGAC CAAAGCCCCCAAACTCA GCTACGCACAGAAGTTACACACGGTCACCGTCTCCTCA TGATATATGATGTCAGTA GGGCAGAGTCACCATGACC(SEQ ID NO: 3471) ATCGGCCCTCAGGGGTTT AGGGACACGTCCACGAGCACTAATCGCTTCTCTGGCT CAGTCTACATGGAGCTGAG CCAAGTCTGGCAACACGCAGCCTGAGATCTGAGGAC GCCTCCCTGACCATCTCT ACGGCCGTGTATTACTGTGGGGCTCCAGGCTGAGGA CGAGAGCCAATCATGAAAC CGAGGCTGATTATTACTGAACTATGGACACTTACTAC CAGCTCATACACAAGCA TACTACTACTACATGGACGGCAGCACTTCTGTGGTGT TCTGGGGCAAAGGGACCAC TCGGCGGAGGGACCCAGGGTCACCGTCTCCTCAGCGT CTGACCGTCCTAGGTCA CGACCAAGGGCCCATCGGTGCCCAAGGCTGCCCCCT CTTCCCCCTGGCACCCTCCT CGGTCACTCTGTTCCCGCCCAAGAGCACCTCTGGGGG CCTCGAGTGAGGAGCTT CACAGCGGCCCTGGGCTGCCAAGCCAACAAGGCCAC CTGGTCAAGGACTACTTCC ACTGGTGTGTCTCATAAGCCGAACCTGTGACGGTCTC TGACTTCTACCCGGGAG GTGGAACTCAGGCGCCCTGCCGTGACAGTGGCCTGG ACCAGCGGCGTGCACACCT AAGGCAGATAGCAGCCCTCCCGGCTGTCCTACAGTCC CGTCAAGGCGGGAGTGG TCANGACTCTACTCCCTCAGAGACCACCACACCCTCC CAGCGTGGTGACCGTGCCC AAACAAAGCAACAACAATCCAGCAGCTTGGGCACCC GTACGCGGCCAGCAGCT AGACCTACATCTGCAACGTACCTGAGCCTGACGCCT GAATCACAAGCCCAGCAAC GAGCAGTGGAAGTCCCAACCNANGTGGACAAGAGAG CAGAAGCTACAGCTGCC TTGAGCCCAAATCTTGTGAAGGTCACGCATGAAGGG CAAAACTCACACATGCCCA AGCACCGNGGNGAAGACCCGTGCCCAGCACCTGAAC AGTGGCCCCTACAGAAT TCCTGGGGGGACCGTCAGTGTTCATAGAAGCTTGGN CTTCCTCTTCCCCCCNAAAC CGCCATGGCCCAACTTGTCCNNNGACACCCTCATGAT TTATTGCAGCTTATAATG CTCCCGGACCCCTGAGGTCGTTACAAATAAAGCAAT ACATGCGTGGNNGNNGACG AGCATCACAAATTTCACTGAGCCACGAANACCCTGA AAATAANCATTTTTTTCA NNCAAGTTCAACTGGNACNCTGCATNTANTGNNGNT TNNNGGNNNNNNNGNGCAT NNTCCAAACTCATCNATNANGNNANAANAAGCNNN GNATNTNTCATGTCTGG NGGGAGGANCANNANNAANTCGGGNANTNANTCGN CAGCNNNNNACCNNNGNN NNNNAGCANNATNN NGNCNNNCNNNCCNTCACC(SEQ ID NO: 3472) NN (SEQ ID NO: 3470) V-C020 NNNNNNNNNNATGNNTCNAGAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNNNNTATGNAT GACATCCAGATGACCCAGTCCOV107_ CACATACGATTTAGGTGAC CTGGAGGAGGCTTGATCCA P2_C8 CNTACACATACGATTTATCCATCCTCCCTGTCTGCAT P2_C8 ACTATAGAATAACATCCAC GCCTGGGGGGTCCCTGAGAGGTGACACTATAGAATA CTGTAGGAGACACAGTCAC TTTGCCTTTCTCTCCACAGGCTCTCCTGTGCAGCCTCTGG ACATCCACTTTGCCTTTC CATCACTTGCCAGGCGAGTCTGTCCACTCCCAGGTCCAA GTTCACCGTCAGTAGCAAC TCTCCACAGGTGTCCACTAGGACATTAGCAAGTATTTA CTGCACCTCGGTTCTATCGA TACATGACCTGGGTCCGCCCCCAGGTCCAACTGCAC AATTGGTATCAGCAGAAAC TTGAATTCCACCATGGGATAGGCTCCAGGGAAGGGGCT CTCGGTTCTATCGATTGA CAGGGAAAGCCCCTAAGCTGGTCATGTATCATCCTTTTT GGAGTGGGTCTCACTTATTT ATTCCACCATGGGATGGCCTGATCTACGATGCATCCA CTAGTAGCAACTGCAACCG ATCCCGGTGGTAGCACATATCATGTATCATCCTTTTT ATTTGGAAACAGGGGTCCC GTGTACATTCTGAGGTGCACTACGCAGACTCCGTGAAG CTAGTAGCAACTGCAAC ATCAAGGTTCAGTGGAAGTGCTGGTGGAGTCTGGAGGA GGCCGATTCACCATCTCCA CGGTGTACATTGTGCCATGGATCTGGGACAGATTTTAC GGCTTGATCCAGCCTGGGG GAGACAATTCCAAGAACACCCGGATGACCCAGTCTC TTTCACCATCAGCAGCCTGC GGTCCCTGAGACTCTCCTGTGCTGTATCTTCAAATGAAC CATCCTCCCTGTCTGCAT AGCCTGAAGATATTGCAACGCAGCCTCTGGGTTCACCG AGCCTGAGAGCCGAGGACA CTGTAGGAGACACAGTCATATTACTGTCAACAGTATG TCAGTAGCAACTACATGAC CGGCCGTCTATTACTGTGCGACCATCACTTGCCAGGC ATAATCTCCCTCAGACTTTC CTGGGTCCGCCAGGCTCCAAGAGAGGGTATGGGTATGG GAGTCAGGACATTAGCA GGCGGAGGGACCAAGGTGGGGGAAGGGGCTGGAGTGGG CAGCAGCTGGTACGTGGGG AGTATTTAAATTGGTATCAGATCAAAC (SEQ ID  TCTCACTTATTTATCCCGGT CCAGGGAACCCTGGTCACCAGCAGAAACCAGGGAAA NO: 3477) GGTAGCACATACTACGCAG GTCTCCTCAG (SEQ IDGCCCCTAAGCTCCTGATC ACTCCGTGAAGGGCCGATT NO: 3475) TACGATGCATCCAATTTGCACCATCTCCAGAGACAAT GAAACAGGGGTCCCATC TCCAAGAACACGCTGTATCAAGGTTCAGTGGAAGTG TTCAAATGAACAGCCTGAG GATCTGGGACAGATTTTAGCCGAGGACACGGCCGTC ACTTTCACCATCAGCAGC TATTACTGTGCGAGAGAGGCTGCAGCCTGAAGATAT GTATGGGTATGGCAGCAGC TGCAACATATTACTGTCATGGTACGTGGGGCCAGGGA ACAGTATGATAATCTCCC ACCCTGGTCACCGTCTCCTCTCAGACTTTCGGCGGAG AGCGTCGACCAAGGGCCCA GGACCAAGGTGGAGATCTCGGTCTTCCCCCTGGCACC AAACGTACGGTGGCTGC CTCCTCCAAGAGCACCTCTACCATCTGTCTTCATCTT GGGGGCACAGCGGCCCTGG CCCGCCATCTGATGAGCGCTGCCTGGTCAAGGACTA AGTTGAAATCTGGAACT CTTCCCCGAACCTGTGACGGCCTCTGTTGTGTGCCTG GTCTCGTGGAACTCAGGCG CTGAATAACTTCTATCCCCCCTGACCAGCGGCGTGCA AGAGAGGCCAAAGTACA CACCTTCCCGGCTGTCCTACGTGGAAGGTGGATAACG AGTCCTCAGGACTCTACTCC CCCTCCAATCGGGTAACTCTCAGCAGCGTGGTGACCG CCCAGGAGAGTGTCACA TGCCCTCCAGCAGCTTGGGGAGCAGGACAGCAAGGA CACCCAGACCTACATCTGC CAGCACCTACAGCCTCAAACGTGAATCACAAGCCCA GCAGCACCCTGACGCTG GCAACACCAAGGTGGACAAAGCAAAGCAGACTACGA GAGAGTTGAGCCCAAATCT GAAACACAAAGTCTACGTGTGACAAAACTCACACAT CCTGCGAAGTCACCCAT GCCCACCGTGCCNNNNCTGCAGGGCCTGAGCTCGCC AACNTCTGNNNNGGNNGGN CGTCACAAAGAGCTTCANNNNNTTCCTNNTTCCTCCN ACAGGGGAGAGTGTTAG TNCCCCCNAAGNCNNNGNGAAGCTTGGCCCGCCATG AANNCNTNNNNGNNTNNCN GCCCAACTTGTTTATTGCCGAANCCNNTNNNNNNNNN AGCTTATAATGGTTACA NNNNNGGNNGNNNNACNNAATAAAGCAATAGCATC NANCCNNNNANNNNCNNN ACAAATTTCACAAATAANNNNNANNNNNNNNNNNN AGCATTTTTTTCACTGCA NGNGGANNGNNNNGNNNGTTCTAGTTGNNGTTTGTC TNNNTNNNNCNNNNNNNNC CAAACTCATCAATGTATCNNNGNNNNNNNNTNNNNN TTATCATGTCTGGATCGG NNNCNNGTNNNNNNGNNAGNATNNNCGGCGCAGCA NNNCNNNCNCCGTCNGCNC NCATGGCCTGAANNNAC NNACTNNNNN (SEQ CTNNGAAGANGANNNNG ID NO: 3474) NNAGGNACNTNNTGAGN NNNN (SEQ ID NO: 3476)V-C021 NNNNNNNNNNNATGNATCA CAGGTGCAGCTGGTGCAGT COV107_ NNNNNNNNNNATGTATCCAGTCTGTGCTGACTCAGCC COV107_ TACACATACGATTTAGGTG CTGGGGCTGAGGTGAAGAAP2_H10 NTACACATACGATTTAG TGCCTCCGTGTCTGGGTCTC P2_H10 ACACTATAGAATAACATCCGCCTGGGGCCTCAGTGAAG GTGACACTATAGAATAA CTGGACAGTCGATCACCATCACTTTGCCTTTCTCTCCACA GTCTCCTGCAAGGCTTCTGG CATCCACTTTGCCTTTCTTCCTGCACTGGAACCAGCAG GGTGTCCACTCCCAGGTCC ATACACCTTCACCGGCTACTCTCCACAGGTGTCCACTC TGATGTTGGGAGTTATAACC AACTGCACCTCGGTTCTATCATATGCACTGGGTGCGACA CCAGGTCCAACTGCACC TTGTCTCCTGGTACCAACAGGATTGAATTCCACCATGGG GGCCCCTGGACAAGGGCTT TCGGTTCTATCGATTGAACACCCAGGCAAAGCCCCCA ATGGTCATGTATCATCCTTT GAGTGGATGGGATGGATCATTCCACCATGGGATGGTC AACTCATGATTTATGAGGGC TTCTAGTAGCAACTGCAACGCCCTGTCAGTGGTGGCAC ATGTATCATCCTTTTTCT AGTAAGCGGCCCTCAGGGGCGGTGTACATTCCCAGGTG AAACTATGCACAGAAGTTT AGTAGCAACTGCAACCGTTTCTAATCGCTTCTCTGGCT CAGCTGGTGCAGTCTGGGG CAGGGCAGGGTCACCATGAGTTCCTGGGCCCAGTCTG CCAAGTCTGGCAACACGGC CTGAGGTGAAGAAGCCTGGCCAGGGACACGTCCATCAG CCCTGACTCAGCCTGCCT CTCCCTGACAATCTCTGGACGGCCTCAGTGAAGGTCTCC CACAGCCTACATGGAGCTG CCGTGTCTGGGTCTCCTGTCCAGGCTGAGGACGAGGC TGCAAGGCTTCTGGATACA AGCAGGCTGAGATCTGACGGACAGTCGATCACCATC TGATTATTACTGCTGCTCAT CCTTCACCGGCTACTATATGACACGGCCGTGTATTACTG TCCTGCACTGGAACCAG ATGCAGGTAGTAGCACTTTGCACTGGGTGCGACAGGCCC TGCGAGAGCCCCACTGTTC CAGTGATGTTGGGAGTTGTATTCGGCGGAGGGACCA CTGGACAAGGGCTTGAGTG CCCACAGGGGTGCTAGCTGATAACCTTGTCTCCTGGT AGCTGACCGTCCTAG (SEQ GATGGGATGGATCAGCCCTGGGACTACTACTACTACGG ACCAACAGCACCCAGGC ID NO: 3481) GTCAGTGGTGGCACAAACTTATGGACGTCTGGGGCCAA AAAGCCCCCAAACTCAT ATGCACAGAAGTTTCAGGGGGGACCACGGTCACCGTCT GATTTATGAGGGCAGTA CAGGGTCACCATGACCAGGCCTCA (SEQ ID NO: AGCGGCCCTCAGGGGTT GACACGTCCATCAGCACAG 3479)TCTAATCGCTTCTCTGGC CCTACATGGAGCTGAGCAG TCCAAGTCTGGCAACACGCTGAGATCTGACGACACG GGCCTCCCTGACAATCTC GCCGTGTATTACTGTGCGATGGACTCCAGGCTGAGG GAGCCCCACTGTTCCCCAC ACGAGGCTGATTATTACTAGGGGTGCTAGCTGGGGAC GCTGCTCATATGCAGGT TACTACTACTACGGTATGGAGTAGCACTTTGGTATTC ACGTCTGGGGCCAAGGGAC GGCGGAGGGACCAAGCTCACGGTCACCGTCTCCTCA GACCGTCCTAGGTCAGC GCGTCGACCAAGGGCCCATCCAAGGCTGCCCCCTCG CGGTCTTCCCCCTGGCACCC GTCACTCTGTTCCCACCCTCCTCCAAGAGCACCTCTG TCGAGTGAGGAGCTTCA GGGGCACAGCGGCCCTGGGAGCCAACAAGGCCACAC CTGCCTGGTCAAGGACTAC TGGTGTGTCTCATAAGTGTTCCCCGAACCTGTGACGG ACTTCTACCCGGGAGCC TCTCGTGGAACTCAGGCGCGTGACAGTGGCCTGGAA CCTGACCAGCGGCGTGCAC GGCAGATAGCAGCCCCGACCTTCCCGGCTGTCCTACA TCAAGGCGGGAGTGGAG GTCCTCAGGACTCTACTCCCACCACCACACCCTCCAA TCAGCAGCGTGGTGACCGT ACAAAGCAACAACAAGTGCCCTCCAGCAGCTTGGGC ACGCGGCCAGCAGCTAC ACCCAGACCTACATCTGCACTGAGCCTGACGCCTGA ACGTGAATCACAAGCCCAG GCAGTGGAAGTCCCACACAACACCAAGGTGGACAAG GAAGCTACAGCTGCCAG AGAGTTGAGCCCAAATCTTGTCACGCATGAAGGGAG GTGACAAAACTCACACATG CACCGTGGAGAAGACAGCCCACCGTGCCCAGCACCT TGGCCCCTACAGAATGTT GAACTCCTGGGGGGACCGTCATAGAAGCTTGGCCGC CAGTCTTCCTCTTCCCCCCA CATGGCCCAACTTGTTTAAAACCCAAGGACACCCTCA TTGCAGCTTATAATGGTT TGATCTCCCGGACCCCTGAACAAATAAAGCAATAGC NNCACATGCGTGGNGGNNG ATCACAAATTTCACAAAACGTGAGCCACGAANACCC TAAAGCATTTTTTTCACT TGAGGTCAAGTTCAACTGGGCATTCTANTTGTGGTTT NACGNNGNNGGCNNGN GTCCAAACTCATCAATGT (SEQ ID NO: 3478)ATCTTATCATGTCTGGNT CGGGAATTAATTCGNCG CAGCACCATGNNNTGAA ATANCTCTGAAAGAGNANTTGGNNNNNACCTTCT GAGCNGAAAGAACCATC TGNNGGAANNNGNNNN (SEQ ID NO: 3480)V-C022 NNNNNNNNNNNANNNNTC GAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNNNNNTGNNNNGACATCCAGTTGACCCAGTC COV107_ NTACACATACGATTTAGGT CTGGAGGAGGCTTGATCCAP1_B3 NTACACATACGATTTAG TCCATCCTTCCTGTCTGCAT P1_B3 GACACTATAGAATAACATCGCCTGGGGGGTCCCTGAGA GTGACACTATAGAATAA CTGTAGGAGACAGAGTCACCACTTTGCCTTTCTCTCCAC CTCTCCTGTGCAGCCTCTGG CATCCACTTTGCCTTTCTCATCACTTGCCGGGCCAGTC AGGTGTCCACTCCCAGGTC GCTCACCGTCAGTAGCAACCTCCACAGGTGTCCACTC AGGGCATTAGCAGTTATTTA CAACTGCACCTCGGTTCTATTACATGAGCTGGGTCCGCC CCAGGTCCAACTGCACC GCCTGGTATCAGCAAAAACCGATTGAATTCCACCATGG AGGCTCCAGGGAAGGGGCT TCGGTTCTATCGATTGAACAGGGAAAGCCCCTAAGCT GATGGTCATGTATCATCCTT GGAGTGGGTCTCAGTTCTTTTTCCACCATGGGATGGTC CCTGATCTATGCTGCATCCA TTTCTAGTAGCAACTGCAAATAGCGGTGGTAGCTCATT ATGTATCATCCTTTTTCT CTTTGCAAAGTGGGGTCCCACCGGTGTACATTCTGAGGT CTACGCAGACTCCGTGAAG AGTAGCAACTGCAACCGTCAAGGTTCAGCGGCAGTG GCAGCTGGTGGAGTCTGGA GGCCGATTCACCATCTCCAGTGTACATTCAGACATCC GATCTGGGACAGAATTCACT GGAGGCTTGATCCAGCCTGGAGACAATTCCAAGAACAC AGTTGACCCAGTCTCCAT CTCACAATCAGCAGCCTGCAGGGGGTCCCTGAGACTCTC GCTGTATCTTCAAATGAAC CCTTCCTGTCTGCATCTGGCCTGAAGATTTTGCAACTT CTGTGCAGCCTCTGGGCTC AGCCTGAGAGCCGAAGACATAGGAGACAGAGTCACC ATTACTGTCAACAGCTTAAT ACCGTCAGTAGCAACTACACGGCCGTGTATTACTGTGC ATCACTTGCCGGGCCAG AGTGACTCGTACACTTTTGGTGAGCTGGGTCCGCCAGGC GAGAGAAAGTGGGGATACA TCAGGGCATTAGCAGTTCCAGGGGACCAAGCTGGAG TCCAGGGAAGGGGCTGGAG ACTATGGCCTTTGACTACTGATTTAGCCTGGTATCAGC ATCAAAC (SEQ ID  TGGGTCTCAGTTCTTTATAGGGGCCAGGGAACCCTGGTC AAAAACCAGGGAAAGCC NO: 3485) CGGTGGTAGCTCATTCTACACCGTCTCCTCAG (SEQ  CCTAAGCTCCTGATCTAT GCAGACTCCGTGAAGGGCC ID NO: 3483)GCTGCATCCACTTTGCAA GATTCACCATCTCCAGAGA AGTGGGGTCCCATCAAGCAATTCCAAGAACACGCTG GTTCAGCGGCAGTGGAT TATCTTCAAATGAACAGCCCTGGGACAGAATTCACT TGAGAGCCGAAGACACGGC CTCACAATCAGCAGCCTCGTGTATTACTGTGCGAGA GCAGCCTGAAGATTTTG GAAAGTGGGGATACAACTACAACTTATTACTGTCAAC TGGCCTTTGACTACTGGGG AGCTTAATAGTGACTCGTCCAGGGAACCCTGGTCACC ACACTTTTGGCCAGGGG GTCTCCTCAGCGTCGACCAACCAAGCTGGAGATCAA AGGGCCCATCGGTCTTCCC ACGTACGGTGGCTGCACCCTGGCACCCTCCTCCAAG CATCTGTCTTCATCTTCC AGCACCTCTGGGGGCACAGCGCCATCTGATGAGCAG CGGCCCTGGGCTGCCTGGT TTGAAATCTGGAACTGCCAAGGACTACTTCCCCGAA CTCTGTTGTGTGCCTGCT CCTGTGACGGTCTCGTGGAGAATAACTTCTATCCCAG ACTCAGGCGCCCTGACCAG AGAGGCCAAAGTACAGTCGGCGTGCACACCTTCCCG GGAAGGTGGATAACGCC GCTGTCCTACAGTCCTCANCTCCAATCGGGTAACTCC GACTCTACTCCCTCAGCAG CAGGAGAGTGTCACAGACGTGGTGACCGTGCCCTCC GCAGGACAGCAAGGACA AGCAGCTTGGGCACCCAGAGCACCTACAGCCTCAGC CCTACATCTGCAACGTGAA AGCACCCTGACGCTGAGTCACAAGCCCAGCAACACC CAAAGCAGACTACGAGA AAGGTGGACAAGANAGTTGAACACAAAGTCTACGCC AGCCCAAATCTTGTGACAA TGCGAAGTCACCCATCAAACTCACACATGCCCACCG GGGCCTGAGCTCGCCCG TGCCCAGCACCTGAACTCCTCACAAAGAGCTTCAAC TGGGGGGACCGTCAGTCTT ANGGGGANANTGTNANACCNCNTCCCCCCAAAACCC ANCTNGGCCGCNNNNNG AAGGACACCCTCATGATCTNCCACNTTGTNTNTNGN CCNGGACCCCNGAGGTCAC GNCNNNTNNTANNNTGNATGCGNNGGTGGNTGGNNG NNACAAATANAACANAT NGAGCCACGANNANCCTGACATCANNNNNTTTNNNA GGTCAAGTTCAACTGGNAC ANANNNNTTTTTTNNNNGTGGACGGNNGNNGNNNN CAGNCNAGNNGNNGTTG NCATAATGCCAAGACCAAAGTNNNNNTNNTCATNNN GCNN (SEQ ID NO:  NNNANNNNTGNCTGNAT 3482)GGATNANNNNNNNCNNN NNNNNNNNNNNNNNNN AACTANNNTNNNNANNA NNTANNTNNNTANNTNCNNNNNNANGANGAANN N (SEQ ID NO:  3484) V-C023 NNNNNNNNNNNTANNNNNGAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNCNNNTGNATC GACATCCAGTTGACCCAGTCCOV107_ TCNTACNNATACGATTTAG CTGGAGGAGGCTTGATCCA P1_B6 NTACACATACGATTTAGTCCATCCTTCCTGTCTGCAT P1_B6 GTGACACTATAGAATAACA GCCTGGGGGGTCCCTGAGAGTGACACTATAGAATAA CTGTAGGAGACAGAGTCAC TCCACTTTGCCTTTCTCTCCCTCTCCTGTGCAGCCTCTGG CATCCACTTTGCCTTTCT CATCACTTGCCGGGCCAGTCACAGGTGTCCACTCCCAGG GGTCACCGTCAGTAGGAAC CTCCACAGGTGTCCACTCAGGGCATTAGCAGTTATTTA TCCAACTGCACCTCGGTTCT TACATGAGCTGGGTCCGCCCCAGGTCCAACTGCACC GCCTGGTATCAGCAAAAAC ATCGATTGAATTCCACCATAGGCTCCAGGGAAGGGGCT TCGGTTCTATCGATTGAA CAGGGAAAGCCCCTAAGCTGGGATGGTCATGTATCATC GGAGTGGGTCTCAGTTATTT TTCCACCATGGGATGGTCCCTGATCTATGCTGCATCCA CTTTTTCTAGTAGCAACTGC ATAGCGGTGGTAGCACATAATGTATCATCCTTTTTCT CTTTGCAAAGTGGGGTCCCA AACCGGTGTACATTCTGAGCTACGCAGACTCCGTGAAG AGTAGCAACTGCAACCG TCAAGGTTCAGCGGCAGTGGTGCAGCTGGTGGAGTCTG GGCCGATTCACCATCTCCA GTGTACATTCAGACATCCGATCTGGGACAGAATTCACT GAGGAGGCTTGATCCAGCC GAGACAATTCCAAGAACACAGTTGACCCAGTCTCCAT CTCACAATCAGCAGCCTGCA TGGGGGGTCCCTGAGACTCGCTGTATCTTCAAATGAAC CCTTCCTGTCTGCATCTG GCCTGAAGATTTTGCAACTTTCCTGTGCAGCCTCTGGGGT AGCCTGAGAGCCGAGGACA TAGGAGACAGAGTCACCATTACTGTCAACAGCTTAAT CACCGTCAGTAGGAACTAC CGGCCGTGTATTACTGTGCATCACTTGCCGGGCCAG AGTTACCCTCCAGCCTTCGG ATGAGCTGGGTCCGCCAGGGAGAGATCTATCTGCTGCTT TCAGGGCATTAGCAGTT CCAAGGGACACGACTGGAGCTCCAGGGAAGGGGCTGGA TTGATATCTGGGGCCAAGG ATTTAGCCTGGTATCAGCATTAAAC (SEQ ID  GTGGGTCTCAGTTATTTATA GACAATGGTCACCGTCTCTTAAAAAccAGGGAAAGcc NO: 3489) GCGGTGGTAGCACATACTA CAG (SEQ ID NO: CCTAAGCTCCTGATCTAT CGCAGACTCCGTGAAGGGC 3487) GCTGCATCCACTTTGCAACGATTCACCATCTCCAGAG AGTGGGGTCCCATCAAG ACAATTCCAAGAACACGCTGTTCAGCGGCAGTGGAT GTATCTTCAAATGAACAGC CTGGGACAGAATTCACTCTGAGAGCCGAGGACACGG CTCACAATCAGCAGCCT CCGTGTATTACTGTGCGAGGCAGCCTGAAGATTTTG AGATCTATCTGCTGCTTTTG CAACTTATTACTGTCAACATATCTGGGGCCAAGGGAC AGCTTAATAGTTACCCTC AATGGTCACCGTCTCTTCAGCAGCCTTCGGCCAAGGG CGTCGACCAAGGGCCCATC ACACGACTGGAGATTAAGGTCTTCCCCCTGGCACCCT ACGTACGGTGGCTGCAC CCTCCAAGAGCACCTCTGGCATCTGTCTTCATCTTCC GGGCACAGCGGCCCTGGGC CGCCATCTGATGAGCAGTGCCTGGTCAAGGACTACT TTGAAATCTGGAACTGC TCCCCGAACCTGTGACGGTCTCTGTTGTGTGCCTGCT CTCGTGGAACTCAGGCGCC GAATAACTTCTATCCCAGCTGACCAGCGGCGTGCACA AGAGGCCAAAGTACAGT CCTTCCCGGCTGTCCTACAGGGAAGGTGGATAACGCC TCCTCAGGACTCTACTCCCT CTCCAATCGGGTAACTCCCAGCAGCGTGGTGACCGTG CAGGAGAGTGTCACAGA CCCTCCAGCAGCTTGGGCAGCAGGACAGCAAGGACA CCCAGACCTACATCTGCAA GCACCTACAGCCTCAGCCGTGAATCACAAGCCCAGC AGCACCCTGACGCTGAG AACACCAANGTGGACAAGACAAAGCAGACTACGAGA GAGTTGAGCCCAAATCTTG AACACAAAGTCTACGCCTGACAAAACTCACACATGC TGCGAAGTCACCCATCA CCNCCGTGCCCAGCACCTGGGGCCTGAGCTCGCCCG NACTCCTGGGGGNNNNTCA TCACAAAGAGCTTCAACGTCTTNNNCTNNNCCCCAA AGGGGAGAGTGTTAGAA AANCCNNNGNNNNCCNCNNGCTTGGNCCGCCATGGC NNNNTCCNCNANNCCNNNN CCAACTTGTTTATTGCAGGNCCCANNNGNGNNNNNN CTTATAATGGTTACAAAT NNNNNNGNCCNNGAACCNAAAGCAATAGCATCACA NCNNNNNNNNNNNNNNNN AATTTCACAAATAAAGCGTTNNNNGGNNCNTGGANN ATTTTTTTCACTGCATTC GNNNNNNANGNNNNNNATTANTTGNNGTTTGTCCAA GNCNNANNAGNCNNNGNA NCTCATCAATGTATNTNNNNNCANTACANNNGNNCGT CATGTCTGGNTCGGGAA ACNNNNNGNCAGCGTCNTCTTNNNNNNGCAGCNCNT NCGTCNTGCACNNNACTGG NNNTGAANNACNNTGAANNNANNGNNN (SEQ ID NAGNNTTGNNNNGTACC NO: 3486) TTCTGAGNGAANNNNTCTNNNGANN (SEQ ID NO: 3488) V-C024 NNNNNNNNTATGTATNNTAGAGGTGCAGCTGGTGGAGT COV107_ NNNNNNNNNNNTGNNTC GAAATTGTGTTGACACAGTCCOV107_ CACATACGATTTAGGTGAC CTGGGGGAGGCTTGGTACA P1_A2 NTACACATACGATTTAGTCCAGCCACCCTGTCTTTGT P1_A2 ACTATAGAATAACATCCAC GCCTGGGGGGTCCCTGAGAGTGACACTATAGAATAA CTCCAGGGGAAAGAGCCAC TTTGCCTTTCTCTCCACAGGCTCTCCTGTGCAGCCTCTGG CATCCACTTTGCCTTTCT CCTCTCCTGCAGGGCCAGTCTGTCCACTCCCAGGTCCAA ATTCACCTTCAGTGGCTATA CTCCACAGGTGTCCACTCAGAGTTTTAGCAGCTACTTA CTGCACCTCGGTTCTATCGA GCATGAACTGGGTCCGCCACCAGGTCCAACTGCACC GCCTGGTACCAACAGAAAC TTGAATTCCACCATGGGATGGCTCCAGGGAAGGGGCCG TCGGTTCTATCGATTGAA CTGGCCAGGCTCCCAGGCTCGGTCATGTATCATCCTTTTT GAGTGGGTTTCATACATTA TTCCACCATGGGATGGTCCTCATCTATGATGCATCCAA CTAGTAGCAACTGCAACCG GTAGGAGTAGTAGTACCATATGTATCATCCTTTTTCT CAGGGCCACTGGCATCCCA GTGTACATTCTGAGGTGCAATACTACGCAGACTCTGTG AGTAGCAACTGCAACCG GCCAGGTTCAGTGGCAGTGGCTGGTGGAGTCTGGGGGA AAGGGCCGATTCACCATCT GTGTACATTCAGAAATTGGTCTGGGACAGACTTCACT GGCTTGGTACAGCCTGGGG CCAGAGACAATGCCAAGAAGTGTTGACACAGTCTCCA CTCACCATCAGCAGCCTAGA GGTCCCTGAGACTCTCCTGTCTCACTGTATCTGCAAATG GCCACCCTGTCTTTGTCT GCCTGAAGATTTTGCAGTTTGCAGCCTCTGGATTCACCTT AACAGCCTGAGAGACGAGG CCAGGGGAAAGAGCCACATTACTGTCAGCAGCGTAAC CAGTGGCTATAGCATGAAC ACACGGCTGTGTATTACTGTCCTCTCCTGCAGGGCCA AACTGGCCTCCCGAGTGGAC TGGGTCCGCCAGGCTCCAGGCGAGAGAAGGGGCTAGA GTCAGAGTTTTAGCAGCT GTTCGGCCAAGGGACCAAGGGAAGGGGCCGGAGTGGGT GTGGGAGCTACATATGACA ACTTAGCCTGGTACCAAGTGGAAATCAAAC (SEQ TTCATACATTAGTAGGAGT CGTACTACTTTGACTACTGGCAGAAACCTGGCCAGGC ID NO: 3493) AGTAGTACCATATACTACG GGCCAGGGAACCCTGGTCATCCCAGGCTCCTCATCTA CAGACTCTGTGAAGGGCCG CCGTCTCCTCAG (SEQ TGATGCATCCAACAGGG ATTCACCATCTCCAGAGAC ID NO: 3491) CCACTGGCATCCCAGCCAATGCCAAGAACTCACTGT AGGTTCAGTGGCAGTGG ATCTGCAAATGAACAGCCTGTCTGGGACAGACTTCA GAGAGACGAGGACACGGCT CTCTCACCATCAGCAGCCGTGTATTACTGTGCGAGAG TAGAGCCTGAAGATTTT AAGGGGCTAGAGTGGGAGCGCAGTTTATTACTGTCAG TACATATGACACGTACTAC CAGCGTAACAACTGGCCTTTGACTACTGGGGCCAGG TCCCGAGTGGACGTTCG GAACCCTGGTCACCGTCTCGCCAAGGGACCAAGGTG CTCAGCGTCGACCAAGGGC GAAATCAAACGTACGGTCCATCGGTCTTCCCCCTGGC GGCTGCACCATCTGTCTT ACCCTCCTCCAAGAGCACCCATCTTCCCGCCATCTGA TCTGGGGGCACAGCGGCCC TGAGCAGTTGAAATCTGTGGGCTGCCTGGTCAAGGA GAACTGCCTCTGTTGTGT CTACTTCCCCGAACCTGTGAGCCTGCTGAATAACTTCT CGGTCTCGTGGAACTCAGG ATCCCAGAGAGGCCAAACGCCCTGACCAGCGGCGTG GTACAGTGGAAGGTGGA CACACCTTCCCGGCTGTCCTTAACGCCCTCCAATCGG ACAGTCCTCAGGACTCTAC GTAACTCCCAGGAGAGTTCCCTCAGCAGCGTGGTGA GTCACAGAGCAGGACAG CCGTGCCCTCCAGCAGCTTCAAGGACAGCACCTACA GGGCACCCAGACCTACATC GCCTCAGCAGCACCCTGTGCAACGTGAATCACAAGC ACGCTGAGCAAAGCAGA CCAGCAACACCAAGGTGGACTACGAGAAACACAAAG CAAGAGAGTTGAGCCCAAA TCTACGCCTGCGAAGTCTCTTGTGACAAAACTCACA ACCCATCAGGGCCTGAG CATGCCCACCGTGCCCAGCCTCGCCCGTCACAAAGA ACCTGAACTCCTGGGGGGA GCTTCAACAGGGGAGAGCCGTCAGTCTTCCTCTTCCC TGTTAGAAGCTTGGCCG CCCAAAACCCAAGGACACCCCATGGCCCAACTTGTTT CTCATGATCTCCCGGACCCC ATTGCAGCTTATAATGGTTGNNNCACATGCGTGGTGG TACAAATAAAGCAATAG TGGNCGTGAGCCACGANACCATCACAAATTTCACAA CCTGNNNCAAGTTCAACTG ATAAAGCATTTTTTTCACGTACGNNGNCGGGCGNNGA TGCATTCTAGTTGTGGTT GGTGCATNATGCCAANANATGTCCAAACTCATCAATG AGCCGCGGGNAGGAGCAGT TATCTTATCATGTCTGGAANAACAGCNCGTACCGNNN TCGGGAANTAATTNNNG NNGNNAGNNN (SEQ IDCANCANCATGGNNTGAA NO: 3490) ATAACCTCTGAAANANA ACTTGGNNNGGTACCTNCTGNANGCGGAAANAAN CATCNNNN (SEQ ID  NO: 3492) V-C025 NNNNNNNNNNATGTATCATCAAATGCAGCTGGTGCAGT COV107_ NNNNNNNNCNNTANGTA GAAATTGTGTTGACGCAGTCCOV107_ ACACATACGATTTAGGTGA CTGGGCCTGAGGTGAAGAA P2_G9 TCATACACATACGATTTATCCAGGCACCCTGTCTTTGT P2_G9 CACTATAGAATAACATCCA GCCTGGGACCTCAGTGAAGGGTGACACTATAGAATA CTCCAGGGGAAAGAGCCAC CTTTGCCTTTCTCTCCACAGGTCTCCTGCAAGGCTTCTGG ACATCCACTTTGCCTTTC CCTCTCCTGCAGGGCCAGTCGTGTCCACTCCCAGGTCCA ATTCACCTTTACTAGCTCTG TCTCCACAGGTGTCCACTAGAGTGTTAGCAGCAGCTA ACTGCACCTCGGTTCTATCG CTGTGCAGTGGGTGCGACACCCAGGTCCAACTGCAC CTTAGCCTGGTACCAGCAGA ATTGAATTCCACCATGGGAGGCTCGTGGACAACGCCTT CTCGGTTCTATCGATTGA AACCTGGCCAGGCTCCCAGTGGTCATGTATCATCCTTTT GAGTGGATAGGATGGATCG ATTCCACCATGGGATGGGCTCCTCATCTATGGTGCAT TCTAGTAGCAACTGCAACC TCGTTGGCAGTGGTAACACTCATGTATCATCCTTTTT CCAGCAGGGCCACTGGCAT GGTGTACATTCCCAGGTGCAAACTACGCACAGAAGTTC CTAGTAGCAACTGCAAC CCCAGACAGGTTCAGTGGCAGCTGGTGCAGTCTGGGCC CAGGAAAGAGTCACCATTA CGGTGTACATTCAGAAAAGTGGGTCTGGGACAGACTT TGAGGTGAAGAAGCCTGGG CCAGGGACATGTCCACAAGTTGTGTTGACGCAGTCTC CACTCTCACCATCAGCAGAC ACCTCAGTGAAGGTCTCCTCACAGCCTACATGGAGCTG CAGGCACCCTGTCTTTGT TGGAGCCTGAAGATTTTGCAGCAAGGCTTCTGGATTCAC AGCAGCCTGAGATCCGAGG CTCCAGGGGAAAGAGCCGTGTATTACTGTCAGCAGTA CTTTACTAGCTCTGCTGTGC ACACGGCCGTGTATTACTGACCCTCTCCTGCAGGGCC TGGTAGCTCACCGTGGACGT AGTGGGTGCGACAGGCTCGTGCGGCACCTTATTGTAGTG AGTCAGAGTGTTAGCAG TCGGCCAAGGGACCAAGGTTGGACAACGCCTTGAGTGG GTGGTAGCTGCTCTGATGCT CAGCTACTTAGCCTGGTAGGAAATCAAAC (SEQ ID ATAGGATGGATCGTCGTTG TTTGATATCTGGGGCCAAGCCAGCAGAAACCTGGCC NO: 3497) GCAGTGGTAACACAAACTA GGACAATGGTCACCGTCTCAGGCTCCCAGGCTCCTC CGCACAGAAGTTCCAGGAA TTCAG (SEQ ID NO:ATCTATGGTGCATCCAGC AGAGTCACCATTACCAGGG 3495) AGGGCCACTGGCATCCCACATGTCCACAAGCACAGC AGACAGGTTCAGTGGCA CTACATGGAGCTGAGCAGCGTGGGTCTGGGACAGAC CTGAGATCCGAGGACACGG TTCACTCTCACCATCAGCCCGTGTATTACTGTGCGGC AGACTGGAGCCTGAAGA ACCTTATTGTAGTGGTGGTATTTTGCAGTGTATTACTG GCTGCTCTGATGCTTTTGAT TCAGCAGTATGGTAGCTATCTGGGGCCAAGGGACAA CACCGTGGACGTTCGGC TGGTCACCGTCTCTTCAGCGCAAGGGACCAAGGTGGA TCGACCAAGGGCCCATCGG AATCAAACGTACGGTGGTCTTCCCCCTGGCACCCTCC CTGCACCATCTGTCTTCA TCCAAGAGCACCTCTGGGGTCTTCCCGCCATCTGATG GCACAGCGGCCCTGGGCTG AGCAGTTGAAATCTGGACCTGGTCAAGGACTACTTC ACTGCCTCTGTTGTGTGC CCCGAACCTGTGACGGTCTCTGCTGAATAACTTCTAT CGTGGAACTCAGGCGCCCT CCCAGAGAGGCCAAAGTGACCAGCGGCGTGCACACC ACAGTGGAAGGTGGATA TTCCCGGCTGTCCTACAGTCACGCCCTCCAATCGGGT CTCAGGACTCTACTCCCTCA AACTCCCAGGAGAGTGTGCAGCGTGGTGACCGTGCC CACAGAGCAGGACAGCA CTCCAGCAGCTTGGGCACCAGGACAGCACCTACAGC CAGACCTACATCTGCAACG CTCAGCAGCACCCTGACTGAATCACAAGCCCAGCAA GCTGAGCAAAGCAGACT CACCNNGTGGACAAGAGAGACGAGAAACACAAAGTC TTGAGNCCAAATCNTGTGN TACGCCTGCGAAGTCACNNAACTNANACNTNNNCNN CCATCAGGGCCTGAGCT NCCNNCNNGNCCAGNACCNCGCCCGTCACAAAGAGC NNNNNNNCGGGGGGGNNN TTCAACAGGGGAGAGTGNNNNCATTTNNNNNNNNNN TTAGAAGCTTGGCCGCC NNAAACCCAGGGACNCCCTATGGCCCAACTTGTTTAT CANTGATCTCCNNNNNCCC TGCAGCTTATAATGGTTANNGANGTCACNTGNNGTGG CAAATAAAGCAATAGCA TGGTGNNCGTGANCCANNATCACAAATTTCACNATA NANNNGNNNCANTNAACTN AAGCATTTTTTTCACTGCNNCGTGNNGNNNTNNNNTG ATTCTANTTGTGGTTTGT CATANGCANANNNCNCGGGCCANCTCATCAATGTATC ANGNNCANTANACAGCNCG TNATCATGTCTGGATCGGTACGNGNNGNCANNNTCNT GANTNANTNNNGCAGCA CNNNGNCNN (SEQ IDNCATGGNNTGAAATACN NO: 3494) TCTGAANNAGGANTTGG NTANGTACCTNNNGAGNGAANNNANCATNNNNNG N (SEQ ID NO: 3496) V-C026 NNNNNNNNNNNCNNNNTGTCAGGTGCAGCTGCAGGAGT COV107_ NNNNNNNNNNNNTGTAT AATTTTATGCTGACTCAGCCCOV107_ ATCNTACACATACGATTTA CGGGCCCAGGACTGGTGAA P2_C4 CNTACACATACGATTTACCACTCTGTGTCGGAGTCTC P2_C4 GGTGACACTATAGAATAAC GCCTTCGGAGACCCTGTCCGGTGACACTATAGAATA CGGGGAAGACGGTAACCAT ATCCACTTTGCCTTTCTCTCCTCTCCTGCGCTGTCTCTGG ACATCCACTTTGCCTTTC CTCCTGCACCGGCAGCAGTGCACNNNNNNCCACTCCCAG TGGCTCCATCGGTAGTTACT TCTCCACAGGTGTCCACTGCAGCATTGCCAGCAACTAT GTCCAACTGCACCTCGGTTC TCTGGAGCTGGATCCGGCACCCAGGTCCAACTGCAC GTGCAGTGGTACCAGCAGC TATCGATTGAATTCCACCATGCCCCCAGGGAAGGGACTG CTCGGTTCTATCGATTGA GCCCGGGCAGTGCCCCCACCGGGATGGTCATGTATCATC GAGTGGATTGGATATCTCC ATTCCACCATGGGATGGACTGTGATCAATGAAGATA CTTTTTCTAGTAGCAACTGC ATTACAGTGGGAGCACCAATCATGTATCATCCTTTTT ACCAAAGACCCTCTGGGGTC AACCGGTGTACATTCCCAGCTACAACCCCTCCCTGAAG CTAGTAGCAACTGCAAC CCTGATCGGTTCTCTGGCTCGTGCAGCTGCAGGAGTCGG AGTCGAGTCACCATATCAG CGGTTCTTGGGCCAATTTCATCGACAGCTCCTCCAACT GCCCAGGACTGGTGAAGCC TAGACACGTCCAAGAATCATATGCTGACTCAGCCCCA CTGCCTCCCTCACCATCTCT TTCGGAGACCCTGTCCCTCTGTTCTCCCTGAAGCTGAGCT CTCTGTGTCGGAGTCTCC GGACTGAAGACTGAGGACGCCTGCGCTGTCTCTGGTGGC CTGTGACCGCTGCGGACAC GGGGAAGACGGTAACCAAGGCTGACTACTACTGTCAG TCCATCGGTAGTTACTTCTG GGCCGTGTATTACTGTGCGTCTCCTGCACCGGCAGC TCTTATGATAGCAGCAATTT GAGCTGGATCCGGCAGCCCAGATTGCAGTGGCTACGCG AGTGGCAGCATTGCCAG GGTATTCGGCGGAGGGACCCCAGGGAAGGGACTGGAGT GAGCTTTTGATATCTGGGG CAACTATGTGCAGTGGTAAGCTGACCGTCCTAG  GGATTGGATATCTCCATTAC CCAAGGGACAATGGTCACCACCAGCAGCGCCCGGGC (SEQ ID NO: 3501) AGTGGGAGCACCAACTACAGTCTCTTCAG (SEQ ID AGTGCCCCCACCACTGT ACCCCTCCCTGAAGAGTCG NO: 3499)GATCAATGAAGATAACC AGTCACCATATCAGTAGAC AAAGACCCTCTGGGGTCACGTCCAAGAATCAGTTCT CCTGATCGGTTCTCTGGC CCCTGAAGCTGAGCTCTGTTCCATCGACAGCTCCTCC GACCGCTGCGGACACGGCC AACTCTGCCTCCCTCACCGTGTATTACTGTGCGAGATT ATCTCTGGACTGAAGAC GCAGTGGCTACGCGGAGCTTGAGGACGAGGCTGACT TTTGATATCTGGGGCCAAG ACTACTGTCAGTCTTATGGGACAATGGTCACCGTCTC ATAGCAGCAATTTGGTA TTCAGCGTCGACCAAGGGCTTCGGCGGAGGGACCAA CCATCGGTCTTCCCCCTGGC GCTGACCGTCCTAGGTCACCCTCCTCCAAGAGCACC AGCCCAAGGCTGCCCCC TCTGGGGGCACAGCGGCCCTCGGTCACTCTGTTCCCG TGGGCTGCCTGGTCAAGGA CCCTCGAGTGAGGAGCTCTACTTCCCCGAACCTGTGA TCAAGCCAACAAGGCCA CGGTCTCGTGGAACTCAGGCACTGGTGTGTCTCATAA CGCCCTGACCAGCGGCGTG GTGACTTCTACCCGGGACACACCTTCCCGGCTGTCCT GCCGTGACAGTGGCCTG ACAGTCCTCNNACTCTACTCGAAGGCAGATAGCAGCC CCTCAGCAGCGTGGTGACC CCGTCAAGGCGGGAGTGGTGCCCTCCAGCAGCTTGG GAGACCACCACACCCTC GCACCCAGACCTACATCTGCAAACAAAGCAACAACA CAACGTGAATCACAAGCCC AGTACGCGGCCAGCAGCAGCAACACCAAGGTGGANN TACCTGAGCCTGACGCCT GAGAGTTGAGCCCAAATCTGAGCAGTGGAAGTCCCA TGTGACAAAACTCACACAT CAGAAGCTACAGCTGCCGCCCACCGNGCCCAGCACC AGGTCACGCATGNANGG TGACTCCTGGGGGGACCGTGAGCACCGTGGAGAAGA CAGTCTTCCTCTTCCCCCAA CAGTGGCCCCTACAGAAAACNCNNGGANNNCCCNNA TGTTCATAGAAGCTTGGC TGATCTCCCNNANCCCTGACGCCATGGCCCAACTTGT GNCACATGNNNNNGGTGGG TTATTGCAGCTTATAATGNGNNGTGAGCCACNANACC GTTACAAATAAAGCAAT CNNGAGNTNAGTTCNANTTAGCATCACAAATTTCAC GGNNCGNNGNANGGCGNG AAATAAGCATTTTTTTCANAGGNNNNNTAATGNCANN CTGCATTCTAGTTGNNGG NNNNAAGNNNN (SEQ IDNTTGTCCAAACTCATCAA NO: 3498) TGNNTCTNATCATGTCTG GATCGGGAATTNNNCGNNNAGCACCATNNNTNAA ANNACNTCTGAANAGNN NTGGTNAGGTACCTTCTN NNNNAAANAANCATCTNNNGNAANGN (SEQ ID NO: 3500) V-C027 NNNNNNNNNNNTATGNATNCAGGTGCAGCTGGTGCAGT COV107_ NNNNNNNNNNNNNNNTC CAGTCTGTGCTGACTCAGCCCOV107_ ATACACATACGATTTAGGT CTGGGGCTGAGGTGAAGAA P1_C3 ATACACATACGATTTAGACCCTCAGCGTCTGGGACCC P1_C3 GACACTATAGAATAACATC GCCTGGGGCCTCAGTGAAGGTGACACTATAGAATAA CCGGGCAGAGGGTCACCAT CACTTTGCCTTTCTCTCCACGTCTCCTGCAAGGCTTCTGG CATCCACTTTGCCTTTCT CTCTTGTTCTGGAAGCAGCTAGGTGTCCACTCCCAGGTC ATACACCTTCACCGGCTACT CTCCACAGGTGTCCACTCCCAACATCGGAAGTAATACT CAACTGCACCTCGGTTCTAT ATATGCACTGGGTGCGACACCAGGTCCAACTGCACC GTAAACTGGTACCAGCAGCT CGATTGAATTCCACCATGGGGCCCCTGGACAAGGGCTT TCGGTTCTATCGATTGAA CCCAGGAACGGCCCCCAAAGATGGTCATGTATCATCCTT GAGTGGATGGGATGGATCA TTCCACCATGGGATGGTCCTCCTCATCTATAGTAATAA TTTCTAGTAGCAACTGCAA ACCCTAACAGTGGTGGCACATGTATCATCCTTTTTCT TCAGCGGCCCTCAGGGGTCC CCGGTGTACATTCCCAGGTAAACTATGCACAGAAGTTT AGTAGCAACTGCAACCG CTGACCGATTCTCTGGCTCCGCAGCTGGTGCAGTCTGGG CAGGGCAGGGTCACCATGA GTTCCTGGGCCCAGTCTGAAGTCTGGCACCTCAGCCTC GCTGAGGTGAAGAAGCCTG CCAGGGACACGTCCATCAGTGCTGACTCAGCCACCCT CCTGGCCATCAGTGGGCTCC GGGCCTCAGTGAAGGTCTCCACAGCCTACATGGAGCTG CAGCGTCTGGGACCCCC AGTCTGAGGATGAGGCTGACTGCAAGGCTTCTGGATAC AGCAGGCTGAGATCTGACG GGGCAGAGGGTCACCATTTATTACTGTGCAGCATGGG ACCTTCACCGGCTACTATAT ACACGGCCGTGTATTACTGCTCTTGTTCTGGAAGCAG ATGACAGCCTGAATGGCGT GCACTGGGTGCGACAGGCCTGCGACGGCGCACCCCCGG CTCCAACATCGGAAGTA GGTATTCGGCGGAGGGACCCCTGGACAAGGGCTTGAGT AGGATCCAAGGGGTATTTT ATACTGTAAACTGGTACAAGCTGACCGTCCTAG  GGATGGGATGGATCAACCC TTTTGGGGCCGGGCGTCTGCAGCAGCTCCCAGGAAC (SEQ ID NO: 3505) TAACAGTGGTGGCACAAACGGGCCAAGGGACCACGGTC GGCCCCCAAACTCCTCAT TATGCACAGAAGTTTCAGGACCGTCTCCTCA (SEQ  CTATAGTAATAATCAGC GCAGGGTCACCATGACCAG ID NO: 3503)GGCCCTCAGGGGTCCCT GGACACGTCCATCAGCACA GACCGATTCTCTGGCTCCGCCTACATGGAGCTGAGCA AAGTCTGGCACCTCAGC GGCTGAGATCTGACGACACCTCCCTGGCCATCAGTGG GGCCGTGTATTACTGTGCG GCTCCAGTCTGAGGATGACGGCGCACCCCCGGAGGA AGGCTGATTATTACTGTG TCCAAGGGGTATTTTTTTTGCAGCATGGGATGACAGC GGGCCGGGCGTCTGGGGCC CTGAATGGCGTGGTATTCAAGGGACCACGGTCACCGT GGCGGAGGGACCAAGCT CTCCTCAGCGTCGACCAAGGACCGTCCTAGGTCAGC GGCCCATCGGTCTTCCCCCT CCAAGGCTGCCCCCTCGGGCACCCTCCTCCAAGAGC GTCACTCTGTTCCCACCC ACCTCTGGGGGCACAGCGGTCGAGTGAGGAGCTTCA CCCTGGGCTGCCTGGTCAA AGCCAACAAGGCCACACGGACTACTTCCCCGAACCT TGGTGTGTCTCATAAGTG GTGACGGTCTCGTGGAACTACTTCTACCCGGGAGCC CAGGCGCCCTGACCAGCGG GTGACAGTGGCCTGGAACGTGCACACCTTCCCGGCT GGCAGATAGCAGCCCCG GTCCTACAGTCCTCANGACTCAAGGCGGGAGTGGAG TCTACTCCCTCAGCAGCGTG ACCACCACACCCTCCAAGTGACCGTGCCCTCCAGCA ACAAAGCAACAACAAGT GCTTGGGCACCCAGACCTAACGCGGCCAGCAGCTAC CATCTGCAACGTGAATCAC CTGAGCCTGACGCCTGAAAGCCCAGCAACACCNAAG GCAGTGGAAGTCCCACA TGGACAAGANAGTTGAGCCGAAGCTACAGCTGCCAG CAAATCTTGTGACAAAACT GTCACGCATGAAGGGAGCACACATGCCCACCGTGCC CACCGTGGAGAAGACAG CAGCACCTGAACTCCTGGGTGGCCCCTACAGAATGTT GGGANCGTCAGTCTTCCTCT CATAGAAGCTTGGCCGCTCCCCCNAAANCCCAANGA CATGGCCCAACTTGTTTA CACCCTCATGATNTCCCNNTTGCAGCTTATAATGGTT ACCCCTGAGGTCNNATNCG ACAAATAAAGCAATAGCTGGNNNNNGNNGTGANCCA ATCACAAATTTCACAAA CNANACCCNGANNCAGTTCTAAAGCATTTTTTTCACT AACTGGNACNTNNNGGCGN GCATTCTANTTGTGGTTTNNNNTGCANNANNCNANA GTCCAAACTCATCAATGT N (SEQ ID NO: 3502)ATCTTATCNTGTCTGGAT CGGGAATTANTTCGGCG CANCACCNTGGCCTGAA TANCCTCTGAAANANNAACTTGNNTANNGNACCT TCTGNNNGNNANNTANN NAANNNNNNNAANNNN NGTCTNNNNNNNNNNNNNGNNANNTNNNNNNNNN N (SEQ ID NO: 3504) V-C028 NNNNNNNNNNNTATGTATCGAGGTGCAGCTGTTGGAGT COV072_ NNNNNNNNCNNNNNGTA GAAATTGTGTTGACGCAGTCCOV072_ NTACACATACGATTTAGGT CTGGGGGAGGCTTGGTACA P2_B12TCNTACACATACGATTTA TCCAGGCACCCTGTCTTTGT P2_B12 GACACTATAGAATAACATCGCCTGGGGGGTCCCTGAGA GGTGACACTATAGAATA CTCCAGGGGAAAGAGCCACCACTTTGCCTTTCTCTCCAC CTCTCCTGTGCAGCCTCTGG ACATCCACTTTGCCTTTCCCTCTCCTGCAGGGCCAGTC AGGTGTCCACTCCCAGGTC ATTCACCTTTAGCACCTATGTCTCCACAGGTGTCCACT AGAGTGTTAACAGCAGGCA CAACTGCACCTCGGTTCTATCCATGAGTTGGGTCCGCCA CCCAGGTCCAACTGCAC GTTAGCCTGGTACCAGCAGACGATTGAATTCCACCATGG GGCTCCAGGGAAGGGGCTG CTCGGTTCTATCGATTGAAACCTGGCCAGGCTCCCAG GATGGTCATGTATCATCCTT GAGTGGGTCTCAACTATTAATTCCACCATGGGATGG GCTCCTCATCTATGGTGCGT TTTCTAGTAGCAACTGCAACTGGTAGTGGTCGTGACAC TCATGTATCATCCTTTTT CCAGCAGGGCCACTGGCATCCGGTGTACATTCTGAGGT ATACTACGCAGACTCCGTG CTAGTAGCAACTGCAACCCCAGAGAGGTTCAGTGGC GCAGCTGTTGGAGTCTGGG AAGGGCCGGTTCACCATCTCGGTGTACATTCAGAAA AGTGGATCTGGGACAGACTT GGAGGCTTGGTACAGCCTGCCAGAGACAATTCCAAGAA TTGTGTTGACGCAGTCTC CACTCTCACCATCAGCAGACGGGGGTCCCTGAGACTCTC CACGCTGTTTCTGCAACTGA CAGGCACCCTGTCTTTGTTGGAGTCTGAAGATTTTGCA CTGTGCAGCCTCTGGATTCA ACAGCCTGAGAGCCGAGGACTCCAGGGGAAAGAGCC GTGTATCACTGTCAGCAATA CCTTTAGCACCTATGCCATGCGCGGCCGTGTATTCCTGTG ACCCTCTCCTGCAGGGCC TGGTAGCTCAAGGGCGCTCAAGTTGGGTCCGCCAGGCTC CGAACCACCCTCTGGCATC AGTCAGAGTGTTAACAGCTTTCGGCGGAGGGACCAA CAGGGAAGGGGCTGGAGTG AGGCGACGACTACTACCACCAGGCAGTTAGCCTGGT GGTGGAGATCAAAC (SEQ GGTCTCAACTATTACTGGTATACTACATGGACGTCTGGG ACCAGCAGAAACCTGGC ID NO: 3509) GTGGTCGTGACACATACTAGCAAAGGGACCACGGTCAC CAGGCTCCCAGGCTCCTC CGCAGACTCCGTGAAGGGCCGTCTCCTCA (SEQ ID ATCTATGGTGCGTCCAGC CGGTTCACCATCTCCAGAG NO: 3507)AGGGCCACTGGCATCCC ACAATTCCAAGAACACGCT AGAGAGGTTCAGTGGCAGTTTCTGCAACTGAACAGC GTGGATCTGGGACAGAC CTGAGAGCCGAGGACGCGGTTCACTCTCACCATCAGC CCGTGTATTCCTGTGCGAAC AGACTGGAGTCTGAAGACACCCTCTGGCATCAGGCG TTTTGCAGTGTATCACTG ACGACTACTACCACTACTATCAGCAATATGGTAGCT CATGGACGTCTGGGGCAAA CAAGGGCGCTCACTTTCGGGACCACGGTCACCGTCT GGCGGAGGGACCAAGGT CCTCAGCGTCGACCAAGGGGGAGATCAAACGTACGG CCCATCGGTCTTCCCCCTGG TGGCTGCACCATCTGTCTCACCCTCCTCCAAGAGCAC TCATCTTCCCGCCATCTG CTCTGGGGGCACAGCGGCCATGAGCAGTTGAAATCT CTGGGCTGCCTGGTCAAGG GGAACTGCCTCTGTTGTGACTACTTCCCCGAACCTGTG TGCCTGCTGAATAACTTC ACGGTCTCGTGGAACTCAGTATCCCAGAGAGGCCAA GCGCCCTGACCAGCGGCGT AGTACAGTGGAAGGTGGGCACACCTTCCCGGCTGTCC ATAACGCCCTCCAATCG TACAGTCCTCAGGACTCTAGGTAACTCCCAGGAGAG CTCCCTCAGCAGCGTGGTG TGTCACAGAGCAGGACAACCGTGCCCTCCAGCAGCT GCAAGGACAGCACCTAC TGGGCACCCAGACCTACATAGCCTCAGCAGCACCCT CTGCAACGTGAATCACAAG GACGCTGAGCAAAGCAGCCCAGCAACACCNAAGGTG ACTACGAGAAACACAAA GACAAGAGAGTTGAGCCCAGTCTACGCCTGCGAAGT AATCTTGTGACAAAACTCA CACCCATCAGGNCCTGACACATGCCCACCGTGCCCA GCTCGCCCGTCACAAAG GCACCTGAACTNCTGGGGGAGCTTCAACAGGGGANA GACCGTCAGTCTTCCTCTTC GTGTTAGAAGCTTGGNCCCCCCAAAACCCNANGACA GCCATGGCCCAACTTGTT CCCTCATGATCTNCNNGACTANTGCAGCTTANNTGG CCNNGAGTCACATGCCGTG TTACAAATAAAGCAATAGNGGNGGNNGTGANCCACN GCATCACAAATTTCACA ANGACCNTGAGTCAGTTCAAATAAAGCATTTTTTTCA NTNNNCNTGNNGGCGTGNN CTGCATTCTANTGNGGNTNGCANNANGCNANNNANN TGTCCNAACTCATCAAN ANCNNNNGGAGGANCANTNNNNCTTATCATGTCTGG ACNANNNNCNNNNNCNNN NTCGGGAATTAATTCCGNNNNNNANNCNNN (SEQ NNNN (SEQ ID NO: ID NO: 3506) 3508) V-C029NNNNNNNNNNTTATGTATC CAGGTGCAGCTGGTGGAGT COV072_ GNNNNNNNNNNNTTATNGACATCCAGATGACCCAGTC COV072_ NTACACATACGATTTAGGT CTGGGGGAGGCGTGGTCCAP2_C7 NNATCNTACACATACGA TCCATCCTCCCTGTCTGCAT P2_C7 GACACTATAGAATAACATCGCCTGGGAGGTCCCTGAGA TTTAGGTGACACTATAG CTGTAGGAGACAGAGTCACCACTTTGCCTTTCTCTCCAC CTCTCCTGTGCAGCCTCTGG AATAACATCCACTTTGCCCATCACTTGCCAGGCGAGTC AGGTGTCCACTCCCAGGTC ATTCACCTTCAGTAGCTATGTTTCTCTCCACAGGTGTC AGGACATTAGCAACTATTTA CAACTGCACCTCGGTTCTATGCATGAACTGGGTCCGCCA CACTCCCAGGTCCAACT AATTGGTATCAGCAGAAACCGATTGAATTCCACCATGG GGCTCCAGGCAAGGGGCTG GCACCTCGGTTCTATCGACAGGGAAAGCCCCTAAGCT GATGGTCATGTATCATCCTT GAGTGGGTGGCAGTTATATTTGAATTCCACCATGGG CCTGATCTACGATGCATCCA TTTCTAGTAGCAACTGCAACATATGATGGAAGTAATAC ATGGTCATGTATCATCCT ATTTGGAAACAGGGGTCCCCCGGTGTACATTCTCAGGT ATACTATACAGACTCCGTG TTTTCTAGTAGCAACTGCATCAAGGTTCAGTGGAAGT GCAGCTGGTGGAGTCTGGG AAGGGCCGATTCACCATCTAACCGGTGTACATTCTG GAATCTGGGACAGATTTTAC GGAGGCGTGGTCCAGCCTGCCAGAGACAATTCCAAGAA ACATCCAGATGACCCAG TTTCACCATCAGCAGCCTGCGGAGGTCCCTGAGACTCTC CACGCTGTATCTGCAAATG TCTCCATCCTCCCTGTCTAGCCTGAAGATATTGCAAC CTGTGCAGCCTCTGGATTCA AACAGCCTGAGAGTTGACGGCATCTGTAGGAGACAG ATATTACTGTCAACAGTATG CCTTCAGTAGCTATGGCATACACGGCTACATATTACTG AGTCACCATCACTTGCCA ATAATCTCCCGATCACCTTCGAACTGGGTCCGCCAGGCT TGCGAAAGGGCCCCGGTTT GGCGAGTCAGGACATTAGGCCAAGGGACACGACTGG CCAGGCAAGGGGCTGGAGT GGCTGGAGCTATAGAGGGGGCAACTATTTAAATTGGT AGATTAAAC (SEQ ID GGGTGGCAGTTATATCATAGGTCTGGTTTTGATATCTGG ATCAGCAGAAACCAGGG NO: 3513) TGATGGAAGTAATACATACGGCCAAGGGACAATGGTCA AAAGCCCCTAAGCTCCT TATACAGACTCCGTGAAGGCCGTCTCTTCAG (SEQ  GATCTACGATGCATCCA GCCGATTCACCATCTCCAG ID NO: 3511)ATTTGGAAACAGGGGTC AGACAATTCCAAGAACACG CCATCAAGGTTCAGTGGCTGTATCTGCAAATGAACA AAGTGAATCTGGGACAG GCCTGAGAGTTGACGACACATTTTACTTTCACCATCA GGCTACATATTACTGTGCG GCAGCCTGCAGCCTGAAAAAGGGCCCCGGTTTGGCT GATATTGCAACATATTAC GGAGCTATAGAGGGGGGTCTGTCAACAGTATGATAA TGGTTTTGATATCTGGGGCC TCTCCCGATCACCTTCGGAAGGGACAATGGTCACCGT CCAAGGGACACGACTGG CTCTTCAGCGTCGACCAAGAGATTAAACGTACGGTG GGCCCATCGGTCTTCCCCCT GCTGCACCATCTGTCTTCGGCACCCTCCTCCAAGAGC ATCTTCCCGCCATCTGAT ACCTCTGGGGGCACAGCGGGAGCAGTTGAAATCTGG CCCTGGGCTGCCTGGTCAA AACTGCCTCTGTTGTGTGGGACTACTTCCCCGAACCT CCTGCTGAATAACTTCTA GTGACGGTCTCGTGGAACTTCCCAGAGAGGCCAAAG CAGGCGCCCTGACCAGCGG TACAGTGGAAGGTGGATCGTGCACACCTTCCCGGCT AACGCCCTCCAATCGGG GTCCTACAGTCCTCAGGACTAACTCCCAGGAGAGTG TCTACTCCCTCAGCAGCGTG TCACAGAGCAGGACAGCGTGACCGTGCCCTCCAGCA AAGGACAGCACCTACAG GCTTGGGCACCCAGACCTACCTCAGCAGCACCCTGA CATCTGCAACGTGAATCAC CGCTGAGCAAAGCAGACAAGCCCAGCAACACCAAGG TACGAGAAACACAAAGT TGGACAAGAGAGTTGAGCCCTACGCCTGCGAAGTCA CAAATCTTGTGACAAAACT CCCATCAGGGCCTGAGCCACACATGCCCACCGTGCC TCGCCCGTCACAAAGAG CAGCACCTGAACTCCTGGGCTTCAACAGGGGAGAGT GGGACCGTCAGTCTTCCTCT GTTAGAAGCTTGGNCGCTCCCCCCAAAACCCAAGGA CATGGCCCAACTTGTTTA CACCCTCATGATCTCCCGGTTGCAGCTTATAATGGTT ACCCCTGAGGTCACATGCG ACAAATAAAGCAATAGCTGGNGGNNGACGTGAGCCA ATCACAAATTTCNNNAA CGAANANCCTGAGGTCAAGTAAAGCATTTTTTTCACT TTCAACTGGNACGNNGNNG GCATTCTAGTTGTGGTTTGCGTNNNNTGCATNANGCC GTCCAAACTCATCAATGT ANACAAAGCCNNNGGGANATCTTATCATGTCTGGNT GNANCAGTACACAGCNNNT CGGGAATTNANTCGGCGACCGNGNGGNCAGCNNCCN CAGCNNCCANGN (SEQ NNNCCGNCNN (SEQ ID ID NO: 3512)NO: 3510) V-C030 NNNNNNNNNNNNNNNTGN CAGGTGCAGCTGGTGCAGT COV072_NNNNNNNNNNNNNNNN TCCTATGTGCTGACTCAGCC COV072_ NNNNTACACATACGATTTACTGGGGCTGAGGTGAAGAA P3_E1 GTATCNTACNCNTACGA ACCCTCAGTGTCAGTGGCCC P3_E1GGTGACACTATAGAATAAC GCCTGGGGCCTCAGTGAAG TTTAGGTGACACTATAGCAGGAAAGACGGCCAGGAT ATCCACTTTGCCTTTCTCTC GTTTCCTGCAAGGCATCTGAATAACATCCACTTTGCC TACCTGTGGGGGAAACAAC CACNGGTGTCCACTCCCAGGATACACCTTCACCAACTA TTTCTCTCCACNGGTGTC ATTGGAAGTAAAAGTGTGCGTCCAACTGCACCTCGGTTC CTATATGCACTGGGTGCGA CACTCCCAGGTCCAACTACTGGTACCAGCAGAAGCC TATCGATTGAATTCCACCAT CAGGCCCCTGGACAAGGGCGCAACCGGTTCTGTGAC AGGCCAGGCCCCTGTGCTGG GGGATGGTCATGTATCATCTTGAGTGGATGGGAATAAT CTCCTATGAGCTGACAC TCATCTATTATGATAGCGACCTTTTTCTAGTAGCAACTGC CAACCCTAGTGGTGGTAGC AGCCACCCTCAGTGTCACGGCCCTCAGGGATCCCTGA AACCGGTGTACATTCCCAG ACAGGCTACGCACAGAAGTGTGGCCCCAGGAAAGAC GCGATTCTCTGGCTCCAACT GTGCAGCTGGTGCAGTCTGTCCAGGGCAGAGTCACCAT GGCCAGGATTACCTGTG CTGGGAACACGGCCACCCTGGGCTGAGGTGAAGAAGCC GACCAGGGACACGTCCACG GGGGAAACAACATTGGAGACCATCAGCAGGGTCGAA TGGGGCCTCAGTGAAGGTT AGCACAGTCTACATGGAGCAGTAAAAGTGTGCACTG GCCGGGGATGAGGCCGACT TCCTGCAAGGCATCTGGATTGAGCAGCCTGAGATCTGA GTACCAGCAGAAGCCAG ATTACTGTCAGGTGTGGGATACACCTTCACCAACTACTAT GGACACGGCCGTGTATTAC GCCAGGCCCCTGTGCTGAGTAGTAGTGATCATCCGGG ATGCACTGGGTGCGACAGG TGTGCGAGATCCCGACCGAGTCATCTATTATGATAGC GGTGGTATTCGGCGGAGGG CCCCTGGACAAGGGCTTGACTCCTGACTGGTACTTCGAT GACCGGCCCTCAGGGAT ACCAAGCTGACCGTCCTAGGTGGATGGGAATAATCAAC CTCTGGGGCCGTGGCACCC CCCTGAGCGATTCTCTGG(SEQ ID NO: 3517) CCTAGTGGTGGTAGCACAG TGGTCACTGTCTCCTCAGCTCCAACTCTGGGAACA GCTACGCACAGAAGTTCCA (SEQ ID NO: 3515)CGGCCACCCTGACCATC GGGCAGAGTCACCATGACC AGCAGGGTCGAAGCCGGAGGGACACGTCCACGAGCA GGATGAGGCCGACTATT CAGTCTACATGGAGCTGAGACTGTCAGGTGTGGGAT CAGCCTGAGATCTGAGGAC AGTAGTAGTGATCATCCACGGCCGTGTATTACTGTG GGGGGTGGTATTCGGCG CGAGATCCCGACCGACTCCGAGGGACCAAGCTGACC TGACTGGTACTTCGATCTCT GTCCTAGGTCAGCCCAAGGGGCCGTGGCACCCTGGT GGCTGCCCCCTCGGTCAC CACCGTCTCCTCAGCGTCGTCTGTTCCCACCCTCGAG ACCAAGGGCCCATCGGTCT TGAGGAGCTTCAAGCCATCCCCCTGGCACCCTCCTCC ACAAGGCCACACTGGTG AAGAGCACCTCTGGGGGCATGTCTCATAAGTGACTTC CAGCGGCCCTGGGCTGCCT TACCCGGGAGCCGTGACGGTCAAGGACTACTTCCCC AGTGGCCTGGAAGGCAG GAACCTGTGACGGTCTCGTATAGCAGCCCCGTCAAG GGAACTCAGGCGCCCTGAC GCGGGAGTGGAGACCACCAGCGGCGTGCACACCTTC CACACCCTCCAAACAAA CCGGCTGTCCTACAGTCCTCGCAACAACAAGTACGCG AGGACTCTACTCCCTCAGC GCCAGCAGCTACCTGAGAGCGTGGTGACCGTGCCCT CCTGACGCCTGAGCAGT CCAGCAGCTTGGGCACCCAGGAAGTCCCACAGAAGC GACCTACATCTGCAACGTG TACAGCTGCCAGGTCACAATCACAAGCCCAGCAACA GCATGAANNGGAGCACC CCNAGGTGGANAGAGAGTTGTGGAGAAGACAGTGGC GAGCCCAAATCTTGTGACA CCCTACAGAATGTTCATAAACTCACACATGCCCACCG GAAGCTTGGCCGCCATG TGCCCAGCACCTGAACTCCGCCCAACTTGTTTATTGC TGGGGGGACCGTCAGTCTT AGCTTATAATGGTTACACCTCNTCCCCCCAAAACCC AATAAAGCAATAGCATC ANGGANACCCNTCATGATCACAANNTTCACAAATAA TCCNNNACCCTGAGNCNCN AGCATTTTTTTCACTGCANTGCGTGNNNGACNNNNAN TTCTANTTGTGGTTTGTC CCACNAANACCCTGAGNCACAACTCATCANGTATCTT NNTCAACTGGNNCGNNGNN ATCATGTCTGGATCGGN(SEQ ID NO: 3514) ATTAATTCGGCGCANCA NCATGGCCTGAAATAAC CTCTGAAANANGAANTTGGNNAGGNACCTTCNGA NGCNGAAAGAANCNTNN (SEQ ID NO: 3516) V-C031NNNNNNNNNNNNNGNATN CAGGTGCAGCTGGTGCAGT COV072_ NNNNNNNNNNNNNANNGAAATAGTGATGACGCAGT COV072_ NTACACATACGATTTAGGT CTGGGTCTGAGGTGAAGAAP3_B5 NNNNNNTACACNTACGA CTCCAGCCACCCTGTCTGTG P3_B5 GACACTATAGAATAACATCGCCTGGGTCCTCGGTGAAG TTTAGGTGACACTATAG TCTCCAGGGGAAAGAGCCACACTTTGCCTTTCTCTCCAC GTCTCCTGCAAGGCTTCTGG AATAACATCCACTTTGCCCCCTCTCCTGCAGGGCCAGT AGGTGTCCACTCCCAGGTC AGGCACCTTCAGCAGCTATTTTCTCTCCACAGGTGTC CAGAGTGTTAGCAGCAACTT CAACTGCACCTCGGTTCTATGCTTTCAGCTGGGTGCGAC CACTCCCAGGTCCAACT AGCCTGGTACCAGCAGAAACGATTGAATTCCACCATGG AGGCCCCTGGACAAGGGCT GCACCTCGGTTCTATCGACCTGGCCAGGCTCCCAGGCT GATGGTCATGTATCATCCTT TGAGTGGATGGGAAGGATCTTGAATTCCACCATGGG CCTCATCTATGGTGCATCCA TTTCTAGTAGCAACTGCAAATCCCTATCCTTGCTTTAGC ATGGTCATGTATCATCCT CCAGGGCCACTGGTATCCCACCGGTGTACATTCCCAGGT AAACTACGCACAGAAGTTC TTTTCTAGTAGCAACTGCGCCAGGTTCAGTGGCAGTG GCAGCTGGTGCAGTCTGGG CAGGGCAGAGTCACGATTAAACCGGTGTACATTCAG GGTCTGGGACAGAGTTCACT TCTGAGGTGAAGAAGCCTGCCGCGGACAAATCCACGAG AAATAGTGATGACGCAG CTCACCATCAGCAGCCTGCAGGTCCTCGGTGAAGGTCTC CACAGCCTACATGGAGCTG TCTCCAGCCACCCTGTCTGTCTGAAGATTTTGCAGTTT CTGCAAGGCTTCTGGAGGC AGCAGCCTGAGATCTGAGGGTGTCTCCAGGGGAAAG ATTACTGTCAGCAGTATAAT ACCTTCAGCAGCTATGCTTTACACGGCCGTGTATTACTG AGCCACCCTCTCCTGCAG AACTGGCCGATCACCTTCGGCAGCTGGGTGCGACAGGCC TGCGAGAGTCAATCAAGCA GGCCAGTCAGAGTGTTACCAAGGGACACGACTGGAG CCTGGACAAGGGCTTGAGT GTAACTACTCCCTTCTCCATGCAGCAACTTAGCCTGG ATTAAAC (SEQ ID  GGATGGGAAGGATCATCCCGGACGTCTGGGGCCAAGGG TACCAGCAGAAACCTGG NO: 3521) TATCCTTGCTTTAGCAAACTACCACGGTCACCGTCTCCTC CCAGGCTCCCAGGCTCCT ACGCACAGAAGTTCCAGGGA (SEQ ID NO: 3519) CATCTATGGTGCATCCAC CAGAGTCACGATTACCGCGCAGGGCCACTGGTATCC GACAAATCCACGAGCACAG CAGCCAGGTTCAGTGGCCCTACATGGAGCTGAGCAG AGTGGGTCTGGGACAGA CCTGAGATCTGAGGACACGGTTCACTCTCACCATCAG GCCGTGTATTACTGTGCGA CAGCCTGCAGTCTGAAGGAGTCAATCAAGCAGTAAC ATTTTGCAGTTTATTACT TACTCCCTTCTCCATGGACGGTCAGCAGTATAATAAC TCTGGGGCCAAGGGACCAC TGGCCGATCACCTTCGGCGGTCACCGTCTCCTCAGCGT CAAGGGACACGACTGGA CGACCAAGGGCCCATCGGTGATTAAACGTACGGTGG CTTCCCCCTGGCACCCTCCT CTGCACCATCTGTCTTCACCAAGAGCACCTCTGGGGG TCTTCCCGCCATCTGATG CACAGCGGCCCTGGGCTGCAGCAGTTGAAATCTGGA CTGGTCAAGGACTACTTCC ACTGCCTCTGTTGTGTGCCCGAACCTGTGACGGTCTC CTGCTGAATAACTTCTAT GTGGAACTCANGCGCCCTGCCCAGAGAGGCCAAAGT ACCAGCGGCGTGCACACCT ACAGTGGAAGGTGGATATCCCGGCTGTCCTACAGTCC ACGCCCTCCAATCGGGT TCAGGACTCTACTCCCTCAGAACTCCCAGGAGAGTGT CAGCGTGGTGACCGTGCCC CACAGAGCAGGACAGCATCCAGCAGCTTGGGCACCC AGGACAGCACCTACAGC AGACCTACATCTGCAACGTCTCAGCAGCACCCTGAC GAATCACAAGCCCAGCAAC GCTGAGCAAAGCAGACTACCAAGGTGGACAAGAGAG ACGAGAAACACAAAGTC TTGAGCCCAAATCTTGTGATACGCCTGCGAAGTCAC CAAAACTCACACATGCCCA CCATCAGGGCCTGAGCTCCGTGCCCAGCACCTGAAC CGCCCGTCACAAAGAGC TNCTGGGGGGACCGTCAGTTTCAACNGGGGAGANTG CTTCNTCTTCCCCCCAAANC TTAGAAGCTTGGCCGCCCNAGGANNCCCTCATGATC ATGGCCCAACTTGTTTAT TCNNNACCCNGAGTCNACATGCAGCTTATAATGGTTA TGCGTGGNGGTGNNGTGAN CAAATAAGCAATAGCATCNNCNAANNNCCNGAGGTC CACAAATTTCACAAATA AAGTTCAACTGGNNNCNTNAAGCATTTTTTCACTGCA (SEQ ID NO: 3518) TTCTANTNNNNNNTNGN CCAAACTCATCAATGNNNTCTTATCATGTCNGGNT CGGNAATTAANTN  (SEQ ID NO: 3520) V-C032NNNNNNNNNNNNNTGTATC CAGGTGCAGCTGCAGGAGT COV072_ NNNNNNNNNNNNNNNNCAGTCTGTGCTGACTCAGCC COV072_ ATACACATACGATTTAGGT CGGGCCCAGGACTGGTGAAP3_C1 NTNNTNNNNTACNNNTA TGCCTCCGTGTCTGGGTCTC P3_C1 GACACTATAGAATAACATCGCCTTCGGGGACCCTGTCC CNATTTAGGTGACACTAT CTGGACAGTCGATCACCATCCACTTTGCCTTTCTCTCCAC CTCACCTGCGCTGTCTCTGG AGAATAACATCCACTTTTCCTGCACTGGAACCAGCAG NGGTGTCCACTCCCAGGTC TGGCTCCATCAGCAGTAATGCCTTTCTCTCCCCNGGT TGACGTTGGTGGTTATAACT CAACTGCACCTCGGTTCTATAACTGGTGGAGTTGTGTCC GTCCACTCCCAGGTCCA ATGTCTCCTGGTACCAACAACGATTGAATTCCACCATGG GCCAGCCCCCAGGGAAGGG ACTGCACCTCGGTTCTATCACCCAGGCAAAGCCCCCA GATGGTCATGTATCATCCTT GCTGGAGTGGATTGGGGAACGATTGAATTCCACCATG AACTCATGATTTATGATGTC TTTCTAGTAGCAACTGCAAATCTATCATAGTGGGAGCA GGATGGTCATGTATCATC AGTAATCGGCCCTCAGGGGTCCGGTGTACATTCCCAGGT CCAACTACAACCCGTCCCT CTTTTTCTAGTAGCAACTTTCTAATCGCTTCTCTGGCT GCAGCTGCAGGAGTCGGGC CAAGAGTCGAGTCACCATAGCAACCGGTTCCTGGGC CCAAGTCTGGCAACACGGC CCAGGACTGGTGAAGCCTTTCAGTAGACAAGTCCAAGA CCAGTCTGCCCTGACTCA CTCCCTGACCATCTCTGGGCCGGGGACCCTGTCCCTCAC ACCAGTTCTCCCTGAAGCT GCCTGCCTCCGTGTCTGGTCCAGGCTGAGGACGAGGC CTGCGCTGTCTCTGGTGGCT GAGCTCTGTGACCGCCGCGGTCTCCTGGACAGTCGAT TGATTATTACTGCAGCTCAT CCATCAGCAGTAATAACTGGACACGGCCGTGTATTACT CACCATCTCCTGCACTGG ATACAAGCAGCAGCACTCTTGTGGAGTTGTGTCCGCCAG GTGCGAGAGGGGGGGATAC AACCAGCAGTGACGTTGTTGTTCGGCGGAGGGACCA CCCCCAGGGAAGGGGCTGG AGCTATGGGCCCCGAATACGTGGTTATAACTATGTCT AGCTGACCGTCCTAG  AGTGGATTGGGGAAATCTATTTGACTACTGGGGCCAGG CCTGGTACCAACAACAC (SEQ ID NO: 3525)TCATAGTGGGAGCACCAAC GAACCCTGGTCACCGTCTC CCAGGCAAAGCCCCCAATACAACCCGTCCCTCAAGA CTCAG (SEQ ID NO: ACTCATGATTTATGATGTGTCGAGTCACCATATCAGT 3523) CAGTAATCGGCCCTCAG AGACAAGTCCAAGAACCAGGGGTTTCTAATCGCTTCT TTCTCCCTGAAGCTGAGCTC CTGGCTCCAAGTCTGGCTGTGACCGCCGCGGACACG AACACGGCCTCCCTGAC GCCGTGTATTACTGTGCGACATCTCTGGGCTCCAGGC GAGGGGGGGATACAGCTAT TGAGGACGAGGCTGATTGGGCCCCGAATACTTTGAC ATTACTGCAGCTCATATA TACTGGGGCCAGGGAACCCCAAGCAGCAGCACTCTT TGGTCACCGTCTCCTCAGCG TTGTTCGGCGGAGGGACTCGACCAAGGGCCCATCGG CAAGCTGACCGTCCTAG TCTTCCCCCTGGCACCCTCCGTCAGCCCAAGGCTGCC TCCAAGAGCACCTCTGGGG CCCTCGGTCACTCTGTTCGCACAGCGGCCCTGGGCTG CCACCCTCGAGTGAGGA CCTGGTCAAGGACTACTTCGCTTCAAGCCAACAAGG CCCGAACCTGTGACGGTCT CCACACTGGTGTGTCTCACGTGGAACTCAGGCGCCCT TAAGTGACTTCTACCCGG GACCAGCGGCGTGCACACCGAGCCGTGACAGTGGCC TTCCCGGCTGTCCTACAGTC TGNAAGGCAGATANCAGCTCAGGACTCTACTCCCTCA CCCCGTCAAGGCGGGAN GCAGCGTGGTGACCGTGCCTGGAGACCACCACACCC CTCCAGCAGCTTGGGCACC TCCAAACAAAGCAACAACAGACCTACATCTGCAACG CAAGTACGCGGGCCAGC TGAATCACAAGCCCAGCAAAGCTACCTGANCCNTGA CACCAAGGTGGACAAGAGA CGCCTGAGCANTGGAAGGTTGAGCCCAAATCTTGTG TCCCACAGAAGCNTACA ACAAAACTCACACATGCCCGCTGCCANGTCACGCAT ACCGTGCCCAGCACCTGAA GAAGGGAGCACCGNGNACTCCTGGGGGGACCGTCAG GAGANANTGGCNCCTAC TCTTCCTCTTCCCCCCAAAAAGAATGTTCATANAANC NCCNAAGGACACCCTCATG TTGGCCGCCCANGGCCCATCTCCCNGACCCNTGAGG AACTTGTTATTGNNGCTT TCNACATGCGTGGTGGNGGATNN (SEQ ID NO: NCGTGANCCACNAAGACCC 3524) TGNNNGTCAAGTTCAACTGGNTACGTGGNANGGGNGNN NNNGGNNCANN (SEQ ID NO: 3522) V-C033NNNNNNNNNNNNNNNGNN CAGGTGCAGCTGGTGGAGT COV072_ GNNNNNNNNNNNNGTATGACATCCAGATGACCCAGTC COV072_ TNNTACACATACGATTTAG CTGGGGGAGGCGTGGTCCAP3_E5 CNNNCNCATACGATTTA TCCATCCTCCCTGTCTGCAT P3_E5 GTGACACTATAGAATAACAGCCTGGGAGGTCCCTGAGA GGTGACACTATAGAATA CTGTAGGAGACAGAGTCACTCCACTTTGCCTTTCTCTCC CTCTCCTGTGCAGCCTCTGG ACATCCACTTTGCCTTTCCATCACTTGCCGGGCAAGTC ACNGNTGTCCACTCCCAGG ATTCACCTTCAGTAGCTATGTCTCCACNGGTGTCCACT AGAGCATTAGCAGCTATTTA TCCAACTGCACCTCGGTTCTCTATGCACTGGGTCCGCCA CCCAGGTCCAACTGCAC AATTGGTATCAGCAGAAACATCGATTGAATTCCACCAT GGCTCCAGGCAAGGGGCTG CTCGGTTCTATCGATTGACAGGGAAAGCCCCTAAGCT GGGATGGTCATGTATCATC GAGTGGGTGGCAGTTATATATTCCACCATGGGATGG CCTGATCTATGCTGCATCCA CTTTTTCTAGTAGCAACTGCTATATGATGGAAGCAATAA TCATGTATCATCCTTTTT GTTTGCAAAGTGGGGTCCCAAACCGGTGTACATTCTCAG ATACTACGCAGACTCCGTG CTAGTAGCAACTGCAACTCAAGGTTCAGTGGCAGTGG GTGCAGCTGGTGGAGTCTG AAGGGCCGATTCACCATCTCGGTGTACATTCTGACAT ATCTGGGACAGATTTCACTC GGGGAGGCGTGGTCCAGCCCCAGAGACAATTCCAAGAA CCAGATGACCCAGTCTC TCACCATCAGCAGTCTGCAATGGGAGGTCCCTGAGACTC CACGCTGTATCTGCAAATG CATCCTCCCTGTCTGCATCCTGAAGATTTTGCAACTTA TCCTGTGCAGCCTCTGGATT AACAGCCTGAGAGCTGAGGCTGTAGGAGACAGAGTC CTACTGTCAACAGAGTTACA CACCTTCAGTAGCTATGCTAACACGGCTGTGTATTACTGT ACCATCACTTGCCGGGC GTACCCCTCCGTGGACGTTCTGCACTGGGTCCGCCAGGC GCGAGAGATTCGGACGTAG AAGTCAGAGCATTAGCAGGCCAAGGGACCAAGGTGG TCCAGGCAAGGGGCTGGAG ATACATCTATGGTTACTTGGGCTATTTAAATTGGTATC AAATCAAAC (SEQ ID TGGGTGGCAGTTATATTATTTCGACTACTGGGGCCAGG AGcAGAAAccAGGGAAA NO:3 529) ATGATGGAAGCAATAAATAGAACCCTGGTCACCGTCTC GCCCCTAAGCTCCTGATC CTACGCAGACTCCGTGAAGCTCAG (SEQ ID NO: TATGCTGCATCCAGTTTG GGCCGATTCACCATCTCCA 3527)CAAAGTGGGGTCCCATC GAGACAATTCCAAGAACAC AAGGTTCAGTGGCAGTGGCTGTATCTGCAAATGAAC GATCTGGGACAGATTTC AGCCTGAGAGCTGAGGACAACTCTCACCATCAGCAGT CGGCTGTGTATTACTGTGCG CTGCAACCTGAAGATTTTAGAGATTCGGACGTAGATA GCAACTTACTACTGTCAA CATCTATGGTTACTTGGTTCCAGAGTTACAGTACCCC GACTACTGGGGCCAGGGAA TCCGTGGACGTTCGGCCCCCTGGTCACCGTCTCCTCA AAGGGACCAAGGTGGAA GCGTCGACCAAGGGCCCATATCAAACGTACGGTGGC CGGTCTTCCCCCTGGCACCC TGCACCATCTGTCTTCATTCCTCCAAGAGCACCTCTG CTTCCCGCCATCTGATGA GGGGCACAGCGGCCCTGGGGCAGTTGAAATCTGGAA CTGCCTGGTCAAGGACTAC CTGCCTCTGTTGTGTGCCTTCCCCGAACCTGTGACGG TGCTGAATAACTTCTATC TCTCGTGGAACTCAGGCGCCCAGAGAGGCCAAAGTA CCTGACCAGCGGCGTGCAC CAGTGGAAGGTGGATAAACCTTCCCGGCTGTCCTACA CGCCCTCCAATCGGGTA GTCCTCAGGACTCTACTCCCACTCCCAGGAGAGTGTC TCAGCAGCGTGGTGACCGT ACAGAGCANGACAGCAAGCCCTCCAGCAGCTTGGGC GGACAGCACCTACAGCC ACCCAGACCTACATCTGCATCAGCAGCACCCTGACG ACGTGAATCACAAGCCCAG CTGAGCAAAGCAGACTACAACACCNAAGGTGGACAA CGAGAAACACAAAGTCT GAGAGTTGANCCCAAATCTACGCCTGCGAAGTCACC TGTGACAAAACTCACACAT CATCNGGGCCTGAGCTCGCCCACCGTGCCCAGCACC GCCCGTCACAAAGAGCT TGAACTCCTGGGGGGACCGTCAACAGGGGAGAGTGT TCAGTCTTCCTCTTCCCCCN TAGAAGCTTGGCCGCCANAAACCCANGGANACCCNC TGGNCCAACTTGTTTATT ATGATCTCCCNGACCCCTGGCAGCTTATNATGGTTAC AGNCACNTGNNNTGGNGGN AAATAAGCAATAGCATCGGANNNNGANCCNCGAAG ACAAATTTCACAAATAA ACCCTGGAGGTNAGTTCAAAGCATTTTTTNNNNCTGC CTGGNNCNNNGGAANGNN ATNCTAGTTGNNGGTTNNNNNN (SEQ ID NO: GTCCAAACTN (SEQ ID 3526) NO: 3528) V-C034NNNNNNNNCNNNNTGTATC GAGGTGCAGCTGTTGGAGT COV072_ NNNNNNNNNNNNTGTATTCCTATGTGCTGACTCAGCC COV072_ NTACACATACGATTTAGGT CTGGGGGAGGCTTGGTACAP3_H9 CATACACATACGATTTA ACCCTCAGTGTCAGTGGCCC P3_H9 GACACTATAGAATAACATCGCCTGGGGGGTCCCTGAGA GGTGACACTATAGAATA CAGGAAAGACGGCCAGGATCACTTTGCCTTTCTCTCCAC CTCTCCTGTGCAGCCTCTGG ACATCCACTTTGCCTTTCTACCTGTGGGGGAAACAAC AGGTGTCCACTCCCAGGTC ATTCACCTTTAGCAACTATGTCTCCACAGGTGTCCACT ATTGGAAGTAAAAGTGTGC CAACTGCACCTCGGTTCTATCCATGAGCTGGGTCCGCCA CCCAGGTCCAACTGCAC ACTGGTACCAGCAGAAGCCCGATTGAATTCCACCATGG GGCTCCAGGGAAGGGGCTG CTCGGTTCTATCGATTGAAGGCCAGGCCCCTGTGCTGG GATGGTCATGTATCATCCTT GAGTGGGTCTCAGCTATTAATTCCACCATGGGATGG TCATCTATTATGATAGCGAC TTTCTAGTAGCAACTGCAAGTGGTAGTGATGGTAGCAC TCATGTATCATCCTTTTT CGGCCCTCAGGGATCCCTGACCGGTGTACATTCTGAGGT ATACTACGCAGGCTCCGTG CTAGTAGCAACTGCAACGCGATTCTCTGGCTCCAACT GCAGCTGTTGGAGTCTGGG AAGGGCCGGTTCACCATCTCGGTTCTGTGACCTCCTA CTGGGAACACGGCCACCCT GGAGGCTTGGTACAGCCTGCCAGAGACAATTCCAAGAA TGAGCTGACACAGCCAC GACCATCAGCAGGGTCGAAGGGGGTCCCTGAGACTCTC CACACTGTATCTGCAAATG CCTCAGTGTCAGTGGCCCGCCGGGGATGAGGCCGAAT CTGTGCAGCCTCTGGATTCA AACAGCCTGAGAGCCGAGGCAGGAAAGACGGCCAGG ATCACTGTCAGGTGTGGGAT CCTTTAGCAACTATGCCATGACACGGCCGTATATTACTG ATTACCTGTGGGGGAAA AGTAGTAGTGATCGTCCGGGAGCTGGGTCCGCCAGGCTC TGCGAAAGATCCCCTTATA CAACATTGGAAGTAAAAGGTGGTTTTCGGCGGAGGG CAGGGAAGGGGCTGGAGTG ACTGGACCTACCTATCAATGTGTGCACTGGTACCAG ACCAAGCTGACCGTCCTAG GGTCTCAGCTATTAGTGGTACTTTCACTACTGGGGCCA CAGAAGCCAGGCCAGGC (SEQ ID NO: 3533)AGTGATGGTAGCACATACT GGGAACCCTGGTCACCGTC CCCTGTGCTGGTCATCTAACGCAGGCTCCGTGAAGGG TCCTCAG (SEQ ID  TTATGATAGCGACCGGCCCGGTTCACCATCTCCAGA NO: 3531) CCTCAGGGATCCCTGAG GACAATTCCAAGAACACACCGATTCTCTGGCTCCAAC TGTATCTGCAAATGAACAG TCTGGGAACACGGCCACCCTGAGAGCCGAGGACACG CCTGACCATCAGCAGGG GCCGTATATTACTGTGCGATCGAAGCCGGGGATGAG AAGATCCCCTTATAACTGG GCCGAATATCACTGTCAACCTACCTATCAATACTTTC GGTGTGGGATAGTAGTA ACTACTGGGGCCAGGGAACGTGATCGTCCGGGGGTG CCTGGTCACCGTCTCCTCAG GTTTTCGGCGGAGGGACCGTCGACCAAGGGCCCATC CAAGCTGACCGTCCTAG GGTCTTCCCCCTGGCACCCTGTCAGCCCAAGGCTGCC CCTCCAAGAGCACCTCTGG CCCTCGGTCACTCTGTTCGGGCACAGCGGCCCTGGGC CCACCCTCGAGTGAGGA TGCCTGGTCAAGGACTACTGCTTCAAGCCAACAAGG TCCCCGAACCTGTGACGGT CCACACTGGTGTGTCTCACTCGTGGAACTCAGGCGCC TAAGTGACTTCTACCCGG CTGACCAGCGGCGTGCACAGAGCCGTGACAGTGGCC CCTTCCCGGCTGTCCTACAG TGGAAGGCAGATAGCAGTCCTCNNACTCTACTCCCTC CCCCGTCAAGGCGGGAG AGCAGCGTGGTGACCGTGCTGGAGACCACCACACCC CCTCCAGCAGCTTGGGCAC TCCAAACAAAGCAACAACCAGACCTACATCTGCAAC CAAGTACGCGGCCAGCA GTGAATCACAAGCCCAGCAGCTACCTGAGCCTGACG ACACCNAAGGTGGACAAGA CCTGAGCAGTGGAAGTCNAGTTGAGCCCAAATCTTG CCACAGAAGCTACAGCT TGACAAAACTCACACATGCGCCAGGTCACGCATGAA CCACCGTGCCCAGCACCTG GGGAGCACCGTGGAGAAAACTNCTGGGGGGGACCGT GACAGTGGCCCCTACAG CAGTCTTCCTCTTCCCCCNAAATGTTCATAGAAGCTT AANCCNAGGANACCCTCAT GGCCGCCATGGNCCAACGATCTCCCNNACCCCNGAA TTGTTTATTGCAGCTTAN GGTCNCATGCNTGGNNGGTNATGGTTACAAATAAAG GGACGTGAGCCNCGAANNA CAATAGCATCACAAATTNCCNN (SEQ ID NO: TCACAAANAAAGCATTT 3530) TTTTCACTGCATCTANTGTGGNTNNTCCNAACNCA TCNATGNNNNNTNNCAT GTCTGGATCN (SEQ ID NO: 3532) V-C035NNNNNNNNNNNTGTATCNT CAGGTGCAGCTGGTGGAGT COV072_ NNNNNNNNNNNNTNTGTGACATCCAGATGACCCAGTC COV072_ ACACATACGATTTAGGTGA CTGGGGGAGGCGTGGTCCAP3_D9 ATCNTACNCNTACGATTT TCCTTCCACCCTGTCTGCAT P3_D9 CACTATAGAATAACATCCAGCCTGGGAGGTCCCTGAGA AGGTGACACTATAGAAT CTGTAGGAGACAGAGTCACCTTTGCCTTTCTCTCCACAG CTCTCCTGTGCAGCCTCTGG AACATCCACTTTGCCTTTCATCACTTGCCGGGCCAGTC GTGTCCACTCCCAGGTCCA ATTCACCTTCAGTAGCTATGCTCTCCACAGGTGTCCAC AGAGTATTAGTAACTGGTTG ACTGCACCTCGGTTCTATCGCTATGCACTGGGTCCGCCA TCCCAGGTCCAACTGCA GCCTGGTTTCAGCAGAAACCATTGAATTCCACCATGGGA GGCTCCAGGCAAGGGGCTG CCTCGGTTCTATCGATTGAGGGAAAGCCCCTAAGCTC TGGTCATGTATCATCCTTTT GAGTGGGTGGCAGTTATACAATTCCACCATGGGATG CTGATCTATGAGGCGTNTAG TCTAGTAGCAACTGCAACCCATTTGATGGAAGAAATAA GTCATGTATCATCCTTTT TTTAGAAAGTGGGGTCCCATGGTGTACATTCTCAGGTGC GTACTACGCAGACTCCGTG TCTAGTAGCAACTGCAACAAGGTTCAGCGGCAGTGG AGCTGGTGGAGTCTGGGGG ACGGGCCGATTCACCATCTCCGGTGTACATTCTGACA ATCTGGGACAGAATTCACTC AGGCGTGGTCCAGCCTGGGCCAGAGACAATTCCAAGAA TCCAGATGACCCAGTCTC TCACCATCAGCAGCCTGCAGAGGTCCCTGAGACTCTCCT CACACTGTATCTGCAAATG CTTCCACCCTGTCTGCATCCTGATGATTTTGCAACTTA GTGCAGCCTCTGGATTCAC AACAGCCTGAGAGCTGAGGCTGTAGGAGACAGAGTC TTACTGCCAACAGTATAATA CTTCAGTAGCTATGCTATGCACACGGCTGTGTATTACTGT ACCATCACTTGCCGGGC GTTATCCGTGGACGTTCGGCACTGGGTCCGCCAGGCTCC GCGAGTAGTAGTGGTTATC CAGTCAGAGTATTAGTACAAGGGACCAAGGTGGAAA AGGCAAGGGGCTGGAGTGG TTTTCCACTCTGACTACTGGACTGGTTGGCCTGGTTTC TCAAAC (SEQ ID NO:  GTGGCAGTTATACCATTTGGGCCAGGGAACCCTGGTCA AGCAGAAACCAGGGAAA 3537) ATGGAAGAAATAAGTACTACCGTCTCCTCAG (SEQ ID GCCCCTAAGCTCCTGATC CGCAGACTCCGTGACGGGC NO: 3535)TATGAGGCGTCTAGTTTA CGATTCACCATCTCCAGAG GAAAGTGGGGTCCCATCACAATTCCAAGAACACACT AAGGTTCAGCGGCAGTG GTATCTGCAAATGAACAGCGATCTGGGACAGAATTC CTGAGAGCTGAGGACACGG ACTCTCACCATCAGCAGCTGTGTATTACTGTGCGAGT CCTGCAGCCTGATGATTT AGTAGTGGTTATCTTTTCCATGCAACTTATTACTGCCA CTCTGACTACTGGGGCCAG ACAGTATAATAGTTATCCGGAACCCTGGTCACCGTCT GTGGACGTTCGGCCAAG CCTCAGCGTCGACCAAGGGGGACCAAGGTGGAGATC CCCATCGGTCTTCCCCCTGG AAACGTACGGTGGCTGCCACCCTCCTCCAAGAGCAC ACCATCTGTCTTCATCTT CTCTGGGGGCACAGCGGCCCCCGCCATCTGATGAGC CTGGGCTGCCTGGTCAAGG AGTTGAAATCTGGAACTACTACTTCCCCGAACCTGTG GCCTCTGTTGTGTGCCTG ACGGTCTCGTGGAACTCAGCTGAATAACTTCTATCCC GCGCCCTGACCAGCGGCGT AGAGAGGCCAAAGTACAGCACACCTTCCCGGCTGTCC GTGGAAGGTGGATAACG TACAGTCCTCANGACTCTACCCTCCAATCGGGTAACT CTCCCTCAGCAGCGTGGTG CCCAGGAGAGTGTCACAACCGTGCCCTCCAGCAGCT GAGCAGGACAGCAAGGA TGGGCACCCAGACCTACATCAGCACCTACAGCCTCA CTGCAACGTGAATCACAAG GCAGCACCCTGACGCTGCCCAGCAACACCNAAGGTG AGCAAAGCAGACTACGA GACAAGANAGTTGAGCCCAGAAACACAAAGTCTACG AATCTTGTGACAAAACTCA CCTGCGAAGTCACCCATCACATGCCCACCGTGCCCA CNGGGCCTGAGCTCGCC GCACCTGAACTCCTGGGGGCGTCACAAAGAGCTTCA GACCGTCAGTCTTCCTCTTC ACAGGGGAGAGTGTTAGCCCCCAAAACCCANNNNAC AAGCTTGGCCGCCATGG CCNCATGATCTCCCNNACCCCCAACTTGTTTATTGCA CCTGANNCNCATGNNNGGN GCTTATAATGGNTACAAGGNNNCGTGAGCCACNAAG ATAAAGCAATAGCATCA ACCNTGNNNCAGTTCAACTCAATTTCACAAATAAAG GGNACNNNGNNGNNNNGG CATTTTTTTCACTGCATTNNGTGCATAATGNCAANAA CTAGTTGTGGTTTGTCCA NNAAGCCNCGGGANNANCANCTCATNANGNATNNN ANTANNANNGCNNCGTACC NCATGTCTNGNTCGGGNGNNNNNNGNNNNNNNGTN NNNTCGNNGCAGCACCA NNNNNCGNCCNGCACNNNNNGGNCNNGAANNNACCN GNAANNNNNNTNN (SEQ CNNANNAN (SEQ ID ID NO: 3534)NO: 3536) V-C036 NNNNNNNNNNATGNATCNT GAGGTGCAGCTGGTGCAGT COV072_NNNNNNNNNTATGTATC CAGTCTGTGCTGACTCAGCC COV072_ ACACNTACGATTTAGGTGACTGGAGTAGAGGTGAAAAA P2_B10 NTACNCATACGATTTAG TCCCTCCGTGTCCGGGTCTC P2_B10CACTATAGAATAACATCCA GTCGGGGGAGTCTCTGAAG GTGACACTATAGAATAACTGGACAGTCAGTCACCATC CTTTGCCTTTCTCTCCACAG ATCTCCTGTAAGGGCTCTGCATCCACTTTGCCTTTCT TCCTGCACTGGAACCAGCAG GTGTCCACTCCCAGGTCCAGATACAACTTTGCCACCTCC CTCCACAGGTGTCCACTC TGACGTTGGTAGTTATAACCACTGCACCTCGGTTCTATCG TGGCTCGGCTGGGTGCGCC CCAGGTCCAACTGCACCGTGTCTCTTGGTACCAGCAG ATTGAATTCCACCATGGGA AGATGCCCGGCAAAGGCCTTCGGTTCTATCGATTGAA CCCCCAGGCACAGCCCCCA TGGTCATGTATCATCCTTTTGGAGTGGATGGGGATCATC TTCCACCATGGGATGGTC AACTCATGATTTATGAGGTCTCTAGTAGCAACTGCAACC TATCCTGGTGACTCTGATAC ATGTATCATCCTTTTTCTAATAATCGGCCCTCAGGGGT GGTGTACATTCCGAGGTGC CAGATACAGCCCGTCCTTCAGTAGCAACTGCAACCG CCCTGATCGCTTCTCTGGGT AGCTGGTGCAGTCTGGAGTCAAGGCCAGGTCACCATCT GTTCCTGGGCCCAGTCTG CCAAGTCTGGCAACACGGCAGAGGTGAAAAAGTCGGGG CAGCCGACAAGTCCATCAG CCCTGACTCAGCCTCCCTCTCCCTGACCATCTCTGGGC GAGTCTCTGAAGATCTCCT CACCGCCTACCTGCAGTGGCCGTGTCCGGGTCTCCTG TCCAGGCTGAAGACGAGGC GTAAGGGCTCTGGATACAAAGCAGCCTGAAGGCCTCGG GACAGTCAGTCACCATC TGATTATTACTGCAGCTCATCTTTGCCACCTCCTGGCTCG ACACCGCCATGTATTACTGT TCCTGCACTGGAACCAGATACAAGCAGTAGCAATTTC GCTGGGTGCGCCAGATGCC GCGAGACTCACATATACCACAGTGACGTTGGTAGTT GATGTCTTCGGAACTGGGAC CGGCAAAGGCCTGGAGTGGGTGGCTGGTACTGGGGCCA ATAACCGTGTCTCTTGGT CAAGGTCACCGTCCTAGATGGGGATCATCTATCCTG GGGAACCCTGGTCACCGTC ACCAGCAGCCCCCAGGC(SEQ ID NO: 3541) GTGACTCTGATACCAGATA TCGTCAG (SEQ ID NO:ACAGCCCCCAAACTCAT CAGCCCGTCCTTCCAAGGC 3539) GATTTATGAGGTCAATACAGGTCACCATCTCAGCCG ATCGGCCCTCAGGGGTC ACAAGTCCATCAGCACCGCCCTGATCGCTTCTCTGGG CTACCTGCAGTGGAGCAGC TCCAAGTCTGGCAACACCTGAAGGCCTCGGACACCG GGCCTCCCTGACCATCTC CCATGTATTACTGTGCGAGTGGGCTCCAGGCTGAAG ACTCACATATACCAGTGGC ACGAGGCTGATTATTACTTGGTACTGGGGCCAGGGAA GCAGCTCATATACAAGC CCCTGGTCACCGTCTCCTCAAGTAGCAATTTCGATGTC GCGTCGACCAAGGGCCCAT TTCGGAACTGGGACCAACGGTCTTCCCCCTGGCACCC GGTCACCGTCCTAGGTC TCCTCCAAGAGCACCTCTGAGCCCAAGGCCAACCCC GGGGCACAGCGGCCCTGGG ACTGTCACTCTGTTCCCGCTGCCTGGTCAAGGACTAC CCCTCGAGTGAGGAGCT TTCCCCGAACCTGTGACGGTCAAGCCAACAAGGCCA TCTCGTGGAACTCAGGCGC CACTGGTGTGTCTCATAACCTGACCAGCGGCGTGCAC GTGACTTCTACCCGGGA ACCTTCCCGGCTGTCCTACAGCCGTGACAGTGGCCTG GTCCTCNNACTCTACTCCCT GAAGGCAGATAGCAGCCCAGCAGCGTGGTGACCGTG CCGTCAAGGCGGGAGTG CCCTCCAGCAGCTTGGGCAGAGACCACCACACCCTC CCCAGACCTACATCTGCAA CAAACAAAGCAACAACACGTGAATCACAAGCCCAGC AGTACGCGGCCAGCAGC AACACCNANGTGGACAAGATACCTGAGCCTGACGCCT NAGTTGAGCCCAAATCTTG GAGCAGTGGAAGTCCCATGACAAAACTCACACATGC CAGAAGCTACAGCTGCC CCACCGTGCCCAGCACCTGAGGTCACGCATGANGGN AACTCCTGGGGGGACCGTC NCACCGTGGANAANACAAGTCTTCCNCTTCCCCCCAA GTGGNCCCTACAGAATG ANCNNNNNCACCCTCATGATTCATAGAAGCTTGGCC TCTCCCNGACCCCTGAGTC GCCATGGCCCAACTTGTTACATGCGTGNGNNNNGTGA TATTGCAGCTTANNATG NCCACGANACCCTGNNNCAGNTACAAATAAAGCAAT GTCANTNNNCGTGNNGGCG AGCATCACAAATTTCACTGNNNGCNTANNCNNAANN NAATAAAGCATTTTTTNN AGCNCNGGANNNNNANTACACTGCATTCTANTNNNN NANNNNNNGTACNNNNNG NNTNGNCNAACTCATNANNAGCGTCCNNCNNNNTCN NGNATCTNATCATGNNC NNNCNNNNTNNNGAANNNTGGNTCGGGNNNNNGNN ANGGANNNCAANNNGCAN CANCNNNTNNNNANNACGGNNNN (SEQ ID NO: NNTGAANAGACNNNGNN 3538) GNACTNCTGNNGNGGAANNAACATNNNNNNNGAA N (SEQ ID NO:  3540) V-C037 NNNNNNNNNNNATGNATCNGAGGTGCAGCTGGTGCAGT COV072_ NNNNNNNNNNATGTATC CAGTCTGCCCTGACTCAGCCCOV072_ TACACNTACGATTTAGGTG CTGGAGTAGAGGTGAAAAA P2_D6 NTACACNTACGATTTAGTCCCTCCGTGTCCGGGTCTC P2_D6 ACACTATAGAATAACATCC GTCGGGGGAGTCTCTGAAGGTGACACTATAGAATAA CTGGACAGTCAGTCACCATC ACTTTGCCTTTCTCTCCACAATCTCCTGTAAGGGCTCTG CATCCACTTTGCCTTTCT TCCTGCACTGGAACCAGCAGGGTGTCCACTCCCAGGTCC GATACAACTTTGCCACCTCC CTCCACAGGTGTCCACTCTGACGTTGGTAGTTATAACC AACTGCACCTCGGTTCTATC TGGCTCGGCTGGGTGCGCCCCAGGTCCAACTGCACC GTGTCTCTTGGTACCAGCAG GATTGAATTCCACCATGGGAGATGCCCGGCAAAGGCCT TCGGTTCTATCGATTGAA CCCCCAGGCACAGCCCCCAATGGTCATGTATCATCCTTT GGAGTGGATGGGGATCATC TTCCACCATGGGATGGTCAACTCATGATTTATGAGGTC TTCTAGTAGCAACTGCAAC TATCCTGGTGACTCTGATACATGTATCATCCTTTTTCT AATAATCGGCCCTCAGGGGT CGGTGTACATTCCGAGGTGCAGATACAGCCCGTCCTTC AGTAGCAACTGCAACCG CCCTGATCGCTTCTCTGGGTCAGCTGGTGCAGTCTGGAG CAAGGCCAGGTCACCATTT GTTCCTGGGCCCAGTCTGCCAAGTCTGGCAACACGGC TAGAGGTGAAAAAGTCGGG CAGCCGACAAGTCCATCAGCCCTGACTCAGCCTCCCT CTCCCTGACCATCTCTGGGC GGAGTCTCTGAAGATCTCCCACCGCCTACCTGCAGTGG CCGTGTCCGGGTCTCCTG TCCAGGCTGAAGACGAGGCTGTAAGGGCTCTGGATACA AGCAGCCTGAAGGCCTCGG GACAGTCAGTCACCATCTGATTATTACTGCAGCTCAT ACTTTGCCACCTCCTGGCTC ACACCGCCATGTATTACTGTTCCTGCACTGGAACCAG ATACAAGCAGTAGCAATTTC GGCTGGGTGCGCCAGATGCGCGAGACTCATATATACCA CAGTGACGTTGGTAGTT GATGTCTTCGGAACTGGGACCCGGCAAAGGCCTGGAGTG GTGGCTGGTACTGGGGCCA ATAACCGTGTCTCTTGGTCAAGGTCACCGTCCTAG GATGGGGATCATCTATCCT GGGAACCCTGGTCACCGTCACCAGCAGCCCCCAGGC (SEQ ID NO: 3545) GGTGACTCTGATACCAGAT TCCTCAG (SEQ ID ACAGCCCCCAAACTCAT ACAGCCCGTCCTTCCAAGG NO: 3543) GATTTATGAGGTCAATACCAGGTCACCATTTCAGCC ATCGGCCCTCAGGGGTC GACAAGTCCATCAGCACCGCCTGATCGCTTCTCTGGG CCTACCTGCAGTGGAGCAG TCCAAGTCTGGCAACACCCTGAAGGCCTCGGACACC GGCCTCCCTGACCATCTC GCCATGTATTACTGTGCGATGGGCTCCAGGCTGAAG GACTCATATATACCAGTGG ACGAGGCTGATTATTACTCTGGTACTGGGGCCAGGGA GCAGCTCATATACAAGC ACCCTGGTCACCGTCTCCTCAGTAGCAATTTCGATGTC AGCGTCGACCAAGGGCCCA TTCGGAACTGGGACCAATCGGTCTTCCCCCTGGCACC GGTCACCGTCCTAGGTC CTCCTCCAAGAGCACCTCTAGCCCAAGGCCAACCCC GGGGGCACAGCGGCCCTGG ACTGTCACTCTGTTCCCGGCTGCCTGGTCAAGGACTA CCCTCGAGTGAGGAGCT CTTCCCCGAACCTGTGACGTCAAGCCAACAAGGCCA GTCTCGTGGAACTCANGCG CACTGGTGTGTCTCATAACCCTGACCAGCGGCGTGCA GTGACTTCTACCCGGGA CACCTTCCCGGCTGTCCTACGCCGTGACAGTGGCCTG AGTCCTCAGGACTCTACTCC GAAGGCAGATAGCAGCCCTCAGCAGCGTGGTGACCG CCGTCAAGGCGGGAGTG TGCCCTCCAGCAGCTTGGGGAGACCACCACACCCTC CACCCAGACCTACATCTGC CAAACAAAGCAACAACAAACGTGAATCACAAGCCCA AGTACGCGGCCAGCAGC GCAACACCAAAGGTGGANATACCTGAGCCTGACGCCT AGANAGTTGAGCCCAAATC GAGCAGTGGAAGTCCCATTGTGACAAAACTCACACA CAGAAGCTACAGCTGCC TGCCCACCGNGCCCAGCACAGGTCACGCATGAAGGG CTGAACTNCTGGGGGGACC AGCACCGTGGAGAAGACGTCAGTCTTCCTCTTCCCCC AGTGGCCCCTACAGAAT CAAAACCCNNNCACCCTCAGTTCATAGAAGCTTGGN TGATCTCCCNGACCCCNGA CGCCATGGCCCAACTTGTGTCACATGCGTGNGNGNCG TTATTGCAGCTTATAATG TGANCCACGANANCCTGAGGNTACAAATAAAGCAAT TCAGTNACTNNNCNNNNNG AGCATCACAAATTTCACGNNNGGANNNGCATANNC AAATAAAGCATTTTTTTC NNAANNAGCNNNGNAGAGACTGCATTCTANTTGTGG CANTANANAGCNNNTNCGN TTTNTCCNAACTCATCANGNNNGNCANCGTCNNNNNN GTATCTNNCATGTCTGGA CNNN (SEQ ID NO:TCGGGAATTANNCGNCG 3542) CAGCNNNTGGCCTGAAA NNACNCTGAAAGAGANNNNNNGNNCTNCTGAGNG AAANANNTCNGNNGAAN GNNNNGNTCANTNNGGN NNNNGNANGTCCAGNNNCCCNNCAGNNNNNANNN TGNNNGCATNCANNNNN NNNNCNGCNNNNNGNNN NNGGNNNNNN (SEQ ID NO: 3544) V-C038 NNNNNNNNNNNATGTATCN GAGGTGCAGCTGGTGGAGT COV072_NNNNNNNNNNNNNTGTA AATTTTATGCTGACTCAGCC COV072_ TACACATACGATTTAGGTGCTGGGGGAGGCTTGGTCCA P2_C9 TCNTACACATACGATTTA CCACTCTGTGTCGGAGTCTC P2_C9ACACTATAGAATAACATCC GCCTGGGGGGTCCCTGAGA GGTGACACTATAGAATACGGGGAAGACGGTAACCAT ACTTTGCCTTTCTCTCCACA CTCTCCTGTGCAGCCTCTGGACATCCACTTTGCCTTTC CTCCTGCACCGGCAGCAGTG GGTGTCCACTCCCAGGTCCATTCACCTTTAGTACCTATT TCTCCACAGGTGTCCACT GCAGCATTGCCAGCAACTATAACTGCACCTCGGTTCTATC GGATGAGCTGGGTCCGCCA CCCAGGTCCAACTGCACGTGCAGTGGTACCAGCAGC GATTGAATTCCACCATGGG GCCTCCAGGGAAGGGGCTGCTCGGTTCTATCGATTGA GCCCGGGCAGTGCCCCCACC ATGGTCATGTATCATCCTTTGAGTGGGTGGCCAACATAA ATTCCACCATGGGATGG ACTGTGATCTATGAGGATAATTCTAGTAGCAACTGCAAC AGCAAGATGGAAGTGAGAA TCATGTATCATCCTTTTTCCAAAGACCCTCTGGGGTCC CGGTGTACATTCTGAGGTG ATACTATGTGGATTCTGTGACTAGTAGCAACTGCAAC CTGATCGGTTCTCTGGCTCC CAGCTGGTGGAGTCTGGGGAGGGCCGATTCACCATCTC CGGTTCTTGGGCCAATTT ATCGACAGCTCCTCCAACTCGAGGCTTGGTCCAGCCTGG CAGAGACAACGCCAAGAAC TATGCTGACTCAGCCCCATGCCTCCCTCACCATCTCTG GGGGTCCCTGAGACTCTCC TCACTGTATCTGCAAATGACTCTGTGTCGGAGTCTCC GACTGAAGACTGAGGACGA TGTGCAGCCTCTGGATTCACACAGCCTGAGAGCCGACGA GGGGAAGACGGTAACCA GGCTGACTACTACTGTCAGTCTTTAGTACCTATTGGATGA CACGGCCGTGTATTACTGT TCTCCTGCACCGGCAGCCTTATGATAGCAGCAATTGG GCTGGGTCCGCCAGCCTCC GCCGGGGGGACATGGCTACAGTGGCAGCATTGCCAG GTGTTCGGCGGAGGGACCA AGGGAAGGGGCTGGAGTGGGATCCTCTTTTGACTACTGG CAACTATGTGCAGTGGT AGCTGACCGTCCTA (SEQGTGGCCAACATAAAGCAAG GGCCAGGGAACCCTGGTCA ACCAGCAGCGCCCGGGC ID NO: 3549)ATGGAAGTGAGAAATACTA CCGTCTCCTCAG (SEQ ID AGTGCCCCCACCACTGTTGTGGATTCTGTGAAGGGC NO: 3547) GATCTATGAGGATAACC CGATTCACCATCTCCAGAGAAAGACCCTCTGGGGTC ACAACGCCAAGAACTCACT CCTGATCGGTTCTCTGGCGTATCTGCAAATGAACAGC TCCATCGACAGCTCCTCC CTGAGAGCCGACGACACGGAACTCTGCCTCCCTCACC CCGTGTATTACTGTGCCGG ATCTCTGGACTGAAGACGGGGACATGGCTACGATCC TGAGGACGAGGCTGACT TCTTTTGACTACTGGGGCCAACTACTGTCAGTCTTATG GGGAACCCTGGTCACCGTC ATAGCAGCAATTGGGTGTCCTCAGCGTCGACCAAGG TTCGGCGGAGGGACCAA GCCCATCGGTCTTCCCCCTGGCTGACCGTCCTACGTCA GCACCCTCCTCCAAGAGCA GCCCAAGGCTGCCCCCTCCTCTGGGGGCACAGCGGC CGGTCACTCTGTTCCCGC CCTGGGCTGCCTGGTCAAGCCTCGAGTGAGGAGCTT GACTACTTCCCCGAACCTGT CAAGCCAACAAGGCCACGACGGTCTCGTGGAACTCA ACTGGTGTGTCTCATAAG GGCGCCCTGACCAGCGGCGTGACTTCTACCCGGGAG TGCACACCTTCCCGGCTGTC CCGTGACAGTGGCCTGGCTACAGTCCTCANGACTCT AAGGCAGATAGCAGCCC ACTCCCTCAGCAGCGTGGTCGTCAAGGCGGGAGTGG GACCGTGCCCTCCAGCAGC AGACCACCACACCCTCCTTGGGCACCCAGACCTACA AAACAAAGCAACAACAA TCTGCAACGTGAATCACAAGTACGCGGCCAGCAGCT GCCCAGCAACACCNAAGGT ACCTGAGCCTGACGCCTGGACNAGAGAGTTGAGCCC GAGCAGTGGAAGTCCCA AAATCTTGTGACNAAACTCCAGAAGCTACAGCTGCC ACACATGCCCACCGTGCCC AGGTCACGCATGAAGGGAGCACCTGAACTCCTGGGG AGCACCGTGGANAAGAC GGACCGTCAGTCTTCCTCNTAGTGGCCCCTACAGAAT CCCCCAAACCCAAGGACAC GTTCATAGAAGCTTGGCCCTCATGATCTCCCGGACCC CGCCATGGCCCAACTTGT TGANTCACATGCNTGGTGGTTATTGCAGCTTATAATG TGGANGTGAGCCACNANNN GTTACNAATAAAGCAATCNTGAGGTCANTCANTGGN ANCATCACAAATTTCAC ACGNNGNNGGCNNNGAGGAAATAAAGCATTTTTTTC TGCATAANNCNNNNNNAAG ACTGCATTCTANTNGNGCNNNGGNAGGANCNNTACA GTTTGTCCAANCTCATCA ANNNNCNCGTACNNNNNNNNGNATNNNNNATGTCTG NANNNGTCNTNNNCGTNNN GATCGGNATTNNNGNNNNNNNCNNNAANNNNNNTG NNNNCNNCNTGGCCTGA AANNG (SEQ ID NO: AANNACCTCTGAAAGAN3546) NNTNNNNGNANNNNGAG NNNANNNNTCNGNNNNG NNNNGTCANTNGGGTGNNGAANNNCCAGNTNCCC NNCAGNNNANNNNTGNA AGCATGNATNTCNNNNN CANNNNNNNNNGNGNN(SEQ ID NO: 3548) V-C039 NNNNNNNNNNATGNATCNT CAGGTGCAGCTGGTGGAGT COV072_NNNNNNNNNNNTATGNA GACATCCAGATGACCCAGTC COV072_ ACACATACGATTTAGGTGACTGGGGGAGGCGTGGTCCA P2_F3 TCNTACACNTACGATTTA TCCATCCTCCCTGTCTGCAT P2_F3CACTATAGAATAACATCCA GCCTGGGAGGTCCCTGAGA GGTGACACTATAGAATACTGTAGGAGACAGAGTCAC CTTTGCCTTTCTCTCCACAG CTCTCCTGTGCAGCCTCTGGACATCCACTTTGCCTTTC CATCACTTGCCAGGCGAGTC GTGTCCACTCCCAGGTCCAATTCACCTTCAGTAGCTATG TCTCCACAGGTGTCCACT AGGACATTAGCAACTATTTAACTGCACCTCGGTTCTATCG CCATGCACTGGGTCCGCCA CCCAGGTCCAACTGCACAATTGGTATCAGCAGAAAC ATTGAATTCCACCATGGGA GGCTCCAGGCAAGGGGCTGCTCGGTTCTATCGATTGA CAGGGAAAGCCCCTAAGCT TGGTCATGTATCATCCTTTTGAGTGGGTGGCAGTTATAT ATTCCACCATGGGATGG CCTGATCTACGATGCATCCATCTAGTAGCAACTGCAACC CATATGATGGAAGTAATAA TCATGTATCATCCTTTTTATTTGGAAACAGGGGTCCC GGTGTACATTCTGAGGTGC ATACTCTGCAGACTCCGTGCTAGTAGCAACTGCAAC ATCAAGGTTCAGTGGAAGT AGCTGGTGGAGTCTGGGGGAAGGGCCGATTCACCATCT CGGTGTACATTCTGACAT GGATCTGGGACAGATTTTACAGGCGTGGTCCAGCCTGGG CCAGAGACAATTCCAAGAA CCAGATGACCCAGTCTCTTTCACCATCAGCAGCCTGC AGGTCCCTGAGACTCTCCT CACGCTGTATCTGCAAATGCATCCTCCCTGTCTGCAT AGCCTGAAGATATTGCAAC GTGCAGCCTCTGGATTCACAACAGCCTGAGAGCTGAGG CTGTAGGAGACAGAGTC ATATTACTGTCAACAGTATGCTTCAGTAGCTATGCCATGC ACACGGCTGTGTATTACTGT ACCATCACTTGCCAGGCATAATCTCCCGCTCACTTTC ACTGGGTCCGCCAGGCTCC GCGAAAGGGGGGGCCTACAGAGTCAGGACATTAGCA GGCGGAGGGACCAAGGTGG AGGCAAGGGGCTGGAGTGGGCTACTACTACTACATGGA ACTATTTAAATTGGTATC AGATCAAAC (SEQ IDGTGGCAGTTATATCATATG CGTCTGGGGCAAAGGGACC AGCAGAAACCAGGGAAA NO: 3553)ATGGAAGTAATAAATACTC ACGGTCACCGTCTCCTCA GCCCCTAAGCTCCTGATCTGCAGACTCCGTGAAGGGC (SEQ ID NO: 3551) TACGATGCATCCAATTTGCGATTCACCATCTCCAGAG GAAACAGGGGTCCCATC ACAATTCCAAGAACACGCTAAGGTTCAGTGGAAGTG GTATCTGCAAATGAACAGC GATCTGGGACAGATTTTCTGAGAGCTGAGGACACGG ACTTTCACCATCAGCAGC CTGTGTATTACTGTGCGAACTGCAGCCTGAAGATAT AGGGGGGGCCTACAGCTAC TGCAACATATTACTGTCATACTACTACATGGACGTCT ACAGTATGATAATCTCCC GGGGCAAAGGGACCACGGTGCTCACTTTCGGCGGAG CACCGTCTCCTCAGCGTCG GGACCAAGGTGGAAATCACCAAGGGCCCATCGGTCT AAACGTACGGTGGCTGC TCCCCCTGGCACCCTCCTCCACCATCTGTCTTCATCTT AAGAGCACCTCTGGGGGCA CCCGCCATCTGATGAGCCAGCGGCCCTGGGCTGCCT AGTTGAAATCTGGAACT GGTCAAGGACTACTTCCCCGCCTCTGTTGTGTGCCTG GAACCTGTGACGGTCTCGT CTGAATAACTTCTATCCCGGAACTCANGCGCCCTGAC AGAGAGGCCAAAGTACA CAGCGGCGTGCACACCTTCGTGGAAGGTGGATAACG CCGGCTGTCCTACAGTCCTC CCCTCCAATCGGGTAACTNNNCTCTACTCCCTCAGCA CCCAGGAGAGTGTCACA GCGTGGTGACCGTGCCCTCGAGCAGGACAGCAAGGA CAGCAGCTTGGGCACCCAG CAGCACCTACAGCCTCAACCTACATCTGCAACGTGA GCAGCACCCTGACGCTG ATCACAAGCCCAGCAACACAGCAAAGCAGACTACGA CAAGGTGGACAAGAGAGTT GAAACACAAAGTCTACGGAGCCCAAATCTTGTGANN CCTGCGAAGTCACCCAT AAACTCACACATGCCCACCCNGGCCTGAGCTCGCCC GTGCCCAGCANCTGAACTN GTCACAAAGAGCTTCAACTGGGGGGACCGTCAGTCT CAGGGGAGAGTGTTAGA TCCTCNTCCCCCNAANCCNAGCTTGGCCGCCATGGN AGGACACCCNNCATGATCT CCAACTTGNTTATTGCAGNCCNNACCNNGAGTCACAT CTTATNATGGTTACAATA GCGTGNNNNNNGTNAGCACAAGCAATAGCATCACAA GANANCCTGAGTCAGTCAN ATTTCACAAATAAAGCATGGNACNNNGNNGGNNNN TTTTTTTCACTGCATTCT GNNNNGCNTANNCNNANNANTNGNNGGTTNGTCCA NCNNNGGNAGNANCNNTAC ANCTCATCAATGNATNNANNNNNCGTACNNNNNGNC NNCATGTCTGGNTCGGG AGCNNNNTNNNCGTCNNNNANTNNNNGNGCAGCNNC CCNNGNNNGNNNNAANGG NTGGCNTGAANNNNNTC NA (SEQ ID NO: TGAAGAGANTNNNAGNA 3550) CNNTGAGNGNNNCNTNN NNNNNNNNNNNNNNNTCAGTNGNNNNNNGAANNN (SEQ ID NO: 3552) V-C040 NNNNNNNNNATGNATCNTAGAGGTGCAGCTGGTGGAGT COV072_ NNNNNNNNNNNNNGNAT GACATCCAGTTGACCCAGTCCOV072_ CACATACGATTTAGGTGAC CTGGGGGAGGCTTGGTCCA P2_C12 CNTACACATACGATTTATCCATCCTTCCTGTCTGCAT P2_C12 ACTATAGAATAACATCCAC GCCTGGGGGGTCCCTGAGAGGTGACACTATAGAATA CTGTAGGAGACAGAGTCAC TTTGCCTTTCTCTCCACAGGCTCTCCTGTGCAGCCTCTGG ACATCCACTTTGCCTTTC CATCACTTGCCGGGCCAGTCTGTCCACTCCCAGGTCCAA AGTCACCGTCAGTAGCAAC TCTCCACAGGTGTCCACTAGGGCATTAGCAGTTATTTA CTGCACCTCGGTTCTATCGA TACATGAGCTGGGTCCGCCCCCAGGTCCAACTGCAC GCCTGGTATCAGCAAAAAC TTGAATTCCACCATGGGATAGGCTCCAGGGAAGGGGCT CTCGGTTCTATCGATTGA CAGGGAAAGCCCCTAAGCTGGTCATGTATCATCCTTTTT GGAGTGGGTCTCACTTATTT ATTCCACCATGGGATGGCCTGATCTATGCTGCATCCA CTAGTAGCAACTGCAACCG ATAGCGGTGGTAGCACATTTCATGTATCATCCTTTTT CTTTGCAAAGTGGGGTCCCA GTGTACATTCTGAGGTGCACTACGCAGACTCCGTGAAG CTAGTAGCAACTGCAAC TCAAGGTTCAGCGGCAGTGGCTGGTGGAGTCTGGGGGA GGCAGATTCACCATCTCCA CGGTGTACATTCAGACAGATCTGGGACAGAATTCACT GGCTTGGTCCAGCCTGGGG GAGACAATTCCGAGAACACTCCAGTTGACCCAGTCTC CTCACAATCAGCAGCCTGCA GGTCCCTGAGACTCTCCTGTGCTGTATCTTCAAATGAAC CATCCTTCCTGTCTGCAT GCCTGAAGATTTTGCAACTTGCAGCCTCTGGAGTCACCG ACCCTGAGAGCCGAGGACA CTGTAGGAGACAGAGTCATTACTGTCAACAGCTTAAT TCAGTAGCAACTACATGAG CGGCTGTGTATTACTGTGCGACCATCACTTGCCGGGC AGTTACTCTTACACTTTTGG CTGGGTCCGCCAGGCTCCAAGAGATCTGTATTACTACG CAGTCAGGGCATTAGCA CCAGGGGACCAAGCTGGAGGGGAAGGGGCTGGAGTGGG GTATGGACGTCTGGGGCCA GTTATTTAGCCTGGTATCATCAAAC (SEQ ID NO: TCTCACTTATTTATAGCGGT AGGGACCACGGTCACCGTCAGCAAAAACCAGGGAAA 3557) GGTAGCACATTCTACGCAG TCCTCA (SEQ ID NO:GCCCCTAAGCTCCTGATC ACTCCGTGAAGGGCAGATT 3555) TATGCTGCATCCACTTTGCACCATCTCCAGAGACAAT CAAAGTGGGGTCCCATC TCCGAGAACACGCTGTATCAAGGTTCAGCGGCAGTG TTCAAATGAACACCCTGAG GATCTGGGACAGAATTCAGCCGAGGACACGGCTGTG ACTCTCACAATCAGCAG TATTACTGTGCGAGAGATCCCTGCAGCCTGAAGATTT TGTATTACTACGGTATGGA TGCAACTTATTACTGTCACGTCTGGGGCCAAGGGACC ACAGCTTAATAGTTACTC ACGGTCACCGTCTCCTCAGTTACACTTTTGGCCAGGG CGTCGACCAAGGGCCCATC GACCAAGCTGGAGATCAGGTCTTCCCCCTGGCACCCT AACGTACGGTGGCTGCA CCTCCAAGAGCACCTCTGGCCATCTGTCTTCATCTTC GGGCACAGCGGCCCTGGGC CCGCCATCTGATGAGCATGCCTGGTCAAGGACTACT GTTGAAATCTGGAACTG TCCCCGAACCTGTGACGGTCCTCTGTTGTGTGCCTGC CTCGTGGAACTCAGGCGCC TGAATAACTTCTATCCCACTGACCAGCGGCGTGCACA GAGAGGCCAAAGTACAG CCTTCCCGGCTGTCCTACAGTGGAAGGTGGATAACGC TCCTCAGGACTCTACTCCCT CCTCCAATCGGGTAACTCCAGCAGCGTGGTGACCGTG CCAGGAGAGTGTCACAG CCCTCCAGCAGCTTGGGCAAGCANGACAGCAAGGAC CCCAGACCTACATCTGCAA AGCACCTACAGCCTCAGCGTGAATCACAAGCCCAGC CAGCACCCTGACGCTGA AACACCNANGTGGACAAGANCAAAGCAGACTACGAG NAGTTGAGCCCAAATCTTG AAACACAAAGTCTACGCTGACAAAACTCACACATGC CTGCGAAGTCACCCATC CCACCGTGCCCAGCACCTGAGGGCCTGAGCTCGCCC AACTCCTGGGGGGACCGTC GTCACAAAGAGCTTCAAAGTCTTCCTCTTCCCCCCAA CAGGGGAGAGTGTTAGA AANCCAAGGACACCCTNATAGCTTGGCCGCCATGGC GATCNCCCNGACCCCNGAN CCAACTTGTTTATTGCAGTCACATGCGTGGNGNNGAC CTTATAATGGNTACAAA GTGAGCCACGANACCCNGATAAAGCAATAGCATCAC GTCAGTTCAACTGGNACGN AAATTTCACAAATAAAGNGNNGGNNNNGGAGGTGC CATTTTTTTCACTGCATT ANANNCNNNAANAAGCCNCTANTTGNGGNTTGNCC NNGGNAGGANNAGTANAN AAACTCATNNNGNATNTNGNNCGTACNNNNNNNNCA NTCATGTCTGNATCNGN NCGTCNNCNNCNNNNNNNCNNTNATTCGNCGCAGCN AGNNTNNNGAANGGCNNG CNTNNNNAANNACNCTGNNNNNNNANNGCAANGNN AANAGNNNNNNNNACN NNNCNNNNAANNNNNN NNGAGNGAANAACNTNN(SEQ ID NO: 3554) TGNGANNNNNNNTCAGT NGGNNGNNGAAAGTCCC NNGNTNCCNANCAGNANANNNTGNNNCANGCATT NNCANNNNNNNCNNCNG NNNNGGAAANTCNNNNN NNNN (SEQ ID NO:3556) V-C041 NNNNNNNNNATGTATCNTA CAGGTGCAGCTGGTGGAGT COV072_NNNNNNNNNNTATGNAT AATTTTATGCTGACTCAGCC COV072_ CACNTACGATTTAGGTGACCTGGGGGAGGCGTGGTCCA P3_H7 CNTACACATACGATTTA CCACTCTGTGTCGGAGTCTC P3_H7ACTATAGAATAACATCCAC GCCTGGGAGGTCCCTGAGA GGTGACACTATAGAATACGGGGAAGACGGTAACCAT TTTGCCTTTCTCTCCACAGG CTCTCCTGTGCAGCCTCTGGACATCCACTTTGCCTTTC CTCCTGCACCGGCAGCAGTG TGTCCACTCCCAGGTCCAAATTCACCTTCAGTAGCTATG TCTCCACAGGTGTCCACT GCAGCATTGCCAGCAACTATCTGCACCTCGGTTCTATCGA CTATGTTCTGGGTCCGCCAG CCCAGGTCCAACTGCACGTGCAGTGGTACCAGCAGC TTGAATTCCACCATGGGAT GCTCCAGGCAAGGGGCTGGCTCGGTTCTATCGATTGA GCCCGGGCAGTGCCCCCACC GGTCATGTATCATCCTTTTTAGTGGGTGGCAGTTATATC ATTCCACCATGGGATGG ACTGTGATCTATGAGGATAACTAGTAGCAACTGCAACCG ATATGATGGAAGCAATAAA TCATGTATCATCCTTTTTCCAAAGACCCTCTGGGGTCC GTGTACATTCTGAGGTGCA TACTACGCAGACTCCGTGACTAGTAGCAACTGCAAC CTGATCGGTTCTCTGGCTCC GCTGGTGGAGTCTGGGGGAAGGGCCGATTCACCATCTC CGGTTCTTGGGCCAATTT ATCGACAGCTCCTCCAACTCGGCGTGGTCCAGCCTGGGA CAGAGACAATTCCAAGAAC TATGCTGACTCAGCCCCATGCCTCCCTCACCATCTCTG GGTCCCTGAGACTCTCCTGT ACGCTGTATCTGCAAATGACTCTGTGTCGGAGTCTCC GACTGAAGACTGAGGACGA GCAGCCTCTGGATTCACCTTACAGCCTGAGAGCTGAGGA GGGGAAGACGGTAACCA GGCTGACTACTACTGTCAGTCAGTAGCTATGCTATGTTCT CACGGCTGTGTATTACTGTG TCTCCTGCACCGGCAGCCTTATGATAGCAGCAATTGG GGGTCCGCCAGGCTCCGGG CGAGGGCGGATTTAGGATAAGTGGCAGCATTGCCAG GTGTTCGGCGGAGGGACCA CAAGGGGCTGGAGTGGGTGTTGTACTAATGGTGTATGCT CAACTATGTGCAGTGGT AGCTGACCGTCCTAG (SEQGCAGTTATATCATATGATG ATGTTGACTACTGGGGCCA ACCAGCAGCGCCCGGGC ID NO: 310)GAAGCAATAAATACTACGC GGGAACCCTGGTCACCGTC AGTGCCCCCACCACTGTAGACTCCGTGAAGGGCCGA TCCTCA (SEQ ID NO: GATCTATGAGGATAACCTTCACCATCTCCAGAGACA 3559) AAAGACCCTCTGGGGTC ATTCCAAGAACACGCTGTACCTGATCGGTTCTCTGGC TCTGCAAATGAACAGCCTG TCCATCGACAGCTCCTCCAGAGCTGAGGACACGGCTG AACTCTGCCTCCCTCACC TGTATTACTGTGCGAGGGCATCTCTGGACTGAAGAC GGATTTAGGATATTGTACT TGAGGACGAGGCTGACTAATGGTGTATGCTATGTTG ACTACTGTCAGTCTTATG ACTACTGGGGCCAGGGAACATAGCAGCAATTGGGTG CCTGGTCACCGTCTCCTCAG TTCGGCGGAGGGACCAACGTCGACCAAGGGCCCATC GCTGACCGTCCTAGGTC GGTCTTCCCCCTGGCACCCTAGCCCAAGGCTGCCCCC CCTCCAAGAGCACCTCTGG TCGGTCACTCTGTTCCCGGGGCACAGCGGCCCTGGGC CCCTCGAGTGAGGAGCT TGCCTGGTCAAGGACTACTTCAAGCCAACAAGGCCA TCCCCGAACCTGTGACGGT CACTGGTGTGTCTCATAACTCGTGGAACTCANGCGCC GTGACTTCTACCCGGGA CTGACCAGCGGCGTGCACAGCCGTGACAGTGGCCTG CCTTCCCGGCTGTCCTACAG GAAGGCAGATAGCAGCCTCCTCAGGACTCTACTCCCT CCGTCAAGGCGGGAGTG CAGCAGCGTGGTGACCGTGGAGACCACCACACCCTC CCCTCCAGCAGCTTGGGCA CAAACAAAGCAACAACACCCAGACCTACATCTGCAA AGTACGCGGCCAGCAGC CGTGAATCACAAGCCCAGCTACCTGAGCCTGACGCCT AACACCANNNGGACAAGA GAGCAGTGGAAGTCCCANAGTTGAGCCCAAATCTTG CAGAAGCTACAGCTGCC TGACAAAACTCACACATGCAGGTCACGCATGAAGGG CCACCGTGCCCAGCACCTG AGCACCGTGGNNAAGACACTCCTGGGGGGACCGTCA AGTGGCCCCTACAGAAT GTCTTCNNNTCCCCCAAAAGTTCATAGAAGCTTGGC NCCAANNNANCCNTCATGA CGCCATGGCCCAACTTGTTCTNCCNNCCNNGAGTCAC TTATTGCAGCTTATAATG NTGNNGTGGNGNNNGNNGTGTTACAAATAAAGCANA GANCNCNANANCCTGAGTC GCATCACAAATTTCACAAGTCACTNNNCNTGNNNNN AATAAAGCATTTTTTTCA NNNGANNNGCNNANNCNNCTGCATNCTANTNGNGG NNNNANCNNNGANNANAG TTTGTCCAAACTCATCNNTNCANNGNNCNNNCNNNNN NNATNNNTCATGTCTGG NGNCANCNNNNNNNNNNCATCGGGAATNNNTNGNC CGTNNNNNNNCNNNNGNA GCANCNCNTGCCTGANN ANNNGGCNNNNN (SEQACCTCTGAANANNNTNN ID NO: 3558) NGTACTNCNGAGNGAAA NNANNTCTGNGNNNNNNGTCAGTTNGGGNGNNNN NNCCNGNTNCCCNNNNN GNANANNNTGCAAGCAT GCNTNNTNNNTNANTCANN (SEQ ID NO: 3560) V-C042 GAGGTGCAGCTGGTGGAGT COV047_NNNNNNNNNNTNNNGNN GACATCGTGATGACCCAGTC COV047_ CTGGGGGAGGCTTGGTCCA P5_H7TNNTACNCATACGATTTA TCCAGACTCCCTGGCTGTGT P5_H7 GCCGGGGGGGTCCCTGAGAGGTGACACTATAGAATA CTNTGGGCGAGAGGGCCAC CTCTCCTGTGCAGCCTCTGGACATCCACTTTGCCTTTC CATCAACTGCAAGTCCAGCC ATTCAGTGTCAGCACGAAGTCTCCACAGGTGTCCACT AGAGTGTTTTATACAGCTCC TACATGACATGGGTCCGTCCCCAGGTCCAACTGCAC AACAATAAGAACTACTTAG AGGCTCCAGGGAAGGGACTCTCGGTTCTATCGATTGA CTTGGTACCAGCAGAAACC GGAGTGGGTCTCAGCTCTTTATTCCACCATGGGATGG AGGACAGCCTCCTAAGCTGC ACAGCGGTGGTAGTGATTATCATGTATCATCCTTTTT TCATTTACTGGGCATCTACC CTACGCAGACTCCGTGAAGCTAGTAGCAACTGCAAC CGGGAATCCGGGGTCCCTG GGCAGATTCACCATCTCCACGGTGTACATTCGGACA ACCGATTCAGTGGCAGCGG GAGACAATTCCAAGAACACTCGTGATGACCCAGTCTC GTCTGGGACAGATTTCACTC TTTATATCTTCAAATGAGCACAGACTCCCTGGCTGTGT TCACCATCAGCAGCCTGCAG GCTTGAGAGTCGAGGACACCTCTGGGCGAGAGGGCC GCTGAAGATGTGGCAGTTTA GGGTGTTTATTACTGTGCCAACCATCAACTGCAAGTC TTACTGTCAGCAATATTATA GAGACTCGTCGGAAGTCCGCAGCCAGAGTGTTTTATA GTACTCCGCTCACTTTCGGC TGACCACCCCGGGCACCCACAGCTCCAACAATAAGA GGAGGGACCAAGGTGGAGA GGGCGCTCGGTGGGGGCTTACTACTTAGCTTGGTACC TCAAAC (SEQ ID NO: TTGATATTTGGGGCCAAGGAGCAGAAACCAGGACAG 3564) GACAATGGTC (SEQ ID CCTCCTAAGCTGCTCATT NO: 3562)TACTGGGCATCTACCCG GGAATCCGGGGTCCCTG ACCGATTCAGTGGCAGC GGGTCTGGGACAGATTTCACTCTCACCATCAGCA GCCTGCAGGCTGAAGAT GTGGCAGTTTATTACTGTCAGCAATATTATAGTACT CCGCTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGTACGGTGGCTG CACCATCTGTCTTCATCT TCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT GCCTCTGTTGTGTGCCTG CTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA GTGGAAGGTGGATAACG CCCTCCAATCGGGTAACT CCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGA CAGCACCTACAGCCTCA GCAGCACCCTGACGCTG AGCAAAGCAGACTACGAGAAACACAAAGTCTACG CCTGCGAAGTCACCCAT CANGGCCTGAGCTCGCC CGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG AAGCTTGGCCGCCATGG CCCAACTTGTTTATTGCA GCTTATAATGGTTACAAATAAAGCAATAGCATCA CAAATTTCACAAATAAA GCATTTTTTTCACTGCATTCTANTTGTGGTTTGTCC AAACTCATCAATGTATCT NATCATGTCTGGATCGGGAATTNATTCGGCGCAG CANCATGGNCCTGAAAT AACCTNNNAAAGANNAC TTGNTTAGNACNTNCTGANNNNANNACATCNNNN GAATGNNNGTCANNNNN NGGNNGAAAGTCCCNNN CTCCCCNNCNGNNANNNTGCNNANNNNNNNNNNN NNNNCAGCACNGNNNGA ANNNNNNNNNNNNNNN GCNAANNNNCANCANNNANNNNNNNNNNNNNNN ANC (SEQ ID NO: 3563) V-C043 NNNNNNNNNNATGNATCNTGAGGTGCAGCTGGTGGAGT COV047_ NNNNNNNNCCNNNNNNT CAGTCTGTGCTGACTCAGCCCOV047_ ACACATACGATTTAGGTGA CTGGGGGAGGCTTGGTCCA P5_E9 ANNNTACNCATACGATTTGCCTCCGTGTCTGGGTCTC P5_E9 CACTATAGAATAACATCCA GCCGGGGGGGTCCCTGAGATAGGTGACACTATAGAA CTGGACAGTCGATCACCATC CTTTGCCTTTCTCTCCACAGCTCTCCTGTGCAGCCTCTGG TAACATCCACTTTGCCTT TCCTGCACTGGAACCAGCAAGTGTCCACTCCCAGGTCCA ATTCAGTGTCAGCACCAAG TCTCTCCACAGGTGTCCATGATGTTGGGAGTTATACCC ACTGCACCTCGGTTCTATCG TACATGACATGGGTCCGTCCTCCCAGGTCCAACTGC TTGTCTCCTGGTACCAACAG ATTGAATTCCACCATGGGAAGGCTCCAGGGAAGGGGCT ACCTCGGTTCTATCGATT TACCCAGGCAAAGCCCCCATGGTCATGTATCATCCTTTT GGAGTGGGTCTCAGTTCTTT GAATTCCACCATGGGATAACTCTTAATTTTTGAGGGC TCTAGTAGCAACTGCAACC ACAGCGGTGGTAGTGATTAGGTCATGTATCATCCTTT ACTAAGCGGTCCTCAGGGAT GGTGTACATTCTGAGGTGCCTACGCAGACTCCGTGAAG TTCTAGTAGCAACTGCA TTCTAATCGCTTCTCTGGTTCAGCTGGTGGAGTCTGGGGG GGCAGATTCACCATCTCCA ACCGGTTCCTGGGCCCACAAGTCTGGCAACACGGCCT AGGCTTGGTCCAGCCGGGG GAGACAATTCCAAGAACGCGTCTGCCCTGACTCAGCC CCCTGACAATCTCTGGGCTC GGGTCCCTGAGACTCTCCTTTTATATCTTCAAATGAACA TGCCTCCGTGTCTGGGTC CAGGGTGAAGACGAGGCTGGTGCAGCCTCTGGATTCAG GCTTGAGAGTCGAGGACAC TCCTGGACAGTCGATCAATTATTATTGCTGCTCATAT TGTCAGCACCAAGTACATG GGGTGTTTATTACTGTGCCACCATCTCCTGCACTGGAA GCAGGTGCTAGCACTTTCGT ACATGGGTCCGTCAGGCTCGAGACTCGTCGGAAGTCCG CCAGCAATGATGTTGGG GTTCGGCGGAGGGACCAAGCAGGGAAGGGGCTGGAGTG TGACCACCCCGGGCACCCA AGTTATACCCTTGTCTCCCTGACCGTCCTAG (SEQ GGTCTCAGTTCTTTACAGCG GGGCGCTCGGTGGGGGCTTTGGTACCAACAGTACCC ID NO: 3568) GTGGTAGTGATTACTACGC TTGATATCTGGGGCCAAGGAGGCAAAGCCCCCAAAC AGACTCCGTGAAGGGCAGA GACAATGGTCACCGTCTCTTTCTTAATTTTTGAGGGCA TTCACCATCTCCAGAGACA CAG (SEQ ID NO: CTAAGCGGTCCTCAGGG ATTCCAAGAACGCTTTATAT 3566) ATTTCTAATCGCTTCTCTCTTCAAATGAACAGCTTGA GGTTCCAAGTCTGGCAA GAGTCGAGGACACGGGTGTCACGGCCTCCCTGACAA TTATTACTGTGCCAGAGACT TCTCTGGGCTCCAGGGTGCGTCGGAAGTCCGTGACCA AAGACGAGGCTGATTAT CCCCGGGCACCCAGGGCGCTATTGCTGCTCATATGCA TCGGTGGGGGCTTTTGATAT GGTGCTAGCACTTTCGTGCTGGGGCCAAGGGACAATG TTCGGCGGAGGGACCAA GTCACCGTCTCTTCAGCGTCGCTGACCGTCCTAGGTC GACCAAGGGCCCATCGGTC AGCCCAAGGCTGCCCCCTTCCCCCTGGCACCCTCCTC TCGGTCACTCTGTTCCCA CAAGAGCACCTCTGGGGGCCCCTCGAGTGAGGAGCT ACAGCGGCCCTGGGCTGCC TCAAGCCAACAAGGCCATGGTCAAGGACTACTTCCC CACTGGTGTGTCTCATAA CGAACCTGTGACGGTCTCGGTGACTTCTACCCGGGA TGGAACTCAGGCGCCCTGA GCCGTGACAGTGGCCTGCCAGCGGCGTGCACACCTT GAAGGCAGATAGCAGCC CCCGGCTGTCCTACAGTCCTCCGTCAAGGCGGGAGTG CAGGACTCTACTCCCTCAG GAGACCACCACACCCTCCAGCGTGGTGACCGTGCCC CAAACAAAGCAACAACA TCCAGCAGCTTGGGCACCCAGTACGCGGCCAGCAGC AGACCTACATCTGCAACGT TACCTGAGCCTGACGCCTGAATCACAAGCCCAGCAAC GAGCAGTGGAAGTCCCA ACCAANGTGGACAAGAGAGCAGAAGCTACAGCTGCC TTGAGCCCAAATCTTGTGA AGGTCACGCATGAAGGGNNNAANTNANNCNNGNCCA AGCACCGTGGAGAAGAC TGNNCCGNCCGNGCCCAGNAGTGGCCCCTACAGAAT ACTNGNANNNCNNGGGGG GTTCATAGAAGCTTGGCGANCNNTCANNNTTNCNTC CGCCATGGCCCAACTTGT TTCCCCCCAAAACCCANGGTTATTGCAGCTTATAATG ACACCNNCATGATCTCCCG GTTACAAATAAAGCAATGACCCNTGAGTCANNNTGG AGCATCACAAATTTCAC CGATTTTTGGAGTGGTTATTAGCTCATATACAAGCAG CTAGAGACCGTTACTACTTT CACCACTCGAGTCTTCGGGACTACTGGGGCCAGGGAA AACTGGGACCAGGGTCA CCCTGGTCACCGTCTCCTCACCGTCCTAGGTCAGCCC GCGTCGACCAAGGGCCCAT AAGGCCAACCCCACTGTCGGTCTTCCCCCTGGCACCC CACTCTGTTCCCACCCTC TCCTCCAAGAGCACCTCTGGAGTGAGGAGCTTCAAG GGGGCACAGCGGCCCTGGG CCAACAAGGCCACACTGCTGCCTGGTCAAGGACTAC GTGTGTCTCATAAGTGAC TTCCCCGAACCTGTGACGGTTCTACCCGGGAGCCGT TCTCGTGGAACTCANGCGC GACAGTGGCCTGGAAGGCCTGACCAGCGGCGTGCAC CAGATAGCAGCCCCGTC ACCTTCCCGGCTGTCCTACAAAGGCGGGAGTGGAGAC GTCCTCANGACTCTACTCCC CACCACACCCTCCAAACTCAGCAGCGTGGTGACCGT AAAGCAACAACAAGTAC GCCCTCCAGCAGCTTGGGCGCGGCCAGCAGCTACCT ACCCAGACCTACATCTGCA GAGCCTGACGCCTGAGCACGTGAATCACAAGCCCAG AGTGGAAGTCCCACAGA CAACACCNAAGGTGGACAAAGCTACAGCTGCCAGGT GANAGTTGAGCCCAAATCT CACGCATGAAGGGAGCATGTGACAAAACTCACACAT CCGTGGAGAAGACAGTG GCCCACCGTGCCCAGCACCGCCCCTACAGAATGTTC TGACTCCTGGGGGGACCGT ATAGAAGCTTGGCCGCCCAGTCTTCCTCTTCCCCCCA ATGGCCCAACTTGTTTAT AACCCAAGGACACCCTCATTGCAGCTTATAATGGTTA GATCTCCCGGACCCCTGAG CAAATAAAGCAATAGCATCACATGNCGNGGNGGNGG TNNNNAATTTCACAAAT NCGTGNNCCACNAANANCCAAAGCATTTTTTTCACTG TGAGNNAGTTCAACTGGNA CATTCTAGTTGTGGTTTGCGTNNNGGNNNNGNNNNN TCCAAACTCATCNATGN GCANNNNNNNNNANNAAAANNTTATCATGNNCTGG NNNNCNGGNAGGANNANN ATNGGGNATNANTNNNNANNANNANCNCNTNCNNNN NNAGCNNCNTGGNNTGN NGNNCNNNCGNNNNNNNCAANNCNNNTNAANNNGA NNCNNNNCNNNNNNNNNN NTTGGNNNNGTANCTTNNNANNGNNNNNNNNNANA NNNNNNNNGGNANNACC NANNNNANNNNNNNNNNNNTNNNGNGNNGNGNNTC NNNNNNNNNNNNNNNNNN AGTNNNNNNGANNNCCNNCNNNNNCNNNNCNNNNG NGNNNCCNNNNGNNNNN NNGNANNCNTGCANNNNCGNNGGNNGNGGNCGTGA AAATAAAGCATTTTTTTC GCCANNAANANNCTGANNCACTGCATNCCNANTTGT ANNNANTGNNNCNNNGNN GGTTTGTCCAAACTCATCGGGCNNGGNNGGTNCATAA AATGTATCTTATCATGTC NGNNANANAAGCNNNNGGTGGATCGGGAATTAANT NNNGNANCANNACANNNN TNNGCGCANCACCATGNNNNTACCGNNNNNNANCNN NNTGAAATNACCTCTGA CNNNNNNCGTCNNNNNNCNAAGANGAACTNNNNTAN GNNNNNNNNNNNGNNAGG GTACCTTCTGNNNNNAANNNNNNNNNNNNNNNNNA GNANNTCNNNGNNTGNN NNNANNNNCTNCNNNNCCCNNNNCNNNNGGGNGNN ATNNGNANNNNNNTNNNN GNANNTCCCAGNNNCCC NNNNNANNGNCNNNCCNCNNNNGNANANNNATGNN NNNNNNNNNNNNNNN NNATNCATNNNNNNNNC (SEQ ID NO: 3565)ANCANNNNNNGNNNNN NNNCCNNNNNCCNNNGN NANNTGCANNNNANGNN ANNNNNNNTNNNNNNNNNNNNCANANNNCNNNNN CCNNNN (SEQ ID NO: 3567) V-C044 ANNNNNNNNATGNATCNTAGAGGTGCAGCTGGTGGAGT COV047_ NNNNNNNNNNNNNNTGN CAGTCTGTGCTGACTCAGCCCOV047_ CACATACGATTTAGGTGAC CTGGAGGAGGCTTGATCCA P3_D7 NTNNTANNCATACGATTTGCCTCCGTGTCTGGGTCTC P3_D7 ACTATAGAATAACATCCAC GCCTGGGGGGTCCCTGAGATAGGTGACACTATAGAA CTGGACAGTCGATCACCATC TTTGCCTTTCTCTCCACAGGCTCTCCTGTGCAGCCTCTGG TAACATCCACTTTGCCTT TCCTGCACTGGAACCAGCAGTGTCCACTCCCAGGTCCAA GTTCACCGTCAGTAACAAC TCTCTCCACAGGTGTCCATGACGTTGGTGGTTATAACT CTGCACCTCGGTTCTATCGA TACATGAGCTGGGTCCGCCCTCCCAGGTCCAACTGC ATGTCTCCTGGTACCAACAA TTGAATTCCACCATGGGATAGGCTCCAGGGAAGGGGCT ACCTCGGTTCTATCGATT CACCCAGGCAAAGCCCCCAGGTCATGTATCATCCTTTTT GGAGTGGGTCTCAGTTATTT GAATTCCACCATGGGATAACTCATGATTTATGATGTC CTAGTAGCAACTGCAACCG ATAGCGGTGGTAGCACATAGGTCATGTATCATCCTTT AGTAATCGGCCCTCAGGGGT GTGTACATTCTGAGGTGCACTACGCAGACTCCGTGAAG TTCTAGTAGCAACTGCA TTCTAATCGCTTCTCTGGCTGCTGGTGGAGTCTGGAGGA GGCCGATTCACCATCTCCA ACCGGTTCCTGGGCCCACCAAGTCTGGCAACACGGC GGCTTGATCCAGCCTGGGG GAGACAAATCCAAGAACACGTCTGCCCTGACTCAGCC CTCCCTGACCATCTCTGGGC GGTCCCTGAGACTCTCCTGTGCTGTATCTTCAAATGAAC TGCCTCCGTGTCTGGGTC TCCAGGCTGAGGACGAGGCGCAGCCTCTGGGTTCACCG AGGCTGAGAGCCGAGGACA TCCTGGACAGTCGATCATGATTATTACTGCAGCTCAT TCAGTAACAACTACATGAG CGGCCGTGTATTATTGTGCGCCATCTCCTGCACTGGAA ATACAAGCAGCAGCACTCG CTGGGTCCGCCAGGCTCCAAGAGAAGGGGAGGTAGAA CCAGCAGTGACGTTGGT AGTCTTCGGAACTGGGACCAGGGAAGGGGCTGGAGTGGG GGGTATAACGATTTTTGGA GGTTATAACTATGTCTCCAGGTCACCGTCCTAG (SEQ TCTCAGTTATTTATAGCGGT GTGGTTATTCTAGAGACCGTGGTACCAACAACACCC ID NO: 3572) GGTAGCACATACTACGCAG TTACTACTTTGACTACTGGGAGGCAAAGCCCCCAAAC ACTCCGTGAAGGGCCGATT GCCAGGGAACCCTGGTCACTCATGATTTATGATGTCA CACCATCTCCAGAGACAAA CGTCTCCTCAG (SEQ GTAATCGGCCCTCAGGG TCCAAGAACACGCTGTATC ID NO: 3570) GTTTCTAATCGCTTCTCTTTCAAATAAACAGGCTGAG GGCTCCAAGTCTGGCAA AGCCGAGGACACGGCCGTGCACGGCCTCCCTGACCAT TATTATTGTGCGAGAGAAG CTCTGGGCTCCAGGCTGGGGAGGTAGAAGGGTATAA AGGACGAGGCTGATTAT CGATTTTTGGAGTGGTTATTTACTGCAGCTCATATACA CTAGAGACCGTTACTACTTT AGCAGCAGCACTCGAGTGACTACTGGGGCCAGGGAA CTTCGGAACTGGGACCA CCCTGGTCACCGTCTCCTCAAGGTCACCGTCCTAGGT GCGTCGACCAAGGGCCCAT CAGCCCAAGGCCAACCCCGGTCTTCCCCCTGGCACCC CACTGTCACTCTGTTCCC TCCTCCAAGAGCACCTCTGACCCTCGAGTGAGGAGC GGGGCACAGCGGCCCTGGG TTCAAGCCAACAAGGCCCTGCCTGGTCAAGGACTAC ACACTGGTGTGTCTCATA TTCCCCGAACCTGTGACGGAGTGACTTCTACCCGGG TCTCGTGGAACTCAGGCGC AGCCGTGACAGTGGCCTCCTGACCAGCGGCGTGCAC GGAAGGCAGATAGCAGC ACCTTCCCGGCTGTCCTACACCCGTCAAGGCGGGAGT GTCCTCANGACTCTACTCCC GGAGACCACCACACCCTTCANCAGCGTGGGGANNCN CCAAACAAAGCAACAAC GNNCNCCTCCANCANTTTGAAGTACGCGGCCAGCAG GGCNNCCNNAAANCTANNT CTACCTGAGCCTGACGCTNNGCAACGTNAANTCAAN CTGAGCAGTGGAAGTCC ANCCCAGCANCNNCCAAGGCACAGAAGCTACAGCTG NGNNNANAAAANTTGANCC CCAGGTCACGCATGAAGCAAATCTTGNGACAAAACT GGAGCACCGTGGAGAAG CACACATGCCCCANCGTGCACAGTGGCCCCTACAGA CCAGCNCNGACTNCTGGGG ATGTTCATAGAAGCTTGGGACNTCAGTNTCNNTNCC GCCGCCATGGCCCAACT CNNAANCNNNNNNCCTNATTGTTTATTGCAGCTTATA GATCNCCNNCCCNGAGTCA ATGGTTACAAATAAAGCNNTGNNNGTGNNGNNNTGA AATAGCATCACAAATTT NCNNGANACCNGAGNCAGTCACAAATAAAGCATTTTT CACTNNNCNTGNNGNNNNN TTCACTGCATTCTAGTTGNNGNNCANANNCNNANNA TGGTTTGTCCAAACTCAT NCNNNNNNNNNNCANNNNCAATGTATCTTATCATGT NNGTNCNNGNNGTNNNNTC CTGGNTCGGGAATTAATNNNCGTCNNNNNNGNANTG TCNGNGNCANCNCCATG NNNNNNNNNNNNNNNNNNGCCTGAAATAACNNNTG NNNNNNNNNANCNNCNNN AAAGANNNCTTGGTNGNCNNNNAANNNNNNNCNAN ACCTTCTGAGNGNAANN NCNNNNNNNNN (SEQ ANNNTCTGNNGAANNNNID NO: 3569) NNTCAGTTNGGNNNNNN AAGTCCCCNGNNNCCCN NNNGNNNAANNNNGCAAGCATGCATCTCANNNN NAGCANNNNNNNNNNCC NNGNTCCNNNNGNNNNT GCNNNNNNNNNANNNNNNNNNNNCNNNNNNNN NCNNNCCCCNTANN (SEQ ID NO: 3571) V-C045NNNNNNNNNATGNNTCNTA GAGGTGCAGCTGGTGGAGT COV047_ NNNNNNCNNTATGNATNCAGTCTGTGCTGACTCAGCC COV047_ CACATACGATTTAGGTGAC CTGGAGGAGGCTTGATCCAP5_E1 NTACACATACGATTTAG TGCCTCCGTGTCTGGGTCTC P5_E1 ACTATAGAATAACATCCACGCCTGGGGGGTCCCTGAGA GTGACACTATAGAATAA CTGGACAGTCGATCACCATCTTTGCCTTTCTCTCCACAGG CTCTCCTGTGCAGCCTCTGG CATCCACTTTGCCTTTCTTCCTGCACTGGAACCAGCAG TGTCCACTCCCAGGTCCAA GTTCAGCGTCAGTAGCAACCTCCACAGGTGTCCACTC TGACGTTGGTGGTTATAACT CTGCACCTCGGTTCTATCGATACATGAGCTGGGTCCGCC CCAGGTCCAACTGCACC ATGTCTCCTGGTACCAACAATTGAATTCCACCATGGGAT AGGCTCCAGGGAAGGGGCT TCGGTTCTATCGATTGAACACCCAGGCAAAGCCCCCA GGTCATGTATCATCCTTTTT GGAGTGGGTCTCAGTTATTTTTCCACCATGGGATGGTC AACTCATGATTTATGATGTC CTAGTAGCAACTGCAACCGATAGCGGTGGTAGTACATA ATGTATCATCCTTTTTCT AGTAATCGGCCCTCAGGGGTGTGTACATTCTGAGGTGCA CTACGCAGACTCCGTGAAG AGTAGCAACTGCAACCGTTCTAATCGCTTCTCTGGCT GCTGGTGGAGTCTGGAGGA GGCCGATTCACCATCTCCAGTTCCTGGGCCCAGTCTG CCAAGTCTGGCAACACGGC GGCTTGATCCAGCCTGGGGGAGACAATTCCAAGAACAC CCCTGACTCAGCCTGCCT CTCCCTGACCATCTCTGGGCGGTCCCTGAGACTCTCCTGT GCTGTATCTTCAAATGAAC CCGTGTCTGGGTCTCCTGTCCAGGCTGAGGACGAGGC GCAGCCTCTGGGTTCAGCG AGCCTGAGAGCCGAGGACAGACAGTCGATCACCATC TGATTATTACTGCAGCTCAT TCAGTAGCAACTACATGAGCGGCCGTGTATTACTGTGC TCCTGCACTGGAACCAG ATACAAGCAGCACCACTCGCTGGGTCCGCCAGGCTCCA GAGAGAAGGGGAGGTAGA CAGTGACGTTGGTGGTTAGTCTTCGGAACTGGGACCA GGGAAGGGGCTGGAGTGGG AGGGTATTACGATTTTTGGATAACTATGTCTCCTGGT GGGTCACCGTCCTAG (SEQ TCTCAGTTATTTATAGCGGTAGTGGTTATTCTAGAGACC ACCAACAACACCCAGGC ID NO: 3576) GGTAGTACATACTACGCAGGTTACTACTTTGACTACTGG AAAGCCCCCAAACTCAT ACTCCGTGAAGGGCCGATTGGCCAGGGAACCCTGGTCA GATTTATGATGTCAGTAA CACCATCTCCAGAGACAATCCGTCTCCTCAG (SEQ TCGGCCCTCAGGGGTTTC TCCAAGAACACGCTGTATC ID NO: 315)TAATCGCTTCTCTGGCTC TTCAAATGAACAGCCTGAG CAAGTCTGGCAACACGGAGCCGAGGACACGGCCGTG CCTCCCTGACCATCTCTG TATTACTGTGCGAGAGAAGGGCTCCAGGCTGAGGAC GGGAGGTAGAAGGGTATTA GAGGCTGATTATTACTGCNNANNNGNNNN (SEQ ID ATNNNCNNNNNGNNNNN NO: 3573) NNAGNNNNNNNNNANGNNAANNNNAANCNNNN NNNNNNANNN (SEQ ID NO: 3575) V-C046 NNNNNNNNNATGNATCNTAGAGGTGCAGCTGGTGGAGT COV047_ NNNNNNNNATGTATCNT CAGTCTGCCCTGACTCAGCCCOV047_ CACATACGATTTAGGTGAC CTGGGGGAGGCCTGGTCAA P3_F12 ACACATACGATTTAGGTTGCCTCCGTGTCTGGGTCTC P3_F12 ACTATAGAATAACATCCAC GCCTGGGGGGTCCCTGAGAGACACTATAGAATAACA CTGGACAGTCGATCACCATC TTTGCCTTTCTCTCCACAGGCTCTCCTGTGCAGCCTCTGG TCCACTTTGCCTTTCTCT TCCTGCACTGGAACCAGCAGTGTCCACTCCCAGGTCCAA ACTCACCTTCACTGCCTATA CCACAGGTGTCCACTCCCTGACATTGGTGTTTATAACT CTGCACCTCGGTTCTATCGA GAATGAATTGGGTCCGCCAAGGTCCAACTGCACCTC ATATCTCCTGGAGCCAACAA TTGAATTCCACCATGGGATGGCTCCAGGGAAGGGGCTG GGTTCTATCGATTGAATT CACCCAGGCAAAGCCCCCAGGTCATGTATCATCCTTTTT GAGTGGCTCTCATCAATTA CCACCATGGGATGGTCAAAGTCATGATTTATGATGTC CTAGTAGCAACTGCAACCG GTAATACAAATGGCGACATTGTATCATCCTTTTTCTA ACTAATCGGCCCTCAGGGGT GTGTACATTCTGAGGTGCAATACTATGCAGACTCAGTG GTAGCAACTGCAACCGG TTCTAATCGCTTCTCTGGCTGCTGGTGGAGTCTGGGGGA AAGGGCCGATTCACCATCT TTCCTGGGCCCAGTCTGCCCAAGTCTGGCAACACGGC GGCCTGGTCAAGCCTGGGG CCAGAGACAACGCCAAGAACCTGACTCAGCCTGCCTC CTCCCTGACCATCTCTGGGC GGTCCCTGAGACTCTCCTGTTTCTCTGTATCTGCAAATGA CGTGTCTGGGTCTCCTGG TCCAGGCTGAGGACGAGGCGCAGCCTCTGGACTCACCTT ACAGCCTGAGGGCCGACGA ACAGTCGATCACCATCTCTGATTATTATTGCAGCTCAT CACTGCCTATAGAATGAAT CACGGCTGTATATTACTGTGCTGCACTGGAACCAGCA ATAGAGGCAGCAGCACTCC TGGGTCCGCCAGGCTCCAGCGAGAGATGTTGCATCTAA GTGACATTGGTGTTTATA CTATGTCTTCGGAACTGGGAGGAAGGGGCTGGAGTGGCT CTACGCTTACTTTGACCTTT ACTATATCTCCTGGAGCCCCAAGGTCACCNTCCTAG CTCATCAATTAGTAATACA GGGGCCAGGGAACCCTGGTAACAACACCCAGGCAAA (SEQ ID NO: 3580) AATGGCGACATATACTATGCACCGTCTCCTCAG (SEQ GCCCCCAAAGTCATGAT CAGACTCAGTGAAGGGCCG ID NO: 3578)TTATGATGTCACTAATCG ATTCACCATCTCCAGAGAC GCCCTCAGGGGTTTCTAAAACGCCAAGAATTCTCTGT TCGCTTCTCTGGCTCCAA ATCTGCAAATGAACAGCCTGTCTGGCAACACGGCCT GAGGGCCGACGACACGGCT CCCTGACCATCTCTGGGCGTATATTACTGTGCGAGAG TCCAGGCTGAGGACGAG ATGTTGCATCTAACTACGCTGCTGATTATTATTGCAGC TACTTTGACCTTTGGGGCCA TCATATAGAGGCAGCAGGGGAACCCTGGTCACCGTC CACTCCCTATGTCTTCGG TCCTCAGCGTCGACCAAGGAACTGGGACCAAGGTCA GCCCATCGGTCTTCCCCCTG CCGTCCTAGGTCAGCCCGCACCCTCCTCCAAGAGCA AAGGCCAACCCCACTGT CCTCTGGGGGCACAGCGGCCACTCTGTTCCCACCCTC CCTGGGCTGCCTGGTCAAG GAGTGAGGAGCTTCAAGGACTACTTCCCCGAACCTGT CCAACAAGGCCACACTG GACGGTCTCGTGGAACTCAGTGTGTCTCATAAGTGAC GGCGCCCTGACCAGCGGCG TTCTACCCGGGAGCCGTTGCACACCTTCCCGGCTGTC GACAGTGGCCTGGAAGG CTACAGTCCTCAGGANTCTCAGATAGCAGCCCCGTC ACTCCCTCAGCAGCGTGGT AAGGCGGGAGTGGAGACGACCGTGCCCTCCAGCAGC CACCACACCCTCCAAAC TTGGGCACCCAGACCTACAAAAGCAACAACAAGTAC TCTGCAANGTGAANNNCAA GCGGCCAGCAGCTACCTNCCCANNAACACCNNANGN GAGCCTGACGCCTGAGC GNGANANNAGANNNNAGAAGTGGAAGTCCCACAGA NCCNANATTNNTGAGANAA AGCTACAGCTGCCAGGTAACTCACACATGCCCCACC CACGCATGAAGGGAGCA GTGCCCAGCANCTGAACTCCCGTGGAGAAGACAGTG CTGGGGGGACCGTCAGTCT GCCCCTACAGAATGNTCTCCTCNTCCCCCAAACCCA ATAGAAGCTTGGCCGCC NNNCACCTCATGATCTCCNATGGCCCAACTTGTTTAT GACCNNGANNCACNTGCGT TGCANCTTATNATGGTTANNNNNNCGTGAGCCACGAN CGNATANAGCAATAGCA ACCNGANTCAGTCACTNNNTCACNNTCNCACATTTCN CNNGNNGGCGTNNNNNCAT NANANNAANCTTTNTTTANGCNNACAAGCNCGGGA NTNNCTGCATTCTANTTN GNNNAGTNNNANNGNNNGNNGNNNNGNNCNAACNT TNCNNGNNGNCANCNTCNN CNNNNNNNGNNTNCNTANCNTCCTGNNNNGNNNGNN NNNNGGNNNGNNNCNN TNNNTGNNNNNNNTANNNNNANNNANNNNNNCANCA NNNNGNNTCNNNNNANNN CNTGNNNTGAAATNACNNNNNNNNNNNNNNNNNNN NCTGAAGAGANTNNNNN CAANNNNNGNNNNNNNNAGTACTNCTGAGNNNANA NNCNNGNNTANCCNNNN CNTCNGNGANGNNNNNC (SEQ ID NO: 3577)ANTNGGNNNNNNNNCCC CNGNTNCCNNCAGNNNA ANNNNGNANCATGCATN NNATNNNNCNNNNNNGNNNNGANNCCNNNNNNNN NNNNGNNNNNNNTNNNN ANNNNNNNNNNNNNNNN (SEQ ID NO: 3579)V-C047 NNNNNNNNNNNNTATGNN GAGGTGCAGCTGGTGCAGT COV047_ NNNNNNNNTTANGNATCCAGTCTGTGCTGACTCAGGA COV047_ NNNACACATACGATTTAGG CTGGAGCAGAGGTGAAAAAP3_H7 NTACACATACGATTTAG GCCCTCACTGACTGTGTCCC P3_H7 TGACACTATAGAATAACATGCCCGGGGAGTCTCTGAAG GTGACACTATAGAATAA CAGGAGGGACAGTCACTCTCCACTTTGCCTTTCTCTCCA ATCTCCTGTAAGGGTTCTGG CATCCACTTTGCCTTTCTCACCTGTGGCTCCAGCACTG CAGGTGTCCACTCCCAGGT ATACAGATTTACCAACTACCTCCACAGGTGTCCACTC GAGCTGTCACCAGTGGTCAT CCAACTGCACCTCGGTTCTATGGATCGGCTGGGTGCGCC CCAGGTCCAACTGCACC TATCCCTACTGGTTCCAGCATCGATTGAATTCCACCATG AGATGCCCGGGAAAGGCCT TCGGTTCTATCGATTGAAGAAGTCTGGCCAAGCCCCC GGATGGTCATGTATCATCCT GGAGTGGATGGGGATCATCTTCCACCATGGGATGGTC AGGACACTGATTTATGAAAC TTTTCTAGTAGCAACTGCAATATCCTGGTGACTCTGATAC ATGTATCATCCTTTTTCT AAGCATCAAACACTCCTGGCCGGTGTACATTCCGAGGT CAGATACAGCCCGTCCTTC AGTAGCAACTGCAACCGACCCCTGCCCGGTTCTCAGG GCAGCTGGTGCAGTCTGGA CAAGGCCAGGTCACCATCTGTTCCAATTCCCAGGCTG CTCCCTCCTTGGGGGCAAAG GCAGAGGTGAAAAAGCCCGCAGCCGACAAGTCCATCAC TGGTGACCCAGGAGCCC CTGCCCTGACCCTTTCGGGTGGGAGTCTCTGAAGATCTC CACCGCCTACCTGCAGTGG TCACTGACTGTGTCCCCAGCGCAGCCTGAGGATGAGG CTGTAAGGGTTCTGGATAC AGCAGCCTGAAGGCCTCGGGGAGGGACAGTCACTCT CTGATTATTACTGCTTGCTC AGATTTACCAACTACTGGAACACCGCCATGTATTACTGT CACCTGTGGCTCCAGCA TCCTATAGTGGTGCTCGGCCTCGGCTGGGTGCGCCAGAT GCGAGACTCAGTGACCGCT CTGGAGCTGTCACCAGTGGTGTTCGGCGGAGGGACC GCCCGGGAAAGGCCTGGAG GGTACAGTCCGTTCGACCCGGTCATTATCCCTACTGG AAGCTGACCGTCCTAG TGGATGGGGATCATCTATCCTGGGGCCAGGGAACCCTG TTCCAGCAGAAGTCTGG (SEQ ID NO: 3584)CTGGTGACTCTGATACCAG GTCACCGTCTCCTCAG  CCAAGCCCCCAGGACACATACAGCCCGTCCTTCCAA (SEQ ID NO: 3582) TGATTTATGAAACAAGCGGCCAGGTCACCATCTCAG ATCAAACACTCCTGGAC CCGACAAGTCCATCACCACCCCTGCCCGGTTCTCAGG CGCCTACCTGCAGTGGAGC CTCCCTCCTTGGGGGCAAAGCCTGAAGGCCTCGGACA AGCTGCCCTGACCCTTTC CCGCCATGTATTACTGTGCGGGGTGCGCAGCCTGAGG AGACTCAGTGACCGCTGGT ATGAGGCTGATTATTACTACAGTCCGTTCGACCCCTG GCTTGCTCTCCTATAGTG GGGCCAGGGAACCCTGGTCGTGCTCGGCCGGTGTTCG ACCGTCTCCTCAGCGTCGA GCGGAGGGACCAAGCTGCCAAGGGCCCATCGGTCTT ACCGTCCTAGGTCAGCC CCCCCTGGCACCCTCCTCCACAAGGCTGCCCCCTCGG AGAGCACCTCTGGGGGCAC TCACTCTGTTCCCACCCTAGCGGCCCTGGGCTGCCTG CGAGTGAGGAGCTTCAA GTCAAGGACTACTTCCCCGGCCAACAAGGCCACACT AACCTGTGACGGTCTCGTG GGTGTGTCTCATAAGTGGAACTCAGGCGCCCTGACC ACTTCTACCCGGGAGCC AGCGGCGTGCACACCTTCCGTGACAGTGGCCTGGAA CGGCTGTCCTACAGTCCTCA GGCAGATAGCAGCCCCGGGACTCTACTCCCTCAGCA TCAAGGCGGGAGTGGAG GCGTGGTGACCGTGCCCTCACCACCACACCCTCCAA CAGCAGCTTGGGCACCCAG ACAAAGCAACAACAAGTACCTACATCTGCAACGTGA ACGCGGCCAGCAGCTAC ATCACAAGCCCAGCAACACCTGAGCCTGACGCCTGA CAAGGTGGACAAGAGAGTT GCAGTGGAAGTCCCACAGAGCCCAAATCTTGTGACA GAAGCTACAGCTGCCAG AAACTCACACATGCCCACCGTCACGCATGAAGGGAG GTGCCCAGCACCTGAACTC CACCGTGGAGAAGACAGCTGGGGGGACCGTCAGTCT TGGCCCCTACAGAATGTT TCCTCTTNCCCCCNAAACCCCATAGAAGCTTGGCCGC AAGGACACCCTCNTGATCT CATGGCCCAACTTGTTTACCCGGACCCCTGANGTCAC TTGCAGCTTATAATGGTT ATGCGTGGTGGTGGANGTGACAAATAAAGCAATAGC AGCCACGAANANCCTGANG ATCACAAATTTCACAAANCAGGTCAACTGNTNNGTN TAAAGCATTTTTTTCACT GACGGCGNGGANNTGNNNGCATTCTANTTGTGGTTN NTGNCAAGACNAANNNNAC NNCCAAACTCATCAATGANGNNNNNNNNGGANNNN TATNNNATCATGTNTGG NNNANGNNNNGNNNNNNNNNCGGGAATNANNNNNT CNGGGNNNNNNNNNNNCN NNNNNCNNCNNNNNNNNNCCCCNNNNCNNGNNCNGA NNNNNNNNNNNNNNNA ANNNNAGNNNNNNNNGNN NNNNNNNNAANNNANNNGATNNNNNNNTNNNNGN NANNNNNNNNNNNNCN NNNNCNNNNNCCCNTNCNN NNNNGNANGCNNAAANNNCNCNNTCNANAANNNNN NANCATNNTGNNNGNAN NNNNNNNCCNAANNNNGCNNNNNGNNANTNNGGNN NNNCCCNNCNNNAANNNN NNNANNTCCCNGNTCCC NNNGNNNGNNNNNCN ANNNGNANAANTNTNNN (SEQ ID NO: 3581) NCNNNNNTNNNNNNNCA NNNNNNNNGNNNNNCNNNNNNNNNGNNNNNNN NANAGNNATNNNNNNNN NNNNNNNNNNNNNNCN NCNN (SEQ ID NO:3583) V-C048 NNNNNNNNNNNTGNATCNT GAGGTGCAGCTGGTGGAGT COV047_NNNNNCNNATGNATNNT GAAATAGTGATGACGCAGT COV047_ ACACATACGATTTAGGTGACTGGGGGAGGCTTGGTCCA P3_B12 ACACATACGATTTAGGT CTCCAGCCACCCTGTCTGTG P3_B12CACTATAGAATAACATCCA GCCTGGGGGGTCCCAGAGA GACACTATAGAATAACATCTCCAGGGGAAAGAGCCA CTTTGCCTTTCTCTCCACAG CTCTCCTGTGCAGCCTCTGGTCCACTTTGCCTTTCTCT CCCTCTCCTGCAGGGCCAGT GTGTCCACTCCCAGGTCCAATTCACCGTCAGTAGCAAT CCACAGGTGTCCACTCCC CAGAGTGTTAGCAGCCACTTACTGCACCTCGGTTCTATCG TACATGAGCTGGATCCGCC AGGTCCAACTGCACCTCAGCCTGGTACCAGCAGAAA ATTGAATTCCACCATGGGA AGGCTCCAGGGAAGGGGCTGGTTCTATCGATTGAATT CCTGGCCAGGCTCCCAGGCT TGGTCATGTATCATCCTTTTGGAGTGGGTCTCAGTTATTT CCACCATGGGATGGTCA CCTCATCTATGGTGCATCCATCTAGTAGCAACTGCAACC ATAGCGGTGGTAGCGCATA TGTATCATCCTTTTTCTACCAGGGCCACTGGTATCCCA GGTGTACATTCTGAGGTGC CTACGTAGACTCCGTGAAGGTAGCAACTGCAACCGG ACCAGGTTCAGTGGCAGTG AGCTGGTGGAGTCTGGGGGGGCAGATTCACCATCTCCA TGTACATTCAGAAATAG GGTCTGGGACAGAGTTCACTAGGCTTGGTCCAGCCTGGG GAGACAATTCCAAGAACAC TGATGACGCAGTCTCCACTCACCATCAGCAGCCTGCA GGGTCCCAGAGACTCTCCT CCTGTATCTTCAAATGAACGCCACCCTGTCTGTGTCT GTCTGAAGATTTTGCAGTTT GTGCAGCCTCTGGATTCACAGCCTGAGACCCGAGGACA CCAGGGGAAAGAGCCAC ATTACTGCCAGCAGTATAATCGTCAGTAGCAATTACATG CGGCTGTGTATTACTGTGCG CCTCTCCTGCAGGGCCAAACTGGCCTCCGCTCACTTT AGCTGGATCCGCCAGGCTC AGAATCGCAAACTACATGGGTCAGAGTGTTAGCAGC CGGCGGAGGGACCAAGGTG CAGGGAAGGGGCTGGAGTGACGTCTGGGGCAAAGGGAC CACTTAGCCTGGTACCA GAGATCAAAC (SEQ IDGGTCTCAGTTATTTATAGCG CACGGTCACCGTCTCCTCA GCAGAAACCTGGCCAGG NO: 3588)GTGGTAGCGCATACTACGT (SEQ ID NO: 3586) CTCCCAGGCTCCTCATCTAGACTCCGTGAAGGGCAGA ATGGTGCATCCACCAGG TTCACCATCTCCAGAGACAGCCACTGGTATCCCAAC ATTCCAAGAACACCCTGTA CAGGTTCAGTGGCAGTGTCTTCAAATGAACAGCCTG GGTCTGGGACAGAGTTC AGACCCGAGGACACGGCTGACTCTCACCATCAGCAG TGTATTACTGTGCGAGAAT CCTGCAGTCTGAAGATTTCGCAAACTACATGGACGTC TGCAGTTTATTACTGCCA TGGGGCAAAGGGACCACGGGCAGTATAATAACTGGC TCACCGTCTCCTCAGCGTCG CTCCGCTCACTTTCGGCGACCAAGGGCCCATCGGTCT GAGGGACCAAGGTGGAG TCCCCCTGGCACCCTCCTCCATCAAACGTACGGTGGC AAGAGCACCTCTGGGGGCA TGCACCATCTGTCTTCATCAGCGGCCCTGGGCTGCCT CTTCCCGCCATCTGATGA GGTCAAGGACTACTTCCCCGCAGTTGAAATCTGGAA GAACCTGTGACGGTCTCGT CTGCCTCTGTTGTGTGCCGGAACTCAGGCGCCCTGAC TGCTGAATAACTTCTATC CAGCGGCGTGCACACCTTCCCAGAGAGGCCAAAGTA CCGGCTGTCCTACAGTCCTC CAGTGGAAGGTGGATAAAGGACTCTACTCCCTCAGC CGCCCTCCAATCGGGTA AGCGTGGTGACCGTGCCCTACTCCCAGGAGAGTGTC CCAGCAGCTTGGGCACCCA ACAGAGCAGGACAGCAAGACCTACATCTGCAACGTG GGACAGCACCTACAGCC AATCACAAGCCCAGCAACATCAGCAGCACCCTGACG CCAAGGTGGACAAGAGAGT CTGAGCAAAGCAGACTATGAGCCCAAATCTTGTGAC CGAGAAACACAAAGTCT AAAACTNNNNNNNNNCCCCACGCCTGCGAAGTCACC CGNNNCCNNNNCNCNNNNN CATCAGGGCCTGAGCTCCNNCNGGGGGNGANNNNN GCCCGTCACAAAGAGCT NANTNTTCTNNTNCCCCCATCAACAGGGGAGAGTGT AANCCNAGGNNNNCCNNN TAGAAGCTTGGCCGCCANNNNNNTTNNNCNNGNCCC TGGNNCCANNTNNNTNT NNNNNGNNNNNTGNGNGNATNNCAGNNNANAATGN GNNGGGNNNNNGNGNNCN NTNCAAATAAAGCNATAAAAAANNCNCNNGAGNNN NCATCACANATTTCACA NNNTTNNNNNNNGNNNNNAATAAAGCATTTTTTTCA NNANNNNNNGNANGNNNN CTGCNTNCTAGTGTGGNTNTNANNNNNANANNNNCN TGTNNNCANNNCNNNNN GNNNNNANGNNNNNNNAC NNNNNNNNNNNNNNNNAACNNNNCNTNCGNGNNNN NCNNNNNNNNNNNNNN NGNNNCTNNNNNTCNNNNCNNNNNNCGCANCACNNG NNNACTNNNGNANGNANG NNNTNAAANTNNCTNNNNANNNNNNNANNNNNANN NAANNNNNNNNNNNGN NNNNCNNNNNNTNNNNCNT NNCNNNGAGGNNAANNNNANNNNNNNNNNANNNN ANCNNNNNNNNNNNGTC NNNNNCNNNNNNNNNNGNANTNNGNNGNNNNNNNN GNANNNNN (SEQ ID NNCCNNNNGNNNANNNG NO: 3585)NNANCNTNNNTNANNNN CNNNNNNNNNNNNCCNN NNNNANGNANNGNANCN (SEQ ID NO: 3587)V-C049 NNNNNNNNNNNNNNNNNN CAGGTGCAGCTGGTGGAGT COV047_ NNNNNNNNNATGNATCNGACATCCAGATGACCCAGTC COV047_ TCNTACACATACGATTTAG CTGGGGGAGGCGTGGTCCAP5_F8 TACACNTACGATTTAGGT TCCATCCTCCCTGTCTGCAT P5_F8 GTGACACTATAGAATAACAGCCTGGGAGGTCCCTGAGA GACACTATAGAATAACA CTGTAGGAGACAGAGTCACTCCACTTTGCCTTTCTCTCC CTCTCCTGTGCAGCCTCTGG TCCACTTTGCCTTTCTCTCATCACTTGCCGGGCAAGTC ACAGGTGTCCACTCCCAGG ATTCACCTTCAGTACCTATGCCACAGGTGTCCACTCCC AGAGCATTAGCAGTTATTTA TCCAACTGCACCTCGGTTCTGCATGCACTGGGTCCGCCA AGGTCCAACTGCACCTC AATTGGTATCAGCAGAAACATCGATTGAATTCCACCAT GGCTCCAGGCAAGGGGCTG GGTTCTATCGATTGAATTCAGGGAAAGTCCCTAAGCT GGGATGGTCATGTATCATC GAGTGGGTGGCCGTTATATCCACCATGGGATGGTCA CCTGATCTATGCTGCATCCA CTTTTTCTAGTAGCAACTGCCATATGATGGAAGTAATAA TGTATCATCCTTTTTCTA GTTTGCAAAGTGGGGTCCCAAACCGGTGTACATTCTCAG ATACTTTGCAGACTCCGTG GTAGCAACTGCAACCGGTCAAGGTTCAGTGGCAGTGG GTGCAGCTGGTGGAGTCTG AAGGGCCGATTCACCATCTGTACATTCTGACATCCAG ATCTGGGACAGACTTCACTC GGGGAGGCGTGGTCCAGCCCCAGAGACAATTCCAAGAA ATGACCCAGTCTCCATCC TCACCATCAGCAGTCTGCAATGGGAGGTCCCTGAGACTC CACGCTTTATTTGCAAATGA TCCCTGTCTGCATCTGTACCTGAAGATTTTGCAACTTA TCCTGTGCAGCCTCTGGATT ACAGCCTGAGACCTGAGGAGGAGACAGAGTCACCAT CTACTGTCAACAGAGTTACA CACCTTCAGTACCTATGGCCACGGCTGTATATTACTGTG CACTTGCCGGGCAAGTC GAACCCCGCTCACTTTCGGCATGCACTGGGTCCGCCAGG CGAAAGTGGGGATGGAGTA AGAGCATTAGCAGTTATGGAGGGACCAAGGTGGAGA CTCCAGGCAAGGGGCTGGA CAGCAGTGGCTGGTACGGGTTAAATTGGTATCAGCA TCAAAC (SEQ ID NO: GTGGGTGGCCGTTATATCAGAAGAAATTGACTTCTGGG GAAACCAGGGAAAGTCC 3592) TATGATGGAAGTAATAAATGCCAGGGAACCCTGGTCAC CTAAGCTCCTGATCTATG ACTTTGCAGACTCCGTGAACGTCTCCTCAG (SEQ ID CTGCATCCAGTTTGCAAA GGGCCGATTCACCATCTCC NO: 3590)GTGGGGTCCCATCAAGG AGAGACAATTCCAAGAACA TTCAGTGGCAGTGGATCTCGCTTTATCTGCAAATGAA GGGACAGACTTCACTCT CAGCCTGAGACCTGAGGACCACCATCAGCAGTCTGC ACGGCTGTATATTACTGTGC AACCTGAAGATTTTGCAGAAAGTGGGGATGGAGTAC ACTTACTACTGTCAACAG AGCAGTGGCTGGTACGGGGAGTTACAGAACCCCGCT AAGAAATTGACTTCTGGGG CACTTTCGGCGGAGGGACCAGGGAACCCTGGTCACC CCAAGGTGGAGATCAAA GTCTCCTCAGCGTCGACCACGTACGGTGGCTGCACC AGGGCCCATCGGTCTTCCC ATCTGTCTTCATCTTCCCCCTGGCACCCTCCTCCAAG GCCATCTGATGAGCAGT AGCACCTCTGGGGGCACAGTGAAATCTGGAACTGCC CGGCCCTGGGCTGCCTGGT TCTGTTGTGTGCCTGCTGCAAGGACTACTTCCCCGAA AATAACTTCTATCCCAGA CCTGTGACGGTCTCGTGGAGAGGCCAAAGTACAGTG ACTCAGGCGCCCTGACCAG GAAGGTGGATAACGCCCCGGCGTGCACACCTTCCCG TCCAATCGGGTAACTCCC GCTGTCCTACAGTCCTCAGAGGAGAGTGTCACAGAG GACTCTACTCCCTCAGCAG CAGGACAGCAAGGACAGCGTGGTGACCGTGCCCTCC CACCTACAGCCTCAGCA AGCAGCTTGGGCACCCAGAGCACCCTGACGCTGAGC CCTACATCTGCAACGTGAA AAAGCAGACTACGAGAATCACAAGCCCAGCAACACC ACACAAAGTCTACGCCT AAGGTGGACAAGAGAGTTGGCGAAGTCACCCATCAG AGCCCAAATCTTGTGACAA GGCCTGAGCTCGCCCGTAACTCACACATGCCCACCG CACAAAGAGCTTCAACA TGCCCAGCACCTGANNTCCGGGGAGAGTGTTAGAAG TGGGGGGACCGTCAGTCTT CTTGGCCGCCATGGCCCCCTCTTCCCCCCAAAACCN AACTTGTTTATTGCAGCT NNGACACCCTCATGATCNNTATAATGGTTACAAATA CCGGACCCCTGAGGTCACA AAGCAATAGCATCACAATGCGTGGTGGNNGGACGTG ATTTCACAAATAAAGCA AGCCACGAANANCCTGAGGTTTTTTTCACTGCATTCT TCAAGTTCAACTGGNACNT AGTTGTGGNTTGTCCAANNCGGCGNNGGNANGGNN ACTCATCAATGNATCTTA CATANATGNNCNNNNNNNNTCATGTCTGNNTCGGGA NNNCNNNGGGNAGNANCA ATTNATTCNGCGCAGCNGTTACAANCAGCNNCNTAC NNTNNNNGAANNNANNC NNGNTNGTGGTCANCNTCCTGAAANAGNACTNNNNN TCNCGTCNGCNNCANNNAN NNACNNNGAGNGAANNTGNNTTNAANNGNNAGGAN ACNTCTGNNNNGNNNGT NNCNAGNGNANGGGTNNNCANTNGGNNNNGAAGTC CANNAANNCCNTNCCNNNC CCAGNTCCCNNCNGNNNCCCATTNNANAAAANNCNN AANNATGCAANNNNGCA TNNNNNNNNNNNNNGGNNNNNNNNNNNNCANNNNC NAANCNNCNNNNAANNNN NNNNNNNNNANNNNNN NGGNGNNACNNNNNNNNCNNNCNNNNGNNAAANNT CCCNCNNNNNNCCNNGNNN GNANNNNNNNNNNNNN NNNN (SEQ ID NO:NNNNNNNNNNNNNNCNC 3589) CCNANTNGNNNNN (SEQ ID NO: 3591) V-C050NNNNNNNNNNATGNATNNT GAGGTGCAGCTGGTGGAGT COV047_ NNNNNNNNNATGNATCNCAGTCTGTGCTGACTCAGCC COV047_ ACNCATACGATTTAGGTGA CCGGGGGAGGCTTAGTTCAP3_C1 TACACATACGATTTAGGT TGCCTCCGTGTCTGGGTCTC P3_C1 CACTATAGAATAACATCCAGCCTGGGGGGTCCCTGAGA GACACTATAGAATAACA CTGGACAGTCGATCACCATCCTTTGCCTTTCTCTCCACAG CTCTCCTGTGTAGCCTCTGG TCCACTTTGCCTTTCTCTTCCTGCACTGGAACCAGCAG GTGTCCACTCCCAGGTCCA ATTCACCTTCAGTAGCTACTCCACAGGTGTCCACTCCC TGACGTTGGTTATTATAACT ACTGCACCTCGGTTCTATCGGGATGCACTGGGTCCGCCA AGGTCCAACTGCACCTC TTGTCTCCTGGTACCAACAAATTGAATTCCACCATGGGA AGTCCCAGGGAAGGGGCCG GGTTCTATCGATTGAATTCACCCAGGCAAAGCCCCCA TGGTCATGTATCATCCTTTT GTGTGGGTCTCACATATTACCACCATGGGATGGTCA AACTCATGATTTATGAGGTC TCTAGTAGCAACTGCAACCACAGTGAAGGGAGTAGCAC TGTATCATCCTTTTTCTA AGTAATCGGCCCTCTGGGGTGGTGTACATTCTGAGGTGC AAACTACGCGGACTCCGTG GTAGCAACTGCAACCGGTTCTAATCGCTTCTCTGGCT AGCTGGTGGAGTCCGGGGG AGGGGCCGATTCACCATCTTTCCTGGGCCCAGTCTGC CCAAGTCTGGCAACACGGC AGGCTTAGTTCAGCCTGGGCCAGAGACAACGCCAAGGA CCTGACTCAGCCTGCCTC CTCCCTGATCATCTCTGGGCGGGTCCCTGAGACTCTCCT CACGCTATATCTTCAAATG CGTGTCTGGGTCTCCTGGTCCAGGCTGAGGACGAGGC GTGTAGCCTCTGGATTCACC AACAATCTGAGAGCCGAGGACAGTCGATCACCATCTC TGATTATTACTGCAGCTCAT TTCAGTAGCTACTGGATGCACACGGCTGTATATTACTGT CTGCACTGGAACCAGCA ATAGAAGCAGCAGCACTCTACTGGGTCCGCCAAGTCCC GCAAGACCGACGGCTGTAG GTGACGTTGGTTATTATAGGTGTTCGGCGGGGGGACC AGGGAAGGGGCCGGTGTGG CAGCAGCTGGCAATTACTTACTTTGTCTCCTGGTACC AAGCTGACCGTCCTAG GTCTCACATATTAACAGTGCTACTACTACGGTATGGAC AACAACACCCAGGCAAA (SEQ ID NO: 3596)AAGGGAGTAGCACAAACTA GTCTGGGGCCAAGGGACCA GCCCCCAAACTCATGATTCGCGGACTCCGTGAGGGGC CGGTCACCGTCTCTTCA TATGAGGTCAGTAATCGCGATTCACCATCTCCAGAG (SEQ ID NO: 3594) GCCCTCTGGGGTTTCTAAACAACGCCAAGGACACGCT TCGCTTCTCTGGCTCCAA ATATCTTCAAATGAACAATGTCTGGCAACACGGCCT CTGAGAGCCGAGGACACGG CCCTGATCATCTCTGGGCCTGTATATTACTGTGCAAG TCCAGGCTGAGGACGAG ACCGACGGCTGTAGCAGCAGCTGATTATTACTGCAGC GCTGGCAATTACTTCTACTA TCATATAGAAGCAGCAGCTACGGTATGGACGTCTGG CACTCTGGTGTTCGGCGG GGCCAAGGGACCACGGTCAGGGGACCAAGCTGACCG CCGTCTCCTCAGCGTCGACC TCCTAGGTCAGCCCAAGAAGGGCCCATCGGTCTTCC GCTGCCCCCTCGGTCACT CCCTGGCACCCTCCTCCAACTGTTCCCACCCTCGAGT GAGCACCTCTGGGGGCACA GAGGAGCTTCAAGCCAAGCGGCCCTGGGCTGCCTGG CAAGGCCACACTGGTGT TCAAGGACTACTTCCCCGAGTCTCATAAGTGACTTCT ACCTGTGACGGTCTCGTGG ACCCGGGAGCCGTGACAAACTCAGGCGCCCTGACCA GTGGCCTGGAAGGCAGA GCGGCGTGCACACCTTCCCTAGCAGCCCCGTCAAGG GGCTGTCCTACAGTCCTCA CGGGAGTGGAGACCACCGGACTCTACTCCCTCAGCA ACACCCTCCAAACAAAG GCGTGGTGACCGTGCCCTCCAACAACAAGTACGCGG CAGCAGCTTGGGCACCCAG CCAGCAGCTACCTGAGCACCTACATCTGCAACGTGA CTGACGCCTGAGCAGTG ATCACAAGCCCAGCAACACGAAGTCCCACAGAAGCT CNAAGTGGACAAGAGAGTT ACAGCTGCCAGGTCACGGAGCCCAAATCTTGTGACA CATGAAGGGAGCACCGT AAACTCACACATGCCCACCGGAGAAGACAGTGGCCC GTGCCCAGCACCTGAACTC CTACAGAATGTTCATAGNTGGGGGGGACNNTCAGTC AAGCTTGGCCGCCATGG TTCNTCTTCNNCCCNNNAACNCAACNNGTTTNTTNN NNCAANNGANANNNTCNTG NGCTNNTTATGATGGNTATNNNNNCTNNCCNNNGNN ACNAATAAAGCAATAGC GNNNNNTGNNNTGGTGGNGATCACNANTTTCACAAA GGNNGNGANNNNNNAACN TAAAGCATTTTTTTCACTANCCAANNNNNNCNNGNN GCATTCTANTTGTGNNTG NNNANNTNNNNNNNNNGNTCCNAACTCATCATGTAT NNNNNNNNNNNNNNNNNN NTNTCATGNCTGGNTCGNNNCNNNANNNCNNANAN GNANTAANNNNGCAGCN NAANNNNNGGNANNAANACATGNCTGNNNNNNNCN NNNCNANNNNNNGTNCNN NANNANANNNNNNGTACNNNNNNNNNNNNCTNNCCN TCNNNNNGANNNNNCNN NNCNNNNNNNNNNANNGNNGANGANGNNGNNNNTN NNANGGNNANGNNNNNNN GGNGNNNNANNNNNCN ANNNNNNNNANANNNNNNNNCNNCNNNNGNNNNNN NANCATGNANNNTTNANCN NNNCNNNCNTNCNNNNN NNNNNNNNCNNNNNNNNNNNNNNNNNNNNNNN (SEQ ID NO: 3593) NNNNCNNNGNCCNNNNN GNNNNNTGNNNNNNNN(SEQ ID NO: 3595) V-C051 NNNNNNCNNATGNATCNTA GAGGTGCAGCTGGTGGAGT COV047_NNNNNNNNNNNATGNAT AATTTTATGCTGACTCAGCC COV047_ CACATACGATTTAGGTGACCTGGGGGAGGCCTGGTCAA P5_B12 CNTACNCATACGATTTA CCACTCTGTGTCGGAGTCTC P5_B12ACTATAGAATAACATCCAC GCCTGGGGGGTCCCTGAGA GGTGACACTATAGAATACGGGGAAGACGGTAACCAT TTTGCCTTTCTCTCCACAGG CTCTCCTGTGCAGCCTCTGGACATCCACTTTGCCTTTC CTCCTGCACCGGCAGCAGTG TGTCCACTCCCAGGTCCAAATTCACCTTCAGTAGCTATA TCTCCACAGGTGTCCACT GCAGCATTGCCAGCAACTATCTGCACCTCGGTTCTATCGA ACATGAACTGGGTCCGCCA CCCAGGTCCAACTGCACGTGCAGTGGTACCAGCAGC TTGAATTCCACCATGGGAT GGCTCCAGGGAAGGGGCTGCTCGGTTCTATCGATTGA GCCCGGGCAGTGCCCCCACC GGTCATGTATCATCCTTTTTGAGTGGGTCTCATGCATTA ATTCCACCATGGGATGG ACTGTGATCTATGAGGATAACTAGTAGCAACTGCAACCG GTAGTAGTAGTAGTTACAT TCATGTATCATCCTTTTTCCAAAGACCCTCTGGGGTCC GTGTACATTCTGAGGTGCA ATACTACGCAGACTCAGTGCTAGTAGCAACTGCAAC CTGATCGGTTCTCTGGCTCC GCTGGTGGAGTCTGGGGGAAAGGGCCGATTCACCATCT CGGTTCTTGGGCCAATTT ATCGACAGCTCCTCCAACTCGGCCTGGTCAAGCCTGGGG CCAGAGACAACGCCAAGAA TATGCTGACTCAGCCCCATGCCTCCCTCACCATCTCTG GGTCCCTGAGACTCTCCTGT CTCACTGTATCTGCAAATGCTCTGTGTCGGAGTCTCC GACTGAAGACTGAGGACGA GCAGCCTCTGGATTCACCTTAACAGCCTGAGAGCCGAGG GGGGAAGACGGTAACCA GGCTGACTACTACTGTCAGTCAGTAGCTATAACATGAAC ACACGGCTGTGTATTACTGT TCTCCTGCACCGGCAGCCTTATGATAGCAGCAATTAT TGGGTCCGCCAGGCTCCAG GCGAGAGAGAGGGGGTATGAGTGGCAGCATTGCCAG TGGGTGTTCGGCGGAGGGA GGAAGGGGCTGGAGTGGGTACGGTGGTAAAACCCCCCC CAACTATGTGCAGTGGT CCAAGCTGACCGTCCTAGCTCATGCATTAGTAGTAGT ATTTCTTGGGGGCCAGGGA ACCAGCAGCGCCCGGGC(SEQ ID NO: 3600) AGTAGTTACATATACTACG ACCCTGGTCACCGTCTCCTCAGTGCCCCCACCACTGT CAGACTCAGTGAAGGGCCG AG (SEQ ID NO: 3598)GATCTATGAGGATAACC ATTCACCATCTCCAGAGAC AAAGACCCTCTGGGGTCAACGCCAAGAACTCACTGT CCTGATCGGTTCTCTGGC ATCTGCAAATGAACAGCCTTCCATCGACAGCTCCTCC GAGAGCCGAGGACACGGCT AACTCTGCCTCCCTCACCGTGTATTACTGTGCGAGAG ATCTCTGGACTGAAGAC AGAGGGGGTATGACGGTGGTGAGGACGAGGCTGACT TAAAACCCCCCCATTTCTTG ACTACTGTCAGTCTTATGGGGGCCAGGGAACCCTGGT ATAGCAGCAATTATTGG CACCGTCTCCTCAGCGTCGGTGTTCGGCGGAGGGAC ACCAAGGGCCCATCGGTCT CAAGCTGACCGTCCTAGTCCCCCTGGCACCCTCCTCC GTCAGCCCAAGGCTGCC AAGAGCACCTCTGGGGGCACCCTCGGTCACTCTGTTC CAGCGGCCCTGGGCTGCCT CCGCCCTCGAGTGAGGAGGTCAAGGACTACTTCCCC GCTTCAAGCCAACAAGG GAACCTGTGACGGTCTCGTCCACACTGGTGTGTCTCA GGAACTCAGGCGCCCTGAC TAAGTGACTTCTACCCGGCAGCGGCGTGCACACCTTC GAGCCGTGACAGTGGCC CCGGCTGTCCTACAGTCCTCTGGAAGGCAGATAGCAG AGGACTCTACTCCCTCAGC CCCCGTCAAGGCGGGAGAGCGTGGTGACCGTGCCCT TGGAGACCACCACACCC CCAGCAGCTTGGGCACCCATCCAAACAAAGCAACAA GACCTACATCTGCAACGTG CAAGTACGCGGCCAGCAAATCACAAGCCCAGCAACA GCTACCTGAGCCTGACG CCNANNTGGACAAGAGAGTCCTGAGCAGTGGAAGTC TGAGCCCCAATCTTGTGAC CCACAGAAGCTACAGCTAAAACTCACACATGCCCAC GCCAGGTCACGCATGAA CGTGCCCANCACCTGNANTGGGAGCACCGTGGAGAA CNNNNGGGGGAGGGNNNG GACAGTGGCCCCTACAGTCTTNTTNTTNNTCNNCCCN AATGTTCATAGAAGCTT NCCNAAANNNNAGGANNNGGCCGCCATGGCCCNAC NCNTNNTNNTTNNCCCGGA TNGTTGNTTATNGCANCTCCNNTGANGNTNNCNNGGN TATGNTGGTTANNAATA GTGGGGGGNGGNNNNTGNAAGCAATATCATCACAN NNNACNAANNCCCNGNAG NTTTCACAAATAAAGCAGTCAAGTTCAACTGGNACG ttttntttcnntgcnntc TGGNCGGNNTNNNNTGCNNTANNNNNGGNTTGTCNN NNNNCAANAANNAAGCCG ACTCNTCAATGTATCTNNCNGGANGNNNNNTANANA TCATGNCNGGNTCGNGA GCACNNACCGNNGNGNNNATTAANTCNNCNCNNCN NNCNNCNTCNCCGTCNGNN CNTGNNNNNNNNNNAANNNNNNTNNNNANNGNANN NNNNNGNANNNNNNAN NNNANNNNNNNNNNNNAN GTAGNNNNNNNNNNCNNANCNTNCNNNNCCNNNGNN NNNNGNNGNNNACNAN NACNNNCAANNNCANNNNNNNCNGANNNNGGTNNG NNNCNNNNANNNNNNNTA TNAGNTAGGGGNGNNGNNNNNCNNNNCCCNCNCNNN NNNNNNCNNNCNNNNNN (SEQ ID NO: 3597)NNAGNNNNANNNATGNN NNNNTNCANNNNNNNNC NNNNNNNNNNNNNANN CCNANNNNNNNNNNGNNNNNGNANNNNNNNANTN NNNNNNNANNNNTNNNN CNNNNNNNNNNNN  (SEQ ID NO: 3599)V-C052 NNNNNNNNNTGNATCNTAC CAGGTTCAGCTGGTGCAGT COV047_ NNNNNNNNNATGNATNNGACATCCAGATGACCCAGTC COV047_ ACATACGATTTAGGTGACA CTGGAGCTGAGGTGAAGAAP3_A10 TACACATACGATTTAGGT TCCATCCTCCCTGTCTGCAT P3_A10CTATAGAATAACATCCACT GCCTGGGGCCTCAGTGAAG GACACTATAGAATAACACTGTAGGAGACAGAGTCAC TTGCCTTTCTCTCCACAGGT GTCTCCTGCAAGGCTTCTGGTCCACTTTGCCTTTCTCT CATCACTTGCCGGGCGAGTC GTCCACTCCCAGGTCCAACTTACACCTTTACCAGCTACG CCACAGGTGTCCACTCCC AGGGCATAAGCAATTACTTATGCACCTCGGTTCTATCGAT GTATCAGCTGGGTGCGACA AGGTCCAACTGCACCTCGCCTGGTATCAGCAGAGAC TGAATTCCACCATGGGATG GGCCCCTGGACAAGGGCTTGGTTCTATCGATTGAATT CAGGGAAAGTTCCTAAGCTC GTCATGTATCATCCTTTTTCGAGTGGATGGGATGGATCA CCACCATGGGATGGTCA CTGATCTTTGCTGCATCCACTAGTAGCAACTGCAACCGG GCGCTTACAATGGTAACAC TGTATCATCCTTTTTCTATTTGCAATCAGGGGTCCCAT TGTACATTCCCAGGTTCAGC AAACTATGCACAGAAGCTCGTAGCAACTGCAACCGG CTCGGTTCAGTGGCAGTGGA TGTGCAGTCTGGAGCTGAGCAGGGCAGAGTCACCATGA TGTACATTCTGACATCCA TCTGGGACAGATTTCACTCTGTGAAGAAGCCTGGGGCCT CCACAGACACATCCACGAG GATGACCCAGTCTCCATCCACCATCAGCAGCCTGCAGC CAGTGAAGGTCTCCTGCAA CACAGCCTACATGGAGCTGCTCCCTGTCTGCATCTGT CTGAAGATGTTGCAACTTAT GGCTTCTGGTTACACCTTTAAGGAGCCTGAGATCTGACG AGGAGACAGAGTCACCA TACTGTCAAAAGTATAACAGCCAGCTACGGTATCAGCTG ACACGGCCGTGTTTTACTGT TCACTTGCCGGGCGAGTTGCCCCTCGGACGTTCGGCC GGTGCGACAGGCCCCTGGA GCGAGAGATCGGGGGGGGCCAGGGCATAAGCAATTA AAGGGACCAAGGTGGAAAT CAAGGGCTTGAGTGGATGGACGATTTTTGGAGTGGTTAT CTTAGCCTGGTATCAGCA CAAAC (SEQ ID NO:GATGGATCAGCGCTTACAA GGGTTCTACTACTACTACG GAGACCAGGGAAAGTTC 3604)TGGTAACACAAACTATGCA GTATGGACGTCTGGGGCCA CTAAGCTCCTGATCTTTGCAGAAGCTCCAGGGCAGAG AGGGACCACGGTCACCGTC CTGCATCCACTTTGCAATTCACCATGACCACAGACAC TCCTCA (SEQ ID NO: CAGGGGTCCCATCTCGGATCCACGAGCACAGCCTAC 3602) TTCAGTGGCAGTGGATCT ATGGAGCTGAGGAGCCTGAGGGACAGATTTCACTCTC GATCTGACGACACGGCCGT ACCATCAGCAGCCTGCAGTTTTACTGTGCGAGAGAT GCCTGAAGATGTTGCAA CGGGGGGGGCACGATTTTTCTTATTACTGTCAAAAGT GGAGTGGTTATGGGTTCTA ATAACAGTGCCCCTCGGCTACTACTACGGTATGGAC ACGTTCGGCCAAGGGAC GTCTGGGGCCAAGGGACCACAAGGTGGAAATCAAAC CGGTCACCGTCTCCTCAGC GTACGGTGGCTGCACCAGTCGACCAAGGGCCCATCG TCTGTCTTCATCTTCCCG GTCTTCCCCCTGGCACCCTCCCATCTGATGAGCAGTT CTCCAAGAGCACCTCTGGG GAAATCTGGAACTGCCTGGCACAGCGGCCCTGGGCT CTGTTGTGTGCCTGCTGA GCCTGGTCAAGGACTACTTATAACTTCTATCCCAGAG CCCCGAACCTGTGACGGTC AGGCCAAAGTACAGTGGTCGTGGAACTCANGCGCCC AAGGTGGATAACGCCCT TGACCAGCGGCGTGCACACCCAATCGGGTAACTCCC CTTCCCGGCTGTCCTACAGT AGGAGAGTGTCACAGAGCCTCANGACTCTACTCCCTC CAGGACAGCAAGGACAG AGCAGCGTGGTGACCGTGCCACCTACAGCCTCAGCA CCTNCCNNNNNNTTGGGNC GCACCCTGACGCTGAGCNCNNACANNTATNTGTGNN AAAGCAGACTACGAGAA ANGNGAANTCACAANCCCCACACAAAGTCTACGCCT ANCAACACNNNGNNNNAA GCGAAGTCACCCATCAGGANAGTTGAGCCCAAATCT GGCCTGAGCTCGCCCGT TGTGANAAACTCACACATGCACAAAGAGCTTCAACA CCCACCGTGCCCAGCACCT GGGGGAGAGTGTTAGAAGACTCNGGGGGGACGTCAG GCTTGGCCGCCATGGCC TCTTCNNTCCCCCNNNCCNCAACTTGTTTATTGCAGC NNNNCCCTCATGATCTCCG TTATAATGGNTACAAATACCCTGAGTCANNTGCGTG AAAGCAATAGCATCACA NGNGNCGTGANCNCNANANAATTTCACAAATAAAGC CNTGANGNCAGTCANTGNA ATTTTTTTCACTGCATTCCNTGNNGGNNNNNNGNNC TAGTTGTGGTTTGTCCAA NTANNCANANNANCNNNGACTCATCAATGTATNTNT GAGNNNANTNNANNNNNN CATGTCTGGATCGGNANGNNNCNNNNNGNNANCNN TNANTNGNGCAGNNCNT CNNNCNNNCNNNNNNNNNNNNTGAAANACNCTGAA NTGNNNNANNNNNNNNNN NAGNNNTNNNNNNGTACNNNNNNNNNNNNNNNNAN TNCTGAGNGNAGANNNN NNNNNNNNNNNNNNNNNCCNNNGANNNNNGTCANN NTNNAANCNNNGGGNNNC NNNNGGNGNANNNNCCN NCNNNNA (SEQ ID NNGCNNNCNNCNGNNNA NO: 3601) NNNNNNNAGCATGCNTN CNNNNNNNNNNNNNNNNGNAGNNNACNNNCNNN NNNNGNNNNNNNNNNN GCNANNNNNNCNNNNNN TN (SEQ ID NO: 3603) V-C053 NNNNNNNNTTATGTATCNT GAGGTGCAGCTGGTGGAGT COV047_NNNNNNCNNATGNATNN CAGTCTGCCCTGACTCAGCC COV047_ ACACATACGATTTAGGTGACTGGAGGAGGCTTGATCCA P5_E10 TACACATACGATTTAGGT TGCCTCCGTGTCTGGGTCTCP5_E10 CACTATAGAATAACATCCA GCCTGGGGGGTCCCTGAGA GACACTATAGAATAACACTGGACAGTCGATCACCATC CTTTGCCTTTCTCTCCACAG CTCTCCTGTGCAGCCTCTGGTCCACTTTGCCTTTCTCT TCCTGCACTGGAACCAGCAG GTGTCCACTCCCAGGTCCAGTTCACCGTCAGTAGCAAC CCACAGGTGTCCACTCCC TGATGTTGGGAGTTATAACCACTGCACCTCGGTTCTATCG TACATGAGCTGGGTCCGCC AGGTCCAACTGCACCTCTTGTCTCCTGGTACCAACAG ATTGAATTCCACCATGGGA AGGCTCCAGGGAAGGGGCTGGTTCTATCGATTGAATT CACCCAGGCAAAGCCCCCA TGGTCATGTATCATCCTTTTGGAGTGGGTCTCAGTTATTT CCACCATGGGATGGTCA AACTCATGATTTATGAGGGCTCTAGTAGCAACTGCAACC ATAGCGGTTATAGCACATA TGTATCATCCTTTTTCTAAGTAAGCGGCCCTCAGGGG GGTGTACATTCTGAGGTGC CTACGTAGACTCCGTGAAGGTAGCAACTGCAACCGG TTTCTAATCGCTTCTCTGGCT AGCTGGTGGAGTCTGGAGGGGCCGATTCACCATCTCCA TTCCTGGGCCCAGTCTGC CCAAGTCTGGCAACACGGCAGGCTTGATCCAGCCTGGG GAGACAATTCCAAGAACAC CCTGACTCAGCCTGCCTCCTCCCTGACAATCTCTGGGC GGGTCCCTGAGACTCTCCT GCTGTATCTTCAAATGAACCGTGTCTGGGTCTCCTGG TCCAGGCTGAGGACGAGGC GTGCAGCCTCTGGGTTCACAGCCTGAGAGCCGAGGACA ACAGTCGATCACCATCTC TGATTATTACTGCTGCTCATCGTCAGTAGCAACTACATG CGGCCGTGTATTACTGTGC CTGCACTGGAACCAGCAATGCAGGTAGTAGCACTTGG AGCTGGGTCCGCCAGGCTC GAGAGTGGGGGGAGCACATGTGATGTTGGGAGTTAT GTGTTCGGCGGAGGGACCA CAGGGAAGGGGCTGGAGTGAGTGGCTACGACGGATCCT AACCTTGTCTCCTGGTAC AGCTGACCGTCCTAG (SEQGGCCTCAGTTATTTATAGCG TTGACTACTGGGGCCAGGG CAACAGCACCCAGGCAA ID NO: 3608)GTTATAGCACATACTACGT AACCCTGGTCACCGTCTCCT AGCCCCCAAACTCATGAAGACTCCGTGAAGGGCCGA CAG (SEQ ID NO: TTTATGAGGGCAGTAAGTTCACCATCTCCAGAGACA 3606) CGGCCCTCAGGGGTTTCT ATTCCAAGAACACGCTGTAAATCGCTTCTCTGGCTCC TCTTCAAATGAACAGCCTG AAGTCTGGCAACACGGCAGAGCCGAGGACACGGCCG CTCCCTGACAATCTCTGG TGTATTACTGTGCGAGAGTGCTCCAGGCTGAGGACG GGGGGGAGCACATAGTGGC AGGCTGATTATTACTGCTTACGACGGATCCTTTGACT GCTCATATGCAGGTAGT ACTGGGGCCAGGGAACCCTAGCACTTGGGTGTTCGG GGTCACCGTCTCCTCAGCGT CGGAGGGACCAAGCTGACGACCAAGGGCCCATCGGT CCGTCCTAGGTCAGCCC CTTCCCCCTGGCACCCTCCTAAGGCTGCCCCCTCGGT CCAAGAGCACCTCTGGGGG CACTCTGTTCCCACCCTCCACAGCGGCCCTGGGCTGC GAGTGAGGAGCTTCAAG CTGGTCAAGGACTACTTCCCCAACAAGGCCACACTG CCGAACCTGTGACGGTCTC GTGTGTCTCATAAGTGACGTGGAACTCAGGCGCCCTG TTCTACCCGGGAGCCGT ACCAGCGGCGTGCACACCTGACAGTGGCCTGGAAGG TCCCGGCTGTCCTACAGTCC CAGATAGCAGCCCCGTCTCAGGACTCTACTCCCTCAG AAGGCGGGAGTGGAGAC CAGCGTGGTGACCGTGCCCCACCACACCCTCCAAAC TCCAGCAGCTTGGGCACCC AAAGCAACAACAAGTACAGACCTACATCTGCAACGT GCGGCCAGCAGCTACCT GAATCACAAGCCCAGCAACGAGCCTGACGCCTGAGC ACCAAGGTGGACAAGAGAG AGTGGAAGTCCCACAGATTGAGCCCAAATCTTGTGA AGCTACAGCTGCCAGGT CAAAACTCACACATGCCCACACGCATGAAGGGAGCA CCGTGCCCAGCACCTGAAC CCGTGGAGAAGACAGTGTCCTGGGGGGACCGTCAGT GCCCCTACAGAATGTTC CTTCCTCTTCCCCCCAAAACATAGAAGCTTGGCCGNC CCAANGACACCCTCATGAT NNNGNCCNANNTTNGTTCTCCCGGACCCCTGANNCA ANNTNNNNNNTTANNNN CATGCGTGGTGGNGGACGTGNTTACANATAANGCNA GAGCCACGAAGACCTGANN TANTCATCACANATTTTCCAAGTTCANTGGTACNTGG ACANAATAANAGNNNTT NNNGCNTGNNNGCATGATGTTNTTNNCTGNNNTTCTA NCNNNANNANNCNNNNNA GTNGTGNGTTNTGNNNAGANNNGTNNNNNANNANN NNTCNNCNTCAGTGTAT TANCNGGNNNNNNNCNGTGCATNANNGTNTNNNNNA NNNGNNCNNNNNTNCNCNN TCGANNANTTANNTNNNNNCTNNNNNNNANNNGGG CGCANCNNNNNGNCNGN NNNNANNGGNANNNNNNNAANNNNCNNNTNNNNNN NNNNNNANNGGNNTNNNN NNNNNNNNAGNNCTNCTNNANNNNNNNNNNCNNNN GAGNNNNNNNCNTCNGN NNNNANNNNNNNNNNNNNGNNNGNNNNCAGTNGNN NNNNNNNNAAANCNNNNN CNNNNNNNCCNNNNCCN GGNNNNNCCCN (SEQNCAGCNNANNNGCANNC ID NO: 3605) ATNNNTNNANNANNNNN NNNNNNNNAGTCCNGNCNNNGNNNNNNANNNNN NNNNNNNNNN (SEQ ID NO: 3607) V-C054 NNNNNNNNNNNNNNNNNNCAGGTGCAGCTGGTGGAGT COV047_ NNNNNNNNNNTGNATCN GACATCCAGATGACCCAGTCCOV047_ NNNTACACNTACGATTTAG CTGGGGGAGGCGTGGTCCA P5_H7 TACACATACGATTTAGGTTCCATCCTCCCTGTCTGCAT P5_H7 GTGACACTATAGAATAACA GCCTGGGAGGTCCCTGAGAGACACTATAGAATAACA CTGTAGGAGACAGAGTCAC TCCACTTTGCCTTTCTCTCCCTCTCCTGTGCAGCCTCTGG TCCACTTTGCCTTTCTCT CATCACTTGCCAGGCGAGTCACAGGTGTCCACTCCCAGG ATTCACCTTCAGTCGCTATG CCACAGGTGTCCACTCCCAGGGCATTAGCAACTATTTA TCCAACTGCACCTCGGTTCT GCATGCACTGGGTCCGCCAAGGTCCAACTGCACCTC AATTGGTATCAGCAGAAAC ATCGATTGAATTCCACCATGGCTCCAGGCAAGGGGCTG GGTTCTATCGATTGAATT CAGGGAAAGCCCCTAAGCTGGGATGGTCATGTATCATC GAGTGGGTGGCAGTTATGT CCACCATGGGATGGTCACCTGATCTACGATGCATCCA CTTTTTCTAGTAGCAACTGC CATATGATGGAAGTAGTAATGTATCATCCTTTTTCTA ATTTGGAAACAGGGGTCCC AACCGGTGTACATTCTCAGATACTATGCAGACTCCGTG GTAGCAACTGCAACCGG ATCAAGGTTCAGTGGAAGTGTGCAGCTGGTGGAGTCTG AAGGGCCGATTCACCATCT TGTACATTCTGACATCCAGGATCTGGGACAGATTTTAC GGGGAGGCGTGGTCCAGCC CCAGAGACAATTCCAAGAAGATGACCCAGTCTCCATC TTTCACCATCAGCAGCCTGC TGGGAGGTCCCTGAGACTCCACGCTGTGTCTGCAAATG CTCCCTGTCTGCATCTGT AGCCTGAAGATATTGCAACTCCTGTGCAGCCTCTGGATT AACAGCCTGAGAGCTGAGG AGGAGACAGAGTCACCAATATTACTGTCAACAGTATG CACCTTCAGTCGCTATGGC ACACGGCTGTGTATTACTGTTCACTTGCCAGGCGAGT ATAATCTCCCGATCACCTTC ATGCACTGGGTCCGCCAGGGCGAAACAGGCGGGCCCAT CAGGGCATTAGCAACTA GGCCAAGGGACACGACTGGCTCCAGGCAAGGGGCTGGA ATTGTAGTGGTGGTAGCTG TTTAAATTGGTATCAGCAAGATTAAAC (SEQ ID NO: GTGGGTGGCAGTTATGTCA CTACTCCGCGCCCTTTGACTGAAAccAGGGAAAGccc 3612) TATGATGGAAGTAGTAAAT ACTGGGGCCAGGGAACCCTCTAAGCTCCTGATCTACG ACTATGCAGACTCCGTGAA GGTCACCGTCTCCTCAGATGCATCCAATTTGGAA GGGCCGATTCACCATCTCC (SEQ ID NO: 3610)ACAGGGGTCCCATCAAG AGAGACAATTCCAAGAACA GTTCAGTGGAAGTGGATCGCTGTGTCTGCAAATGAA CTGGGACAGATTTTACTT CAGCCTGAGAGCTGAGGACTCACCATCAGCAGCCTG ACGGCTGTGTATTACTGTGC CAGCCTGAAGATATTGCGAAACAGGCGGGCCCATAT AACATATTACTGTCAAC TGTAGTGGTGGTAGCTGCTAGTATGATAATCTCCCG ACTCCGCGCCCTTTGACTAC ATCACCTTCGGCCAAGGTGGGGCCAGGGAACCCTGG GACACGACTGGAGATTA TCACCGTCTCCTCAGCGTCGAACGTACGGTGGCTGCA ACCAAGGGCCCATCGGTCT CCATCTGTCTTCATCTTCTCCCCCTGGCACCCTCCTCC CCGCCATCTGATGAGCA AAGAGCACCTCTGGGGGCAGTTGAAATCTGGAACTG CAGCGGCCCTGGGCTGCCT CCTCTGTTGTGTGCCTGCGGTCAAGGACTACTTCCCC TGAATAACTTCTATCCCA GAACCTGTGACGGTCTCGTGAGAGGCCAAAGTACAG GGAACTCAGGCGCCCTGAC TGGAAGGTGGATAACGCCAGCGGCGTGCACACCTTC CCTCCAATCGGGTAACTC CCGGCTGTCCTACAGTCCTCCCAGGAGAGTGTCACAG AGGACTCTACTCCCTCAGC AGCAGGACAGCAAGGACAGCGTGGTGACCGTGCCCT AGCACCTACAGCCTCAG CCAGCAGCTTGGGCACCCACAGCACCCTGACGCTGA GACCTACATCTGCAACGTG GCAAAGCAGACTACGAGAATCACAAGCCCAGCAACA AAACACAAAGTCTACGC CCAAGGTGGACAAGAGAGTCTGCGAAGTCACCCATC TGAGCCCAAATCTTGTGAC AGGGCCTGAGCTCGCCCAAAACTCACACATGCCCAC GTCACAAAGAGCTTCAA CGTGCCCAGCACCTGAACTCAGGGGAGAGTGTTAGA CCTGGGGGGACCGTCAGTC AGCTTGGCCGCCATGGCTTCCTCTTCCCCCCAAAACC CCAACTTGTTTATTGCAG CAANGACACCCTCNTGATCCTTATAATGGTTACAAAT TCCCGGACCCCTGAGGTCN AAAGCAATAGCATCACANATGCGTGGTGGTGGNNGT AATTTCACAAATAAAGC GAGCCACGAAGACCCNGANATTTTTTTCACTGCATTC NCNAGTTCAACTGGNACGN TNNNNTGTGGGNTTNTGGGACGGNGNNNNGGNGCA NNNNANNNNNNNNNNN NNANGCCAAGACAAAGCCGGTNTCATANCNNNTCGG CGGGAGGANCNNT ANNAN GGNNNGGGNNATTAATTN_(A)GC_(A)CNN_(A)CCGNNNNGNC CGNNGCAGCNNNTGNNN AGCGNNCCNTNNNCGNCNGGAAANANNNTGAAAGAG NNCCNNNNACTNNNNAANG NNNNNNNNNACTNNGAGGCNNNNTACANNNCNNGNN NGAANAACNNCNGNNNN NTCCANNNANNNNNNNNNGNNNNGTCAGTNGNNGN NCNTNNNNAANCNNNNNN NGAAAGTCNNNGNTCCNNCAANNNNNNNNNNNNCC NNNGNNNANNNATGNNA CCCNNNNNNN (SEQ ID NO:ANNNTNNNNNNNNTNNN 3609) CNGCANCNGNNNNNNNA NNNNNNNNNNNNNGGNNNNNNANNNNNNNNNN NNNNNNNNNNCCNNNNN NNNNN (SEQ ID  NO: 3611) V-CO55NNNNNNNNNNNNTGNNNN GAGGTGCAGCTGGTGGAGT COV047_ NNNNNNNNNATGTATCNGAAATAGTGATGACGCAGT COV047_ NTACANNTACGATTTAGGT CTGGAGGAGGCTTGATCCAP5_C3 TACACATACGATTTAGGT CTCCAGCCACCCTGTCTGTG P5_C3 GACACTATAGAATAACATCGCCTGGGGGGTCCCTGAGA GACACTATAGAATAACA TCTCCAGGGGAAAGAGCCACACTTTGCCTTTCTCTCCAC CTCTCCTGTGCAGCCTCTGG TCCACTTTGCCTTTCTCTCCCTCTCCTGCAGGGCCAGT NNGNGTCCACTCCCAGGTC GTTCATCGTCAGTAGCAACCCACAGGTGTCCACTCCC CAGAGTGTTAGCAGCAACTT CAACTGCACCTCGGTTCTATTACATGAGCTGGGTCCGCC AGGTCCAACTGCACCTC AGCCTGGTACCAGCAGAAACGATTGAATTCCACCATGG AGGCTCCAGGGAAGGGCCT GGTTCTATCGATTGAATTCCTGGCCAGGCTCCCAGGCT GATGGTCATGTATCATCCTT GGAGTGGGTCTCAGTTATTTCCACCATGGGATGGTCA CCTCATCTATGGTGCATCCA TTTCTAGTAGCAACTGCAAATAGCGGTGGTAGCACATT TGTATCATCCTTTTTCTA CCAGGGCCACTGCTATCCCACCGGTGTACATTCTGAGGT CTACGCAGACTCCGTGAAG GTAGCAACTGCAACCGGGCCAGGTTCAGTGGCAGTG GCAGCTGGTGGAGTCTGGA GGCCGATTCACCATCTCCATGTACATTCAGAAATAG GGTCTGGGACAGAGTTCACT GGAGGCTTGATCCAGCCTGGAGACAATTCCAAGAACAC TGATGACGCAGTCTCCA CTCACCATCAGCAGCCTGCAGGGGGTCCCTGAGACTCTC GCTGTATCTTCAAATGAAC GCCACCCTGTCTGTGTCTGTCTGAAGATTTTGCAGTTT CTGTGCAGCCTCTGGGTTCA AGCCTGAGAGCCGAGGACACCAGGGGAAAGAGCCAC ATTACTGTCAGCAGTATAAT TCGTCAGTAGCAACTACATCGGCCGTGTATTACTGTGC CCTCTCCTGCAGGGCCA AACTGGCCTCGGACGTTCGGGAGCTGGGTCCGCCAGGCT GAGAGATTTTGGAGAGTTC GTCAGAGTGTTAGCAGCCCAAGGGACCAAGGTGGAA CCAGGGAAGGGCCTGGAGT TACTTTGACTACTGGGGCCAACTTAGCCTGGTACCA ATCAAAC (SEQ ID NO: GGGTCTCAGTTATTTATAGCAGGGAACCCTGGTCACCGT GCAGAAACCTGGCCAGG 3616) GGTGGTAGCACATTCTACGCTCCTCAG (SEQ ID CTCCCAGGCTCCTCATCT CAGACTCCGTGAAGGGCCG NO: 3614)ATGGTGCATCCACCAGG ATTCACCATCTCCAGAGAC GCCACTGCTATCCCAGCCAATTCCAAGAACACGCTGT AGGTTCAGTGGCAGTGG ATCTTCAAATGAACAGCCTGTCTGGGACAGAGTTCA GAGAGCCGAGGACACGGCC CTCTCACCATCAGCAGCCGTGTATTACTGTGCGAGAG TGCAGTCTGAAGATTTTG ATTTTGGAGAGTTCTACTTTCAGTTTATTACTGTCAGC GACTACTGGGGCCAGGGAA AGTATAATAACTGGCCTCCCTGGTCACCGTCTCCTCA CGGACGTTCGGCCAAGG GCGTCGACCAAGGGCCCATGACCAAGGTGGAGATCA CGGTCTTCCCCCTGGCACCC AACGTACGGTGGCTGCATCCTCCAAGAGCACCTCTG CCATCTGTCTTCATCTTC GGGGCACAGCGGCCCTGGGCCGCCATCTGATGAGCA CTGCCTGGTCAAGGACTAC GTTGAAATCTGGAACTGTTCCCCGAACCTGTGACGG CCTCTGTTGTGTGCCTGC TCTCGTGGAACTCAGGCGCTGAATAACTTCTATCCCA CCTGACCAGCGGCGTGCAC GAGAGGCCAAAGTACAGACCTTCCCGGCTGTCCTACA TGGAAGGTGGATAACGC GTCCTCAGGACTCTACTCCCCCTCCAATCGGGTAACTC TCAGCAGCGTGGTGACCGT CCAGGAGAGTGTCACAGGCCCTCCAGCAGCTTGGGC AGCAGGACAGCAAGGAC ACCCAGACCTACATCTGCAAGCACCTACAGCCTCAG ACGTGAATCACAAGCCCAG CAGCACCCTGACGCTGACAACACCAAGGTGGACAAG GCAAAGCAGACTACGAG AGAGTTGAGCCCAAATCTTAAACACAAAGTCTACGC GTGACAAAACTCACACATG CTGCGAAGTCACCCATCCCCACCGTGCCCAGCACCT AGGGCCTGAGCTCGCCC GAACTCCTGGGGGGANCGTGTCACAAAGAGCTTCAA CAGTCTTCCTCTTCCCCCCA CAGGGGAGAGTGTTAGAAAACCCAAGGACACCCTCA AGCTTGGNCCGCCATGG TGATCTCCCGGACCCCTGANNNCNNCNNNTTGTNTA GGTCACATGCGTGGTGGNG NNGCATCTTATNNTGNTTGNACGTGANCCACGAAGAC ACAAATAAGCAATANCA CCTNNNGTCAGTTCAACTGTCACNAATTTCACAAAT GNACNNGGAANGGNNNTG AAAGCATTTTTNTCACTGGANGTGCNNNATGNCAAGA CATNTANNNTGNTTGTCC ANNAAGCCNCGGGNANGGNAACTCNTNANGTATCT ANCAGTACACAGCACGTAC NNNNTGNNNNNNCNGNACGNNNNGGNCANCNNCCNN NNNTNNNNCANNNCNTG CNNCGTNCNNCACCANNNCNNNGNAATANNCTGAAN TNNNNANNNNANNNNNNA AGAANTNNNGTACTCTNCANNGCAGNNNNCANCAA AGNGNNNNAANANCNN ANCCCNNNNNCCCNNTNNN NNNNNNNGNNNNNNNNNNANNNNNNNNANNNNNN GNNGNGNNANNNNNCN NNNNNNNNNANNNNGGNN NNNNCNNNNNNNNNNNNANNCCNNNNNNNNTNNCC NNNNNNANGNTNNNNNN NNNNNNNN (SEQ ID NNNNNCNGNNNNNNNCCNO: 3613) NNNNNNNNN (SEQ ID NO: 3615) V-C056 NNNNNNNNNNNNNNGNGNCAGGTGCAGCTGGTGGAGT COV047_ NNNNNNCNNATGNATCN TCCTATGTGCTGACTCAGCCCOV047_ TNNTNNNNNTACGATTTAN CTGGGGGAGGCGTGGTCCA P3_F4 TACACATACGATTTAGGTACCCTCGGTGTCAGTGGCCC P3_F4 GTGACACTATANAATAACA GCCTGGGAGGTCCCTGAGAGACACTATAGAATAACA CAGGACAGACGGCCAGGAT TCCACTTTGCCTTTCTCTCCCTCTCCTGTGCAGCCTCTGG TCCACTTTGCCTTTCTCT TTCCTGTGGGGGAAACAACACNGGTGTCCACTCCCAGG ATTCACCTTCAGTAACTATG CCACAGGTGTCCACTCCCATTGGAAGTAAAAATGTGC TCCAACTGCACCTCGGTTCT GCATGCACTGGGTCCGCCAAGGTCCAACTGCACCTC ACTGGTACCAGCAGAAGCC ATCGATTGAATTCCACCATGGCTCCAGGCAAGGGGCTG GGTTCTATCGATTGAATT AGGCCAGGCCCCTGTGCTGGGGGATGGTCATGTATCATC GAGTGGGTGGCAGTTATAT CCACCATGGGATGGTCATCGTCTATGATGATAGCGAC CTTTTTCTAGTAGCAACTGC CATATGATGGAAATAATAATGTATCATCCTTTTTCTA CGGCCCTCAGGGATCCCTGA AACCGGTGTACATTCTCAGATACTATGCAGACTCCGTG GTAGCAACTGCAACCGG GCGATTCTCTGGCTCCAACTGTGCAGCTGGTGGAGTCTG AAGGGCCGATTCACCATCT TTCTGTGACCTCCTATGACTGGGAACACGGCCACCCT GGGGAGGCGTGGTCCAGCC CCAGAGACAATTCCAAGAAGCTGACTCAGCCACCCTC GACCATCAGCAGGGTCGAA TGGGAGGTCCCTGAGACTCCACGCTGTATCTGCAAATG GGTGTCAGTGGCCCCAG GCCGGGGATGAGGCCGACTTCCTGTGCAGCCTCTGGATT AACAGCCTGAGAGCTGAGG GACAGACGGCCAGGATTATTACTGTCAGGTGTGGGAT CACCTTCAGTAACTATGGC ACACGGCTGTGTATTACTGTTCCTGTGGGGGAAACAA AGTAGTAGTGATCCTTGGGT ATGCACTGGGTCCGCCAGGGCGAAAGATCCTTTCCCCTT CATTGGAAGTAAAAATG GTTCGGCGGAGGGACCAAGCTCCAGGCAAGGGGCTGGA AGCAGTGGCTGGGACGGGC TGCACTGGTACCAGCAGCTGACCGTCCTAG (SEQ GTGGGTGGCAGTTATATCA TACTTTGACTACTGGGGCCAAGccAGGccAGGcccc ID NO: 3620) TATGATGGAAATAATAAAT AGGGAACCCTGGTCACCGTTGTGCTGGTCGTCTATGA ACTATGCAGACTCCGTGAA CTCCTCAG (SEQ ID NO:TGATAGCGACCGGCCCT GGGCCGATTCACCATCTCC 3618) CAGGGATCCCTGAGCGAAGAGACAATTCCAAGAACA TTCTCTGGCTCCAACTCT CGCTGTATCTGCAAATGAAGGGAACACGGCCACCCT CAGCCTGAGAGCTGAGGAC GACCATCAGCAGGGTCGACGGCTGTGTATTACTGTGC AAGCCGGGGATGAGGCC GAAAGATCCTTTCCCCTTAGGACTATTACTGTCAGGTG CAGTGGCTGGGACGGGCTA TGGGATAGTAGTAGTGACTTTGACTACTGGGGCCAG TCCTTGGGTGTTCGGCGG GGAACCCTGGTCACCGTCTAGGGACCAAGCTGACCG CCTCAGCGTCGACCAAGGG TCCTAGGTCAGCCCAAGCCCATCGGTCTTCCCCCTGG GCTGCCCCCTCGGTCACT CACCCTCCTCCAAGAGCACCTGTTCCCGCCCTCGAGT CTCTGGGGGCACAGCGGCC GAGGAGCTTCAAGCCAACTGGGCTGCCTGGTCAAGG CAAGGCCACACTGGTGT ACTACTTCCCCGAACCTGTGGTCTCATAAGTGACTTCT ACGGTCTCGTGGAACTCAG ACCCGGGAGCCGTGACAGCGCCCTGACCAGCGGCGT GTGGCCTGGAAGGCAGA GCACACCTTCCCGGCTGTCCTAGCAGCCCCGTCAAGG TACAGTCCTCAGGACTCTA CGGGAGTGGAGACCACCCTCCCTCAGCAGCGTGGTG ACACCCTCCAAACAAAG ACCGTGCCCTCCAGCAGCTCAACAACAAGTACGCGG TGGGCACCCAGACCTACAT CCAGCAGCTACCTGAGCCTGCAACGTGAATCACAAG CTGACGCCTGAGCAGTG CCCAGCAACACCAAGGTGGGAAGTCCCACAGAAGCT ACAAGAGAGTTGAGCCCAA ACAGCTGCCAGGTCACGATCTTGTGACAAAACTCAC CATGAAGGGAGCACCGT ACATGCCCACCGTGCCCAGGGAGAAGACAGTGGCCC CACCTGAACTCCTGGGGGG CTACAGAATGTTCATAGACCGTCAGTCTTCCTCTTCC AAGCTTGGCCGCCATGG CCCCAAAACCCAAGGACACCCCAACTTGTTTATTGCA CCTCNNTGATCTCCCNGNA GCTTATAATGGTTACAACCCCTGAGGTCACATGCGT ATAAAGCAATAGCATCA GGTGGNGGACGTGAGCCACCAAATTTCACAAATAAA GAANACCCTGAGNCAAGTT GCATTTTTTTTCACTGCATCAACTGGNNACNTGGANG TTCTAGTTGTGGTTTGNC GCGNNNNNNGCATNANGCCCAAACTCATCAATGTATC NANNNAAAGCCNNNGAGG TTATCATGTCTGGATCGGANCAGTANANNGCACGTNN GAATNANTTCTGCNCAG CCGNNNNNNANNNTCNTCNCNCCATGGNCCTGGNNN NCGNNCNNCACCNNNNTNN TAGCACTGANNNNNNANNNANNNNAGNANNANANN NNNGNNNNNGNNNNNN NNAGNNNCNACAANNCNTNNTTNNNNTNNNANNNNN CCNNCNNNNNNNANNNNNT ANCNNNNNNNNCNNTNNNNANNNNANNNNNCCCNC NNNNNNATGNNGTGTCA NNNNNNNNNNNGNNNNNNGNTNNGNNNNNNNANNN N(SEQ ID NO: 3617) TCCNCNGGNNNCCCNNN AGNANANNNTNNNNNNCNTNCATNTCNNNNNCNN NANCNNGNNNNNNANN NNCCNNNNNNCNNNNNG NNNNNNNNNNNNNANNNNNNNNNNNNNNNNNN NNNNNNNNNNNNCNNA ANC (SEQ ID NO: 3619) V-C057NNNNNNNNTATGTATCNTA GAGGTGCAGCTGTTGGAGT COV047_ NNNNNNNCNTATGNATCGACATCGTGATGACCCAGTC COV047_ CACNTACGATTTAGGTGAC CTGGGGGAGGCTTGGTACAP3_C5 NTACACATACGATTTAG TCCAGACTCCCTGGCTGTGT P3_C5 ACTATAGAATAACATCCACACCTGGGGGGTCCCTGAGA GTGACACTATAGAATAA CNNTGGGCGAGAGGGCCACTTTGCCTTTCTCTCCACAGG CTCTCCTGTGCAGCCTCTGG CATCCACTTTGCCTTTCTCATCAACTGCAAGTCCAGCC TGTCCACTCCCAGGTCCAA ATTCACCTTTAGCAGCTATGCTCCACAGGTGTCCACTC AGAATGTTTTATACAGCTCC CTGCACCTCGGTTCTATCGACCATGAGCTGGGTCCGCCA CCAGGTCCAACTGCACC AACAATAAGAACTACTTAGTTGAATTCCACCATGGGAT GGCTCCAGGGAAGGGGCTG TCGGTTCTATCGATTGAACTTGGTACCAGCAGAAACC GGTCATGTATCATCCTTTTT GAGTGGGTCTCAGCTACCATTCCACCATGGGATGGTC AAGACAGCCTCCTAAACTGC CTAGTAGCAACTGCAACCGGTGATAGTGGTGGTACCAC ATGTATCATCCTTTTTCT TCATTTACTGGGCATCTACCGTGTACATTCTGAGGTGCA ATACTACGCAGACTCCGTG AGTAGCAACTGCAACCGCGGGAATCCGGGGTCCCTG GCTGTTGGAGTCTGGGGGA AAGGGGCGGTTCACCATCTGTGTACATTCGGACATC ACCGATTCAGTGGCAGCGG GGCTTGGTACAACCTGGGGCCAGAGACAATTCCAAGAA GTGATGACCCAGTCTCC GTCTGGGACAGATTTCACTCGGTCCCTGAGACTCTCCTGT CACGCTGTATCTGCAAATG AGACTCCCTGGCTGTGTCTCACCATCAGCAGCCTGCAG GCAGCCTCTGGATTCACCTT AATAGTCTGAGAGCCGAGGTCTGGGCGAGAGGGCCA GCCGAAGATGTGGCAGTTTA TAGCAGCTATGCCATGAGCACACGGCCATATATTACTG CCATCAACTGCAAGTCC TTACTGTCAGCAATATTATATGGGTCCGCCAGGCTCCAG TGCGAGGAGAGGAAATAGT AGCCAGAATGTTTTATACCTCTTCGTTGGACGTTCGGC GGAAGGGGCTGGAGTGGGT GGGAGCTACCCTGACCCTGAGCTCCAACAATAAGAA CAAGGGACCAAGGTGGAAA CTCAGCTACCAGTGATAGTACTACTGGGGCCAGGGAAC CTACTTAGCTTGGTACCA TCAAAC (SEQ ID NO:GGTGGTACCACATACTACG CCTGGTCACCNTCTCCTCAG GCAGAAACCAAGACAGC 3624)CAGACTCCGTGAAGGGGCG (SEQ ID NO: 3622) CTCCTAAACTGCTCATTTGTTCACCATCTCCAGAGAC ACTGGGCATCTACCCGG AATTCCAAGAACACGCTGTGAATCCGGGGTCCCTGA ATCTGCAAATGAATAGTCT CCGATTCAGTGGCAGCGGAGAGCCGAGGACACGGCC GGTCTGGGACAGATTTC ATATATTACTGTGCGAGGAACTCTCACCATCAGCAG GAGGAAATAGTGGGAGCTA CCTGCAGGCCGAAGATGCCCTGACCCTGACTACTGG TGGCAGTTTATTACTGTC GGCCAGGGAACCCTGGTCAAGCAATATTATACTCTTC CCGTCTCCTCAGCGTCGACC GTTGGACGTTCGGCCAAAAGGGCCCATCGGTCTTCC GGGACCAAGGTGGAAAT CCCTGGCACCCTCCTCCAACAAACGTACGGTGGCTG GAGCACCTCTGGGGGCACA CACCATCTGTCTTCATCTGCGGCCCTGGGCTGCCTGG TCCCGCCATCTGATGAGC TCAAGGACTACTTCCCCGAAGTTGAAATCTGGAACT ACCTGTGACGGTCTCGTGG GCCTCTGTTGTGTGCCTGAACTCAGGCGCCCTGACCA CTGAATAACTTCTATCCC GCGGCGTGCACACCTTCCCAGAGAGGCCAAAGTACA GGCTGTCCTACAGTCCTCA GTGGAAGGTGGATAACGGGACTCTACTCCCTCAGCA CCCTCCAATCGGGTAACT GCGTGGTGACCGTGCCCTCCCCAGGAGAGTGTCACA CAGCAGCTTGGGCACCCAG GAGCAGGACAGCAAGGAACCTACATCTGCAACGTGA CAGCACCTACAGCCTCA ATCACAAGCCCAGCAACACGCAGCACCCTGACGCTG CAAGGTGGACAAGAGAGTT AGCAAAGCAGACTACGAGAGCCCAAATCTTGTGACA GAAACACAAAGTCTACG AAACTCACACATGCCCACCCCTGCGAAGTCACCCAT GTGCCCAGCACCTGAACTC CAGGGCCTGAGCTCGCCCTGGGGGGACCGTCAGTCT CGTCACAAAGAGCTTCN TCCTCTTCCCCCCAAAACCCANNNGGGGGAGAGTGTT ANNNCACCCTCATGATCTC AGAAGCTTGGNCCGCCACCGGACCCCTGAGGTCACA TGGCCCAACTTGNTTTNT TGCGTGGTGGTGGAGGTGATNGCAGNTNTATANNNN GNCACGAGACCNNGAAGN TNNCAAATAAAGCAATANNNNNNAGNNNNGNTNNA GCATCACAAATTTCACA GNTNGGNANNGNNANGGCAATAAAGCATTTTTTTCA NTNGNAGGTGCATAATGNN CTGCATTCTAGTTGTGGTNNNNAAANNCCNNNGGGA TTGTCCAAACTCATCAAN NGANCAGTACAANNGCACNGNATNTNATCATGNCTG NACCNNNNNGGNNNNNNN GNTCGNNATNATTCGNGNNNNNNNCNGTNCNNNNN CAGCNNCATNNNCTGAA NNN(SEQ ID NO: TACNTCTGAANAGACTN3621) NNNNACTNNGAGNGAAG ANNNCNNNGANGGNNN GTCNNTNNNNNGGGGNANNNNNNCCNNNNNC (SEQ ID NO: 3623) V-C058 NNNNNNNNNNNTGNNTCNTCAGGTGCAGCTGGTGCAGT COV047_ NNNNNNNNNNNNNNTGT GACATCCAGATGACCCAGTCCOV047_ ACACNTACGATTTAGGTGA CTGGGGCTGAGGTGAAGAA P5_F6 NTNNACNCNTACGATTTTCCATCCTCCCTGTCTGCAT P5_F6 CACTATAGAATAACATCCA GCCTGGGGCCTCAGTGAAGAGGTGACACTATAGAAT CTGTAGGAGACAGAGTCAC CTTTGCCTTTCTCTCCACAGGTTTCCTGCAAGGCATCTG AACATCCACTTTGCCTTT CATCACTTGCCGGGCAAGTCGTGTCCACTCCCAGGTCCA GATACACCTTCATCAGCTA CTCTCCACAGGTGTCCACAGAGCATTAGCAGCTATTTA ACTGCACCTCGGTTCTATCG CTATATGCACTGGGTGCGATCCCAGGTCCAACTGCA AATTGGTATCAGCAGAAAC ATTGAATTCCACCATGGGACAGGCCCCTGGACAAGGGC CCTCGGTTCTATCGATTG CAGGGAAAGCCCCTAAGCTTGGTCATGTATCATCCTTTT TTGAGTGGATGGGAATAAT AATTCCACCATGGGATGCCTGATCTATGCTGCATCCA TCTAGTAGCAACTGCAACC CAACCCTAGTGGTGGTAGCGTCATGTATCATCCTTTT GTTTGCAAAGTGGGGTCCCA GGTGTACATTCCCAGGTGCACAAGCTACGCACAGAAGT TCTAGTAGCAACTGCAA TCAAGGTTCAGTGGCAGTGGAGCTGGTGCAGTCTGGGGC TCCAGGGCAGAGTCACCAT CCGGTGTACATTCTGACAATCTGGGACAGATTTCACTC TGAGGTGAAGAAGCCTGGG GACCAGGGACACGTCCACGTCCAGATGACCCAGTCTC TCACCATCAGCAGTCTGCAA GCCTCAGTGAAGGTTTCCTAGCACAGTCTACATGGAGC CATCCTCCCTGTCTGCAT CCTGAAGATTTTGCAACTTAGCAAGGCATCTGGATACAC TGAGCAGCCTGAGATCTGA CTGTAGGAGACAGAGTCCTACTGTCAACAGAGTTACA CTTCATCAGCTACTATATGC GGACACGGCCGTGTATTACACCATCACTTGCCGGGC GTACCCCTCCGGAGGGCAGT ACTGGGTGCGACAGGCCCCTGTGCTAGGGCAAATGAGG AAGTCAGAGCATTAGCA TTTGGCCAGGGGACCAAGCTTGGACAAGGGCTTGAGTGG GAGCAGCTGTTTCATTTGAC GCTATTTAAATTGGTATCGGAGATCAAAC (SEQ ID ATGGGAATAATCAACCCTA TACTGGGGCCAGGGAACCCAGCAGAAACCAGGGAAA NO: 3628) GTGGTGGTAGCACAAGCTA TGGTCACCNTNTCCTCAGGCCCCTAAGCTCCTGATC CGCACAGAAGTTCCAGGGC (SEQ ID NO: 3626)TATGCTGCATCCAGTTTG AGAGTCACCATGACCAGGG CAAAGTGGGGTCCCATCACACGTCCACGAGCACAGT AAGGTTCAGTGGCAGTG CTACATGGAGCTGAGCAGCGATCTGGGACAGATTTC CTGAGATCTGAGGACACGG ACTCTCACCATCAGCAGTCCGTGTATTACTGTGCTAGG CTGCAACCTGAAGATTTT GCAAATGAGGGAGCAGCTGGCAACTTACTACTGTCAA TTTCATTTGACTACTGGGGC CAGAGTTACAGTACCCCCAGGGAACCCTGGTCACCG TCCGGAGGGCAGTTTTG TCTCCTCAGCGTCGACCAAGCCAGGGGACCAAGCTG GGGCCCATCGGTCTTCCCCC GAGATCAAACGTACGGTTGGCACCCTCCTCCAAGAG GGCTGCACCATCTGTCTT CACCTCTGGGGGCACAGCGCATCTTCCCGCCATCTGA GCCCTGGGCTGCCTGGTCA TGAGCAGTTGAAATCTGAGGACTACTTCCCCGAACC GAACTGCCTCTGTTGTGT TGTGACGGTCTCGTGGAACGCCTGCTGAATAACTTCT TCAGGCGCCCTGACCAGCG ATCCCAGAGAGGCCAAAGCGTGCACACCTTCCCGGC GTACAGTGGAAGGTGGA TGTCCTACAGTCCTCAGGATAACGCCCTCCAATCGG CTCTACTCCCTCAGCAGCGT GTAACTCCCAGGAGAGTGGTGACCGTGCCCTCCAGC GTCACAGAGCAGGACAG AGCTTGGGCACCCAGACCTCAAGGACAGCACCTACA ACATCTGCAACGTGAATCA GCCTCAGCAGCACCCTGCAAGCCCAGCAACACCAAN ACGCTGAGCAAAGCAGA GTGGACAAGAGAGTTGAGCCTACGAGAAACACAAAG CCAAATCTTGTGACAAAAC TCTACGCCTGCGAAGTCTCACACATGCCCACCGTGC ACCCATCANGGCCTGAG CCAGCACCTGAACTCCTGGCTCGCCCGTCACAAAGA GGGGGANCGTCAGTCTTNN GCTTCAACAGGGGAGAGTCTTNNNNNCNNAANANAA TGTTAGAAGCTTGGCCG NGNANANGNNCNNNNNNNNCCATGNCCCAACTTGTT NNNNNTNCCCGNNNNNNNG TATTGCAGCTTATAATGGNNGNNNCNTGGGGTGGNNG TTACAAATAAAGCAATA GTGNNNNNGANCNNNNAAGCATCACAAATTTCACA NANCCNNGANGTCAAGTTC AATAAAGCATTTTTTTCAAACTGGNACNGTNGNNGGG CTGCATTCTAGTTGTGGT CGTNNNNGCANNANGNCAATTGTCCAAACTCATCAAT NANNAGCCNNNGGANGNN GTATCTNATCATGTCTGGCANTANANAGCNCGTACCG NTCGGGAATTNATTCGN NGNNNGNCAGCGTCCTNNNCGCAGCANCATGNNNNA NNCNGCNCANNACNGGNTG ANNACTNNGANNNANNNAANGGNANGGNANTNNNA NNNNNNNNNNNNNNNN NNNNNN (SEQ ID  NNNNTGAGCGAAAGAACNO: 3625) ATCTGNNGANTNNGNGT CANTTNNNNNGN (SEQ ID NO: 3627) V-CO59NNNNNNNNNNNANGNNTC GAGGTGCAGCTGGTGGAGT COV047_ NNNNNNNNTTATGTATNCAGTCTGCCCTGACTCAGCC COV047_ NTACACATACGATTTAGGT CTGGGGGAGACTTGGTCCAP5_G9 NNCNCATACGATTTAGG TGCCTCCGTGTCTGGGTCTC P5_G9 GACACTATAGAATAACATCGCCTGGGGGGTCCCTGAGA TGACACTATAGAATAAC CTGGACAGTCGATCACCATCCACTTTGCCTTTCTCTCCAC CTCTCCTGTTCAGCCTCTGG ATCCACTTTGCCTTTCTCTCCTGCACTGGAACCAGCAG AGGTGTCCACTCCCAGGTC ATTCACCTTCAGTAGCTATGTCCACAGGTGTCCACTCC TGACATTGGTGATTATAACT CAACTGCACCTCGGTTCTATCTATGCACTGGGTCCGCCA CAGGTCCAACTGCACCT ATGTCTCCTGGTACCAACACCGATTGAATTCCACCATGG GGCTCCAGGGAAGGGACTG CGGTTCTATCGATTGAATCACCCAGGCAAAGCCCCCA GATGGTCATGTATCATCCTT GAATATGTTTCAGTTATTAGTCCACCATGGGATGGTC AACTCATGATTTATGAAGTC TTTCTAGTAGCAACTGCAATAATACTGGGGGTGACACA ATGTATCATCCTTTTTCT AGTAATCGGCCCTCAGGGGTCCGGTGTACATTCTGAGGT TACTACGCAGACTCCGTGA AGTAGCAACTGCAACCGTTCTAATCGCTTCTCTGGCT GCAGCTGGTGGAGTCTGGG AGGGCAGATTCACCATCTCGTTCCTGGGCCCAGTCTG CCAAGTCTGGCAACACGGC GGAGACTTGGTCCAGCCTGCAGAGACAATTCCAAGAAC CCCTGACTCAGCCTGCCT CTCCCTGACCATCTCTGGGCGGGGGTCCCTGAGACTCTC ACGTTGTATCTTCAAGTGA CCGTGTCTGGGTCTCCTGTCCAGGCTGAGGACGAGAC CTGTTCAGCCTCTGGATTCA GCAGTCTGAGACCTGAAGAGACAGTCGATCACCATC TGATTATTACTGCATCTCAT CCTTCAGTAGCTATGCTATGCACGGCTGTGTATTACTGTG TCCTGCACTGGAACCAG ATACAAGCAGCAGCACTCTTCACTGGGTCCGCCAGGCTC TGAAAGATCAAGGGGGCCG CAGTGACATTGGTGATTCCCTATGTCTTCGGAACTGG CAGGGAAGGGACTGGAATA GGGGTGGCCAAGTTACTACATAACTATGTCTCCTGGT GACCAAGGTCACCGTCCTAG TGTTTCAGTTATTAGTAATATACTACCACTACATGGACG ACCAACACCACCCAGGC (SEQ ID NO: 3632)CTGGGGGTGACACATACTA TCTGGGGCAAAGGGACCAC AAAGCCCCCAAACTCATCGCAGACTCCGTGAAGGGC GGTCACCGTCTCCTCA  GATTTATGAAGTCAGTAAGATTCACCATCTCCAGAG (SEQ ID NO: 3630) ATCGGCCCTCAGGGGTTTACAATTCCAAGAACACGTT CTAATCGCTTCTCTGGCT GTATCTTCAAGTGAGCAGTCCAAGTCTGGCAACACG CTGAGACCTGAAGACACGG GCCTCCCTGACCATCTCTCTGTGTATTACTGTGTGAAA GGGCTCCAGGCTGAGGA GATCAAGGGGGCCGGGGGTCGAGACTGATTATTACTG GGCCAAGTTACTACTACTA CATCTCATATACAAGCACCACTACATGGACGTCTGG GCAGCACTCTTCCCTATG GGCAAAGGGACCACGGTCATCTTCGGAACTGGGACC CCGTCTCCTCAGCGTCGACC AAGGTCACCGTCCTAGGAAGGGCCCATCGGTCTTCC TCAGCCCAAGGCCAACC CCCTGGCACCCTCCTCCAACCACTGTCACTCTGTTCC GAGCACCTCTGGGGGCACA CACCCTCGAGTGAGGAGGCGGCCCTGGGCTGCCTGG CTTCAAGCCAACAAGGC TCAAGGACTACTTCCCCGACACACTGGTGTGTCTCAT ACCTGTGACGGTCTCGTGG AAGTGACTTCTACCCGGAACTCAGGCGCCCTGACCA GAGCCGTGACAGTGGCC GCGGCGTGCACACCTTCCCTGGAAGGCAGATAGCAG GGCTGTCCTACAGTCCTCA CCCCGTCAAGGCGGGAGGGACTCTACTCCCTCAGCA TGGAGACCACCACACCC GCGTGGTGACCGTGCCCTCTCCAAACAAAGCAACAA CAGCAGCTTGGGCACCCAG CAAGTACGCGGCCAGCAACCTACATCTGCAACGTGA GCTACCTGAGCCTGACG ATCACAAGCCCAGCAACACCCTGAGCAGTGGAAGTC CAAGGTGGACAAGAGAGTT CCACAGAAGCTACAGCTGAGCCCAAATCTTGTGACA GCCAGGTCACGCATGAA AAACTCACACATGCCCACCGGGAGCACCGTGGAGAA GTGCCCAGCACCTGAACTC GACAGTGGCCCCTACAGCTGGGGGGACCGTCAGTCT AATGTTCATAGAAGCTT TCCTCTTCCCCCCAAAACCCGGCCGCCATGGCCCAAC AAGGACACCCTCATGATCT TTGTTTATTGTNNCNNNNCCCGGACCCCTGAGGTCAC TATNNTGATTACNAAAT ATGCGTGGGNGGNGGANNTAAAGCAATAGCATCACA GANCCACNANACCCTGAGN AATTTCACAAATAAAGCCAAGTTCAACTGGNACNNG ATTTTTTTCACTGCATTC GNNGGCGNNGAGGTGCATATAGTTGTGGTTNGTCCAA ATGNNAANAANNAANNCG ACTCATCNATGNNNNNNCGGGAGGANCAGTACNANN TTATCNTGNCTGGATCNG NGCNNNTACCGNNNGGNNAGAATNNNNNNNGCANCN GNCNNNNNNNNNNCNNNN CNTNNNNAAATNACCNNNNNNNANTGNNNNAANGG TGAANNNNNNANTNNNN NN (SEQ ID NO:  NNGTACTNNNNNNNGNN3629) NNNNNAACNNNNNNNG NANNNNNNNGTNNNNNT NNNNNNNAANNNCCNNGNNNNNNNNNGGNANNN NTNNNNNAANNNNNN (SEQ ID NO: 3631) V-C060NNNNNNNCNNATGTATCNT CAGGTTCAGCTGGTGCAGT COV107_ NNNNNNNTATGTATCNTTCCTATGTGCTGACTCAGCC COV107_ ACNCATACGATTTAGGTGA CTGGAGCTGAGGTGAAGAAP3_E5 ACACNTACGATTTAGGT ACCCTCGGTGTCAGTGTCCC P3_E5 CACTATAGAATAACATCCAGCCTGGGGCCTCAGTGAAG GACACTATAGAATAACA CAGGACAGACGGCCAGGATCTTTGCCTTTCTCTCCACAG GTCTCCTGCAAGGCTTCTGG TCCACTTTGCCTTTCTCTCACCTGCTCTGGAGATGCAT GTGTCCACTCCCAGGTCCA TTACACCTTTACCAGCTACGCCACAGGTGTCCACTCCC TGCCAAAGCAATATGCTTAT ACTGCACCTCGGTTCTATCGGTATCAGCTGGGTGCGACA AGGTCCAACTGCACCTC TGGTACCAGCAGAAGCCAGATTGAATTCCACCATGGGA GGCCCCTGGACAAGGGCTT GGTTCTATCGATTGAATTGCCAGGCCCCTGTGCTGGTG TGGTCATGTATCATCCTTTT GAGTGGATGGGATGGATCACCACCATGGGATGGTCA ATATATAAAGACAGTGAGA TCTAGTAGCAACTGCAACCGCGCTTACAATGGTAACAC TGTATCATCCTTTTTCTA GGCCCTCAGGGATCCCTGAGGGTGTACATTCCCAGGTTC AAACTATGCACAGAAGCTC GTAGCAACTGCAACCGGCGATTCTCTGGCTCCAGCTC AGCTGGTGCAGTCTGGAGC CAGGGCAGAGTCACCATGATTCTGTGACCTCCTATGA AGGGACAACAGTCACGTTG TGAGGTGAAGAAGCCTGGGCCACAGACACATCCACGAG GCTGACACAGCCACCCT ACCATCAGTGGAGTCCAGGGCCTCAGTGAAGGTCCCCT CACAGCCTACATGGAGCTG CGGTGTCAGTGTCCCCACAGAAGACGAGGCTGACTA GCAAGGCTTCTGGTTACAC AGGAGCCTGAGATCTGACGGGACAGACGGCCAGGAT TTACTGTCAATCAGCAGACA CTTTACCAGCTACGGTATCAACACGGCCGTGTATTACTG CACCTGCTCTGGAGATG GCAGTGGTACTCTTTGGGTGGCTGGGTGCGACAGGCCCC TGCGAGAGTTCCCGCCTCG CATTGCCAAAGCAATATTTCGGCGGAGGGACCAAGC TGGACAAGGGCTTGAGTGG TACGGTGACGACGATTACTGCTTATTGGTACCAGCA TGACCGTCCTAG (SEQ ID ATGGGATGGATCAGCGCTTACTACTACTACGGTATGGA GAAGCCAGGCCAGGCCC NO: 3636) ACAATGGTAACACAAACTACGTCTGGGGCCAAGGGACC CTGTGCTGGTGATATATA TGCACAGAAGCTCCAGGGCACGGTCACCGTCTCCTCA AAGACAGTGAGAGGCCC AGAGTCACCATGACCACAG(SEQ ID NO: 339) TCAGGGATCCCTGAGCG ACACATCCACGAGCACAGCATTCTCTGGCTCCAGCTC CTACATGGAGCTGAGGAGC AGGGACAACAGTCACGTCTGAGATCTGACGACACGG TGACCATCAGTGGAGTC CCGTGTATTACTGTGCGAGCAGGCAGAAGACGAGGC AGTTCCCGCCTCGTACGGT TGACTATTACTGTCAATCGACGACGATTACTACTACT AGCAGACAGCAGTGGTA ACTACGGTATGGACGTCTGCTCTTTGGGTGTTCGGCG GGGCCAAGGGACCACGGTC GAGGGACCAAGCTGACCACCGTCTCCTCAGCGTCGA GTCCTAGGTCAGCCCAA CCAAGGGCCCATCGGTCTTGGCTGCCCCCTCGGTCAC CCCCCTGGCACCCTCCTCCA TCTGTTCCCACCCTCGAGAGAGCACCTCTGGGGGCAC TGAGGAGCTTCAAGCCA AGCGGCCCTGGGCTGCCTGACAAGGCCACACTGGTG GTCAAGGACTACTTCCCCG TGTCTCATAAGTGACTTCAACCTGTGACGGTCTCGTG TACCCGGGAGCCGTGAC GAACTCAGGCGCCCTGACCAGTGGCCTGGAAGGCAG AGCGGCGTGCACACCTTCC ATAGCAGCCCCGTCAAGCGGCTGTCCTACAGTCCTCA GCGGGAGTGGAGACCAC GGACTCTACTCCCTCAGCACACACCCTCCAAACAAA GCGTGGTGACCGTGCCCTC GCAACAACAAGTACGCGCAGCAGCTTGGGCACCCAG GCCAGCAGCTACCTGAG ACCTACATCTGCAACGTGACCTGACGCCTGAGCAGT ATCACAAGCCCAGCAACAC GGAAGTCCCACAGAAGCCNANGTGGACAAGAGAGTT TACAGCTGCCAGGTCAC GAGCCCAAATCTTGTGACAGCATGAAGGGAGCACCG AAACTCACACATGCCCACC TGGAGAAGACAGTGGCCGTGCCCAGCACCTGAACTC CCNANNNNNAATGTTCA CTGGGGGGACCGTCAGTCTTAGAAGCTTGGCCCGCC TCCTCTTCCCCCCAAAACCC ATGGCCCAACTTGTTTATAAGGNNNCCCTCATGATNN TGCAGCTTATAATGGTTA NCCCGNACCCCNGAGGTCACAAATAAAGCAATAGCA CATGCGTGGNGGTGGACGT TCACAAATTTCACAAATGANCCACGAANACCCTGAG AAAGCATTTTTTTCACTG NCAAGTTCAACTGGNACNNCATTCTAGTTGTGGTTTG GGNNGGCNNNNNNGCATA TCCAAACTCATCAATGNANGNNANAANNAAGCCGN NTCTTATCATGTCTGGNT NGGNAGGANCANNNNNNNCGGGNATTNATTTNGNN NAGCNCGNNCCGNGNNNN GCAGCNNNTGNNNGAAN NCANNNTTCNNN (SEQNANNNTGAAAGAGNNTN ID NO: 3633) NNNNGNNCTTCTGAGNG AANACNTCNNNNGANNNNNGTCANTNNNNNGAAN GTCCCAGNTCCCNNNNG GNNNNTNNGNNNNNNNN NNNTNNNCANTNNNTCANNNNNN (SEQ ID NO: 3635) V-C061 NNNNNNNNCNNATGTATCN CAGGTGCAGCTACAGCAGTCOV107_ NNNNNNNNNNNTATGNN GAAATTGTGTTGACGCAGTC COV107_TACNCNTACGATTTAGGTG GGGGCGCAGGACTGTTGAA P1_G12 TCNTACNCATACGATTTATCCAGGCACCCTGTCTTTGT P1_G12 ACACTATAGAATAACATCC GCCTTCGGAGACCCTGTCTCGGTGACACTATAGAATA CTCCAGGGGAAAGAGCCAC ACTTTGCCTTTCTCTCCACATCACCTGCGCTGTCTCTGGT ACATCCACTTTGCCTTTC CCTCTCCTGCAGGGCCAGTCGGTGTCCACTCCCAGGTCC GGGTCACTCAGTGGTTTCTA TCTCCACAGGTGTCCACTAGACTCTTACCGCCAACTAC AACTGCACCTCGGTTCTATC CTGGACCTGGATCCGCCAGCCCAGGTCCAACTGCAC TTAGCCTGGTACCAGCAGAA GATTGAATTCCACCATGGGCCCCCCGGAAAGGGGCTGG CTCGGTTCTATCGATTGA ACCTGGCCAGGCTCCCAGACATGGTCATGTATCATCCTTT AGTGGATTGGGGAAACCAA ATTCCACCATGGGATGGTCCTCATCTATGGTGCATCC TTCTAGTAGCAACTGCAAC TCATTTTGGAAGCACCGACTCATGTATCATCCTTTTT AAGAGGGCCACTGGCATCC CGGTGTACATTCCCAGGTGTACAAGCCGTCCCTCAAGA CTAGTAGCAACTGCAAC CAGACAGGTTCAGTGGCAGCAGCTACAGCAGTGGGGCG GTCGAGTCACCATATCAGT CGGTGTACATTCAGAAATGGGTCTGGGACAGACTTCA CAGGACTGTTGAAGCCTTC AGACATGTCCAGGAACCAATTGTGTTGACGCAGTCTC CTCTCAGCATCAGCAGACTG GGAGACCCTGTCTCTCACCTTTTTCCCTGATTATGACCTC CAGGCACCCTGTCTTTGT GAGCCTGAAGATTTTGCAGTGCGCTGTCTCTGGTGGGTC TGTGACCGCCGCGGACACG CTCCAGGGGAAAGAGCCGTATTACTGTCAGCAGTATG ACTCAGTGGTTTCTACTGGA GCTGTGTATTACTGTGCGAACCCTCTCCTGCAGGGCC GTACTACACCTCGGACTTTC CCTGGATCCGCCAGCCCCCGAAAGACCCTCCTCTTCAG AGTCAGACTCTTACCGCC GGCGGAGGGACCAAGGTGGCGGAAAGGGGCTGGAGTGG TGACTTTTCTCCTGGTGCTT AACTACTTAGCCTGGTACAGATCAA (SEQ ID NO: ATTGGGGAAACCAATCATT TTGATATCTGGGGCCAAGGCAGCAGAAACCTGGCCA 3640) TTGGAAGCACCGACTACAA GACAATGGTCGTAGTCTCTTGGCTCCCAGACTCCTCAT GCCGTCCCTCAAGAGTCGA CAG (SEQ ID NO: CTATGGTGCATCCAAGA GTCACCATATCAGTAGACA 3638) GGGCCACTGGCATCCCATGTCCAGGAACCAATTTTCC GACAGGTTCAGTGGCAG CTGATTATGACCTCTGTGACTGGGTCTGGGACAGACT CGCCGCGGACACGGCTGTG TCACTCTCAGCATCAGCATATTACTGTGCGAGAAAGA GACTGGAGCCTGAAGAT CCCTCCTCTTCAGTGACTTTTTTGCAGTGTATTACTGT TCTCCTGGTGCTTTTGATAT CAGCAGTATGGTACTACCTGGGGCCAAGGGACAATG ACCTCGGACTTTCGGCG GTCACCGTCTCTTCAGCGTCGAGGGACCAAGGTGGAA GACCAAGGGCCCATCGGTC ATCAAACGTACGGTGGCTTCCCCCTGGCACCCTCCTC TGCACCATCTGTCTTCAT CAAGAGCACCTCTGGGGGCCTTCCCGCCATCTGATGA ACAGCGGCCCTGGGCTGCC GCAGTTGAAATCTGGAATGGTCAAGGACTACTTCCC CTGCCTCTGTTGTGTGCC CGAACCTGTGACGGTCTCGTGCTGAATAACTTCTATC TGGAACTCAGGCGCCCTGA CCAGAGAGGCCAAAGTACCAGCGGCGTGCACACCTT CAGTGGAAGGTGGATAA CCCGGCTGTCCTACAGTCCTCGCCCTCCAATCGGGTA CAGGACTCTACTCCCTCAG ACTCCCAGGAGAGTGTCCAGCGTGGTGACCGTGCCC ACAGAGCAGGACAGCAA TCCAGCAGCTTGGGCACCCGGACAGCACCTACAGCC AGACCTACATCTGCAACGT TCAGCAGCACCCTGACGGAATCACAAGCCCAGCAAC CTGAGCAAAGCAGACTA ACCAAGGTGGACAAGAGAGCGAGAAACACAAAGTCT TTGAGCCCAAATCTTGTGA ACGCCTGCGAAGTCACCCAAAACTCACACATGCCCA CATCAGGGCCTGAGCTC CCGTGCCCAGCACCTGAACGCCCGTCACAAAGAGCT TCCTGGGGGGACCGTCAGT TCAACAGGGGANANNNNCTTCCTCTTCCCCCCAAAAC NGAAGCTTNGGCCNCCN CCAAGGACACCCTCATGATTGNGCCCNCNNNNTGTN NNNCCGGACCCCTGANGTC TNNNNNNNNTNNNNNNNNNNTGCNTGGTGGTGGACG NTNACAAATAAAGCAAT TGAGCCACGANNACCCTGNANCATCNCANNTTCNCA NNCAGTCANTGGNACGNNG AAAAANNNNTTTTTTTNTNNGGNNNGNAGGTNCATAA CACTGCATNNNGTGNGN TGNCAANANNAAGCCNNNGTTGTCCAACTCATCATGN GNAGGAGCAGNNNNANCA NNCTNNCATGNCNGNTCGCNNCGTACCCNNNNNNNN GGNNTNNNGNGCANCAC ANCNNN (SEQ ID NO:NTNNNNANNNNNNNGNA 3637) NNGANTGNNNGTACTNN NNNNGNAANACNTCNGNGANGNNNNCAGTNGGNG NNGANGTCCCNGNNNN (SEQ ID NO: 3639) V-C062NNNNNNNNNATGNATCNTA CAGGTGCAGCTACAGCAGT COV107_ NNNNNNNNNNNNATGNAGAAATTGTGTTGACGCAGTC COV107_ CACATACGATTTAGGTGAC GGGGCGCAGGACTGTTGAAP1_A11 TNNNCACNTACGATTTA TCCAGGCACCCTGTCTTTGT P1_A11 ACTATAGAATAACATCCACGCCTTCGGAGACCCTGTCC GGTGACACTATAGAATA CTCCAGGGGAAAGAGCCACTTTGCCTTTCTCTCCACAGG CTCACCTGCGCTGTCTCTGG ACATCCACTTTGCCTTTCCCTCTCCTGCAGGGCCAGTC TGTCCACTCCCAGGTCCAA TGGGTCACTCAGTGGTTTCTTCTCCACAGGTGTCCACT AGACTCTTACCGCCAACTAC CTGCACCTCGGTTCTATCGAACTGGACCTGGATCCGCCA CCCAGGTCCAACTGCAC TTAGCCTGGTACCAGCAGAATTGAATTCCACCATGGGAT GCCCCCAGGAAAGGGGCTG CTCGGTTCTATCGATTGAACCTGGCCAGGCTCCCAGAC GGTCATGTATCATCCTTTTT GAGTGGATTGGGGAAACCAATTCCACCATGGGATGG TCCTCATCTATGGTGCATCC CTAGTAGCAACTGCAACCGATCATTTTGGAAGCACCGA TCATGTATCATCCTTTTT AAGAGGGCCGCTGGCATCCGTGTACATTCCCAGGTGCA CTACAAGGCGTCCCTCAAG CTAGTAGCAACTGCAACCAGACAGGTTCAGTGGCAG GCTACAGCAGTGGGGCGCA AGTCGAGTCACCATATCAGCGGTGTACATTCAGAAA TGGGTCTGGGACAGACTTCA GGACTGTTGAAGCCTTCGGTAGGCATGTCCAGGAACCA TTGTGTTGACGCAGTCTC CTCTCAGCATCACCAGACTGAGACCCTGTCCCTCACCTGC ATTTTCCCTGAAGGTGACTT CAGGCACCCTGTCTTTGTGAGCCTGAAGATTTTGCAGT GCTGTCTCTGGTGGGTCACT CTCTGACCGCCGCGGACACCTCCAGGGGAAAGAGCC GTATTACTGTCAGCAGTATC CAGTGGTTTCTACTGGACCTGGCTGTGTATTACTGTGCG ACCCTCTCCTGCAGGGCC ATACTACACCTCGGACTTTCGGATCCGCCAGCCCCCAGG AGAAAGCCCCTCCTCTACA AGTCAGACTCTTACCGCCGGCGGAGGGACCAAGGTGG AAAGGGGCTGGAGTGGATT GTGACTTTTCTCCTGGTGCTAACTACTTAGCCTGGTAC AGATCAA (SEQ ID NO: GGGGAAACCAATCATTTTGTTTGATATCTGGGGCCAAG CAGCAGAAACCTGGCCA 344) GAAGCACCGACTACAAGGCGGACAATGATCGTAGTCTC GGCTCCCAGACTCCTCAT GTCCCTCAAGAGTCGAGTCTTCAG (SEQ ID NO: CTATGGTGCATCCAAGA ACCATATCAGTAGGCATGT 3642)GGGCCGCTGGCATCCCA CCAGGAACCAATTTTCCCT GACAGGTTCAGTGGCAGGAAGGTGACTTCTCTGACC TGGGTCTGGGACAGACT GCCGCGGACACGGCTGTGTTCACTCTCAGCATCACCA ATTACTGCGCGAGAAAGCC GACTGGAGCCTGAAGATCCTCCTCTACAGTGACTTTT TTTGCAGTGTATTACTGT CTCCTGGTGCTTTTGATGTCCAGCAGTATCATACTAC TGGGGCCAAGGGACAATGG ACCTCGGACTTTCGGCGTCACCGTCTCTTCAGCGTCG GAGGGACCAAGGTGGAG ACCAAGGGCCCATCGGTCTATCAAACGTACGGTGGC TCCCCCTGGCACCCTCCTCC TGCACCATCTGTCTTCATAAGAGCACCTCTGGGGGCA CTTCCCGCCATCTGATGA CAGCGGCCCTGGGCTGCCTGCAGTTGAAATCTGGAA GGTCAAGGACTACTTCCCC CTGCCTCTGTTGTGTGCCGAACCTGTGACGGTCTCGT TGCTGAATAACTTCTATC GGAACTCAGGCGCCCTGACCCAGAGAGGCCAAAGTA CAGCGGCGTGCACACCTTC CAGTGGAAGGTGGATAACCGGCTGTCCTACAGTCCTC CGCCCTCCAATCGGGTA AGGACTCTACTCCCTCAGCACTCCCAGGAGAGTGTC AGCGTGGTGACCGTGCCCT ACAGAGCAGGACAGCAACCAGCAGCTTGGGCACCCA GGACAGCACCTACAGCC GACCTACATCTGCAACGTGTCAGCAGCACCCTGACG AATCACAAGCCCAGCAACA CTGAGCAAAGCAGACTACCAAGGTGGACAAGAGAGT CGAGAAACACAAAGTCT TGAGCCCAAATCTTGTGACACGCCTGCGAAGTCACC AAAACTCACACATGCCCAC CATCAGGGCCTGAGCTCCGTGCCCAGCACCTGAACT GCCCGTCACAAAGAGCT CCTGGGGGGACCGTCAGTCTCAACAGGGGAGAGTGT TTCCTCTTCCCCCCAAAACC TAGAAGCTTGGCCGCCACAAGGACNNCCTCATGATC TGGCCCAACTTGTTTATT TCCCGGACCCCTGNNNCACGCAGCTTATAATGGNTA ATGCGTGNNNNGACGTGAG CAAATAAAGCAATAGCACCACGAANANCCTGANTCA TCACAAATTTCACAAAT GTCANTGGNACGNNGNNGGAAAGCATTTTTTTCACTG CNNNNNNGCATANNCNNAN CATTCTAGTTGTGGNTNGAAGCNNNGGANGANCANT TCCAAACTCATCAATGN ANANAGCACGTACCGNGNNATCTTATCATGTCTGGAT NCAGCGTCNTNNNGTCNGN CGGNNNNNNCGNNNCAGNCCNGANTGNNGAATGNN CNNNNNNNNAANNNNN (SEQ ID NO: 3641) NNTGAANNNNCTNGNNGTACTNCTGAGNGAANAA CNTCNGNNNANNNNNNN NCAGTAGGGNNNNNGAA GTCCCNNGGNNC (SEQID NO: 3643) V-C063 NNNNNNNNTNTGNATCNTA CAGGTGCAGCTACAGCAGT COV107_NNNNNNNNNTATGNATC GAAATTGTGTTGACGCAGTC COV107_ CACATACGATTTAGGTGACGGGGCGCAGGACTGTTGAA P2_C7 NTACACATACGATTTAG TCCAGGCACCCTGTCTTTGT P2_C7ACTATAGAATAACATCCAC GCCTTCGGAGACCCTGTCC GTGACACTATAGAATAACTCCAGGGGAAAGAGCCAC TTTGCCTTTCTCTCCACAGG CTCACCTGCGCTGTCTCTGGCATCCACTTTGCCTTTCT CCTCTCCTGCAGGGCCAGTC TGTCCACTCCCAGGTCCAATGGGTCACTCAGTGGTTTCT CTCCACAGGTGTCCACTC AGACTGTTTCCGCCAACTACCTGCACCTCGGTTCTATCGA ACTGGACCTGGATCCGCCA CCAGGTCCAACTGCACCTTAGCCTGGTACCAGCAGAA TTGAATTCCACCATGGGAT GCCCCCAGGAAAGGGGCTGTCGGTTCTATCGATTGAA AGCTGGCCAGGCTCCCAGA GGTCATGTATCATCCTTTTTGAGTGGATTGGGGAAACCA TTCCACCATGGGATGGTC CTCCTCATCTATGGTGCATCCTAGTAGCAACTGCAACCG ATCATTTTGGAAGCACCGA ATGTATCATCCTTTTTCTCAAGAGGGCCACTGGCATC GTGTACATTCCCAGGTGCA CTACAAGCCGTCCCTCAAGAGTAGCAACTGCAACCG CCAGACAGGTTCAGTGGCA GCTACAGCAGTGGGGCGCAAGTCGAGTCACCATATCAG GTGTACATTCAGAAATT GTGGGTCTGGGACAGACTTCGGACTGTTGAAGCCTTCGG TAGACATGTCCAGGAACCA GTGTTGACGCAGTCTCCAACTCTCAGCATCAGCAGACT AGACCCTGTCCCTCACCTGC GTTCTCCCTGAAGGTGACCTGGCACCCTGTCTTTGTCT GGAGCCTGAAGATTTTGCTG GCTGTCTCTGGTGGGTCACTCTGTGACCGCCGCGGACAC CCAGGGGAAAGAGCCAC TGTATTACTGTCAGCAGTATCAGTGGTTTCTACTGGACCT GGCTGTTTATTACTGTGCGA CCTCTCCTGCAGGGCCAGTTACTACACCTCGGACTTT GGATCCGCCAGCCCCCAGG GAAAGCCCCTCCTCCACAGGTCAGACTGTTTCCGCCA CGGCGGAGGGACCAAGGTG AAAGGGGCTGGAGTGGATTTGACTTATCTCCTGGTGCTT ACTACTTAGCCTGGTACC GAGATCAA (SEQ ID NO:GGGGAAACCAATCATTTTG TTGATATCTGGGGCCAAGG AGCAGAAAGCTGGCCAG 3648)GAAGCACCGACTACAAGCC GACAATGGTCGCCGTCTCTT GCTCCCAGACTCCTCATCGTCCCTCAAGAGTCGAGTC CAG (SEQ ID NO: TATGGTGCATCCAAGAGACCATATCAGTAGACATGT 3646) GGCCACTGGCATCCCAG CCAGGAACCAGTTCTCCCTACAGGTTCAGTGGCAGT GAAGGTGACCTCTGTGACC GGGTCTGGGACAGACTTGCCGCGGACACGGCTGTTT CACTCTCAGCATCAGCA ATTACTGTGCGAGAAAGCCGACTGGAGCCTGAAGAT CCTCCTCCACAGTGACTTAT TTTGCTGTGTATTACTGTCTCCTGGTGCTTTTGATATC CAGCAGTATGTTACTAC TGGGGCCAAGGGACAATGGACCTCGGACTTTCGGCG TCACCGTCTCTTCAGCGTCG GAGGGACCAAGGTGGAAACCAAGGGCCCATCGGTCT ATCAAACGTACGGTGGC TCCCCCTGGCACCCTCCTCCTGCACCATCTGTCTTCAT AAGAGCACCTCTGGGGGCA CTTCCCGCCATCTGATGACAGCGGCCCTGGGCTGCCT GCAGTTGAAATCTGGAA GGTCAAGGACTACTTCCCCCTGCCTCTGTTGTGTGCC GAACCTGTGACGGTCTCGT TGCTGAATAACTTCTATCGGAACTCAGGCGCCCTGAC CCAGAGAGGCCAAAGTA CAGCGGCGTGCACACCTTCCAGTGGAAGGTGGATAA CCGGCTGTCCTACAGTCCTC CGCCCTCCAATCGGGTAAGGACTCTACTCCCTCAGC ACTCCCAGGAGAGTGTC AGCGTGGTGACCGTGCCCTACAGAGCAGGACAGCAA CCAGCAGCTTGGGCACCCA GGACAGCACCTACAGCCGACCTACATCTGCAACGTG TCAGCAGCACCCTGACG AATCACAAGCCCAGCAACACTGAGCAAAGCAGACTA CCAANGTGNACAAGAGAGT CGAGAAACACAAAGTCTTGAGCCCNNATCTTGTGAC ACGCCTGCGAAGTCACC ANAACTCACACATGCNCNCCATCAGGGCCTGAGCTC CGTGCNCNNCACCTGANNN GCCCGTCACAAAGAGCTCCNNNGGGGGANNNNNCA TCAACAGGGGAGAGTGT NNGTTCTTCTTCCTCCTCCCTAGAAGCTTGGCCGCCA CCCCAAAANCNNANGACAN TGGCCCAACTTGTTTATTCCTCATGATCTCCCNGACCC GCAGCTTATAATGGTTAC CTGAGGTCACATGCGTGGTAAATAAAGCAATAGCAT GGNGGACGTGAGCNACGAN CACAAATTTCACAAATAGACCCNGNNNCAANTTCAN AAGCATTTTTTTCACTGC TGGNACNNNGNCGGCGTGNATTCTAGTTGTGGTTTGT AGNTGCANANGNNAANAN CCAAACTCATCAATGTATAANNCNNNGGGNANNANC CTTATCATGTCTGGNTCG ANTANACAGCNCGNNNCNNGGAATTAATTCGGCGCA NNNNGGNNNNNNNCNTNN GCNCNTGNNNTGNAATANCNNNCNNCNNNNNNGNA NNNTGAAAGANNANNNN NTNNNNNGNAATGNNNNNNNNNANNNTGAGNGAAN NNANNNN (SEQ ID  ACNTCTNNGANNNNNGT NO: 3645)CANTNGGNNGNNNNGTC CCAGNNNCCCNNNNGNA NAANNNTGNAAGNNNNN NNNNNTNNNNNNCANNNNN (SEQ ID NO: 3647) V-C064 NNNNNNNNNNNNNNNTCNT GAGGTGCAGCTGGTGGAGTCOV047_ NNNNNNNNTATGNATNN CAGTCTGTGCTGACTCAGCC COV047_ACACATACGATTTAGGTGA CTGGGGGAGGCTTGGTCCA P4_A3 TACACATACGATTTAGGTTGCCTCCGTGTCTGGGTCTC P4_A3 CACTATAGAATAACATCCA GCCGGGGGGGTCCCTGAGAGACACTATAGAATAACA CTGGACAGTCGATCACCATC CTTTGCCTTTCTCTCCACAGCTCTCCTGTGCAGCCTCTGG TCCACTTTGCCTTTCTCT TCCTGCACTGGAACCAGCAAGTGTCCACTCCCAGGTCCA ATTCAGTGTCAGCACCAAG CCACAGGTGTCCACTCCCTGATGTTGGGAGTTATACCC ACTGCACCTCGGTTCTATCG TACATGACATGGGTCCGTCAGGTCCAACTGCACCTC TTGTCTCCTGGTACCAACAG ATTGAATTCCACCATGGGAAGGCTCCAGGGAAGGGGCT GGTTCTATCGATTGAATT TACCCAGGCAAAGCCCCCATGGTCATGTATCATCCTTTT GGAGTGGGTCTCAGTTCTTT CCACCATGGGATGGTCAAGCTCTTAATTTTTGAGGTC TCTAGTAGCAACTGCAACC ACAGCGGTGGTAGTGATTATGTATCATCCTTTTTCTA ACTAAGCGGTCCTCAGGGAT GGTGTACATTCTGAGGTGCCTACGCAGACTCCGTGAAG GTAGCAACTGCAACCGG TTCTAATCGCTTCTCTGGTTCAGCTGGTGGAGTCTGGGGG GGCAGATTCACCATCTCCA TTCCTGGGCCCAGTCTGCCAAGTCTGGCAACACGGCCT AGGCTTGGTCCAGCCGGGG GAGACAATTCCAAGAACGCCCTGACTCAGCCTGCCTC CCCTGACAATCTCTGGGCTC GGGTCCCTGAGACTCTCCTTTTATATCTTCAAATGAACA CGTGTCTGGGTCTCCTGG CAGGGTGAAGACGAGGCTGGTGCAGCCTCTGGATTCAG GCTTGAGAGTCGAGGACAC ACAGTCGATCACCATCTCATTATTATTGCTGCTCATAT TGTCAGCACCAAGTACATG GGGTGTTTATTACTGTGCCACTGCACTGGAACCAGCA GCAGGTGCTAGCACTTTCGT ACATGGGTCCGTCAGGCTCGAGACTCGTCGGAAGTCCG ATGATGTTGGGAGTTAT GTTCGGCGGAGGGACCAAGCAGGGAAGGGGCTGGAGTG TGACCACCCCGGGCACCCA ACCCTTGTCTCCTGGTACCTGACCGTCCTAG (SEQ GGTCTCAGTTCTTTACAGCG GGGCGCTCGGTGGGGGCTTCAACAGTACCCAGGCAA ID NO: 3651) GTGGTAGTGATTACTACGC TTGATATCTGGGGCCAAGGAGCCCCCAAGCTCTTAAT AGACTCCGTGAAGGGCAGA GACAATGGTCACCGTCTCTTTTTTGAGGTCACTAAGCG TTCACCATCTCCAGAGACA CAG (SEQ ID NO: 311)GTCCTCAGGGATTTCTAA ATTCCAAGAACGCTTTATAT TCGCTTCTCTGGTTCCAACTTCAAATGAACAGCTTGA GTCTGGCAACACGGCCT GAGTCGAGGACACGGGTGTCCCTGACAATCTCTGGGC TTATTACTGTGCCAGAGACT TCCAGGGTGAAGACGAGCGTCGGAAGTCCGTGACCA GCTGATTATTATTGCTGC CCCCGGGCACCCAGGGCGCTCATATGCAGGTGCTAG TCGGTGGGGGCTTTTGATAT CACTTTCGTGTTCGGCGGCTGGGGCCAAGGGACAATG AGGGACCAAGCTGACCG GTCACCGTCTCTTCAGCGTCTCCTAGGTCAGCCCAAG GACCAAGGGCCCATCGGTC GCTGCCCCCTCGGTCACTTTCCCCCTGGCACCCTCCTC CTGTTCCCACCCTCGAGT CAAGAGCACCTCTGGGGGCGAGGAGCTTCAAGCCAA ACAGCGGCCCTGGGCTGCC CAAGGCCACACTGGTGTTGGTCAAGGACTACTTCCC GTCTCATAAGTGACTTCT CGAACCTGTGACGGTCTCGACCCGGGAGCCGTGACA TGGAACTCAGGCGCCCTGA GTGGCCTGGAAGGCAGACCAGCGGCGTGCACACCTT TAGCAGCCCCGTCAAGG CCCGGCTGTCCTACAGTCCTCGGGAGTGGAGACCACC CAGGACTCTACTCCCTCAG ACACCCTCCAAACAAAGCAGCGTGGTGACCGTGCCC CAACAACAAGTACGCGG TCCAGCAGCTTGGGCACCCCCAGCAGCTACCTGAGC AGACCTACATCTGCAACGT CTGACGCCTGAGCAGTGGAATCACAAGCCCNGCAAC GAAGTCCCACAGAAGCT ACCCAAGNGGACAANANAACAGCTGCCAGGTCACG GATGAGNCCNNATNTTGTG CATGAAGGGAGCACCGTNNNAAAATNNNNNATGNNC GGAGAAGACAGTGGCCC TCCCCGNNNNNNNCNANNNCTACAGAATGTTCATAG NNNNNNGGGGGGGGGNAA AAGCTTGGCCGCCATGGCNTTNNTCTTTNNNNNNNC CCCAACTTGTTTATTGCA CCCCNAAAAANNNAANNNGCTTATAATGGTTACAA NNNCNNTNNTGNNNNNCNN ATAAAGCAATAGCATCANNNCCNNNNANGTCNNNNN CAAATTTCACAAATAAA NGNGGNNGNNGNNNGTGAGCATTTTTTTCACTGCAT CCNNNNAAANNCCTNNNNG TCTAGTTGTGGTTTGTCCTCAANTTCAANNGGTNNNN AAACTCATCAATGTATCT GNANNN (SEQ ID NO:TATCATGTCTGGATCGGG 3649) AATTAATTCGGCGCAGC ACCATGGNCTGAAATANCTCTGAAAGAGGACTTG GNTAGGTACCTTCTGAN CGGAAANNACCATCTGN NGAATGNNTGTCANTTAGGGTGNNGAAAGTCCCC AGGNNNCCCNNNNNN (SEQ ID NO: 3650) V-C065NNNNNNNNNNNNNNNNNN CAGGTGCAGCTGGTGCAGT COV072_ NNNNNNCNNNATGNATNGAAATTGTGTTGACGCAGTC COV072_ NNTACNCATACGATTTAGG CTGGGGCTGAGGTGAAGAAP3_D12 NTACNCATACGATTTAG TCCAGGCACCCTGTCTTTGT P3_D12 TGACACTATAGAATAACATGCCTGGGTCGTCGGTGAAG GTGACACTATAGAATAA CTCCAGGGGAAAGAGCCACCCACTTTGCCTTTCTCTCCA GTCTCCTGCAAGGCTTCTGG CATCCACTTTGCCTTTCTCCTCTCCTGCAGGGCCAGTC CAGGTGTCCACTCCCAGGT AGGCACCTTCAGTAGCTATCTCCACAGGTGTCCACTC AGAGTGTTAGCAGCACCTAC CCAACTGCACCTCGGTTCTAGCTATCAACTGGGTGCGAC CCAGGTCCAACTGCACC TTAGCCTGGTACCAGCAGAATCGATTGAATTCCACCATG AGGCCCCTGGACAAGGGCT TCGGTTCTATCGATTGAAACCTGGCCAGGCTCCCAGGC GGATGGTCATGTATCATCCT TGAGTGGATGGGAAGGATCTTCCACCATGGGATGGTC TCCTCATCTATGGTGCATCC TTTTCTAGTAGCAACTGCAAATCCCTATCGTTGGTATAGC ATGTATCATCCTTTTTCT AGCAGGGCCACTGGCATCCCCGGTGTACATTCCCAGGT AAACTACGCACAGAAGTTC AGTAGCAACTGCAACCGCAGACAGGTTCAGTGGCAG GCAGCTGGTGCAGTCTGGG CAGGGCAGAGTCACGATTAGTGTACATTCAGAAATT TGGGTCTGGGACAGACTTCA GCTGAGGTGAAGAAGCCTGCGGCGGACAAATCCTCGAG GTGTTGACGCAGTCTCCA CTCTCACCATCAGCAGACTGGGTCGTCGGTGAAGGTCTC CACAGCCTACATGGAGCTG GGCACCCTGTCTTTGTCTGAGCCTGAAGATTTTGCAGT CTGCAAGGCTTCTGGAGGC AGCAGCCTGAGATCTGAGGCCAGGGGAAAGAGCCAC GTATTACTGTCAGCAGTATG ACCTTCAGTAGCTATGCTATACACGGCCGTGTATTACTG CCTCTCCTGCAGGGCCA GTAGCTCACCGTGGACGTTCCAACTGGGTGCGACAGGCC TGCGAGAGATCTCCTGGAC GTCAGAGTGTTAGCAGCGGCCAAGGGACCAAGGTGG CCTGGACAAGGGCTTGAGT CCCCAGCTAGATGATGCTTTACCTACTTAGCCTGGTAC AAATCAAAC (SEQ ID GGATGGGAAGGATCATCCCTGATATCTGGGGCCAAGGG CAGCAGAAACCTGGCCA NO: 3655) TATCGTTGGTATAGCAAACACAATGGTCACCGTCTCTTC GGCTCCCAGGCTCCTCAT TACGCACAGAAGTTCCAGGAG (SEQ ID NO: 3653) CTATGGTGCATCCAGCA GCAGAGTCACGATTACGGCGGGCCACTGGCATCCCA GGACAAATCCTCGAGCACA GACAGGTTCAGTGGCAGGCCTACATGGAGCTGAGCA TGGGTCTGGGACAGACT GCCTGAGATCTGAGGACACTCACTCTCACCATCAGCA GGCCGTGTATTACTGTGCG GACTGGAGCCTGAAGATAGAGATCTCCTGGACCCCC TTTGCAGTGTATTACTGT AGCTAGATGATGCTTTTGATCAGCAGTATGGTAGCTC ATCTGGGGCCAAGGGACAA ACCGTGGACGTTCGGCCTGGTCACCGTCTCTTCAGCG AAGGGACCAAGGTGGAA TCGACCAAGGGCCCATCGGATCAAACGTACGGTGGC TCTTCCCCCTGGCACCCTCC TGCACCATCTGTCTTCATTCCAAGAGCACCTCTGGGG CTTCCCGCCATCTGATGA GCACAGCGGCCCTGGGCTGGCAGTTGAAATCTGGAA CCTGGTCAAGGACTACTTC CTGCCTCTGTTGTGTGCCCCCGAACCTGTGACGGTCT TGCTGAATAACTTCTATC CGTGGAACTCAGGCGCCCTCCAGAGAGGCCAAAGTA GACCAGCGGCGTGCACACC CAGTGGAAGGTGGATAATTCCCGGCTGTCCTACAGTC CGCCCTCCAATCGGGTA CTCAGGACTCTACTCCCTCAACTCCCAGGAGAGTGTC GCAGCGTGGTGACCGTGCC ACAGAGCAGGACAGCAACTCCAGCAGCTTGGGCACC GGACAGCACCTACAGCC CAGACCTACATCTGCAACGTCAGCAGCACCCTGACG TGAATCACAAGCCCAGCAA CTGAGCAAAGCAGACTACACCNNNTGGACAAGAGAG CGAGAAACACAAAGTCT TTGAGCCCAAATCTTGTGAACGCCTGCGAAGTCACC CAAACTCACACATGCCCAC CATCAGGGCCTGAGCTCCGTGCCCAGCACCTGAACT GCCCGTCACAAAGAGCT CCTGGGGGGACCGTCAGTCTCAACAGGGGAGAGTGT TTCCTCTNNCCCCAAACCCA TAGAAGCTTGGCCGCCAANGACNCCCTCATGATCNC TGGCCCAACTTGTTTATT CCNGANCCCTGANGNCNCNGCAGCTTATAATGGTTAC TGCGTGNNGGNGGANGNGN AAATAAAGCAATAGCATGNNNNNANNANCCNNNNN CACAAATTTCACAAATA NNNCCNNGANNNNNAANNAAGCATTTTTTTCACTGC TCNNCTGGNTACNNNGGAC ATTCTANTTGTGGTTTGNNGCNNNGNNGGTGCATAAT CCAAACTCATCAATGTAT GCCANNANNAANCCNNGGCTTATCATGTCTGGATCN NAGNANNNNNNNNAACNG GGNATTAATTCNGCGCANNCGTTNCNNNNNN (SEQ NCACCATGNNCTGAAAT ID NO: 3652) NACCTCTGAAANAGGAACNTGNNNAAGGTACNNT CTGAAGCCGNANNNNCA TCNNNNGAANGNNGGTC AAATNNNGGGGNNNGNAANGNNN (SEQ ID NO: 3654)

TABLE 16 Crystallographic data collection and refinement statistics forC105 Fab structure (related to FIG. 21) C105 Fab (12-1, SSRL) PDB IDXXXX Data collection^(a) Space group 1222 Unit cell (Å) 67.4, 120.1,123.3 α, β, γ (°) 90, 90, 90 Wavelength (Å) 1.0 Resolution (Å) 38.9-1.80(1.84-1.80) Unique Reflections 46,713 (2752) Completeness (%) 100 (99.8)Redundancy 6.8 (6.5) CCl/2 (%) 98.8 (54.1) <I/σI> 5.7 (1.2) Mosaicity(°) 0.19 Rmerge (%) 18.1 (157) Rpim (%) 7.9 (70.5) Wilson B -factor 16.8Refinement and Validation Resolution (Å) 38.9-1.80 Number of atomsProtein 3,132 Ligand 10 Waters 477 Rwork/Rfree (%) 18.7/21.6 R.m.s.deviations Bond lengths (Å) 0.006 Bond angles (°) 0.853 MolProbity score1.29 Clashscore (all atom) 4.2 Poor rotamers (%) 0 Ramachandran plotFavored (%) 97.6 Allowed (%) 2.4 Disallowed (%) 0 Average B -factor (Å)27.1 ^(a)Numbers in parentheses correspond to the highest resolutionshell

TABLE 16 Cryo-EM data collection and refinement statistics for C105-Scomplex structure (related to FIG. 21). C105 C105 SARS-CoV-2 SARS-CoV-2P D B S 2P S 2P E M D (state 1) (state 2) Microscope Titan Krios TitanKrios Camera GatanK3 GatanK3 Summit Summit Magnification 105,000x105,000x Voltage (kV) 300 300 Recording mode counting counting Dose rate(e−/pixel/s) 22.1 22.1 Electron dose (e−/Å²) 60 60 Defocus range (μm)1.0-2.5 1.0-2.5 Pixel size (Å) 0.418 0.418 (super resolution); (superresolution); 0.836 (binned) 0.836 (binned) Micrographs collected 5,9405,940 Micrographs used 5,336 5,336 Total extracted particles 71,28971,289 Refined particles 37,615 14,119 Symmetry imposed C1 C3 NominalResolution (Å) FSC 0.5 3.90/3.60 4.30/3.90 (unmasked/masked) FSC 0.1433.40/3.20 3.70/3.50 (unmasked · masked) Map sharpening B -factorRefinement and Validation Number of atoms Protein 25,973 Ligand 711MapCC (global/local) 0.86/0.84 R.m.s. deviations Bond lengths (Å) 0.008Bond angles (°) 0.812 MolProbity score 2.17 Clashscore (all atom) 13.6Poor rotamers (%) 0.04 Ramachandran plot Favored (%) 90.9 Allowed (%) 9Disallowed (%) 461

TABLE 17 S protein mutations found in different SARS-CoV-2 isolates(related to FIG. 22) Frequency Mutation Count (%) Location D614G 968863.2 S1 domain D P1263L 115 0.7 S2 cytoplasmic tail L5F 91 0.6 signalsequence D936Y 88 0.6 S2 HR1 L54F 58 0.4 S1 domain A G1124V 56 0.4 S2N439K 38 0.2 S1 domain B (RBD) H49Y 35 0.2 S1 domain A L18F 31 0.2 S1domain A L8V 30 0.2 signal sequence A831V 29 0.2 S2 D839Y 28 0.2 S2V483A 28 0.2 S1 domain B (RBD) Q675H 24 0.2 S1 domain D S50L 24 0.2 S1domain A S943P 22 0.1 S2 HR1 A1078S 21 0.1 S2 R21I 19 0.1 S1 domain AV367F 18 0.1 S1 domain B (RBD) T29I 18 0.1 S1 domain AList of SARS-CoV-2 spike mutations with a frequency ≥0.1% in a set of15335 isolates downloaded from the Global Initiative for Sharing AllInfluenza Data (GISAID) SARS-CoV-2 sequence database on May 3, 2020(Elbe and Buckland-Merrett, 2017; Shu and McCauley, 2017). The genomeswere processed with the nextstrain augur pipeline(https://github.com/nextstrain/augur) (Hadfield et al., 2018), usingMAFFT v7.464 (Katoh and Standley, 2013) for sequence alignment andFastTree (Price et al., 2010) to generate a phylogenetic tree. Theresulting data were then analyzed with a custom Swift program.

REFERENCES

-   Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, L    W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J.,    Grosse-Kunstleve, R. W., et al. (2010). PHENIX: a comprehensive    Python-based system for macromolecular structure solution. Acta    Crystallogr D Biol Crystallogr 66, 213-221.-   Bell, J. M., Chen, M., Baldwin, P. R., and Ludtke, S. J. (2016).    High resolution single particle refinement in EMAN2.1. Methods 100,    25-34.-   Bianchi, M., Turner, H. L., Nogal, B., Cottrell, C. A., Oyen, D.,    Pauthner, M., Bastidas, R., Nedellec, R., McCoy, L. E., Wilson, I.    A., et al. (2018). Electron-Microscopy-Based Epitope Mapping Defines    Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505    Envelope Trimer Immunization. Immunity 49, 288-300 e288.-   Briney, B., Inderbitzin, A., Joyce, C., and Burton, D. R. (2019).    Commonality despite exceptional diversity in the baseline human    antibody repertoire. Nature 566, 393-397.-   Brouwer, P. J. M., Caniels, T. G., van der Straten, K.,    Snitselaar, J. L., Aldon, Y., Bangaru, S., Tones, J. L., Okba, N. M.    A., Claireaux, M., Kerster, G., et al. (2020). Potent neutralizing    antibodies from COVID-19 patients define multiple targets of    vulnerability. bioRxiv 10.1101/2020.05.12.088716.-   Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q.,    Zhang, X., Zheng, Y., Geng, C., et al. (2020). Potent neutralizing    antibodies against SARS-CoV-2 identified by high-throughput    single-cell sequencing of convalescent patients' B cells. Cell    10.1016/j.cell.2020.05.025. Chen, V. B., Arendall, W. B., 3rd,    Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J.,    Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010).    MolProbity: all-atom structure validation for macromolecular    crystallography. Acta Crystallogr D Biol Crystallogr 66, 12-21.    Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J.,    Liu, P., Gao, L., Li, Z., et al. (2020). Human monoclonal antibodies    block the binding of SARS-CoV-2 Spike protein to angiotensin    converting enzyme 2. medRxiv 10.1101/2020.04.06.20055475-   Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang,    Z., Fan, P., Dong, Y., Yang, Y., et al. (2020). A potent    neutralizing human antibody reveals the N-terminal domain of the    Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv    10.1101/2020.05.08.083964. Crawford, K. H. D., Eguia, R.,    Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y.,    Tortorici, A. M., Veesler, D., Murphy, M., et al. (2020). Protocol    and reagents for pseudotyping lentiviral particles with SARS-CoV-2    Spike protein for neutralization assays. bioRxiv    10.1101/2020.04.20.051219.-   de Wit, E., van Doremalen, N., Falzarano, D., and Munster, V. J.    (2016). SARS and MERS: recent insights into emerging coronaviruses.    Nat Rev Microbiol 14, 523-534.-   Dunbar, J., Krawczyk, K., Leem, J., Baker, T., Fuchs, A., Georges,    G., Shi, J., and Deane, C. M. (2014). SAbDab: the structural    antibody database. Nucleic Acids Res 42, D1140-1146. Elbe, S., and    Buckland-Merrett, G. (2017). Data, disease and diplomacy: GISAID's    innovative contribution to global health. Glob Chall 1, 33-46.-   Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010).    Features and development of Coot. Acta Crystallogr D Biol    Crystallogr 66, 486-501.-   Fung, T. S., and Liu, D. X. (2019). Human Coronavirus: Host-Pathogen    Interaction. Annu Rev Microbiol 73, 529-557.-   Goddard, T. D., Huang, C. C., and Ferrin, T. E. (2007). Visualizing    density maps with UCSF Chimera. J Struct Biol 157, 281-287.-   Graham, R. L., Donaldson, E. F., and Baric, R. S. (2013). A decade    after SARS: strategies for controlling emerging coronaviruses. Nat    Rev Microbiol 11, 836-848.-   Gralinski, L. E., and Baric, R. S. (2015). Molecular pathology of    emerging coronavirus infections. The Journal of pathology 235,    185-195.-   Gristick, H. B., von Boehmer, L., West, A. P., Jr., Schamber, M.,    Gazumyan, A., Golijanin, J., Seaman, M. S., Fatkenheuer, G., Klein,    F., Nussenzweig, M. C., et al. (2016). Natively glycosylated HIV-1    Env structure reveals new mode for antibody recognition of the    CD4-binding site. Nat Struct Mol Biol 23, 906-915.-   Gui, M., Song, W., Zhou, H., Xu, J., Chen, S., Xiang, Y., and    Wang, X. (2017). Cryo-electron microscopy structures of the SARS-CoV    spike glycoprotein reveal a prerequisite conformational state for    receptor binding. Cell Res 27, 119-129.-   Guindon, S., Dufayard, J. F., Lefort, V., Anisimova, M., Hordijk,    W., and Gascuel, O. (2010). New algorithms and methods to estimate    maximum-likelihood phylogenies: assessing the performance of PhyML    3.0. Syst Biol 59, 307-321.-   Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B.,    Callender, C., Sagulenko, P., Bedford, T., and Neher, R. A. (2018).    Nextstrain: real-time tracking of pathogen evolution. Bioinformatics    34, 4121-4123.-   Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler,    T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H.,    Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2    and TMPRSS2 and Is Blocked by a Clinically Proven Protease    Inhibitor. Cell 181, 271-280 e278.-   Hwang, W. C., Lin, Y., Santelli, E., Sui, J., Jaroszewski, L., Stec,    B., Farzan, M., Marasco, W. A., and Liddington, R. C. (2006).    Structural basis of neutralization by a human anti-severe acute    respiratory syndrome spike protein antibody, 80R. J Biol Chem 281,    34610-34616.-   Ju, B., Zhang, Q., Ge, X., Wang, R., Yu, J., Ge, J., Lan, J., Yuan,    J., Wang, H., Zhao, J., et al. (2020). Potent human neutralizing    antibodies elicited 1 by SARS-CoV-2 infection. bioRxiv    10.1101/2020.03.21.990770.-   Kabsch, W. (2010). XDS. Acta Crystallogr D Biol Crystallogr 66,    125-132.-   Kane, M., Zang, T. M., Rihn, S. J., Zhang, F., Kueck, T., Alim, M.,    Schoggins, J., Rice, C. M., Wilson, S. J., and Bieniasz, P. D.    (2016). Identification of Interferon-Stimulated Genes with    Antiretroviral Activity. Cell Host Microbe 20, 392-405.-   Katoh, K., and Standley, D. M. (2013). MAFFT multiple sequence    alignment software version 7: improvements in performance and    usability. Mol Biol Evol 30, 772-780.-   Kirchdoerfer, R. N., Bhandari, M., Martini, O., Sewall, L. M.,    Bangaru, S., Yoon, K.-J., and Ward, A. B. (2020). Structure and    immune recognition of the porcine epidemic diarrhea virus spike    protein. bioRxiv 10.1101/2020.02.18.955195.-   Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J.,    Yassine, H. M., Turner, H. L., Corbett, K. S., Graham, B. S.,    McLellan, J. S., and Ward, A. B. (2016). Pre-fusion structure of a    human coronavirus spike protein. Nature 531, 118-121.-   Kirchdoerfer, R. N., Wang, N., Pallesen, J., Wrapp, D., Turner, H.    L., Cottrell, C. A., Corbett, K. S., Graham, B. S., McLellan, J. S.,    and Ward, A. B. (2018). Stabilized coronavirus spikes are resistant    to conformational changes induced by receptor recognition or    proteolysis. Scientific reports 8, 15701.-   Klein, J. S., and Bjorkman, P. J. (2010). Few and far between: how    HIV may be evading antibody avidity. PLoS Pathog 6, e1000908.-   Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J.,    Abfalterer, W., Foley, B., Giorgi, E. E., Bhattacharya, T.,    Parker, M. D., et al. (2020). Spike mutation pipeline reveals the    emergence of a more transmissible form of SARS-CoV-2. bioRxiv    10.1101/2020.04.29.069054. Landau, M., Mayrose, I., Rosenberg, Y.,    Glaser, F., Martz, E., Pupko, T., and Ben-Tal, N. (2005). ConSurf    2005: the projection of evolutionary conservation scores of residues    on protein structures. Nucleic Acids Res 33, W299-302.-   Lefranc, M. P., Giudicelli, V., Duroux, P., Jabado-Michaloud, J.,    Folch, G., Aouinti, S., Carillon, E., Duvergey, H., Houles, A.,    Paysan-Lafosse, T., et al. (2015). IMGT®, the international    ImMunoGeneTics information System® 25 years on. Nucleic Acids Res    43, D413-422.-   Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M.    A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T.    C., et al. (2003). Angiotensin-converting enzyme 2 is a functional    receptor for the SARS coronavirus. Nature 426, 450-454.-   Li, Z., Tomlinson, A. C., Wong, A. H., Zhou, D., Desforges, M.,    Talbot, P. J., Benlekbir, S., Rubinstein, J. L., and Rini, J. M.    (2019). The human coronavirus HCoV-229E S-protein structure and    receptor binding. Elife 8.-   Mastronarde, D. N. (2005). Automated electron microscope tomography    using robust prediction of specimen movements. J Struct Biol 152,    36-51.-   McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D.,    Storoni, L. C., and Read, R. J. (2007). Phaser crystallographic    software. J Appl Crystallogr 40, 658-674.-   Neuman, B. W., Kiss, G., Kunding, A. H., Bhella, D., Baksh, M. F.,    Connelly, S., Droese, B., Klaus, J. P., Makino, S., Sawicki, S. G.,    et al. (2011). A structural analysis of M protein in coronavirus    assembly and morphology. J Struct Biol 174, 11-22.-   Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie,    L., Qin, H., Wang, M., et al. (2020). Establishment and validation    of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes    Infect 9, 680-686.-   Nogal, B., Bianchi, M., Cottrell, C. A., Kirchdoerfer, R. N.,    Sewall, L. M., Turner, H. L., Zhao, F., Sok, D., Burton, D. R.,    Hangartner, L., et al. (2020). Mapping Polyclonal Antibody Responses    in Non-human Primates Vaccinated with HIV Env Trimer Subunit    Vaccines. Cell reports 30, 37553765 e3757.-   Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R.,    Chen, T., Hu, J., et a !. (2020). Characterization of spike    glycoprotein of SARS-CoV-2 on virus entry and its immune    cross-reactivity with SARS-CoV. Nat Commun 11, 1620.-   Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R.    N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi,    W., et al. (2017). Immunogenicity and structures of a rationally    designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA    114, E7348-E7357. Pettersen, E. F., Goddard, T. D., Huang, C. C.,    Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E.    (2004). UCSF Chimera—a visualization system for exploratory research    and analysis. J Comput Chem 25, 1605-1612.-   Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M.    A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et    al. (2020). Structural and functional analysis of a potent    sarbecovirus neutralizing antibody. Nature    10.1038/s41586-020-2349-y.-   Plotkin, S. A. (2001). Immunologic correlates of protection induced    by vaccination. Pediatr Infect Dis J 20, 63-75.-   Plotkin, S. A. (2008). Vaccines: correlates of vaccine-induced    immunity. Clin Infect Dis 47, 401-409.-   Plotkin, S. A. (2010). Correlates of protection induced by    vaccination. Clin Vaccine Immunol 17, 1055-1065.-   Prabakaran, P., Gan, J., Feng, Y., Zhu, Z., Choudhry, V., Xiao, X.,    Ji, X., and Dimitrov, D. S. (2006). Structure of severe acute    respiratory syndrome coronavirus receptor-binding domain complexed    with neutralizing antibody. J Biol Chem 281, 15829-15836.-   Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut,    R., Markmann, A., Conraby, C., Barbtelt, L., Weiss, S. C., Park, Y.    J., et al. (2020). The RBD Of The Spike Protein Of SARS-Group    Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies    But Not Other Pathogenic Human and Animal Coronavirus Antibodies.    medRxiv 10.1101/2020.05.06.20093377.-   Price, M. N., Dehal, P. S., and Arkin, A. P. (2010). FastTree    2—approximately maximum-likelihood trees for large alignments. PLoS    One 5, e9490.-   Punjani, A., Rubinstein, J. L., Fleet, D. J., and Brubaker, M. A.    (2017). cryoSPARC: algorithms for rapid unsupervised cryo-EM    structure determination. Nat Methods 14, 290-296.-   Quinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A.,    Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020). The    SARS-CoV-2 receptor-binding domain elicits a potent neutralizing    response without antibody dependent enhancement.    10.1101/2020.04.10.036418.-   Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H., Muller, M. A.,    Dijkman, R., Muth, D., Demmers, J. A., Zaki, A., Fouchier, R. A., et    al. (2013). Dipeptidyl peptidase 4 is a functional receptor for the    emerging human coronavirus-EMC. Nature 495, 251-254.-   Reguera, J., Santiago, C., Mudgal, G., Ordono, D., Enjuanes, L., and    Casasnovas, J. M. (2012). Structural bases of coronavirus attachment    to host aminopeptidase N and its inhibition by neutralizing    antibodies. PLoS Pathog 8, e1002859.-   Robbiani, D. F., Gaebler, C., Muecksch, F., Cetrulo Lorenzi, J. C.,    Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Finkin, S., Hagglof,    T., et al. (2020). Convergent Antibody Responses to SARS-CoV-2    Infection in Convalescent Individuals. bioRxiv    10.1101/2020.05.13.092619. Rockx, B., Corti, D., Donaldson, E.,    Sheahan, T., Stadler, K., Lanzavecchia, A., and Baric, R. (2008).    Structural basis for potent cross-neutralizing human monoclonal    antibody protection against lethal human and zoonotic severe acute    respiratory syndrome coronavirus challenge. J Virol 82, 3220-3235.-   Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Abbott, R. K.,    Callaghan, S., Garcia, E., He, W.-t., Hurtado, J., Limbo, O., et al.    (2020). Rapid isolation of potent SARS-CoV-2 neutralizing antibodies    and protection in a small animal model. bioRxiv    10.1101/2020.05.11.088674. Rohou, A., and Grigorieff, N. (2015).    CTFFIND4: Fast and accurate defocus estimation from electron    micrographs. J Struct Biol 192, 216-221.-   Scharf, L., Wang, H., Gao, H., Chen, S., McDowall, A. W., and    Bjorkman, P. J. (2015). Broadly Neutralizing Antibody 8ANC195    Recognizes Closed and Open States of HIV-1 Env. Cell 162, 1379-1390.-   Schoofs, T., Barnes, C. O., Suh-Toma, N., Golijanin, J., Schommers,    P., Gruell, H., West, A. P., Jr., Bach, F., Lee, Y. E., Nogueira,    L., et al. (2019). Broad and Potent Neutralizing Antibodies    Recognize the Silent Face of the HIV Envelope. Immunity 50,    1513-1529 e1519.-   Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R.,    Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan,    Y.-H., Feng, J., et al. (2020). Characterization of neutralizing    antibodies 1 from a SARS-CoV-2 infected individual. bioRxiv    10.1101/2020.05.12.091298.-   Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q.,    Auerbach, A., and Li, F. (2020). Structural basis of receptor    recognition by SARS-CoV-2. Nature 10.1038/s41586-0202179-y.-   Shang, J., Zheng, Y., Yang, Y., Liu, C., Geng, Q., Tai, W., Du, L.,    Zhou, Y., Zhang, W., and Li, F. (2018). Cryo-Electron Microscopy    Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion    State. J Virol 92.-   Shu, Y., and McCauley, J. (2017). GISAID: Global initiative on    sharing all influenza data—from vision to reality. Euro Surveill 22.-   Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li,    W., Lopez, R., McWilliam, H., Remmert, M., Soding, J., et al.    (2011). Fast, scalable generation of high-quality protein multiple    sequence alignments using Clustal Omega. Mol Syst Biol 7, 539.-   Terwilliger, T. C., Adams, P. D., Afonine, P. V., and Sobolev, O. V.    (2018). A fully automatic method yielding initial models from    high-resolution cryo-electron microscopy maps. Nat Methods 15,    905-908.-   Tortorici, M. A., and Veesler, D. (2019). Structural insights into    coronavirus entry. Adv Virus Res 105, 93-116.-   Tortorici, M. A., Walls, A. C., Lang, Y., Wang, C., Li, Z.,    Koerhuis, D., Boons, G. J., Bosch, B. J., Rey, F. A., de Groot, R.    J., et al. (2019). Structural basis for human coronavirus attachment    to sialic acid receptors. Nat Struct Mol Biol 26, 481-489.-   Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A.    T., and Veesler, D. (2020). Structure, Function, and Antigenicity of    the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281-292 e286.-   Walls, A. C., Tortorici, M. A., Bosch, B. J., Frenz, B.,    Rottier, P. J. M., DiMaio, F., Rey, F. A., and Veesler, D. (2016).    Cryo-electron microscopy structure of a coronavirus spike    glycoprotein trimer. Nature 531, 114-117.-   Walls, A. C., Tortorici, M. A., Snijder, J., Xiong, X., Bosch, B.    J., Rey, F. A., and Veesler, D. (2017). Tectonic conformational    changes of a coronavirus spike glycoprotein promote membrane fusion.    Proc Natl Acad Sci USA 114, 11157-11162.-   Walls, A. C., Xiong, X., Park, Y. J., Tortorici, M. A., Snijder, J.,    Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et    al. (2019). Unexpected Receptor Functional Mimicry Elucidates    Activation of Coronavirus Fusion. Cell 176, 1026-1039 e1015.-   Wan, Y., Shang, J., Graham, R., Baric, R. S., and Li, F. (2020).    Receptor Recognition by the Novel Coronavirus from Wuhan: an    Analysis Based on Decade-Long Structural Studies of SARS    Coronavirus. J Virol 94.-   Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R.,    Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L.,    Grosveld, F., and Bosch, B.-J. (2020). A human monoclonal antibody    blocking SARS-CoV-2 infection. Nature Communications 11.-   Wang, L., Shi, W., Joyce, M. G., Modjarrad, K., Zhang, Y., Leung,    K., Lees, C. R., Zhou, T., Yassine, H. M., Kanekiyo, M., et al.    (2015). Evaluation of candidate vaccine approaches for MERS-CoV. Nat    Commun 6, 7712.-   Widjaja, I., Wang, C., van Haperen, R., Gutierrez-Alvarez, J., van    Dieren, B., Okba, N. M. A., Raj, V. S., Li, W., Fernandez-Delgado,    R., Grosveld, F., et al. (2019). Towards a solution to MERS:    protective human monoclonal antibodies targeting different domains    and functions of the MERS-coronavirus spike glycoprotein. Emerg    Microbes Infect 8, 516-530.-   Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley,    P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G.,    McCoy, A., et al. (2011). Overview of the CCP4 suite and current    developments. Acta Crystallogr D Biol Crystallogr 67, 235-242.-   Wrapp, D., and McLellan, J. S. (2019). The 3.1-Angstrom    Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea    Virus Spike Protein in the Prefusion Conformation. Journal of    Virology 93, e00923-00919.-   Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L.,    Abiona, O., Graham, B. S., and McLellan, J. S. (2020). Cryo-EM    structure of the 2019-nCoV spike in the prefusion conformation.    Science 367, 1260-1263.-   Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y.,    Zhang, Y., Xun, J., Lu, L., et al. (2020a). Neutralizing antibody    responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and    their implications. bioRxiv 10.1101/2020.03.30.20047365.-   Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu,    Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., et al. (2020b). A new    coronavirus associated with human respiratory disease in China.    Nature 579, 265-269.-   Wu, H., Pfarr, D. S., Tang, Y., An, L. L., Patel, N. K., Watkins, J.    D., Huse, W. D., Kiener, P. A., and Young, J. F. (2005).    Ultra-potent antibodies against respiratory syncytial virus: effects    of binding kinetics and binding valence on viral neutralization. J    Mol Biol 350, 126-144.-   Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li,    S., Bi, Y., Yang, Y., et al. (2020c). A noncompeting pair of human    neutralizing antibodies block COVID-19 virus binding to its receptor    ACE2. Science 10.1126/science.abc2241.-   Xiong, H., Wu, Y., Cao, J., Yang, R., Ma, J., Qiao, X., Yao, X.,    Zhang, B., Zhang, Y., Hou, W., et al. (2020). Robust neutralization    assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV)    pseudovirus and ACE2-overexpressed BHK21 cells.    10.1101/2020.04.08.026948.-   Xiong, X., Tortorici, M. A., Snijder, J., Yoshioka, C., Walls, A.    C., Li, W., McGuire, A. T., Rey, F. A., Bosch, B. J., and    Veesler, D. (2018). Glycan Shield and Fusion Activation of a    Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric    Infections. J Virol 92.-   Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., and Zhou, Q. (2020).    Structural basis for the recognition of SARS-CoV-2 by full-length    human ACE2. Science 367, 1444-1448.-   Yuan, M., Wu, N. C., Zhu, X., Lee, C. D., So, R. T. Y., Lv, H.,    Mok, C. K. P., and Wilson, I. A. (2020). A highly conserved cryptic    epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV.    Science 10.1126/science.abb7269.-   Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu,    Y., Yan, J., Shi, Y., et al. (2017). Cryo-EM structures of MERS-CoV    and SARS-CoV spike glycoproteins reveal the dynamic receptor binding    domains. Nat Commun 8, 15092.-   Zhou, G., and Zhao, Q. (2020). Perspectives on therapeutic    neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.    Int J Biol Sci 16, 1718-1723.-   Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W.,    Si, H. R., Zhu, Y., Li, B., Huang, C. L., et al. (2020). A pneumonia    outbreak associated with a new coronavirus of probable bat origin.    Nature 579, 270-273.-   Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X.,    Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E.    C., et al. (2020). Rapid isolation and profiling of a diverse panel    of human monoclonal antibodies targeting the SARS-CoV-2 spike    protein. bioRxiv 10.1101/2020.05.12.091462.

What is claimed is:
 1. A recombinantly produced anti-SARS-CoV-2 antibodyor antigen-binding fragment thereof that binds specifically to aSARS-CoV-2 antigen comprising a Spike (S) polypeptide of a human or ananimal SARS-CoV-2, comprising a heavy chain variable region (HCVR)having the amino acid sequence of SEQ ID NO: 2900 and a light chainvariable region (LCVR) having the amino acid sequence of SEQ ID NO:2912.
 2. The antibody or antigen-binding fragment thereof of claim 1,wherein the antibody or antigen-binding fragment thereof is capable ofneutralizing a plurality of SARS-CoV-2 strains.
 3. A recombinantlyproduced anti-SARS-CoV-2 antibody or antigen-binding fragment thereofthat binds specifically to a SARS-CoV-2 antigen comprising a Spike (S)polypeptide of a human or an animal SARS-CoV-2, comprising a heavychain/light chain sequence pair of SEQ ID NOs: 2886/2898, 2886/2899,2887/2898, 2887/2899, 2910/2921, 2910/2922, 2911/2921, or 2911/2922. 4.The antibody or antigen-binding fragment thereof of claim 1, wherein theantibody or antigen-binding fragment thereof is a multivalent antibodycomprising (a) a first target binding site that specifically binds to anepitope within the Spike (S) polypeptide, and (b) a second targetbinding site that binds to an epitope on a different epitope on theSpike (S) polypeptide or a different molecule.
 5. The antibody orantigen-binding fragment thereof of claim 4, wherein the multivalentantibody is a bivalent or bispecific antibody.
 6. The antibody or theantigen-binding fragment thereof of claim 1, further comprising avariant Fc constant region.
 7. The antibody or the antigen-bindingfragment thereof of claim 1, wherein the variant Fc constant regioncomprises M428L and N434S substitutions according to the EU numbering.8. The antibody or the antigen-binding fragment thereof of claim 1,wherein the antibody is a chimeric antibody, a humanized antibody, orhumanized monoclonal antibody.
 9. A pharmaceutical compositioncomprising the antibody or antigen-binding fragment thereof of claim 1and a pharmaceutically acceptable carrier or excipient.
 10. Thepharmaceutical composition of claim 9, further comprising a secondtherapeutic agent.
 11. A kit comprising a pharmaceutically acceptabledose unit of the antibody or antigen-binding fragment thereof ofclaim
 1. 12. A kit for the diagnosis, prognosis or monitoring treatmentof SARS-CoV-2 in a subject, comprising: the antibody or antigen-bindingfragment thereof of claim 1; and a least one detection reagent thatbinds specifically to the antibody or antigen-binding fragment thereof.